Clustering O 0 2.2721551431459375e-05
of O 0 5.085920520286891e-07
missense O 0 3.6970247947465396e-06
mutations O 0 2.104940577396519e-08
in O 0 1.3040316382273431e-08
the O 0 1.3227854651631787e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 2.173624807255692e-06
in O 0 2.068101068175565e-08
a O 0 4.40064091833392e-08
sporadic B-Disease 0 3.4658971799217397e-06
T I-Disease 0 0.013737835921347141
- I-Disease 0 0.06836527585983276
cell I-Disease 1 0.5743906497955322
leukaemia I-Disease 1 0.9998650550842285
. O 0 1.7531590401631547e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
telangiectasia I-Disease 1 1.0
( O 1 0.8496760725975037
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.804770543069935e-08
is O 0 1.512232228328969e-09
a O 0 5.5646691698996165e-09
recessive B-Disease 0 1.3655403563461732e-07
multi I-Disease 0 0.007093620020896196
- I-Disease 1 0.9997979998588562
system I-Disease 0 0.0005601114244200289
disorder I-Disease 0 0.0318957157433033
caused O 0 1.087763408236242e-07
by O 0 1.7474309776943642e-09
mutations O 0 9.38790822857527e-10
in O 0 1.4917006518899711e-09
the O 0 3.068113585413812e-08
ATM O 0 3.30561088048853e-05
gene O 0 2.2169549751538398e-08
at O 0 8.890318525800467e-08
11q22 O 0 3.846152594633168e-06
- O 0 3.205664143024478e-06
q23 O 0 2.0061163013451733e-05
( O 0 1.4349443233641068e-07
ref O 0 1.773402004801028e-06
. O 0 3.4379712410270713e-09
3 O 0 8.514405891446586e-08
) O 0 3.1943276468382464e-08
. O 0 9.737917139318597e-08

The O 0 2.1124500904079468e-07
risk O 0 2.3232210821788613e-07
of O 0 3.2031994123826735e-07
cancer B-Disease 0 0.0002667912922333926
, O 0 2.3194171916429696e-08
especially O 0 2.9037414606136736e-07
lymphoid B-Disease 1 0.999987006187439
neoplasias I-Disease 1 0.9993619322776794
, O 0 1.3381475483242866e-08
is O 0 2.3114445912852943e-09
substantially O 0 3.3651033959358756e-08
elevated O 0 2.0257621713426488e-07
in O 0 3.909616452801856e-08
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999899864196777
T I-Disease 1 1.0
patients O 0 6.336366453751907e-08
and O 0 5.80359094115579e-10
has O 0 4.0743197704529166e-10
long O 0 1.697121665422685e-09
been O 0 1.9664025963095355e-09
associated O 0 1.4404171189141834e-08
with O 0 1.827405782250935e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 6.6763268478098325e-06

By O 0 3.863346478283347e-07
analysing O 0 2.4976086933747865e-05
tumour B-Disease 1 0.9999997615814209
DNA O 0 1.4676458022222505e-06
from O 0 1.6704733596384358e-08
patients O 0 2.4037467571957905e-09
with O 0 1.031608798385264e-09
sporadic B-Disease 0 4.0354325392399915e-06
T I-Disease 0 0.00030911335488781333
- I-Disease 0 4.03561134589836e-05
cell I-Disease 0 3.982698035542853e-05
prolymphocytic I-Disease 0 3.881577868014574e-05
leukaemia I-Disease 0 0.3929348289966583
( O 0 1.6736568397845986e-07
T B-Disease 0 4.531837930699112e-06
- I-Disease 0 4.304010417399695e-06
PLL I-Disease 0 0.002532470505684614
) O 0 8.215393698662865e-09
, O 0 5.168904748664715e-10
a O 0 2.9967079928638896e-09
rare O 0 1.1680950429138193e-08
clonal B-Disease 0 1.1065197895732126e-06
malignancy I-Disease 0 2.9057046049274504e-05
with O 0 2.0085970664496244e-09
similarities O 0 1.606135491272198e-08
to O 0 1.6134360514286072e-09
a O 0 4.64885410167426e-08
mature B-Disease 0 7.829636956557806e-07
T I-Disease 0 2.7939155188505538e-05
- I-Disease 0 4.539052497420926e-06
cell I-Disease 0 8.832394996716175e-06
leukaemia I-Disease 0 2.1710893634008244e-05
seen O 0 1.565700635808298e-08
in O 0 4.336017322970065e-09
A B-Disease 1 0.9928930401802063
- I-Disease 0 0.00015909777721390128
T I-Disease 1 0.9658105969429016
, O 0 3.1945257550347606e-10
we O 0 6.593197099391546e-10
demonstrate O 0 6.269762042876437e-09
a O 0 1.2467810117655631e-09
high O 0 1.7041931199557325e-09
frequency O 0 1.3106238316851204e-09
of O 0 2.5765722888593245e-09
ATM O 0 1.0979214266626514e-06
mutations O 0 9.107463228019697e-09
in O 0 7.721980921360228e-08
T B-Disease 0 0.0003026010235771537
- I-Disease 0 0.0006404497544281185
PLL I-Disease 1 0.6642334461212158
. O 0 2.104980239892029e-06

In O 0 4.5522423874899687e-07
marked O 0 3.0292449082480744e-07
contrast O 0 3.799846481911118e-08
to O 0 3.2365077284879362e-09
the O 0 2.8818744723935197e-08
ATM O 0 3.6964152059226763e-06
mutation O 0 3.1473590400565854e-09
pattern O 0 3.076599242035627e-08
in O 0 2.548489419496036e-08
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9979196190834045
T I-Disease 1 0.9999996423721313
, O 0 1.79309234127345e-09
the O 0 3.322955022255769e-09
most O 0 2.467262505412293e-10
frequent O 0 1.0548969475721037e-09
nucleotide O 0 6.4795284693275335e-09
changes O 0 1.8061761808407795e-10
in O 0 3.7104178063351867e-10
this O 0 1.4801655456864182e-09
leukaemia B-Disease 0 1.0602393558656331e-05
were O 0 1.1076552652866667e-07
missense O 0 4.157507191848708e-06
mutations O 0 2.2738967686564138e-07
. O 0 1.1959637902236864e-07

These O 0 2.1867644761641714e-07
clustered O 0 1.4684957250210573e-06
in O 0 1.0680166084853226e-08
the O 0 9.8663912595498e-09
region O 0 2.4973198620159565e-08
corresponding O 0 6.52477325502332e-08
to O 0 4.702790157296022e-09
the O 0 3.446317720090519e-08
kinase O 0 1.3657374893227825e-06
domain O 0 4.7654481249992386e-08
, O 0 3.3167208562945305e-11
which O 0 2.019235126327068e-11
is O 0 3.187348301958437e-11
highly O 0 4.616025339743146e-10
conserved O 0 1.7649840700073582e-08
in O 0 2.7112376788096526e-09
ATM O 0 6.016860879753949e-06
- O 0 6.060530921558893e-08
related O 0 1.294367368842586e-08
proteins O 0 2.2373098929051594e-09
in O 0 2.092199080649948e-09
mouse O 0 1.5515677631583458e-08
, O 0 2.548098121391007e-10
yeast O 0 2.0033869674307425e-08
and O 0 1.0243390136110975e-08
Drosophila O 0 1.476790089327551e-06
. O 0 1.0807589490013925e-07

The O 0 1.0028247743321117e-06
resulting O 0 2.49575151656245e-07
amino O 0 1.5425274568769964e-07
- O 0 9.073396256553679e-08
acid O 0 8.12042433295801e-09
substitutions O 0 5.232690281076202e-09
are O 0 5.326812324568664e-10
predicted O 0 1.824076711898215e-08
to O 0 5.060719843186234e-09
interfere O 0 1.2349342171091848e-07
with O 0 1.0133478944851504e-08
ATP O 0 0.0007643593708053231
binding O 0 7.2356812097496e-08
or O 0 3.0870975109564824e-08
substrate O 0 6.782793775528262e-07
recognition O 0 2.3691238482115295e-07
. O 0 2.2112018882580742e-07

Two O 0 4.2996805404982297e-07
of O 0 2.9499636866603396e-07
seventeen O 0 2.0849854536209023e-06
mutated O 0 1.2732039067486767e-06
T B-Disease 0 2.451872751407791e-05
- I-Disease 0 8.40431221149629e-06
PLL I-Disease 0 0.000666646403260529
samples O 0 5.938234437508072e-08
had O 0 1.9447364607572126e-08
a O 0 1.1842854696908489e-08
previously O 0 5.700775673744829e-08
reported O 0 2.623962132020097e-07
A B-Disease 1 0.9986948370933533
- I-Disease 1 0.9340305924415588
T I-Disease 1 0.9999611377716064
allele O 0 1.0869064226426417e-06
. O 0 5.637202207253722e-07

In O 0 3.980868825692596e-07
contrast O 0 6.301198141045461e-08
, O 0 1.691756734700789e-09
no O 0 2.2868913429618942e-09
mutations O 0 8.379261173807606e-10
were O 0 1.7075183489367873e-09
detected O 0 1.1015617751297668e-08
in O 0 2.470729620895895e-09
the O 0 5.3302429137147556e-08
p53 O 0 1.3553648159359e-07
gene O 0 3.189273289905259e-09
, O 0 6.65660471188545e-10
suggesting O 0 1.792289694435567e-08
that O 0 8.184453670345704e-10
this O 0 1.2653798009409911e-08
tumour B-Disease 1 1.0
suppressor O 0 0.00018158924649469554
is O 0 7.752373187841499e-10
not O 0 2.337713356226345e-10
frequently O 0 2.0998989214149333e-09
altered O 0 1.1301349189807297e-08
in O 0 5.373111289230792e-09
this O 0 3.817237015368846e-08
leukaemia B-Disease 0 0.0006911082891747355
. O 0 5.144463557371637e-07

Occasional O 0 3.60938829544466e-05
missense O 0 1.38629429784487e-05
mutations O 0 4.407663212191437e-08
in O 0 1.3263620424197597e-08
ATM O 0 3.458791297816788e-06
were O 0 1.4877233667220935e-08
also O 0 9.958042168634051e-10
found O 0 3.3643061669863528e-09
in O 0 8.112374771940267e-09
tumour B-Disease 1 0.9999982118606567
DNA O 0 1.681201098335805e-07
from O 0 1.8824664049788e-09
patients O 0 1.270045180135071e-10
with O 0 1.1669337718345218e-10
B B-Disease 0 4.202171476208605e-05
- I-Disease 0 7.714323874097317e-05
cell I-Disease 0 0.00797592755407095
non I-Disease 0 0.00018741765234153718
- I-Disease 0 0.001147694536484778
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 2.693018132049474e-06
( O 0 7.805553536854859e-09
B B-Disease 0 8.040823473720593e-08
- I-Disease 0 1.1223287188499853e-08
NHL I-Disease 0 3.339642162814016e-08
) O 0 7.08664849025098e-10
and O 0 2.4655030794740185e-10
a O 0 9.333688488766256e-09
B B-Disease 0 1.4372989198818686e-06
- I-Disease 0 1.0314321343685151e-06
NHL I-Disease 0 7.20504385753884e-06
cell O 0 4.327469287090935e-05
line O 0 2.21641744246881e-06
. O 0 5.459529006657249e-07

The O 0 3.8990685879980447e-07
evidence O 0 5.258170290289854e-07
of O 0 6.757904458254416e-08
a O 0 6.189770918041404e-09
significant O 0 3.4266718351716463e-09
proportion O 0 3.147251126378592e-09
of O 0 1.9921918337217903e-08
loss O 0 1.668631881557303e-07
- O 0 8.488089520142239e-08
of O 0 7.402115898003103e-08
- O 0 1.7323529277746275e-07
function O 0 1.8577132721020462e-08
mutations O 0 7.98093119369625e-11
and O 0 2.184809451410974e-11
a O 0 3.3812361244223155e-10
complete O 0 6.557182352651125e-09
absence O 0 2.7155243387255723e-08
of O 0 1.4498826139686116e-08
the O 0 5.596078711533892e-09
normal O 0 1.2255946479911017e-08
copy O 0 3.005714077630728e-08
of O 0 8.796632755547762e-09
ATM O 0 1.3766879192189663e-06
in O 0 7.619442299322543e-10
the O 0 1.3071113080798114e-09
majority O 0 5.73900815759032e-10
of O 0 2.8739481905404318e-08
mutated O 0 2.7853405981659307e-07
tumours B-Disease 1 0.9999953508377075
establishes O 0 1.7771405680377939e-07
somatic O 0 6.160480836570059e-08
inactivation O 0 8.777028881468141e-08
of O 0 5.747950559964465e-09
this O 0 3.9291461750856627e-10
gene O 0 6.414659914355525e-10
in O 0 3.7197997460047816e-10
the O 0 5.1148885127361154e-09
pathogenesis O 0 2.9399805498542264e-05
of O 0 1.1969431170655298e-06
sporadic B-Disease 0 8.528239413863048e-05
T I-Disease 0 0.3941264748573303
- I-Disease 0 0.0013123012613505125
PLL I-Disease 1 0.9996683597564697
and O 0 4.2506025366151334e-09
suggests O 0 2.6225054128303782e-08
that O 0 8.890174152398345e-10
ATM O 0 7.170114031396224e-07
acts O 0 8.266871631690265e-09
as O 0 1.90875226735443e-08
a O 0 5.515178145287791e-07
tumour B-Disease 1 1.0
suppressor O 0 0.00011602927406784147
. O 0 2.0002985934297612e-07

As O 0 9.640524467613432e-08
constitutional O 0 6.78172753509898e-08
DNA O 0 1.5663555075207114e-07
was O 0 3.591622999010724e-08
not O 0 3.4800018422487256e-10
available O 0 2.409861421526216e-09
, O 0 3.0833180453271325e-09
a O 0 8.255514671873243e-08
putative O 0 1.4388458112080116e-05
hereditary O 1 0.6476043462753296
predisposition O 0 0.0028835462871938944
to O 0 2.9711040951951873e-06
T B-Disease 1 0.9999964237213135
- I-Disease 1 0.986555814743042
PLL I-Disease 1 0.9999349117279053
will O 0 4.775244644150689e-09
require O 0 4.114822704792687e-09
further O 0 1.0020827723167258e-08
investigation O 0 1.9418459373810038e-07
. O 0 1.1916222675267818e-08
. O 0 9.551554569497966e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00019387603970244527
kinase O 0 3.7193572097748984e-06
is O 0 6.447791744967901e-10
involved O 0 6.704335975271647e-10
in O 0 1.3277402788336445e-10
the O 0 7.108714727976917e-10
modulation O 0 1.3728469028251311e-08
of O 0 3.6199565567329728e-09
the O 0 3.602222520271425e-08
Ca2 O 0 2.329506241949275e-05
+ O 0 2.0745487745443825e-06
homeostasis O 0 4.11879273087834e-06
in O 0 3.71826409661935e-08
skeletal O 0 0.04350380599498749
muscle O 0 1.0097679478349164e-05
cells O 0 3.804999778367346e-06
. O 0 3.7085791859681194e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9965476393699646
DM B-Disease 1 1.0
) O 0 8.354070502036848e-08
, O 0 8.408688190186808e-10
the O 0 4.002137732328492e-09
most O 0 3.2880898004350456e-09
prevalent O 0 9.40961945161689e-06
muscular B-Disease 1 0.9995606541633606
disorder I-Disease 0 0.3729747235774994
in O 0 2.2751196482317937e-08
adults O 0 8.498452608307616e-09
, O 0 7.319667649774431e-10
is O 0 1.4506426060378885e-09
caused O 0 4.745246418025317e-09
by O 0 5.642389666604686e-09
( O 0 3.8788215306340135e-08
CTG O 0 1.5122958757274318e-05
) O 0 4.21468548950088e-09
n O 0 1.9527689687492966e-08
- O 0 1.4467610220947336e-08
repeat O 0 1.6397544655433194e-08
expansion O 0 2.193309533993215e-08
in O 0 1.6310790496021355e-09
a O 0 4.171991641044315e-09
gene O 0 1.1820664447270701e-09
encoding O 0 1.756674139485881e-09
a O 0 9.308408266406332e-09
protein O 0 1.4209004461918084e-07
kinase O 0 2.3957484245329397e-06
( O 0 1.9161211639584508e-07
DM B-Disease 1 1.0
protein O 0 2.8066349955224723e-07
kinase O 0 1.725948095554486e-07
; O 0 1.8888783592796443e-10
DMPK O 0 1.0862952876777854e-05
) O 0 2.1367136948668985e-09
and O 0 1.8507936849765372e-10
involves O 0 8.069812373889818e-09
changes O 0 3.995212161100881e-09
in O 0 1.3784355878954102e-08
cytoarchitecture O 0 6.399319772754097e-06
and O 0 1.0384640347638197e-07
ion O 0 6.244976975722238e-05
homeostasis O 1 0.702329695224762
. O 0 2.383765149716055e-06

To O 0 2.0051021465405938e-07
obtain O 0 1.3414317834303802e-07
clues O 0 9.494408459431725e-07
to O 0 1.6576308103921633e-09
the O 0 4.31506164133566e-09
normal O 0 5.790328572174985e-08
biological O 0 2.6126207330889883e-07
role O 0 4.77292552147901e-08
of O 0 1.9822503816158132e-07
DMPK O 0 0.0983467549085617
in O 0 5.540302794315721e-08
cellular O 0 4.677065987834794e-07
ion O 0 2.8381782612996176e-07
homeostasis O 0 1.2777942174579948e-05
, O 0 5.476095688017324e-10
we O 0 9.737128880971113e-10
have O 0 2.0901955166685582e-10
compared O 0 1.7800207974261184e-09
the O 0 2.709785063004233e-09
resting O 0 6.508347496492206e-07
[ O 0 2.8647872341025504e-07
Ca2 O 0 2.709430475533736e-07
+ O 0 1.3017055877639905e-08
] O 0 4.588158297735845e-09
i O 0 7.383059164034478e-10
, O 0 5.412996439968509e-11
the O 0 2.5957541671672857e-10
amplitude O 0 3.3623559492212962e-09
and O 0 1.2381118352777776e-10
shape O 0 2.129237053338784e-08
of O 0 1.332384584884494e-07
depolarization O 0 5.99773841258866e-07
- O 0 9.431597618458909e-07
induced O 0 3.2822754292283207e-06
Ca2 O 0 1.1610491128521971e-06
+ O 0 2.5516218471466345e-08
transients O 0 1.081616485265613e-08
, O 0 5.111440784522081e-11
and O 0 3.5114640362099436e-11
the O 0 6.139233010848955e-10
content O 0 2.865079951064331e-09
of O 0 2.7093211230067027e-08
ATP O 0 1.3507207768270746e-05
- O 0 3.6620289733946265e-07
driven O 0 4.777097046826384e-07
ion O 0 1.3020674316521763e-07
pumps O 0 5.989512885662407e-08
in O 0 4.062681746574981e-09
cultured O 0 2.382467300776625e-06
skeletal O 0 7.231086055980995e-05
muscle O 0 7.696365855736076e-08
cells O 0 1.8869572571134086e-08
of O 0 9.631919262176325e-09
wild O 0 6.110241645984615e-09
- O 0 1.8688904646069204e-08
type O 0 1.4035145490254308e-08
and O 0 5.358187227244571e-10
DMPK O 0 1.659269219089765e-05
[ O 0 2.884795264890272e-07
- O 0 5.200599844101816e-07
/ O 0 8.744091815060528e-07
- O 0 1.2057132607878884e-06
] O 0 3.6468617281570914e-07
knockout O 0 7.050050498946803e-06
mice O 0 1.7466539929955616e-06
. O 0 9.599899897239084e-08

In O 0 8.731075809009781e-07
vitro O 0 1.3364879123400897e-06
- O 0 2.8853071398771135e-07
differentiated O 0 3.9843595800448384e-07
DMPK O 0 3.30862239934504e-05
[ O 0 9.487421266385354e-07
- O 0 1.5422641581608332e-06
/ O 0 3.1469157875108067e-06
- O 0 2.175001782234176e-06
] O 0 3.983329861512175e-07
myotubes O 0 1.084062773770711e-06
exhibit O 0 1.0027921604205403e-08
a O 0 4.811816722849471e-09
higher O 0 8.071105561668901e-09
resting O 0 3.160897108500649e-07
[ O 0 3.014941114543035e-07
Ca2 O 0 5.892235890314623e-07
+ O 0 1.990972364751542e-08
] O 0 7.3793180455083984e-09
i O 0 2.2398973786863507e-09
than O 0 1.7022755427476e-10
do O 0 4.343017612207234e-10
wild O 0 5.780140810429657e-09
- O 0 5.791632062823737e-08
type O 0 2.446991516080743e-07
myotubes O 0 7.3776423050730955e-06
because O 0 2.935429899153519e-09
of O 0 7.1906760545914494e-09
an O 0 9.58969792463904e-10
altered O 0 7.217677122639543e-09
open O 0 7.610354124665264e-09
probability O 0 1.8244595167971056e-08
of O 0 1.1231596097616148e-08
voltage O 0 1.0002671757547432e-07
- O 0 3.69134838251739e-08
dependent O 0 9.239813891781523e-08
l O 0 3.049153818324157e-08
- O 0 7.824304759651568e-09
type O 0 1.9967909992146815e-08
Ca2 O 0 9.454529248387189e-08
+ O 0 6.333427560178961e-09
and O 0 1.6399226421270896e-09
Na O 0 9.529974704491906e-06
+ O 0 1.4911600487721444e-07
channels O 0 9.45604412549983e-08
. O 0 2.7440460570460345e-08

The O 0 1.4618487966799876e-06
mutant O 0 3.133654672637931e-06
myotubes O 0 5.411458460002905e-06
exhibit O 0 8.584737543060328e-08
smaller O 0 2.7544482250618785e-09
and O 0 1.1640154395919922e-09
slower O 0 9.217212948442466e-08
Ca2 O 0 2.516614472369838e-07
+ O 0 5.158653948456049e-09
responses O 0 3.395881353895902e-10
upon O 0 1.180797792876831e-09
triggering O 0 3.884468746662151e-09
by O 0 8.19591949863252e-10
acetylcholine O 0 3.9953665265102245e-08
or O 0 1.0534854100185953e-09
high O 0 1.714064978841634e-08
external O 0 3.3927847198356176e-07
K O 0 8.244660421041772e-06
+ O 0 1.3725689314014744e-06
. O 0 1.4661181069186568e-07

In O 0 1.0351614321280067e-07
addition O 0 1.6113700596065428e-08
, O 0 1.492785117740425e-09
we O 0 6.775657812596592e-10
observed O 0 3.282325078401982e-09
that O 0 1.7146321862338e-10
these O 0 2.328334192114312e-09
Ca2 O 0 5.979182787996251e-06
+ O 0 3.7391521345853107e-07
transients O 0 6.990746470592057e-08
partially O 0 9.906915288127038e-09
result O 0 2.4322424629907857e-10
from O 0 1.569268881507213e-10
an O 0 1.5972255462681773e-10
influx O 0 1.5933679931023903e-09
of O 0 3.016319860549288e-09
extracellular O 0 9.593017580300511e-08
Ca2 O 0 3.923383928849944e-08
+ O 0 5.499017907695247e-10
through O 0 5.981935086163404e-11
the O 0 3.6840508421676077e-10
l O 0 1.1232367036484447e-08
- O 0 8.129909190301987e-09
type O 0 6.243283934281862e-08
Ca2 O 0 1.414324856341409e-06
+ O 0 1.8172899274304655e-07
channel O 0 1.6549644499264105e-07
. O 0 3.826421846042649e-08

Neither O 0 8.159845492627937e-06
the O 0 1.1503632180165368e-07
content O 0 4.6662837149824554e-08
nor O 0 8.135807405551532e-08
the O 0 1.6669975622107813e-08
activity O 0 7.862247031198422e-08
of O 0 5.508513467589182e-08
Na O 0 2.6676541892811656e-05
+ O 0 2.1858595289359073e-07
/ O 0 1.0938656913594969e-07
K O 0 7.9095639193838e-07
+ O 0 1.0810887829393323e-07
ATPase O 0 1.6224390719798976e-06
and O 0 2.3448594177466475e-09
sarcoplasmic O 0 2.8991639737796504e-06
reticulum O 0 2.4947262318164576e-06
Ca2 O 0 1.2399597153489594e-06
+ O 0 8.820779839879833e-08
- O 0 4.51694148750903e-08
ATPase O 0 1.2852033250965178e-06
are O 0 2.0426176028376375e-10
affected O 0 8.932156680963033e-10
by O 0 7.953449454589645e-09
DMPK O 0 0.0006436862167902291
absence O 0 7.796020327077713e-06
. O 0 1.594678337824007e-06

In O 0 6.758367590009584e-07
conclusion O 0 6.572724373654637e-07
, O 0 9.109582421729101e-09
our O 0 1.4983797314016556e-08
data O 0 3.405166637548973e-08
suggest O 0 2.430019208077283e-08
that O 0 1.9323564970363805e-09
DMPK O 0 9.829884947976097e-05
is O 0 1.2110619174166004e-08
involved O 0 5.800520597176728e-08
in O 0 9.707870063380142e-09
modulating O 0 3.685763090288674e-07
the O 0 1.5879685122399678e-08
initial O 0 4.8796948703966336e-08
events O 0 6.0093183762433e-09
of O 0 1.5893501625896533e-08
excitation O 0 7.224709861475276e-07
- O 0 6.1922401073388755e-06
contraction O 0 1.6042117749748286e-06
coupling O 0 2.776517078473262e-07
in O 0 2.239881347065875e-08
skeletal O 0 0.000290428230073303
muscle O 0 2.797615650251828e-07
. O 0 3.4011225835683945e-08
. O 0 1.6351984299944888e-07

Constitutional O 0 0.00011611205991357565
RB1 O 1 0.9999620914459229
- O 0 3.57707504008431e-05
gene O 0 8.313347166222229e-08
mutations O 0 3.0018107999296717e-09
in O 0 8.193574707604512e-10
patients O 0 7.841152727117162e-10
with O 0 4.334593239896378e-10
isolated O 0 8.772900059739186e-07
unilateral B-Disease 0 9.062229082701379e-07
retinoblastoma I-Disease 0 0.05055541172623634
. O 0 1.7077070424420526e-06

In O 0 6.795607987442054e-08
most O 0 1.2729657328236499e-09
patients O 0 7.645092892083483e-10
with O 0 2.545911814699764e-10
isolated O 0 7.534818280419131e-08
unilateral B-Disease 0 8.155523545383403e-08
retinoblastoma I-Disease 0 0.09016812592744827
, O 0 1.360641732617296e-08
tumor B-Disease 0 1.0514049790799618e-05
development O 0 2.5784910206994027e-08
is O 0 2.8157143283635833e-10
initiated O 0 3.7228535809674668e-09
by O 0 1.8811553703645956e-10
somatic O 0 6.926135220908236e-09
inactivation O 0 1.863999088413948e-08
of O 0 3.1677513945282954e-09
both O 0 3.822544503151448e-10
alleles O 0 6.57325804898079e-10
of O 0 4.70688199527558e-09
the O 0 1.5460781810361368e-07
RB1 O 0 0.0020239679142832756
gene O 0 4.7434392058676167e-07
. O 0 7.620845110523078e-08

However O 0 1.3966760548100865e-07
, O 0 9.704700376644837e-10
some O 0 5.874542519102022e-11
of O 0 4.760728478103715e-10
these O 0 9.448607452000601e-10
patients O 0 4.476559567478944e-09
can O 0 6.2685661106343105e-09
transmit O 0 9.267626410291996e-06
retinoblastoma B-Disease 1 0.9999980926513672
predisposition O 1 0.9651859998703003
to O 0 5.626208832154589e-08
their O 0 1.530067947896896e-07
offspring O 0 1.3091499795336858e-06
. O 0 2.155367866407687e-07

To O 0 2.6581297163374984e-08
determine O 0 2.4019513489292876e-08
the O 0 6.647269845672099e-09
frequency O 0 1.2046251107733497e-08
and O 0 2.4932622633144774e-10
nature O 0 1.057213872002194e-08
of O 0 5.086754484295852e-08
constitutional O 0 1.0559724614722654e-06
RB1 O 1 0.9986603260040283
- O 0 1.8591827029013075e-06
gene O 0 7.473983210104507e-09
mutations O 0 4.2905046182539763e-10
in O 0 9.052312371915505e-11
patients O 0 4.2604277744606733e-11
with O 0 4.31754354490721e-11
isolated O 0 1.3938278975444973e-08
unilateral B-Disease 0 1.2786800951403166e-08
retinoblastoma I-Disease 0 8.372014121960092e-07
, O 0 1.7419325704093325e-10
we O 0 2.284405303809578e-10
analyzed O 0 9.046107862786812e-09
DNA O 0 3.616790422711347e-08
from O 0 9.65130286800786e-09
peripheral O 0 1.281397089769598e-06
blood O 0 3.036988260873841e-08
and O 0 4.111723850286353e-09
from O 0 4.3584324771472893e-07
tumor B-Disease 1 0.9498751759529114
tissue O 0 0.0008004179690033197
. O 0 1.412315214111004e-06

The O 0 8.450456334685441e-07
analysis O 0 5.804310490020725e-07
of O 0 6.075508167668886e-07
tumors B-Disease 1 1.0
from O 0 7.674685065239828e-08
54 O 0 9.497291841853439e-08
( O 0 4.015242804911168e-09
71 O 0 1.4655694435816713e-08
% O 0 2.4311710977720224e-10
) O 0 3.9407924840029196e-11
of O 0 2.3462812248631337e-10
76 O 0 7.979402028013283e-09
informative O 0 3.0972774567317174e-08
patients O 0 1.931943716115825e-09
showed O 0 1.0041664388893423e-08
loss O 0 8.181854838085201e-08
of O 0 2.0978666270821122e-07
constitutional O 0 1.2248185612406814e-06
heterozygosity O 1 0.9999940395355225
( O 0 0.0009184892987832427
LOH O 1 1.0
) O 0 1.8719180161497206e-07
at O 0 6.187507324284525e-07
intragenic O 0 4.163178164162673e-05
loci O 0 1.793878595890419e-06
. O 0 3.9803981621844287e-07

Three O 0 1.140365839091828e-06
of O 0 7.400992672046414e-07
13 O 0 1.0205205853708321e-06
uninformative O 0 0.0012901427689939737
patients O 0 2.5533313419146e-07
had O 0 1.4066102949072956e-07
constitutional O 0 1.6062723489085329e-06
deletions O 0 7.317186828004196e-06
. O 0 1.023760773932736e-06

For O 0 1.8097458109878062e-07
39 O 0 2.1931069227321132e-07
randomly O 0 2.2702126400986344e-08
selected O 0 2.4083769289973134e-07
tumors B-Disease 1 1.0
, O 0 8.552459718202954e-08
SSCP O 1 0.5078322887420654
, O 0 4.0698651559978316e-08
hetero O 0 6.783629942219704e-06
- O 0 1.0576620468327746e-07
duplex O 0 7.25759491615463e-07
analysis O 0 6.9397287916217465e-09
, O 0 1.0766795094374615e-10
sequencing O 0 2.863326242774633e-09
, O 0 1.1991174719838682e-10
and O 0 1.8743574747848157e-10
Southern O 0 1.2145455308143482e-08
blot O 0 7.026866910564422e-08
analysis O 0 7.927959622122671e-09
were O 0 1.5602950043103192e-09
used O 0 1.4063730180424727e-09
to O 0 1.3113814478771246e-09
identify O 0 4.3786211989527146e-08
mutations O 0 2.385936568316538e-07
. O 0 2.687863513983757e-07

Mutations O 0 1.2948262337886263e-06
were O 0 1.0424449925494628e-07
detected O 0 1.4164331219035375e-07
in O 0 1.3170748047741654e-08
21 O 0 4.165266886957397e-08
( O 0 9.789909327651003e-09
91 O 0 6.230567350939964e-08
% O 0 5.507018396855301e-09
) O 0 1.8620047725903532e-09
of O 0 3.33965495258326e-08
23 O 0 1.154758774646325e-05
tumors B-Disease 1 1.0
with O 0 0.00010244482109555975
LOH O 1 1.0
. O 0 9.120682989305351e-06

In O 0 4.507917310547782e-07
6 O 0 1.5292656030396756e-07
( O 0 4.9546651226251015e-09
38 O 0 6.251014816882616e-09
% O 0 5.816656600821091e-10
) O 0 1.444338815215218e-10
of O 0 3.2459170906662393e-09
16 O 0 4.2219934925924463e-07
tumors B-Disease 1 1.0
without O 0 0.005028168670833111
LOH O 1 1.0
, O 0 4.960584387703193e-09
one O 0 1.2002164817559446e-09
mutation O 0 1.9129198225442678e-10
was O 0 3.4225895451100996e-09
detected O 0 4.8680166564452065e-09
, O 0 1.0634135239051545e-10
and O 0 9.687403657032689e-11
in O 0 1.294724660816371e-09
9 O 0 3.717278218573483e-08
( O 0 2.7212261333176002e-09
56 O 0 7.801534529505716e-09
% O 0 7.640194588098836e-10
) O 0 1.3137065046908702e-10
of O 0 1.118003800648637e-09
the O 0 5.229340516166303e-08
tumors B-Disease 1 1.0
without O 1 0.8167533874511719
LOH O 1 1.0
, O 0 4.772385597817674e-09
both O 0 1.0926761717655609e-09
mutations O 0 2.8230020543418277e-09
were O 0 6.448312106499543e-09
found O 0 4.209192283610719e-08
. O 0 1.408452163786933e-07

Thus O 0 1.7679290067462716e-06
, O 0 7.812002600360302e-09
a O 0 5.932944358022496e-09
total O 0 3.827251848775859e-09
of O 0 2.3161621509615316e-09
45 O 0 1.9851280619320733e-09
mutations O 0 2.493167061690116e-10
were O 0 7.042935679102413e-10
identified O 0 2.0382531218388067e-08
in O 0 3.431683737176172e-08
tumors B-Disease 1 1.0
of O 0 3.8762696931371465e-05
36 O 0 2.253085040138103e-05
patients O 0 2.3005166838174773e-07
. O 0 2.0294864100378618e-07

Thirty O 0 2.661010148585774e-05
- O 0 8.393583357246825e-07
nine O 0 7.33602760760732e-08
of O 0 8.87791085091294e-09
the O 0 9.728148953058735e-09
mutations O 0 1.951449890569279e-09
- O 0 1.519753745071739e-08
including O 0 1.4647610901974417e-09
34 O 0 1.7260493478943317e-08
small O 0 1.8170960291996607e-09
mutations O 0 5.460992213990323e-10
, O 0 1.610686445330245e-10
2 O 0 1.9258914463193832e-09
large O 0 1.305974883791805e-09
structural O 0 8.996647125059098e-07
alterations O 0 3.757734248210909e-07
, O 0 4.914851192694414e-09
and O 0 5.194861429913544e-09
hypermethylation O 0 0.00018871448992285877
in O 0 1.5768861771903175e-07
3 O 0 2.831605115716229e-06
tumors O 1 1.0
- O 0 2.356817532245259e-07
were O 0 7.561088644081337e-09
not O 0 6.677510766550654e-10
detected O 0 4.275524378982709e-09
in O 0 2.9917662791589805e-10
the O 0 3.1021827329169582e-09
corresponding O 0 1.3440133272979438e-07
peripheral O 0 4.710558187071001e-06
blood O 0 1.0913134929069201e-06
DNA O 0 1.3257647879072465e-05
. O 0 6.067940034881758e-07

In O 0 8.841369663059595e-07
6 O 0 4.128614818910137e-07
( O 0 1.2354967715566545e-08
17 O 0 1.3967686562921244e-08
% O 0 1.0269540773322205e-09
) O 0 1.566705931654866e-10
of O 0 5.091437826898471e-10
the O 0 1.3789451802637132e-09
36 O 0 1.542420768885222e-08
patients O 0 6.356042359101366e-10
, O 0 1.531774013185938e-10
a O 0 1.6530464774788811e-09
mutation O 0 2.7508137434573143e-10
was O 0 4.891900218240153e-09
detected O 0 3.166422235523214e-09
in O 0 1.8752695229995453e-10
constitutional O 0 3.3014251332730282e-09
DNA O 0 4.076111181916531e-08
, O 0 9.225713248905976e-11
and O 0 7.618014552512875e-11
1 O 0 1.263182225486048e-09
of O 0 4.2554432200248016e-10
these O 0 6.562080739902498e-11
mutations O 0 3.04360758818234e-10
is O 0 9.048860272198311e-11
known O 0 3.563431494324476e-10
to O 0 1.7398407714530606e-10
be O 0 2.435976309556054e-09
associated O 0 3.9330792844793905e-08
with O 0 7.98020849401837e-09
reduced O 0 8.398379236496112e-07
expressivity O 0 8.813181193545461e-05
. O 0 5.423824518402398e-07

The O 0 5.642376095238433e-07
presence O 0 6.414702369283987e-08
of O 0 4.668456199397042e-08
a O 0 9.821742530391475e-09
constitutional O 0 1.756611389680529e-08
mutation O 0 9.931885314173883e-10
was O 0 9.788191590587303e-09
not O 0 2.283656042045834e-10
associated O 0 1.0177676479372622e-09
with O 0 1.2729747811413006e-10
an O 0 1.5001575537354483e-09
early O 0 2.1994928545154835e-08
age O 0 8.91800127078568e-08
at O 0 8.961444564192789e-07
treatment O 0 1.7413255193332589e-07
. O 0 4.924091854263679e-07

In O 0 3.481449937225989e-07
1 O 0 2.0384771914905286e-07
patient O 0 1.5505034411944507e-07
, O 0 4.046472490415454e-09
somatic O 0 5.511008112080162e-07
mosaicism O 0 0.00011718409950844944
was O 0 8.582298249848463e-08
demonstrated O 0 7.263484924635577e-09
by O 0 3.9322728406787633e-10
molecular O 0 2.7826834170241455e-09
analysis O 0 7.013310487913316e-10
of O 0 1.2398422288839583e-09
DNA O 0 1.08692104205943e-08
and O 0 9.736164097162714e-10
RNA O 0 9.590810350346146e-07
from O 0 3.62781023000025e-08
peripheral O 0 2.5088027541642077e-05
blood O 0 3.3360915949742775e-06
. O 0 5.083026053398498e-07

In O 0 2.199818567305556e-07
2 O 0 1.421971376203146e-07
patients O 0 4.39817204878068e-09
without O 0 1.0870138122953676e-09
a O 0 4.007622234070141e-09
detectable O 0 2.3446779096047976e-07
mutation O 0 2.5476327714102354e-09
in O 0 2.5924651314568337e-09
peripheral O 0 1.9333970158186276e-06
blood O 0 6.633466682615108e-07
, O 0 1.8367812160136054e-08
mosaicism O 1 0.8549437522888184
was O 0 2.842406559011579e-07
suggested O 0 1.4913599244437137e-08
because O 0 2.7670477020791395e-10
1 O 0 6.486164938479533e-10
of O 0 1.088661272241609e-09
the O 0 8.072398749447984e-09
patients O 0 4.359887029181664e-08
showed O 0 1.8875331079470925e-05
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.1917336451006122e-08
the O 0 2.8218893888265484e-08
other O 0 5.85541559683378e-10
later O 0 1.2793436532376745e-08
developed O 0 2.5432161265825926e-08
bilateral B-Disease 0 2.0056234006915474e-06
retinoblastoma I-Disease 0 0.0006706878775730729
. O 0 1.133189016400138e-06

In O 0 1.728362803987693e-07
conclusion O 0 2.43808386812816e-07
, O 0 3.31067573355881e-09
our O 0 1.505492797093666e-08
results O 0 3.2211731060272086e-09
emphasize O 0 9.047073312729026e-09
that O 0 1.8388442157846185e-10
the O 0 5.649917422800854e-09
manifestation O 0 3.916050275165617e-07
and O 0 1.87122584094368e-09
transmissibility O 0 7.082363026711391e-06
of O 0 1.1974977098816453e-07
retinoblastoma B-Disease 0 1.0586612006591167e-05
depend O 0 2.823859901468495e-08
on O 0 3.944120141596841e-09
the O 0 1.7110654004781622e-09
nature O 0 1.0809399597633274e-08
of O 0 2.4511095375601144e-09
the O 0 7.170621318941528e-10
first O 0 4.2487766083176837e-10
mutation O 0 1.0398619465501469e-10
, O 0 2.3556965406124064e-11
its O 0 2.0282983625996565e-11
time O 0 1.5807052888838768e-10
in O 0 2.626552586537656e-10
development O 0 5.980754558265744e-09
, O 0 1.6796602997359855e-10
and O 0 5.507369907342685e-11
the O 0 2.0820387081066372e-10
number O 0 7.341419833162277e-11
and O 0 2.916107633144094e-11
types O 0 3.3849528735530043e-10
of O 0 4.932995789630468e-09
cells O 0 1.3955622435446458e-08
that O 0 2.1041797471088586e-10
are O 0 3.0942154394253407e-10
affected O 0 2.004700849767005e-09
. O 0 3.99320088106947e-09
. O 0 1.2406215432747558e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.6715616583824158
the I-Disease 0 8.327427167387214e-06
fifth I-Disease 0 3.137503517791629e-05
component I-Disease 0 7.229952643683646e-06
of I-Disease 0 4.93132404244534e-07
complement I-Disease 0 6.84965073105559e-07
in O 0 2.833859014117479e-07
man O 0 3.334994471515529e-05
. O 0 1.020162471832009e-06

I O 0 0.0019357142737135291
. O 0 3.47007044183556e-05

Clinical O 0 0.35244232416152954
, O 0 2.2462781146259658e-07
immunochemical O 0 0.0009441759320907295
, O 0 4.136401443588511e-08
and O 0 2.5520014546032144e-08
family O 0 7.475182997040974e-07
studies O 0 1.9610870367614552e-06
. O 0 4.405209779179131e-07

The O 0 4.577443917241908e-07
first O 0 5.184312357187082e-08
recognized O 0 4.3079669609369375e-08
human O 0 1.7766814153219457e-07
kindred O 0 0.003027072176337242
with O 0 4.7080877152438916e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999957084655762
the I-Disease 0 2.9280303351697512e-05
fifth I-Disease 0 1.9350412912899628e-05
component I-Disease 0 7.036066563159693e-06
of I-Disease 0 4.5038223106530495e-07
complement I-Disease 0 4.1091102502832655e-06
( O 0 1.3274905541038606e-05
C5 O 0 0.014401009306311607
) O 0 6.425049292602125e-08
is O 0 3.730816899860656e-08
described O 0 1.4389612488230341e-06
. O 0 1.0255998859065585e-06

The O 0 6.265254796744557e-06
proband O 0 3.5216267860960215e-05
, O 0 3.776083445927725e-08
a O 0 6.164583510326338e-08
20 O 0 2.73797606809012e-08
- O 0 2.481498917461522e-08
year O 0 2.5960590122053873e-08
- O 0 2.895749560138938e-07
old O 0 5.904554996050138e-07
black O 0 5.001114544711527e-08
female O 0 1.8146660352158506e-07
with O 0 6.970348209733856e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 2.074364829240949e-06
age O 0 1.0785694257720024e-06
11 O 0 3.227103491099115e-07
, O 0 1.3052857461559597e-08
lacked O 0 5.69140502193477e-06
serum O 0 0.0001093453902285546
hemolytic O 1 0.999221920967102
complement O 0 8.647168215247802e-06
activity O 0 5.855880954186432e-05
, O 0 3.341513732380008e-09
even O 0 3.2563098883997554e-09
during O 0 1.9188769329048228e-07
remission O 0 4.70832628707285e-06
. O 0 3.23057065543253e-07

C5 O 0 0.0055602011270821095
was O 0 5.410018729889998e-06
undetectable O 0 1.7620730432099663e-05
in O 0 3.706092854827148e-08
her O 0 8.298882647750361e-08
serum O 0 2.3153204153913975e-07
by O 0 7.945185842572755e-09
both O 0 1.3778153729049336e-08
immunodiffusion O 0 2.5599349100957625e-05
and O 0 2.000044929673095e-07
hemolytic O 1 0.848957896232605
assays O 0 5.123634036863223e-05
. O 0 1.7992019820667338e-06

Other O 0 1.0886824775013793e-08
complement O 0 3.145230209611327e-08
components O 0 1.2138258398408652e-07
were O 0 9.553810187412637e-09
normal O 0 7.222003262086218e-08
during O 0 2.8775296812000306e-08
remission O 0 4.7572478933943785e-07
of O 0 2.590811334357568e-07
lupus O 0 1.0401117833680473e-06
, O 0 2.148106359456392e-09
but O 0 3.961294847698582e-09
C1 O 0 0.000536158331669867
, O 0 5.0787274830099705e-08
C4 O 0 0.0021753364708274603
, O 0 2.412819988251158e-08
C2 O 0 1.1648792678897735e-05
, O 0 1.3005640120411499e-08
and O 0 2.6832834620904578e-08
C3 O 0 0.030095046386122704
levels O 0 3.664366431621602e-06
fell O 0 0.0007149379816837609
during O 0 6.2215995058068074e-06
exacerbations O 0 0.0014993279473856091
. O 0 1.0195905133514316e-06

A O 0 9.175410013995133e-06
younger O 0 1.3029307410761248e-07
half O 0 9.408979195768552e-08
- O 0 9.240137615051935e-07
sister O 0 9.011700399241818e-07
, O 0 4.709611811648529e-09
who O 0 2.0196533334626565e-09
had O 0 2.0875560835520446e-08
no O 0 2.1791863957787427e-07
underlying O 1 0.9999978542327881
disease O 0 0.03725529462099075
, O 0 3.657677716262242e-09
was O 0 4.33453976711462e-07
also O 0 1.669676175097834e-09
found O 0 4.846467227537232e-09
to O 0 7.427626069755888e-09
lack O 0 2.4320511329278816e-06
immunochemically O 0 0.03652368485927582
detectable O 0 0.0017041844548657537
C5 O 0 0.0006665181135758758
. O 0 6.10969607350853e-07

By O 0 4.230847025610274e-06
hemolytic O 1 0.9221355319023132
assay O 0 6.777306225558277e-06
, O 0 1.832215090757927e-08
she O 0 1.127645887777362e-08
exhibited O 0 6.156029996873258e-08
1 O 0 5.748118070414421e-08
- O 0 4.630712524544833e-08
2 O 0 1.1959325085797445e-08
% O 0 7.038302718420653e-10
of O 0 5.927330848365386e-10
the O 0 2.1259896065828343e-09
normal O 0 5.6677944115790524e-08
serum O 0 3.666323777906655e-07
C5 O 0 2.201116558353533e-06
level O 0 2.0834550085169212e-08
and O 0 1.4345154231154567e-10
normal O 0 3.169769779987064e-09
concentrations O 0 3.6038565465190686e-09
of O 0 6.532711593898455e-10
other O 0 9.974061854212124e-11
complement O 0 1.645783065384876e-08
components O 0 2.074941249929907e-07
. O 0 1.2903413448839274e-07

C5 O 0 0.008495221845805645
levels O 0 8.923818199946254e-07
of O 0 1.3222175709870498e-07
other O 0 2.0720207771773858e-09
family O 0 1.4528030334304276e-08
members O 0 2.1311323539219273e-10
were O 0 1.992479514711931e-09
either O 0 2.9647342358885e-09
normal O 0 4.139368670053045e-08
or O 0 1.8889476649519565e-09
approximately O 0 4.0730316896997465e-09
half O 0 5.589197993316475e-09
- O 0 2.4329361636432623e-08
normal O 0 1.1053248982761943e-08
, O 0 9.516626375827286e-11
consistent O 0 4.385924512462225e-09
with O 0 4.320577229321998e-10
autosomal O 0 4.961912054568529e-07
codominant O 0 2.1689370441890787e-06
inheritance O 0 2.0790373866930167e-07
of O 0 5.4229666091032414e-08
the O 0 7.727402362434077e-08
gene O 0 4.851362405133841e-07
determining O 0 8.710422116564587e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.637493010610342e-06

Normal O 0 0.05790960043668747
hemolytic O 1 0.9999421834945679
titers O 0 0.0016386245843023062
were O 0 1.638279769622386e-07
restored O 0 1.6992919427138986e-07
to O 0 8.048844257757537e-09
both O 0 2.008743749115638e-08
homozygous O 0 1.8504215404391289e-06
C5 B-Disease 1 1.0
- I-Disease 1 0.9999969005584717
deficient I-Disease 1 1.0
( O 0 4.575568254949758e-06
C5D B-Disease 1 1.0
) O 0 9.008695656120835e-08
sera O 0 2.7856862061526044e-07
by O 0 3.637444234705356e-10
addition O 0 1.4046385166111008e-09
of O 0 8.707027099319475e-09
highly O 0 8.499948478402075e-08
purified O 0 4.847398940910352e-06
human O 0 8.233591870521195e-07
C5 O 0 0.00019212158804293722
. O 0 4.5424977201946604e-07

In O 0 6.806536703152233e-07
specific O 0 3.263114081164531e-07
C5 O 0 0.00039862460107542574
titrations O 0 3.0583694751840085e-05
, O 0 3.59393070858971e-09
however O 0 2.0059169880681793e-09
, O 0 4.2790629373179456e-10
it O 0 2.0098914199628837e-10
was O 0 1.5395167807241705e-08
noted O 0 5.4848476871427465e-09
that O 0 1.6775855704587173e-10
when O 0 5.653784662662531e-10
limited O 0 1.0773620884307888e-09
amounts O 0 4.962174227074456e-09
of O 0 7.520230838053976e-08
C5 O 0 7.251511306094471e-06
were O 0 1.2953528027992434e-08
assayed O 0 4.1349943558088853e-07
in O 0 5.684602233380076e-10
the O 0 9.570018111304535e-10
presence O 0 1.1074029471203062e-09
of O 0 7.977925875479741e-09
low O 0 1.0485989321296074e-07
dilutions O 0 1.5968302022884018e-06
of O 0 1.1295998803007024e-07
either O 0 6.239236540750426e-07
C5D B-Disease 1 1.0
serum O 0 6.623367517022416e-05
, O 0 2.1990722576248345e-09
curving O 0 4.008977683156445e-08
rather O 0 5.857694329591823e-10
than O 0 8.175898846829455e-11
linear O 0 2.3958555139813598e-09
dose O 0 5.822864412863282e-09
- O 0 2.987172287305384e-09
response O 0 3.9444492117013397e-10
plots O 0 3.931547087887566e-09
were O 0 3.589530617187364e-10
consistently O 0 1.6033584460117822e-09
obtained O 0 3.5567719880447157e-09
, O 0 4.4421272216155216e-10
suggesting O 0 6.055976164986987e-09
some O 0 1.784940306670535e-09
inhibitory O 0 2.3444900421054626e-07
effect O 0 3.645643786853725e-08
. O 0 7.293795079021947e-08

Further O 0 2.83041799775674e-07
studies O 0 1.1335441740811802e-07
suggested O 0 4.435045397599424e-08
that O 0 1.4039127638199034e-09
low O 0 1.4565493700047227e-07
dilutions O 0 1.2302562026889063e-05
of O 0 3.1667218536313158e-06
C5D B-Disease 1 1.0
serum O 0 1.6715572201064788e-05
contain O 0 2.6942583275513243e-08
a O 0 5.925774537729467e-09
factor O 0 6.905873206619617e-09
( O 0 1.4637241418924418e-10
or O 0 3.2483801759575215e-10
factors O 0 3.4007707760963513e-09
) O 0 5.779597911370615e-10
interfering O 0 1.7016084541410237e-08
at O 0 2.0666579558792364e-08
some O 0 4.798011987716677e-10
step O 0 1.4620794352993016e-08
in O 0 9.982655591045386e-09
the O 0 6.360110660352802e-08
hemolytic O 0 0.039382774382829666
assay O 0 1.079238427337259e-05
of O 0 2.126291292370297e-05
C5 O 0 0.34192466735839844
, O 0 2.39083397524098e-09
rather O 0 5.934279734276515e-09
than O 0 1.906953706054537e-09
a O 0 1.6563927118795618e-08
true O 0 2.774799270355288e-07
C5 O 0 2.4945906261564232e-05
inhibitor O 0 6.921343356225407e-07
or O 0 2.8140902941231616e-08
inactivator O 0 2.4575236238888465e-05
. O 0 9.95291202343651e-07

Of O 0 2.773740789052681e-06
clinical O 0 7.272031325555872e-06
interest O 0 7.714324823382412e-08
are O 0 9.622769248096574e-10
( O 0 2.0378010390231793e-09
a O 0 1.7924152162507312e-09
) O 0 3.8515404754413396e-10
the O 0 5.539315117708554e-10
documentation O 0 5.857979772372346e-07
of O 0 2.275995711897849e-06
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 0.0005453379708342254
vasculitis B-Disease 1 1.0
, O 0 4.797257702193747e-07
and O 0 3.044817503905506e-06
arthritis B-Disease 1 1.0
in O 0 1.3138402437107288e-06
an O 0 3.047328505090263e-07
individual O 0 4.790308594238013e-07
lacking O 0 9.848218905972317e-05
C5 O 0 0.001479204511269927
( O 0 2.2161433577139178e-08
and O 0 1.414419248391141e-09
its O 0 2.0216111007442805e-09
biologic O 0 1.749281750562659e-07
functions O 0 3.80299125524175e-09
) O 0 2.5364990663412357e-10
, O 0 4.212189971819491e-11
and O 0 1.8255226497121413e-10
( O 0 8.412493812670618e-09
b O 0 8.728580525030338e-08
) O 0 5.275541337113054e-09
a O 0 8.518755478803541e-09
remarkable O 0 2.649573218604928e-07
propensity O 0 1.8171335796068888e-06
to O 0 3.41088686184321e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.162060480121909e-08
the O 0 3.8557782744419455e-08
proband O 0 6.059503721189685e-05
, O 0 3.2837138563834856e-10
even O 0 1.6168699712437729e-10
during O 0 2.0163122282923496e-09
periods O 0 1.1156782164789547e-08
of O 0 2.3157660677952663e-08
low O 0 3.39277761440826e-08
- O 0 8.610791191188127e-09
dose O 0 6.930628071444289e-09
or O 0 2.7056828999505456e-10
alternate O 0 4.280305887505165e-09
- O 0 2.1327121402237026e-08
day O 0 3.558829675398556e-08
corticosteroid O 0 3.4439765386196086e-06
therapy O 0 4.906882168143056e-06
. O 0 1.6600687047230167e-07

Other O 0 9.673237144625091e-08
observations O 0 9.208178539665823e-07
indicate O 0 2.9307244631127105e-07
that O 0 2.667839948955475e-09
the O 0 5.4520686632031357e-08
C5D B-Disease 1 1.0
state O 0 1.3464477532920682e-08
is O 0 7.44134864838486e-10
compatible O 0 3.11517989182164e-09
with O 0 1.5296369726414127e-10
normal O 0 7.300559445866384e-08
coagulation O 0 3.512769808367011e-07
function O 0 3.037254714399751e-08
and O 0 2.830079504079208e-10
the O 0 5.185990747946789e-09
capacity O 0 2.726901371374879e-08
to O 0 1.3260635256528985e-08
mount O 0 4.42363707406912e-05
a O 0 2.037397734966362e-06
neutrophilic O 1 0.9964755177497864
leukocytosis O 0 0.005895163863897324
during O 0 6.87067176841083e-06
pyogenic B-Disease 0 0.16999171674251556
infection I-Disease 0 5.247002263786271e-06
. O 0 1.1458931581387333e-08
. O 0 6.166864352508128e-08

Susceptibility O 0 0.1491156816482544
to O 0 1.860829070210457e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 4.288678610464558e-05
twins O 0 6.616927294089692e-06
: O 0 4.985283297287424e-09
the O 0 4.975081679958748e-09
role O 0 1.9891579938757786e-08
of O 0 5.4450847386533496e-08
genes O 0 3.167529527559054e-08
, O 0 4.937881659117238e-09
HLA O 0 1.4043939700059127e-05
, O 0 2.1024475493902628e-09
and O 0 2.456726155841693e-09
the O 0 1.760891024105149e-07
environment O 0 3.8859298001625575e-06
. O 0 4.4959560341339966e-07

OBJECTIVE O 0 8.469561726087704e-05
To O 0 1.306922570165625e-08
determine O 0 1.4478652055061048e-08
the O 0 3.9031617937723695e-09
relative O 0 5.208655196042855e-08
effects O 0 7.900293041984696e-08
of O 0 1.972665764071735e-08
genetic O 0 5.2653909676791955e-08
and O 0 1.3170935175832454e-10
environmental O 0 9.600483075189459e-09
factors O 0 8.119092953506879e-09
in O 0 2.680821564737812e-09
susceptibility O 0 2.9682163926736393e-07
to O 0 2.631128666052973e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9973057508468628
AS B-Disease 1 0.9999973773956299
) O 0 1.8716467309332074e-07
. O 0 8.963737485601087e-08

METHODS O 0 0.00023546491865999997
Twins O 0 4.829453973798081e-05
with O 0 1.816618677707993e-08
AS B-Disease 0 0.029118258506059647
were O 0 2.2726649007154265e-08
identified O 0 1.1821392753574855e-08
from O 0 1.645741543043755e-09
the O 0 6.393190421505324e-09
Royal O 0 2.5742247089510784e-05
National O 0 1.1459298548288643e-05
Hospital O 1 0.6482253670692444
for O 0 1.6154467630258296e-07
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 1 0.9696404933929443
. O 0 2.1944576928945025e-06

Clinical O 0 0.0001914950116770342
and O 0 3.5548001875440605e-08
radiographic O 0 4.893125151284039e-06
examinations O 0 3.6775577427761164e-06
were O 0 2.9449763516709027e-08
performed O 0 7.797637202600072e-09
to O 0 7.756958408933201e-10
establish O 0 3.626267286449547e-08
diagnoses O 0 3.455744206348754e-07
, O 0 2.2979711467030484e-09
and O 0 3.44616490899341e-09
disease O 0 1.712810444587376e-06
severity O 0 4.297974953715311e-07
was O 0 6.34797956422517e-08
assessed O 0 1.3579143143260808e-08
using O 0 5.058903296273343e-10
a O 0 3.360712819144851e-10
combination O 0 6.335973967708242e-10
of O 0 2.0395898303604554e-09
validated O 0 4.7013575255050455e-08
scoring O 0 9.403023426557411e-08
systems O 0 8.676458378431562e-07
. O 0 1.862673997266029e-07

HLA O 0 0.0003329037281218916
typing O 0 7.967723831825424e-06
for O 0 7.805973467611693e-08
HLA O 0 7.564058250864036e-06
- O 0 3.6960940974495315e-07
B27 O 0 2.2063113647163846e-06
, O 0 8.925740146992212e-09
HLA O 0 7.172651521614171e-07
- O 0 4.6802604458662245e-08
B60 O 0 3.841464319975785e-07
, O 0 1.683041150890574e-09
and O 0 2.5579454110413735e-09
HLA O 0 1.794018317013979e-05
- O 0 4.609906682162546e-06
DR1 O 0 0.00036192283732816577
was O 0 4.4741376825641055e-08
performed O 0 4.207930004440641e-09
by O 0 1.0378294890145412e-09
polymerase O 0 1.6812364833640459e-07
chain O 0 7.081814246134854e-09
reaction O 0 1.7823165165964383e-10
with O 0 7.559076281582477e-11
sequence O 0 1.001454208449104e-08
- O 0 1.3244964236491796e-08
specific O 0 1.1962899559847529e-09
primers O 0 1.5300207323321047e-08
, O 0 9.329127470536491e-10
and O 0 1.1265081090172657e-09
zygosity O 0 9.691341347206617e-07
was O 0 1.1015789880275406e-07
assessed O 0 2.997001331550564e-07
using O 0 2.392930014138983e-07
microsatellite O 0 1.7489745005150326e-05
markers O 0 4.984262886864599e-06
. O 0 3.4100352763744013e-07

Genetic O 0 9.476648847339675e-05
and O 0 1.0231518743353263e-08
environmental O 0 6.00550507101616e-08
variance O 0 1.4469430986707721e-08
components O 0 2.5371258871587088e-08
were O 0 4.433157396732668e-09
assessed O 0 2.5647079127111283e-08
with O 0 4.749246551583042e-10
the O 0 6.78034117740367e-09
program O 0 4.029299560670552e-08
Mx O 0 1.179834725917317e-06
, O 0 1.1013989026364968e-10
using O 0 2.833071555130573e-10
data O 0 1.3587944103221616e-09
from O 0 1.0699749419806892e-10
this O 0 1.2519728309623446e-10
and O 0 1.7585975731204684e-10
previous O 0 9.163151126756475e-09
studies O 0 1.6369671840266165e-08
of O 0 1.965222651278964e-08
twins O 0 2.0703416225842375e-07
with O 0 1.6512164080495495e-08
AS B-Disease 1 0.9999982118606567
. O 0 3.701434707181761e-06

RESULTS O 0 8.092956704786047e-06
Six O 0 5.542997882912459e-07
of O 0 4.192682752091059e-07
8 O 0 2.6776806407724507e-06
monozygotic O 0 0.00016791719826869667
( O 0 1.3403706361714285e-05
MZ O 1 0.9999774694442749
) O 0 7.811603808249856e-08
twin O 0 6.336100000225997e-07
pairs O 0 1.606506039308897e-08
were O 0 5.663720159532204e-08
disease O 0 3.3349178920616396e-06
concordant O 0 4.234370408084942e-06
, O 0 3.1181344173347725e-09
compared O 0 3.910241019866589e-09
with O 0 1.3309425783702977e-10
4 O 0 1.946889049975198e-08
of O 0 2.67385225072303e-08
15 O 0 1.9180513177730063e-08
B27 O 0 7.84385122187814e-07
- O 0 2.3691509909440356e-07
positive O 0 4.145215370954247e-08
dizygotic O 0 4.9457910790806636e-05
( O 0 4.1816176121756143e-07
DZ O 0 0.002662590006366372
) O 0 5.5761784523156166e-08
twin O 0 3.1267720146388456e-07
pairs O 0 1.2902165558159595e-08
( O 0 4.760621674648746e-09
27 O 0 3.102427115209139e-08
% O 0 4.6568566780536e-09
) O 0 6.24555296369067e-10
and O 0 8.579982280210174e-10
4 O 0 4.1055820076962846e-08
of O 0 3.1167630254458345e-07
32 O 0 6.216469046194106e-06
DZ O 1 0.9999721050262451
twin O 0 1.3460618902172428e-05
pairs O 0 5.5507427987322444e-08
overall O 0 2.728270374063868e-07
( O 0 7.333366802697583e-09
12 O 0 5.110363687776953e-09
. O 0 2.6909069417158094e-10
5 O 0 8.081487479216776e-09
% O 0 4.898342620407448e-09
) O 0 4.981538292980758e-09
. O 0 3.609003584870152e-08

Nonsignificant O 0 0.0040575857274234295
increases O 0 2.697776153581799e-07
in O 0 6.964179455337671e-09
similarity O 0 1.3796456421744097e-08
with O 0 9.689972435555916e-11
regard O 0 7.592014128476876e-09
to O 0 9.187927640930127e-10
age O 0 1.6013352421850868e-07
at O 0 1.102438363886904e-05
disease O 0 2.5192917746608146e-05
onset O 0 8.858858200255781e-05
and O 0 1.9809476281551497e-10
all O 0 1.2892066580949546e-10
of O 0 1.89266957661971e-09
the O 0 3.4857428055090622e-09
disease O 0 8.147637231559202e-09
severity O 0 2.0316845983359144e-09
scores O 0 5.239198519468857e-10
assessed O 0 1.070055044571916e-09
were O 0 5.131223779208938e-10
noted O 0 1.1664936794275604e-09
in O 0 2.7673077163115067e-09
disease O 0 4.0492236053069064e-07
- O 0 2.591187012512819e-06
concordant O 0 0.0002967816253658384
MZ O 1 0.9906534552574158
twins O 0 1.3262756510812324e-06
compared O 0 8.453739042124653e-08
with O 0 7.878034224972907e-09
concordant O 0 0.00024995525018312037
DZ O 1 0.9986396431922913
twins O 0 6.630698771914467e-05
. O 0 1.7852837572718272e-06

HLA O 0 0.2333880513906479
- O 0 3.882651435560547e-05
B27 O 0 3.053465479752049e-05
and O 0 2.5940197545537558e-08
B60 O 0 2.738274588409695e-06
were O 0 1.0279050499661935e-08
associated O 0 1.2167993723721793e-08
with O 0 5.161289173827299e-10
the O 0 9.861390992682573e-08
disease O 0 9.040295481099747e-06
in O 0 1.514568026550478e-08
probands O 0 0.0019040401093661785
, O 0 9.788411192701574e-10
and O 0 1.580204855855527e-10
the O 0 1.7909388416725847e-09
rate O 0 1.508600000477145e-08
of O 0 6.877257430204509e-09
disease O 0 1.4723279662121058e-07
concordance O 0 1.778430771537387e-07
was O 0 2.0946675505228995e-08
significantly O 0 2.052495506887908e-09
increased O 0 7.335198670688214e-09
among O 0 4.18450341044263e-09
DZ O 0 0.0005924340221099555
twin O 0 5.298106771078892e-07
pairs O 0 4.666815378584488e-09
in O 0 1.0773744119063622e-09
which O 0 1.5393920860251598e-10
the O 0 3.629075040478824e-09
co O 0 2.7982136430182436e-07
- O 0 1.582191515581144e-07
twin O 0 2.5643541334829933e-07
was O 0 2.3074461452665673e-08
positive O 0 1.0061751432033361e-09
for O 0 1.4011573012950862e-09
both O 0 7.791260081546625e-09
B27 O 0 1.0530929102969822e-05
and O 0 3.673305855045328e-07
DR1 O 1 0.959376335144043
. O 0 1.5855009678489296e-06

Additive O 0 3.9048950384312775e-06
genetic O 0 1.7424335396754032e-07
effects O 0 7.608078789189676e-08
were O 0 6.487257397935764e-09
estimated O 0 1.667801452498452e-09
to O 0 1.3551547384249574e-10
contribute O 0 3.0129041483917263e-09
97 O 0 1.1232030061592013e-07
% O 0 5.843299732966045e-10
of O 0 2.3036487994954058e-10
the O 0 4.0257927547138195e-10
population O 0 1.3871907789120286e-10
variance O 0 6.090925541712977e-09
. O 0 1.9821058572233596e-08

CONCLUSION O 0 9.0661364083644e-05
Susceptibility O 0 3.6091372749069706e-05
to O 0 2.3718088826285566e-08
AS B-Disease 0 0.0032390898559242487
is O 0 4.588613045086731e-09
largely O 0 1.5511240292198636e-08
genetically O 0 5.200628261370355e-10
determined O 0 4.070950243573179e-09
, O 0 1.1285204021271866e-10
and O 0 6.890853859742307e-11
the O 0 1.6991169582425414e-09
environmental O 0 9.579885329458193e-09
trigger O 0 3.2622093915080086e-09
for O 0 2.1894701329738808e-10
the O 0 2.5686736293550894e-08
disease O 0 3.6350320442579687e-06
is O 0 4.221169636053901e-09
probably O 0 2.4617094140921836e-07
ubiquitous O 0 1.3858865486326977e-06
. O 0 1.1882976735932971e-07

HLA O 0 0.01893273927271366
- O 0 1.3694409062736668e-05
B27 O 0 8.7922408056329e-06
accounts O 0 2.6154021171009845e-08
for O 0 1.2569383311955562e-09
a O 0 6.6665442055580115e-09
minority O 0 1.7410199948386662e-09
of O 0 4.707043643747966e-09
the O 0 9.718950089165901e-09
overall O 0 5.130720523993659e-07
genetic O 0 7.117620839380834e-07
susceptibility O 0 2.7354454346095736e-07
to O 0 4.9295369564106295e-08
AS B-Disease 1 0.9997825026512146
. O 0 2.098531922456459e-06

Cell O 0 0.0006654402823187411
cycle O 0 1.6267063983832486e-05
- O 0 3.3251808417844586e-06
dependent O 0 5.597927383860224e-07
colocalization O 0 4.361602350400062e-06
of O 0 2.4049845137597003e-07
BARD1 O 0 0.008656944148242474
and O 0 1.9924881300426023e-08
BRCA1 O 0 6.838920540985782e-08
proteins O 0 1.7765272586345304e-09
in O 0 1.1687630863121967e-09
discrete O 0 5.3720278003766e-08
nuclear O 0 3.068718797294423e-06
domains O 0 8.218770744861104e-06
. O 0 5.842135237799084e-07

Germ O 1 0.999902606010437
- O 0 7.397514855256304e-05
line O 0 5.595461516350042e-07
mutations O 0 1.3602317494587624e-08
of O 0 9.530350730813097e-09
the O 0 5.433392757936417e-08
BRCA1 O 0 5.0072708290827e-07
gene O 0 1.526039383747957e-08
predispose O 0 5.5948326860288944e-08
women O 0 3.476876841990162e-10
to O 0 5.177064332784198e-10
early O 0 2.662354461335781e-07
- O 0 5.212028918322176e-05
onset O 1 0.9999992847442627
breast B-Disease 1 0.9999997615814209
and I-Disease 0 0.3756691813468933
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 9.07024713114879e-08
compromising O 0 3.6609537801268743e-06
the O 0 3.236423040675618e-08
genes O 0 1.496483292839912e-08
presumptive O 0 2.519346935514477e-07
function O 0 9.023206182234844e-09
as O 0 4.5531476366988954e-09
a O 0 1.1328870641591493e-07
tumor B-Disease 0 2.673354174476117e-05
suppressor O 0 2.4793502234388143e-05
. O 0 2.5608815690247866e-07

Although O 0 2.769569960037188e-07
the O 0 8.659828409918191e-08
biochemical O 0 1.1637856914603617e-05
properties O 0 4.2433366616023704e-06
of O 0 9.061071182259184e-07
BRCA1 O 0 6.262312126636971e-07
polypeptides O 0 6.249347705988839e-08
are O 0 1.3493901829253474e-10
not O 0 1.575708313827917e-10
understood O 0 8.731107392634385e-09
, O 0 3.790417701932114e-10
their O 0 4.761472882641726e-10
expression O 0 3.611108745360525e-09
pattern O 0 9.494752539751516e-09
and O 0 9.809811851724248e-10
subcellular O 0 1.0190257853537332e-05
localization O 0 3.4423871966282604e-06
suggest O 0 1.616060885112347e-08
a O 0 4.8920871797975e-09
role O 0 1.2435255491993757e-08
in O 0 7.658845113667212e-09
cell O 0 2.272800657010521e-06
- O 0 7.81689379891759e-07
cycle O 0 6.057802693248959e-06
regulation O 0 5.774138003289409e-07
. O 0 1.3034241419518366e-07

When O 0 3.2537093375140103e-06
resting O 0 0.00014279507740866393
cells O 0 3.6120929962635273e-06
are O 0 3.6825702487419676e-09
induced O 0 1.6312486650349456e-07
to O 0 1.5432676248039456e-09
proliferate O 0 5.521409107700492e-08
, O 0 9.422691515936776e-10
the O 0 6.18809492536343e-09
steady O 0 7.854885097913211e-07
- O 0 5.339520381397733e-09
state O 0 3.5323841074408335e-10
levels O 0 1.2163764440131786e-09
of O 0 1.4588695806949659e-09
BRCA1 O 0 1.629076762377224e-09
increase O 0 1.268926352882005e-10
in O 0 2.982968871911851e-10
late O 0 7.865637030590733e-08
G1 O 0 1.508970512986707e-06
and O 0 4.531770791960099e-10
reach O 0 5.182035689443865e-09
a O 0 1.201609256540337e-09
maximum O 0 6.8233347860768845e-09
during O 0 3.8032617055705487e-08
S O 0 1.3797385918223881e-06
phase O 0 2.577935902081663e-06
. O 0 3.8879068142705364e-07

Moreover O 0 3.7422453260660404e-06
, O 0 1.0569396913240325e-08
in O 0 2.1880781631011814e-08
S O 0 1.2927939678775147e-06
phase O 0 1.649839646233886e-06
cells O 0 1.0060394970423658e-06
, O 0 4.2246655063138405e-09
BRCA1 O 0 3.3592741033317e-08
polypeptides O 0 3.805111958854468e-08
are O 0 5.417295501075614e-10
hyperphosphorylated O 0 4.236561892412283e-07
and O 0 1.7929007167793998e-09
accumulate O 0 1.2484335343287967e-07
into O 0 5.000580571845603e-08
discrete O 0 1.0153938774237758e-06
subnuclear O 0 1.2838953807658982e-05
foci O 0 9.299285920860711e-06
termed O 0 7.206680834315193e-07
" O 0 4.0307912740900065e-07
BRCA1 O 0 1.1226679816900287e-06
nuclear O 0 3.866630322590936e-06
dots O 0 4.193380846118089e-06
. O 0 6.12039173120138e-07

" O 0 1.4062782611290459e-05
BRCA1 O 0 3.686518539325334e-05
associates O 0 9.697871973912697e-06
in O 0 3.2536235039515304e-08
vivo O 0 8.217612617045233e-07
with O 0 1.5451643298192153e-09
a O 0 1.1407678357500117e-07
structurally O 0 4.291509867471177e-06
related O 0 1.0148187357117422e-06
protein O 0 6.558499990205746e-06
termed O 0 1.866288403107319e-05
BARD1 O 1 0.9828405380249023
. O 0 3.8084410789451795e-06

Here O 0 1.0504821830181754e-06
we O 0 1.916592040629439e-08
show O 0 1.8465643236709184e-08
that O 0 2.778423324745205e-10
the O 0 6.847480360505642e-09
steady O 0 2.0438801584532484e-06
- O 0 3.38827632617722e-08
state O 0 6.381527528631636e-10
levels O 0 3.2184095388743117e-09
of O 0 5.3999884563893374e-09
BARD1 O 0 6.602676876354963e-05
, O 0 4.794124541795952e-10
unlike O 0 6.500308624701745e-10
those O 0 1.3657468211913937e-10
of O 0 4.229720573789564e-09
BRCA1 O 0 1.11407478797787e-08
, O 0 8.907924398116052e-11
remain O 0 2.481232552753454e-09
relatively O 0 1.5774201944651622e-09
constant O 0 1.3992138114815589e-08
during O 0 3.4256082415140554e-08
cell O 0 7.038644298518193e-07
cycle O 0 2.144068957932177e-06
progression O 0 5.448577212519012e-06
. O 0 1.2359946310880332e-07

However O 0 3.454825446169707e-06
, O 0 2.529878315726819e-07
immunostaining O 0 0.00010940431820927188
revealed O 0 8.167022315319628e-06
that O 0 1.486029503894315e-07
BARD1 O 0 0.2668900191783905
resides O 0 1.3072713954898063e-05
within O 0 4.7682121362413454e-07
BRCA1 O 0 4.1618690715949924e-07
nuclear O 0 1.731840598040435e-06
dots O 0 1.7541914587582141e-07
during O 0 1.0440108866305309e-07
S O 0 4.817214289687399e-07
phase O 0 1.1244976860780298e-07
of O 0 1.4666263759011144e-08
the O 0 6.308507050079015e-09
cell O 0 8.471850776459178e-08
cycle O 0 9.210882723209579e-09
, O 0 5.877175829338555e-11
but O 0 4.688804206010033e-11
not O 0 1.3122690434297368e-10
during O 0 1.8411553170949446e-08
the O 0 9.510270615464833e-08
G1 O 0 2.0141118511673994e-05
phase O 0 2.700952563827741e-06
. O 0 4.80528910884459e-07

Nevertheless O 0 6.92194516886957e-05
, O 0 2.764651014786068e-07
BARD1 O 0 0.00032219619606621563
polypeptides O 0 8.997565714707889e-07
are O 0 9.421721181013254e-10
found O 0 1.0485420309791493e-09
exclusively O 0 1.2076526445525815e-08
in O 0 2.210654104217724e-09
the O 0 4.284520738195852e-09
nuclear O 0 1.5375515260984685e-07
fractions O 0 7.421539294227841e-08
of O 0 2.7859508477945383e-08
both O 0 2.0861739002953072e-09
G1 O 0 5.148561967871501e-07
- O 0 9.166786441028307e-09
and O 0 1.3382949193285754e-09
S O 0 4.7650664214415883e-07
- O 0 6.217484838089149e-08
phase O 0 8.63956586272252e-07
cells O 0 8.519398875250772e-07
. O 0 1.790673849200175e-07

Therefore O 0 6.741450420122419e-07
, O 0 1.5671886899326637e-08
progression O 0 4.2792635213118047e-07
to O 0 5.578441264475487e-09
S O 0 5.614710971713066e-07
phase O 0 1.928907664705548e-07
is O 0 1.7679211428145436e-09
accompanied O 0 6.761589066428542e-09
by O 0 4.1528719352257326e-10
the O 0 1.5926145957578797e-09
aggregation O 0 9.608433160224195e-09
of O 0 1.7784538286491625e-08
nuclear O 0 1.9087651708105113e-06
BARD1 O 0 0.0034140017814934254
polypeptides O 0 1.736168201205146e-06
into O 0 9.566723946363709e-08
BRCA1 O 0 5.039848929300206e-07
nuclear O 0 2.5386518700543093e-06
dots O 0 3.8292623685265426e-06
. O 0 4.2349137174824136e-07

This O 0 8.106026712084713e-07
cell O 0 1.6269168554572389e-06
cycle O 0 9.08711911051796e-07
- O 0 1.167091568277101e-06
dependent O 0 7.064535338940914e-07
colocalization O 0 7.4891781878250185e-06
of O 0 4.7205503506120294e-07
BARD1 O 0 0.0035278054419904947
and O 0 2.6952863052542853e-08
BRCA1 O 0 1.3666530662703735e-07
indicates O 0 2.2750935357862545e-08
a O 0 3.3684153244450954e-09
role O 0 7.822514191957453e-09
for O 0 9.88191040107722e-09
BARD1 O 0 0.0017981610726565123
in O 0 1.6417456549788767e-07
BRCA1 O 0 2.3479365154344123e-06
- O 0 7.214387096610153e-06
mediated O 0 4.787441503140144e-05
tumor B-Disease 0 0.006736417766660452
suppression O 0 1.1073570021835621e-05
. O 0 2.444810434099054e-07

Ethnic O 0 1.0719737701947452e-06
differences O 0 4.670665134653973e-07
in O 0 8.397797301995524e-08
the O 0 4.989462354387797e-07
HFE O 0 0.0006551179103553295
codon O 0 4.678913683164865e-06
282 O 0 4.126274689042475e-06
( O 0 7.733519851171877e-07
Cys O 0 0.04802907258272171
/ O 0 2.38488610193599e-05
Tyr O 0 5.972293365630321e-05
) O 0 1.0803426420125106e-07
polymorphism O 0 1.1051889714508434e-06
. O 0 1.6185401818802347e-07

Recent O 0 2.6081994519699947e-07
studies O 0 3.7844689160237976e-08
have O 0 6.325444057431184e-10
shown O 0 7.151421232975963e-09
that O 0 8.86197781824194e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 1.0
HH B-Disease 1 1.0
) O 0 1.3234640050541202e-07
is O 0 2.1438493202907694e-09
likely O 0 7.89679099888474e-10
to O 0 7.623658371258557e-10
be O 0 2.845973678944347e-09
caused O 0 3.6274297343652506e-08
by O 0 5.88663917611143e-09
homozygosity O 0 3.8340967876138166e-06
for O 0 1.1472009120438997e-08
a O 0 7.94276502347202e-08
Cys282Tyr O 0 1.3749594472756144e-05
mutation O 0 9.755277474710056e-09
in O 0 3.8726102324915246e-09
the O 0 1.1930372068036377e-07
HFE O 0 0.022763026878237724
gene O 0 2.3379882918561634e-07
located O 0 2.7025916438105924e-07
4 O 0 3.968121973230154e-07
. O 0 2.1404066785635223e-07

5 O 0 5.4098454711493105e-05
Mb O 0 0.0005915561341680586
telomeric O 0 0.00011366341641405597
to O 0 7.716965342297044e-07
HLA O 0 0.00024176535953301936
- O 0 6.434795977838803e-06
A O 0 3.4101890378224198e-06
. O 0 3.456086972164485e-07

Population O 0 4.7779440848216836e-08
studies O 0 8.642992987972775e-09
of O 0 2.8022251186143876e-09
this O 0 6.945181096895681e-10
polymorphism O 0 2.7284100312385817e-08
are O 0 1.4701735662203674e-10
facilitated O 0 1.087169820834788e-08
by O 0 5.77361491949091e-10
the O 0 1.6435519611945892e-09
fact O 0 2.2564836665850407e-09
that O 0 2.2344941175145294e-10
the O 0 7.837987148207048e-09
Cys282Tyr O 0 1.7159974959213287e-05
mutation O 0 2.161295498126492e-08
creates O 0 2.853280101078326e-08
a O 0 4.178021484335659e-08
Rsal O 0 2.0252482499927282e-05
restriction O 0 1.2582803776695073e-07
site O 0 4.3595420606834523e-07
. O 0 9.810193546400114e-08

We O 0 1.7653820805207943e-07
have O 0 3.2550306894307823e-09
studied O 0 3.950529503526923e-08
the O 0 3.337833476280139e-08
codon O 0 2.2501244245631824e-07
282 O 0 3.0103041126494645e-07
( O 0 1.2580859731770033e-07
Cys O 0 0.006454814225435257
/ O 0 6.473647317761788e-06
Tyr O 0 6.87137981003616e-06
) O 0 2.731069148609322e-09
polymorphism O 0 4.6937929099044595e-09
in O 0 9.778217818778856e-11
different O 0 1.1588864590184045e-10
ethnic O 0 4.340022563553703e-09
groups O 0 2.9476048268861632e-09
. O 0 4.7972850580890736e-08

In O 0 5.879903142158582e-07
agreement O 0 1.2295848250687413e-07
with O 0 4.506036876961161e-09
previous O 0 1.156743820729389e-07
observations O 0 4.956979182679788e-07
the O 0 4.341912074323773e-08
Tyr O 0 6.830747679487104e-06
allele O 0 1.1568845437182063e-08
appeared O 0 4.587825230828457e-09
to O 0 3.673042425766937e-10
be O 0 1.8782415622808912e-09
rare O 0 7.5226385121141e-09
or O 0 1.339097366326314e-08
absent O 0 1.9797829509116127e-07
in O 0 2.1761204394010747e-08
Asiatic O 0 1.1756557796616107e-05
( O 0 4.708931911068248e-08
Indian O 0 2.1609868383620778e-07
, O 0 2.680749844330421e-09
Chinese O 0 7.743528840364888e-08
) O 0 3.4028728723711765e-09
populations O 0 3.1876190575985675e-09
. O 0 2.2084467588001644e-08

The O 0 1.4272866337705636e-06
highest O 0 4.867843017564155e-07
allele O 0 1.3283064426161673e-08
frequency O 0 1.0505123881898726e-08
( O 0 1.7791518258647443e-09
7 O 0 3.4627289924316074e-09
. O 0 1.3468573478725432e-10
5 O 0 1.062817833741292e-09
% O 0 2.558022127452375e-10
) O 0 1.2631623524939073e-10
was O 0 2.3352901834527984e-09
found O 0 1.164608520731747e-09
in O 0 8.858357603003242e-09
Swedes O 0 2.260602286696667e-06
. O 0 6.059237307454168e-07

Saamis O 0 0.0015133360866457224
( O 0 3.343543539813254e-07
2 O 0 1.3014640387609688e-07
% O 0 9.489574459564665e-09
) O 0 1.2308531971427783e-09
and O 0 1.0202905187384204e-09
Mordvinians O 0 2.763177235465264e-06
( O 0 6.97925939263655e-09
1 O 0 4.398474029443378e-09
. O 0 2.1553447915323432e-10
8 O 0 4.57653381857881e-09
% O 0 7.19670933957417e-10
) O 0 1.1854593695570514e-10
had O 0 4.333038927661903e-10
significantly O 0 1.3336088899862375e-09
lower O 0 4.130801478652302e-09
frequencies O 0 6.4973497693188165e-09
of O 0 1.3704975820871823e-08
the O 0 7.226977771779275e-08
Tyr O 0 3.708927761181258e-05
allele O 0 3.830994046438718e-07
. O 0 1.7625660575504298e-07

Comparisons O 0 6.321035925793694e-07
with O 0 5.431058713867287e-09
allele O 0 2.5709772089044236e-08
frequencies O 0 7.621307140937006e-09
based O 0 3.0840592302183722e-09
on O 0 7.14769843312979e-09
prevalence O 0 1.6219829035435396e-07
estimates O 0 1.9464659217760527e-08
of O 0 7.082439168470955e-08
HH B-Disease 1 0.9999977350234985
showed O 0 7.42144052878757e-08
some O 0 4.549655374663786e-10
disagreements O 0 1.8838898441231322e-08
with O 0 3.34121896816697e-10
the O 0 8.411563001686773e-09
RFLP O 0 4.376050242171914e-07
data O 0 6.678545272365e-09
, O 0 2.687219335939517e-10
particularly O 0 2.055688286262125e-09
in O 0 6.512834715977078e-09
Finns O 0 1.7918439425557153e-06
. O 0 2.868302715341997e-07

The O 0 1.560494411023683e-06
newly O 0 5.214940756559372e-06
described O 0 9.007832886709366e-06
HFE O 1 0.8782397508621216
marker O 0 2.1737328097515274e-06
provides O 0 2.1641128000737808e-08
a O 0 1.356670886742961e-09
new O 0 3.056417341440465e-10
approach O 0 3.386465774468661e-09
to O 0 2.941245857979169e-10
the O 0 2.281715261176487e-09
screening O 0 4.553503796245195e-09
of O 0 8.97997765036962e-08
HH B-Disease 1 0.9999983310699463
as O 0 1.910849478647947e-09
well O 0 3.436750328766891e-10
as O 0 3.811878035442362e-10
studies O 0 3.0833415820552545e-09
of O 0 3.569541995318559e-09
the O 0 8.36302760376384e-09
relationship O 0 5.599465779937418e-08
between O 0 8.593026734615705e-08
the O 0 3.5428641353973944e-07
HFE O 1 0.7020102739334106
Tyr O 0 2.4903263692976907e-05
allele O 0 7.348039954280239e-09
and O 0 2.87593004966169e-10
different O 0 4.721556479125866e-09
disorders O 0 0.04224026948213577
including O 0 8.499301657138858e-06
cancer B-Disease 1 0.9999998807907104

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.99998939037323
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999995231628418
associated O 0 1.6230241328685224e-07
with O 0 3.478430654624276e-09
a O 0 3.7309877853886064e-08
missense O 0 2.703870336517866e-07
mutation O 0 6.14831741074795e-09
encoding O 0 1.9375390181153307e-08
Gly23 O 0 4.793269908986986e-06
- O 0 3.598807325033704e-06
- O 0 1.0569836376816966e-05
> O 0 8.702647392055951e-06
Val O 0 1.0154113624594174e-05
in O 0 1.3173593060855637e-07
neurophysin O 0 0.00010354874393669888
II O 1 0.9696849584579468
. O 0 1.8921922446679673e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999946355819702
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.00035990128526464105
ADNDI B-Disease 1 1.0
) O 0 1.3879946436645696e-07
is O 0 9.761103036964869e-09
an O 0 1.4323178731956432e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.8342573046684265
by O 0 7.638830652467732e-07
progressive O 1 0.9999117851257324
degeneration O 1 0.9999985694885254
of O 0 4.5729544240202813e-07
the O 0 3.097383967087808e-07
magnocellular O 0 0.0007498893537558615
neurons O 0 6.277572310864343e-07
of O 0 2.7308725947250423e-08
the O 0 7.979207339303684e-08
hypothalamus O 0 3.823850420303643e-06
leading O 0 3.845899598786673e-08
to O 0 3.1148710277761893e-09
decreased O 0 3.518862001783418e-07
ability O 0 7.909080501633525e-09
to O 0 2.045511315884596e-09
produce O 0 5.620435228337328e-09
the O 0 4.255334218328244e-08
hormone O 0 9.950874613195992e-08
arginine O 0 3.6793218782804615e-07
vasopressin O 0 3.3482916705906973e-07
( O 0 2.1918122428132847e-08
AVP O 0 4.306038590584649e-06
) O 0 7.833533821610672e-09
. O 0 2.5345478604776872e-08

Affected O 0 8.573288710067573e-07
individuals O 0 3.2756644063880458e-09
are O 0 4.1963782448917186e-10
not O 0 2.3039004037883615e-09
symptomatic O 0 1.2035810641464195e-06
at O 0 6.345648557726236e-07
birth O 0 4.535969821972685e-07
, O 0 9.375596965455202e-10
but O 0 9.40902467050364e-10
usually O 0 1.3603354886981833e-08
develop O 0 2.463917780914926e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9999217987060547
at O 0 1.0885893061640672e-05
1 O 0 1.0899364042415982e-06
- O 0 9.8395094028092e-07
6 O 0 8.149713153215998e-07
yr O 0 1.5736392015242018e-05
of O 0 9.327357020083582e-08
age O 0 5.670843279403925e-07
. O 0 2.1680715178717946e-07

The O 0 1.8302542912351782e-06
genetic O 0 7.371902938757557e-06
locus O 0 1.0280264177708887e-06
of O 0 4.3892573131643076e-08
the O 0 1.1146151024377104e-07
disease O 0 6.722384569002315e-06
is O 0 7.654318068262e-09
the O 0 3.1668170663579076e-07
AVP O 0 0.000867697352077812
- O 0 2.5951512725441717e-06
neurophysin O 0 3.0410679755732417e-05
II O 1 0.6515021324157715
( O 0 3.130662946659868e-07
NPII O 0 0.0008488759049214423
) O 0 8.066888490532165e-09
gene O 0 1.1746205119678166e-09
, O 0 1.1396147914233268e-10
and O 0 1.9692053543352017e-10
mutations O 0 4.273958964517988e-09
that O 0 5.455037532797746e-10
cause O 0 3.3084495498769684e-07
ADNDI B-Disease 1 0.9999489784240723
have O 0 7.362471743377341e-10
been O 0 6.592417722828259e-10
found O 0 1.6316942241800803e-10
in O 0 5.0670221490856093e-11
both O 0 1.0292851293502991e-10
the O 0 2.8236861737696017e-09
signal O 0 4.043079826487883e-08
peptide O 0 2.8027931975316278e-08
of O 0 2.432783041683706e-08
the O 0 8.530872719347826e-08
prepro O 0 0.00010908814874710515
- O 0 0.0003916409332305193
AVP O 0 0.3007691502571106
- O 0 1.3534504432755057e-05
NPII O 0 0.0009893312817439437
precursor O 0 2.3121351659938227e-06
and O 0 1.1739111016595416e-08
within O 0 2.2608925576150796e-07
NPII O 0 0.000500594440381974
itself O 0 8.327183422807138e-07
. O 0 6.581166758223844e-07

An O 0 1.1895850775545114e-06
affected O 0 1.580118151878196e-07
girl O 0 1.4715110410179477e-06
who O 0 6.625144877148159e-09
presented O 0 1.1918044862113675e-07
at O 0 1.3657765975949587e-06
9 O 0 1.1419783163546526e-07
months O 0 1.1410296707481393e-08
of O 0 7.2854633437202665e-09
age O 0 4.452004986887914e-08
and O 0 1.1216990669637994e-09
her O 0 8.551852559435247e-09
similarly O 0 6.674177654986124e-09
affected O 0 3.2983409337106195e-09
younger O 0 5.348224974000004e-09
brother O 0 6.336402691431431e-08
and O 0 1.3859273728655808e-09
father O 0 6.66709283336786e-08
were O 0 3.492244937675082e-09
all O 0 2.449052072250879e-10
found O 0 5.702542882346506e-10
to O 0 1.512153458005372e-10
have O 0 1.163843951768051e-10
a O 0 2.8775499760769208e-09
novel O 0 1.6068339547814503e-08
missense O 0 4.3484430278795116e-08
mutation O 0 4.1550113349941853e-10
( O 0 3.7083236481549875e-10
G1758 O 0 3.3477800087666765e-08
- O 0 9.347446194851727e-08
- O 0 7.663450105610536e-07
> O 0 7.1724804229234e-07
T O 0 1.1181754189237836e-07
) O 0 6.038061162172426e-10
encoding O 0 4.934846975501728e-10
the O 0 9.139355383602776e-10
amino O 0 5.4076356725829555e-09
acid O 0 4.642259465725829e-09
substitution O 0 2.524893183419863e-08
Gly23 O 0 6.663331987510901e-06
- O 0 5.718794454878662e-06
- O 0 1.6507101463503204e-05
> O 0 1.3505739843822084e-05
Val O 0 1.6702218999853358e-05
within O 0 2.523001967347227e-06
NPII O 0 0.0046911416575312614
. O 0 1.9728593088075286e-06

The O 0 2.342901325391722e-06
mutation O 0 1.383841805591146e-07
was O 0 6.795776386070429e-08
confirmed O 0 8.009624075100419e-09
by O 0 4.873033088159673e-09
restriction O 0 6.177436517873502e-08
endonuclease O 0 1.8851533241104335e-06
analysis O 0 2.8563957243932236e-07
. O 0 1.300061143183484e-07

A O 0 0.00012498484284151345
T1 O 0 0.0029204501770436764
- O 0 1.2897191936644958e-06
weighted O 0 1.8638468191056745e-07
magnetic O 0 2.365155182815215e-07
resonance O 0 2.165839561030225e-07
imaging O 0 3.690359733354853e-07
of O 0 7.544338131992845e-08
the O 0 5.396524898060306e-07
fathers O 0 0.006803206633776426
pituitary O 0 0.019542546942830086
gland O 0 3.852092049783096e-06
demonstrates O 0 2.1634674851611635e-07
an O 0 3.165916950820247e-08
attenuated O 0 8.47675710247131e-06
posterior O 0 2.0212733943480998e-05
pituitary O 0 2.7172576665179804e-05
bright O 0 2.533504812163301e-06
spot O 0 1.041156610881444e-05
. O 0 1.7290333289565751e-06

This O 0 6.207626057630478e-08
mutation O 0 8.279953611634028e-09
may O 0 1.4512181456538542e-09
be O 0 2.4852100932726273e-10
valuable O 0 1.459972676087773e-08
for O 0 9.097302355876025e-10
developing O 0 9.527406419351792e-09
models O 0 1.3603977500054043e-08
of O 0 1.4014592863986763e-07
dominantly B-Disease 1 0.9997356534004211
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 2.600846471523255e-08
as O 0 7.938244506178194e-10
the O 0 8.762567338393978e-10
early O 0 3.4460201359109988e-09
age O 0 2.069505811164163e-08
of O 0 9.181348303854975e-08
onset O 0 0.12798605859279633
of O 0 1.7344008256259258e-06
symptoms O 0 0.0014959992840886116
suggests O 0 2.533151928219013e-07
that O 0 2.476182314747888e-10
this O 0 2.237496438128872e-10
mutation O 0 5.836438554673862e-10
may O 0 2.1853897858026272e-10
be O 0 3.0143856855069373e-10
particularly O 0 2.6504634043078568e-09
deleterious O 0 7.213385089244184e-08
to O 0 1.0901661795514883e-08
the O 0 2.8052514267074e-07
magnocellular O 0 0.00031573628075420856
neuron O 0 1.8811964764609e-05
. O 0 5.395285995746235e-08
. O 0 1.467820567313538e-07

Frequent O 0 5.354144377633929e-06
inactivation O 0 3.735949212568812e-05
of O 0 8.188019273802638e-05
PTEN O 1 1.0
/ O 1 0.9997135996818542
MMAC1 O 1 0.9999991655349731
in O 0 2.528776121835108e-06
primary O 1 0.9999969005584717
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.529662353685126e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 8.108975180221023e-08
the O 0 9.684106849761065e-09
most O 0 4.677025433608151e-10
common O 0 1.3848967528318212e-09
male B-Disease 0 3.640807832994142e-08
cancer I-Disease 0 1.024968288021455e-08
in O 0 1.4816625704128228e-09
the O 0 5.871175989824451e-09
Western O 0 2.2599735416406475e-08
world O 0 1.725485754278111e-09
, O 0 1.0792002014259339e-10
yet O 0 1.676606770084632e-10
many O 0 1.4908288145654147e-11
of O 0 2.4452059821378214e-10
the O 0 6.132679364334592e-10
major O 0 9.321875715784245e-09
genetic O 0 2.780578434169456e-08
events O 0 2.652354780252608e-09
involved O 0 2.9602478246459896e-09
in O 0 4.6269818532174156e-10
the O 0 3.1638747177709092e-09
progression O 0 2.9529473977163434e-07
of O 0 1.4605900933162275e-09
this O 0 4.914755269425086e-10
often O 0 5.946902525977293e-09
fatal O 0 7.559240657428745e-06
cancer B-Disease 0 9.687265674074297e-07
remain O 0 1.3763410322553682e-07
to O 0 7.193200257660237e-09
be O 0 9.958544922028523e-08
elucidated O 0 0.0007847265223972499
. O 0 1.3625968904307229e-06

Numerous O 0 7.368768365267897e-06
cytogenetic O 0 0.011685136705636978
and O 0 8.724685329752901e-08
allelotype O 0 0.00021203125652391464
studies O 0 6.060936357243918e-07
have O 0 5.036185246609648e-09
reported O 0 5.736026764679991e-08
frequent O 0 4.571484879534182e-08
loss O 0 1.241329243839573e-07
of O 0 9.683267307991628e-07
heterozygosity O 1 0.9996355772018433
on O 0 3.951881808461621e-06
chromosomal O 0 0.03701809048652649
arm O 0 0.1923757642507553
10q O 0 0.09565204381942749
in O 0 1.1310869467706652e-06
sporadic B-Disease 1 0.9999830722808838
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.972562626586296e-05

Deletion O 0 5.13298436999321e-05
mapping O 0 5.899269581277622e-06
studies O 0 2.1633911728713429e-07
have O 0 1.5639568529124404e-09
unambiguously O 0 6.830759957665578e-08
identified O 0 2.2176655178896e-08
a O 0 1.1007091238468547e-08
region O 0 2.765272455462764e-08
of O 0 1.318997249200038e-07
chromosome O 0 3.2709858714952134e-06
10q23 O 0 1.30562398226175e-06
to O 0 1.3437352341938436e-09
be O 0 1.0226050006778564e-09
the O 0 9.528514866019577e-09
minimal O 0 5.160433715900581e-07
area O 0 6.27596179469947e-08
of O 0 2.3712260599495494e-07
loss O 0 1.1066190381825436e-05
. O 0 1.0504882084205747e-06

A O 0 5.177240836928831e-06
new O 0 1.6690424331500253e-07
tumor B-Disease 0 4.182030897936784e-05
suppressor O 0 1.760477425705176e-05
gene O 0 7.037557736566669e-08
, O 0 7.983314453952062e-09
PTEN O 0 0.00041507018613629043
/ O 0 9.22383969736984e-06
MMAC1 O 1 0.9484497308731079
, O 0 5.0261284023633834e-09
was O 0 9.079922591581635e-08
isolated O 0 4.9053479500571484e-08
recently O 0 1.0938361327816892e-08
at O 0 7.925963885213605e-09
this O 0 5.07819952755284e-10
region O 0 4.425672273100645e-09
of O 0 4.992003965753611e-08
chromosome O 0 5.927082042944676e-07
10q23 O 0 5.68454254334938e-07
and O 0 4.550939902703277e-10
found O 0 5.287505988604835e-10
to O 0 2.7749913478203325e-10
be O 0 4.360548033766065e-10
inactivated O 0 8.199520173945984e-09
by O 0 5.666675462201454e-10
mutation O 0 5.806923830675714e-10
in O 0 6.093548998720166e-10
three O 0 5.847229900268758e-08
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999994039535522
lines O 0 8.031003744690679e-06
. O 0 3.802489914050966e-07

We O 0 1.0970913990604458e-06
screened O 0 3.391469135749503e-06
80 O 0 3.936035682272632e-06
prostate B-Disease 0 0.018553348258137703
tumors I-Disease 1 1.0
by O 0 3.0944487861006564e-08
microsatellite O 0 7.828166417311877e-06
analysis O 0 2.8037128174673853e-08
and O 0 7.174411065236086e-10
found O 0 7.062525675394227e-09
chromosome O 0 1.6158504934082885e-07
10q23 O 0 3.77049559574516e-07
to O 0 2.5459909736014197e-09
be O 0 9.546250900882569e-09
deleted O 0 1.910894837919841e-07
in O 0 4.543812437418637e-09
23 O 0 1.1709373382018384e-07
cases O 0 3.351351196556607e-08
. O 0 9.177217208389266e-08

We O 0 3.867947384605941e-07
then O 0 2.2740653804476096e-08
proceeded O 0 5.176615047730593e-08
with O 0 3.3387473341583984e-10
sequence O 0 1.504823821107948e-08
analysis O 0 5.390417889827859e-09
of O 0 5.688715720708615e-09
the O 0 2.3739859855709255e-08
entire O 0 4.38085362475249e-06
PTEN O 0 0.08886165916919708
/ O 0 2.120297540386673e-05
MMAC1 O 0 0.0014509077882394195
coding O 0 1.5771660173413693e-06
region O 0 7.05037184189905e-09
and O 0 3.980408780357436e-10
tested O 0 1.317136955059084e-09
for O 0 5.814027592698778e-10
homozygous O 0 1.8717301486503857e-08
deletion O 0 1.2589207898372479e-08
with O 0 2.4769664097590294e-10
new O 0 5.8381557366260495e-09
intragenic O 0 0.00012670960859395564
markers O 0 3.2819141893014603e-07
in O 0 1.610048316891266e-09
these O 0 3.876517440382088e-10
23 O 0 1.7246376771140604e-08
cases O 0 6.426011944782317e-10
with O 0 3.481570143293311e-09
10q23 O 0 0.004576748702675104
loss O 0 0.0017265271162614226
of O 0 0.0005537679535336792
heterozygosity O 1 0.9999984502792358
. O 0 6.2879835240892135e-06

The O 0 4.4090594997214794e-07
identification O 0 1.297557759016854e-07
of O 0 9.788437438373876e-08
the O 0 7.807016544347789e-08
second O 0 7.542711841779237e-07
mutational O 0 1.7545558876008727e-05
event O 0 6.602201096939098e-08
in O 0 1.8703980586565194e-09
10 O 0 3.785145530343925e-09
( O 0 1.0466517652574225e-09
43 O 0 7.225362530505208e-09
% O 0 1.2926896886256145e-08
) O 0 6.224961168754817e-08
tumors B-Disease 1 0.9999998807907104
establishes O 0 5.7584125897847116e-05
PTEN O 1 0.999936580657959
/ O 0 8.778139454079792e-05
MMAC1 O 0 0.0016696640523150563
as O 0 6.393397367077114e-09
a O 0 1.2382240122121857e-08
main O 0 2.8844040045328256e-08
inactivation O 0 3.93367933781974e-08
target O 0 9.063015227184223e-09
of O 0 2.1838252095562893e-08
10q O 0 1.534429975436069e-05
loss O 0 1.2770685771101853e-06
in O 0 1.4702203543492942e-07
sporadic B-Disease 1 0.9995177984237671
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.217866042679816e-06
. O 0 5.002536340725783e-07

Risk O 0 1.5808695025043562e-05
reversals O 0 4.579143933369778e-06
in O 0 1.2166601059959703e-08
predictive O 0 1.0948509299169018e-07
testing O 0 1.9657399263905972e-08
for O 0 1.7951913378055906e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.1736598177521955e-06

The O 0 1.0361709001927011e-07
first O 0 8.932535600081337e-09
predictive O 0 3.188897679251568e-08
testing O 0 2.6958402177257312e-09
for O 0 1.3274655152883952e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.156102022534469e-07
HD B-Disease 0 1.4342960639623925e-05
) O 0 6.678949615590568e-10
was O 0 6.942452723812664e-10
based O 0 6.604144314747984e-11
on O 0 2.244211205759683e-10
analysis O 0 1.4286618554848474e-09
of O 0 1.54367674198852e-09
linked O 0 2.1667975858008504e-08
polymorphic O 0 2.757293415811546e-08
DNA O 0 1.4352002608575276e-07
markers O 0 5.922658630197475e-08
to O 0 4.5168593865163587e-10
estimate O 0 1.271238758704385e-08
the O 0 1.3676556553932073e-09
likelihood O 0 2.2677847155705422e-08
of O 0 7.645096999908674e-09
inheriting O 0 1.3681422217359795e-07
the O 0 1.062088905712244e-08
mutation O 0 2.364747286875968e-09
for O 0 4.529258745833431e-09
HD B-Disease 0 1.1222665307286661e-05
. O 0 3.94634270151073e-07

Limits O 0 2.8148829755991756e-07
to O 0 6.901120119806592e-09
accuracy O 0 1.1403893296346723e-07
included O 0 4.2637648967058794e-09
recombination O 0 1.7930110729480475e-08
between O 0 3.187558217376818e-09
the O 0 2.014601818700612e-09
DNA O 0 7.242461208534223e-08
markers O 0 1.0622509094559973e-08
and O 0 1.664308274529347e-10
the O 0 1.4496053246659812e-09
mutation O 0 8.96140495143527e-10
, O 0 3.680714621978609e-10
pedigree O 0 3.264794301571783e-08
structure O 0 2.958273626063601e-08
, O 0 3.4665403880751455e-10
and O 0 1.6202628128070273e-10
whether O 0 7.161791715226684e-10
DNA O 0 1.113654235496142e-08
samples O 0 6.091387394491221e-10
were O 0 1.3915401053665732e-09
available O 0 1.3862445635837162e-09
from O 0 8.342253110527054e-09
family O 0 5.487769882961402e-08
members O 0 1.875994115607682e-08
. O 0 1.0916939174876461e-07

With O 0 7.795376788521935e-09
direct O 0 7.841276961073618e-09
tests O 0 3.027488260087807e-10
for O 0 2.3265306348108084e-10
the O 0 4.249362195452022e-09
HD B-Disease 0 1.0547978490649257e-06
mutation O 0 6.512432815242164e-10
, O 0 3.0886831287046945e-11
we O 0 4.3296994461927696e-11
have O 0 1.615377449859512e-11
assessed O 0 2.0229380393033125e-09
the O 0 2.149483480096137e-09
accuracy O 0 1.91128783910699e-08
of O 0 2.279270994165472e-09
results O 0 1.0303286002155687e-09
obtained O 0 6.698293475437822e-09
by O 0 8.174031451702035e-10
linkage O 0 4.138563625133429e-08
approaches O 0 3.5584344360017894e-09
when O 0 3.431222250771526e-10
requested O 0 3.6421115012785776e-09
to O 0 1.0561330698877214e-09
do O 0 9.438682058160452e-10
so O 0 4.650694274133116e-10
by O 0 5.371080247229543e-10
the O 0 4.01547239903266e-09
test O 0 6.787250317330518e-09
individuals O 0 1.2369469892803409e-08
. O 0 1.18093282708287e-07

For O 0 8.51679331503874e-08
six O 0 1.0375429404518854e-08
such O 0 6.163472510145596e-10
individuals O 0 8.190871869651062e-10
, O 0 5.397092217584998e-10
there O 0 1.899004731242826e-09
was O 0 8.321691780110996e-08
significant O 0 1.1976970526461628e-08
disparity O 0 1.538043647997256e-08
between O 0 4.757989113812755e-09
the O 0 6.5516192471193335e-09
tests O 0 1.2677737970534508e-08
. O 0 3.163616923984591e-08

Three O 0 3.412729085994215e-07
went O 0 1.738096955250512e-07
from O 0 1.4573296347464293e-08
a O 0 1.2689010731037342e-08
decreased O 0 2.3704934903889807e-07
risk O 0 4.751495641386327e-09
to O 0 2.30603577899835e-10
an O 0 1.1972396407600172e-09
increased O 0 4.586023116814886e-09
risk O 0 1.5240237516422894e-08
, O 0 4.261835884200593e-10
while O 0 6.790225048902698e-10
in O 0 3.4976291307664553e-10
another O 0 7.829585868535105e-10
three O 0 3.199873421788624e-10
the O 0 2.5231920997015322e-09
risk O 0 1.5280258836014582e-08
was O 0 2.830931009611959e-07
decreased O 0 1.8967161850014236e-06
. O 0 8.462967571176705e-08

Knowledge O 0 9.251318260794505e-05
of O 0 4.97816927236272e-07
the O 0 5.587772733406382e-08
potential O 0 4.849290391462091e-08
reasons O 0 8.528818540298744e-09
for O 0 2.256086567564708e-10
these O 0 1.0474440759189463e-10
changes O 0 2.612617344688317e-10
in O 0 7.460363438127615e-10
results O 0 1.2588745601505025e-09
and O 0 1.8742074558986133e-10
impact O 0 3.347120802743575e-09
of O 0 9.274077061860453e-10
these O 0 1.6377275924295276e-10
risk O 0 4.394213881653286e-09
reversals O 0 4.220141391897414e-08
on O 0 8.434532516865545e-10
both O 0 1.32621913451203e-10
patients O 0 6.93699542253512e-11
and O 0 4.365472219824973e-11
the O 0 1.0365277525181682e-09
counseling O 0 3.833959372201434e-09
team O 0 2.4756721672680726e-10
can O 0 1.9080405311289184e-10
assist O 0 5.14011100349876e-09
in O 0 1.2876664179373165e-09
the O 0 3.8895993093035486e-09
development O 0 1.1603164651319275e-08
of O 0 1.257226101003539e-09
strategies O 0 3.1293414526345487e-09
for O 0 1.1865361471130598e-10
the O 0 1.4013924465317018e-09
prevention O 0 2.2434216262468e-08
and O 0 5.0257110972840024e-11
, O 0 2.5966591724047028e-11
where O 0 8.481894353540298e-11
necessary O 0 2.325875048114767e-09
, O 0 6.745239367056399e-10
management O 0 1.2807864990804774e-08
of O 0 6.004437391737838e-09
a O 0 8.844631693705196e-09
risk O 0 9.059229810759462e-09
reversal O 0 9.697802560992841e-09
in O 0 3.1413599499430234e-10
any O 0 5.201958308553856e-10
predictive O 0 1.8616079344724312e-08
testing O 0 1.1250522735650748e-09
program O 0 1.5673679243377592e-08
. O 0 3.435794759809596e-09
. O 0 3.872131770776832e-08

A O 0 8.781825272308197e-06
novel O 0 1.0328614052923513e-06
common O 0 1.2207237887196243e-07
missense O 0 2.237743501609657e-06
mutation O 0 2.9083244257321894e-08
G301C O 0 7.838377200641844e-07
in O 0 1.024772888769121e-08
the O 0 3.278122662209171e-08
N O 0 2.192708734582993e-06
- O 0 9.052667451214802e-07
acetylgalactosamine O 0 2.5117229597526602e-05
- O 0 3.909161478077294e-06
6 O 0 1.2963582776137628e-06
- O 0 8.604340564488666e-07
sulfate O 0 1.6621802387817297e-06
sulfatase O 0 9.051787492353469e-05
gene O 0 3.009224940342392e-07
in O 0 7.741475371858542e-08
mucopolysaccharidosis B-Disease 0 0.00048118989798240364
IVA I-Disease 1 0.9988536834716797
. O 0 4.889323008683277e-06

Mucopolysaccharidosis B-Disease 1 0.8729642033576965
IVA I-Disease 1 0.999991774559021
( O 0 4.0718645323067904e-05
MPS B-Disease 1 0.999998927116394
IVA I-Disease 1 1.0
) O 0 8.650896887729687e-08
is O 0 1.5194629998660503e-09
an O 0 1.3984027269486887e-08
autosomal B-Disease 1 0.9912336468696594
recessive I-Disease 1 0.9999994039535522
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9529842734336853
by O 0 1.6078325870694243e-07
a O 0 1.2129746210121084e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999732971191406
in O 0 2.402132963652548e-07
N O 0 2.48378019023221e-05
- O 0 3.389438688827795e-06
acetylgalactosamine O 0 9.981774201150984e-05
- O 0 8.857904504111502e-06
6 O 0 5.563659215113148e-06
- O 0 7.562384325865423e-06
sulfate O 0 1.1617243217187934e-05
sulfatase O 0 0.002659320132806897
( O 0 1.5007858564786147e-06
GALNS O 0 0.00436586095020175
) O 0 3.916737512099644e-07
. O 0 1.251415966407876e-07

In O 0 1.545784726886268e-07
previous O 0 5.559028082302575e-08
studies O 0 1.49571857122055e-08
, O 0 3.56233070819556e-10
we O 0 4.123022756541417e-10
have O 0 8.328095157938975e-11
found O 0 2.2815749289861742e-10
two O 0 1.6483700515657063e-10
common O 0 4.1149700313880544e-10
mutations O 0 8.86869910843302e-10
in O 0 2.4294199985064324e-09
Caucasians O 0 1.1395620447274268e-07
and O 0 4.706612433125201e-09
Japanese O 0 1.4603002455260139e-05
, O 0 1.3343296245693637e-08
respectively O 0 5.77386799704982e-07
. O 0 2.7076762876276916e-07

To O 0 4.4049323832950904e-07
characterize O 0 2.6654815883375704e-06
the O 0 1.0239408965162511e-07
mutational O 0 1.0371282769483514e-05
spectrum O 0 1.3750928395950268e-08
in O 0 2.2631115037530236e-10
various O 0 1.874675831237127e-10
ethnic O 0 4.40523867384357e-10
groups O 0 8.738063050905964e-11
, O 0 5.6705216910923895e-11
mutations O 0 7.787760020194767e-11
in O 0 4.1133846329088897e-10
the O 0 1.7424326870241202e-08
GALNS O 0 0.0003003900055773556
gene O 0 1.3623530747963741e-08
in O 0 5.238401712404084e-09
Colombian O 0 1.1525114587129792e-06
MPS B-Disease 1 0.9918758869171143
IVA I-Disease 1 1.0
patients O 0 3.078600840922263e-08
were O 0 1.8234982412934642e-09
investigated O 0 2.7852868456079705e-08
, O 0 3.7909603234353995e-10
and O 0 3.771811196706665e-10
genetic O 0 6.379571981796062e-09
backgrounds O 0 2.7255167012185666e-09
were O 0 1.599012477981887e-09
extensively O 0 3.6247167489733556e-09
analyzed O 0 3.1255058541290737e-09
to O 0 1.417808231929385e-10
identify O 0 1.1108999276032705e-09
racial O 0 1.1344321038109229e-09
origin O 0 5.407086445252673e-10
, O 0 1.8900350728934256e-10
based O 0 6.232201976708041e-10
on O 0 1.5887734461372816e-09
mitochondrial O 0 2.0257807875623257e-08
DNA O 0 1.6022006832372426e-08
( O 0 3.934983006104176e-09
mtDNA O 0 2.383877450995442e-08
) O 0 4.1587235877216244e-09
lineages O 0 8.002251661309856e-08
. O 0 2.0171480485942084e-08

Three O 0 8.309596637445793e-07
novel O 0 1.9150227217323845e-06
missense O 0 6.6925886130775325e-06
mutations O 0 1.7870021906674083e-08
never O 0 2.6404437747373777e-08
identified O 0 2.198611959158825e-08
previously O 0 1.4835211281649663e-08
in O 0 8.225580772069918e-10
other O 0 1.1322374982025707e-10
populations O 0 1.9927522132423547e-10
and O 0 2.018924333269112e-10
found O 0 1.1961964752060794e-09
in O 0 2.3041464292106184e-09
16 O 0 6.116258166599664e-09
out O 0 1.8839605431253403e-09
of O 0 2.824570977111307e-08
19 O 0 2.2005298205840518e-07
Colombian O 0 2.5894651116686873e-06
MPS B-Disease 1 0.9939191341400146
IVA I-Disease 1 1.0
unrelated O 0 1.1242151458645822e-06
alleles O 0 4.340519055290315e-09
account O 0 7.198744711445215e-09
for O 0 2.572516200061159e-09
84 O 0 4.968181315234688e-07
. O 0 2.6304664402232447e-07

2 O 0 1.179251967187156e-06
% O 0 2.3460865250513052e-08
of O 0 9.176146065215107e-09
the O 0 6.827813425758222e-09
alleles O 0 2.1442747577538057e-09
in O 0 1.1932114185597698e-09
this O 0 3.3640494834230594e-09
study O 0 1.1324571147497409e-07
. O 0 1.2590365372489032e-07

The O 0 5.057199359725928e-06
G301C O 0 6.328632298391312e-05
and O 0 6.369324268007404e-08
S162F O 0 8.979016456578393e-06
mutations O 0 5.056477192511011e-08
account O 0 4.263864639142412e-08
for O 0 1.822254525052358e-08
68 O 0 2.419072188786231e-06
. O 0 5.537607989936078e-07

4 O 0 5.3897388170298655e-06
% O 0 1.203477353328708e-07
and O 0 1.6562093918537357e-08
10 O 0 3.9916847072163364e-07
. O 0 2.583971365766047e-07

5 O 0 1.590632109582657e-06
% O 0 3.525952507743568e-08
of O 0 7.031369264609566e-09
mutations O 0 2.0044714776901174e-09
, O 0 2.4742088933216166e-10
respectively O 0 5.526643143127785e-09
, O 0 3.7165659438898047e-10
whereas O 0 2.469636495305849e-09
the O 0 3.4101823587207036e-09
remaining O 0 1.6623690157757665e-07
F69V O 0 0.0002594712714198977
is O 0 1.2776871782804733e-09
limited O 0 7.965605952620081e-10
to O 0 1.3706955570569335e-09
a O 0 1.114759307085933e-08
single O 0 2.5185777019487432e-08
allele O 0 8.594108891202268e-08
. O 0 9.560285008092251e-08

The O 0 4.770486157212872e-07
skewed O 0 9.20433308237989e-07
prevalence O 0 4.097696546523366e-07
of O 0 1.9743257695381544e-08
G301C O 0 5.359486294764793e-07
in O 0 1.3841678914161548e-09
only O 0 7.386383726881718e-10
Colombian O 0 5.185914986327589e-08
patients O 0 4.69639660494181e-10
and O 0 7.418613640064464e-11
haplotype O 0 6.754138581754887e-09
analysis O 0 7.113353239773801e-10
by O 0 1.4564055517141128e-10
restriction O 0 2.6828368415721116e-09
fragment O 0 8.783070271078941e-09
length O 0 3.666506653843271e-09
polymorphisms O 0 1.621235234949836e-08
in O 0 7.863273920882818e-10
the O 0 1.7346867053902315e-08
GALNS O 0 0.013101360760629177
gene O 0 9.559701652506192e-08
suggest O 0 2.791860786999223e-08
that O 0 2.481175709334593e-09
G301C O 0 1.3553780036090757e-06
originated O 0 2.321942957905776e-07
from O 0 1.3957619948712363e-08
a O 0 3.4387994674034417e-08
common O 0 4.276048670703858e-08
ancestor O 0 3.858644049614668e-06
. O 0 1.9840489073885692e-07

Investigation O 0 9.309152119385544e-06
of O 0 1.481683682413859e-07
the O 0 4.362149397252324e-08
genetic O 0 9.253676580556203e-08
background O 0 2.078263605653774e-08
by O 0 5.542105108169437e-10
means O 0 1.0935085725805038e-08
of O 0 4.274980369700643e-08
mtDNA O 0 2.3561972284369403e-07
lineages O 0 7.529399326244857e-09
indicate O 0 6.205276292803319e-10
that O 0 1.0160248510582282e-11
all O 0 3.545342144861685e-11
our O 0 2.05662176178123e-09
patients O 0 3.836078399377385e-10
are O 0 6.491644721773326e-11
probably O 0 1.1645467701271173e-08
of O 0 8.455141653485043e-08
native O 0 2.9769279308311525e-07
American O 0 6.455171387642622e-06
descent O 0 0.00014903063129168004

Low O 0 9.14482768621383e-07
frequency O 0 1.2492768064475968e-07
of O 0 5.578295159125446e-08
BRCA1 O 0 3.8629815435342607e-07
germline O 0 3.022189787316165e-07
mutations O 0 7.914689459376234e-10
in O 0 4.868775937971748e-10
45 O 0 1.1423230361629066e-08
German O 1 0.9997013211250305
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.3577151750941994e-06
. O 0 1.978531543045392e-07

In O 0 1.2233215329615632e-07
this O 0 1.7474042213194707e-09
study O 0 3.385212776763069e-09
we O 0 1.2784429070933356e-09
investigated O 0 5.262549862550259e-08
45 O 0 9.356453745112958e-08
German O 1 0.7007128596305847
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.35932487067248e-09
for O 0 2.9296574055592828e-09
germline O 0 2.2105259631644003e-06
mutations O 0 1.805233296181541e-09
in O 0 6.510619821042951e-10
the O 0 2.4687713207072193e-08
BRCA1 O 0 3.785631861319416e-07
gene O 0 1.4735682896116487e-07
. O 0 7.730792361826389e-08

We O 0 1.6537669011995604e-07
identified O 0 1.5996347713098658e-07
four O 0 4.8616723091754466e-08
germline O 0 3.7664487990696216e-06
mutations O 0 6.972234345425932e-09
in O 0 1.5874224157386152e-09
three O 0 1.263404669771262e-08
breast B-Disease 0 0.0162741020321846
cancer I-Disease 0 0.0004153155896347016
families O 0 1.1371188435305157e-08
and O 0 2.215905681168806e-09
in O 0 1.66085243336056e-07
one O 0 3.382013528607786e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.12934964010492e-05
. O 0 1.619647888029263e-10
among O 0 7.589295511478689e-12
these O 0 7.8545269246999e-12
were O 0 3.6238717582293134e-10
one O 0 6.284041620396863e-10
frameshift O 0 3.974222551050843e-08
mutation O 0 3.901396150585157e-10
, O 0 1.0191464339115441e-10
one O 0 1.5294917554697918e-09
nonsense O 0 2.7105133426630346e-07
mutation O 0 5.256818536025776e-09
, O 0 3.030804773818119e-10
one O 0 1.5909233930244682e-09
novel O 0 1.1348475936756586e-07
splice O 0 8.341634156749933e-07
site O 0 3.4809939819524516e-08
mutation O 0 1.4075913767896964e-09
, O 0 3.0456281940871577e-10
and O 0 1.0614807921527358e-09
one O 0 4.417763221908899e-08
missense O 0 8.805852303339634e-06
mutation O 0 3.3629291351644497e-07
. O 0 2.9415528501886e-07

The O 0 5.3409817155625205e-06
missense O 0 2.0899338778690435e-05
mutation O 0 1.3492993389263574e-07
was O 0 1.4892258093368582e-07
also O 0 1.9632133696489973e-09
found O 0 4.2539523015250325e-09
in O 0 1.2300300333834002e-08
2 O 0 1.2027766160827014e-06
. O 0 3.888266348894831e-07

8 O 0 1.026132167680771e-06
% O 0 1.610454525291516e-08
of O 0 2.285932110268618e-09
the O 0 7.777194999114556e-10
general O 0 3.3514073738416528e-09
population O 0 3.634462175661213e-10
, O 0 2.0555147861589518e-10
suggesting O 0 2.0866353089843415e-09
that O 0 4.472808581845733e-11
it O 0 6.981209360601426e-11
is O 0 3.906034939937797e-10
not O 0 4.919437746053745e-09
disease O 0 4.973813361175417e-07
associated O 0 1.1516170843606233e-06
. O 0 1.323271362707601e-06

The O 0 1.3979807818031986e-06
average O 0 4.2975565861524956e-07
age O 0 9.718100812960984e-08
of O 0 7.711219609518594e-07
disease O 1 0.8204359412193298
onset O 1 0.9999599456787109
in O 0 3.2669309035782135e-08
those O 0 7.1287322711555134e-09
families O 0 2.9152943170629442e-08
harbouring O 0 0.0005899756215512753
causative O 0 4.517528577707708e-05
mutations O 0 1.3119850095222318e-08
was O 0 1.324611815789467e-07
between O 0 5.145744097490024e-08
32 O 0 1.7328156332041544e-07
. O 0 6.35534505022406e-08

3 O 0 7.4260451583541e-06
and O 0 1.5530177677192114e-07
37 O 0 3.3020901355484966e-06
. O 0 9.04235662346764e-07

4 O 0 1.0258522706863005e-06
years O 0 3.330037401383379e-08
, O 0 2.3501025570027423e-09
whereas O 0 2.1214862755414288e-08
the O 0 2.0355374275027316e-08
family O 0 9.454258531604864e-08
harbouring O 0 3.035377449123189e-05
the O 0 1.7692586595785542e-07
missense O 0 2.222104512838996e-06
mutation O 0 5.63707613920883e-09
had O 0 2.4161206368944477e-09
an O 0 1.2315131137086155e-09
average O 0 1.0666281191618054e-08
age O 0 1.1493428431208486e-08
of O 0 3.5092674011139025e-07
onset O 0 0.002979434560984373
of O 0 1.9714152585947886e-05
51 O 0 1.7147247490356676e-05
. O 0 1.1105657904408872e-06

2 O 0 1.7963224308914505e-05
years O 0 1.7074496554414509e-06
. O 0 1.68493920682522e-06

These O 0 8.993124112066653e-08
findings O 0 1.1858998050229275e-07
show O 0 3.450283614370164e-08
that O 0 1.6417597281659368e-09
BRCA1 O 0 8.214613700374684e-08
is O 0 1.239218061499514e-09
implicated O 0 1.9331240608266853e-08
in O 0 1.1155669721318873e-09
a O 0 1.1427060409019418e-09
small O 0 7.789190403784119e-10
fraction O 0 1.0217788393163119e-08
of O 0 2.8376714453770546e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.481384507926123e-07
suggesting O 0 9.399669664844623e-08
the O 0 3.0844826692799643e-09
involvement O 0 1.1896919005494055e-08
of O 0 8.831062103809018e-09
another O 0 1.5494739713517447e-08
susceptibility O 0 7.434432092168208e-08
gene O 0 2.8927011896939803e-08
( O 0 4.845638201800284e-08
s O 0 9.220991614711238e-07
) O 0 3.495739235859219e-07

Paternal O 1 0.9998595714569092
transmission O 1 0.9999858140945435
of O 1 0.999995231628418
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.000364431063644588

We O 0 5.520440140571736e-07
report O 0 1.4003462922573817e-07
a O 0 1.2927882764302012e-08
rare O 0 5.60565016627379e-09
case O 0 1.2837949370236856e-08
of O 0 5.101869078316668e-07
paternally O 1 0.9999996423721313
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999992847442627
DM B-Disease 1 1.0
) O 0 2.2825252017355524e-06
. O 0 3.8746222230656713e-07

The O 0 8.437616088485811e-06
proband O 0 0.00025197933427989483
is O 0 2.9740920837184603e-08
a O 0 1.4599613962218427e-08
23 O 0 2.1120628801440944e-08
year O 0 2.171745006052106e-09
old O 0 7.650496058886347e-07
, O 0 1.1138713063019168e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0012384168803691864
who O 0 1.6237503075444693e-07
suffers O 0 0.31540265679359436
severe O 1 0.9974544644355774
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 1.8705864931689575e-05

He O 0 6.692740157632215e-07
presented O 0 1.1930433174711652e-06
with O 0 3.007193640769401e-07
respiratory O 1 0.9999855756759644
and O 0 2.322902048490505e-07
feeding O 0 0.0804925337433815
difficulties O 1 0.9997206330299377
at O 0 0.1371600180864334
birth O 0 0.00039636334986425936
. O 0 1.1587151220737724e-06

His O 0 4.899297437077621e-06
two O 0 7.280978593371401e-07
sibs O 1 0.9984294772148132
suffer O 0 6.910909178259317e-06
from O 0 1.1214833648409694e-06
childhood O 1 0.9999994039535522
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 2.998716627189424e-05

Their O 0 5.786166070720355e-07
late O 0 1.5754326341266278e-06
father O 0 5.673829832630872e-07
had O 0 2.1732875055135992e-08
the O 0 8.603223911052282e-09
adult O 0 9.019024638234896e-09
type O 0 1.2228606749431492e-07
of O 0 9.313509508501738e-05
DM B-Disease 1 1.0
, O 0 6.678204300669677e-08
with O 0 1.3130816434170356e-08
onset O 1 0.8208966255187988
around O 0 1.429164626642887e-07
30 O 0 6.70746231890007e-08
years O 0 3.138620030540551e-08
. O 0 7.239477639586767e-08

Only O 0 6.520592421566107e-08
six O 0 1.0399620720136227e-08
other O 0 2.913318197794723e-10
cases O 0 5.402272518217899e-10
of O 0 5.57840174053581e-08
paternal O 0 0.07496920228004456
transmission O 1 0.9999885559082031
of O 1 0.9999998807907104
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.3975756019135588e-06
been O 0 1.7513481509467965e-07
reported O 0 1.6183857098894805e-07
recently O 0 2.755785146746348e-07
. O 0 2.895763202559465e-07

We O 0 2.7412298209128494e-07
review O 0 1.1029203506041085e-07
the O 0 1.195759136152219e-08
sex O 0 9.574003811962939e-09
related O 0 1.9318378008392756e-08
effects O 0 2.82565224551945e-07
on O 0 5.009836172575888e-07
transmission O 0 0.0014408939750865102
of O 0 0.16046486794948578
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0002084274892695248

Decreased O 0 0.09272069483995438
fertility O 0 1.7557427781866863e-05
of O 0 2.3428309958717364e-08
males O 0 2.520248676418646e-09
with O 0 3.624590627637758e-10
adult O 0 4.677070251091209e-07
onset O 1 0.9999996423721313
DM B-Disease 1 1.0
and O 0 2.423968936682286e-08
contraction O 0 6.584983935908895e-08
of O 0 2.377020358323989e-09
the O 0 2.3669044502128145e-09
repeat O 0 9.65130286800786e-09
upon O 0 2.1177990916498857e-08
male O 0 4.570473421949828e-08
transmission O 0 1.6298669081038497e-08
contribute O 0 7.524958989257868e-10
to O 0 3.029949346977645e-10
the O 0 2.237040996888595e-09
almost O 0 1.0523693916297816e-08
absent O 0 4.250702190233824e-08
occurrence O 0 3.327611963754862e-08
of O 0 2.2492313789257423e-08
paternal O 0 5.03669616591651e-06
transmission O 0 3.5278451832709834e-05
of O 0 0.004235861357301474
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0004591538163367659

Also O 0 9.100995157496072e-07
the O 0 1.8225435383101285e-07
fathers O 0 1.023817503664759e-06
of O 0 1.351116196701696e-07
the O 0 1.464443926124659e-07
reported O 0 9.42329904773942e-07
congenitally O 0 8.371089643333107e-05
affected O 0 1.0113803128319887e-08
children O 0 1.1208904915349649e-09
showed O 0 6.540445074421086e-09
, O 0 3.216493182911506e-10
on O 0 3.782965940501981e-09
average O 0 1.483122247236679e-08
, O 0 8.985435173691769e-10
shorter O 0 9.024586233863374e-08
CTG O 0 0.0002643182233441621
repeat O 0 2.392770284131984e-07
lengths O 0 1.2687047501458437e-06
and O 0 1.11933529112207e-09
hence O 0 1.5388652130354785e-08
less O 0 3.489940780809775e-09
severe O 0 4.675692011346655e-08
clinical O 0 6.463324098149315e-07
symptoms O 0 1.0602454381114512e-07
than O 0 5.714672068890536e-10
the O 0 8.57962678679769e-09
mothers O 0 2.796732267995594e-08
of O 0 1.776121649754714e-08
children O 0 2.6262094721118956e-08
with O 0 7.954057537062909e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00017830512661021203

We O 0 3.3325827075714187e-07
conclude O 0 1.7490125401309342e-06
that O 0 1.047327291558986e-08
paternal O 0 1.5300349332392216e-05
transmission O 0 0.0013531979639083147
of O 1 0.9823566675186157
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 5.468311428558081e-06
rare O 0 2.499116114051958e-08
and O 0 6.782976402774921e-10
preferentially O 0 1.1088259199709682e-08
occurs O 0 3.1805134081963615e-09
with O 0 3.0482899537886965e-10
onset O 1 0.6595966219902039
of O 1 0.8636602759361267
DM B-Disease 1 1.0
past O 0 1.4774943792872364e-06
30 O 0 1.9918383387107497e-08
years O 0 1.4723658958715191e-09
in O 0 1.0791101345830612e-09
the O 0 6.060251855899423e-09
father O 0 2.101707536894537e-07
. O 0 3.360818823239242e-08
. O 0 2.9248303690110333e-07

The O 0 2.4634553483338095e-05
RB1 O 1 0.6538627743721008
gene O 0 4.152488770614582e-07
mutation O 0 1.1684694101177229e-08
in O 0 2.6075506198708354e-09
a O 0 1.757630307963609e-08
child O 0 3.4797005810105475e-07
with O 0 1.0307585398550145e-06
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 2.466214937157929e-05

The O 0 1.781816899892874e-05
RB1 O 0 0.14474500715732574
gene O 0 1.5901119354566617e-07
mutation O 0 6.094783788768154e-09
was O 0 3.608666077070666e-08
investigated O 0 9.239532516858162e-08
in O 0 4.798929698068832e-09
a O 0 1.5361086624920972e-08
child O 0 1.2422115958088398e-07
with O 0 1.1060803473128544e-07
ectopic B-Disease 1 0.9999990463256836
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 0 0.0009398534893989563
using O 0 3.323793507092887e-08
DNA O 0 5.964876237385397e-08
obtained O 0 2.0189185434560386e-08
from O 0 2.6239850292597566e-09
both O 0 6.75833611296639e-10
the O 0 2.9606217921696043e-08
pineal B-Disease 0 0.0006242126110009849
and I-Disease 0 7.185194306202902e-08
retinal I-Disease 1 0.9832805395126343
tumours I-Disease 1 1.0
of O 0 1.3625340216094628e-05
the O 0 2.190535042245756e-06
patient O 0 2.066600791295059e-05
. O 0 2.2793986431679514e-07

A O 0 2.0290548491175286e-05
nonsense O 0 2.4779554223641753e-05
mutation O 0 1.6423265947196342e-07
in O 0 6.378795802675086e-08
exon O 0 2.0244810912117828e-06
17 O 0 1.8383414612799243e-07
( O 0 2.803595400280301e-08
codon O 0 2.071404026082746e-07
556 O 0 1.2647095104512118e-07
) O 0 5.684995585397701e-09
of O 0 2.456160430597265e-08
the O 0 2.740046056715073e-07
RB1 O 0 0.039127327501773834
gene O 0 1.6580111505959394e-08
was O 0 2.2512571362653944e-08
found O 0 8.900252757015892e-10
to O 0 2.233603441093024e-10
be O 0 4.861342994821882e-10
present O 0 1.4064972297944678e-08
homozygously O 0 2.270827280881349e-05
in O 0 1.1440107527960208e-08
both O 0 4.36470237730191e-09
the O 0 9.507368758931989e-08
retinal B-Disease 0 1.4449662558035925e-05
and I-Disease 0 3.8535063140443526e-08
the I-Disease 0 7.901920071162749e-06
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 4.351473307906417e-06

The O 0 3.522901295127667e-07
same O 0 2.9590298211701338e-08
mutation O 0 2.887584171773483e-09
was O 0 9.37570820980227e-09
present O 0 5.738923558595843e-09
heterozygously O 0 6.696877790091094e-07
in O 0 2.5851818463706877e-09
the O 0 3.1084728124852745e-09
DNA O 0 1.6760360210810177e-08
from O 0 3.51178058854984e-10
the O 0 5.01976404887472e-10
constitutional O 0 1.6136915137465735e-09
cells O 0 9.202379414041673e-10
of O 0 8.290205744110324e-10
the O 0 2.2971211599553953e-09
patient O 0 3.712743534833862e-08
, O 0 4.29422969405735e-10
proving O 0 1.5697874289344327e-07
it O 0 1.6954514181488634e-10
to O 0 3.9535558160608275e-10
be O 0 1.4696891481591479e-09
of O 0 1.4285146221482137e-07
germline O 0 1.0503376870474312e-05
origin O 0 5.554793460760266e-07
. O 0 4.44755329453983e-07

The O 0 9.204701996168296e-07
initial O 0 3.396773138319986e-07
mutation O 0 1.0366013825091613e-08
was O 0 2.2231967378161244e-08
shown O 0 4.394658414952346e-09
to O 0 7.396322443398162e-10
have O 0 6.20158480124644e-10
occurred O 0 9.77517231603997e-08
in O 0 2.1556665341648795e-09
the O 0 2.0278760004543983e-08
paternally O 0 7.436399300786434e-06
derived O 0 1.5685454854974523e-06
RB1 O 0 0.00014054833445698023
allele O 0 2.86919174641298e-07
. O 0 1.217819090015837e-07

The O 0 2.0230631037065905e-07
mutation O 0 1.60945337057683e-08
is O 0 1.035436958396474e-09
in O 0 2.6233232253147776e-10
an O 0 1.8204471263771893e-09
area O 0 1.645623015633646e-08
of O 0 2.042611768615643e-08
the O 0 4.96418337547766e-08
gene O 0 1.3778073792991563e-08
that O 0 4.5975118156960093e-10
encodes O 0 1.0040649200959706e-08
the O 0 1.7958236009363304e-09
protein O 0 6.865789270449341e-09
- O 0 3.048838070895954e-09
binding O 0 1.6498965527134146e-09
region O 0 4.503106776354571e-09
known O 0 3.893666722376565e-09
as O 0 8.141046725640422e-10
the O 0 8.301427989465537e-09
pocket O 0 1.4232240573619492e-05
region O 0 3.4926195269235905e-08
and O 0 1.3139126453509675e-09
has O 0 2.7112517786420653e-10
been O 0 3.7668648755762035e-10
detected O 0 2.6564710431387084e-09
in O 0 1.4508548529246212e-10
other O 0 6.894258774980955e-11
cases O 0 9.542968637532567e-10
of O 0 7.602580609500365e-08
retinoblastoma B-Disease 0 0.0001639501570025459
. O 0 1.0805528205537485e-07
. O 0 4.447544768027001e-07

Low O 0 5.566525032918435e-06
levels O 0 1.1387623999326024e-07
of O 0 4.5236145496119207e-08
beta O 0 3.89908677789208e-07
hexosaminidase O 0 1.8875909972848604e-06
A O 0 3.951396010393182e-08
in O 0 8.617688229684006e-10
healthy O 0 1.6067511765527343e-08
individuals O 0 3.281322158432687e-10
with O 0 7.770226129188984e-10
apparent O 0 0.00018600480689201504
deficiency O 1 0.9997920393943787
of O 0 1.125329526985297e-05
this O 0 6.160950505318397e-08
enzyme O 0 4.123884878026729e-07
. O 0 7.039852789603174e-08

Appreciable O 0 0.00014406452828552574
beta O 0 1.1704450116667431e-05
hexosaminidase O 0 1.530093140900135e-05
A O 0 1.127222162722319e-06
( O 0 1.9298417086588415e-08
hex O 0 3.176320433340152e-07
A O 0 8.798465955806023e-08
) O 0 1.7161314591618293e-09
activity O 0 5.994802432240931e-09
has O 0 6.578923517075452e-11
been O 0 2.7206017993997023e-10
detected O 0 5.362371879868988e-09
in O 0 3.45890049935349e-09
cultured O 0 1.0767589628812857e-05
skin O 0 1.1411336345190648e-05
fibroblasts O 0 0.003409460885450244
and O 0 2.6783133932894998e-08
melanoma B-Disease 1 0.999993085861206
tissue O 0 0.006062205880880356
from O 0 7.280271319132225e-08
healthy O 0 9.407292367313858e-08
individuals O 0 1.923115555690913e-10
previously O 0 2.799383169715952e-09
reported O 0 2.4890915995001706e-09
as O 0 7.710493354906589e-10
having O 0 5.260632818249178e-08
deficiency B-Disease 0 0.0035101904068142176
of I-Disease 0 1.4615708096243907e-05
hex I-Disease 0 4.6450157242361456e-05
A I-Disease 0 3.029484787475667e-07
activity O 0 1.6158759663653655e-08
indistinguishable O 0 4.2742200889733795e-09
from O 0 5.926287932611629e-11
that O 0 1.1893224252657042e-11
of O 0 4.4824441380875157e-10
patients O 0 9.225260555467685e-10
with O 0 7.026786619235281e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.081544830114581e-06
TSD B-Disease 1 0.9770795702934265
) O 0 2.740950151292054e-07
. O 0 1.7265490726003918e-07

Identification O 0 8.46634338813601e-06
and O 0 1.1564493007654164e-07
quantitation O 0 0.0018958603031933308
of O 0 3.007930536114145e-05
hex O 0 0.00023440184304490685
A O 0 5.8821688071475364e-06
, O 0 1.1541493982747397e-08
amounting O 0 4.278006429103698e-07
to O 0 2.1937529126603295e-08
3 O 0 7.541805189248407e-07
. O 0 2.1802881633448123e-07

5 O 0 3.287105982963112e-06
% O 0 3.232629524063668e-07
- O 0 6.151875027171627e-07
6 O 0 1.3732550314671244e-06
. O 0 2.2571244073787966e-07

9 O 0 2.3959585178090492e-06
% O 0 1.2020567652371028e-08
of O 0 1.0308776055012459e-08
total O 0 1.7470284774390166e-08
beta O 0 1.09708345519266e-07
hexosaminidase O 0 4.7636851263632707e-07
activity O 0 2.7253310719288493e-08
, O 0 1.395060594822084e-10
has O 0 2.7844592950798663e-11
been O 0 1.3344199356613018e-10
obtained O 0 2.879927629706458e-09
by O 0 6.731503798818039e-09
cellulose O 0 2.7507674076332478e-06
acetate O 0 2.910431362579402e-07
gel O 0 5.091885100227955e-07
electrophoresis O 0 1.5178032981566503e-06
, O 0 1.7158114928861323e-08
DEAE O 0 7.335375994443893e-05
- O 0 1.5211710433504777e-06
cellulose O 0 1.6148304666785407e-06
ion O 0 6.883572041260777e-07
- O 0 1.639356469240738e-06
exchange O 0 1.5050281945150346e-06
chromatography O 0 4.735745824291371e-05
, O 0 4.4422503009400316e-08
radial O 0 1.229693225468509e-06
immunodiffusion O 0 1.249744036613265e-05
, O 0 4.4802689558309794e-08
and O 0 1.0036554698444888e-07
radioimmunoassay O 0 0.00075885298429057
. O 0 2.519835334169329e-06

Previous O 0 3.358519825269468e-05
family O 0 2.0581637727445923e-07
studies O 0 1.5402630282324026e-08
suggested O 0 2.825065292810791e-09
that O 0 3.139070600677307e-11
these O 0 9.218712598846324e-11
individuals O 0 1.3739299975501496e-10
may O 0 6.573107613760953e-10
be O 0 2.9985089966544365e-09
compound O 0 1.9284584595880006e-06
heterozygotes O 0 6.111945083375758e-08
for O 0 1.8899197484767427e-10
the O 0 2.04512917711952e-09
common O 0 6.42400532768761e-09
mutant O 0 6.233443627934321e-07
TSD B-Disease 0 0.0011082359123975039
gene O 0 6.980936273492944e-09
and O 0 2.5310961659918974e-10
a O 0 4.527091146400153e-09
rare O 0 8.140243146215198e-09
( O 0 8.423540087676429e-09
allelic O 0 1.3246459218407836e-07
) O 0 1.8401863144390518e-08
mutant O 0 3.9069112744982704e-07
gene O 0 1.461546048631135e-07
. O 0 1.336589434686175e-07

Thus O 0 1.2573581216202001e-06
, O 0 7.510051247550109e-09
the O 0 7.87636711407913e-09
postulated O 0 4.697350846072368e-07
rate O 0 4.0033608428302614e-08
mutant O 0 1.5696477007054455e-08
gene O 0 1.0728425925421448e-09
appears O 0 1.1616799744373907e-09
to O 0 2.344919744490248e-11
code O 0 1.6818786641170647e-10
for O 0 1.5452276611038762e-11
the O 0 7.130795953713687e-10
expression O 0 2.797141407384629e-09
of O 0 3.8559382353753335e-09
low O 0 1.2450350084236561e-08
amounts O 0 1.665268811734677e-08
of O 0 1.4132082526430167e-07
hex O 0 4.375951448309934e-06
A O 0 1.8361880620432203e-06
. O 0 1.9734585521291592e-07

Heterozygotes O 0 0.00010066655522678047
for O 0 1.5305927192343916e-08
the O 0 3.727360109451183e-08
rare O 0 1.7134111018890508e-08
mutant O 0 6.080411907305461e-08
may O 0 1.4956350602446378e-09
be O 0 7.757934850083359e-10
indistinguishable O 0 6.06351449050635e-08
from O 0 2.6918736129033505e-09
heterozygotes O 0 3.1979855208419394e-08
for O 0 5.596278440656022e-10
the O 0 2.5374356837915002e-08
common O 0 1.6816213133097335e-07
TSD B-Disease 0 0.004995696246623993
mutant O 0 7.395295597234508e-06
. O 0 2.769496063592669e-07

However O 0 2.71350046432417e-07
, O 0 1.3539341203738786e-08
direct O 0 1.8729787143456633e-07
visualization O 0 9.835261153057218e-06
and O 0 2.7742217412196624e-08
quantitation O 0 0.004299690015614033
of O 0 7.436470696120523e-06
hex O 0 2.8769247364834882e-05
A O 0 1.3344293847694644e-07
by O 0 3.8215164366306453e-10
the O 0 7.685825309522443e-10
methods O 0 5.291181270905554e-09
described O 0 1.4007038195984478e-08
may O 0 2.5836242034671386e-09
prevent O 0 3.6824578941718755e-09
false O 0 5.872825425967676e-08
- O 0 3.837956086272243e-08
positive O 0 4.001221576288572e-09
prenatal O 0 5.050780487181328e-07
diagnosis O 0 2.104818577208789e-07
of O 0 1.261043394151784e-07
TSD B-Disease 1 0.9996598958969116
in O 0 8.049922683994737e-08
fetuses O 0 1.9614522273059265e-07
having O 0 1.500169943824403e-08
the O 0 1.5316732770997987e-08
incomplete O 0 1.1980155250057578e-06
hex B-Disease 0 2.0750607291120104e-05
A I-Disease 0 1.2346201401669532e-05
deficiency I-Disease 0 0.013515735045075417
of O 0 7.613666639372241e-07
the O 0 1.8271971669037157e-07
type O 0 4.068390353495488e-06
described O 0 2.1091547353080387e-07
in O 0 9.369111708679156e-09
the O 0 5.793521395958123e-08
four O 0 9.428885050510871e-08
healthy O 0 9.949002333087265e-07
individuals O 0 3.586492880458536e-07

The O 0 2.187028258049395e-05
tumor B-Disease 0 0.0013207593001425266
suppressor O 0 0.00018287227430846542
gene O 0 1.1734989584510913e-06
Smad4 O 0 0.00045496600796468556
/ O 0 1.0443159226269927e-05
Dpc4 O 0 5.872041219845414e-05
is O 0 1.5724366253522248e-09
required O 0 1.126847615218196e-09
for O 0 6.915307770860579e-10
gastrulation O 0 2.8287818167882506e-06
and O 0 1.1126705112829427e-09
later O 0 2.6791871832188008e-08
for O 0 7.433819337876457e-09
anterior O 0 6.718577424180694e-06
development O 0 6.097798177506775e-07
of O 0 2.1802715366447956e-07
the O 0 1.8170992177601875e-07
mouse O 0 1.346431872661924e-06
embryo O 0 4.491263609907037e-07
. O 0 6.64826131924201e-08

Mutations O 0 2.290945303684566e-06
in O 0 6.154949261372167e-08
the O 0 8.45131864934956e-07
SMAD4 O 1 0.9999985694885254
/ O 1 0.9984796643257141
DPC4 O 1 0.9999980926513672
tumor B-Disease 0 0.3530939221382141
suppressor O 0 7.9109231592156e-06
gene O 0 6.257886209226626e-09
, O 0 2.7467347840648415e-10
a O 0 7.257987100217633e-09
key O 0 9.109933785111934e-08
signal O 0 1.2011794581212598e-07
transducer O 0 3.0960637786847656e-07
in O 0 4.294363087353759e-09
most O 0 2.1075063916242698e-09
TGFbeta O 0 4.760454976349138e-05
- O 0 1.2103988638045848e-06
related O 0 1.1841328841910581e-06
pathways O 0 1.4113523150172114e-07
, O 0 2.849557256823232e-10
are O 0 3.06905161007176e-11
involved O 0 7.73802855125183e-10
in O 0 1.0611407308402931e-09
50 O 0 1.0008756490265114e-08
% O 0 4.177629353563361e-09
of O 0 1.400187557010213e-07
pancreatic B-Disease 1 0.9999990463256836
cancers I-Disease 1 0.9907123446464539
. O 0 1.8535882873038645e-06

Homozygous O 0 0.001562104094773531
Smad4 O 0 0.02440107986330986
mutant O 0 8.271708793472499e-05
mice O 0 2.6403690753795672e-06
die O 0 3.0180365229171e-07
before O 0 2.09933773476223e-07
day O 0 1.5268378774635494e-06
7 O 0 2.255152367069968e-06
. O 0 2.976808559651545e-07

5 O 0 7.98691780801164e-06
of O 0 3.7395839171949774e-06
embryogenesis O 0 0.00022681769041810185
. O 0 3.7009829156886553e-06

Mutant O 0 1.6356445485143922e-05
embryos O 0 1.926273398566991e-07
have O 0 7.37775229797677e-10
reduced O 0 2.526240550082548e-09
size O 0 1.5280550158536244e-08
, O 0 2.1741073386039034e-09
fail O 0 3.377127200110408e-08
to O 0 9.455011884540454e-09
gastrulate O 0 3.448100687819533e-05
or O 0 8.365216075389981e-08
express O 0 1.9476246393423935e-08
a O 0 2.731362336305665e-08
mesodermal O 0 4.237614575686166e-06
marker O 0 3.2545329986533034e-07
, O 0 1.1353218365428575e-09
and O 0 1.8592295480956977e-09
show O 0 1.3809520282848098e-07
abnormal O 0 5.2809382395935245e-06
visceral O 0 5.948866601102054e-06
endoderm O 0 0.00022729374177288264
development O 0 5.854154096596176e-06
. O 0 4.211955229038722e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 3.400024752409081e-06
the O 0 1.4035941831025411e-06
Smad4 O 1 0.9999996423721313
- O 0 0.004040327854454517
deficient O 0 4.478817572817206e-06
embryos O 0 7.323050610352766e-09
results O 0 4.498880989967091e-10
from O 0 3.5407216048000123e-10
reduced O 0 2.1723831622466605e-09
cell O 0 1.1515695064190368e-07
proliferation O 0 1.538733727102226e-07
rather O 0 2.7553834769378227e-09
than O 0 8.695139608327906e-10
increased O 0 1.3531853859660714e-08
apoptosis O 0 8.309493750857655e-07
. O 0 5.653564016938617e-08

Aggregation O 0 2.6493018594919704e-05
of O 0 1.6036458418966504e-06
mutant O 0 2.5275168809457682e-05
Smad4 O 1 0.9451385140419006
ES O 0 0.007150834426283836
cells O 0 5.301384220501859e-09
with O 0 2.6781984963086813e-10
wild O 0 6.8997647595381295e-09
- O 0 1.2079041766810406e-07
type O 0 3.4607009524734167e-07
tetraploid O 0 4.072446699865395e-06
morulae O 0 3.9431528421118855e-05
rescues O 0 4.736866685561836e-06
the O 0 2.3989395003809477e-07
gastrulation B-Disease 0 0.00031022634357213974
defect I-Disease 0 5.416892236098647e-05
. O 0 1.3333459492059774e-06

These O 0 2.271761871952549e-07
results O 0 1.7945238539596176e-07
indicate O 0 2.3108027846774348e-07
that O 0 4.687119137258833e-09
Smad4 O 0 7.821778126526624e-06
is O 0 9.493008601424435e-10
initially O 0 1.7686698772223508e-09
required O 0 4.1826822561041865e-10
for O 0 1.8033671778105997e-10
the O 0 2.196837600720869e-09
differentiation O 0 4.74063526212376e-08
of O 0 6.728756662965907e-09
the O 0 1.4592236752264398e-08
visceral O 0 1.099427464623659e-07
endoderm O 0 1.5824496131244814e-06
and O 0 8.756118607955443e-10
that O 0 4.830462696503446e-10
the O 0 1.4472798071096804e-08
gastrulation B-Disease 0 2.7747892090701498e-05
defect I-Disease 0 1.922686578836874e-06
in O 0 6.5776633029202e-09
the O 0 3.499327405620534e-08
epiblast O 0 7.615743379574269e-05
is O 0 8.39134006724862e-09
secondary O 0 7.76961144310917e-08
and O 0 3.431079864668618e-09
non O 0 4.528653335000854e-06
- O 0 6.0076687077526e-05
cell O 0 3.1879379093879834e-05
autonomous O 0 1.6051789089033264e-06
. O 0 1.871910910722363e-07

Rescued O 0 0.0002631997049320489
embryos O 0 2.2426422674470814e-06
show O 0 4.130962167891994e-07
severe O 0 2.4816608856781386e-06
anterior O 0 0.00018501498561818153
truncations O 1 0.970829963684082
, O 0 1.399043441097092e-07
indicating O 0 1.7836840697782463e-06
a O 0 2.8207537638991198e-08
second O 0 2.871071558274707e-08
important O 0 1.6159560800588224e-08
role O 0 4.278945198166184e-08
for O 0 1.7538761554192206e-08
Smad4 O 1 0.9890576004981995
in O 0 7.78077662744181e-07
anterior O 0 0.003261133097112179
patterning O 0 0.0004979263176210225
during O 0 0.00010374563134973869
embryogenesis O 0 0.002031035488471389
. O 0 3.4229417451570043e-06

Prevalence O 0 0.00030746625270694494
of O 0 9.000345926324371e-07
p16 O 0 2.4580582248745486e-05
and O 0 1.3975872548144253e-07
CDK4 O 1 0.9979863166809082
germline O 0 0.00046160651254467666
mutations O 0 9.446561222148375e-08
in O 0 1.4282266924681153e-08
48 O 0 4.6314852397699724e-07
melanoma B-Disease 1 0.9572553038597107
- O 0 0.0007243368308991194
prone O 0 1.3321218830242287e-05
families O 0 1.1648888964543858e-08
in O 0 2.671527710162991e-08
France O 0 8.108671067930118e-07
. O 0 1.0856281278392999e-06

The O 0 8.333084224432241e-06
French O 0 0.00013570945884566754
Familial B-Disease 1 0.9999997615814209
Melanoma I-Disease 1 1.0
Study O 0 4.463563527679071e-05
Group O 0 8.688870707374008e-07
. O 0 1.890037566454339e-07

Germline O 0 0.0031271546613425016
mutations O 0 5.423601692200464e-07
in O 0 2.0594569605236757e-08
the O 0 6.95770339120827e-08
p16 O 0 5.4910651670070365e-06
and O 0 3.549197202801224e-08
CDK4 O 1 0.9809329509735107
genes O 0 7.205643726138078e-08
have O 0 4.3882403266692904e-10
been O 0 1.8645742727585457e-09
reported O 0 3.921675872931019e-09
in O 0 5.377620015956097e-10
a O 0 1.975760222094891e-09
subset O 0 4.5979987817190704e-08
of O 0 5.653962986684746e-08
melanoma B-Disease 0 0.002831639489158988
pedigrees O 0 5.247977696853923e-06
, O 0 2.844367408272319e-09
but O 0 5.220206489298107e-10
their O 0 1.5709467060531779e-09
prevalence O 0 5.59709576464229e-08
is O 0 4.1707481912567346e-10
not O 0 1.721356113204564e-10
well O 0 2.468751203466013e-09
known O 0 8.275252127987187e-08
. O 0 1.1579358272229001e-07

We O 0 2.4900526796045597e-07
searched O 0 8.531009143553092e-07
for O 0 4.318618795906559e-09
such O 0 6.324434309590288e-09
germline O 0 7.676069799344987e-06
mutations O 0 1.163241414303684e-08
in O 0 8.288455255467397e-09
48 O 0 9.616209695195721e-08
French O 0 1.1639287549769506e-05
melanoma B-Disease 1 0.9999502897262573
- O 0 0.0001254403468919918
prone O 0 1.5262002079907688e-06
families O 0 1.0972583952550963e-09
selected O 0 1.5659715746352276e-09
according O 0 2.374781704617135e-09
to O 0 1.531905435836478e-10
two O 0 6.637609212267748e-11
major O 0 6.348930270405617e-10
criteria O 0 1.7873013069547028e-09
families O 0 2.3024802897619878e-10
with O 0 9.88683995784001e-11
at O 0 1.3955144595456659e-08
least O 0 3.000103498962403e-10
three O 0 1.6550837089734927e-10
affected O 0 3.1286834234478533e-10
members O 0 2.577603130937689e-10
( O 0 1.0796988858530199e-09
n O 0 2.3069398835673383e-08
= O 0 3.6495610089559705e-08
20 O 0 3.923442015718592e-09
) O 0 3.1613636708449633e-10
or O 0 2.921826669499694e-10
families O 0 5.682344525470562e-11
with O 0 5.2793613231072456e-11
two O 0 4.66912786212248e-10
affected O 0 2.1211370437868027e-09
members O 0 2.8635488424910704e-10
, O 0 2.472010651732859e-10
one O 0 6.882305836342084e-10
of O 0 2.189634029647891e-09
them O 0 7.145473102099231e-10
affected O 0 1.632815882501859e-09
before O 0 5.132694269605054e-09
the O 0 9.499680153624013e-09
age O 0 1.2590793296851643e-08
of O 0 2.086684247615267e-08
50 O 0 7.895875953067844e-09
( O 0 9.031742020937372e-10
n O 0 9.270419987217338e-09
= O 0 1.691312334628492e-08
28 O 0 5.721283891091389e-09
) O 0 2.3997784315277215e-10
, O 0 5.1004648421448806e-11
and O 0 5.911284656212601e-11
one O 0 2.768245910278466e-10
additional O 0 4.7806398839611575e-09
minor O 0 1.2373391200526385e-07
criterion O 0 1.4865531738905702e-05
. O 0 7.425369403790683e-07

Sixteen O 0 8.185666956705973e-06
different O 0 9.969187431124737e-08
p16 O 0 2.1793204723508097e-05
germline O 0 4.638926384359365e-06
mutations O 0 3.127521575052583e-09
were O 0 1.9965271658151096e-09
found O 0 1.3247433150453958e-09
in O 0 6.933123519736739e-10
21 O 0 6.96234714325783e-09
families O 0 6.138974883995729e-10
, O 0 2.650462072040227e-10
while O 0 4.643756490452233e-09
one O 0 2.7948711789349545e-08
germline O 0 1.0019223282142775e-06
mutation O 0 5.3429021207307414e-09
, O 0 1.9073320700613294e-09
Arg24His O 0 1.765531487762928e-05
, O 0 4.464340452869919e-09
was O 0 3.9240724447608955e-08
detected O 0 3.548229088323751e-08
in O 0 7.451649963741147e-09
the O 0 2.9065756734780734e-07
CDK4 O 1 0.9706181287765503
gene O 0 1.9139783944410738e-06
. O 0 2.645326446781837e-07

The O 0 2.7468928465168574e-07
frequency O 0 1.471544663900204e-07
of O 0 7.491069453635646e-08
p16 O 0 1.1732449820556212e-06
gene O 0 1.135948313191193e-08
mutation O 0 5.672136094148073e-10
in O 0 2.535425203120667e-10
our O 0 3.9627887082893665e-10
sample O 0 5.363934296731543e-10
( O 0 5.308343209442512e-10
44 O 0 1.938968763326443e-09
% O 0 6.682887576658914e-10
) O 0 2.030192264301789e-10
is O 0 6.064119345561281e-11
among O 0 4.2193141341906326e-11
the O 0 3.7381639450551063e-10
highest O 0 1.4698581907168773e-08
rates O 0 2.875437665750269e-09
yet O 0 1.7515821015834376e-09
reported O 0 3.3608298366516465e-09
and O 0 2.498489470870169e-10
the O 0 1.6879285524851184e-08
CDK4 O 0 4.1987670556409284e-05
mutation O 0 3.5613541005119487e-09
is O 0 2.589864156465893e-10
the O 0 7.063572504684146e-10
second O 0 3.360881350999989e-09
mutation O 0 7.01357805166225e-10
detected O 0 3.84185039337126e-09
in O 0 2.1596079091690257e-10
this O 0 1.1150862455622246e-09
gene O 0 1.3594199543831564e-08
worldwide O 0 1.3165524670455397e-08
. O 0 8.014976060621848e-08

In O 0 3.869962199587462e-07
summary O 0 2.5371946321683936e-06
, O 0 9.07205954803203e-09
our O 0 1.4652646207480302e-08
results O 0 8.696785513961913e-09
show O 0 1.9874022427757154e-08
frequent O 0 1.387372083883065e-08
involvement O 0 3.80755835749369e-08
of O 0 3.5548680443753256e-08
the O 0 7.668759138823589e-08
p16 O 0 7.969182661327068e-06
gene O 0 4.2952990497724386e-08
in O 0 8.724515332403371e-09
familial B-Disease 0 3.086541619268246e-05
melanoma I-Disease 0 0.00557774817571044
and O 0 4.979543888339322e-09
confirm O 0 5.015768778093843e-08
the O 0 2.7946578384785425e-08
role O 0 9.654399235614619e-08
of O 0 8.440978405133137e-08
the O 0 1.5167354661116406e-07
CDK4 O 0 0.30268850922584534
gene O 0 2.0754034935066556e-08
as O 0 2.495775586197624e-09
a O 0 1.143843135764655e-07
melanoma B-Disease 0 0.0003152165445499122
- O 0 4.0600534703116864e-05
predisposing O 0 8.567600889364257e-05
gene O 0 1.3939414600372402e-07
. O 0 1.4097093270493133e-08
. O 0 9.026927472177704e-08

Progression O 0 0.00026654088287614286
of O 0 2.165066234738333e-06
somatic O 0 5.7301134802401066e-05
CTG O 0 0.13758660852909088
repeat O 0 9.712613291412708e-07
length O 0 1.5124440722047439e-07
heterogeneity O 0 4.479359176912112e-07
in O 0 2.9482176699957563e-09
the O 0 5.419551474261652e-09
blood O 0 2.3345792499185336e-07
cells O 0 1.0410198001409299e-06
of O 0 0.00015828294272068888
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.500073792878538e-05
. O 0 3.179542034104088e-07

The O 0 3.223535429697222e-07
genetic O 0 6.030390409250685e-07
basis O 0 6.019639613441541e-07
of O 0 3.73838993255049e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6222324371337891
DM B-Disease 1 1.0
) O 0 1.0229995517363477e-08
is O 0 3.4031438778114875e-10
the O 0 6.649802930525084e-10
expansion O 0 9.108036991278823e-09
of O 0 2.504479645892843e-08
an O 0 1.5771989581025991e-07
unstable O 0 0.0001705229951767251
CTG O 1 0.5666043758392334
repeat O 0 1.0317234000467579e-06
in O 0 2.938361198800976e-08
the O 0 2.7456270146331008e-08
34 O 0 1.5751201942748594e-07
UTR O 0 0.00010528400162002072
of O 0 2.9664730050171784e-07
the O 0 1.3346677860681666e-06
DM B-Disease 1 1.0
protein O 0 4.449099378689425e-06
kinase O 0 1.3749586287303828e-06
gene O 0 4.727666258474983e-09
on O 0 7.468482721151304e-09
chromosome O 0 2.45110925334302e-07
19 O 0 4.126756607547577e-07
. O 0 3.0276967777354e-07

One O 0 4.172102023858315e-07
of O 0 4.5517257518667975e-08
the O 0 1.6178928419208205e-08
principal O 0 1.7519073480798397e-06
features O 0 2.412281574493136e-08
of O 0 5.8486911314048484e-08
the O 0 7.923500788820093e-07
DM B-Disease 1 1.0
mutation O 0 2.4523266972664715e-08
is O 0 5.428953397945691e-10
an O 0 4.808419218349513e-10
extraordinarily O 0 3.4642898327774674e-08
high O 0 1.2344768762773128e-08
level O 0 1.2729596221561224e-07
of O 0 5.4131387372535755e-08
somatic O 0 3.5621278584585525e-06
mosaicism O 0 0.014177695848047733
, O 0 1.4010397286767784e-09
due O 0 9.999711281238888e-09
to O 0 6.480303516021024e-10
an O 0 1.9077104340681217e-09
extremely O 0 5.219651821875004e-09
high O 0 5.443171247065948e-09
degree O 0 1.1098207863824427e-07
of O 0 2.1463788968389963e-08
somatic O 0 3.871840874580812e-07
instability O 0 7.375648891638775e-08
both O 0 5.117637424945087e-10
within O 0 3.392238490107502e-09
and O 0 3.591222319521137e-10
between O 0 5.0348210045569886e-09
different O 0 3.950474614100585e-09
tissues O 0 4.347315609720681e-07
. O 0 2.1128711580331583e-07

This O 0 6.338808020700526e-07
instability O 0 3.255469209761941e-06
appears O 0 1.4165519246489566e-07
to O 0 1.3255115893784364e-09
be O 0 1.3303697032895911e-09
biased O 0 2.8351825775985162e-08
towards O 0 1.0404243688810766e-08
further O 0 8.314354760230458e-10
expansion O 0 4.342580517402439e-09
and O 0 2.059431236656195e-10
continuous O 0 3.222182698436882e-08
throughout O 0 5.754913767752612e-10
the O 0 5.045355244703842e-10
life O 0 1.0533849348348667e-09
of O 0 5.312657536116205e-10
an O 0 1.0073017420175745e-10
individual O 0 1.1649588238515918e-10
, O 0 3.029982514890506e-11
features O 0 2.1353802059920213e-10
that O 0 9.336934003734143e-12
could O 0 4.1638789638476226e-11
be O 0 2.306295293630356e-10
associated O 0 1.6092653876143004e-09
with O 0 1.9610567336680873e-10
the O 0 2.659712095010036e-08
progressive O 0 7.529961862928758e-07
nature O 0 1.0058555943714964e-07
of O 0 5.878171194240167e-08
the O 0 3.330155493586062e-07
disease O 0 7.047281087579904e-06
. O 0 1.9148039598348987e-07

Although O 0 2.6517852802498965e-07
increasing O 0 2.8946880448188494e-08
measured O 0 3.206866949767573e-08
allele O 0 1.8402941392992034e-09
size O 0 1.509350533446252e-09
between O 0 2.405774024438756e-09
patients O 0 3.1689599833129023e-09
clearly O 0 6.010453024174467e-09
correlates O 0 2.798877396514854e-08
with O 0 5.0369580034681505e-11
an O 0 3.243724455703756e-10
increased O 0 5.718356899109267e-10
severity O 0 5.7530176178488546e-09
of O 0 4.362397110213578e-09
symptoms O 0 1.3346656224655362e-08
and O 0 8.813485358194484e-11
an O 0 2.0334205153016427e-10
earlier O 0 5.444954487288101e-10
age O 0 1.0911225256649004e-09
of O 0 3.471828824430645e-09
onset O 0 7.249273039633408e-07
, O 0 1.0892526464134633e-10
this O 0 9.100143555373919e-11
correlation O 0 1.2771705915071152e-09
is O 0 9.019836960666439e-12
not O 0 6.773014440963898e-12
precise O 0 8.56474335897417e-10
and O 0 5.7636433820063004e-11
measured O 0 1.8409717084111321e-09
allele O 0 1.7921680806054496e-10
length O 0 1.8226906095542006e-10
cannot O 0 1.3439575841101004e-10
be O 0 8.807300722057931e-11
used O 0 1.9144894003453317e-10
as O 0 1.434430629831951e-10
an O 0 7.261597434471412e-10
accurate O 0 8.71986074457709e-08
predictor O 0 4.177336734301207e-07
of O 0 8.44216607731596e-09
age O 0 1.209731266271774e-07
of O 0 1.3531783906728378e-06
onset O 1 0.7508153915405273
. O 0 1.7392490008205641e-06

In O 0 1.0519884341420038e-07
order O 0 9.494390162956279e-09
to O 0 1.3673426835225655e-09
further O 0 3.2146181272452168e-09
characterize O 0 1.4189816965881619e-07
the O 0 3.263984638124384e-08
dynamics O 0 1.1258823178650346e-05
of O 0 3.8460653740912676e-05
DM B-Disease 1 1.0
CTG O 1 0.9992386102676392
repeat O 0 5.447275839287613e-07
somatic O 0 3.1938103006723395e-07
instability O 0 6.936079444130883e-08
, O 0 4.093340943978063e-10
we O 0 4.4091894024766987e-10
have O 0 1.2692895345889355e-10
studied O 0 8.148274055486127e-09
repeat O 0 1.0137055639347636e-08
length O 0 2.095018158954076e-09
changes O 0 1.1604880251203653e-10
over O 0 1.7194856649638268e-10
time O 0 1.8593075967743289e-09
in O 0 1.2770933643935223e-08
111 O 0 1.3961427612230182e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 2.58798893426615e-09
with O 0 3.548717916745936e-11
varying O 0 8.917618865567079e-10
clinical O 0 3.9441975019371966e-08
severity O 0 4.191375424511534e-08
and O 0 7.332555451711187e-09
CTG O 0 0.00021492890664376318
repeat O 0 2.855196434836671e-08
size O 0 2.711247892861479e-09
over O 0 5.976805717011757e-10
time O 0 1.5688237375854897e-09
intervals O 0 2.388355824223254e-08
of O 0 1.3996675818361837e-08
1 O 0 4.994518221224098e-08
- O 0 9.408243073494305e-08
7 O 0 7.787890154986599e-08
years O 0 2.0333992267751455e-08
. O 0 6.341952030197717e-08

We O 0 1.6036689487464173e-07
have O 0 2.7688598080999327e-09
found O 0 3.898021461168355e-09
a O 0 5.7767244321382805e-09
direct O 0 1.584694686584953e-08
progression O 0 3.1803548949937976e-07
of O 0 7.839392246467014e-09
the O 0 4.998518488008585e-09
size O 0 6.662082441266648e-09
heterogeneity O 0 1.5750879711617927e-08
over O 0 3.816839899695168e-10
time O 0 1.8767949416798047e-09
related O 0 3.740904919169452e-09
to O 0 1.1160096180518053e-09
initial O 0 2.4371004769818683e-07
CTG O 0 5.7116252719424665e-05
repeat O 0 2.659919928760246e-08
size O 0 3.4333447196388533e-09
and O 0 1.2857490072626376e-10
the O 0 5.348834153373616e-10
time O 0 1.7440877631003104e-09
interval O 0 1.70210512351332e-08
and O 0 4.453257484993145e-10
always O 0 5.766552568786665e-09
biased O 0 2.323109704605031e-08
towards O 0 1.6543530989565625e-08
further O 0 1.2879397992549002e-08
expansion O 0 3.8103127053545904e-07
. O 0 2.1958611284844665e-07

Attempts O 0 7.913517379165569e-07
to O 0 3.1492926044762726e-09
mathematically O 0 1.7860163836758147e-07
model O 0 1.447180419944516e-08
the O 0 3.889784938593266e-09
dynamics O 0 4.2788593646037043e-07
have O 0 4.226420324826563e-10
proved O 0 3.941851289823717e-08
only O 0 8.131114670462125e-10
partially O 0 3.7784683826203036e-08
successful O 0 4.533458941580193e-09
suggesting O 0 1.4043787244233386e-09
that O 0 1.0731279580233899e-11
individual O 0 3.2476105138457e-11
specific O 0 9.59582205362075e-11
genetic O 0 2.4761455108546215e-09
and O 0 7.682571800948779e-10
/ O 0 9.457663736611721e-07
or O 0 3.1590523974500684e-08
environmental O 0 6.343803704567108e-08
factors O 0 1.8209966867743788e-08
also O 0 3.4339064924893137e-10
play O 0 4.367791905934837e-09
a O 0 8.524102312890136e-09
role O 0 5.214738862946433e-08
in O 0 2.1565723429262107e-08
somatic O 0 3.3564101613592356e-06
mosaicism O 0 0.00010081989603349939
. O 0 7.544439029061323e-08
. O 0 2.507032661469566e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 3.5845787351718172e-06
Palestinian O 0 0.00040080779581330717
Arabs O 0 2.6287427317583933e-05
. O 0 2.7647640763461823e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9989810585975647
AGU B-Disease 1 1.0
) O 0 2.128632701214883e-07
is O 0 6.306510424991529e-09
a O 0 3.677370941090885e-08
rare O 0 4.379824076750083e-07
disorder B-Disease 1 0.9989827275276184
of I-Disease 1 0.9999949932098389
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 1.0
caused O 0 8.733923664294707e-07
by O 0 3.4162566109330328e-09
the O 0 9.498921826889273e-08
deficiency B-Disease 0 0.03704898804426193
of I-Disease 0 4.0393138078798074e-06
the I-Disease 0 5.886248345632339e-06
lysosomal I-Disease 1 0.9999949932098389
enzyme I-Disease 0 1.009598418022506e-05
aspartylglucosaminidase I-Disease 0 0.00037297955714166164
( O 0 1.4011641269462416e-06
AGA O 0 0.10355652868747711
) O 0 5.682900336978491e-07
. O 0 3.196967384155869e-07

AGU B-Disease 1 1.0
is O 0 1.1061600844186614e-06
inherited O 0 0.00020750999101437628
as O 0 1.458194844872196e-07
an O 0 2.0855002276221057e-06
autosomal O 1 0.9997479319572449
recessive O 0 0.09905606508255005
trait O 0 5.834596322529251e-06
and O 0 3.765135758726501e-09
occurs O 0 1.46171688086838e-08
with O 0 3.341346366259046e-10
a O 0 1.9112951221700314e-08
high O 0 8.511872806593601e-08
frequency O 0 2.4835538070533403e-08
in O 0 4.114602880633811e-09
Finland O 0 9.300868697437181e-08
because O 0 3.41728623176607e-09
of O 0 7.354941544690519e-08
a O 0 1.2096771229153092e-07
founder O 0 7.00229475114611e-06
effect O 0 6.09861274369905e-07
. O 0 1.9978411103238614e-07

While O 0 5.345739282347495e-07
very O 0 9.354238272862858e-09
few O 0 1.6474194453053315e-08
patients O 0 5.619899212661039e-09
with O 0 5.411763037699302e-09
AGU B-Disease 1 1.0
have O 0 4.7044586004574285e-09
been O 0 2.650675678950165e-09
reported O 0 2.8077677960425262e-09
from O 0 3.9991596145760866e-10
non O 0 1.5739978209694527e-08
- O 0 2.2562090862265904e-08
Finnish O 0 8.314725050695415e-07
origin O 0 7.760751152829926e-09
, O 0 1.1241234609826734e-09
we O 0 7.128895695984738e-09
diagnosed O 0 1.6358768561985926e-06
the O 0 1.4504750822652568e-07
disorder O 0 3.970520992879756e-05
in O 0 1.0917808879185031e-08
8 O 0 1.6595478768977046e-07
patients O 0 1.0038556652602892e-09
originating O 0 6.42942366013699e-09
from O 0 1.5109549167391378e-09
3 O 0 8.503350024113843e-09
unrelated O 0 2.6900783822725316e-08
families O 0 6.311982048146092e-10
, O 0 3.032712969641693e-10
all O 0 5.044325512848502e-10
Palestinian O 0 1.909367711050436e-06
Arabs O 0 4.2419713963681716e-08
from O 0 3.0753419810736204e-09
the O 0 4.002450371132227e-09
region O 0 2.747942673408943e-08
of O 0 1.9067188361532317e-07
Jerusalem O 0 0.00011265023204032332
. O 0 7.877307552917046e-07

The O 0 1.8401464103590115e-06
clinical O 0 0.0005945725715719163
diagnosis O 1 0.9925428628921509
of O 1 0.6724651455879211
AGU B-Disease 1 1.0
is O 0 1.727584901800583e-07
often O 0 1.6418474357848822e-09
difficult O 0 9.317147053877761e-09
, O 0 4.3372891389559243e-10
in O 0 9.494910413465618e-10
particular O 0 1.875399169293246e-09
early O 0 9.778264420390315e-09
in O 0 9.195255668004165e-10
the O 0 1.6629321253347484e-09
course O 0 4.0742225593248804e-08
of O 0 2.4588451275064926e-09
the O 0 1.0662091654012329e-08
disease O 0 2.3176002628133574e-07
, O 0 8.18469875207839e-11
and O 0 9.208624834888823e-11
most O 0 6.31732721689815e-11
of O 0 8.127424289128271e-10
the O 0 3.0487974367332527e-09
patients O 0 2.5663753344673523e-09
are O 0 2.5812732507013436e-10
diagnosed O 0 9.993003402541945e-08
after O 0 3.929210379283177e-08
the O 0 4.2604828109915616e-08
age O 0 2.5656677848928666e-07
of O 0 1.8875084606406745e-07
5 O 0 5.10409314813387e-08
years O 0 4.7352585852422635e-08
. O 0 1.031255649763807e-07

However O 0 1.612164055586618e-07
, O 0 2.817864830362282e-09
since O 0 8.04618482952435e-10
these O 0 3.571508366828624e-10
patients O 0 1.5763854666062116e-09
excrete O 0 2.4699959411123018e-08
early O 0 3.730736608531515e-09
large O 0 1.4479805132694423e-09
amounts O 0 2.366461915315199e-09
of O 0 2.09001029816136e-08
aspartylglucosamine O 0 8.570273166697007e-07
in O 0 1.0642905445834572e-09
urine O 0 2.2790795917160267e-09
, O 0 1.5259972452330572e-10
biochemical O 0 1.1663340515610798e-08
screening O 0 5.091544963420347e-10
is O 0 2.877279525748122e-10
easy O 0 3.156364725143135e-09
by O 0 1.498316137826805e-09
urine O 0 5.7712210121962926e-08
chromatography O 0 2.0354544176370837e-05
. O 0 1.9582149946018035e-07
. O 0 5.176048034627456e-07

Detection O 0 1.2747390428557992e-05
of O 0 1.9455774236121215e-07
heterozygous O 0 5.477145847976317e-08
carriers O 0 7.889793707249737e-09
of O 0 3.0240574488971106e-08
the O 0 2.6910797714663204e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.635168417938985e-05
ATM O 0 0.0002035249344771728
) O 0 4.370692252564368e-09
gene O 0 1.6003397496078264e-09
by O 0 1.4285692628845936e-09
G2 O 0 7.654504770471249e-06
phase O 0 1.3811985581924091e-06
chromosomal O 0 8.259771675511729e-06
radiosensitivity O 0 3.5447170375846326e-05
of O 0 4.93184097649646e-06
peripheral O 0 0.23068563640117645
blood O 0 0.0004107668937649578
lymphocytes O 0 5.783755477750674e-05
. O 0 1.0651958746166201e-06

In O 0 7.989729783730581e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 1 0.998394787311554
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.6002877951423216e-08
patients O 0 1.0775059733347803e-09
, O 0 4.791014113214587e-11
mutations O 0 1.0827919116884743e-10
in O 0 8.521558458873812e-11
a O 0 3.8423467185744187e-10
single O 0 5.028349958635658e-10
gene O 0 1.9658578931380788e-10
, O 0 8.940299195403512e-11
ATM O 0 8.571187777306477e-07
, O 0 1.770076307749946e-10
result O 0 1.3448043789665576e-09
in O 0 1.2550320782622748e-08
an O 0 0.00010090827709063888
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.8701791165985924e-08
embraces O 0 1.2742664523557323e-07
a O 0 6.389910822690581e-09
variety O 0 9.75778347012124e-10
of O 0 3.431212647342363e-08
clinical O 0 1.5703445797043969e-06
features O 0 1.8067844109737052e-08
and O 0 1.6785209888681152e-09
manifests O 0 9.403633072224693e-08
extreme O 0 1.6750301767842757e-07
radiosensitivity O 0 2.8499996915343218e-05
and O 0 6.265314933528998e-09
a O 0 4.883251847331849e-08
strong O 0 1.835467955402237e-08
pre O 0 1.0494194611965213e-05
- O 0 1.5152998003031826e-06
disposition O 0 6.407111413864186e-06
to O 0 2.318519847221978e-07
malignancy B-Disease 1 0.8968773484230042
. O 0 1.5736517298137187e-06

Heterozygotes O 0 3.765511428355239e-05
for O 0 4.004934339718602e-08
the O 0 1.2937879034780053e-07
ATM O 0 6.62204110994935e-05
gene O 0 1.0711747044922504e-08
have O 0 1.302702667960176e-10
no O 0 1.6354246845651232e-09
clinical O 0 4.4540772847767585e-08
expression O 0 1.2430275475594499e-08
of O 0 4.445988679435686e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.846323871568245e-09
may O 0 3.0938629436150222e-09
be O 0 4.9615778152656276e-09
cancer B-Disease 0 2.5963863663491793e-06
prone O 0 1.1543447442363686e-07
with O 0 5.532462266089055e-10
a O 0 2.281785960178695e-08
moderate O 0 1.7284577324971906e-08
increase O 0 2.1926809257166724e-09
in O 0 1.9488943792111968e-09
in O 0 3.622713862228011e-08
vitro O 0 3.6434516914596315e-06
radiosensitivity O 0 2.52992376772454e-05
. O 0 3.917903086403385e-07

We O 0 6.673988650618412e-07
performed O 0 2.262061400415405e-07
a O 0 1.1608005934249377e-07
blind O 0 7.067155820550397e-07
chromosomal O 0 4.5915047053313174e-07
analysis O 0 6.982683942169388e-08
on O 0 8.303030796241728e-08
G2 O 0 1.861609962361399e-05
- O 0 1.548795012240589e-07
phase O 0 6.314016900432762e-07
lymphocytes O 0 5.125575341935473e-08
from O 0 6.232466542854809e-09
7 O 0 4.536921593967236e-08
unrelated O 0 4.296831548344926e-07
A B-Disease 1 0.9999773502349854
- I-Disease 1 0.9933184385299683
T I-Disease 1 1.0
patients O 0 3.8751018394123093e-08
, O 0 2.5643644985251512e-09
13 O 0 2.2010455680288032e-08
obligate O 0 3.212083186099335e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999972581863403
T I-Disease 1 1.0
heterozygotes O 0 4.936885943607194e-06
( O 0 5.863376451031854e-09
parents O 0 4.820981946984659e-10
of O 0 1.3961952705088265e-09
the O 0 1.885294365067125e-09
patients O 0 5.747662346067273e-10
) O 0 1.6528406421301156e-10
, O 0 1.064629079339241e-10
and O 0 2.287871836426092e-10
14 O 0 1.552396788895294e-08
normal O 0 4.224506255923188e-08
controls O 0 4.714015844342612e-09
following O 0 1.207163813354839e-09
X O 0 3.77742395585301e-07
- O 0 3.429217088068981e-08
irradiation O 0 4.2706691516514184e-08
with O 0 1.2170378038689478e-09
1 O 0 7.215683694994368e-08
Gy O 0 6.83336702422821e-06
in O 0 2.732771786639887e-10
order O 0 1.3450449087848426e-10
to O 0 6.476087027751376e-11
evaluate O 0 4.3371590763285894e-09
this O 0 9.278340873386526e-10
cytogenetic O 0 6.728040489178966e-07
method O 0 8.044224841796677e-09
as O 0 2.5136129289116127e-10
a O 0 1.4931039737930973e-09
tool O 0 2.3929795034405288e-08
for O 0 6.339721525527864e-10
detection O 0 2.5457669039496977e-07
of O 0 5.715058364330616e-07
ATM O 0 0.019074169918894768
carriers O 0 1.1930512755498057e-06
. O 0 9.255791724172013e-07

Both O 0 7.211636784631992e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.001886111800558865
and O 0 2.3672034998867275e-08
heterozygotes O 0 2.4082739855657564e-06
showed O 0 1.2819964645416349e-08
significantly O 0 1.1091679796848553e-09
increased O 0 4.961471788966776e-10
levels O 0 1.6961378968005647e-09
of O 0 3.2707072605830945e-09
radiation O 0 9.525003406452015e-06
- O 0 2.3651762148801936e-06
induced O 0 3.2190364436246455e-06
chromatid O 0 0.00016617498476989567
damage O 0 2.8266362050999305e-07
relative O 0 3.462413644683693e-08
to O 0 2.7374041922101355e-10
that O 0 2.2476466521315075e-10
of O 0 2.0564817404533642e-08
normal O 0 5.708952244276588e-07
controls O 0 1.8001338730755378e-07
. O 0 6.34414192290933e-08

These O 0 1.0357796753623916e-07
results O 0 3.751238608629137e-08
show O 0 1.956911255263094e-08
that O 0 1.2502672230851886e-09
the O 0 3.8327474527477534e-08
G2 O 0 4.690414425567724e-05
- O 0 9.662694537837524e-07
phase O 0 4.677865035773721e-06
chromosomal O 0 1.268618416361278e-05
radiosensitivity O 0 3.3334551972075133e-06
assay O 0 5.4106720881463843e-08
can O 0 4.023835153965649e-10
be O 0 2.012346400626086e-10
used O 0 6.963830623263334e-10
for O 0 3.325832109712934e-10
the O 0 4.383607699054437e-09
detection O 0 1.499425223983053e-07
of O 0 2.0404370388860116e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 8.235614950535819e-05
. O 0 6.877600640109449e-07

In O 0 2.0346199391951814e-07
combination O 0 4.575785794713738e-08
with O 0 3.782915758421268e-09
molecular O 0 2.644421101649641e-06
genetic O 0 1.67015542729132e-07
analyses O 0 2.141320898374488e-08
, O 0 1.2034756524670343e-10
this O 0 5.686291021378409e-11
test O 0 7.329695184132845e-11
may O 0 1.4107622015036014e-10
be O 0 7.280204911142008e-11
of O 0 8.906417270360123e-10
value O 0 2.5429527372722305e-09
in O 0 2.741814553175459e-10
studies O 0 2.50742759888567e-09
of O 0 4.2803716127082225e-09
familial B-Disease 0 4.344327066974074e-07
and I-Disease 0 1.6819949877344698e-09
sporadic I-Disease 0 3.3346188956784317e-06
cancers I-Disease 0 3.7931376937194727e-06
aimed O 0 2.1249978487958288e-07
at O 0 2.0866522731921577e-08
determination O 0 7.337228158377229e-09
of O 0 2.605671456379355e-09
the O 0 1.615656386455555e-09
potential O 0 4.6711439161128965e-09
involvement O 0 2.302447299484811e-08
of O 0 6.620574311000382e-08
ATM O 0 4.6644625399494544e-05
mutations O 0 3.740369791671583e-09
in O 0 2.1378836478902485e-09
tumor B-Disease 0 1.1485819413792342e-05
risk O 0 4.136046172220631e-08
or O 0 1.0693945284856454e-08
development O 0 3.3447170721956354e-07
. O 0 1.4198881181926026e-08
. O 0 5.6805653514402366e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.64135428804002e-07
identification O 0 4.162550837349954e-08
and O 0 1.1124902110637436e-09
detection O 0 2.6631187211023644e-07
of O 0 2.9830630410287995e-07
founder O 0 0.0002995135437231511
- O 0 6.918974122527288e-07
effect O 0 9.11639652656504e-09
mutations O 0 6.010163478009645e-10
in O 0 2.3932966719542037e-10
the O 0 5.0461559375492016e-09
ATM O 0 2.1912868760409765e-05
gene O 0 2.355114769869715e-09
in O 0 2.793567877024117e-10
ethnic O 0 2.898167039688815e-09
populations O 0 9.569695258448974e-09
. O 0 2.4349695593173237e-08

To O 0 4.4586503378241105e-08
facilitate O 0 7.834164250652975e-08
the O 0 1.2371263125032783e-08
evaluation O 0 1.8401446766347362e-07
of O 0 4.122721009025554e-07
ATM O 0 0.07752819359302521
heterozygotes O 0 1.5026633946035872e-06
for O 0 2.8397164619775594e-09
susceptibility O 0 9.564698899566793e-08
to O 0 6.006496411359308e-10
other O 0 6.264881391437882e-10
diseases O 0 3.456011836533435e-05
, O 0 3.846856444500446e-10
such O 0 2.045541652728744e-10
as O 0 1.358061840761593e-08
breast B-Disease 0 0.0012734975898638368
cancer I-Disease 0 1.0352782737754751e-05
, O 0 1.3827166078783648e-09
we O 0 1.2647540792443124e-09
have O 0 8.378825411270441e-11
attempted O 0 4.5491548306131335e-09
to O 0 1.5997560220970541e-10
define O 0 1.9799553108157397e-09
the O 0 1.0626070023889156e-09
most O 0 3.7603736097180374e-11
common O 0 4.1314437981831986e-11
mutations O 0 3.2164423902081296e-11
and O 0 3.112575128194628e-11
their O 0 1.6996053175954984e-10
frequencies O 0 3.4702929418983786e-09
in O 0 2.2652988818094855e-08
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999983310699463
telangiectasia I-Disease 1 1.0
( O 1 0.7859074473381042
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 2.7030186089405106e-08
homozygotes O 0 1.621426122255798e-07
from O 0 1.0729489519079038e-09
10 O 0 1.2001386551219184e-09
ethnic O 0 1.8070659413282897e-09
populations O 0 6.87236623164722e-09
. O 0 3.47705260139719e-08

Both O 0 8.544078866634663e-08
genomic O 0 5.313808628670813e-07
mutations O 0 8.005973661795451e-09
and O 0 3.00737962311004e-10
their O 0 5.057002594455184e-10
effects O 0 2.9106217880325858e-08
on O 0 3.534584891440318e-08
cDNA O 0 7.760204994156084e-07
were O 0 3.434604423091514e-08
characterized O 0 1.8039904148281494e-07
. O 0 1.3088251193948963e-07

Protein O 0 1.4257099792303052e-05
- O 0 4.210011752547871e-07
truncation O 0 1.4286033547250554e-06
testing O 0 1.4888021482306613e-08
of O 0 1.6704349903307047e-08
the O 0 2.215576877517833e-08
entire O 0 2.403478163159889e-07
ATM O 0 4.9404461606172845e-06
cDNA O 0 2.5221788746421225e-07
detected O 0 8.227027947782517e-09
92 O 0 1.2221071266083072e-08
( O 0 6.625545112548537e-10
66 O 0 7.3562569369300945e-09
% O 0 9.494204311621957e-10
) O 0 6.537897445646479e-10
truncating O 0 5.018639726017682e-08
mutations O 0 6.572543065352932e-10
in O 0 3.81787379488685e-10
140 O 0 9.449117044368904e-09
mutant O 0 2.12575947955429e-08
alleles O 0 2.1332928756834235e-09
screened O 0 6.925358064790998e-08
. O 0 6.871687929788095e-08

The O 0 3.2967595871014055e-06
haplotyping O 0 0.00011028048174921423
of O 0 3.79639118364139e-07
patients O 0 3.063961528937398e-08
with O 0 1.0730472066455832e-09
identical O 0 6.490533337455417e-07
mutations O 0 4.745801263084104e-08
indicates O 0 6.911186289926263e-08
that O 0 8.927246442080872e-11
almost O 0 6.906238914083929e-10
all O 0 7.016490860545233e-11
of O 0 4.988819357620855e-10
these O 0 7.541680474565382e-11
represent O 0 8.013608665535799e-10
common O 0 2.0809043377312264e-09
ancestry O 0 4.8438244526494145e-09
and O 0 1.051236875326822e-10
that O 0 1.378018948949844e-10
very O 0 9.216677421264308e-10
few O 0 3.4162044304508754e-09
spontaneously O 0 1.4223036259863875e-07
recurring O 0 7.965307304402813e-06
ATM O 0 0.0001184985667350702
mutations O 0 9.682447910108749e-08
exist O 0 2.2949419076212507e-07
. O 0 3.3047189162971335e-07

Assays O 0 4.098656972928438e-06
requiring O 0 2.572969037828443e-08
minimal O 0 5.32159809552013e-08
amounts O 0 1.6467839314415755e-09
of O 0 3.904412793076517e-09
genomic O 0 1.829742579673166e-08
DNA O 0 1.5205220194047797e-08
were O 0 1.1657107501505948e-09
designed O 0 1.1354841511490577e-09
to O 0 1.1371784763847259e-10
allow O 0 4.4518644326529966e-10
rapid O 0 1.3762027073482841e-08
screening O 0 1.8453801819973137e-09
for O 0 5.79736203487613e-10
common O 0 2.4108728347016495e-09
ethnic O 0 1.2359116396964964e-08
mutations O 0 4.050427904189746e-08
. O 0 5.3726427751144e-08

These O 0 8.45077323674559e-08
rapid O 0 6.204494980011077e-07
assays O 0 1.6266191948943742e-07
detected O 0 6.289814535875848e-08
mutations O 0 1.3421063149721135e-09
in O 0 5.588363660713469e-10
76 O 0 2.1742993183693216e-08
% O 0 2.5236350786883577e-09
of O 0 1.160661877719349e-08
Costa O 0 4.807516518212651e-08
Rican O 0 1.8243382271521114e-07
patients O 0 2.290274414562532e-09
( O 0 3.951949878455707e-10
3 O 0 9.652714183516764e-10
) O 0 1.1090490331655545e-10
, O 0 6.041284139612912e-11
50 O 0 7.249530420416761e-10
% O 0 2.2242546693362897e-10
of O 0 1.4984103957615957e-09
Norwegian O 0 3.3406986403861083e-06
patients O 0 3.5766707373596773e-09
( O 0 7.630204246211747e-10
1 O 0 2.324181069823794e-09
) O 0 1.8769226450832122e-10
, O 0 3.772507306543105e-11
25 O 0 4.083749172156814e-10
% O 0 1.6678419756388507e-10
of O 0 9.639118392357204e-10
Polish O 0 9.241326779374504e-07
patients O 0 1.3622361016984996e-08
( O 0 1.756865208868419e-09
4 O 0 4.4786605535307444e-09
) O 0 2.515915253908929e-10
, O 0 3.72265794579274e-11
and O 0 4.2348423379134914e-11
14 O 0 9.451815996541768e-10
% O 0 2.977506297074939e-10
of O 0 8.193355993668661e-10
Italian O 0 3.5758674243879796e-08
patients O 0 1.0051200982630348e-09
( O 0 3.631953626737072e-10
1 O 0 2.240375884809964e-09
) O 0 1.628541468345901e-10
, O 0 1.9462476769094295e-11
as O 0 5.16149345486383e-11
well O 0 7.147840652699244e-11
as O 0 1.8375959087713056e-10
in O 0 1.0082864543292658e-09
patients O 0 1.2342360466988112e-09
of O 0 1.0010000295324062e-07
Amish O 0 0.004370891954749823
/ O 0 0.0005180989974178374
Mennonite O 0 0.0002773917804006487
and O 0 1.0740675016052137e-08
Irish O 0 1.3089090771245537e-06
English O 0 1.8807321566782775e-06
backgrounds O 0 8.412046099692816e-07
. O 0 4.799875341632287e-07

Additional O 0 4.227408396673127e-07
mutations O 0 4.26819362076003e-08
were O 0 8.10590972122327e-09
observed O 0 6.11775119452318e-09
in O 0 3.5217970761891593e-09
Japanese O 0 1.0711581808209303e-06
, O 0 2.295421630549299e-09
Utah O 0 2.6402631192468107e-07
Mormon O 0 2.515539279102086e-07
, O 0 2.073723831541585e-10
and O 0 2.612547678193522e-10
African O 0 3.7439335187627876e-08
American O 0 4.1616786461418087e-07
patients O 0 2.2268549670911852e-08
. O 0 5.031310124081756e-08

These O 0 1.6624506216089685e-08
assays O 0 4.867016301091098e-08
should O 0 1.7076746683386546e-09
facilitate O 0 2.5487908672516824e-08
screening O 0 1.5460024371805048e-08
for O 0 3.678093563053153e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 1.5194717661870527e-06
in O 0 9.456612160008149e-10
the O 0 1.1822941514694207e-09
populations O 0 6.352721682034712e-10
studied O 0 1.860738230163861e-08
. O 0 2.8109508054541266e-09
. O 0 2.5963363015080176e-08

The O 0 1.6346357369911857e-05
von B-Disease 1 0.9881677031517029
Hippel I-Disease 1 0.9999992847442627
- I-Disease 1 0.9999666213989258
Lindau I-Disease 1 0.9999992847442627
tumor I-Disease 0 0.06493104994297028
suppressor O 0 2.0098088953091064e-06
gene O 0 1.4644201407065793e-09
is O 0 5.913009665237112e-11
required O 0 2.0919743715097638e-10
for O 0 9.487615137970806e-10
cell O 0 2.750554983776965e-07
cycle O 0 2.1105411462940538e-07
exit O 0 4.101363160202709e-08
upon O 0 4.570551936922129e-08
serum O 0 2.3461884666176047e-06
withdrawal O 0 1.0008757271862123e-06
. O 0 6.891007160447771e-07

The O 0 2.7732382932299515e-06
inactivation O 0 2.325670538994018e-05
of O 0 9.099215958485729e-07
the O 0 1.0005893500419916e-06
von B-Disease 1 0.9999731779098511
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999994039535522
Lindau I-Disease 1 1.0
( I-Disease 0 8.364968380192295e-05
VHL I-Disease 1 0.9999943971633911
) I-Disease 0 2.5420290512556676e-06
tumor I-Disease 0 0.0003460294974502176
suppressor O 0 9.30799578782171e-05
gene O 0 2.0029819580713593e-08
predisposes O 0 7.528913670284965e-08
affected O 0 5.12238362837536e-10
individuals O 0 6.216076958720507e-11
to O 0 1.8887665043099133e-10
the O 0 1.249910752676442e-07
human O 1 0.9890572428703308
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 8.700248854687231e-10
is O 0 1.2022877138306853e-09
associated O 0 8.061811662685159e-09
with O 0 3.154294159202209e-09
sporadic B-Disease 1 0.9909562468528748
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.19029898941516876
RCC B-Disease 1 1.0
) O 0 7.980666509865841e-07
and O 0 2.1011322814956657e-07
brain B-Disease 1 0.9957311749458313
hemangioblastomas I-Disease 1 0.9986523985862732
. O 0 5.899944881093688e-06

VHL O 0 0.4962616562843323
- O 0 3.463864777586423e-05
negative O 0 9.463456649427826e-07
786 O 0 8.022460860956926e-06
- O 0 2.3077577679941896e-06
0 O 0 1.3482021188337967e-07
RCC B-Disease 0 0.0008189629879780114
cells O 0 1.6309903116962232e-07
are O 0 1.0102576553094877e-09
tumorigenic O 0 6.189884061313933e-06
in O 0 5.4432366169976376e-08
nude O 0 6.538234447361901e-05
mice O 0 7.520546319028654e-08
which O 0 1.149098455277553e-10
is O 0 1.5133884423423893e-10
suppressed O 0 2.5453985585954797e-09
by O 0 1.9864299094507487e-10
the O 0 2.7156004112072196e-09
reintroduction O 0 7.76235324906338e-08
of O 0 1.455577347542203e-07
VHL B-Disease 0 0.00037524569779634476
. O 0 5.059989689470967e-07

Remarkably O 0 0.00036442637792788446
, O 0 5.657153412386151e-09
this O 0 6.653672612877415e-10
occurs O 0 1.8320464034715656e-09
without O 0 2.1874675404376376e-09
affecting O 0 2.6932291952164178e-09
the O 0 1.475427335861923e-09
growth O 0 5.0975526022511986e-09
rate O 0 4.716497858936464e-09
and O 0 2.563482759398994e-10
cell O 0 6.594712687046922e-08
cycle O 0 1.6453970630436743e-08
profile O 0 5.400809244271443e-10
of O 0 2.753564321000823e-10
these O 0 9.803316491918679e-11
cells O 0 3.0466174028020987e-09
in O 0 3.777126167392453e-09
culture O 0 1.7269738350478292e-07
. O 0 1.4630563782702666e-07

The O 0 2.9690252176806098e-06
786 O 0 6.834800842625555e-06
- O 0 4.761273544318101e-07
0 O 0 3.964561656744081e-08
cell O 0 6.631822202507465e-08
line O 0 5.8473164088468366e-09
, O 0 1.915037156630106e-10
like O 0 5.321562079885211e-10
many O 0 2.7734303742477096e-10
cancer B-Disease 0 9.199649042557212e-08
cells O 0 3.218233146640159e-08
, O 0 1.410762950904143e-09
fails O 0 1.140755401252136e-08
to O 0 1.1725074244850475e-09
exit O 0 3.831490147376826e-08
the O 0 1.0782054360447546e-08
cell O 0 1.1403610500337891e-07
cycle O 0 3.471830822832089e-08
upon O 0 2.3170384721993287e-08
serum O 0 7.878464316490863e-07
withdrawal O 0 1.049795059770986e-06
. O 0 3.527950980242167e-07

Here O 0 9.968462109100074e-07
, O 0 5.585063522772771e-09
it O 0 2.1181281728566148e-10
is O 0 9.331543870949588e-11
shown O 0 3.177577367896589e-10
that O 0 6.469864227698352e-11
reintroduction O 0 8.047340571692985e-09
of O 0 1.9449879484767507e-09
the O 0 5.979021278079699e-09
wild O 0 1.902282953381018e-08
- O 0 4.848383809985535e-07
type O 0 1.2876912478532176e-06
VHL B-Disease 0 0.0018128727097064257
gene O 0 5.4522761416819776e-08
restores O 0 7.845333982459124e-08
the O 0 2.3944757288063556e-09
ability O 0 4.840416512053025e-09
of O 0 1.3725961878208182e-07
VHL O 1 0.999661922454834
- O 0 0.0005851078312844038
negative O 0 1.6566066278755898e-06
RCC B-Disease 1 0.9997133612632751
cancer I-Disease 0 4.36172570061899e-07
cells O 0 3.3681777367178256e-09
to O 0 2.8040039734555933e-10
exit O 0 6.245223005407752e-09
the O 0 2.438872659382696e-09
cell O 0 1.7676995867077494e-08
cycle O 0 1.8391862255384694e-08
and O 0 1.0317268150927816e-09
enter O 0 4.203632784083311e-07
G0 O 1 0.6348016262054443
/ O 0 9.916501585394144e-05
quiescence O 0 4.736748815048486e-05
in O 0 1.0392368210432323e-07
low O 0 9.105066851589072e-07
serum O 0 6.709824447170831e-06
. O 0 2.2521233233874227e-07

Both O 0 1.4762339333174168e-06
VHL O 0 0.0012750880559906363
- O 0 1.5455800621566596e-06
positive O 0 1.274105621007493e-08
and O 0 9.631349939809297e-09
VHL O 0 0.004472040571272373
- O 0 4.96348229717114e-06
negative O 0 1.433473926226725e-07
RCC B-Disease 0 0.0002357122430112213
cells O 0 2.1124899163282862e-08
exit O 0 7.472586105450318e-09
the O 0 5.562398097680443e-09
cell O 0 5.2744574929874943e-08
cycle O 0 4.7815998271971694e-08
by O 0 4.64548355338934e-09
contact O 0 8.999041369861516e-07
inhibition O 0 2.4411904178123223e-06
. O 0 1.256608612720811e-07

The O 0 4.396636541059706e-06
cyclin O 0 8.83121756487526e-05
- O 0 1.7842079387264675e-06
dependent O 0 8.058623279794119e-07
kinase O 0 8.717231025912042e-07
inhibitor O 0 4.9212228958595006e-08
, O 0 5.802384683839534e-10
p27 O 0 2.821545592723851e-07
, O 0 8.272404428133484e-10
accumulates O 0 2.3366457213569447e-08
upon O 0 5.8953810722073285e-09
serum O 0 4.233685757526473e-08
withdrawal O 0 1.137965099928806e-08
, O 0 5.35230360032557e-10
only O 0 2.1866157495775695e-10
in O 0 3.2423633222755655e-10
the O 0 1.1684264666911304e-09
presence O 0 7.035581894854204e-09
of O 0 7.482002217784611e-08
VHL B-Disease 0 0.21222053468227386
, O 0 3.3671563315351705e-09
as O 0 7.254676304135899e-10
a O 0 1.0072082057277498e-09
result O 0 2.8396987539203167e-10
of O 0 1.1477147010552358e-09
the O 0 7.923828260203436e-10
stabilization O 0 9.193422556563746e-08
of O 0 6.920248551978148e-08
the O 0 9.846186088680042e-08
protein O 0 3.3390185194548394e-07
. O 0 8.319660338429458e-08

We O 0 3.979498330863862e-07
propose O 0 1.1876439032221242e-07
that O 0 4.234539829894857e-09
the O 0 1.6674301051011753e-08
loss O 0 1.6204151620513585e-07
of O 0 1.5605793635131704e-07
wild O 0 5.002259513275931e-07
- O 0 1.0679720617190469e-05
type O 0 1.1792917575803585e-05
VHL B-Disease 1 0.9321279525756836
gene O 0 1.847610597849325e-08
results O 0 1.1462510940418724e-09
in O 0 2.2411698885616005e-10
a O 0 8.980414745174414e-10
specific O 0 3.288754601982191e-09
cellular O 0 7.835163273739454e-07
defect O 0 1.349322360510996e-07
in O 0 2.7862046003690466e-09
serum O 0 2.108803982991958e-06
- O 0 6.879514694446698e-05
dependent O 0 2.9924083264631918e-06
growth O 0 1.2488808209809577e-08
control O 0 3.3026974488592487e-09
, O 0 8.143620500167259e-11
which O 0 8.862776484930279e-11
may O 0 1.0310383657952116e-09
initiate O 0 6.886408954187573e-08
tumor B-Disease 0 2.359717655053828e-05
formation O 0 5.213841632212279e-06
. O 0 7.113480933185201e-07

This O 0 9.622667818121045e-08
is O 0 6.426910115209239e-09
corrected O 0 1.3798685927213228e-07
by O 0 1.2335207300040452e-09
the O 0 2.056076642276139e-09
reintroduction O 0 1.8973619120288276e-08
of O 0 1.308166908131625e-08
wild O 0 6.492842885563732e-08
- O 0 3.383370085430215e-06
type O 0 2.3078362573869526e-05
VHL B-Disease 1 0.9999897480010986
, O 0 2.0223339447511535e-07
implicating O 1 0.5414580702781677
VHL B-Disease 0 0.4338354766368866
as O 0 5.8744022979340116e-09
the O 0 4.832897637641054e-09
first O 0 2.0972301228994183e-08
tumor B-Disease 0 7.476351697732753e-07
suppressor O 0 1.8688696457047627e-07
involved O 0 1.8552371860991457e-09
in O 0 2.884213978759931e-10
the O 0 3.412947924275045e-09
regulation O 0 2.1552111206801783e-08
of O 0 4.698058830854279e-08
cell O 0 3.391574523448071e-07
cycle O 0 5.806841230082682e-08
exit O 0 1.6959576853992075e-08
, O 0 1.1655189313675152e-10
which O 0 5.518305604135243e-11
is O 0 2.064922122180235e-10
consistent O 0 5.9175739863803756e-09
with O 0 2.1510900005683453e-10
its O 0 1.563449814057094e-09
gatekeeper O 0 2.3806020976735454e-07
function O 0 1.1993041226787682e-08
in O 0 1.5674180842140117e-09
the O 0 2.9341215679323795e-08
kidney O 0 9.80148706730688e-06
. O 0 3.1739944006403675e-08
. O 0 2.909995657773834e-07

Piebaldism B-Disease 1 1.0
with O 0 0.0014188360655680299
deafness B-Disease 1 1.0
: O 0 5.538067853194661e-07
molecular O 0 8.096106284938287e-06
evidence O 0 2.2913401664936828e-07
for O 0 3.485364219457665e-09
an O 0 6.498591176296031e-08
expanded O 0 8.975805940281134e-06
syndrome O 1 0.9959114789962769
. O 0 8.978536811810045e-07

In O 0 3.108264365891955e-07
a O 0 1.1090801166346864e-07
South O 0 2.0459891914015316e-07
African O 0 7.189485273784157e-08
girl O 0 6.103651344346872e-07
of O 0 2.6195965574515867e-07
Xhosa O 1 0.8234527707099915
stock O 0 2.3589784348132525e-07
with O 0 1.5182057833129647e-09
severe O 0 4.1050288928090595e-06
piebaldism B-Disease 1 0.997171938419342
and O 0 1.2351856639725156e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 7.715950687270379e-07
identified O 0 1.4732493980318395e-07
a O 0 2.061567272448883e-08
novel O 0 3.7422484666649325e-08
missense O 0 8.544844831703813e-08
substitution O 0 1.0549216611366319e-08
at O 0 1.894573742333705e-08
a O 0 3.5508542772788587e-09
highly O 0 7.08384106928861e-09
conserved O 0 9.754275254181266e-08
residue O 0 2.990474570196966e-07
in O 0 3.937543180398961e-09
the O 0 2.1412635220485754e-08
intracellular O 0 2.4111191123665776e-06
kinase O 0 8.789103844719648e-07
domain O 0 4.6971898370884446e-08
of O 0 1.2973581320352423e-08
the O 0 6.825342069305407e-08
KIT O 0 0.0008533659856766462
proto O 0 0.001904948614537716
- O 0 0.00038665474858134985
oncogene O 0 0.0010709998896345496
, O 0 1.0569643649205318e-07
R796G O 0 4.0281829569721594e-05
. O 0 7.23063806162827e-07

Though O 0 7.586597803310724e-06
auditory B-Disease 0 0.011990007944405079
anomalies I-Disease 0 0.000561263645067811
have O 0 3.6515017676208572e-09
been O 0 5.954211346193006e-09
observed O 0 4.083784332920004e-08
in O 0 1.173640207241533e-08
mice O 0 2.322161662959843e-08
with O 0 5.383141155057558e-10
dominant O 0 1.9784654625709663e-07
white O 0 2.844054236561533e-08
spotting O 0 4.281135625205934e-05
( O 0 1.2528601018857444e-06
W O 1 0.9707660675048828
) O 0 6.142913733242494e-09
due O 0 1.4626902355985294e-08
to O 0 6.6978715906884645e-09
KIT O 1 0.9962961077690125
mutations O 0 2.155984111595899e-05
, O 0 1.6886713183339452e-06
deafness B-Disease 1 1.0
is O 0 3.158793404622884e-08
not O 0 4.069102832460203e-09
typical O 0 2.5873495701489446e-07
in O 0 3.156294070549848e-08
human O 0 1.2002097093954944e-07
piebaldism B-Disease 0 0.00013148463040124625
. O 0 4.5805882109561935e-07

Thus O 0 1.661609644543205e-06
, O 0 1.5606916647925573e-08
the O 0 2.284895650461749e-08
occurrence O 0 7.453168109350372e-06
of O 0 0.003141768043860793
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 2.3925770165078575e-06
this O 0 3.1408600165150347e-08
patient O 0 4.265898780886346e-07
extends O 0 8.595547384970814e-09
considerably O 0 2.347280370074145e-09
the O 0 3.993747554886795e-10
phenotypic O 0 2.4996442693492327e-09
range O 0 1.6794625690152998e-09
of O 0 4.428171607173681e-09
piebaldism B-Disease 0 4.903178023596411e-07
due O 0 1.9876296164511587e-08
to O 0 3.1594484806163337e-09
KIT O 0 1.1997398360108491e-05
gene O 0 2.5160760586118158e-08
mutation O 0 1.1730285631728066e-09
in O 0 1.663667120732626e-10
humans O 0 2.5239526024734005e-09
and O 0 7.248285860406156e-10
tightens O 0 2.0352771912257595e-08
the O 0 1.2658835091272636e-09
clinical O 0 9.492980979075583e-08
similarity O 0 1.332015564514677e-08
between O 0 2.3077321387177108e-08
piebaldism B-Disease 0 5.838425749971066e-06
and O 0 1.6760376420066336e-10
the O 0 2.749848404537403e-10
various O 0 2.977602608922325e-10
forms O 0 3.350997923590171e-09
of O 0 4.872715180681553e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.999997615814209
. O 0 1.6230319488386158e-07
. O 0 5.405080401033047e-07

Cycloheximide O 0 0.002384585328400135
facilitates O 0 2.9681586966034956e-06
the O 0 4.6887400628747855e-08
identification O 0 9.60185957410431e-08
of O 0 7.823054914979366e-08
aberrant O 0 1.0472872418176848e-06
transcripts O 0 2.182677690143464e-06
resulting O 0 5.075667175447052e-08
from O 0 2.2581552627798374e-08
a O 0 4.028170152992061e-08
novel O 0 2.2834367996438232e-07
splice O 0 2.763983729892061e-06
- O 0 1.685839521314847e-07
site O 0 7.818311331675432e-08
mutation O 0 5.539085190520154e-09
in O 0 5.00804242520303e-09
COL17A1 O 0 0.00019773044914472848
in O 0 1.0618417256580415e-08
a O 0 2.122178166530375e-08
patient O 0 6.392972551338971e-08
with O 0 6.191341217487434e-09
generalized O 0 9.741127723827958e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999974966049194
. O 0 3.6137575989414472e-06

Patients O 0 1.0320163710275665e-05
with O 0 1.1750876893756868e-07
generalized O 0 0.0012689292198047042
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 5.3559755741616755e-08
show O 0 4.6383323848431246e-08
decreased O 0 1.794467294757851e-07
expression O 0 1.1438143765474251e-08
of O 0 3.4303617724162905e-08
type O 0 1.237463493453106e-06
XVII O 1 0.9999247789382935
collagen O 0 0.04174458980560303
, O 0 6.602402180533318e-08
a O 0 4.1349588286720973e-07
transmembrane O 0 8.278580025944393e-06
hemidesmosomal O 0 5.025468908570474e-06
protein O 0 8.335099010992053e-08
encoded O 0 3.027664519095197e-08
by O 0 2.1011219430988604e-08
COL17A1 O 0 0.00015624122170265764
. O 0 6.792425892854226e-07

This O 0 3.5098966577606916e-07
report O 0 8.097475756585482e-08
documents O 0 2.4925856223489973e-07
a O 0 4.329012170956048e-08
novel O 0 4.562138258279447e-07
splice O 0 4.4319949665805325e-06
- O 0 2.8636534921133716e-07
site O 0 1.468169159579702e-07
mutation O 0 6.699047094826938e-09
in O 0 3.6665346314634917e-09
COL17A1 O 0 0.001226640772074461
in O 0 2.765346351907283e-08
a O 0 4.1191359656522764e-08
patient O 0 6.691234943900781e-08
with O 0 3.250855140635167e-09
generalized O 0 7.36943693482317e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999996423721313
, O 0 1.1792994136783364e-08
and O 0 1.2312829644756107e-09
applies O 0 3.5336258363827255e-09
a O 0 1.4037521145482401e-09
new O 0 7.094789755690556e-10
methodology O 0 3.972562723220108e-08
to O 0 7.809093927058086e-10
define O 0 2.6842764455636825e-08
and O 0 3.756062127990845e-09
characterize O 0 3.353884210355318e-07
the O 0 3.865121911417191e-08
resulting O 0 1.547920902567057e-07
mRNA O 0 1.4715475344928564e-06
splice O 0 2.115672941727098e-06
variants O 0 9.060391192861061e-08
. O 0 5.022910798402336e-08

Mutational O 0 0.008500220254063606
analysis O 0 7.13413328412571e-06
of O 0 2.0838760974584147e-06
COL17A1 O 0 0.004528059624135494
identified O 0 1.0031997135229176e-06
a O 0 1.5535628961060866e-07
maternally O 0 2.4065934667305555e-06
inherited O 0 4.228576017339947e-06
G O 0 1.272551526199095e-05
- O 0 1.5866837657085853e-06
to O 0 1.4837128503586428e-07
- O 0 0.00016192485054489225
T O 0 6.461956218117848e-05
transversion O 0 1.3684526493307203e-05
at O 0 2.797159766032564e-07
the O 0 3.772210988017832e-08
- O 0 3.3794858467217637e-08
1 O 0 2.5402101755389594e-08
position O 0 3.898975009519745e-08
of O 0 9.114035748325477e-08
exon O 0 2.4979638055810938e-06
32 O 0 5.707508989871712e-07
. O 0 2.8061612056262675e-07

This O 0 3.589473180909408e-07
acceptor O 0 3.612599073221645e-07
splice O 0 7.099599770299392e-06
- O 0 5.206916853239818e-07
site O 0 9.795815003599273e-08
mutation O 0 4.2684682455274015e-09
led O 0 2.1898054480828932e-09
to O 0 5.994273410969697e-10
the O 0 7.152376024777141e-09
formation O 0 1.4494739275505708e-07
of O 0 1.3928439557275851e-06
aberrant O 0 2.5731758341862587e-06
transcripts O 0 1.019023898152227e-06
present O 0 3.2053989684754924e-08
at O 0 1.233280642054524e-07
extremely O 0 4.0465437223247136e-08
low O 0 1.6707417671568692e-07
levels O 0 1.028611507081223e-07
. O 0 1.2202255561533093e-07

Based O 0 9.910488643072313e-07
on O 0 4.145381637954415e-08
our O 0 1.53009942494009e-08
recent O 0 2.2165564939058413e-09
finding O 0 1.4697516093065133e-08
that O 0 1.4746873722160103e-09
cycloheximide O 0 4.246041044098092e-06
stabilized O 0 1.2066717317793518e-05
mutant O 0 9.263942502002465e-07
COL17A1 O 0 4.9323203711537644e-05
transcripts O 0 7.096676881701569e-07
in O 0 3.166603645965438e-09
keratinocytes O 0 5.260261559669743e-08
homozygous O 0 6.256382523162074e-09
for O 0 3.2779440273245086e-10
a O 0 1.0060912103426745e-08
frameshift O 0 2.396095055701153e-07
mutation O 0 1.1431878776946292e-09
, O 0 1.057182674735202e-10
the O 0 6.860733092750593e-10
effects O 0 4.186381730164612e-08
of O 0 6.531795548880837e-08
the O 0 1.082547669284395e-07
splice O 0 1.778031787580403e-06
- O 0 8.08704214705358e-08
site O 0 2.770689100373147e-08
mutation O 0 4.925875818351244e-10
on O 0 1.3542613697126171e-09
splicing O 0 3.841302742557673e-08
of O 0 2.7323261875267235e-08
COL17A1 O 0 1.0230219231743831e-05
transcripts O 0 1.5865370528445055e-07
were O 0 1.734272170317297e-09
determined O 0 3.089752675933255e-09
using O 0 3.431459338898435e-09
reverse O 0 8.161826059449595e-08
transcriptase O 0 2.0557017421651835e-07
polymerase O 0 1.7775542460185534e-07
chain O 0 1.5445227319332844e-08
reaction O 0 6.09645445237561e-10
of O 0 4.283213339562053e-09
total O 0 2.36127810637754e-08
RNA O 0 4.949340564053273e-07
from O 0 7.13279924013932e-09
keratinocytes O 0 6.977544586561635e-08
incubated O 0 1.446662167836621e-07
for O 0 2.3319339792493565e-09
2 O 0 1.566993574897424e-07
. O 0 1.2837574558943743e-07

5 O 0 4.208159680274548e-06
h O 0 2.4720304736547405e-06
in O 0 7.855378569843197e-09
the O 0 1.0083254231574301e-08
presence O 0 3.6659070445921316e-08
or O 0 1.3034821222390747e-08
absence O 0 2.4970157141979143e-07
of O 0 8.955839803093113e-07
10 O 0 3.9288809716708784e-07
microg O 0 4.766282290802337e-05
cycloheximide O 0 9.284955012844875e-05
per O 0 3.096364252996864e-06
ml O 0 1.1278521924396046e-05
. O 0 1.764978065921241e-07

Using O 0 1.4344955445722007e-07
this O 0 5.394593660668079e-09
approach O 0 5.787722656691585e-08
, O 0 3.6537171066441942e-09
an O 0 5.681884296393491e-09
abnormally O 0 1.4010666973263142e-06
spliced O 0 8.964436233327433e-07
transcript O 0 1.7968338852369925e-06
was O 0 2.708659785355394e-08
identified O 0 2.1956481077722856e-09
that O 0 6.386930567758853e-11
contains O 0 1.6702995930817366e-10
an O 0 2.5598964614736985e-10
extra O 0 1.7685146680435082e-09
264 O 0 9.533695610741688e-09
bases O 0 4.5501176160200885e-09
upstream O 0 8.960848418837486e-08
from O 0 2.4500905748681134e-09
exon O 0 3.062290687694258e-08
32 O 0 2.7984756734156235e-09
, O 0 1.9015408692091285e-10
resulting O 0 1.453281717189725e-09
in O 0 1.7049602840657485e-09
a O 0 2.737250426321225e-08
premature O 0 4.6952413867984433e-07
termination O 0 1.580461798766919e-06
codon O 0 4.612809334503254e-06
27 O 0 3.7541703932220116e-06
bp O 0 7.89508794696303e-06
downstream O 0 2.0718678115372313e-06
from O 0 6.106212424583646e-08
the O 0 2.3266977677849354e-07
cryptic O 0 1.8797545635607094e-05
splice O 0 3.863644815282896e-05
site O 0 8.53317578730639e-06
. O 0 5.838057859364199e-07

Three O 0 2.357561612598147e-07
other O 0 9.619801843996356e-09
splice O 0 5.588304929915466e-07
variants O 0 1.7464254042920402e-08
, O 0 6.692938980812357e-10
including O 0 6.490966653061037e-10
one O 0 1.7274943697742629e-09
derived O 0 1.0039940434580785e-08
from O 0 8.8914164919629e-09
the O 0 3.0309234233527604e-08
skipping O 0 2.645621748342819e-07
of O 0 1.9782730475981225e-07
exon O 0 3.9025019304972375e-07
32 O 0 2.3799159976078954e-08
, O 0 7.067076368549863e-10
were O 0 5.769500877050859e-09
also O 0 1.0193106803058072e-08
identified O 0 2.1667690930371464e-07
. O 0 4.6745196868869243e-07

These O 0 3.872205667221351e-08
results O 0 3.660610659039776e-08
indicate O 0 3.218828581452726e-08
the O 0 7.795406986588205e-09
usefulness O 0 4.412231078276818e-07
of O 0 3.8233139321164344e-08
cycloheximide O 0 3.2794876005937112e-06
treatment O 0 7.660086787097953e-09
in O 0 6.901603177844606e-10
evaluating O 0 9.114032195611799e-09
the O 0 3.5476861448557884e-09
abnormal O 0 5.509038558670909e-08
processing O 0 4.1692729269016127e-08
of O 0 3.5549899024545084e-08
mRNA O 0 9.843031278933267e-08
due O 0 1.355318968165875e-08
to O 0 3.6887848331446094e-09
splice O 0 3.536531210102112e-07
- O 0 4.224490268711634e-08
site O 0 6.705566768516746e-09
mutations O 0 1.322253556645947e-10
, O 0 4.867064737346105e-11
because O 0 2.8578306388027386e-10
( O 0 2.977893709399382e-09
i O 0 2.5559765859384243e-08
) O 0 3.711228302449854e-08
aberrant O 0 2.5735880626598373e-07
splicing O 0 1.526770887494422e-07
often O 0 2.1507382541585685e-09
generates O 0 7.990413664060725e-09
a O 0 5.995351326504306e-09
premature O 0 4.3182421194387643e-08
termination O 0 8.978984311625027e-08
codon O 0 1.2896167334019992e-07
, O 0 4.5103965007342595e-09
( O 0 6.681781350437177e-09
ii O 0 1.2833538676204626e-06
) O 0 2.862159220740068e-08
transcripts O 0 3.8701352877978934e-07
with O 0 5.520879753362351e-09
premature O 0 7.855476837903552e-07
termination O 0 4.1559275132385665e-07
codons O 0 6.343658043306277e-08
can O 0 7.496379628157968e-10
occur O 0 3.942239867882336e-09
at O 0 1.178530837364633e-07
low O 0 1.6256453250207414e-07
or O 0 4.682811471923287e-09
undetectable O 0 1.7723237988320761e-07
levels O 0 6.8488126281351924e-09
due O 0 2.723853587127678e-09
to O 0 1.1874083938323565e-09
nonsense O 0 3.8218126974243205e-07
- O 0 5.5266564658040807e-08
mediated O 0 4.572731882035441e-08
mRNA O 0 1.675818595003875e-08
decay O 0 5.633421729100974e-09
, O 0 5.513823425618014e-11
and O 0 5.950969578227827e-11
( O 0 2.8446373034896055e-10
iii O 0 1.5990254453868147e-08
) O 0 3.3699110169038704e-10
the O 0 4.778331064159147e-10
levels O 0 1.1470778771283108e-09
of O 0 4.410770637619521e-10
these O 0 1.2793056891613475e-10
transcripts O 0 3.839244300252176e-08
can O 0 1.7091400517088573e-10
be O 0 6.709465760756927e-10
increased O 0 5.087790189151065e-09
by O 0 2.6878062442392547e-08
cycloheximide O 0 3.37519304594025e-05
. O 0 7.14002226231969e-07

A O 0 1.4797147741774097e-05
deletion O 0 3.887939328706125e-06
mutation O 0 7.073542462876503e-08
in O 0 2.3804334503552127e-08
COL17A1 O 0 0.0016633959021419287
in O 0 2.39546373848043e-08
five O 0 2.1402062344577644e-08
Austrian O 0 5.468400104291504e-06
families O 0 1.849761588346155e-08
with O 0 1.0248608184326713e-08
generalized O 0 1.6561278243898414e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999994039535522
represents O 0 4.767766768054571e-07
propagation O 0 1.354888240712171e-06
of O 0 7.908720789373547e-08
an O 0 8.044290211728367e-08
ancestral O 0 4.6461191232083365e-05
allele O 0 8.215488946916594e-07
. O 0 4.3514012304513017e-07

Patients O 0 1.098670509236399e-05
with O 0 1.0520085425014258e-07
generalized O 0 0.00032628237386234105
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 2.9198574225119955e-08
a O 0 1.1560573831559395e-08
usually O 0 3.775376011816434e-09
nonlethal O 0 2.99895702937647e-07
form O 0 1.0365187819161292e-07
of O 0 0.001287633553147316
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.1486283924000418e-08
have O 0 8.367714299239992e-10
generalized O 0 4.41858922783922e-08
blistering B-Disease 0 1.760178633958276e-06
, O 0 1.7506685878743156e-07
nail B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
, O 0 2.535216253818362e-06
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 8.276655307781766e-07
and O 0 1.8968366930494085e-05
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.010335934348404408

Skin B-Disease 1 0.9999439716339111
fragility I-Disease 1 0.9998165965080261
in O 0 4.619914406589487e-08
most O 0 1.0159639796114561e-09
cases O 0 3.6172284612057126e-10
is O 0 1.788139081249085e-10
due O 0 1.3992343950164354e-09
to O 0 2.573589674703669e-10
mutations O 0 2.860808256954783e-10
in O 0 2.4576202184434237e-10
the O 0 1.901549140370662e-09
gene O 0 3.119282387942235e-09
encoding O 0 6.951015318890086e-09
type O 0 2.1240477110495704e-07
XVII O 1 0.8431881070137024
collagen O 0 0.07098180055618286
( O 0 3.0038458135095425e-05
COL17A1 O 1 0.9938030242919922
) O 0 3.0652714144707716e-07
. O 0 2.6759218485494785e-07

Recently O 0 1.2077965038770344e-05
, O 0 2.5168967354716187e-08
we O 0 8.563735498512415e-09
reported O 0 3.167728834796435e-08
five O 0 1.0663494975915455e-08
Austrian O 0 1.5687654695284436e-06
families O 0 8.598564527062535e-09
with O 0 3.5608513915263984e-09
generalized O 0 1.8544067643233575e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 1.3337651694200758e-07
share O 0 7.778952948456208e-08
the O 0 4.7460634533535995e-08
same O 0 1.5693728983023902e-07
COL17A1 O 0 0.004005490802228451
mutation O 0 6.221684429874585e-07
. O 0 2.687017683911108e-07

Affected O 0 1.0780860293380101e-06
individuals O 0 3.944436333114254e-09
in O 0 1.520529924192715e-09
three O 0 5.185296081400281e-10
families O 0 1.8893142605946878e-10
are O 0 4.2855788362494707e-11
homozygous O 0 1.488154044437806e-09
for O 0 2.687070566054217e-10
4003delTC O 0 1.4288349348134943e-07
, O 0 1.1051346504586945e-09
whereas O 0 7.021130343787263e-09
those O 0 2.2075433148138757e-10
in O 0 7.677752877910393e-10
two O 0 4.1122941163429516e-10
others O 0 1.9378707527550887e-09
are O 0 2.4929067699019924e-09
compound O 0 4.900708972854773e-06
heterozygotes O 0 8.311844794661738e-06
. O 0 4.801871682502679e-07

To O 0 1.0120039206640286e-07
determine O 0 9.117616883713708e-08
if O 0 9.883549978439987e-09
the O 0 2.325188752649865e-08
occurrence O 0 2.432342967040313e-07
of O 0 1.6155061288714023e-08
4003delTC O 0 1.8674906243631995e-07
in O 0 3.611706489436983e-10
these O 0 1.469105531670678e-10
unrelated O 0 2.6869503955140317e-08
families O 0 1.1989077508545165e-09
signifies O 0 1.0444267672937713e-08
propagation O 0 5.4262777382518834e-08
of O 0 1.223553169893421e-08
an O 0 9.114379473373901e-09
ancestral O 0 1.220980379912362e-06
allele O 0 1.5851057355575904e-08
or O 0 4.837841238725105e-09
a O 0 1.9739530898732482e-08
mutational O 0 3.101580432485207e-06
hot O 0 1.2395535975429084e-07
spot O 0 6.14695991885128e-08
, O 0 1.6691443782690385e-09
haplotypes O 0 4.7170402694973745e-08
were O 0 1.390062620565402e-09
determined O 0 3.941969417553537e-09
for O 0 2.0634980391065483e-09
polymorphisms O 0 1.1485522577459051e-07
both O 0 2.232033002869116e-09
within O 0 4.511430873321842e-08
and O 0 3.694715644542157e-08
flanking O 0 0.00021470054343808442
COL17A1 O 1 0.9999891519546509
. O 0 9.909648724715225e-06

Five O 0 1.233836155734025e-05
intragenic O 0 8.354063902515918e-05
polymorphisms O 0 3.222381337764091e-06
were O 0 4.155102573122349e-08
chosen O 0 5.515430601121807e-08
based O 0 7.517133582268798e-08
on O 0 1.8108350730017264e-07
their O 0 1.7673428942543978e-07
informativeness O 0 0.0001540716184535995
. O 0 2.175476765842177e-06

One O 0 8.672900548845064e-07
of O 0 1.2649000780129427e-07
these O 0 4.799570518798646e-09
, O 0 4.2434495917120785e-09
not O 0 1.6550781856139452e-09
previously O 0 4.9211575259278106e-08
reported O 0 9.525447808300669e-08
, O 0 2.0512860299248814e-09
was O 0 5.930423867539503e-07
2988 O 0 9.413164661964402e-06
A O 0 7.049540045045433e-07
or O 0 8.398162165690337e-09
C O 0 6.580639251296816e-07
that O 0 5.249301548992946e-10
introduces O 0 8.429904774232e-09
a O 0 4.613958992649714e-09
new O 0 1.1052315729287443e-09
restriction O 0 7.6480421995484e-09
site O 0 5.027377270039324e-08
for O 0 1.4281532401128061e-08
Eco0109 O 0 2.2981397705734707e-05
I O 0 7.518695201724768e-05
. O 0 5.8913647080771625e-06

All O 0 2.936518797014287e-07
the O 0 1.3391986897204333e-07
4003delTC O 0 2.435711621728842e-06
alleles O 0 3.240147705696472e-08
showed O 0 1.5381315776608062e-08
the O 0 2.2047081937870416e-09
same O 0 3.1528146759995934e-09
haplotype O 0 2.0179406590159488e-08
for O 0 4.256287544635029e-10
these O 0 8.034177212401516e-10
five O 0 2.4446116242415883e-08
polymorphic O 0 6.899845743646438e-07
markers O 0 1.530079771328019e-06
. O 0 3.5169898637832375e-07

Fourteen O 0 5.0800179451471195e-05
microsatellite O 0 0.0001437213650206104
polymorphisms O 0 4.8574920583632775e-06
were O 0 4.353314153604515e-08
selected O 0 1.0146688822487704e-08
based O 0 1.8939740442647235e-08
on O 0 2.4220508265671015e-08
their O 0 9.06815067480693e-09
high O 0 2.246704582375969e-07
heterozygosity O 0 0.0002533321385271847
and O 0 6.311420275295632e-09
their O 0 5.71236435931155e-09
location O 0 3.8150466252773185e-07
within O 0 7.996575845936604e-08
10q23 O 0 1.864998739620205e-05
- O 0 1.6095376849989407e-05
q25 O 0 0.00011208426440134645
near O 0 3.251084854127839e-05
COL17A1 O 0 0.0018363057170063257
. O 0 1.2290718132135225e-06

Three O 0 4.594058395923639e-07
families O 0 5.976081496328334e-08
shared O 0 4.119124810131325e-07
microsatellite O 0 0.00014134759840089828
polymorphisms O 0 1.3458283319778275e-05
covering O 0 8.598634849477094e-06
at O 0 3.768094074985129e-06
most O 0 5.555273130397609e-09
19 O 0 2.4554905664331272e-08
cM O 0 6.674409291917982e-08
, O 0 4.429867028754586e-10
whereas O 0 3.0082301094580544e-09
the O 0 1.5881401749240354e-09
others O 0 7.297294435382184e-10
shared O 0 3.571455575723803e-09
smaller O 0 5.485420451201151e-10
regions O 0 6.178950684443407e-10
consistent O 0 4.693568644853485e-09
with O 0 1.034465291205322e-10
cross O 0 1.0818102857967915e-08
- O 0 2.3453035069564976e-08
over O 0 8.403028273207269e-10
events O 0 1.6004588765383687e-09
during O 0 1.5399096442436644e-09
passage O 0 4.145624732387887e-09
of O 0 5.931470314912701e-10
this O 0 6.584346956550746e-11
mutation O 0 5.6121919611573645e-11
through O 0 2.729047265948026e-10
several O 0 1.584760322970169e-09
generations O 0 7.797849121971012e-08
. O 0 6.435658406189759e-08

These O 0 1.456527201071367e-07
results O 0 1.9154451535996486e-07
indicate O 0 1.6369678235150786e-07
that O 0 2.434903390025056e-09
4003delTC O 0 7.194183240244456e-07
occurs O 0 1.6030625715757196e-08
on O 0 1.1182944348320234e-08
a O 0 1.3001970167181298e-08
single O 0 1.63898850047417e-08
ancestral O 0 9.647280876379227e-07
allele O 0 3.2899233559646746e-08
. O 0 6.3114442561129636e-09
. O 0 1.4522994717935944e-07

The O 0 2.7528403734322637e-06
haptoglobin O 0 0.00020642679010052234
- O 0 9.105518074647989e-06
gene O 0 1.8870765927658795e-07
deletion O 0 2.6919937567981833e-07
responsible O 0 9.143077051021464e-08
for O 0 9.574336701234643e-08
anhaptoglobinemia B-Disease 0 0.005828639958053827
. O 0 3.7856498238397762e-06

We O 0 5.091928869660478e-07
have O 0 1.1138644673280851e-08
found O 0 1.1135054656108423e-08
an O 0 1.0246672843550186e-08
allelic O 0 5.388168347053579e-07
deletion O 0 3.124327747627831e-07
of O 0 4.911086648462515e-07
the O 0 6.542986739077605e-07
haptoglobin O 0 0.000507913704495877
( O 0 6.972848041186808e-07
Hp O 0 2.9433529107336653e-06
) O 0 2.3647745983623736e-09
gene O 0 5.03121877493129e-10
from O 0 2.8014862651914996e-10
an O 0 1.2459513420992607e-09
individual O 0 7.947732250102035e-09
with O 0 8.527842432215493e-09
anhaptoglobinemia B-Disease 0 0.04565485194325447
. O 0 1.9061529883401818e-06

The O 0 1.0871575796045363e-05
Hp O 0 2.0110830519115552e-05
gene O 0 3.180927521384547e-08
cluster O 0 2.2552111289542154e-08
consists O 0 1.5020710009139293e-08
of O 0 4.9453205974714365e-08
coding O 0 4.0717168303672224e-06
regions O 0 1.6503506117260258e-08
of O 0 5.115047230219716e-08
the O 0 9.270371492675622e-08
alpha O 0 1.3801978866467834e-06
chain O 0 2.344212290950054e-08
and O 0 3.008687743388805e-10
beta O 0 3.5054465996608997e-08
chain O 0 7.91306398184588e-09
of O 0 2.050886793725226e-09
the O 0 1.1583529690994965e-08
haptoglobin O 0 2.0800382571906084e-06
gene O 0 6.624411685862697e-09
( O 0 1.0785381476807743e-09
Hp O 0 2.2075287375855623e-08
) O 0 6.434139332434086e-11
and O 0 1.9834758835379773e-11
of O 0 1.3000226450898822e-09
the O 0 8.761769976217693e-09
alpha O 0 1.5563286126507592e-07
chain O 0 2.661691134164812e-08
and O 0 6.137265695649319e-10
beta O 0 5.56713501964623e-08
chain O 0 1.4009977178375266e-08
of O 0 3.003460147255055e-09
the O 0 1.2238753122062462e-08
haptoglobin O 0 6.899332220200449e-06
- O 0 4.801079285243759e-07
related O 0 4.368419581624039e-07
gene O 0 7.000073054541645e-08
( O 0 2.7228630017361866e-08
Hpr O 0 4.59659167972859e-06
) O 0 3.9279046681883756e-09
, O 0 4.970668876502771e-10
in O 0 2.1128554461569138e-09
tandem O 0 2.1129397964614327e-07
from O 0 2.0744298723229804e-08
the O 0 1.490162162554043e-07
5 O 0 1.5972703693023504e-07
side O 0 2.4301263579218357e-07
. O 0 3.9551744634991337e-07

Southern O 0 5.367057838157052e-06
blot O 0 5.512777079275111e-06
and O 0 1.6255205181892052e-08
PCR O 0 2.92336352458733e-07
analyses O 0 8.384945004991096e-08
have O 0 3.504687651201266e-10
indicated O 0 1.7199719426486126e-09
that O 0 5.5062145815076846e-11
the O 0 4.246978047017791e-10
individual O 0 2.548593835971502e-10
with O 0 4.596687475100225e-10
anhaptoglobinemia B-Disease 0 1.0786249049488106e-06
was O 0 1.0090453628208707e-07
homozygous O 0 4.2831320712366505e-09
for O 0 1.719052816762101e-10
the O 0 1.1801606358829986e-09
gene O 0 1.3239501717166036e-09
deletion O 0 2.458094838786451e-09
and O 0 1.1446774778045565e-10
that O 0 1.6129182711654977e-10
the O 0 5.326195484656182e-09
gene O 0 5.81280001910045e-09
deletion O 0 1.0677701389738559e-08
was O 0 4.514839702096651e-08
included O 0 1.0983099762995607e-08
at O 0 4.6533877195997775e-08
least O 0 1.912537683779192e-09
from O 0 1.2804097782037616e-09
the O 0 1.569192598083191e-08
promoter O 0 1.6369317563658115e-06
region O 0 2.3270482074622123e-07
of O 0 1.9487765712256078e-06
Hp O 0 9.089623745239805e-06
to O 0 1.9292858866037932e-08
Hpr O 0 1.1948711289733183e-05
alpha O 0 1.8831357806448068e-07
but O 0 8.341039525738836e-10
not O 0 6.366938087865037e-10
to O 0 6.794996565417932e-09
Hpr O 0 1.593604429217521e-05
beta O 0 1.3307784456628724e-06
( O 0 7.111690791816727e-08
Hpdel O 0 1.2674164281634148e-05
) O 0 7.100617693822642e-08
. O 0 1.1495955476448216e-07

In O 0 2.6768688599076995e-07
addition O 0 2.7337234698165958e-08
, O 0 2.0301971215275216e-09
we O 0 5.797063384882506e-10
found O 0 1.3801396692159074e-09
seven O 0 2.7647224509763646e-09
individuals O 0 3.1266073063918043e-10
with O 0 7.584208816524551e-10
hypohaptoglobinemia B-Disease 0 2.080793638015166e-05
in O 0 8.432189169127469e-09
three O 0 1.875191779632246e-09
families O 0 7.325785533751628e-10
, O 0 2.5838692296886734e-10
and O 0 3.258917857795751e-10
the O 0 2.2331924753871135e-08
genotypes O 0 1.1167941948997395e-07
of O 0 5.752515974677408e-08
six O 0 1.4809399928594758e-08
of O 0 1.842585106714978e-08
the O 0 8.33471336392222e-09
seven O 0 4.989802349086858e-09
individuals O 0 2.1685689355344095e-10
were O 0 2.0173278603152767e-09
found O 0 1.7708977617658661e-09
to O 0 3.4115030800307977e-09
be O 0 1.4762872524443083e-07
Hp2 O 1 0.998367965221405
/ O 0 0.016733746975660324
Hpdel O 1 0.620482325553894
. O 0 3.1274389584723394e-06

The O 0 1.4188261729941587e-06
phenotypes O 0 1.4912000096956035e-06
and O 0 1.4141581239357492e-08
genotypes O 0 3.601446962875343e-07
in O 0 2.964417378237272e-09
one O 0 8.839449727737758e-10
of O 0 1.1903859009620987e-09
these O 0 1.6993460805192484e-10
three O 0 1.4341660081740315e-09
families O 0 2.133797583070418e-09
showed O 0 1.2312788122414986e-08
the O 0 1.4234430523174524e-08
father O 0 1.0376206205364724e-07
to O 0 5.281108883536945e-09
be O 0 3.023855654760155e-08
hypohaptoglobinemic B-Disease 0 3.5695851693162695e-05
( O 0 2.377486936211426e-07
Hp2 O 0 2.8405733246472664e-05
) O 0 1.0295492458567423e-08
and O 0 3.3523919196198904e-09
Hp2 O 0 0.0018472335068508983
/ O 0 3.5052424209425226e-05
Hpdel O 0 0.002514860825613141
, O 0 8.34306401742424e-09
the O 0 2.1113539361294897e-08
mother O 0 4.4963634593386814e-08
to O 0 1.8126583567479315e-09
be O 0 8.122097661100725e-09
Hp2 O 0 1.0830348401213996e-05
- O 0 2.3291664774660603e-07
1 O 0 5.2664155703041615e-08
and O 0 4.525709584868309e-09
Hp1 O 0 0.0002279695909237489
/ O 0 2.1805053620482795e-06
Hp2 O 0 2.9119129976606928e-05
, O 0 9.146871593479489e-10
one O 0 4.256084651377279e-10
of O 0 1.1520111531382327e-09
the O 0 1.948976091625809e-09
two O 0 6.161933185921953e-10
children O 0 4.823833554823409e-10
to O 0 7.985914707298036e-10
be O 0 9.206631901292894e-09
hypohaptoglobinemic B-Disease 0 1.845019323809538e-05
( O 0 5.214231464378827e-07
Hp2 O 0 5.380883885663934e-05
) O 0 7.712056770969866e-09
and O 0 2.984444247289275e-09
Hp2 O 0 0.00026137716486118734
/ O 0 7.393123723886674e-06
Hpdel O 0 0.0004919813945889473
, O 0 1.5282319854037496e-09
and O 0 3.0515359683569443e-10
the O 0 1.7447598921194185e-09
other O 0 3.6240582756974504e-10
child O 0 4.532819453118009e-09
to O 0 1.1003622457650408e-09
be O 0 1.8604826124146712e-08
Hp1 O 0 0.00013752002269029617
and O 0 1.1568342728196512e-07
Hp1 O 1 0.9996101260185242
/ O 0 0.0005130632198415697
Hpdel O 0 0.018770452588796616
, O 0 1.239384062046156e-08
showing O 0 9.208584828002131e-08
an O 0 1.1808750421948844e-08
anomalous O 0 3.70158295481815e-06
inheritance O 0 6.07016090725665e-06
of O 0 1.3217339073889889e-05
Hp O 0 0.000487976212752983
phenotypes O 0 4.929659667141095e-07
in O 0 1.0688928853141988e-08
the O 0 4.9502844490234565e-08
child O 0 3.3180742775584804e-07
with O 0 1.751236311520188e-07
Hp1 O 1 0.9997226595878601
. O 0 3.7060124213894596e-06

The O 0 2.4944241886259988e-05
Hp2 O 1 0.9999068975448608
/ O 0 0.03816235810518265
Hpdel O 1 0.6159192323684692
individuals O 0 3.046618957114333e-08
had O 0 7.940035295916914e-09
an O 0 2.6014403964325084e-09
extremely O 0 1.7245225691908672e-08
low O 0 5.538664993309794e-08
level O 0 2.46220707822431e-07
of O 0 1.212310252185489e-07
Hp O 0 2.497039588433836e-07
( O 0 1.2438072793941046e-09
mean O 0 6.544063957392154e-09
+ O 0 1.1727988358245511e-08
/ O 0 1.5825019517023975e-08
- O 0 3.573685702917828e-08
SD O 0 2.949375925709319e-07
= O 0 2.336253679402489e-08
0 O 0 4.5170400753136164e-10
. O 0 1.040238797878068e-10
049 O 0 3.214116972571901e-08
+ O 0 2.7769306853997477e-09
/ O 0 1.7018347842068238e-09
- O 0 3.2663185489667512e-09
0 O 0 5.355714760568731e-10
. O 0 1.0223470681136604e-10
043 O 0 9.402628364796328e-08
mg O 0 1.38849447495204e-08
/ O 0 6.750262127042106e-09
ml O 0 7.149647984761032e-09
; O 0 1.491970158529199e-10
n O 0 5.118538481951873e-09
= O 0 8.548166618993491e-09
6 O 0 2.141961052970487e-09
) O 0 1.1030450164373207e-10
, O 0 6.029909210836237e-11
compared O 0 1.9874721313151156e-10
with O 0 2.2040248098820214e-11
the O 0 6.145934872137104e-10
level O 0 3.016453220539006e-08
( O 0 5.884009390833e-10
1 O 0 5.461044394472481e-10
. O 0 3.17208932731905e-11
64 O 0 6.893656756545852e-10
+ O 0 1.9303119103142308e-09
/ O 0 1.8287124037286162e-09
- O 0 1.4270686854445103e-09
1 O 0 2.888300265624366e-09
. O 0 2.759579231792486e-10
07 O 0 3.971948814296411e-08
mg O 0 2.4107452034627386e-08
/ O 0 1.995264398146901e-08
ml O 0 7.83096343326406e-09
) O 0 4.4800229498376254e-11
obtained O 0 2.344509586471588e-10
from O 0 1.0778157533142263e-10
52 O 0 4.258027264114617e-09
healthy O 0 5.302233763160302e-09
volunteers O 0 7.618632835715289e-09
having O 0 3.339603793506285e-08
phenotype O 0 2.8789906991733005e-07
Hp2 O 0 1.6586078345426358e-05
, O 0 4.647255913425852e-09
whereas O 0 8.956863695175343e-09
the O 0 8.997993461434817e-09
serum O 0 7.001875133028079e-07
Hp O 0 6.330126893772103e-07
level O 0 8.176066756959699e-08
of O 0 7.931180157072504e-09
an O 0 2.4471995541119895e-09
individual O 0 2.3578565766513293e-09
with O 0 6.709750532962744e-09
Hp1 O 0 0.005574462004005909
/ O 0 5.525479355128482e-05
Hpdel O 0 0.0003619473718572408
was O 0 2.1005582766520092e-06
0 O 0 4.0652884081282536e-07
. O 0 5.3681461054111423e-08

50 O 0 1.6719034192647086e-06
mg O 0 1.5715700101281982e-06
/ O 0 2.4755197500780923e-06
ml O 0 5.937559990343289e-07
, O 0 1.2593092124646432e-09
which O 0 1.1042827763318996e-10
was O 0 2.608535609738283e-09
approximately O 0 6.429910492933288e-10
half O 0 2.5159729855062096e-10
the O 0 1.1278518119439696e-09
level O 0 3.603734555213123e-08
of O 0 3.798020387080214e-08
Hp O 0 4.1930624661290494e-07
in O 0 3.255043123928658e-09
control O 0 9.713801318866899e-08
sera O 0 5.740491815231508e-07
from O 0 8.512826887852043e-09
the O 0 2.818167210705269e-08
Hp1 O 0 5.997771950205788e-06
phenotype O 0 2.2535942889589933e-08
( O 0 4.931018371401308e-10
1 O 0 5.41927003272491e-10
. O 0 7.405875218635671e-11
26 O 0 3.192608399871233e-09
+ O 0 4.300502176590726e-09
/ O 0 4.2112779929937005e-09
- O 0 3.489860844752002e-09
0 O 0 6.815904507462278e-10
. O 0 7.273251445560902e-11
33 O 0 2.4718984636962205e-09
mg O 0 7.7984996238456e-09
/ O 0 9.370720199797233e-09
ml O 0 6.549258468879771e-09
; O 0 8.764936693106407e-11
n O 0 6.0405640489591406e-09
= O 0 1.2511505609325013e-08
9 O 0 3.364408529549223e-09
) O 0 3.0216387725268135e-10
, O 0 6.618935954882943e-11
showing O 0 3.7125151841621573e-09
a O 0 8.08571165578087e-09
gene O 0 7.231331977664013e-09
- O 0 2.71779381222359e-08
dosage O 0 2.668315062237525e-07
effect O 0 2.8032482646267454e-07
. O 0 2.0380554133225814e-07

The O 0 4.972162628291699e-07
other O 0 1.0423092611233642e-08
allele O 0 5.26480867790724e-08
( O 0 3.507901524812951e-08
Hp2 O 0 1.4822726370766759e-05
) O 0 7.14512182753424e-09
of O 0 1.1391550813755202e-08
individuals O 0 2.329755499630437e-09
with O 0 1.4218230148799194e-08
Hp2 O 1 0.9999986886978149
/ O 0 0.16789263486862183
Hpdel O 0 0.07639358192682266
was O 0 1.3224017436641589e-07
found O 0 1.1240720576566332e-09
to O 0 1.0411638218243979e-10
have O 0 3.989694685735401e-11
, O 0 4.7492797888848415e-11
in O 0 2.0246508636301286e-10
all O 0 4.949524678998785e-10
exons O 0 6.858368095663536e-09
, O 0 1.2837202134630132e-10
no O 0 3.1541660949763184e-10
mutation O 0 8.144210306149091e-11
, O 0 2.887542635554574e-11
by O 0 3.7926453644310243e-10
DNA O 0 7.918457356481667e-08
sequencing O 0 1.6610060527000314e-07
. O 0 9.721919269622958e-08

On O 0 7.944913704704959e-07
the O 0 2.360715356530818e-08
basis O 0 7.27008639955784e-08
of O 0 8.906743786951665e-09
the O 0 2.1655361948091922e-09
present O 0 2.8756461656342935e-09
study O 0 6.282186770789622e-09
, O 0 3.4943084536998015e-10
the O 0 1.9582395704986766e-09
mechanism O 0 7.89337946116575e-08
of O 0 4.882394932792522e-08
anhaptoglobinemia B-Disease 0 1.149649415310705e-05
and O 0 2.815232491570896e-09
the O 0 1.4350588273259746e-08
mechanism O 0 5.047352260589832e-07
of O 0 1.1241845498943803e-07
anomalous O 0 9.473892532696482e-06
inheritance O 0 3.851144811051199e-06
of O 0 3.2396151254943106e-06
Hp O 0 1.179218634206336e-05
phenotypes O 0 6.400073715440158e-08
were O 0 9.742521456246322e-09
well O 0 4.2486028917210206e-08
explained O 0 2.82464930023707e-06
. O 0 1.1006125077983597e-06

However O 0 5.772177473772899e-07
, O 0 1.379961478420455e-08
the O 0 2.051858416507457e-08
mechanism O 0 8.4425545310296e-07
of O 0 1.4563383956556208e-06
hypohaptoglobinemia B-Disease 0 0.04180823266506195
remains O 0 7.252820068970323e-05
unknown O 0 0.0006995224975980818

ATM O 0 0.0017284078057855368
mutations O 0 3.501367871194816e-07
and O 0 1.678019323492208e-08
phenotypes O 0 3.244487743359059e-06
in O 0 2.751984766291571e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 4.5149388938625634e-07
in O 0 8.06165889599697e-09
the O 0 8.64807248035504e-09
British O 0 9.747170537366401e-08
Isles O 0 4.0878217077988666e-07
: O 0 1.1214037476392491e-09
expression O 0 2.5446609264179187e-09
of O 0 2.3250943392838508e-09
mutant O 0 3.200035791905975e-08
ATM O 0 9.212834015670524e-07
and O 0 3.036741691442302e-10
the O 0 2.5216237986569467e-09
risk O 0 1.952660788617777e-08
of O 0 6.163314196783176e-07
leukemia B-Disease 1 1.0
, O 0 0.0007764697074890137
lymphoma B-Disease 1 1.0
, O 0 6.264980129344622e-06
and O 0 6.891171778988792e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
. O 0 1.2372791388770565e-05

We O 0 3.0146452445478644e-07
report O 0 5.23270280439192e-08
the O 0 3.7747782677399755e-09
spectrum O 0 7.91768339780674e-09
of O 0 4.5029029394072495e-08
59 O 0 1.2825952353523462e-06
ATM O 0 5.166793198441155e-05
mutations O 0 2.777398222519878e-08
observed O 0 5.0277893848260646e-08
in O 0 1.342153410632818e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999963045120239
telangiectasia I-Disease 1 1.0
( O 0 0.12614165246486664
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 4.758735627774513e-08
patients O 0 5.4680513450477974e-09
in O 0 1.8552832603546676e-09
the O 0 3.853866559211383e-08
British O 0 4.420850473252358e-06
Isles O 0 3.121608096989803e-05
. O 0 6.481125183199765e-07

Of O 0 7.186851235019276e-06
51 O 0 9.362554010294843e-06
ATM O 0 0.00021419243421405554
mutations O 0 3.611358678767829e-08
identified O 0 2.489415784623361e-08
in O 0 5.146987724913288e-09
families O 0 6.064032831432087e-09
native O 0 1.172559471740442e-08
to O 0 1.6448785666867138e-09
the O 0 2.6245869477747874e-08
British O 0 3.9603753521078033e-07
Isles O 0 2.219207090092823e-06
, O 0 2.2356803075496146e-09
11 O 0 9.829482117140742e-09
were O 0 5.664387625614609e-09
founder O 0 4.599310159392189e-07
mutations O 0 2.5350590515671456e-09
, O 0 2.864302406369035e-10
and O 0 4.481700566216773e-10
2 O 0 1.1666722699033016e-08
of O 0 1.1153802326191453e-08
these O 0 1.02728903161875e-09
11 O 0 1.198579102634767e-08
conferred O 0 2.5236941425532677e-08
a O 0 4.201730519071134e-09
milder O 0 2.485012196018488e-09
clinical O 0 1.4684122362496055e-08
phenotype O 0 1.782752612200511e-09
with O 0 8.276503787874034e-11
respect O 0 2.6014703724541732e-09
to O 0 3.855842312106006e-09
both O 0 7.895035736282807e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 1.449266591180276e-07
cellular O 0 1.106124182115309e-05
features O 0 1.1482148920549662e-07
. O 0 1.0931774596656396e-07

We O 0 3.114195692432986e-07
report O 0 8.166139053855659e-08
, O 0 1.28564181522961e-09
in O 0 1.6850455475392323e-09
two O 0 5.189701557384296e-09
A B-Disease 1 0.9978893399238586
- I-Disease 0 0.3812463879585266
T I-Disease 1 0.9999985694885254
families O 0 6.321166257095001e-09
, O 0 9.98935489882058e-10
an O 0 2.2746933225903376e-09
ATM O 0 3.8710251715201593e-07
mutation O 0 6.173661581954093e-10
( O 0 5.66838354032484e-10
7271T O 0 4.262498620732913e-08
- O 0 4.528345698417979e-08
- O 0 2.3517186775734444e-07
> O 0 1.9624475555701792e-07
G O 0 1.1326029181191188e-07
) O 0 2.347610439379366e-10
that O 0 1.2936521645579013e-11
may O 0 3.674960682986672e-11
be O 0 4.560539099141003e-11
associated O 0 1.161084006717772e-09
with O 0 9.520893101688799e-11
an O 0 1.3758214567616278e-09
increased O 0 3.1201750072540335e-09
risk O 0 2.544200938814356e-08
of O 0 6.864908073112019e-07
breast B-Disease 1 0.9866369962692261
cancer I-Disease 0 1.682791844359599e-05
in O 0 9.606985429400083e-09
both O 0 6.185333578656582e-09
homozygotes O 0 8.043336379159882e-07
and O 0 2.1012849238388753e-09
heterozygotes O 0 1.3400457987700065e-07
( O 0 1.618095657462959e-09
relative O 0 1.718693987129427e-08
risk O 0 5.097669397713389e-09
12 O 0 1.653096881604199e-09
. O 0 1.0500685043712821e-10
7 O 0 2.2681772016142077e-09
; O 0 4.156517074971333e-10
P O 0 1.1319361874484457e-06
= O 0 8.104336046699245e-08
. O 0 2.3779636038057106e-09
0025 O 0 1.918104544529342e-06
) O 0 4.56699206230482e-10
, O 0 4.094541372623439e-11
although O 0 1.2676275307210716e-10
there O 0 1.7834658749826815e-10
is O 0 2.668326948285227e-10
a O 0 1.1032013080836123e-09
less O 0 3.513558111123416e-09
severe O 0 6.882508500893891e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.8573453530734696e-07
in O 0 8.660117067904594e-10
terms O 0 3.1484517215574215e-09
of O 0 3.5034330991834395e-09
the O 0 2.9146420832404374e-09
degree O 0 5.368979714148736e-07
of O 0 1.4711083622387378e-06
cerebellar B-Disease 1 0.9999967813491821
degeneration I-Disease 1 1.0
. O 0 4.505313881963957e-06

This O 0 5.089316701401003e-08
mutation O 0 7.567335202907088e-09
( O 0 3.2988507481235274e-09
7271T O 0 1.7885353997826314e-07
- O 0 1.2909222846246848e-07
- O 0 4.442310057584109e-07
> O 0 3.389330913705635e-07
G O 0 3.2857977316780307e-07
) O 0 7.903858678659503e-10
also O 0 6.40725875133974e-11
allows O 0 7.449055955399686e-11
expression O 0 1.486916284543227e-10
of O 0 7.55024764931278e-10
full O 0 6.562700605172722e-09
- O 0 1.3240371288247843e-07
length O 0 1.2398493254295317e-07
ATM O 0 5.920144758420065e-06
protein O 0 1.913615044202288e-08
at O 0 6.763472004678306e-09
a O 0 1.0463323540932379e-09
level O 0 2.876820115460532e-09
comparable O 0 1.6602001995380533e-09
with O 0 3.0367285075438843e-11
that O 0 6.960586967919014e-11
in O 0 1.746208178055042e-09
unaffected O 0 1.7510443228729855e-07
individuals O 0 1.3953014743606218e-08
. O 0 1.294923492878297e-07

In O 0 1.81361770046351e-07
addition O 0 2.0357120433800446e-08
, O 0 1.6721174445066822e-09
we O 0 1.013169659280777e-09
have O 0 1.7574910970985513e-10
studied O 0 2.8265864315812905e-08
18 O 0 3.0222591362871754e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 4.6088775462749254e-08
, O 0 4.060154157325968e-10
in O 0 4.230694961027126e-10
15 O 0 1.244599756589082e-09
families O 0 2.4896221195724877e-10
, O 0 1.425742995886381e-10
who O 0 4.862029112651101e-10
developed O 0 8.592813571794977e-08
leukemia B-Disease 1 1.0
, O 0 4.480425559449941e-05
lymphoma B-Disease 1 1.0
, O 0 1.9213639461668208e-05
preleukemic O 1 0.9999997615814209
T O 1 0.9999643564224243
- O 0 0.009117276407778263
cell O 0 0.017916420474648476
proliferation O 0 0.22499768435955048
, O 0 2.248755137657099e-08
or O 0 3.683931572595611e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.2151169787321123e-07
mostly O 0 2.534625132000201e-08
in O 0 2.3877591459608993e-08
childhood O 0 5.0346741772955284e-05
. O 0 1.2100249477953184e-06

A O 0 2.990941766256583e-06
wide O 0 7.224235787361977e-08
variety O 0 1.4310517215676555e-08
of O 0 1.6856466800163616e-07
ATM O 0 1.7520227629574947e-05
mutation O 0 2.435098567232785e-09
types O 0 8.911803517364092e-10
, O 0 2.8342819757831705e-10
including O 0 7.645209465501068e-10
missense O 0 4.4606576921069063e-07
mutations O 0 3.097464729151511e-09
and O 0 1.2611239830206955e-09
in O 0 2.8128294360385553e-08
- O 0 1.004649334390706e-06
frame O 0 2.5589977667550556e-05
deletions O 0 5.499652289131518e-08
, O 0 9.135939782467517e-10
were O 0 3.1363325270206133e-09
seen O 0 7.296421244973317e-09
in O 0 2.012013444741001e-09
these O 0 4.832483302408264e-09
patients O 0 4.6302353950977704e-08
. O 0 2.535332157549419e-07

We O 0 6.606313149859488e-07
also O 0 3.137925830287713e-08
show O 0 2.183725200666231e-08
that O 0 7.410499991422625e-10
25 O 0 1.0646443726614052e-08
% O 0 2.0957935387144744e-09
of O 0 3.3621123662896935e-09
all O 0 5.3076973927090876e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 4.438115208671434e-09
carried O 0 3.0066356071500877e-09
in O 0 7.546522517998255e-09
- O 0 2.3966481421666685e-07
frame O 0 6.4773589656397235e-06
deletions O 0 2.2131278853976255e-07
or O 0 1.87852915445319e-08
missense O 0 1.019861386453158e-07
mutations O 0 6.434867083626727e-10
, O 0 4.5016768090988535e-11
many O 0 1.4067847581289428e-11
of O 0 5.22780929657074e-10
which O 0 8.224666780964895e-11
were O 0 7.817111402630417e-10
also O 0 1.8099177712116443e-10
associated O 0 6.907542871026351e-10
with O 0 4.0112371757494714e-10
expression O 0 1.5102036954317555e-08
of O 0 4.577548651241159e-08
mutant O 0 1.3065557595837163e-06
ATM O 0 0.00015453214291483164
protein O 0 1.0136145647265948e-06
. O 0 8.480386526343864e-08

The O 0 8.483308192808181e-06
DMPK O 1 0.92838054895401
gene O 0 1.1563769248823519e-06
of O 0 6.443107736231468e-07
severely O 0 0.3866533041000366
affected O 0 0.001784337917342782
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00015001696010585874
is O 0 2.9323983241624774e-08
hypermethylated O 0 4.578594962367788e-05
proximal O 0 3.4016495646937983e-06
to O 0 2.3838397922304466e-09
the O 0 1.697310381132411e-08
largely O 0 4.10859058774804e-07
expanded O 0 7.939718216221081e-07
CTG O 0 0.00037746946327388287
repeat O 0 4.763071956404019e-06
. O 0 7.233775818349386e-07

Using O 0 2.5950496365112485e-06
methylation O 0 5.068579412181862e-06
- O 0 4.313245938192267e-07
sensitive O 0 3.918859761142812e-07
restriction O 0 7.86875453684388e-09
enzymes O 0 8.162596154548396e-10
, O 0 1.7777905536586758e-10
we O 0 9.42303346462836e-10
characterized O 0 7.310476668465071e-09
the O 0 4.554693955327593e-09
methylation O 0 6.609521108202898e-08
pattern O 0 3.9901120629792786e-08
on O 0 2.733633319706996e-09
the O 0 2.6414195275492602e-09
5 O 0 2.3609978416772037e-09
side O 0 1.946787842044273e-09
of O 0 1.2530994020210073e-08
the O 0 1.0329544863907358e-07
CTG O 0 0.0008312365389429033
repeat O 0 2.0154527646809584e-07
in O 0 9.116883248339036e-09
the O 0 3.255578917560342e-08
DMPK O 0 0.0001820412144297734
gene O 0 5.555400139911626e-09
of O 0 2.680990318637555e-09
normal O 0 1.6539177138952255e-08
individuals O 0 6.536272911805696e-11
and O 0 4.130986525074931e-11
of O 0 2.506716434425016e-08
patients O 0 2.8174900634780897e-08
affected O 0 9.525298771961843e-09
with O 0 1.9346776980455616e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 7.797577694645952e-09
showing O 0 3.003496118481053e-08
expansions O 0 1.5612513948326523e-08
of O 0 5.620831800001724e-09
the O 0 1.9911963633489904e-08
repetitive O 0 6.905045211169636e-07
sequence O 0 4.0929322153715475e-07
. O 0 1.604266941512833e-07

The O 0 2.5159163214993896e-06
gene O 0 1.837182992403541e-07
segment O 0 1.6817865855500713e-07
analyzed O 0 3.3541713406748386e-08
corresponds O 0 6.013470965626766e-08
to O 0 2.747815530668163e-09
the O 0 3.6075032738835944e-08
genomic O 0 2.881055706893676e-06
SacI O 0 0.000551727949641645
- O 0 1.1376437214494217e-06
HindIII O 0 2.0840148863499053e-05
fragment O 0 6.799264156143181e-07
carrying O 0 6.162890286987022e-08
exons O 0 1.0329210198278815e-07
11 O 0 5.389783552800509e-08
- O 0 1.1996432647265465e-07
15 O 0 1.5171839606864523e-07
. O 0 1.5419553278661624e-07

There O 0 6.747940801687946e-07
is O 0 3.813816817910265e-08
constitutive O 0 2.20337210521393e-06
methylation O 0 9.628705583963892e-07
in O 0 6.147932651856536e-08
intron O 0 1.19089636427816e-05
12 O 0 5.2599709476908174e-08
at O 0 2.962180722931862e-08
restriction O 0 7.959215508890338e-09
sites O 0 8.336320078683457e-09
of O 0 3.7485634152290004e-08
SacII O 0 3.3665524824755266e-05
and O 0 3.304085183231109e-08
HhaI O 0 6.034373654983938e-05
, O 0 5.597348806674063e-09
localized O 0 3.224297273618504e-08
1 O 0 4.206268666706592e-09
, O 0 2.304105656270039e-10
159 O 0 1.512823644134187e-09
- O 0 3.5639635687090276e-09
1 O 0 5.61193003179028e-09
, O 0 6.018399667517826e-10
232 O 0 2.2536200461331646e-08
bp O 0 1.459829945815727e-07
upstream O 0 1.3804582010834565e-07
of O 0 7.2398331774081726e-09
the O 0 2.5414507831555966e-08
CTG O 0 0.00012360524851828814
repeat O 0 6.600475899176672e-08
, O 0 9.297314029765857e-10
whereas O 0 1.058205967296999e-09
most O 0 7.410821262210376e-11
, O 0 2.8253049205728686e-11
if O 0 4.717249160735015e-11
not O 0 5.810133971162479e-11
all O 0 2.9053329186901067e-10
, O 0 3.1360800067936623e-10
of O 0 2.00573713193819e-09
the O 0 2.025791534521204e-09
other O 0 2.8318450362441183e-10
sites O 0 6.459119905599664e-09
of O 0 6.038042954514822e-08
SacII O 0 0.00022172842000145465
, O 0 1.6821434911662436e-08
HhaI O 0 0.00025180328520946205
, O 0 4.409645981695576e-09
and O 0 3.086136235452841e-09
HpaII O 0 4.074070602655411e-05
in O 0 2.7786313250288686e-09
this O 0 1.0271401507111477e-09
region O 0 7.290912762414337e-09
are O 0 1.233482982421208e-09
unmethylated O 0 1.637620471228729e-06
, O 0 9.517593380081735e-10
in O 0 1.7645724881276692e-09
normal O 0 3.2320492948656465e-08
individuals O 0 2.791735453921973e-10
and O 0 1.649429898220589e-10
most O 0 2.1726345722505869e-10
of O 0 6.156355869535446e-09
the O 0 5.151243342993439e-08
patients O 0 4.8522601048262004e-08
. O 0 1.1277839462309203e-07

In O 0 1.7970533860989235e-07
a O 0 1.4623303457028669e-08
number O 0 8.86011042311452e-10
of O 0 4.095967121031663e-09
young O 0 4.713916812448815e-09
and O 0 2.8498521320585724e-09
severely O 0 7.691081123084587e-07
affected O 0 8.144964702694324e-09
patients O 0 9.647874721352423e-10
, O 0 1.0813265560738472e-10
however O 0 5.971427241568961e-10
, O 0 4.6482642734879676e-10
complete O 0 2.4496900508097497e-08
methylation O 0 8.140184348803814e-08
of O 0 3.769339063097732e-09
these O 0 2.8616270464354443e-10
restriction O 0 2.1775725667083634e-09
sites O 0 9.401543987763716e-10
was O 0 8.120967009972446e-09
found O 0 1.2957251938061631e-09
in O 0 1.7470810353970023e-09
the O 0 1.3796086939521501e-08
mutated O 0 4.413030296746001e-08
allele O 0 5.0540283069722136e-08
. O 0 3.966225747831231e-08

In O 0 2.2474610261724592e-07
most O 0 1.3036777213315531e-09
of O 0 2.531459486476706e-09
these O 0 8.806432250096918e-10
patients O 0 1.9974717435644607e-09
, O 0 5.104924816201617e-10
the O 0 5.513629108833129e-09
onset O 0 0.007201470900326967
of O 0 7.704530844421242e-07
the O 0 4.9946220315177925e-06
disease O 1 0.999946117401123
was O 1 0.9979614019393921
congenital O 1 1.0
. O 0 3.881937118421774e-06

Preliminary O 0 5.762168711953564e-06
in O 0 2.8741706614709983e-07
vivo O 0 2.243496783194132e-05
footprinting O 0 0.00013114091416355222
data O 0 4.0638770570922134e-08
gave O 0 3.292708994351301e-09
evidence O 0 5.6692512906408865e-09
for O 0 6.584827683120409e-10
protein O 0 2.3694758155556883e-08
- O 0 3.2524383186682826e-08
DNA O 0 8.862789258046178e-08
contact O 0 8.743327128968303e-08
in O 0 3.501856360443867e-09
normal O 0 1.4704615125538112e-07
genes O 0 6.0037503857302e-09
at O 0 1.5606500980425153e-08
an O 0 5.966398930468131e-09
Sp1 O 0 1.0424126912766951e-06
consensus O 0 9.54568690758606e-09
binding O 0 5.144946246815607e-09
site O 0 3.1527200405889744e-08
upstream O 0 1.3003017329538125e-07
of O 0 9.632103115109203e-09
the O 0 4.640916628773084e-08
CTG O 0 0.0007626822334714234
repeat O 0 1.0732364330579003e-07
and O 0 5.096266741944078e-10
for O 0 2.2768797958150344e-10
a O 0 1.0217588997107896e-09
significant O 0 9.379407250875715e-10
reduction O 0 1.5243282192045626e-09
of O 0 1.4739843789968177e-09
this O 0 6.626720838731615e-10
interaction O 0 8.50036574462365e-09
in O 0 8.873707879608617e-10
cells O 0 4.316683455130033e-09
with O 0 5.152102633410038e-10
a O 0 1.0918063253484434e-07
hypermethylated O 0 3.301096148788929e-05
DMPK O 0 0.003396060550585389
gene O 0 1.6800248658910277e-07
. O 0 1.2376314195705618e-08
. O 0 7.314483241316339e-08

The O 0 0.0006821656716056168
hemochromatosis B-Disease 1 1.0
gene O 0 8.485937541991007e-06
product O 0 2.1992248377955548e-07
complexes O 0 2.7906745003747346e-07
with O 0 2.5899840050414014e-09
the O 0 1.6761086385486124e-07
transferrin O 0 5.8660865761339664e-05
receptor O 0 2.495415856174077e-07
and O 0 1.443097530362536e-09
lowers O 0 1.9126954242665306e-08
its O 0 4.850404522471763e-10
affinity O 0 9.20812492921641e-09
for O 0 3.74677444625604e-09
ligand O 0 4.1884584334184183e-07
binding O 0 1.8590111494631856e-07
. O 0 3.1294089808397985e-07

We O 0 6.603680731132044e-07
recently O 0 1.8791101297210844e-07
reported O 0 5.095163757573573e-08
the O 0 3.2270459637828708e-09
positional O 0 1.6226621823989262e-07
cloning O 0 2.0622596963448814e-08
of O 0 4.425351196601923e-09
a O 0 7.677859237276152e-09
candidate O 0 1.7353617209892036e-08
gene O 0 1.0733797495277031e-07
for O 0 7.212586865534831e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 2.221953218395356e-05

The O 0 8.40640893784439e-07
gene O 0 6.838359922767268e-08
product O 0 7.563266457566442e-09
, O 0 9.177156257145214e-10
a O 0 5.028813365726137e-09
member O 0 3.3477527416891917e-09
of O 0 3.1252987753305206e-08
the O 0 5.0551467012383e-08
major O 0 3.5878440485248575e-07
histocompatibility O 0 0.0005492069176398218
complex O 0 0.00010817594011314213
class O 0 8.544019465261954e-07
I O 0 1.0594378181849606e-05
- O 0 2.0330385268607643e-06
like O 0 2.018106215473381e-08
family O 0 4.314043522413158e-08
, O 0 4.687206178743963e-10
was O 0 2.7505331345878403e-08
found O 0 1.0299651131973064e-09
to O 0 4.0810393953094604e-10
have O 0 3.6965797090005026e-10
a O 0 4.887777738105115e-09
mutation O 0 1.2554648431972737e-09
, O 0 9.5114782716621e-10
Cys O 0 5.81158838031115e-06
- O 0 3.3473784810666984e-07
282 O 0 5.941451490798499e-07
- O 0 8.149355608111364e-07
- O 0 1.2269158560229698e-06
> O 0 3.3857671155601565e-07
Tyr O 0 1.2324380804784596e-06
( O 0 2.4858368696811795e-09
C282Y O 0 4.536186182235724e-08
) O 0 3.321749542095631e-10
, O 0 3.825992647699117e-11
in O 0 9.233847020340136e-11
85 O 0 4.237060480249966e-09
% O 0 7.581374417142683e-10
of O 0 8.094430015148646e-09
patient O 0 3.84371844575071e-07
chromosomes O 0 1.2170985428383574e-06
. O 0 3.134947235139407e-07

This O 0 4.6203987835724547e-07
mutation O 0 1.1080292949827708e-07
eliminates O 0 2.6358151217209524e-07
the O 0 3.065341047658876e-08
ability O 0 3.5260736552800154e-08
of O 0 8.836859706207179e-07
HFE O 1 0.9918574690818787
to O 0 4.822237897883497e-08
associate O 0 1.7472571016696747e-06
with O 0 6.538511510001399e-09
beta2 O 0 0.0001866753736976534
- O 0 1.702551162452437e-05
microglobulin O 0 8.162121957866475e-05
( O 0 2.84648553616762e-08
beta2m O 0 1.0317695569028729e-06
) O 0 2.0616726104094596e-09
and O 0 5.44124800772039e-10
prevents O 0 1.8595425643752606e-08
cell O 0 1.5261260841725743e-06
- O 0 1.3948684909337317e-06
surface O 0 1.4353579899761826e-05
expression O 0 2.6965076358465012e-06
. O 0 6.501107918666094e-07

A O 0 2.292182443852653e-06
second O 0 6.558398268907695e-08
mutation O 0 4.1508627646180685e-09
that O 0 1.9607912515873238e-10
has O 0 1.953515682551199e-10
no O 0 7.639072707732453e-10
effect O 0 3.6384455448512654e-09
on O 0 2.1698248531265563e-08
beta2m O 0 3.083270348724909e-05
association O 0 8.864260081509201e-08
, O 0 7.422102932252983e-09
H63D O 0 0.0006379395490512252
, O 0 3.808733328725111e-09
was O 0 3.714882623739868e-08
found O 0 1.5235432915261526e-09
in O 0 5.400933034138689e-10
eight O 0 5.552791559892967e-10
out O 0 3.543518534154799e-10
of O 0 6.21643936327132e-09
nine O 0 2.6013129428292814e-08
patients O 0 2.294112899647871e-09
heterozygous O 0 7.103487131843167e-09
for O 0 2.4584934088522914e-09
the O 0 3.175336189542577e-07
C282Y O 0 6.398405093932524e-05
mutant O 0 4.317548246035585e-06
. O 0 3.3669596177787753e-07

In O 0 1.6827459603518946e-07
this O 0 3.0620905810962995e-09
report O 0 4.6757611116277076e-09
, O 0 1.8088687492312516e-10
we O 0 5.410130121674683e-10
demonstrate O 0 7.190648521060439e-09
in O 0 3.015520055882348e-09
cultured O 0 6.834916916886868e-07
293 O 0 3.7266426033966127e-07
cells O 0 6.553209175308439e-08
overexpressing O 0 6.912998173902452e-07
wild O 0 1.6246216816284687e-08
- O 0 1.4592785646527773e-07
type O 0 1.9353900881924346e-07
or O 0 3.490049138576978e-08
mutant O 0 6.994820296313264e-07
HFE O 0 0.0007241636049002409
proteins O 0 1.971457441740654e-09
that O 0 3.272769555362487e-11
both O 0 3.7492297461083623e-11
the O 0 1.1839912383848628e-09
wild O 0 1.1555107093386141e-08
- O 0 1.7342506453132955e-07
type O 0 4.003277922492998e-07
and O 0 6.046283829164167e-08
H63D O 1 0.9999927282333374
HFE O 1 0.9963462948799133
proteins O 0 5.3426706614345676e-08
form O 0 1.4009229332145878e-08
stable O 0 1.4630426221629023e-06
complexes O 0 1.2004156246803177e-07
with O 0 2.2457922188579005e-09
the O 0 1.3868408643702423e-07
transferrin O 0 2.745809979387559e-05
receptor O 0 4.207332949590636e-06
( O 0 1.6462799123928562e-07
TfR O 0 8.554400847060606e-05
) O 0 1.0453279486455358e-07
. O 0 7.520446132502911e-08

The O 0 1.930513690240332e-06
C282Y O 0 2.050117836915888e-05
mutation O 0 3.438937312694179e-08
nearly O 0 1.645679503781139e-08
completely O 0 8.357609715403669e-08
prevents O 0 1.9123525873965264e-08
the O 0 3.2052751564037862e-09
association O 0 7.289271852783941e-09
of O 0 4.102568240682558e-08
the O 0 1.206793029950859e-07
mutant O 0 6.885988568683388e-06
HFE O 0 0.026868542656302452
protein O 0 4.88483529181849e-08
with O 0 2.2010866462807144e-09
the O 0 3.311170360120741e-07
TfR O 0 0.22271600365638733
. O 0 6.369592142618785e-07

Studies O 0 4.701994839706458e-06
on O 0 3.388322511455044e-07
cell O 0 4.229298156133154e-06
- O 0 4.195494227587915e-07
associated O 0 1.0324797727889745e-07
transferrin O 0 2.650280976013164e-06
at O 0 4.181457669005795e-08
37 O 0 3.0254998506507036e-08
degrees O 0 7.612070618279176e-08
C O 0 1.9637374748526781e-07
suggest O 0 6.627900006606069e-09
that O 0 2.9377023036403216e-10
the O 0 4.229865790961185e-09
overexpressed O 0 1.2369090427455376e-06
wild O 0 4.987530743960633e-08
- O 0 4.662929882215394e-07
type O 0 1.0664765568435541e-06
HFE O 0 0.011417945846915245
protein O 0 1.867723966597623e-07
decreases O 0 3.69284158807659e-08
the O 0 2.5177262497066977e-09
affinity O 0 7.198717622003414e-09
of O 0 1.1896056584248527e-08
the O 0 6.624097892427017e-08
TfR O 0 0.00011182165326317772
for O 0 8.049278221733402e-08
transferrin O 0 3.504744017845951e-05
. O 0 2.8022594733556616e-07

The O 0 3.409442069823854e-05
overexpressed O 1 0.7647987008094788
H63D O 1 0.9962693452835083
protein O 0 1.0541270967223682e-06
does O 0 5.778308387327513e-10
not O 0 1.1641770880643776e-10
have O 0 2.227123346854043e-11
this O 0 4.482886631351768e-11
effect O 0 7.847706373631524e-10
, O 0 1.505945090851668e-10
providing O 0 2.0095245467643963e-09
the O 0 4.733998193451328e-10
first O 0 5.253007473449145e-10
direct O 0 7.972004723022508e-10
evidence O 0 1.1205207872677647e-09
for O 0 8.924301575508053e-11
a O 0 2.765766948797932e-09
functional O 0 7.054261885741653e-08
consequence O 0 5.24428287462797e-08
of O 0 3.0579830223587123e-08
the O 0 9.397429323598772e-08
H63D O 0 0.000869929208420217
mutation O 0 1.1928983667530701e-07
. O 0 7.961238424059047e-08

Addition O 0 3.5929218711316935e-07
of O 0 2.953023567897617e-07
soluble O 0 1.7897945099321078e-06
wild O 0 5.85844361467025e-07
- O 0 3.23932763421908e-05
type O 0 0.005161096807569265
HFE O 1 1.0
/ O 1 0.9992596507072449
beta2m O 0 0.002179833361878991
heterodimers O 0 1.2642402907658834e-05
to O 0 1.7274096819619444e-08
cultured O 0 2.782361661957111e-06
cells O 0 4.37485638826729e-08
also O 0 7.009459124240891e-10
decreased O 0 1.3374636509411175e-08
the O 0 1.0880301104521095e-09
apparent O 0 1.587144815573538e-08
affinity O 0 6.02374283786844e-09
of O 0 2.01628158613687e-09
the O 0 4.5973735929294435e-09
TfR O 0 6.660282451775856e-06
for O 0 2.6056701241117253e-10
its O 0 1.125541049251666e-10
ligand O 0 2.354324513120787e-09
under O 0 1.078176103952444e-09
steady O 0 3.6124407643001177e-07
- O 0 4.0819290170190925e-09
state O 0 2.560394674055999e-10
conditions O 0 1.9375898663298585e-09
, O 0 7.427023579476e-11
both O 0 7.048724104397053e-11
in O 0 6.728060331084862e-10
293 O 0 1.7881271574538005e-08
cells O 0 1.847126784859654e-09
and O 0 6.358321646970921e-10
in O 0 2.8490166670280814e-08
HeLa O 0 0.0006912989774718881
cells O 0 8.258726325038879e-07
. O 0 1.2850092900862364e-07

Furthermore O 0 2.397963271505432e-06
, O 0 1.8114217681386435e-08
at O 0 3.979516804974992e-08
4 O 0 1.0746124878835417e-08
degrees O 0 3.953491400920939e-08
C O 0 1.1412205225269645e-07
, O 0 2.0610030349033082e-10
the O 0 9.083552243716042e-10
added O 0 1.4586283292317148e-08
soluble O 0 2.413793822597654e-07
complex O 0 5.50018683043163e-07
of O 0 7.218188216029375e-07
HFE O 1 0.9999980926513672
/ O 0 0.0007156135980039835
beta2m O 0 7.92604623711668e-05
inhibited O 0 2.3370853341475595e-07
binding O 0 1.1875199490418709e-08
of O 0 3.1378423415162615e-08
transferrin O 0 1.6152293937921058e-06
to O 0 3.334302078883411e-08
HeLa O 0 0.05014974623918533
cell O 0 1.4946931514714379e-05
TfR O 0 4.285220711608417e-05
in O 0 1.192649312642402e-09
a O 0 2.6807753794599876e-09
concentration O 0 3.4553028172013e-07
- O 0 1.260132052038898e-07
dependent O 0 7.756388242796675e-08
manner O 0 1.4065673781260557e-07
. O 0 8.213579860694153e-08

Scatchard O 0 0.0004969810834154487
plots O 0 1.975056193259661e-06
of O 0 3.0311777976521626e-08
these O 0 2.1412749351412685e-09
data O 0 3.737961051797356e-08
indicate O 0 1.2512795244390418e-08
that O 0 4.977774858971884e-10
the O 0 1.3078376603914421e-08
added O 0 7.26969773268138e-08
heterodimer O 0 1.4639666687799036e-06
substantially O 0 8.111325655590917e-08
reduced O 0 6.673210428687071e-09
the O 0 5.617906140287232e-09
affinity O 0 3.9251652594884945e-08
of O 0 9.264414302379009e-08
TfR O 0 0.00018277759954798967
for O 0 6.965909449263563e-08
transferrin O 0 3.997515159426257e-05
. O 0 6.659169002887211e-07

These O 0 5.467147090598701e-08
results O 0 4.85052069620906e-08
establish O 0 1.351834129081908e-07
a O 0 1.655722172699825e-07
molecular O 0 4.130971774429781e-06
link O 0 1.465420723434363e-06
between O 0 3.3158534051835886e-07
HFE O 1 0.9989879727363586
and O 0 1.0998822297381139e-08
a O 0 3.018887895223088e-08
key O 0 1.5475372094897466e-07
protein O 0 5.47110055038047e-08
involved O 0 1.690622219996385e-08
in O 0 4.912217743680003e-09
iron O 0 0.00017852355085778981
transport O 0 1.7159348999484791e-06
, O 0 1.1847576253387615e-08
the O 0 1.7078880887311243e-07
TfR O 1 0.9998138546943665
, O 0 2.7116617840050594e-09
and O 0 7.208276198156227e-10
raise O 0 5.0837063447772834e-09
the O 0 1.8676280522100797e-09
possibility O 0 6.216012149451444e-09
that O 0 1.419859507745258e-10
alterations O 0 9.075313833761811e-09
in O 0 3.324690522887863e-10
this O 0 1.860697429467706e-10
regulatory O 0 3.781039925598861e-09
mechanism O 0 3.2208184563842224e-08
may O 0 9.693175151426203e-10
play O 0 4.041582180036585e-09
a O 0 7.287075387552022e-09
role O 0 1.2576776065031936e-08
in O 0 2.9630948805703383e-09
the O 0 9.796469413458908e-08
pathogenesis O 1 0.9999973773956299
of O 1 0.9994505047798157
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0004076726036146283
. O 0 3.8962275539233815e-06

Genomic O 0 3.573955473257229e-05
organization O 0 3.6087939747631026e-07
of O 0 5.201383146413718e-07
the O 0 1.5166805269473116e-06
UBE3A O 1 0.9841848611831665
/ O 0 0.00012390485790092498
E6 O 0 1.8271104636369273e-05
- O 0 2.111383764713537e-06
AP O 0 1.9430442989687435e-05
gene O 0 1.3394064524163696e-08
and O 0 1.3218961480987446e-09
related O 0 2.7400145086176053e-07
pseudogenes O 0 9.170239536615554e-06
. O 0 5.633713726638234e-07

The O 0 4.641885607270524e-05
UBE3A O 0 0.012568320147693157
gene O 0 4.255555268173339e-06
encodes O 0 5.486560326062317e-07
the O 0 4.1451762911037804e-08
E6 O 0 2.1990560981066665e-06
- O 0 9.824647122513852e-07
AP O 0 2.6003512175520882e-05
ubiquitin O 0 2.7405837954574963e-06
- O 0 1.7903186062540044e-06
protein O 0 1.9149483421188052e-07
ligase O 0 2.74885820772397e-07
and O 0 4.2224962415460254e-10
has O 0 2.662033649070139e-10
recently O 0 1.1731919880020314e-09
been O 0 3.4214781008401474e-10
shown O 0 3.7568484434480354e-10
to O 0 3.2025845864147584e-10
be O 0 3.039745122279669e-09
mutated O 0 2.065768001102697e-07
in O 0 2.1400567220553057e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0001201901031890884
who O 0 6.070747105013652e-08
lack O 0 1.5617537428624928e-05
15q11 O 0 0.3548678159713745
- O 0 0.00013502314686775208
q13 O 0 8.938947576098144e-05
deletions O 0 9.369005624648707e-07
or O 0 1.8868605877742084e-07
chromosome O 0 1.1367586012056563e-05
15 O 0 2.4702371774765197e-06
paternal O 0 0.1895368993282318
uniparental B-Disease 1 0.9999996423721313
disomy I-Disease 1 0.9995768666267395
. O 0 1.490700105932774e-05

Previous O 0 1.840170989453327e-05
UBE3A O 0 0.0004934996250085533
cDNA O 0 6.505960300273728e-06
analysis O 0 3.224445066507542e-08
has O 0 3.116140956382907e-10
shown O 0 5.568318584003862e-10
a O 0 4.078045456878954e-09
coding O 0 8.553536900990366e-08
region O 0 9.41249389541099e-09
of O 0 3.2874769573254525e-08
approximately O 0 2.0147398060998967e-07
2 O 0 4.2834608393604867e-07
. O 0 1.4247976309889054e-07

6 O 0 1.818290547817014e-05
kb O 0 6.510256935143843e-05
and O 0 1.26944099676507e-08
a O 0 5.847274309189743e-08
3 O 0 8.0620921494301e-08
- O 0 2.2527912335590372e-07
untranslated O 0 2.834622500813566e-05
region O 0 1.2203221899653727e-07
( O 0 2.3516058433870057e-08
UTR O 0 1.1905851351912133e-05
) O 0 2.164227463907764e-09
of O 0 7.987883243743e-09
< O 0 1.6947457481819583e-07
50 O 0 9.663975397700142e-09
bp O 0 5.544404757529264e-08
, O 0 3.9996017608956436e-10
whereas O 0 2.447082980694404e-09
Northern O 0 4.570392952985003e-09
analysis O 0 1.0236749226066877e-08
has O 0 1.3105030949311924e-10
indicated O 0 7.185955719357651e-10
mRNA O 0 3.139888127279278e-09
sizes O 0 6.886547443407665e-10
of O 0 8.606079404671618e-09
5 O 0 2.983261992994812e-08
- O 0 2.2315622061341855e-07
8 O 0 4.4116546860095696e-07
kb O 0 1.798207995307166e-05
. O 0 1.7797950135900464e-07

We O 0 1.2812036231935053e-07
have O 0 1.983345487843735e-09
analyzed O 0 9.001048795198585e-09
additional O 0 8.064180434530499e-09
cDNA O 0 4.23124788540008e-07
clones O 0 1.9627799829891046e-08
and O 0 8.018252034558415e-11
provide O 0 3.672509796270873e-10
evidence O 0 5.2840207764859315e-09
for O 0 3.0516639215605323e-10
an O 0 2.4421682454089932e-09
additional O 0 2.4535429687944088e-08
0 O 0 6.652471995494125e-08
. O 0 4.241412909777864e-08

5 O 0 1.0171102985623293e-05
kb O 0 4.1534505726303905e-05
of O 0 5.500490942722536e-07
5 O 0 4.645481794796069e-07
- O 0 1.300563667427923e-06
UTR O 0 7.610269676661119e-05
and O 0 1.4652787427849034e-08
> O 0 7.413051150706451e-08
2 O 0 1.8533318879576655e-08
kb O 0 6.306687510004849e-07
of O 0 5.9227037496611956e-08
3 O 0 5.244553449301748e-07
- O 0 3.016064965777332e-06
UTR O 0 0.0007758411229588091
. O 0 2.935841223461466e-07

We O 0 3.467390854439145e-07
have O 0 2.92879165364468e-09
established O 0 9.7560954870346e-09
the O 0 6.924695483689902e-09
genomic O 0 4.955140298079641e-08
organization O 0 6.370561411728204e-09
of O 0 5.540134040415978e-08
UBE3A O 0 7.294874376384541e-05
and O 0 2.078722527443233e-09
the O 0 7.020287018377758e-09
sequence O 0 4.298519939993639e-08
of O 0 1.0202835909467467e-07
intron O 0 3.354758518980816e-05
- O 0 4.986055500921793e-06
exon O 0 4.364082087704446e-06
borders O 0 1.84638523137437e-07
. O 0 1.5082382276432327e-07

We O 0 3.551602105744678e-07
have O 0 3.500354006646944e-09
also O 0 1.1207559325043803e-09
mapped O 0 1.7562429732720375e-08
two O 0 6.144633135640731e-10
highly O 0 4.870988501437523e-09
homologous O 0 3.9824023190249136e-08
processed O 0 3.1127701305422306e-08
pseudogenes O 0 6.83185362504446e-07
, O 0 2.070003191079195e-08
UBE3AP1 O 0 0.000730656087398529
and O 0 9.127813882514602e-08
UBE3AP2 O 1 0.7318240404129028
, O 0 1.1203567851225671e-08
to O 0 3.221726219138077e-09
chromosomes O 0 1.671219074239616e-08
2 O 0 4.5323522712692466e-09
and O 0 2.6574575873183903e-10
21 O 0 3.951281080105673e-09
, O 0 2.0407328604754582e-10
respectively O 0 1.5672446673775653e-09
, O 0 1.66351807329157e-10
and O 0 8.304017196092417e-11
determined O 0 5.673707725861732e-09
their O 0 3.1889568763432408e-09
genomic O 0 2.9609446983158705e-07
organization O 0 1.499395239079604e-07
. O 0 1.572519181536336e-07

These O 0 3.757196154197118e-08
results O 0 7.437492843820337e-09
will O 0 1.9566480380373008e-10
form O 0 2.0718261828367446e-10
the O 0 3.869101428133348e-10
basis O 0 3.086542577079854e-09
for O 0 2.4560503630866037e-10
studies O 0 1.8496159048808636e-09
of O 0 1.759410395152372e-09
mutation O 0 1.0054308496876274e-09
and O 0 1.2276527572296914e-09
imprinting O 0 2.11578412745439e-06
of O 0 2.8018262128171045e-06
UBE3A O 1 0.9825292825698853
. O 0 2.980119688800187e-06

Mutation O 0 5.876012778571749e-07
spectrum O 0 1.3771406770501926e-07
and O 0 1.1202370586715915e-08
genotype O 0 6.427035259548575e-07
- O 0 6.960211180739861e-07
phenotype O 0 2.1412539297216426e-07
analyses O 0 1.2392735015964718e-07
in O 0 1.934916937784692e-08
Cowden B-Disease 1 0.9987133741378784
disease I-Disease 0 0.00031194684561342
and O 0 9.964815461671606e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.773986456678813e-09
two O 0 1.8030455350981356e-08
hamartoma B-Disease 1 0.9919920563697815
syndromes I-Disease 0 6.978813325986266e-05
with O 0 7.776340567033913e-07
germline O 1 0.9999988079071045
PTEN O 1 0.9999133348464966
mutation O 0 2.147699433407979e-06
. O 0 5.027779934607679e-07

The O 0 0.00010265889432048425
tumour B-Disease 1 1.0
suppressor O 1 0.9999326467514038
gene O 0 3.362592906341888e-05
PTEN O 0 0.00013696907262783498
, O 0 3.201706677558036e-09
which O 0 1.4850605190019905e-09
maps O 0 9.007268886307429e-08
to O 0 9.76667422492028e-08
10q23 O 0 0.00015950060333125293
. O 0 2.8578990622918354e-06

3 O 0 6.57516920909984e-07
and O 0 8.888890512537273e-09
encodes O 0 8.13171183722261e-08
a O 0 1.293597318152706e-08
403 O 0 4.322246738297508e-08
amino O 0 3.935135239885312e-08
acid O 0 4.8205087921360246e-08
dual O 0 8.671032105667109e-07
specificity O 0 1.677982822911872e-06
phosphatase O 0 0.294899046421051
( O 0 6.705799364681297e-07
protein O 0 4.681519385485444e-07
tyrosine O 0 3.7494365301427024e-07
phosphatase O 0 1.725422862364212e-06
; O 0 1.2221111900245774e-09
PTPase O 0 1.593015440448653e-06
) O 0 2.798080656063462e-09
, O 0 1.5775064587941756e-10
was O 0 5.240261113925726e-09
shown O 0 3.8788123823962906e-09
recently O 0 3.859367048164586e-09
to O 0 7.33921146078842e-10
play O 0 7.1773298415678255e-09
a O 0 1.827266338239042e-08
broad O 0 1.1599137650364355e-08
role O 0 5.678452907886822e-08
in O 0 2.1774035019461735e-08
human O 0 2.017722096070429e-07
malignancy B-Disease 0 0.0005578375421464443
. O 0 3.5310043244862754e-07

Somatic O 0 0.025471091270446777
PTEN O 0 0.005476073827594519
deletions O 0 9.665487823440344e-07
and O 0 3.951296179138808e-09
mutations O 0 3.0931313066417943e-09
were O 0 2.5321065244554575e-09
observed O 0 8.661773520657334e-09
in O 0 2.554780831331982e-09
sporadic B-Disease 0 4.803827323485166e-06
breast I-Disease 0 0.02529439516365528
, I-Disease 0 1.745425635135689e-07
brain I-Disease 1 0.9999998807907104
, I-Disease 0 7.729524753585792e-08
prostate I-Disease 1 0.9999450445175171
and I-Disease 0 0.0023890112061053514
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999997615814209
lines O 0 2.656394428868225e-07
and O 0 3.0748067980646e-10
in O 0 4.0676420565155524e-10
several O 0 6.733400503833309e-10
primary O 0 6.935510100447573e-06
tumours B-Disease 1 1.0
such O 0 4.718837320893954e-09
as O 0 6.5308258854201995e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9397143125534058
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999995231628418
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0002063494612229988

In O 0 3.6191300978316576e-07
addition O 0 2.4378212515330233e-07
, O 0 6.0521102795974e-08
PTEN O 0 8.809778228169307e-05
was O 0 7.55930429363616e-08
identified O 0 9.589062877068955e-09
as O 0 1.403262173127473e-09
the O 0 4.7974837436015605e-09
susceptibility O 0 3.706269424696984e-08
gene O 0 3.0747555612720134e-09
for O 0 2.076059768540972e-09
two O 0 1.9535033857209783e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 0.9999994039535522
Cowden B-Disease 1 1.0
disease I-Disease 1 0.999994158744812
( O 0 1.1527005199241103e-06
CD B-Disease 0 1.86291345016798e-05
; O 0 7.65113910006221e-08
MIM O 0 0.0007354403496719897
158350 O 0 1.9199607777409256e-05
) O 0 3.1563303082293714e-08
and O 0 1.2891367084932881e-08
Bannayan B-Disease 0 0.005719026084989309
- I-Disease 0 0.005547428037971258
Zonana I-Disease 1 0.9999672174453735
( I-Disease 0 3.680933104988071e-06
BZS I-Disease 0 0.038517773151397705
) I-Disease 0 1.4060337605314999e-07
or I-Disease 0 5.21438074940761e-08
Ruvalcaba I-Disease 0 2.7056086764787324e-05
- I-Disease 0 3.305662858110736e-06
Riley I-Disease 0 3.592575740185566e-05
- I-Disease 0 0.0015510309021919966
Smith I-Disease 0 0.4069424867630005
syndrome I-Disease 1 0.9999998807907104
( O 0 3.180825660820119e-05
MIM O 1 0.9999959468841553
153480 O 0 0.1867358386516571
) O 0 1.30728608382924e-06
. O 0 3.278435656284273e-07

Constitutive O 0 0.00015361745317932218
DNA O 0 6.975773885642411e-06
from O 0 7.181248662391226e-08
37 O 0 1.300657572755881e-07
CD B-Disease 0 3.758465538794553e-07
families O 0 4.642870532478582e-09
and O 0 1.2141836425172414e-09
seven O 0 6.228523830031918e-08
BZS B-Disease 0 0.005656772293150425
families O 0 4.8395949470148025e-09
was O 0 6.242891004148987e-08
screened O 0 1.4775859824567306e-07
for O 0 1.7917261629918357e-07
germline O 0 0.0029762336052954197
PTEN O 0 0.011590706184506416
mutations O 0 1.9177020931238076e-06
. O 0 7.137714419513941e-07

PTEN O 0 0.096461720764637
mutations O 0 4.540141844699974e-07
were O 0 5.9044086953008446e-08
identified O 0 7.051207973063356e-08
in O 0 8.262000861236629e-09
30 O 0 1.809936911456589e-08
of O 0 1.7619971259819067e-08
37 O 0 1.934046167662018e-08
( O 0 1.789603798485473e-09
81 O 0 5.596494823123521e-09
% O 0 5.300411221043078e-10
) O 0 1.1925509191268446e-10
CD B-Disease 0 5.704851702148517e-09
families O 0 9.7806047982818e-11
, O 0 3.417438901309744e-11
including O 0 1.9975622544965432e-10
missense O 0 7.980318628142413e-08
and O 0 1.9908232840037954e-09
nonsense O 0 1.7049405869329348e-06
point O 0 2.3337713628279744e-07
mutations O 0 1.6133314684196876e-09
, O 0 2.3008250860101498e-10
deletions O 0 6.669889085486602e-09
, O 0 1.1676244415781412e-09
insertions O 0 4.8762711202243736e-08
, O 0 2.983271851775271e-09
a O 0 3.082966770762141e-08
deletion O 0 1.1249389899603557e-06
/ O 0 7.979799192980863e-06
insertion O 0 2.839238732121885e-06
and O 0 9.766301900526742e-08
splice O 0 0.00025316892424598336
site O 0 4.276059371477459e-06
mutations O 0 2.973503114844789e-07
. O 0 2.0087691154913045e-07

These O 0 5.373667377739366e-08
mutations O 0 2.149205613477534e-08
were O 0 6.47322906388581e-09
scattered O 0 1.4855146446279832e-08
over O 0 2.7999278451318332e-09
the O 0 7.945595292824237e-09
entire O 0 1.280038617323953e-07
length O 0 5.9194285029207094e-08
of O 0 1.546584087463998e-07
PTEN O 0 1.2634207450901158e-05
, O 0 3.232502321370845e-10
with O 0 8.135267459685736e-11
the O 0 1.4974361750574872e-09
exception O 0 2.808346222238356e-09
of O 0 2.919432695591695e-09
the O 0 2.1753931989110242e-09
first O 0 2.435386337040768e-09
, O 0 9.036135728557326e-10
fourth O 0 3.784180435673079e-08
and O 0 5.546908710130083e-09
last O 0 5.105403033667244e-07
exons O 0 3.0728158435522346e-06
. O 0 7.74594980157417e-07

A O 0 1.811319452826865e-05
hot O 0 3.4987049275514437e-06
spot O 0 5.989849682919157e-07
for O 0 3.114848823315697e-08
PTEN O 0 3.1626106647308916e-05
mutation O 0 5.053254259479445e-09
in O 0 1.7203328761539183e-09
CD B-Disease 0 1.3856482894425426e-07
was O 0 5.076383757796066e-08
identified O 0 1.8905057075357945e-08
in O 0 6.862372448068754e-09
exon O 0 1.4156687200284068e-07
5 O 0 5.435162098166302e-09
that O 0 9.640364201368712e-11
contains O 0 1.8647698940554847e-09
the O 0 2.0793340382851966e-08
PTPase O 0 0.00033760827500373125
core O 0 1.2628666809177957e-05
motif O 0 2.9681257274205564e-07
, O 0 1.9607351853245802e-10
with O 0 7.479165897716911e-11
13 O 0 2.8545306118843428e-09
of O 0 5.333779196092792e-09
30 O 0 4.2090535501415616e-09
( O 0 5.839845274024924e-10
43 O 0 4.8839012833923334e-09
% O 0 3.3635341734061797e-10
) O 0 3.1754324170130133e-10
CD B-Disease 0 1.738319888033857e-08
mutations O 0 6.91272261654774e-10
identified O 0 2.644888086322794e-09
in O 0 2.475021743109096e-09
this O 0 3.256311487120911e-08
exon O 0 4.182394150120672e-06
. O 0 3.6521171864478674e-07

Seven O 0 3.6844417081738357e-06
of O 0 7.245886308737681e-07
30 O 0 2.7413111070018203e-07
( O 0 1.2481378597328785e-08
23 O 0 3.7153078835672204e-08
% O 0 2.2131136923064787e-09
) O 0 2.1476462275238362e-10
were O 0 9.344907070385489e-10
within O 0 5.946051651051221e-09
the O 0 1.3397257525582518e-08
core O 0 4.3185551135138667e-07
motif O 0 1.0628978941440437e-07
, O 0 2.3676074989431584e-10
the O 0 1.5162612276853338e-09
majority O 0 2.2370953700612262e-10
( O 0 3.669709258691256e-10
five O 0 2.9732610817845284e-10
of O 0 1.9741592804933816e-09
seven O 0 2.3677668714583433e-09
) O 0 6.360517113002118e-10
of O 0 7.806264523679829e-10
which O 0 1.2037280894272584e-10
were O 0 3.419268201909631e-09
missense O 0 2.0269409617412748e-07
mutations O 0 2.2400938881617094e-09
, O 0 6.758388293448547e-10
possibly O 0 9.405624012970293e-08
pointing O 0 5.782359835393436e-07
to O 0 3.563310979615153e-09
the O 0 3.9606241841738665e-08
functional O 0 2.623356749609229e-06
significance O 0 3.07585736436522e-07
of O 0 3.789857672131802e-08
this O 0 7.836836068975117e-09
region O 0 1.4148062632557412e-07
. O 0 2.890573114200379e-07

Germline O 1 0.9999946355819702
PTEN O 0 0.20831811428070068
mutations O 0 9.414185342393466e-08
were O 0 1.7925426476494977e-08
identified O 0 2.5066254849548386e-08
in O 0 2.708084867464322e-09
four O 0 2.424027645275828e-09
of O 0 1.8533176771029503e-08
seven O 0 4.07559852533268e-08
( O 0 2.0520618093655685e-08
57 O 0 1.0324482957457803e-07
% O 0 4.590471291976428e-08
) O 0 3.943445037180027e-08
BZS B-Disease 0 0.007049691863358021
families O 0 6.172407296389792e-08
studied O 0 2.3947500267240684e-06
. O 0 6.537304670928279e-07

Interestingly O 0 9.824921107792761e-06
, O 0 1.2010185734823153e-08
none O 0 1.9948837248762175e-08
of O 0 3.015715677179287e-09
these O 0 5.24441767790762e-10
mutations O 0 1.4466995379436298e-09
was O 0 4.30970104048356e-08
observed O 0 4.451877444466845e-08
in O 0 9.974756132180573e-09
the O 0 5.330258545654942e-07
PTPase O 1 0.7664515972137451
core O 0 0.00022084775264374912
motif O 0 1.446736860089004e-05
. O 0 4.198264207389002e-07

It O 0 1.4245856050365546e-07
is O 0 1.2228812629189179e-08
also O 0 1.2861716136569612e-09
worthy O 0 8.973608345286266e-08
of O 0 3.9220822145580314e-08
note O 0 1.0584451359818559e-07
that O 0 2.3741795196485782e-09
a O 0 8.222510672339922e-09
single O 0 8.397728734621523e-09
nonsense O 0 4.213220847759658e-07
point O 0 5.604915642720698e-08
mutation O 0 1.0038671005574429e-09
, O 0 4.73864114614031e-10
R233X O 0 1.0076394119096221e-07
, O 0 1.2383650771496946e-09
was O 0 3.848849416954181e-08
observed O 0 1.0874415146133742e-08
in O 0 1.12343756519806e-09
the O 0 7.006441649082262e-09
germline O 0 4.72346386004574e-07
DNA O 0 3.708496976173592e-08
from O 0 9.896863328862082e-10
two O 0 3.2189728660370065e-10
unrelated O 0 1.948204086943406e-08
CD B-Disease 0 6.750972829649982e-07
families O 0 4.0998986428064654e-09
and O 0 4.4528007947519654e-09
one O 0 3.1709964787296485e-07
BZS B-Disease 1 0.9955229759216309
family O 0 2.6880684345087502e-06
. O 0 3.2049959486357693e-07

Genotype O 0 0.00011327520769555122
- O 0 3.3930027711903676e-06
phenotype O 0 9.832785963226343e-08
studies O 0 6.027915500084191e-09
were O 0 8.218837277418345e-10
not O 0 1.2900576440433298e-10
performed O 0 1.5616139492635739e-09
on O 0 2.860995440556735e-09
this O 0 3.7018504928099105e-10
small O 0 6.807307162404186e-09
group O 0 1.2480641409240434e-08
of O 0 6.61710203075927e-07
BZS B-Disease 1 0.9998987913131714
families O 0 9.09508685253968e-07
. O 0 1.3751290453001275e-06

However O 0 2.7425818416304537e-07
, O 0 3.065411391389716e-08
genotype O 0 4.934856860927539e-07
- O 0 2.0793487465198268e-07
phenotype O 0 1.0073166123447663e-07
analysis O 0 4.230771821767121e-08
inthe O 0 6.73541023843427e-07
group O 0 4.610211767896999e-09
of O 0 1.1909633279572063e-08
CD B-Disease 0 1.6003199334591045e-06
families O 0 2.446018942947603e-09
revealed O 0 1.3060428294409121e-08
two O 0 2.3040266916574126e-10
possible O 0 1.9552537366962497e-09
associations O 0 2.0799835187546023e-09
worthy O 0 6.010719744153903e-08
of O 0 2.568781454215241e-08
follow O 0 1.680232308842733e-08
- O 0 5.5041439850356255e-08
up O 0 1.1451635195669496e-08
in O 0 5.824941862186961e-09
independent O 0 3.1738373706957645e-08
analyses O 0 3.910922146133089e-07
. O 0 2.3243002544859337e-07

The O 0 8.860142202138377e-07
first O 0 9.294573288798347e-08
was O 0 2.27536546049123e-07
an O 0 2.109928765037239e-08
association O 0 2.8212756575385356e-08
noted O 0 1.3172104296188536e-08
in O 0 1.9177721632956946e-09
the O 0 9.461921912645721e-09
group O 0 5.276648451513211e-09
of O 0 2.2238326735646297e-08
CD B-Disease 0 9.741121175466105e-06
families O 0 1.54676325081482e-08
with O 0 6.176765054988209e-08
breast B-Disease 1 0.9999990463256836
disease I-Disease 1 0.9999830722808838
. O 0 3.539190174706164e-06

A O 0 9.14734755497193e-06
correlation O 0 9.6770713753358e-07
was O 0 7.553063596787979e-08
observed O 0 6.877716618447494e-09
between O 0 5.029887617524764e-09
the O 0 2.2062816018575404e-09
presence O 0 2.2150699052758682e-08
/ O 0 3.3506361774016113e-07
absence O 0 5.068247332928877e-08
of O 0 6.719294276535948e-08
a O 0 8.682022212269658e-08
PTEN O 0 8.615560545877088e-06
mutation O 0 5.272219327778771e-10
and O 0 4.0267889717116034e-11
the O 0 5.71449776387567e-10
type O 0 1.4767315370534106e-08
of O 0 3.323981161429401e-07
breast O 0 0.0031900741159915924
involvement O 0 0.005606287159025669
( O 0 1.550723823129374e-06
unaffected O 0 5.850894467585022e-06
versus O 0 9.78489151748363e-06
benign O 0 0.00014128399197943509
versus O 0 2.7411293558543548e-05
malignant O 0 0.14204296469688416
) O 0 2.465226316417102e-07
. O 0 2.5279464921368344e-07

Specifically O 0 1.5932981796140666e-06
and O 0 8.199253720420074e-09
more O 0 5.470844333110847e-10
directly O 0 1.2080858091678692e-08
, O 0 1.1330891780403363e-09
an O 0 3.372272461277248e-09
association O 0 8.42537239975627e-09
was O 0 6.891888659765755e-08
also O 0 9.228076081058134e-10
observed O 0 5.8368199162828205e-09
between O 0 2.3772381840814205e-09
the O 0 2.7993403151072016e-09
presence O 0 3.2530074189907054e-09
of O 0 4.3794063486757295e-08
a O 0 3.03839641446757e-07
PTEN O 0 0.006732574198395014
mutation O 0 4.9566523330213386e-08
and O 0 1.8837315707287416e-08
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1025077583326492e-05

Secondly O 0 0.0001018016118905507
, O 0 1.979193342549479e-08
there O 0 1.1955128442764362e-08
appeared O 0 1.5933869335071904e-08
to O 0 1.2985010844346334e-09
be O 0 4.34858993259013e-09
an O 0 1.820628625637255e-08
interdependent O 0 2.355359811190283e-06
association O 0 7.85957432469786e-09
between O 0 1.5878867998253554e-08
mutations O 0 2.0503090780721323e-08
upstream O 0 3.4248904512423906e-07
and O 0 4.528314945240197e-10
within O 0 1.0783658410673524e-08
the O 0 6.612989267296143e-08
PTPase O 0 0.008431092835962772
core O 0 5.29219096279121e-06
motif O 0 5.55412611902284e-07
, O 0 9.205275430801407e-10
the O 0 6.092459425843799e-09
core O 0 9.844720949558905e-08
motif O 0 1.8775260457459808e-08
containing O 0 7.065135698702818e-10
the O 0 8.111225580087478e-10
majority O 0 3.846584994970925e-10
of O 0 9.39489819273831e-09
missense O 0 2.1491283064278832e-07
mutations O 0 2.084089789633481e-09
, O 0 2.1420089313384238e-10
and O 0 9.784896504161367e-11
the O 0 3.978604112830908e-09
involvement O 0 8.546508212248227e-08
of O 0 1.6335082619889363e-08
all O 0 9.6109942226974e-10
major O 0 5.8691746573913406e-08
organ O 0 0.15716825425624847
systems O 0 0.0012323625851422548
( O 0 6.012657536302868e-07
central O 0 8.364625682588667e-05
nervous O 0 0.004812417086213827
system O 0 2.6637994778866414e-06
, O 0 1.379550127467155e-07
thyroid O 1 0.9999998807907104
, O 0 1.1321799320285209e-05
breast O 1 1.0
, O 0 2.0429415599210188e-05
skin O 1 0.9999995231628418
and O 0 0.012997573241591454
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 0.0009939431911334395
. O 0 1.207930199598195e-05

However O 0 1.994317528897227e-07
, O 0 2.8456426104384036e-09
these O 0 3.9100225834864943e-10
observations O 0 2.5880053655669144e-08
would O 0 2.863974613021014e-10
need O 0 1.0166637531838774e-09
to O 0 5.277954184812472e-10
be O 0 1.9121182415204885e-09
confirmed O 0 3.271849458030829e-09
by O 0 9.620787499997618e-10
studying O 0 3.998782460712391e-08
a O 0 3.8953160697019484e-09
larger O 0 7.303964655314132e-10
number O 0 6.420633469339521e-10
of O 0 9.892281660484059e-09
CD B-Disease 0 1.2842745036323322e-06
families O 0 4.703007761008848e-08
. O 0 1.5056112090405804e-07

Molecular O 1 0.9999995231628418
defects O 1 0.9999613761901855
leading O 0 1.1918994005100103e-06
to O 0 1.0289760155046679e-08
human O 0 5.9353808978812594e-08
complement B-Disease 0 7.50304534449242e-05
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.099132683814787e-08
an O 0 1.0098593961060942e-08
African O 0 2.885235517169349e-07
- O 0 5.928671384936024e-07
American O 0 7.961706955939007e-07
family O 0 3.237652208554209e-07
. O 0 2.1591657173303247e-07

Complement B-Disease 0 0.0007157977088354528
component I-Disease 1 0.9999991655349731
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.586185473774094e-05
C6D B-Disease 1 0.999944806098938
) O 0 8.128734663159776e-08
was O 0 4.4082733552386344e-07
diagnosed O 0 4.2233182284689974e-07
in O 0 1.0740142109000317e-08
a O 0 2.3215505962070893e-08
16 O 0 2.3061129894585974e-08
- O 0 8.806537721284258e-09
year O 0 5.489128263036491e-09
- O 0 3.282458393982779e-08
old O 0 3.940284329928545e-07
African O 0 9.926834536599927e-07
- O 0 4.713896828434372e-07
American O 0 4.6638636064244565e-08
male O 0 1.297593232862937e-08
with O 0 4.259261832118e-09
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 1.0
. O 0 1.3130636489222525e-06

The O 0 2.822944679792272e-06
patients O 0 1.1541069966369832e-07
father O 0 3.378397366304853e-07
and O 0 8.301206833039032e-09
two O 0 2.3730894582740802e-08
brothers O 0 8.753288057050668e-06
also O 0 2.230102147393609e-08
had O 0 2.2283849432369607e-07
C6D B-Disease 1 0.9343624711036682
, O 0 7.734801243941547e-09
but O 0 1.1688254808461807e-09
gave O 0 9.88937731705164e-09
no O 0 4.54223547663446e-09
history O 0 1.649583367679952e-07
of O 0 1.7133578467110055e-06
meningitis B-Disease 1 0.9999994039535522
or O 0 2.9667294256796595e-06
other O 0 2.1326640364804916e-07
neisserial B-Disease 1 0.9999935626983643
infection I-Disease 1 0.9970977306365967
. O 0 2.596381591501995e-06

By O 0 1.7739318991516484e-07
using O 0 7.570284310531861e-08
exon O 0 2.6893607696365507e-07
- O 0 1.8386145939075504e-08
specific O 0 1.9541428475378098e-09
polymerase O 0 3.6203310571636393e-08
chain O 0 4.0936787293333055e-09
reaction O 0 1.1325251847438267e-09
( O 0 9.098673481311437e-10
PCR O 0 2.8240361160669636e-09
) O 0 5.080001419521807e-10
/ O 0 4.622953131416807e-09
single O 0 2.3702564355687628e-09
- O 0 9.265683331705077e-09
strand O 0 2.463672288399721e-08
conformation O 0 4.886342441778879e-09
polymorphism O 0 1.5233109218470986e-09
as O 0 2.49832619869661e-11
a O 0 1.1451972703468982e-10
screening O 0 4.055492400234506e-11
step O 0 2.348680971930861e-10
and O 0 6.11189016064273e-11
nucleotide O 0 1.1734969440624354e-08
sequencing O 0 2.7634994292924375e-09
of O 0 1.1654794906945654e-09
target O 0 5.314849893522933e-09
exons O 0 3.920539448643012e-09
, O 0 8.090578207387011e-11
we O 0 2.2691107326444637e-10
determined O 0 4.101181172444512e-09
that O 0 3.818150517975738e-10
the O 0 1.6873812569428992e-08
proband O 0 5.0967178140126634e-06
was O 0 4.890997615802917e-07
a O 0 7.8861717156542e-08
compound O 0 8.681557233103376e-07
heterozygote O 0 2.3748084743147047e-07
for O 0 1.5535333020011421e-09
two O 0 1.7260592954926324e-08
C6 O 0 0.0002896285441238433
gene O 0 4.925143457512604e-07
mutations O 0 1.2440740704278141e-07
. O 0 1.6135068392486573e-07

The O 0 8.154867714438296e-07
first O 0 8.269935136695494e-08
, O 0 8.703207932114765e-09
1195delC O 0 6.893807267260854e-07
located O 0 6.873628421999456e-08
in O 0 4.557118238324165e-09
exon O 0 1.2868585486103257e-07
7 O 0 4.1976953468747524e-08
, O 0 5.101148392583355e-10
is O 0 2.578709468181728e-10
a O 0 6.529821683365356e-10
novel O 0 5.95031757200104e-09
mutation O 0 2.569101875682378e-10
, O 0 6.299470667325835e-11
while O 0 2.170791324473953e-10
the O 0 2.0172010728458645e-09
second O 0 1.9177878840537232e-08
, O 0 1.357768564247408e-09
1936delG O 0 1.0397760519254007e-07
in O 0 5.23509591232596e-09
exon O 0 8.763445435988615e-08
12 O 0 6.498515059405463e-09
, O 0 1.9580294330356907e-10
has O 0 7.908951271673459e-11
been O 0 3.3696345713707387e-10
described O 0 1.435006002914463e-09
before O 0 1.5133725383975616e-08
to O 0 1.0900330416063753e-08
cause O 0 1.7533781146994443e-06
C6D B-Disease 1 0.9802885055541992
in O 0 2.9472127849317076e-08
an O 0 1.6808060721018592e-08
unrelated O 0 2.598214337012905e-07
African O 0 4.4373430796440516e-07
- O 0 6.587238772226556e-07
American O 0 3.144744766814256e-07
individual O 0 4.4835175572188746e-08
. O 0 8.20442025428747e-08

Both O 0 3.816458615801821e-07
mutations O 0 2.3881469246589404e-07
result O 0 3.9640628557435775e-08
in O 0 4.5699763973061636e-08
premature O 0 1.6060257621575147e-06
termination O 0 2.9138657282601343e-06
codons O 0 2.7962792046309914e-06
and O 0 1.9861842304180755e-07
C6 O 0 0.00035358822788111866
null O 0 8.594011887907982e-06
alleles O 0 7.211968409137626e-07
. O 0 3.710651981236879e-07

Allele O 0 1.0810512094394653e-06
- O 0 1.7428473597647098e-07
specific O 0 1.0766066260714524e-08
PCR O 0 1.85830387522401e-07
indicated O 0 2.3064032461661554e-08
that O 0 4.9677306712681e-10
the O 0 1.4311827278845612e-08
probands O 0 4.654884378396673e-06
two O 0 1.95290663640435e-08
brothers O 0 6.989665735090966e-07
also O 0 5.98399507723002e-09
inherited O 0 3.062232849515567e-07
the O 0 4.546415866002462e-08
1195delC O 0 4.5287944772098854e-07
mutation O 0 1.1845017189315854e-09
from O 0 5.195869845486811e-10
their O 0 1.1819942802304695e-09
heterozygous O 0 1.2981873354078743e-08
mother O 0 6.2911560405609634e-09
and O 0 2.0852577997665378e-10
the O 0 4.9732031826010825e-09
1936delG O 0 2.0951435431015852e-07
mutation O 0 1.0032928932091068e-09
from O 0 2.086014694313576e-09
their O 0 2.6255673191144524e-09
homozygous O 0 4.830661026744565e-08
father O 0 4.106177868834493e-07
. O 0 3.046630681069473e-08
. O 0 1.6261073199075327e-07

PAX6 O 0 0.23011821508407593
mutations O 0 1.9397006326471455e-05
reviewed O 0 1.5195476407825481e-05
. O 0 1.621886781322246e-06

Mutations O 0 6.359628514474025e-06
in O 0 9.991116911578501e-08
PAX6 O 0 0.00018076488049700856
are O 0 2.162193313282046e-09
responsible O 0 2.5489852006899127e-08
for O 0 4.275328979730375e-09
human O 0 2.1325145098671783e-06
aniridia B-Disease 1 1.0
and O 0 1.0515427639745667e-08
have O 0 2.8858096468020733e-10
also O 0 7.210555763581539e-11
been O 0 1.0813306500212505e-10
found O 0 1.4417790572540667e-10
in O 0 4.570425149452717e-10
patients O 0 4.892952154555985e-10
with O 0 1.2719972852792694e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.583078745985404e-07
with O 0 0.00012015881657134742
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 2.8059121177648194e-05
with O 0 1.6469613910885528e-05
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.999998927116394
keratitis I-Disease 1 0.9999992847442627
, O 0 4.07332940710603e-08
and O 0 1.69629412738459e-08
with O 0 2.1619712242682e-06
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0010093316668644547

No O 0 3.6695771541417344e-06
locus O 0 1.4249703781388234e-06
other O 0 2.0439669956573425e-09
than O 0 4.8070831759616794e-09
chromosome O 0 2.193640540326669e-07
11p13 O 0 8.395776944780664e-07
has O 0 1.0224334712205518e-09
been O 0 3.95543597875303e-09
implicated O 0 1.3966413803245814e-07
in O 0 3.507386381329525e-08
aniridia B-Disease 1 1.0
, O 0 2.4205315085623624e-08
and O 0 1.254759229851743e-08
PAX6 O 0 0.03307296335697174
is O 0 1.504841229404974e-08
clearly O 0 8.518203031826488e-09
the O 0 4.783029083910151e-09
major O 0 1.9932940631406382e-08
, O 0 4.5318659935844607e-10
if O 0 3.815376903304468e-10
not O 0 2.3291057971164264e-10
only O 0 9.655568566913075e-10
, O 0 2.592109193955139e-09
gene O 0 2.412737032386758e-08
responsible O 0 3.416975857817306e-07
. O 0 5.207712092669681e-07

Twenty O 0 1.055078064382542e-05
- O 0 4.3066569332950166e-07
eight O 0 2.0266194056262066e-08
percent O 0 3.939278681031055e-09
of O 0 2.2847725933416996e-09
identified O 0 6.520443207591597e-08
PAX6 O 0 9.829756891122088e-06
mutations O 0 5.634367195028744e-09
are O 0 1.0063632149837076e-09
C O 0 3.396806732780533e-06
- O 0 1.498472374805715e-05
T O 0 3.345685172462254e-06
changes O 0 9.205842310677781e-09
at O 0 3.8194298213056754e-07
CpG O 0 3.743787601706572e-06
dinucleotides O 0 5.169205792299181e-07
, O 0 4.591114710628119e-10
20 O 0 8.47381387281132e-10
% O 0 1.3794416997559011e-10
are O 0 1.4116551677600953e-11
splicing O 0 2.1231933988730134e-09
errors O 0 6.108563432860592e-09
, O 0 2.0475870998737378e-10
and O 0 5.262150090667994e-11
more O 0 2.3649616986975985e-11
than O 0 7.959465725404513e-11
30 O 0 1.1323308957145173e-09
% O 0 4.165111866516469e-10
are O 0 7.578478816716583e-11
deletion O 0 1.1030166113812356e-08
or O 0 1.0253241811142288e-08
insertion O 0 4.220471510052448e-07
events O 0 3.217564881197177e-07
. O 0 3.1990290949579503e-07

There O 0 2.34900244322489e-06
is O 0 8.422291131182646e-08
a O 0 8.912220295087536e-08
noticeably O 0 5.395161792876024e-07
elevated O 0 2.3446196451004653e-07
level O 0 7.545748559323329e-08
of O 0 1.4718556151649409e-08
mutation O 0 2.1285537776805086e-09
in O 0 7.342739749560678e-10
the O 0 2.5664195213437324e-09
paired O 0 4.9962523007707205e-08
domain O 0 9.614338836172465e-08
compared O 0 2.033018198233094e-09
with O 0 6.4269894961555e-11
the O 0 2.5309332407630336e-09
rest O 0 1.6653260104249057e-08
of O 0 8.78919053093341e-08
the O 0 2.0772041864347557e-07
gene O 0 2.9359978270804277e-07
. O 0 1.3165680456950213e-07

Increased O 0 1.725817810438457e-06
mutation O 0 5.791952162326197e-08
in O 0 3.5354190686121e-09
the O 0 7.853939720803282e-09
homeodomain O 0 1.812334630812984e-06
is O 0 7.113815092552045e-10
accounted O 0 7.480772445944694e-09
for O 0 2.6872756797580166e-10
by O 0 1.5398597952298587e-09
the O 0 5.0891614478132396e-08
hypermutable O 0 5.150027936906554e-05
CpG O 0 2.7789310479420237e-05
dinucleotide O 0 5.333270109986188e-06
in O 0 3.5004891429935014e-08
codon O 0 6.298866992437979e-07
240 O 0 3.9723514078104927e-07
. O 0 2.9506436405313252e-08

Very O 0 3.2674734029569663e-07
nearly O 0 4.910842932304149e-08
all O 0 1.2726525389084031e-09
mutations O 0 2.569652046702231e-09
appear O 0 3.5289513533598438e-09
to O 0 4.322203484008469e-09
cause O 0 4.086402896064101e-07
loss O 0 6.64384288029396e-07
of O 0 3.469630485142261e-07
function O 0 2.1763432300758723e-07
of O 0 1.110425973394058e-08
the O 0 3.925792135817119e-09
mutant O 0 4.56877158327984e-09
allele O 0 2.0308855985806673e-10
, O 0 1.4987433169522113e-11
and O 0 6.299359905231894e-12
more O 0 5.43351605028497e-12
than O 0 2.4187278915843713e-11
80 O 0 7.721899786261588e-10
% O 0 3.685266536379572e-10
of O 0 2.7084516851516582e-09
exonic O 0 2.929355389369448e-07
substitutions O 0 2.144235011769524e-08
result O 0 1.0600084365819384e-08
in O 0 7.398516288503743e-08
nonsense O 0 1.439937113900669e-05
codons O 0 5.835903721163049e-06
. O 0 7.488704341085395e-07

In O 0 4.089280309926835e-07
a O 0 5.6534560144427815e-08
gene O 0 3.1691169688485843e-09
with O 0 9.709416604053445e-11
such O 0 2.7674224023499505e-10
extraordinarily O 0 5.333842878485484e-08
high O 0 1.5152558319186937e-08
sequence O 0 9.763280850449974e-09
conservation O 0 3.197886178085696e-09
throughout O 0 3.8442818373063403e-10
evolution O 0 2.708994362166095e-09
, O 0 4.717320978286921e-11
there O 0 3.2890290491138785e-10
are O 0 2.656849462656652e-10
presumed O 0 1.0470935194462072e-06
undiscovered O 0 0.00017613274394534528
missense O 0 1.1076484724981128e-06
mutations O 0 2.3209780763977506e-09
, O 0 9.266804684715524e-11
these O 0 1.0175304349102632e-10
are O 0 2.1367776992242682e-10
hypothesized O 0 1.411789263272567e-08
to O 0 5.81984183067874e-10
exist O 0 1.796081328109267e-08
in O 0 4.616899307308131e-09
as O 0 1.7010339803391616e-08
- O 0 2.0384557330999087e-07
yet O 0 4.583603185892571e-08
unidentified O 0 2.483327762092813e-06
phenotypes O 0 1.3494782535872218e-07
. O 0 4.001618592042178e-09
. O 0 6.677439756685999e-08

Genetic O 0 0.0001282695448026061
heterogeneity O 0 4.122117388760671e-06
and O 0 1.5620793547554968e-08
penetrance O 0 3.805025244218996e-06
analysis O 0 5.413170001133949e-08
of O 0 3.990172814383186e-08
the O 0 1.011205128520487e-07
BRCA1 O 0 6.411479489543126e-07
and O 0 9.462354455536115e-09
BRCA2 O 0 1.5112617575141485e-06
genes O 0 5.7776752271365694e-08
in O 0 1.2406144378473982e-07
breast B-Disease 1 0.9999858140945435
cancer I-Disease 1 0.9997952580451965
families O 0 3.4729548588074977e-06
. O 0 1.8338009795115795e-06

The O 0 0.0007708824123255908
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9999947547912598
Consortium O 0 0.00014084910799283534
. O 0 8.970139901975926e-07

The O 0 2.0440155878986843e-07
contribution O 0 5.906109095121792e-07
of O 0 4.3524096327018924e-07
BRCA1 O 0 1.6665707107677008e-06
and O 0 3.003954418545618e-08
BRCA2 O 0 2.309710907866247e-06
to O 0 1.0286526475056235e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00020650867372751236
assessed O 0 1.0422024132594743e-07
by O 0 7.940515467375064e-10
linkage O 0 1.5740639014438784e-08
and O 0 4.912493675734986e-11
mutation O 0 1.1734420379827526e-10
analysis O 0 4.954303634008284e-10
in O 0 1.1791047305198532e-10
237 O 0 4.097420625015502e-09
families O 0 3.48546858042198e-10
, O 0 7.494731918411546e-11
each O 0 8.15418982336169e-11
with O 0 9.42858430219573e-11
at O 0 1.7906119254007535e-08
least O 0 4.674956533001762e-10
four O 0 2.9359939479611796e-10
cases O 0 2.824309675020231e-10
of O 0 4.812433829215479e-08
breast B-Disease 1 0.7965002059936523
cancer I-Disease 0 3.1369949283543974e-05
, O 0 1.2614390643150841e-09
collected O 0 7.700033499702386e-09
by O 0 3.794680569768616e-09
the O 0 7.706934184170677e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.21589124202728271
Consortium O 0 4.509298832999775e-06
. O 0 9.091603203614795e-08

Families O 0 1.777230522748141e-07
were O 0 1.1828226398336028e-08
included O 0 5.946267034317998e-09
without O 0 7.315177352751334e-09
regard O 0 1.8533459211766967e-08
to O 0 1.316584397059728e-09
the O 0 8.700286713292371e-09
occurrence O 0 7.802072445883823e-07
of O 0 3.7586764847219456e-06
ovarian B-Disease 1 1.0
or I-Disease 0 1.9521192371030338e-05
other I-Disease 0 2.4786731955828145e-07
cancers I-Disease 1 0.9489096403121948
. O 0 1.9857138795487117e-06

Overall O 0 4.666620952775702e-05
, O 0 1.7293454845912493e-07
disease O 0 3.261469828430563e-06
was O 0 2.020686679315986e-06
linked O 0 4.614736553776311e-06
to O 0 1.1732082860760329e-08
BRCA1 O 0 1.4171396855999774e-07
in O 0 1.2912966251832358e-09
an O 0 1.0704327424448934e-09
estimated O 0 1.8246812949485047e-09
52 O 0 3.353415101159385e-09
% O 0 5.325908047915107e-10
of O 0 8.810061569164418e-10
families O 0 4.162467592827568e-10
, O 0 4.115990048791929e-10
to O 0 7.91209375794466e-10
BRCA2 O 0 1.281690753529574e-08
in O 0 6.588344869662421e-10
32 O 0 2.8268116736285265e-09
% O 0 3.631468736831067e-10
of O 0 1.4146619431443241e-09
families O 0 5.297621785693707e-10
, O 0 1.7865164902985953e-10
and O 0 2.0017081048262497e-10
to O 0 1.1306583447279195e-09
neither O 0 3.638447054754579e-08
gene O 0 2.9222739783563156e-09
in O 0 1.0123157867525379e-09
16 O 0 3.1671110178876916e-09
% O 0 5.124553004165477e-10
( O 0 2.419656697227879e-10
95 O 0 1.8098875731453745e-09
% O 0 1.938195021145006e-10
confidence O 0 5.969357896873362e-09
interval O 0 2.5155418370559346e-07
[ O 0 8.507942652613565e-07
CI O 0 0.00039968223427422345
] O 0 9.284774904472215e-08
6 O 0 1.3653106201161336e-08
% O 0 5.621761944851755e-10
- O 0 9.574894210828688e-10
28 O 0 2.6608573122643975e-09
% O 0 2.2032947688543914e-10
) O 0 9.938037892620599e-11
, O 0 3.894717534591585e-11
suggesting O 0 2.435237789200073e-09
other O 0 3.703856110703896e-10
predisposition O 0 1.0516108659430756e-06
genes O 0 3.1267242661670025e-07
. O 0 1.4748462717761868e-07

The O 0 2.645429901804164e-07
majority O 0 3.0446192234023783e-09
( O 0 3.4243199387162804e-09
81 O 0 1.5066905945104736e-08
% O 0 1.1146651379689843e-09
) O 0 1.3387332908898486e-10
of O 0 8.237324156112891e-10
the O 0 1.514641070343714e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.4092192657244595e-07
were O 0 3.9120533479319874e-09
due O 0 1.3457416514484066e-08
to O 0 1.0438346853547387e-09
BRCA1 O 0 6.643036787323808e-09
, O 0 6.944382568985219e-11
with O 0 2.7343034086912965e-11
most O 0 1.561726303833666e-10
others O 0 2.4608470816644967e-10
( O 0 5.331152741483436e-10
14 O 0 3.925956892913973e-09
% O 0 9.278978141402661e-10
) O 0 7.339086005586637e-10
due O 0 8.466741974189063e-09
to O 0 3.388767666478998e-08
BRCA2 O 0 2.252858848805772e-06
. O 0 3.8851305816933746e-07

Conversely O 0 1.1044839993701316e-05
, O 0 6.431140064933061e-09
the O 0 4.4024019985045015e-09
majority O 0 6.64321042620486e-10
of O 0 9.254290667115583e-09
families O 0 2.636838747349657e-09
with O 0 1.1042748937484248e-09
male B-Disease 0 2.4713162929401733e-06
and I-Disease 0 9.438237746905997e-09
female I-Disease 0 4.970491136191413e-05
breast I-Disease 0 0.02426428534090519
cancer I-Disease 0 2.4397904780926183e-05
were O 0 9.257454536282239e-08
due O 0 1.4604634657189308e-07
to O 0 8.752582658644315e-09
BRCA2 O 0 5.798131397227735e-08
( O 0 3.7218881310252527e-09
76 O 0 4.1762927338595546e-08
% O 0 9.37869515382772e-09
) O 0 1.1483721529259583e-08
. O 0 2.530070553063979e-08

The O 0 1.2244657909832313e-06
largest O 0 1.0767610802986383e-07
proportion O 0 1.8459868300624294e-08
( O 0 2.7786262180029553e-09
67 O 0 1.264870519435135e-08
% O 0 1.6066462604769072e-09
) O 0 1.684106465393853e-10
of O 0 7.423090475633387e-10
families O 0 6.622942749778815e-10
due O 0 3.5509355456042613e-09
to O 0 9.502284514795178e-10
other O 0 2.670623167055908e-10
genes O 0 1.735469989938565e-09
was O 0 7.118379219406279e-09
found O 0 6.12346839901079e-10
in O 0 2.671392551611973e-10
families O 0 1.787416326060054e-10
with O 0 1.9517269744806498e-11
four O 0 8.676865892454089e-10
or O 0 6.585794687374857e-10
five O 0 4.6101567008349775e-10
cases O 0 6.153230147631916e-10
of O 0 3.9712489297016873e-07
female O 1 0.8246591091156006
breast B-Disease 1 0.9999510049819946
cancer I-Disease 0 0.14928165078163147
only O 0 3.480523673715652e-07
. O 0 3.2040060204963083e-07

These O 0 4.6467267367233944e-08
estimates O 0 2.854287117770582e-08
were O 0 4.101275319357001e-09
not O 0 3.3979030700237445e-10
substantially O 0 1.0858621557474635e-08
affected O 0 1.4971676121078303e-09
either O 0 1.321497800077509e-09
by O 0 1.4371177581296024e-09
changing O 0 2.0891933516509198e-08
the O 0 5.47121281613272e-09
assumed O 0 1.3388934405611508e-07
penetrance O 0 2.53423934282182e-07
model O 0 6.6952532407071885e-09
for O 0 1.2192264975396938e-09
BRCA1 O 0 9.939887135601566e-09
or O 0 4.517695106898145e-10
by O 0 5.013630621775178e-10
including O 0 2.1921540138691853e-09
or O 0 5.598515784299707e-08
excluding O 0 4.605995854944922e-06
BRCA1 O 0 6.763009992027946e-07
mutation O 0 1.1430597801620479e-08
data O 0 1.2270498928046436e-07
. O 0 5.1976392967389984e-08

Among O 0 8.701186970938579e-08
those O 0 4.177055590304235e-09
families O 0 5.133419023195529e-09
with O 0 2.111844255026085e-09
disease O 0 1.1802188055298757e-05
due O 0 3.5534958442440256e-07
to O 0 1.2454030695607798e-08
BRCA1 O 0 2.089201167621013e-08
that O 0 6.005072827885982e-11
were O 0 2.4237675755323096e-10
tested O 0 1.4222664712626454e-10
by O 0 6.33672003758079e-11
one O 0 1.5997926594568668e-10
of O 0 2.2327771576069466e-10
the O 0 4.413708010186923e-10
standard O 0 9.005989842769679e-10
screening O 0 7.065455165378154e-11
methods O 0 3.7199560098954976e-10
, O 0 2.4833416573111222e-11
mutations O 0 3.317568789129588e-11
were O 0 2.2530075027837881e-10
detected O 0 1.3823158173664751e-09
in O 0 1.7953842579299106e-10
the O 0 2.79730150154478e-09
coding O 0 1.1102526542572377e-07
sequence O 0 3.367723167002623e-08
or O 0 7.449902028611177e-09
splice O 0 8.5007755501465e-08
sites O 0 9.706458969915843e-10
in O 0 1.9995025080099538e-10
an O 0 8.757555236549308e-10
estimated O 0 1.816905514928635e-09
63 O 0 1.3811200183511119e-08
% O 0 1.2417875616677065e-09
( O 0 1.343307354240153e-09
95 O 0 1.384812886584541e-08
% O 0 5.020360571705851e-09
CI O 0 4.956585144100245e-06
51 O 0 2.598853221513764e-08
% O 0 2.003370580538899e-09
- O 0 7.90157095309496e-09
77 O 0 1.8873135942953922e-08
% O 0 6.303431554499639e-09
) O 0 3.232115464157914e-09
. O 0 1.0736414424172835e-08

The O 0 9.403450462741603e-07
estimated O 0 7.478749353140302e-08
sensitivity O 0 2.0976420600504753e-08
was O 0 1.0409067385808157e-08
identical O 0 1.3127303688520442e-09
for O 0 1.4962990568800905e-10
direct O 0 1.0857788002027746e-09
sequencing O 0 1.4975647388837388e-09
and O 0 1.3917118846240584e-10
other O 0 4.1282788298957485e-10
techniques O 0 7.953192380227847e-07
. O 0 4.1495596292406844e-07

The O 0 3.92859146813862e-06
penetrance O 0 0.0001126753631979227
of O 0 1.8320232584301266e-06
BRCA2 O 0 1.8302489479538053e-06
was O 0 2.3138834137625963e-07
estimated O 0 1.1100109276185322e-08
by O 0 2.393434783698467e-09
maximizing O 0 6.952913622626511e-07
the O 0 8.230752257532004e-08
LOD O 0 0.00011650189117062837
score O 0 4.3087311496492475e-08
in O 0 1.2530803061849838e-08
BRCA2 O 0 4.0395335076937045e-08
- O 0 1.2937626969744542e-08
mutation O 0 1.0078653467360255e-09
families O 0 1.2223669298982998e-10
, O 0 6.059563267823975e-11
over O 0 1.4259551872619625e-10
all O 0 5.717277762329331e-10
possible O 0 3.7199665570142315e-08
penetrance O 0 1.2544427590910345e-05
functions O 0 4.065606731273874e-07
. O 0 1.1687875201005227e-07

The O 0 2.1347801748561324e-07
estimated O 0 7.463131623808295e-08
cumulative O 0 2.7230248633713927e-07
risk O 0 1.0067730471519099e-07
of O 0 4.3838443275490135e-07
breast B-Disease 0 0.16369274258613586
cancer I-Disease 0 9.19552257983014e-06
reached O 0 1.9118513137073023e-06
28 O 0 1.195869003822736e-07
% O 0 2.6049706836062114e-09
( O 0 5.952255355268221e-10
95 O 0 6.430600940632303e-09
% O 0 2.1625026214167065e-09
CI O 0 1.8970961264130892e-06
9 O 0 1.784372827273728e-08
% O 0 1.1409724276489897e-09
- O 0 1.239463864877166e-09
44 O 0 1.1105482089490692e-09
% O 0 2.525998299418575e-10
) O 0 3.3164047896772075e-11
by O 0 2.975892102186073e-11
age O 0 4.5414536020693674e-10
50 O 0 3.426278150087114e-10
years O 0 1.1485528500498887e-10
and O 0 6.468790780811418e-11
84 O 0 3.6022760330212122e-09
% O 0 8.893804026577357e-10
( O 0 4.687563670557893e-10
95 O 0 2.9666007428374996e-09
% O 0 1.22191068374633e-09
CI O 0 1.478490958106704e-06
43 O 0 8.540670393131222e-09
% O 0 5.860421592451814e-10
- O 0 2.4991197999923997e-09
95 O 0 7.40256433928721e-09
% O 0 2.2816749878362685e-10
) O 0 3.306475926390107e-11
by O 0 5.151363016708821e-11
age O 0 4.68543870368876e-09
70 O 0 2.6133728070476536e-08
years O 0 2.3251931935419634e-08
. O 0 6.114323980455083e-08

The O 0 6.383532763720723e-06
corresponding O 1 0.8175350427627563
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.002430484862998128
were O 0 4.397607824557781e-07
0 O 0 1.2384288083922002e-07
. O 0 3.835526385387311e-08

4 O 0 3.0802095807302976e-06
% O 0 6.654097006730808e-08
( O 0 8.312391663878316e-09
95 O 0 2.722805803045958e-08
% O 0 4.695512423324999e-09
CI O 0 1.4865386219753418e-06
0 O 0 2.469655369097268e-09
% O 0 4.987887325391682e-10
- O 0 7.517828581882213e-10
1 O 0 1.585340747567443e-09
% O 0 1.7849564881711188e-10
) O 0 3.291386954651365e-11
by O 0 2.6877920028534064e-11
age O 0 7.428613835180897e-10
50 O 0 6.002991437270566e-10
years O 0 1.3453886615888422e-10
and O 0 9.220928187669841e-11
27 O 0 6.056346091298792e-09
% O 0 7.761487008650647e-10
( O 0 3.993107788868855e-10
95 O 0 6.705925148509095e-09
% O 0 1.8423206293860517e-09
CI O 0 1.1378714361853781e-06
0 O 0 2.038329727227506e-09
% O 0 2.0748631979206067e-10
- O 0 4.0691783276258775e-10
47 O 0 1.3611289872983434e-09
% O 0 1.374422797795205e-10
) O 0 2.715913778594814e-11
by O 0 5.6944417931026337e-11
age O 0 4.372676443153978e-09
70 O 0 1.5874597636411636e-08
years O 0 1.4224469602197587e-08
. O 0 3.799259218340012e-08

The O 0 9.84576104201551e-07
lifetime O 0 5.16876025358215e-06
risk O 0 4.070684099133359e-06
of O 0 4.088915738975629e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9415229558944702
appears O 0 1.7614317471270624e-07
similar O 0 4.3911621561143477e-10
to O 0 3.758023614519601e-10
the O 0 5.157483329298884e-09
risk O 0 4.1477147050272833e-08
in O 0 3.635490131159713e-09
BRCA1 O 0 1.2835499774155323e-08
carriers O 0 3.648902846542512e-10
, O 0 9.427972291753406e-11
but O 0 4.7937469965786406e-11
there O 0 4.125366992457913e-10
was O 0 1.719858033766286e-08
some O 0 4.418753418722332e-10
suggestion O 0 5.438034911264822e-09
of O 0 3.753770627668018e-09
a O 0 4.2403427435999674e-09
lower O 0 1.404470584276396e-08
risk O 0 1.783440417568727e-08
in O 0 1.8981292981834486e-08
BRCA2 O 0 1.5824753063498065e-07
carriers O 0 1.835272023242851e-08
< O 0 1.4519699789161677e-06
50 O 0 1.5384808094154323e-08
years O 0 4.607908277165507e-09
of O 0 2.4384970487290047e-08
age O 0 5.515020120583358e-07
. O 0 3.8685226400048123e-07

Eye B-Disease 1 0.9998284578323364
movement I-Disease 0 2.3860531655373052e-05
abnormalities I-Disease 0 0.011231203563511372
correlate O 0 1.1824278089989093e-06
with O 0 4.968614408795702e-09
genotype O 0 2.694680233616964e-06
in O 0 1.6456033335998654e-07
autosomal O 0 0.0006514910492114723
dominant O 0 0.0002643333573359996
cerebellar B-Disease 1 0.9999794960021973
ataxia I-Disease 1 0.9999994039535522
type I-Disease 1 0.9999992847442627
I I-Disease 1 0.9999923706054688
. O 0 1.4755351912754122e-05

We O 0 1.2290331596886972e-06
compared O 0 8.853021427057683e-07
horizontal O 0 1.54109670802427e-06
eye O 0 6.28395491730771e-06
movements O 0 4.6135653519741027e-07
( O 0 4.947887077833002e-08
visually O 0 1.282794244161778e-07
guided O 0 6.675924169030623e-07
saccades O 0 1.2919330401928164e-05
, O 0 1.0001103056822558e-08
antisaccades O 0 1.1379909210518235e-06
, O 0 3.439597939802752e-09
and O 0 1.4990221286481642e-09
smooth O 0 2.3124694337184337e-07
pursuit O 0 2.8811052743549226e-06
) O 0 7.3165447034284625e-09
in O 0 2.7470190566702968e-09
control O 0 8.636764192715418e-09
subjects O 0 4.450340540529396e-08
( O 0 5.466653796304399e-09
n O 0 3.733030595753917e-08
= O 0 4.814104670458619e-08
14 O 0 2.9385558431016534e-09
) O 0 2.6206128933559114e-10
and O 0 3.9417847458311783e-11
patients O 0 7.919427613689578e-11
with O 0 1.2156422569964409e-11
three O 0 1.7055319656567036e-10
forms O 0 4.2039269843030524e-09
of O 0 2.422227044007741e-05
autosomal O 1 0.973846435546875
dominant O 0 0.00298744672909379
cerebellar B-Disease 1 0.9993398785591125
ataxias I-Disease 1 0.9999827146530151
type I-Disease 1 0.999992847442627
I I-Disease 1 0.9999542236328125
spinocerebellar B-Disease 1 0.9999985694885254
ataxias I-Disease 0 0.03149554133415222
1 I-Disease 0 6.990399015194271e-07
and I-Disease 0 9.023876756941718e-09
2 I-Disease 0 9.882536033956058e-08
( O 0 4.455453606055926e-08
SCA1 B-Disease 0 1.1808685485448223e-05
, O 0 1.0829746877050184e-08
n O 0 1.6463270924305107e-07
= O 0 1.67613919188625e-07
11 O 0 1.559715556709307e-08
; O 0 7.00571656242488e-10
SCA2 B-Disease 0 1.7480020915172645e-06
, O 0 3.3179075042966133e-09
n O 0 3.6002578696070486e-08
= O 0 4.14704999229798e-08
10 O 0 2.5815602988643604e-09
) O 0 9.376616150191808e-10
and O 0 3.5331808589944558e-09
SCA3 B-Disease 1 1.0
/ O 0 0.0006594288861379027
Machado B-Disease 0 8.375860488740727e-06
- I-Disease 0 3.059560867768596e-06
Joseph I-Disease 0 0.000338056095642969
disease I-Disease 1 0.7053622603416443
( O 0 6.030442136761849e-07
MJD B-Disease 1 1.0
) O 0 3.96605166486097e-08
( O 0 1.4661118541425822e-08
n O 0 8.596076384037588e-08
= O 0 2.1268795080686687e-07
16 O 0 6.84233967263026e-08
) O 0 3.044527829842991e-08
. O 0 6.100427185629087e-08

In O 0 9.071472959476523e-06
SCA1 B-Disease 0 0.018979545682668686
, O 0 1.4894204980464565e-07
saccade O 0 2.77059825748438e-05
amplitude O 0 3.5951120480604004e-07
was O 0 3.921692837138835e-08
significantly O 0 8.395887540757485e-09
increased O 0 4.4139709665103055e-09
, O 0 6.272198871393186e-10
resulting O 0 1.2445648067682669e-08
in O 0 2.036504298530417e-08
hypermetria B-Disease 0 2.4692886654520407e-05
. O 0 5.501388500306348e-07

The O 0 8.139226338244043e-06
smooth O 0 1.638395588088315e-05
pursuit O 0 0.00011350312706781551
gain O 0 2.1874806407140568e-05
was O 0 6.137007403594907e-06
decreased O 0 1.4889922567817848e-05
. O 0 4.0760693309493945e-07

In O 0 1.0599147572065704e-05
SCA2 B-Disease 0 0.011604727245867252
, O 0 4.820371373170929e-07
saccade O 0 0.0001091087469831109
velocity O 0 5.44602653462789e-06
was O 0 1.565256525282166e-06
markedly O 0 1.2726407021546038e-06
decreased O 0 3.3800645269366214e-06
. O 0 2.5702033212837705e-07

The O 0 9.694335858512204e-07
percentage O 0 4.3447249709061e-07
of O 0 4.4975298152394316e-08
errors O 0 1.762335273269855e-06
in O 0 6.752930659104095e-08
antisaccades O 0 0.00021912109514232725
was O 0 1.7640454643697012e-06
greatly O 0 6.859928447511265e-08
increased O 0 8.461963574291076e-09
and O 0 3.2550040440781913e-10
was O 0 5.820210979834428e-09
significantly O 0 7.590981732086277e-10
correlated O 0 5.253911528058097e-09
with O 0 7.739338336865131e-11
age O 0 3.701811834844193e-08
at O 0 3.5312032196088694e-06
disease O 0 5.7471770560368896e-05
onset O 0 0.0019316475372761488
. O 0 3.478114649624331e-07

In O 0 2.1308505893102847e-07
addition O 0 2.0564817404533642e-08
, O 0 1.7544607988639882e-09
a O 0 2.7682736103429306e-09
correlation O 0 8.839420750916815e-09
between O 0 6.032240040809711e-09
smooth O 0 1.308377051145726e-07
pursuit O 0 3.7326610708987573e-06
gain O 0 2.0953933699274785e-07
and O 0 3.1108199349816346e-10
the O 0 9.167376302521291e-10
number O 0 1.3075276417140458e-09
of O 0 1.98738305812185e-08
trinucleotide O 0 8.444393643003423e-06
repeats O 0 5.386339694268827e-07
was O 0 5.712442998628831e-07
found O 0 2.4164333467524557e-07
. O 0 2.259202744880895e-07

In O 0 5.902245538891293e-05
SCA3 B-Disease 1 1.0
, O 0 1.5808085436219699e-06
gaze B-Disease 0 0.0003758346429094672
- I-Disease 0 8.039821841521189e-05
evoked I-Disease 0 6.6284351305512246e-06
nystagmus I-Disease 0 2.110288005496841e-05
was O 0 3.812166085026547e-07
often O 0 5.570647498842618e-09
present O 0 7.3098775921209835e-09
as O 0 1.3157038125655163e-08
was O 0 6.966460546209419e-07
saccade O 0 3.0183296985342167e-05
hypometria O 0 1.0838791240530554e-05
and O 0 2.4858668012939233e-08
smooth O 0 1.4132676824374357e-06
pursuit O 0 2.9150329282856546e-05
gain O 0 6.123379534983542e-06
was O 0 1.2615585092135007e-06
markedly O 0 1.1952356544497889e-06
decreased O 0 1.8492341951059643e-06
. O 0 9.735632744423128e-08

Three O 0 1.3098440376779763e-07
major O 0 4.6169457590394813e-08
criteria O 0 1.7828282850018695e-08
, O 0 7.04569380616249e-09
saccade O 0 4.133580659981817e-06
amplitude O 0 2.276821930990991e-07
, O 0 2.536239218642322e-09
saccade O 0 1.0290377758792602e-06
velocity O 0 1.2835970153446397e-07
, O 0 5.660971691412442e-10
and O 0 2.4916743668335073e-10
presence O 0 5.7706674994051355e-09
of O 0 1.3827678913003183e-07
gaze B-Disease 0 0.00010543519601924345
- I-Disease 0 1.5473171515623108e-05
evoked I-Disease 0 1.565864181429788e-06
nystagmus I-Disease 0 1.4141764950181823e-06
, O 0 7.096712106857694e-10
permitted O 0 2.6206239400750064e-09
the O 0 1.3139578314280698e-09
correct O 0 8.825707276116646e-09
assignment O 0 4.284898835749118e-08
of O 0 2.4550690369551376e-08
90 O 0 3.124565850498584e-08
% O 0 2.230113871348749e-09
of O 0 6.064448943021716e-09
the O 0 1.566811924647027e-08
SCA1 B-Disease 0 6.797698006266728e-05
, O 0 2.520835318264858e-09
90 O 0 6.530173735086464e-09
% O 0 5.662386115545814e-10
of O 0 2.168392354562343e-09
the O 0 6.6233254436554034e-09
SCA2 B-Disease 0 1.9111286746920086e-05
, O 0 1.6749263087589839e-09
and O 0 2.4281773813861207e-10
93 O 0 2.8497177950725927e-08
% O 0 5.290855531470129e-10
of O 0 8.243328242230064e-10
the O 0 4.942620979164758e-09
patients O 0 2.3812951610580058e-09
with O 0 1.7003229935141917e-09
SCA3 B-Disease 1 1.0
to O 0 1.2871637977696082e-08
their O 0 3.0631071012976463e-09
genetically O 0 9.353680052726077e-10
confirmed O 0 1.9113890470379147e-09
patient O 0 8.468921564031007e-09
group O 0 6.08602224172472e-10
and O 0 9.752997021106324e-11
, O 0 2.1700959085269034e-10
therefore O 0 4.497613392828725e-09
, O 0 1.2423063688871139e-09
may O 0 3.5370175677229554e-09
help O 0 3.435986783983935e-08
orient O 0 8.812265150481835e-05
diagnoses O 0 1.372367364638194e-06
of O 0 5.338331448001554e-07
SCA1 B-Disease 1 0.7500124573707581
, O 0 3.580808538572455e-08
SCA2 B-Disease 0 0.005755136255174875
, O 0 6.938643437592873e-09
and O 0 7.887958730634637e-09
SCA3 B-Disease 1 1.0
at O 0 8.294845770251413e-07
early O 0 6.871609059544426e-08
clinical O 0 1.7199080559748836e-07
stages O 0 9.256677202529318e-08
of O 0 5.668994518259751e-08
the O 0 1.7582580369435163e-07
diseases O 0 9.721750393509865e-05
. O 0 4.100753159264059e-08
. O 0 4.940639541928249e-07

Genetic O 0 4.668349902203772e-06
basis O 0 2.6766977612169285e-07
and O 0 6.810306985016723e-09
molecular O 0 3.3834336932159204e-07
mechanism O 0 4.001405613962561e-06
for O 0 5.9367330322857015e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 4.873707075603306e-05

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.999984622001648
causes O 0 4.940295639244141e-07
more O 0 1.0710679010372814e-09
than O 0 1.461509802069827e-09
300 O 0 4.602058290004152e-09
, O 0 9.806182532656749e-10
000 O 0 1.218641614286753e-07
sudden O 0 5.7832757249798306e-08
deaths O 0 2.805893961621564e-09
each O 0 3.2624627999133793e-10
year O 0 1.085753931207023e-09
in O 0 2.3886825850638616e-09
the O 0 5.550234405404808e-08
USA O 0 1.5290337387341424e-06
alone O 0 4.92273954932898e-07
. O 0 1.3553970745761035e-07

In O 0 3.436308588788961e-07
approximately O 0 1.076752909057177e-07
5 O 0 1.6402552205363463e-08
- O 0 7.929743972567849e-09
12 O 0 2.067413795714401e-09
% O 0 1.7465369428482092e-10
of O 0 4.438542589024763e-11
these O 0 9.94857841940533e-12
cases O 0 5.130438088252198e-11
, O 0 2.1411991971143074e-11
there O 0 2.347480820841241e-10
are O 0 1.373982455588063e-10
no O 0 7.576073102200098e-09
demonstrable O 0 2.029889219556935e-05
cardiac O 0 0.2036503702402115
or O 0 4.2723478088646516e-08
non O 0 0.017502354457974434
- O 1 0.9902783036231995
cardiac O 1 0.9999998807907104
causes O 0 2.2980248814974402e-08
to O 0 4.133305642195495e-10
account O 0 4.045307200328807e-09
for O 0 1.894633339105667e-10
the O 0 2.03378625052153e-09
episode O 0 2.636548401824257e-08
, O 0 3.31623999094699e-11
which O 0 5.888943412774017e-12
is O 0 1.5214307244604264e-11
therefore O 0 2.3101254242874347e-10
classified O 0 3.034926621126033e-08
as O 0 1.2097589774384687e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9994807839393616
IVF B-Disease 1 1.0
) O 0 1.852190621320915e-06
. O 0 8.490953291584447e-07

A O 0 7.855657713662367e-06
distinct O 0 2.1218146173396235e-07
group O 0 5.2117755444669456e-08
of O 0 3.9965284486243036e-06
IVF B-Disease 1 1.0
patients O 0 3.4016196082120587e-07
has O 0 4.88049045621608e-10
been O 0 7.255409606443664e-10
found O 0 4.0928099798165363e-10
to O 0 2.2508256369846436e-10
present O 0 3.2838343155816574e-09
with O 0 1.6217293064002547e-09
a O 0 1.7480410008374747e-07
characteristic O 0 4.2834278701775474e-07
electrocardiographic O 0 0.00023797697213012725
pattern O 0 9.673985005065333e-06
. O 0 4.2039613390443265e-07

Because O 0 5.060081207375333e-07
of O 0 1.4407596893306618e-07
the O 0 2.4634372763898682e-08
small O 0 9.41112876517991e-09
size O 0 1.1637429686572887e-08
of O 0 1.1654800680105382e-08
most O 0 1.1366716456961967e-09
pedigrees O 0 1.1771245311820167e-07
and O 0 3.3270886046210535e-10
the O 0 3.5668195064175734e-09
high O 0 8.496804326796337e-08
incidence O 0 4.632369154933258e-07
of O 0 1.561915574654904e-08
sudden B-Disease 0 1.63601271196967e-07
death I-Disease 0 7.259108425472505e-09
, O 0 5.712750758557483e-11
however O 0 6.614354897127583e-11
, O 0 6.668750274219093e-11
molecular O 0 6.546510444849218e-09
genetic O 0 3.1163862601601977e-09
studies O 0 2.134701304612463e-09
of O 0 4.73001371403825e-08
IVF B-Disease 1 1.0
have O 0 2.5626420430135965e-10
not O 0 1.1005778927097865e-10
yet O 0 3.0052937916025257e-09
been O 0 6.5286296369038155e-09
done O 0 1.0859267973728493e-07
. O 0 2.430165864097944e-07

Because O 0 1.652020182518754e-05
IVF B-Disease 1 1.0
causes O 0 7.263713632710278e-05
cardiac O 1 1.0
rhythm O 1 0.9997847676277161
disturbance O 0 0.0038242980372160673
, O 0 5.208374176390862e-09
we O 0 4.090845440174462e-09
investigated O 0 1.758449315047983e-07
whether O 0 2.548596356177768e-08
malfunction O 0 0.03112623281776905
of O 0 8.414294683234402e-08
ion O 0 1.281079448745004e-06
channels O 0 4.0011096302805527e-07
could O 0 3.007817106492894e-09
cause O 0 3.164570472335981e-08
the O 0 9.544285362039773e-09
disorder O 0 9.274014445281864e-08
by O 0 3.857238140003716e-10
studying O 0 1.9455601574236425e-08
mutations O 0 5.130655900131842e-10
in O 0 4.079280524482698e-10
the O 0 1.158374995924305e-08
cardiac O 0 7.762641871522646e-06
sodium O 0 1.2201221011309826e-07
channel O 0 1.6401086213591043e-06
gene O 0 3.485848480977438e-07
SCN5A O 0 0.00027137057622894645
. O 0 4.731412275305047e-07

We O 0 4.544482123947091e-07
have O 0 1.1298008750770805e-08
now O 0 1.0058896826592445e-08
identified O 0 3.423681604886042e-08
a O 0 3.920892766018369e-08
missense O 0 3.501705236885755e-07
mutation O 0 3.3870211080255785e-09
, O 0 6.413057307419479e-10
a O 0 1.2248071001863536e-08
splice O 0 3.6828993188464665e-07
- O 0 6.271665853319064e-08
donor O 0 4.482831439389656e-09
mutation O 0 8.8944146492409e-10
, O 0 8.30119792349926e-11
and O 0 1.5034166966909623e-10
a O 0 8.44877057204485e-09
frameshift O 0 1.6557316939724842e-07
mutation O 0 4.224325056423339e-10
in O 0 3.8937536528393935e-10
the O 0 4.0186289851362744e-09
coding O 0 1.8643925159267383e-07
region O 0 1.688050765835669e-08
of O 0 1.719232471941723e-07
SCN5A O 1 0.8166115880012512
in O 0 1.3889136596390017e-07
three O 0 4.972276883563609e-07
IVF B-Disease 1 0.9999994039535522
families O 0 7.202043406095981e-08
. O 0 2.706297834720317e-07

We O 0 3.076417556258093e-07
show O 0 4.520906315974571e-08
that O 0 8.696466324842334e-10
sodium O 0 2.5592044039512984e-09
channels O 0 3.2461027199559567e-09
with O 0 9.72702543511339e-11
the O 0 3.519017077735498e-09
missense O 0 2.057981305370049e-07
mutation O 0 9.7790797681796e-10
recover O 0 8.90720208701623e-09
from O 0 1.63598945501775e-09
inactivation O 0 8.538963669479926e-08
more O 0 3.199054562919024e-11
rapidly O 0 2.280749367145063e-09
than O 0 1.2505027568998628e-10
normal O 0 2.2543842348454746e-09
and O 0 4.988074883693905e-11
that O 0 4.092386499121581e-11
the O 0 2.8724775891220133e-09
frameshift O 0 3.0763413860768196e-07
mutation O 0 9.59654133936283e-10
causes O 0 3.9735134627072455e-10
the O 0 1.1464479365841385e-09
sodium O 0 1.1793618304167808e-09
channel O 0 4.704727718518598e-09
to O 0 1.1353471635056067e-10
be O 0 6.294850196653101e-10
non O 0 1.5839307820897375e-07
- O 0 1.1381928288756171e-06
functional O 0 4.048310984217096e-06
. O 0 2.995995487253822e-07

Our O 0 1.869767743301054e-06
results O 0 1.1254277865191398e-07
indicate O 0 9.207145268419481e-08
that O 0 7.985747063621318e-10
mutations O 0 2.6968582922393125e-09
in O 0 3.9582133126714325e-09
cardiac O 0 1.5240170796460006e-06
ion O 0 5.300922225615068e-07
- O 0 6.018066414981149e-06
channel O 0 2.002130656819645e-07
genes O 0 1.9291046537972534e-09
contribute O 0 4.1649053650338885e-10
to O 0 4.320434981996968e-11
the O 0 6.654624074009519e-10
risk O 0 6.110357997357596e-09
of O 0 1.7619971259819067e-08
developing O 0 1.9856759081449127e-06
IVF B-Disease 1 1.0
. O 0 1.4806716741588843e-08
. O 0 3.1059972371849653e-08

Molecular O 0 0.00033785169944167137
heterogeneity O 0 1.792615876183845e-05
in O 0 3.817543188233685e-07
mucopolysaccharidosis B-Disease 0 0.0002500188711564988
IVA I-Disease 0 0.01853904128074646
in O 0 3.6155768157186685e-08
Australia O 0 5.717574858010721e-09
and O 0 5.818720505423869e-10
Northern O 0 1.0906569869462146e-08
Ireland O 0 2.433807377855146e-09
: O 0 1.4309083085084495e-10
nine O 0 9.792070487790738e-10
novel O 0 2.8193807288801054e-09
mutations O 0 7.200801066531426e-10
including O 0 2.692776002177766e-10
T312S O 0 3.5085752188024344e-06
, O 0 3.489181832350141e-09
a O 0 1.1902411500841481e-08
common O 0 2.850667701892462e-09
allele O 0 5.961768856366234e-09
that O 0 3.310781371279603e-10
confers O 0 6.677350938844029e-08
a O 0 3.80922919873683e-08
mild O 0 2.701339383293089e-07
phenotype O 0 9.786997452465585e-07
. O 0 1.732300205503634e-07

Mucopolysaccharidosis B-Disease 1 0.8912923336029053
IVA I-Disease 1 0.9999864101409912
( O 0 3.100232788710855e-05
MPS B-Disease 1 0.9999980926513672
IVA I-Disease 1 1.0
) O 0 1.552945292360164e-07
is O 0 3.974516271654238e-09
an O 0 6.0643003507721e-08
autosomal B-Disease 1 0.999996542930603
recessive I-Disease 1 0.9999998807907104
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.8162651658058167
by O 0 1.5659702512493823e-07
a O 0 1.8427332179271616e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999979734420776
in O 0 3.147121105939732e-07
N O 0 4.822610571864061e-05
- O 0 6.194395609782077e-06
acetylgalactosamine O 0 8.007898577488959e-05
- O 0 4.9619106903264765e-06
6 O 0 4.662228093366139e-06
- O 0 5.861796580575174e-06
sulfate O 0 1.0546526937105227e-05
sulfatase O 0 0.003956791944801807
( O 0 1.7675885146672954e-06
GALNS O 0 0.0038892950396984816
) O 0 5.070461952527694e-07
. O 0 3.1789477361598983e-07

Previous O 0 1.5170796814345522e-06
studies O 0 7.540194957300628e-08
of O 0 8.17035683553513e-09
patients O 0 1.00739261377214e-09
from O 0 1.3515313312950639e-09
a O 0 1.1919722986419856e-08
British O 0 4.18447399397337e-07
- O 0 2.1478948042386037e-07
Irish O 0 1.5235129069424147e-07
population O 0 5.329159891154234e-10
showed O 0 6.995701795631248e-10
that O 0 4.216675272838977e-11
the O 0 1.3464419579278797e-09
I113F O 0 2.2265115262598556e-07
mutation O 0 4.2686448820106193e-10
is O 0 4.818534460326873e-11
the O 0 8.50043854749849e-11
most O 0 1.1345239851745514e-11
common O 0 2.609219784677208e-11
single O 0 1.6723653017969298e-10
mutation O 0 3.193288966585328e-10
among O 0 5.063517383163685e-10
MPS B-Disease 1 0.9999904632568359
IVA I-Disease 1 1.0
patients O 0 1.35430548198201e-06
and O 0 6.819727005336063e-10
produces O 0 2.0877819473241743e-09
a O 0 9.619692598050733e-09
severe O 0 1.0538602168708167e-07
clinical O 0 1.6328406218235614e-06
phenotype O 0 1.2033204939143616e-06
. O 0 1.0946003214939992e-07

We O 0 1.526666153495171e-07
studied O 0 5.56937493456644e-07
mutations O 0 3.4510733826209616e-08
in O 0 1.1143765910048842e-08
the O 0 8.839053577958111e-08
GALNS O 0 0.0009231868316419423
gene O 0 1.7151768005874146e-08
from O 0 1.8188852646261466e-09
23 O 0 2.6712170253517797e-08
additional O 0 2.400330068041967e-08
MPS B-Disease 1 0.9983589053153992
IVA I-Disease 1 1.0
patients O 0 2.5350951204927696e-07
( O 0 1.5232005656784509e-09
15 O 0 9.479764750963682e-10
from O 0 3.335113019087288e-10
Australia O 0 5.199874975048147e-10
, O 0 7.413521185828387e-11
8 O 0 5.896097499125119e-10
from O 0 4.0763795117193524e-10
Northern O 0 2.43037479030761e-09
Ireland O 0 2.3225945611216048e-09
) O 0 2.5379798263003295e-10
, O 0 1.5329862379509507e-11
with O 0 1.0307345255089473e-11
various O 0 1.328027132707632e-09
clinical O 0 6.110598405939527e-06
phenotypes O 0 2.710474291234277e-06
( O 0 3.898558276205222e-08
severe O 0 1.2225505940932635e-07
, O 0 3.945502813351709e-10
16 O 0 2.023570866427349e-09
cases O 0 2.490153916401283e-10
; O 0 1.6237124145224158e-10
intermediate O 0 4.2645964981602447e-08
, O 0 6.282400155654955e-10
4 O 0 4.2888541607055686e-09
cases O 0 2.2189579340636811e-10
; O 0 1.0506635839124812e-10
mild O 0 5.121135959740286e-09
, O 0 1.063815702195825e-09
3 O 0 1.0524135340972407e-08
cases O 0 3.804747183977497e-09
) O 0 9.860728233945792e-09
. O 0 2.894588568835843e-08

We O 0 1.7813590602600016e-07
found O 0 7.786045586044565e-09
two O 0 8.459957734352486e-10
common O 0 8.260184758412947e-10
mutations O 0 4.4837525359220365e-10
that O 0 6.929510437680975e-11
together O 0 5.976384387373912e-10
accounted O 0 1.880220956707035e-08
for O 0 3.5013805743666637e-10
32 O 0 9.108974019511606e-09
% O 0 5.139196845860283e-10
of O 0 1.4571286399700512e-09
the O 0 2.3665160941988006e-09
44 O 0 5.093121036026105e-09
unrelated O 0 1.0832225783019567e-08
alleles O 0 1.0975361591780697e-10
in O 0 9.248934951244792e-11
these O 0 4.2559791801899394e-10
patients O 0 8.788616057131549e-09
. O 0 8.089278935585753e-08

One O 0 7.086843538672838e-07
is O 0 2.1722845744420738e-08
the O 0 4.757646365760593e-08
T312S O 0 9.818158105190378e-06
mutation O 0 2.6219501236823817e-08
, O 0 6.898194793159007e-10
a O 0 1.7958989850797025e-09
novel O 0 1.0240303716102517e-08
mutation O 0 6.169965649505116e-10
found O 0 2.89904461547863e-10
exclusively O 0 2.230658324720025e-09
in O 0 2.0464869798786367e-09
milder O 0 3.4569829665542784e-08
patients O 0 7.701916615587834e-08
. O 0 1.6280826287129457e-07

The O 0 3.361239180321718e-07
other O 0 3.0097795367112212e-09
is O 0 1.5461431024377248e-09
the O 0 3.605217679947259e-09
previously O 0 4.520138574548582e-08
described O 0 1.511636611439826e-07
I113F O 0 3.2902107705012895e-06
that O 0 1.6249184220384905e-09
produces O 0 6.797952423198694e-09
a O 0 2.4319202651668093e-08
severe O 0 1.928959107999617e-07
phenotype O 0 8.984060855254938e-07
. O 0 3.7835170019207e-07

The O 0 8.96647270565154e-06
I113F O 0 5.998057531542145e-05
and O 0 1.634921034110448e-07
T312S O 0 1.5907011402305216e-05
mutations O 0 4.863842306690458e-08
accounted O 0 4.126000163751087e-08
for O 0 3.0540763251707403e-09
8 O 0 7.584288397310956e-08
( O 0 5.474636743940664e-09
18 O 0 1.2130106696872645e-08
% O 0 9.48084943885874e-10
) O 0 1.4445812601682206e-10
and O 0 1.429476120806683e-10
6 O 0 9.839443038117679e-09
( O 0 3.3993308168334124e-09
14 O 0 4.109207196734133e-09
% O 0 1.4364656131249376e-09
) O 0 3.280095639546232e-10
of O 0 1.4679130133643525e-09
44 O 0 5.9862323986692445e-09
unrelated O 0 3.4449900709887515e-08
alleles O 0 1.9092865066738796e-09
, O 0 3.444626806015094e-09
respectively O 0 3.4560176231934747e-07
. O 0 2.9368098353188543e-07

The O 0 4.3372855884626915e-07
relatively O 0 1.84237293865408e-07
high O 0 2.091115334224014e-07
residual O 0 2.8816608391935006e-05
GALNS O 1 0.996344268321991
activity O 0 1.527704625914339e-06
seen O 0 2.0637429543057806e-08
when O 0 7.077678998435033e-10
the O 0 2.9471660667468313e-09
T312S O 0 3.7834016097804124e-07
mutant O 0 4.473147896533192e-08
cDNA O 0 2.4750545435381355e-07
is O 0 3.896398759195563e-10
overexpressed O 0 7.316785399780201e-08
in O 0 6.229730065143713e-10
mutant O 0 5.607179165423304e-09
cells O 0 1.3290305522772883e-09
provides O 0 1.5855335100400936e-10
an O 0 5.820971482606296e-11
explanation O 0 9.195395556105268e-10
for O 0 3.840674306365699e-11
the O 0 1.084536904727429e-09
mild O 0 9.338283923909785e-09
phenotype O 0 1.209718281103278e-08
in O 0 5.920370860224011e-10
patients O 0 1.6693632587383433e-10
with O 0 7.324468115355032e-11
this O 0 1.5733876423951187e-09
mutation O 0 1.2389138603907668e-08
. O 0 3.9213567504248203e-08

The O 0 7.589280670572407e-08
distribution O 0 5.850528950190892e-09
and O 0 2.6213126114171814e-10
relative O 0 1.729816467843648e-08
frequencies O 0 4.592185298690765e-09
of O 0 4.492263450117662e-09
the O 0 1.4012463189772006e-08
I113F O 0 1.8884533119489788e-06
and O 0 3.335439258123074e-09
T312S O 0 1.0412680921945139e-06
mutations O 0 4.1399985661882965e-09
in O 0 5.372842171169623e-10
Australia O 0 1.2355079181958217e-09
corresponded O 0 3.548477955916951e-09
to O 0 1.9634709136351347e-10
those O 0 1.3883501293054934e-10
observed O 0 1.4806341708251125e-09
in O 0 4.919256668678429e-10
Northern O 0 6.23743767746987e-09
Ireland O 0 1.6679064795965814e-09
and O 0 8.747200186398629e-11
are O 0 2.906201668206876e-11
unique O 0 2.786841035717913e-10
to O 0 3.246718519034353e-11
these O 0 1.1022600367172064e-11
two O 0 3.8474341768068854e-11
populations O 0 5.0608406354513136e-11
, O 0 2.8108137345439488e-11
suggesting O 0 8.146094909733392e-10
that O 0 1.9527249608963793e-11
both O 0 3.834416117953765e-11
mutations O 0 4.6733134723142555e-11
were O 0 1.5114672013982755e-10
probably O 0 9.807603618128269e-10
introduced O 0 1.5485683568794428e-10
to O 0 1.3728089498510343e-10
Australia O 0 3.8111294675680085e-10
by O 0 2.738333726437503e-10
Irish O 0 6.408893682419148e-08
migrants O 0 8.998851441788247e-09
during O 0 1.0412959383643283e-08
the O 0 9.7544949895223e-09
19th O 0 5.433231535789673e-07
century O 0 2.5360552626807475e-06
. O 0 3.9103889548641746e-07

Haplotype O 0 3.277791984146461e-05
analysis O 0 2.938087391157751e-07
using O 0 2.8085084480267142e-08
6 O 0 1.6895269538963475e-07
RFLPs O 0 1.1794155398092698e-05
provides O 0 3.39255579184794e-09
additional O 0 5.680700354560031e-10
data O 0 8.546209961934892e-09
that O 0 2.0080828666557693e-10
the O 0 9.555067848054932e-09
I113F O 0 2.5940253181033768e-06
mutation O 0 1.3238548923766302e-08
originated O 0 4.9944993918416e-08
from O 0 4.200672698573271e-09
a O 0 2.043710622956496e-08
common O 0 2.3975207597004555e-08
ancestor O 0 4.088393779966282e-06
. O 0 3.3402224630663113e-07

The O 0 4.87407703531062e-07
other O 0 5.777164968634452e-09
9 O 0 5.878384357060895e-08
novel O 0 3.3573588353874584e-08
mutations O 0 2.7165485416702495e-09
identified O 0 3.7875436120771155e-09
in O 0 4.486661042690798e-10
these O 0 2.0085960672489023e-10
23 O 0 1.757251411049765e-08
patients O 0 7.376964039629286e-10
were O 0 1.00471952979575e-09
each O 0 5.034271333137497e-10
limited O 0 3.1920848186928197e-09
to O 0 2.136656629403433e-09
a O 0 3.557730465786335e-08
single O 0 7.390068645918291e-08
family O 0 2.32654684850786e-07
. O 0 7.971267024231565e-08

These O 0 1.3884786653761694e-08
data O 0 2.1744236633480796e-08
provide O 0 7.437474525140431e-10
further O 0 5.140431968975179e-10
evidence O 0 9.63504298567841e-09
for O 0 5.236561739785373e-10
extensive O 0 3.785306645909259e-08
allelic O 0 1.690909954277231e-07
heterogeneity O 0 1.9234188641803485e-07
in O 0 2.1559470653187418e-08
MPS B-Disease 0 0.0022713523358106613
IVA I-Disease 1 0.9999996423721313
in O 0 1.5565001731943084e-08
British O 0 1.9756090807732107e-07
- O 0 5.865794960868698e-08
Irish O 0 7.493927256518873e-08
patients O 0 4.2401385180745876e-10
and O 0 2.532176378300388e-11
provide O 0 2.3402518811721507e-10
evidence O 0 3.981625695814728e-09
for O 0 2.492663020436936e-10
their O 0 4.455942281822445e-10
transmission O 0 2.7046367367944413e-09
to O 0 9.327735112085733e-11
Australia O 0 4.0550773849901134e-10
by O 0 2.596917958452849e-10
British O 0 6.313782563438508e-08
- O 0 4.569610467797247e-08
Irish O 0 4.259240071746717e-08
migrants O 0 1.438747787574357e-08
. O 0 1.4178873630754651e-09
. O 0 2.8337121094068607e-08

Identification O 0 1.4637083722846e-06
of O 0 4.1401594330636726e-07
constitutional O 0 1.9342473933647852e-06
WT1 O 1 0.9997217059135437
mutations O 0 3.993058328433108e-08
, O 0 2.6636540195745795e-10
in O 0 4.563648070554649e-10
patients O 0 1.8634568887954117e-10
with O 0 1.968334106816627e-10
isolated O 0 3.924856355297379e-05
diffuse B-Disease 1 0.999886155128479
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.743479498081626e-10
and O 0 7.206843455342948e-11
analysis O 0 1.684888006892038e-09
of O 0 6.724163448268428e-09
genotype O 0 3.7144937437005865e-07
/ O 0 4.845887815463357e-07
phenotype O 0 1.2546754746267652e-08
correlations O 0 5.056551621862582e-09
by O 0 2.0274409928688897e-10
use O 0 3.9656694594825126e-10
of O 0 5.135456060401111e-09
a O 0 2.5445601181672828e-08
computerized O 0 4.38032969896085e-07
mutation O 0 3.412038296346509e-08
database O 0 5.559547275879595e-07
. O 0 1.1235757568783811e-07

Constitutional O 0 2.080982540064724e-06
mutations O 0 1.5596687319430202e-07
of O 0 5.560194793474693e-08
the O 0 1.202316468607023e-07
WT1 O 0 0.0001459325576433912
gene O 0 1.3625427008889801e-08
, O 0 3.3954022926607763e-10
encoding O 0 1.3624023686986675e-08
a O 0 3.6845253958972535e-08
zinc O 0 1.483760388509836e-05
- O 0 1.1576742508623283e-05
finger O 0 0.00026910172891803086
transcription O 0 0.0004251404607202858
factor O 0 1.2404535709720221e-07
involved O 0 2.571811030804838e-08
in O 0 2.8486907055480515e-08
renal O 1 0.9999998807907104
and O 0 1.0601624467199144e-07
gonadal O 1 1.0
development O 0 0.2521027624607086
, O 0 5.059124785766755e-10
are O 0 2.8822437492248554e-11
found O 0 1.3052843528260638e-10
in O 0 2.030045159751026e-10
most O 0 1.125139703628264e-10
patients O 0 1.6957941995077164e-10
with O 0 3.650234337015945e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.26258355379104614
DDS B-Disease 1 1.0
) O 0 8.01702526587178e-08
, O 0 3.826127858985728e-09
or O 0 2.1662899030161498e-07
diffuse B-Disease 1 0.9988094568252563
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 1 0.8966063857078552
DMS B-Disease 1 0.9999998807907104
) O 0 2.114279595843982e-08
associated O 0 3.219368949203272e-08
with O 0 1.3803826526270768e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.1168031960551161e-05
/ O 1 0.9999897480010986
or O 1 0.7777080535888672
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 0.001538740354590118
WT B-Disease 1 1.0
) O 0 2.448857003400917e-06
. O 0 5.95246547163697e-07

Most O 0 2.552333171479404e-07
mutations O 0 2.954981255243183e-07
in O 0 2.3475372756820434e-07
DDS B-Disease 1 1.0
patients O 0 3.164180043313536e-06
lie O 0 0.0002900645777117461
in O 0 4.1695523123053135e-07
exon O 0 4.405589152156608e-06
8 O 0 2.9315714300537365e-07
or O 0 2.3182231245755247e-08
exon O 0 2.4336654291801096e-07
9 O 0 8.022578157351745e-08
, O 0 4.643756490452233e-09
encoding O 0 1.6113524736738327e-07
zinc O 0 0.00024286923871841282
finger O 0 0.0006820379639975727
2 O 0 9.39253095566528e-06
or O 0 2.6082443582708947e-06
zinc O 1 0.8849870562553406
finger O 0 0.0003017511626239866
3 O 0 2.573065387423412e-07
, O 0 1.145138872615803e-09
respectively O 0 1.988073172753957e-08
, O 0 3.2444730235781094e-10
with O 0 1.9976764686902015e-10
a O 0 2.328339654411593e-08
hot O 0 1.5944610254337022e-07
spot O 0 4.2622630758160085e-07
( O 0 3.645741486479892e-08
R394W O 0 1.912781272039865e-06
) O 0 1.3162812173561633e-08
in O 0 2.1552645890210442e-08
exon O 0 1.1430104223109083e-06
9 O 0 1.5319237718358636e-06
. O 0 2.191850398958195e-07

We O 0 4.803062552127813e-07
analyzed O 0 5.571394012804376e-07
a O 0 3.0870385359094143e-08
series O 0 1.010067407491988e-08
of O 0 1.9124765771039165e-08
24 O 0 3.6929755253822805e-08
patients O 0 1.4211554155707518e-09
, O 0 2.2752126571656817e-10
10 O 0 9.612937112990494e-10
with O 0 1.4041483531457288e-09
isolated B-Disease 0 4.171285036136396e-05
DMS I-Disease 1 0.999998927116394
( O 0 3.6558146803145064e-06
IDMS B-Disease 1 0.9979795813560486
) O 0 3.829544681366315e-09
, O 0 3.739291098980857e-10
10 O 0 1.6174168671057032e-09
with O 0 2.6827089438796747e-09
DDS B-Disease 1 1.0
, O 0 5.673394198879578e-09
and O 0 1.3244148000524092e-09
4 O 0 3.096072376251868e-08
with O 0 3.246622748420691e-09
urogenital B-Disease 1 0.8596965074539185
abnormalities I-Disease 1 0.9999116659164429
and O 0 7.791374628141057e-06
/ O 1 0.9999997615814209
or O 1 0.9989509582519531
WT B-Disease 1 1.0
. O 0 2.1591178665403277e-05

We O 0 1.4847095144432387e-06
report O 0 1.3702306205232162e-06
WT1 O 0 0.0003539981844369322
heterozygous O 0 1.7852296707587811e-07
mutations O 0 4.087756799719955e-09
in O 0 1.646495051410568e-09
16 O 0 1.7952627828776713e-08
patients O 0 3.2866600552239333e-09
, O 0 1.1083010065249255e-09
4 O 0 5.8751108866772483e-08
of O 0 1.3178919289202895e-07
whom O 0 9.427481728607745e-08
presented O 0 9.706103583084769e-07
with O 0 1.7233377320735599e-06
IDMS B-Disease 1 0.9999996423721313
. O 0 5.565819265029859e-06

One O 0 2.4453051992168184e-06
male O 0 2.519265365208412e-07
and O 0 2.477061888939147e-09
two O 0 1.066931343274291e-08
female O 0 4.315756996220443e-06
IDMS B-Disease 1 1.0
patients O 0 2.4224971184594324e-07
with O 0 1.4729261010870687e-07
WT1 O 1 1.0
mutations O 0 7.880209523136728e-06
underwent O 0 7.173229823820293e-05
normal O 0 5.004330523661338e-05
puberty O 0 0.0001862920034909621
. O 0 5.318315743352287e-07

Two O 0 5.139966674505558e-07
mutations O 0 3.3566487900316133e-07
associated O 0 2.926345530340768e-07
with O 0 5.778512601750663e-08
IDMS B-Disease 1 1.0
are O 0 7.44532380192453e-10
different O 0 2.0996133998085753e-10
from O 0 1.0498067970488023e-09
those O 0 7.600021723064287e-10
described O 0 5.967903149439735e-08
in O 0 4.0384097133028263e-07
DDS B-Disease 1 1.0
patients O 0 2.004195039262413e-06
. O 0 5.203933710618003e-07

No O 0 2.5293375074397773e-05
WT1 O 0 0.0007190775359049439
mutations O 0 4.410438592117316e-08
were O 0 2.1536497030183455e-08
detected O 0 5.129350100219199e-08
in O 0 1.645402591954337e-09
the O 0 5.7352469440274945e-09
six O 0 2.1095544866511773e-08
other O 0 2.028081169669349e-08
IDMS B-Disease 1 1.0
patients O 0 1.0086951363064145e-07
, O 0 1.4862988617636574e-09
suggesting O 0 3.733921118964645e-07
genetic O 0 8.407715768044e-07
heterogeneity O 0 9.895405810311786e-07
of O 0 1.7127830176377756e-07
this O 0 6.963160359418907e-08
disease O 0 2.134000533260405e-05
. O 0 2.7704575700226997e-07

We O 0 3.9492795167461736e-07
analyzed O 0 2.298127128597116e-06
genotype O 0 7.23528455637279e-06
/ O 0 3.865930011670571e-06
phenotype O 0 1.0383016046944249e-07
correlations O 0 1.5804437225597212e-07
, O 0 8.596887091094629e-10
on O 0 1.270901162087057e-09
the O 0 8.091076697525068e-10
basis O 0 6.930350515688133e-09
of O 0 2.2439938796026127e-09
the O 0 1.4021945826669935e-09
constitution O 0 9.28134957778326e-10
of O 0 1.0400017735889833e-08
a O 0 4.327988278873818e-08
WT1 O 0 9.95167010842124e-06
mutation O 0 3.436037454562779e-09
database O 0 1.1250936182705118e-08
of O 0 1.0632644986685591e-08
84 O 0 9.217916385750868e-08
germ O 1 0.9951663017272949
- O 0 8.682160841999575e-05
line O 0 3.8241535094130086e-07
mutations O 0 1.2071960098225532e-09
, O 0 1.1182720027758108e-10
to O 0 1.2731909970753463e-10
compare O 0 3.616650756654849e-09
the O 0 1.946643068961862e-09
distribution O 0 2.69729549806641e-09
and O 0 3.828031225339146e-10
type O 0 3.177428808953664e-08
of O 0 4.370477668658168e-08
mutations O 0 6.853359657554847e-09
, O 0 6.01039273906423e-10
according O 0 1.798250326423556e-09
to O 0 2.7267998969904284e-10
the O 0 2.74693534585424e-09
different O 0 1.6045546002985134e-09
symptoms O 0 1.8702033344197844e-07
. O 0 2.9506421128644433e-07

This O 0 3.9285436059799395e-07
demonstrated O 0 3.2895536605792586e-07
( O 0 3.103367873791285e-08
1 O 0 2.1852462950278095e-08
) O 0 1.6507211153538037e-09
the O 0 2.036557589235599e-09
association O 0 3.199912113061032e-09
between O 0 8.044209742763542e-09
mutations O 0 4.482831439389656e-09
in O 0 5.462704066871993e-09
exons O 0 2.3577049645950865e-08
8 O 0 8.750680180469317e-09
and O 0 4.961585031715288e-10
9 O 0 2.5693006833193976e-08
and O 0 4.658180507988163e-09
DMS B-Disease 0 5.8970239479094744e-05
; O 0 7.438439864060342e-10
( O 0 2.5371680312247236e-09
2 O 0 3.2955425055547494e-09
) O 0 2.1120526161322317e-10
among O 0 4.544484233370838e-11
patients O 0 1.7570619958995337e-10
with O 0 4.804623920939832e-10
DMS B-Disease 1 0.9992902278900146
, O 0 2.9106701493475384e-09
a O 0 5.809951630908472e-09
higher O 0 6.046823486371977e-09
frequency O 0 4.075471959907873e-09
of O 0 4.2524592736015165e-09
exon O 0 9.287750657449578e-08
8 O 0 7.034024918084469e-09
mutations O 0 4.974471945473624e-10
among O 0 1.212232259018009e-10
46 O 0 3.518708657779257e-09
, O 0 1.6702368377252697e-09
XY O 1 0.593829333782196
patients O 0 6.303888522296575e-09
with O 0 8.065468848350577e-10
female O 0 1.4372369605553104e-07
phenotype O 0 8.502896164941376e-09
than O 0 5.2903684905070136e-11
among O 0 5.421407073269435e-11
46 O 0 3.116998659180581e-09
, O 0 1.6399821500812095e-09
XY O 1 0.9487436413764954
patients O 0 6.50166409599251e-09
with O 0 1.9934821848810458e-10
sexual O 0 1.2778224345311173e-07
ambiguity O 0 1.4651188848802121e-06
or O 0 3.005662563282385e-07
male O 0 7.997949325044829e-08
phenotype O 0 2.8426536680115078e-09
; O 0 3.6924203278276835e-11
and O 0 5.99404137435755e-11
( O 0 6.074957759061306e-10
3 O 0 1.316057041123031e-09
) O 0 1.3954865041299058e-10
statistically O 0 3.1462651928215735e-10
significant O 0 1.6340301334238916e-10
evidence O 0 2.903966178635642e-09
that O 0 1.6565269989055054e-10
mutations O 0 4.545075982242963e-10
in O 0 1.090406875903227e-09
exons O 0 9.061787764608198e-09
8 O 0 6.332086854854424e-09
and O 0 2.500711027142444e-10
9 O 0 1.7996166334910413e-08
preferentially O 0 6.628228632621358e-09
affect O 0 1.5558789812075702e-09
amino O 0 1.5421612875599067e-09
acids O 0 1.0139927092422951e-10
with O 0 2.268356683043926e-11
different O 0 1.3287307365494883e-10
functions O 0 1.7063536361661136e-08
. O 0 5.692243121302454e-09
. O 0 8.167073417553183e-08

The O 0 1.0487991858099122e-05
185delAG O 0 8.976653043646365e-05
BRCA1 O 0 1.6992348719213624e-06
mutation O 0 1.0915810477740706e-08
originated O 0 1.7911379046609e-08
before O 0 3.923846136899556e-09
the O 0 2.4232464923557018e-09
dispersion O 0 5.9079571457232305e-08
of O 0 8.898933145928822e-09
Jews O 0 3.310898222252945e-08
in O 0 1.4032809358965892e-09
the O 0 2.530402332112658e-09
diaspora O 0 7.513360600341912e-09
and O 0 2.5768312483798184e-10
is O 0 2.595491876977718e-10
not O 0 2.9673577484068403e-10
limited O 0 8.40760172593491e-09
to O 0 3.481645194369776e-08
Ashkenazim O 0 6.369002949213609e-05
. O 0 6.992225962676457e-07

The O 0 9.71098302215978e-07
185delAG O 0 3.7417457861010917e-06
mutation O 0 2.9094673337226595e-08
in O 0 3.0818601004511947e-09
BRCA1 O 0 7.861553186216952e-09
is O 0 2.1332835498100167e-10
detected O 0 2.129065368450256e-09
in O 0 6.048665457392133e-10
Ashkenazi O 0 1.5271277220563206e-07
Jews O 0 1.4299412320895044e-08
both O 0 1.4077256027533736e-09
in O 0 1.836959917511649e-08
familial B-Disease 1 0.9896223545074463
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999986886978149
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.399846264073858e-06
in O 0 1.1010953926415823e-08
the O 0 1.5154610011336445e-08
general O 0 2.0573446946059448e-08
population O 0 7.47421058377995e-09
. O 0 2.898732454070796e-08

All O 0 1.0387334015149463e-07
tested O 0 2.1174624009745457e-07
Ashkenazi O 0 1.4014166254128213e-06
mutation O 0 1.3164770606977072e-08
carriers O 0 6.5703531504368584e-09
share O 0 7.355612119397392e-09
the O 0 8.898966896708771e-09
same O 0 2.163039880542783e-08
allelic O 0 5.356415044843743e-07
pattern O 0 1.2409558394210762e-06
at O 0 1.2807862503905199e-06
the O 0 1.693446620265604e-06
BRCA1 O 0 9.654989298724104e-06
locus O 0 9.193935511575546e-06
. O 0 2.5560794369994255e-07

Our O 0 1.631114514566434e-06
previous O 0 1.9468544110168295e-07
study O 0 2.632920192979782e-08
showed O 0 3.289193806210733e-09
that O 0 8.650900829021424e-11
this O 0 3.0799190975372426e-10
Ashkenazi O 0 1.1902881169589818e-07
mutation O 0 1.4849387275361892e-09
also O 0 1.5887605120390447e-10
occurs O 0 8.1709145005604e-10
in O 0 7.156821246745437e-10
Iraqi O 0 2.171391770389164e-06
Jews O 0 1.319924649578752e-07
with O 0 1.0858616228404117e-09
a O 0 1.4484396793079668e-08
similar O 0 6.305163058328844e-09
allelic O 0 6.28115913059446e-07
pattern O 0 2.6754141799756326e-06
. O 0 5.691703108823276e-07

We O 0 4.050621669193788e-07
extended O 0 1.0770096281476071e-07
our O 0 1.7042783184706423e-08
analysis O 0 6.5328147336174425e-09
to O 0 6.305424515851143e-10
other O 0 6.231726246141989e-10
non O 0 1.0919271176135226e-07
- O 0 1.1401620980677762e-07
Ashkenazi O 0 5.562341698350792e-07
subsets O 0 9.935227751611819e-08
354 O 0 6.109905825724127e-08
of O 0 9.114136112486904e-09
Moroccan O 0 4.3466522470225755e-07
origin O 0 1.6039923167454617e-08
, O 0 2.453204750452187e-09
200 O 0 4.887332849534687e-08
Yemenites O 0 2.0774409676960204e-06
and O 0 5.5221223149715115e-09
150 O 0 1.041558590486602e-07
Iranian O 0 2.028825747402152e-06
Jews O 0 7.284555749720312e-07
. O 0 3.409781754726282e-07

Heteroduplex O 0 0.00018333125626668334
analysis O 0 1.5237118589084275e-07
complemented O 0 7.359319198485537e-08
by O 0 1.3481070704202125e-09
direct O 0 4.391231378519933e-09
DNA O 0 2.4625681049883497e-08
sequencing O 0 1.6755661746969963e-08
of O 0 5.800727898019886e-09
abnormally O 0 8.142917806708283e-08
migrating O 0 4.157724386999462e-09
bands O 0 1.8386495881372866e-08
were O 0 3.170110574046703e-08
employed O 0 1.8918259456768283e-06
. O 0 2.74239340569693e-07

Four O 0 5.706165211449843e-07
of O 0 1.3344853755370423e-07
Moroccan O 0 6.064316949050408e-06
origin O 0 8.656228089876095e-08
( O 0 4.6483021876042585e-09
1 O 0 2.6221138593740534e-09
. O 0 4.583920049094914e-11
1 O 0 8.18220602383235e-10
% O 0 1.4393364278220133e-10
) O 0 5.938372710234674e-11
and O 0 2.5230742842219378e-11
none O 0 2.1351818091375208e-09
of O 0 4.147080012728566e-09
the O 0 2.571026413988875e-08
Yemenites O 0 9.29957786865998e-06
or O 0 2.281246480606569e-08
Iranians O 0 3.5404415399398204e-08
was O 0 2.4769452267037195e-08
a O 0 6.6433027967605085e-09
carrier O 0 8.601516832129619e-09
of O 0 9.237467679668043e-09
the O 0 5.3513495856805093e-08
185delAG O 0 6.045832833478926e-06
mutation O 0 2.131925782578037e-07
. O 0 1.3105250218359288e-07

BRCA1 O 0 6.0603128076763824e-05
allelic O 0 4.467351573111955e-06
patterns O 0 1.9032287923437252e-07
were O 0 1.2388216674708019e-08
determined O 0 7.066028206992314e-09
for O 0 8.110607185862762e-10
four O 0 8.373589044374796e-10
of O 0 1.4711952767143543e-09
these O 0 8.337647239287094e-11
individuals O 0 6.46712544627448e-11
and O 0 5.191092347645032e-11
for O 0 3.6207833953305624e-10
12 O 0 5.65603075486365e-09
additional O 0 4.616001358925814e-09
non O 0 1.9558483188575337e-07
- O 0 3.88264140838146e-07
Ashkenazi O 0 2.1976042319238331e-07
185delAG O 0 9.634698017180199e-08
mutation O 0 6.435861288345279e-10
carriers O 0 6.364461180297099e-10
who O 0 8.792803707358132e-10
had O 0 2.5670285594969755e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003786685992963612

Six O 0 2.1043238120910246e-06
non O 0 2.041105108219199e-05
- O 0 7.690870006626938e-06
Ashkenazi O 0 3.105312543993932e-06
individuals O 0 3.984025997993967e-09
shared O 0 3.1093165375750687e-08
the O 0 1.6713146422375758e-08
common O 0 2.42502320446647e-08
Ashkenazi O 0 2.4348360057047103e-06
haplotype O 0 4.343047237398423e-07
, O 0 1.9541204210327123e-09
four O 0 4.2798324884074646e-09
had O 0 1.4778135160042893e-08
a O 0 1.4099513556686816e-08
closely O 0 1.3853360236737444e-08
related O 0 7.467773599501015e-08
pattern O 0 6.90189892793569e-07
, O 0 9.874669970599825e-10
and O 0 4.0665093514746786e-10
the O 0 1.0765244695676301e-08
rest O 0 3.300860029753494e-08
( O 0 5.94643756457458e-09
n O 0 6.532169294359846e-08
= O 0 1.2307228303143347e-07
6 O 0 1.3798798548236846e-08
) O 0 4.5338544030215644e-10
displayed O 0 5.961598326109652e-09
a O 0 8.289815056627958e-09
distinct O 0 2.602087079139892e-08
BRCA1 O 0 2.649030079737713e-07
allelic O 0 1.4620928823205759e-06
pattern O 0 6.2260810409497935e-06
. O 0 7.866774467402138e-07

We O 0 3.5720711366593605e-07
conclude O 0 1.066686081685475e-06
that O 0 4.356060845367438e-09
the O 0 3.8418814796159495e-08
185delAG O 0 3.904805453203153e-06
BRCA1 O 0 1.4535159209572157e-07
mutation O 0 6.198829227699321e-10
occurs O 0 1.668096494267246e-10
in O 0 1.0164479674612537e-10
some O 0 1.279740063919732e-10
non O 0 1.660774842093815e-07
- O 0 8.762740435486194e-07
Ashkenazi O 0 1.4251198763304274e-06
populations O 0 1.2222789447235982e-09
at O 0 4.592833668937146e-09
rates O 0 1.46480294560547e-09
comparable O 0 5.5725712932996885e-09
with O 0 1.0249966153619283e-10
that O 0 7.256170664327044e-10
of O 0 1.0048660925576769e-07
Ashkenazim O 0 1.5848381735850126e-05
. O 0 4.5900074496785237e-07

The O 0 3.8354792764039303e-07
majority O 0 1.1152547330084417e-08
of O 0 1.0541698003407873e-07
Jewish O 0 2.5045833353942726e-06
185delAG O 0 3.5476177799864672e-06
mutation O 0 2.0430638514312705e-08
carriers O 0 2.095329909579391e-09
have O 0 2.6571078670656334e-10
a O 0 4.937099618018692e-09
common O 0 1.83850501489502e-09
allelic O 0 7.590931261347578e-08
pattern O 0 5.862931402589311e-07
, O 0 4.249581131432478e-09
supporting O 0 3.512956681106516e-08
the O 0 4.5537575488197035e-08
founder O 0 1.0026544714492047e-06
effect O 0 6.270646668582458e-09
notion O 0 1.1824256240799969e-08
, O 0 1.1748126083066524e-10
but O 0 7.131200491228284e-11
dating O 0 2.6457069424168367e-08
the O 0 2.1752770695826484e-09
mutations O 0 1.2883961675314026e-09
origin O 0 1.1889155215882852e-09
to O 0 5.63931012997898e-10
an O 0 2.2005912647671266e-09
earlier O 0 1.054652010168411e-08
date O 0 6.804570062968196e-08
than O 0 1.9060519829139366e-09
currently O 0 6.050850043237688e-09
estimated O 0 5.67249891503252e-08
. O 0 8.279420171675156e-08

However O 0 6.624514981012908e-07
, O 0 5.1323127969737925e-09
the O 0 3.3663603016265142e-09
different O 0 8.617096480811881e-10
allelic O 0 2.3461316800421628e-07
pattern O 0 3.2682586947885284e-07
at O 0 3.05906866060468e-07
the O 0 4.4934395759810286e-08
BRCA1 O 0 2.0626930563594215e-07
locus O 0 5.30141761601044e-08
even O 0 1.59910931718521e-10
in O 0 1.1500698310351609e-10
some O 0 1.1542803518560518e-10
Jewish O 0 7.610442054328814e-09
mutation O 0 4.5635265011334525e-10
carriers O 0 4.053175017837418e-10
, O 0 2.8518298833546396e-10
might O 0 1.527765691733407e-09
suggest O 0 1.9441245058260392e-08
that O 0 3.775121881766097e-10
the O 0 3.800786796404054e-09
mutation O 0 1.5135652731146365e-09
arose O 0 1.634655255600137e-08
independently O 0 4.164186861999042e-08
. O 0 9.230580744201689e-09
. O 0 6.02536545102339e-08

Crystal O 0 0.06641771644353867
structure O 0 0.00012707416317425668
of O 0 8.28256961540319e-05
the O 0 0.07988699525594711
hemochromatosis B-Disease 1 1.0
protein O 1 0.9999998807907104
HFE O 1 1.0
and O 0 6.492793147572229e-08
characterization O 0 1.285889766222681e-06
of O 0 5.783187617680596e-08
its O 0 7.994376716169427e-09
interaction O 0 7.552285552492322e-08
with O 0 5.6815916416042e-09
transferrin O 0 2.4718097847653553e-05
receptor O 0 1.998819925574935e-06
. O 0 1.2063523513461405e-07

HFE O 1 0.9998568296432495
is O 0 4.1346001466990856e-07
an O 0 6.957969134191444e-08
MHC O 0 3.7728401366621256e-05
- O 0 0.00012577188317663968
related O 0 7.3342889663763344e-06
protein O 0 3.0356130764630507e-07
that O 0 5.016548287883893e-10
is O 0 5.680212966652221e-10
mutated O 0 2.334381576929445e-09
in O 0 1.2375409585985153e-09
the O 0 1.7863861501155043e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9988930821418762

HFE O 1 0.8032742142677307
binds O 0 1.2737389624817297e-05
to O 0 1.6555895854253322e-07
transferrin O 0 2.3465494450647384e-05
receptor O 0 3.2890563943510642e-06
( O 0 5.505193811927711e-08
TfR O 0 3.556364754331298e-05
) O 0 2.195187587261671e-09
and O 0 4.0493730590895893e-10
reduces O 0 4.686466326120353e-09
its O 0 1.4271748227656644e-09
affinity O 0 1.4798415826078326e-08
for O 0 1.0175895681641123e-08
iron O 0 0.0002060040715150535
- O 0 1.2616893400263507e-05
loaded O 0 4.560038632916985e-06
transferrin O 0 4.6269564336398616e-05
, O 0 7.7827081668147e-08
implicating O 0 0.0011448735604062676
HFE O 1 0.9999549388885498
in O 0 2.0435995793377515e-06
iron O 1 0.9998241066932678
metabolism O 1 0.9985697269439697
. O 0 1.8897001154982718e-06

The O 0 1.865528611233458e-05
2 O 0 1.2345105460553896e-05
. O 0 1.778471187208197e-06

6 O 0 7.932708831503987e-05
A O 0 2.081764250760898e-05
crystal O 0 0.0003542441118042916
structure O 0 0.0002405219856882468
of O 0 0.0002308663388248533
HFE O 1 1.0
reveals O 0 3.5570426462072646e-06
the O 0 4.57451179158852e-08
locations O 0 9.78927801043028e-08
of O 0 4.8388819777756e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 7.4142908488283865e-06
and O 0 6.451796252804343e-08
a O 0 1.3051883342996007e-06
patch O 0 0.00024163519265130162
of O 0 2.461834992573131e-05
histidines O 0 0.06774497032165527
that O 0 1.2093945844782183e-09
could O 0 4.3403508565020843e-10
be O 0 6.347743441992293e-10
involved O 0 2.112884800453685e-08
in O 0 3.845855189865688e-08
pH O 0 4.357795478426851e-05
- O 0 8.360130777873565e-06
dependent O 0 1.4321788057714002e-06
interactions O 0 6.56108852581383e-07
. O 0 1.78093600311513e-07

We O 0 4.802989224117482e-07
also O 0 1.1008938649581523e-08
demonstrate O 0 9.830029057411593e-08
that O 0 2.2312169889460165e-08
soluble O 0 7.101574738044292e-05
TfR O 1 0.963844895362854
and O 0 7.948857216888428e-08
HFE O 0 0.29354920983314514
bind O 0 3.3471869187451375e-07
tightly O 0 4.869226586379227e-07
at O 0 2.0532677780238373e-08
the O 0 2.7925144419072012e-09
basic O 0 3.536506909540549e-08
pH O 0 2.897947481983465e-08
of O 0 3.155184780112563e-09
the O 0 5.5813469401755356e-09
cell O 0 8.086578873189865e-08
surface O 0 1.1434697633205815e-08
, O 0 2.722439496061213e-10
but O 0 2.20026274977414e-10
not O 0 9.470384476628624e-10
at O 0 2.8535959373243713e-08
the O 0 2.7432296434426462e-08
acidic O 0 5.846153499078355e-07
pH O 0 1.15186423954583e-06
of O 0 3.1244647402672854e-07
intracellular O 0 1.6484793377458118e-05
vesicles O 0 9.300267993239686e-05
. O 0 1.8514823523219093e-06

TfR O 1 0.9999762773513794
HFE O 1 0.9978792667388916
stoichiometry O 0 0.00010721003491198644
( O 0 7.701210620325583e-07
2 O 0 2.2351404993514734e-07
1 O 0 1.3246673802314035e-07
) O 0 4.667715103323644e-09
differs O 0 7.033327698025005e-09
from O 0 1.881627298416788e-08
TfR O 0 3.7473993870662525e-05
transferrin O 0 1.709968955765362e-06
stoichiometry O 0 8.58663753433575e-08
( O 0 3.4902469803199665e-09
2 O 0 3.1946674194927027e-09
2 O 0 3.998292363860401e-09
) O 0 4.404667186541644e-10
, O 0 1.0611726081188877e-10
implying O 0 4.620264171251165e-09
a O 0 6.923674411574154e-10
different O 0 6.472925667688756e-11
mode O 0 1.490950474192232e-08
of O 0 5.566600957962464e-09
binding O 0 1.3119050734644588e-08
for O 0 3.402134751695485e-08
HFE O 1 0.7568577527999878
and O 0 4.41707257436974e-08
transferrin O 0 1.1814846402558032e-05
to O 0 3.21281170556631e-08
TfR O 0 0.0974530354142189
, O 0 8.532512474346277e-09
consistent O 0 7.366046617107713e-08
with O 0 3.3974625890387244e-10
our O 0 1.537193128342551e-08
demonstration O 0 1.1653494169650003e-07
that O 0 5.499009692044865e-09
HFE O 0 0.00017695996211841702
, O 0 9.913758702850828e-09
transferrin O 0 3.4677455005294178e-06
, O 0 4.212941551173799e-09
and O 0 9.099979436655303e-09
TfR O 0 0.00016721224528737366
form O 0 2.0386533350347236e-08
a O 0 4.032544609344768e-07
ternary O 0 2.0983176000299864e-05
complex O 0 3.280750388512388e-05
. O 0 9.236393907485763e-07

Identification O 0 7.86848488587566e-07
of O 0 3.357935440817528e-08
three O 0 3.816353899566138e-09
novel O 0 3.150604044321881e-08
mutations O 0 1.2824677986245092e-09
and O 0 1.6694333415667728e-10
a O 0 1.6054729767844833e-09
high O 0 1.011957184715584e-08
frequency O 0 8.186892941353108e-09
of O 0 6.236807070791883e-09
the O 0 2.491981199170823e-08
Arg778Leu O 0 6.176482565933838e-05
mutation O 0 5.194207286507435e-09
in O 0 2.206184790409793e-09
Korean O 0 8.82374297361821e-05
patients O 0 1.939327587408002e-09
with O 0 1.409488081804966e-09
Wilson B-Disease 0 0.0004140162782277912
disease I-Disease 0 0.00018494583491701633
. O 0 2.569913988281769e-07

Four O 0 1.262759838027705e-06
mutations O 0 1.2749033828640677e-07
- O 0 7.871637990319869e-07
- O 0 2.256847892567748e-06
R778L O 0 8.882892871042714e-06
, O 0 1.8923888234212427e-08
A874V O 0 8.916306910577987e-07
, O 0 5.3278617073715395e-09
L1083F O 0 5.442514066089643e-07
, O 0 3.1623905716315903e-09
and O 0 1.755558920457645e-09
2304delC O 0 1.913549851906282e-07
- O 0 2.376276455606785e-07
- O 0 9.726519323294269e-08
in O 0 5.1935340472653024e-09
the O 0 1.2492430201405114e-08
copper O 0 2.2512631403515115e-06
- O 0 1.277632293295028e-07
transporting O 0 2.954964486434619e-07
enzyme O 0 1.9239209336774366e-08
, O 0 5.900327448848941e-10
P O 0 1.121658783631574e-06
- O 0 1.342111204394314e-07
type O 0 6.218635348886892e-07
ATPase O 0 0.0010387309594079852
( O 0 9.081582597048055e-09
ATP7B O 0 2.629741857163026e-06
) O 0 2.8008079189234536e-10
, O 0 3.178072735532389e-11
were O 0 1.3464207526681093e-10
identified O 0 1.7202410607097818e-09
in O 0 1.7615796599201872e-09
Korean O 0 0.023012572899460793
Patients O 0 1.8406813850901926e-08
with O 0 1.6768443300563263e-09
Wilson B-Disease 0 0.009777086786925793
disease I-Disease 0 0.011600959114730358
. O 0 4.866074618803395e-07

Arg778Leu O 0 0.0075822267681360245
, O 0 6.98807980370475e-08
the O 0 1.3089506367691683e-08
most O 0 1.052828602077227e-09
frequently O 0 2.2058228577037653e-09
reported O 0 2.426442158309783e-09
mutation O 0 1.1550181644448543e-10
of O 0 1.1571090752227065e-09
this O 0 8.086432634613061e-10
enzyme O 0 9.944723267096833e-09
, O 0 3.721155328317849e-10
was O 0 2.1439936048750496e-08
found O 0 2.415079469741954e-09
in O 0 5.366144195662059e-10
six O 0 1.3600131021362927e-09
of O 0 3.902544065681468e-09
eight O 0 3.985241914250537e-09
unrelated O 0 6.420945197760375e-08
patients O 0 5.934593927392484e-10
studied O 0 1.3101820961480826e-08
, O 0 3.648408797296554e-10
an O 0 8.774743709416555e-10
allele O 0 1.5046336399038296e-09
frequency O 0 6.0563922765766165e-09
of O 0 3.052027963690307e-08
37 O 0 4.5190745368017815e-07
. O 0 1.3353739802823839e-07

5 O 0 1.5121859178179875e-06
% O 0 3.4279747040955044e-08
, O 0 4.737846226454678e-10
which O 0 1.1908848907005165e-10
is O 0 9.599630812484605e-11
considerably O 0 9.073370943468717e-10
higher O 0 2.2079866823787597e-09
than O 0 4.3467944521591306e-11
those O 0 5.823691529016628e-11
in O 0 2.01768102225941e-10
other O 0 3.159018879816955e-10
Asian O 0 7.432929294282076e-08
populations O 0 9.17966413993554e-09
. O 0 1.7817743724890533e-08

The O 0 2.729043160343281e-07
novel O 0 2.3673531757140154e-07
single O 0 4.496080308058481e-08
nucleotide O 0 3.8818083680780546e-07
deletion O 0 1.1379871978078882e-07
, O 0 2.686303401944201e-09
2304delC O 0 1.6126760726820066e-07
, O 0 9.858579508303933e-10
was O 0 3.567896555978223e-08
found O 0 3.843815044035637e-09
in O 0 5.5689906020006674e-09
one O 0 3.1150864998608085e-08
patient O 0 1.0265765695294249e-06
. O 0 4.3409022509877104e-07

Since O 0 1.0864474688787595e-06
a O 0 1.257838846413506e-07
mutation O 0 2.3976030050221198e-08
at O 0 1.5248618012719817e-07
cDNA O 0 3.668842282422702e-06
nucleotide O 0 3.0164878808136564e-06
2302 O 0 3.074922278756276e-05
( O 0 1.2441399910301243e-08
2302insC O 0 9.941634715460168e-08
) O 0 1.2297221019252902e-09
had O 0 1.6804814206849983e-09
been O 0 1.2943172089663335e-09
previously O 0 5.173552697357309e-09
described O 0 1.3706412893554898e-08
, O 0 8.072363333333499e-10
this O 0 5.084848098135808e-10
region O 0 9.71151958850669e-09
of O 0 4.133388742388888e-08
the O 0 3.134881580990623e-07
ATP7B O 1 0.9999970197677612
gene O 0 9.223825969684185e-08
may O 0 2.847607927236595e-09
be O 0 1.9754888835876727e-09
susceptible O 0 4.187235802532996e-08
to O 0 9.67496749382235e-09
gene O 0 7.812652143002197e-07
rearrangements O 0 6.0892834881087765e-05
causing O 0 0.010382266715168953
Wilson B-Disease 1 0.9742982983589172
disease I-Disease 1 0.8337935209274292
. O 0 2.2562001049664104e-06

Disruption O 0 0.00042832965846173465
of O 0 1.8695681092140148e-06
splicing O 0 5.355778739613015e-06
regulated O 0 6.618679435632657e-07
by O 0 1.4403566339638019e-08
a O 0 7.306994831424163e-08
CUG O 0 0.00018726152484305203
- O 0 7.322844339796575e-07
binding O 0 1.3280940436288802e-07
protein O 0 1.153386733676598e-06
in O 0 7.650700126760057e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.047893980896333e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995934367179871
DM B-Disease 1 1.0
) O 0 6.671214123343816e-07
is O 0 1.173053831848847e-08
caused O 0 1.9854091704019083e-08
by O 0 5.573134398417778e-09
a O 0 1.3579432334154262e-07
CTG O 0 0.0006165638915263116
expansion O 0 1.6305222061419045e-07
in O 0 5.314809481404836e-09
the O 0 7.98876786944902e-09
3 O 0 2.7472509600556805e-08
untranslated O 0 5.36026482222951e-06
region O 0 5.0854062294547475e-08
of O 0 1.565814926607345e-07
the O 0 5.02805733049172e-06
DM B-Disease 1 1.0
gene O 0 5.452964160213014e-06
. O 0 3.461479991528904e-07

One O 0 5.438296284410171e-07
model O 0 6.279572062339867e-07
of O 0 8.354058081749827e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999998807907104
suggests O 0 9.57431439019274e-07
that O 0 2.0904438180480156e-09
RNAs O 0 1.2187548463771236e-06
from O 0 1.1831424728825368e-09
the O 0 1.02545272273602e-09
expanded O 0 1.984204356375585e-09
allele O 0 1.2087166822993822e-09
create O 0 4.851080093182247e-10
a O 0 4.743681003560596e-09
gain O 0 5.955475046448555e-08
- O 0 2.9729863015859337e-08
of O 0 3.030021744621081e-08
- O 0 9.94104780716043e-08
function O 0 6.571806654420698e-09
mutation O 0 1.394049875536041e-10
by O 0 8.898126679923735e-11
the O 0 8.0846129790757e-10
inappropriate O 0 8.553190156135315e-09
binding O 0 1.9922477001443895e-09
of O 0 6.377430583626165e-09
proteins O 0 4.3398067361977155e-09
to O 0 2.00973526709447e-09
the O 0 3.972457420786668e-07
CUG O 0 0.14298219978809357
repeats O 0 3.0779297958360985e-05
. O 0 1.8770052747640875e-06

Data O 0 3.0432850053330185e-06
presented O 0 8.062645662221257e-08
here O 0 7.280993230551758e-08
indicate O 0 3.529693870518713e-08
that O 0 3.3108193964181964e-10
the O 0 1.979679531416423e-09
conserved O 0 5.085260568193917e-08
heterogeneous O 0 9.271555256873398e-08
nuclear O 0 8.373335731448606e-06
ribonucleoprotein O 0 0.0003016289265360683
, O 0 1.924864179159158e-08
CUG O 0 3.3305990655208007e-05
- O 0 7.448853267533195e-08
binding O 0 9.58555190777588e-09
protein O 0 3.3868289506244764e-08
( O 0 2.4322668323861762e-09
CUG O 0 3.2876575914997375e-06
- O 0 4.670763189551508e-07
BP O 0 2.838155978679424e-06
) O 0 2.8483415626112674e-09
, O 0 4.969237243912517e-10
may O 0 1.1979385261540187e-09
mediate O 0 3.004905479997433e-08
the O 0 2.542954113948781e-08
trans O 0 1.639633353534009e-07
- O 0 5.116618240208481e-07
dominant O 0 5.687991944114401e-08
effect O 0 6.858250856112136e-09
of O 0 1.6223117071945126e-08
the O 0 7.64584342505259e-08
RNA O 0 7.2432035267411266e-06
. O 0 1.054489615626153e-07

CUG O 1 0.99460369348526
- O 0 0.0009815735975280404
BP O 0 0.0001618080132175237
was O 0 5.232533339949441e-07
found O 0 1.9740584278338247e-08
to O 0 1.744799860148305e-09
bind O 0 1.2195526366554077e-08
to O 0 1.6030892169283106e-09
the O 0 3.737676124160316e-08
human O 0 2.7324523443894577e-07
cardiac O 0 0.013723719865083694
troponin O 0 0.0005425699055194855
T O 0 5.283430073177442e-05
( O 0 4.908651973778433e-08
cTNT O 0 6.758915560567402e-07
) O 0 8.231062054164795e-09
pre O 0 3.1015576951176627e-07
- O 0 1.8962049352921895e-07
messenger O 0 4.214864475216018e-07
RNA O 0 1.6510739442310296e-07
and O 0 5.257528301605419e-10
regulate O 0 3.912150603468945e-09
its O 0 6.95469848377428e-10
alternative O 0 1.0967315944299116e-08
splicing O 0 8.009549219423207e-07
. O 0 1.375800451342002e-07

Splicing O 0 8.744751539779827e-05
of O 0 3.532954906404484e-06
cTNT O 0 8.820554648991674e-05
was O 0 1.0252516403852496e-05
disrupted O 0 0.00015376268129330128
in O 0 5.344864348444389e-06
DM B-Disease 1 1.0
striated O 1 0.918512225151062
muscle O 0 4.506014192884322e-06
and O 0 7.641947519232417e-09
in O 0 2.373836416325048e-08
normal O 0 6.824781735303986e-07
cells O 0 5.056699237115936e-08
expressing O 0 1.835678098416338e-08
transcripts O 0 5.822978437208803e-07
that O 0 3.4234577395153565e-09
contain O 0 1.6609173769666086e-07
CUG O 0 0.000555038801394403
repeats O 0 1.0175217539654113e-05
. O 0 6.687936320304289e-07

Altered O 0 6.12913436270901e-06
expression O 0 3.4663693782022165e-07
of O 0 1.4739590881163167e-07
genes O 0 7.06138294503944e-08
regulated O 0 1.6479545195124956e-07
posttranscriptionally O 0 1.6119008705572924e-06
by O 0 3.5961949862439724e-08
CUG O 0 0.358218789100647
- O 0 1.6627571312710643e-05
BP O 0 6.647539976256667e-06
therefore O 0 6.015694165029117e-09
may O 0 4.10281630891518e-09
contribute O 0 2.6581448153706333e-08
to O 0 3.7249830597829714e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9999983310699463
. O 0 1.1695802726308102e-07
. O 0 3.0325952593557304e-07

Identification O 0 2.6370423711341573e-06
of O 0 1.4836689388175728e-07
a O 0 6.785894157701478e-08
novel O 0 1.9344525981068728e-07
nonsense O 0 1.3376482002058765e-06
mutation O 0 2.3137955995622406e-09
and O 0 4.4984002633974285e-10
a O 0 5.105044387221369e-09
missense O 0 5.843038053399141e-08
substitution O 0 5.456601392950233e-09
in O 0 2.9747941887592333e-09
the O 0 9.279265356099131e-09
vasopressin O 0 4.597911242854025e-07
- O 0 1.8849343064175628e-07
neurophysin O 0 4.894487574347295e-06
II O 0 0.0001413238642271608
gene O 0 9.526534228143646e-09
in O 0 6.226356097371877e-10
two O 0 8.793860639677575e-10
Spanish O 0 2.402240681931289e-07
kindreds O 0 5.748770945501747e-06
with O 0 3.805111958854468e-08
familial B-Disease 1 0.9999985694885254
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 1.2067695024597924e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.812667727470398
FNDI B-Disease 1 1.0
) O 0 1.5959989241309813e-07
is O 0 3.285005822917242e-09
an O 0 5.187200713407947e-08
autosomal B-Disease 1 0.9999963045120239
dominant I-Disease 1 0.9999986886978149
disease I-Disease 1 0.999998927116394
caused O 0 0.00015535508282482624
by O 0 5.032097760704346e-07
deficiency O 1 0.9999996423721313
in O 0 3.9285549746637116e-07
the O 0 5.077060450275894e-06
antidiuretic O 0 9.93140711216256e-05
hormone O 0 1.0506910541607795e-07
arginine O 0 6.839553066129156e-07
vasopressin O 0 7.967069564074336e-07
( O 0 2.314798663860529e-08
AVP O 0 1.0340451126467087e-06
) O 0 6.511812200571399e-10
encoded O 0 1.5491659066668717e-09
by O 0 1.0461927990590425e-09
the O 0 2.0135999534431903e-08
AVP O 0 1.1549615010153502e-05
- O 0 8.427721240877872e-07
neurophysin O 0 2.047788439085707e-05
II O 1 0.9998168349266052
( O 0 1.270726352231577e-05
AVP O 0 0.0032615582458674908
- O 0 7.524702596128918e-06
NPII O 0 0.0011631204979494214
) O 0 7.572031535119095e-08
gene O 0 1.865378962406794e-08
on O 0 7.53457385371803e-08
chromosome O 0 3.651159659057157e-06
20p13 O 0 4.3331761844456196e-05
. O 0 2.1928258320258465e-06

In O 0 1.722943636650598e-07
this O 0 3.42298767108673e-09
study O 0 5.054892948663792e-09
, O 0 1.3490299155538565e-10
we O 0 4.319325175305977e-10
analyzed O 0 5.710294459504439e-09
two O 0 7.433021975700171e-10
families O 0 8.643466498092778e-10
with O 0 1.2947666272467018e-09
FNDI B-Disease 1 1.0
using O 0 4.964694966247407e-08
direct O 0 3.80537308330986e-08
automated O 0 1.3858691261248168e-07
fluorescent O 0 3.1525499988305228e-09
, O 0 8.359606062935399e-11
solid O 0 2.7264941415694466e-09
phase O 0 1.0818227202946673e-08
, O 0 3.634323675338891e-10
single O 0 1.656038084441036e-09
- O 0 3.258807890205162e-09
stranded O 0 8.208188795322258e-09
DNA O 0 1.4619084831579698e-09
sequencing O 0 6.471768121407706e-10
of O 0 4.773041073491413e-09
PCR O 0 9.329919237188733e-08
- O 0 4.996161919734732e-07
amplified O 0 4.36451500718249e-06
AVP O 0 0.00013451528502628207
- O 0 4.391121819935506e-06
NPII O 0 0.0002003405970754102
DNA O 0 1.0272218787577003e-05
. O 0 3.409742532767268e-07

In O 0 1.9162418141149828e-07
one O 0 8.260772510482184e-09
of O 0 6.0196656548328065e-09
the O 0 5.255735846532161e-09
families O 0 2.34905828122578e-09
, O 0 3.985437813103232e-10
affected O 0 1.2868488497019825e-09
individuals O 0 4.0745840035327774e-10
presented O 0 1.9100269810223836e-08
a O 0 2.4212518212607392e-08
novel O 0 3.896150246873731e-08
nonsense O 0 9.964359293235248e-08
mutation O 0 1.2648192493358579e-09
in O 0 8.738300083521722e-10
exon O 0 1.572584373832342e-08
3 O 0 1.396893156702106e-09
of O 0 1.1151457535163445e-09
the O 0 1.5879494386084048e-09
gene O 0 6.605192504061108e-10
, O 0 8.785524391319299e-11
consisting O 0 2.868710824444065e-09
in O 0 5.413146819677195e-09
a O 0 4.789860597043116e-08
G O 0 3.7799719621034455e-07
to O 0 1.9195736555843723e-08
T O 0 6.4910127548500896e-06
transition O 0 1.2118541690142592e-06
at O 0 1.9860149222949985e-06
nucleotide O 0 6.3203460740623996e-06
2101 O 0 4.54701103080879e-06
, O 0 1.9467349954283009e-10
which O 0 2.1101188504846213e-11
produces O 0 6.875348207424636e-11
a O 0 7.198713847245131e-10
stop O 0 2.3791522085758743e-09
signal O 0 1.44577620986297e-08
in O 0 1.3756954464483329e-09
codon O 0 1.4093025413330906e-07
82 O 0 2.2483570205622527e-07
( O 0 1.1144918232730561e-07
Glu O 0 4.1133440390694886e-05
) O 0 2.3501174339912723e-08
of O 0 1.524448833833958e-07
NPII O 0 0.0060476744547486305
. O 0 1.0190976809099084e-06

The O 0 6.520252554764738e-06
premature O 0 6.259157544263871e-06
termination O 0 1.4356494375533657e-06
eliminates O 0 3.958038234941341e-07
part O 0 4.932565644821807e-08
of O 0 1.2343973310180445e-07
the O 0 2.593453984900407e-07
C O 0 0.0003025710175279528
- O 0 1.3987641068524681e-05
terminal O 0 5.023245194024639e-06
domain O 0 9.58214286583825e-07
of O 0 1.5365458239102736e-07
NPII O 0 0.012352977879345417
, O 0 8.622048852657827e-09
including O 0 3.0782350002311887e-09
a O 0 1.626705348201085e-08
cysteine O 0 2.4757122574214918e-08
residue O 0 1.2928725823257992e-07
in O 0 1.6031534988414364e-09
position O 0 2.5858984287197018e-08
85 O 0 2.3604496135476438e-08
, O 0 2.3274715488241782e-10
which O 0 3.428315964448814e-11
could O 0 6.899599641618792e-11
be O 0 4.132517383848011e-10
involved O 0 6.640389127454682e-09
in O 0 5.190137208899159e-09
the O 0 2.3688746964012353e-08
correct O 0 1.591963041391864e-06
folding O 0 1.539064214739483e-05
of O 0 1.6526001900274423e-06
the O 0 4.914525561616756e-06
prohormone O 0 0.047853734344244
. O 0 1.8835789887816645e-06

In O 0 8.05396723535523e-07
the O 0 6.850722655826758e-08
second O 0 1.4678724369332485e-07
family O 0 6.037824817894943e-08
, O 0 1.9579258214719175e-09
a O 0 9.806655043576029e-09
G279A O 0 9.36856139333031e-08
substitution O 0 5.108190759273157e-09
at O 0 2.6796318053357027e-08
position O 0 6.024113474722981e-08
- O 0 3.6752602738943096e-08
1 O 0 1.925433323890502e-08
of O 0 5.7806812669980445e-09
the O 0 7.627152243117052e-09
signal O 0 7.579530603152307e-08
peptide O 0 1.3763811423928018e-08
was O 0 7.451635752886432e-09
observed O 0 2.9855600214290234e-09
in O 0 4.673708087210571e-10
all O 0 7.925566314348487e-10
affected O 0 7.834564108577524e-09
individuals O 0 6.0054681227939e-09
. O 0 1.231086770303591e-07

This O 0 9.430698355572531e-07
missense O 0 6.209276307345135e-06
mutation O 0 4.030744804595088e-08
, O 0 3.964295558489539e-09
which O 0 2.0574222325819846e-09
replaces O 0 7.286465688594035e-07
Ala O 0 8.051399345276877e-05
with O 0 2.8380393146676397e-08
Thr O 1 0.6381003260612488
, O 0 6.562362653284026e-09
is O 0 1.104146996055988e-08
frequent O 0 3.125644454371468e-08
among O 0 1.0857752030801748e-08
FNDI B-Disease 1 1.0
patients O 0 1.485700977355009e-06
and O 0 4.763909711158476e-09
is O 0 9.342541851253827e-09
thought O 0 1.1462430116182531e-08
to O 0 4.102783113246744e-10
reduce O 0 4.7084984799994345e-09
the O 0 2.231212725689602e-08
efficiency O 0 5.941735281567162e-08
of O 0 1.6035457406360365e-08
cleavage O 0 1.766080970355688e-07
by O 0 7.913396160574848e-09
signal O 0 3.8161599036357075e-07
peptidases O 0 4.104723757336615e-06
. O 0 1.2280187533519893e-08
. O 0 1.227998183139789e-07

Genetic O 0 0.0005244223866611719
heterogeneity O 0 6.091200339142233e-05
of O 0 5.4843276302563027e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.0966354047070581e-08
due O 0 1.952080452838345e-07
to O 0 4.404957465453663e-08
TWIST O 0 0.00013805647904518992
and O 0 1.8019358094534255e-07
FGFR O 1 0.9989001750946045
mutations O 0 1.1999101161563885e-06
. O 0 5.392795401348849e-07

Thirty O 0 4.39305767940823e-05
- O 0 1.8196673181591905e-06
two O 0 5.879670528230463e-09
unrelated O 0 1.6048238649091218e-07
patients O 0 8.591756195386324e-10
with O 0 1.786274461679227e-10
features O 0 2.1995012033926287e-08
of O 0 5.7460956668364815e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3420728972590723e-09
a O 0 9.508688947335031e-09
common O 0 4.850169332826226e-08
autosomal B-Disease 0 9.825106826610863e-05
dominant I-Disease 0 7.832332812540699e-06
condition I-Disease 0 0.0014158645644783974
of O 0 0.3748038709163666
craniosynostosis B-Disease 1 1.0
and O 0 0.00010676949750632048
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999549388885498
, O 0 2.0645069653824066e-08
were O 0 2.4036102885816035e-08
screened O 0 3.377745727561887e-08
for O 0 2.3692350303861076e-09
mutations O 0 6.889822490308006e-09
in O 0 1.221678225249434e-08
TWIST O 0 3.40045771736186e-05
, O 0 6.056059476122755e-08
FGFR2 O 1 0.9846131801605225
, O 0 6.157063126011053e-08
and O 0 2.1099172897720564e-07
FGFR3 O 1 0.9999258518218994
. O 0 1.1685044228215702e-05

Nine O 0 2.566729790487443e-06
novel O 0 4.897373742096534e-07
and O 0 1.451919384720668e-08
three O 0 3.689631000725058e-08
recurrent O 0 2.7773201509262435e-05
TWIST O 0 3.529978857841343e-05
mutations O 0 4.596919822574819e-08
were O 0 2.23953531275356e-08
found O 0 1.3883091121158486e-08
in O 0 1.089557066791258e-08
12 O 0 1.309850290454051e-07
families O 0 5.3235371666460196e-08
. O 0 1.8650202093795087e-07

Seven O 0 1.019652813738503e-06
families O 0 9.668160494413769e-09
were O 0 5.080876164242909e-09
found O 0 1.8413088831437108e-09
to O 0 5.551542003878751e-10
have O 0 5.978880723844782e-10
the O 0 4.3500936186546824e-08
FGFR3 O 0 0.2047104388475418
P250R O 0 3.954105977754807e-06
mutation O 0 1.887002998302023e-09
, O 0 1.5997835001169136e-10
and O 0 1.4461222497264004e-10
one O 0 3.97358174142326e-10
individual O 0 8.354860137060882e-10
was O 0 5.458727869722679e-08
found O 0 3.5066487491519638e-09
to O 0 1.056175480407262e-09
have O 0 1.5173691192416072e-09
an O 0 3.2226989077344115e-08
FGFR2 O 0 0.0005380758666433394
VV269 O 0 5.665876960847527e-05
- O 0 8.699029422132298e-06
270 O 0 2.7477965431899065e-06
deletion O 0 1.5240854054354713e-06
. O 0 1.1545110112365364e-07

To O 0 5.659336110852564e-08
date O 0 1.6289432380744984e-07
, O 0 2.582180691490521e-09
our O 0 2.8446063282672185e-09
detection O 0 1.837920216019029e-08
rate O 0 5.577313721971677e-09
for O 0 3.5023689504143363e-10
TWIST O 0 1.0787041446747025e-06
or O 0 2.4199039216910023e-08
FGFR O 0 3.085334901697934e-05
mutations O 0 1.7101909888239675e-09
is O 0 2.0650876841887822e-10
68 O 0 3.2682940798167692e-09
% O 0 4.601503345025293e-10
in O 0 4.983626844534683e-10
our O 0 5.10226314531792e-08
Saethre B-Disease 1 0.9999843835830688
- I-Disease 1 0.9999752044677734
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.212890410329237e-08
, O 0 1.977229352467802e-10
including O 0 6.705627719760798e-10
our O 0 1.060687981890851e-08
five O 0 2.5717212803755274e-09
patients O 0 8.810531748615347e-10
elsewhere O 0 5.503784095139963e-09
reported O 0 7.577821925508488e-09
with O 0 2.012308986110156e-09
TWIST O 0 2.4721586669329554e-05
mutations O 0 2.3373416979666217e-07
. O 0 1.6515132017502765e-07

More O 0 1.1064385851966563e-08
than O 0 9.359819586052254e-10
35 O 0 1.463479115670907e-09
different O 0 1.4540961490450144e-10
TWIST O 0 5.1289390512465616e-08
mutations O 0 5.608010722468748e-10
are O 0 3.910460844025465e-11
now O 0 5.71175162722426e-10
known O 0 2.4240138785103227e-09
in O 0 1.4481682519829064e-09
the O 0 2.052688152787141e-08
literature O 0 1.1062234079872724e-06
. O 0 2.131856717824121e-07

The O 0 8.326151714754815e-07
most O 0 7.295753334801702e-09
common O 0 3.699240691545924e-09
phenotypic O 0 3.6809499448509087e-08
features O 0 9.519522947698533e-09
, O 0 2.7298438509681944e-10
present O 0 8.552892283297808e-10
in O 0 3.043630625310101e-10
more O 0 4.416855076128101e-11
than O 0 3.466545106523e-11
a O 0 1.9645683690949767e-10
third O 0 4.0849801319353674e-10
of O 0 9.850930071664266e-10
our O 0 4.4367269858014424e-09
patients O 0 3.782069657454201e-10
with O 0 6.644347572137832e-11
TWIST O 0 1.6114397567434935e-06
mutations O 0 5.715852235965713e-09
, O 0 4.294540834060001e-10
are O 0 3.3711067271013917e-10
coronal B-Disease 0 3.0729477202839917e-06
synostosis I-Disease 0 0.000252216326771304
, O 0 3.060673492427668e-08
brachycephaly B-Disease 0 0.003338642418384552
, O 0 1.3818993238601252e-07
low B-Disease 0 0.0004120160883758217
frontal I-Disease 1 0.9999988079071045
hairline I-Disease 1 1.0
, O 0 8.335144912052783e-07
facial B-Disease 1 0.839655339717865
asymmetry I-Disease 1 0.9999935626983643
, O 0 1.4719546470587375e-06
ptosis B-Disease 1 0.9999983310699463
, O 0 9.225556141245761e-07
hypertelorism B-Disease 1 0.9938680529594421
, O 0 1.2732120069358643e-07
broad B-Disease 0 8.04095088824397e-06
great I-Disease 0 0.0011932662455365062
toes I-Disease 1 0.9959413409233093
, O 0 2.52646174203619e-07
and O 0 4.405108882110653e-07
clinodactyly B-Disease 1 0.9608010649681091
. O 0 2.2819203877588734e-05

Significant O 0 1.6535523172933608e-05
intra O 0 0.0005438156076706946
- O 0 9.758444321050774e-06
and O 0 1.055066523036885e-08
interfamilial O 0 2.3871547455200925e-05
phenotypic O 0 6.417713507289591e-07
variability O 0 7.558596166745701e-07
is O 0 1.1433622937317978e-09
present O 0 1.2327774356890586e-09
for O 0 5.047664508595062e-10
either O 0 1.9867350431468367e-08
TWIST O 0 1.4756083146494348e-05
mutations O 0 1.1100218699766629e-07
or O 0 6.830968146687155e-08
FGFR O 0 0.005836661905050278
mutations O 0 4.3128591187269194e-07
. O 0 2.9700851200686884e-07

The O 0 1.2176315067335963e-06
overlap O 0 5.421259743343398e-07
in O 0 1.2353507550244558e-08
clinical O 0 1.0049484444607515e-07
features O 0 6.885329195682743e-09
and O 0 2.2680550493259233e-10
the O 0 1.9765440395502765e-09
presence O 0 1.9729657907419096e-09
, O 0 1.819134148872692e-10
in O 0 8.89600476616792e-11
the O 0 4.2051279125487895e-10
same O 0 4.5971959572455035e-10
genes O 0 1.9642462656399573e-10
, O 0 1.1856578219227032e-11
of O 0 1.188135007046398e-10
mutations O 0 4.749832818728983e-11
for O 0 3.3273404864697653e-11
more O 0 2.4143952462307716e-11
than O 0 7.53595727487344e-11
one O 0 5.369379385555817e-10
craniosynostotic B-Disease 0 1.6952985504303797e-07
condition I-Disease 0 2.5454926344536943e-07
- O 0 2.491406192461909e-08
such O 0 6.298117027903061e-10
as O 0 1.179605391143923e-08
Saethre B-Disease 0 0.00023555591178592294
- I-Disease 0 2.5960746370401466e-06
Chotzen I-Disease 0 0.00012247319682501256
, I-Disease 0 9.208353191070273e-09
Crouzon I-Disease 0 2.3455471819033846e-05
, I-Disease 0 5.1269606338166795e-09
and I-Disease 0 8.385132588273336e-09
Pfeiffer I-Disease 1 0.8754449486732483
syndromes I-Disease 0 0.00017527063027955592
- O 0 2.6513855573284673e-06
support O 0 2.5252735014191785e-08
the O 0 4.8275754949145266e-08
hypothesis O 0 8.436342824325038e-08
that O 0 2.508225016573107e-10
TWIST O 0 8.611009150172322e-08
and O 0 5.452645002179679e-10
FGFRs O 0 2.855621232811245e-06
are O 0 4.4100134655167267e-10
components O 0 9.629972375080342e-09
of O 0 2.8851396827178633e-09
the O 0 2.23338303406706e-09
same O 0 4.674352460654063e-09
molecular O 0 2.404436543201882e-07
pathway O 0 2.712583757613629e-08
involved O 0 1.991043552251881e-09
in O 0 6.318233713997756e-10
the O 0 3.3867757487371364e-09
modulation O 0 1.9101533155208017e-07
of O 0 1.6675294034484978e-07
craniofacial O 1 1.0
and O 0 3.327089075355616e-07
limb O 1 1.0
development O 0 0.0005662768380716443
in O 0 9.711356341313149e-08
humans O 0 1.3643013119235547e-07
. O 0 1.0942700967575547e-08
. O 0 1.2398633941756998e-07

Mutation O 0 1.0090335536006023e-06
analysis O 0 2.540623142976983e-07
of O 0 8.487974128001952e-07
UBE3A O 1 0.9999998807907104
in O 0 0.12233509123325348
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.051106225699186325
. O 0 1.7814655848269467e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9996041655540466
AS B-Disease 1 1.0
) O 0 5.937735636507568e-07
is O 0 1.1454779347275235e-08
caused O 0 3.794168534909659e-08
by O 0 1.9757948166443384e-08
chromosome O 0 6.083815605961718e-06
15q11 O 0 0.00043506635120138526
- O 0 0.00012241388321854174
q13 O 0 7.959114736877382e-05
deletions O 0 4.536982203262596e-07
of O 0 9.471784068182387e-08
maternal O 0 3.3815056212915806e-06
origin O 0 5.099013478115921e-08
, O 0 7.455104089615361e-09
by O 0 7.211583152866297e-08
paternal O 1 0.9837077260017395
uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999991655349731
( O 0 0.000969070300925523
UPD B-Disease 1 1.0
) O 0 8.411824126142164e-08
15 O 0 1.9699662345828983e-08
, O 0 1.3367743578740487e-09
by O 0 6.91181689660425e-09
imprinting O 0 0.11208344250917435
defects O 0 0.42928656935691833
, O 0 2.647704722136268e-09
and O 0 9.965148706214677e-10
by O 0 3.400031145517346e-09
mutations O 0 8.959051278623065e-09
in O 0 1.4593767971859961e-08
the O 0 9.466976962357876e-07
UBE3A O 1 0.9965368509292603
gene O 0 2.400748144282261e-06
. O 0 3.155427634737862e-07

UBE3A O 1 0.9624033570289612
encodes O 0 0.00010547129932092503
a O 0 1.2323616829235107e-06
ubiquitin O 0 5.073599368188297e-06
- O 0 7.811327122908551e-06
protein O 0 5.732695740334748e-07
ligase O 0 1.131146291299956e-06
and O 0 4.431027100793017e-09
shows O 0 1.5149342402764887e-07
brain O 0 4.595633072312921e-05
- O 0 5.440547283797059e-07
specific O 0 1.382872198973928e-07
imprinting O 0 7.660823030164465e-05
. O 0 7.822038696758682e-07

Here O 0 1.4867016489006346e-06
we O 0 4.8405574659682316e-08
describe O 0 1.3546542732001399e-06
UBE3A O 0 0.003052026266232133
coding O 0 5.500318729900755e-05
- O 0 5.824655318065197e-07
region O 0 1.6145543568768517e-08
mutations O 0 1.7746307756638657e-09
detected O 0 4.5053405450801165e-09
by O 0 7.898086629154477e-10
SSCP O 0 0.00013754652172792703
analysis O 0 5.438722183725986e-08
in O 0 2.446774782782768e-09
13 O 0 1.2494765222470505e-08
AS B-Disease 0 7.204800203908235e-05
individuals O 0 5.640732769762735e-09
or O 0 4.568965650264545e-08
families O 0 6.768171800786149e-08
. O 0 1.8667925871795887e-07

Two O 0 6.578405304935586e-07
identical O 0 4.754431017772731e-07
de O 0 3.3126750622614054e-06
novo O 0 1.8376017578702886e-06
5 O 0 4.701536795437278e-07
- O 0 1.1771261370085995e-06
bp O 0 3.8708658394170925e-06
duplications O 0 2.926464503616444e-06
in O 0 9.585445326365516e-08
exon O 0 1.0303211865902995e-06
16 O 0 4.0383781652053585e-08
were O 0 3.8815819891624415e-08
found O 0 8.569426057647433e-08
. O 0 1.9368098946870305e-07

Among O 0 8.800530082453406e-08
the O 0 2.3387412895203852e-08
other O 0 7.329251650034507e-10
11 O 0 6.876745839434761e-09
unique O 0 3.0023030728187905e-09
mutations O 0 8.957167785261788e-10
, O 0 3.238951329365136e-10
8 O 0 7.687032343994815e-09
were O 0 4.430908973063197e-09
small O 0 9.701169645381924e-09
deletions O 0 3.671862103260537e-08
or O 0 2.8305249699656088e-08
insertions O 0 5.459872340907168e-07
predicted O 0 2.0581970261446259e-07
to O 0 1.3941257037686228e-08
cause O 0 6.911429295541893e-07
frameshifts O 0 3.970456964452751e-05
, O 0 1.2980560626374427e-08
1 O 0 4.276619591792041e-08
was O 0 7.435623672336078e-08
a O 0 4.67684913019184e-09
mutation O 0 1.7782893213524886e-10
to O 0 1.832608231833177e-10
a O 0 5.2694870689151685e-09
stop O 0 7.466403495470786e-09
codon O 0 5.0273101237507944e-08
, O 0 7.822421044245687e-10
1 O 0 9.09531117088136e-09
was O 0 2.5301043038439275e-08
a O 0 1.2286513140224997e-08
missense O 0 3.652896651828996e-08
mutation O 0 7.974757521012066e-10
, O 0 1.7281295838778021e-10
and O 0 2.8755681169556624e-10
1 O 0 1.969327634299134e-08
was O 0 1.26612022199879e-07
predicted O 0 6.027940457897785e-08
to O 0 2.0627857200139488e-09
cause O 0 2.64264041760498e-08
insertion O 0 1.4171101270221698e-07
of O 0 9.994623439979478e-08
an O 0 7.677056856891795e-08
isoleucine O 0 3.636645124061033e-05
in O 0 1.048686559812495e-08
the O 0 5.750365872358998e-08
hect O 0 1.337251433142228e-05
domain O 0 4.7490337351518974e-07
of O 0 3.161861528155896e-08
the O 0 6.067470792459062e-08
UBE3A O 0 0.0012644050875678658
protein O 0 7.093727560913976e-08
, O 0 3.424899530646286e-10
which O 0 1.8548931834949656e-10
functions O 0 5.871545916136256e-09
in O 0 8.531324091620718e-09
E2 O 0 9.681299388830666e-07
binding O 0 1.676144734119589e-08
and O 0 5.174785933093062e-09
ubiquitin O 0 3.522854115090013e-07
transfer O 0 9.662151114753215e-07
. O 0 1.439042193851492e-06

Eight O 0 1.2796824648830807e-06
of O 0 9.605265915979544e-08
the O 0 1.8390704070725405e-08
cases O 0 9.52462642089813e-09
were O 0 1.4192835351423128e-07
familial O 0 1.886696190922521e-05
, O 0 1.4175879137212632e-08
and O 0 4.272100895263975e-09
five O 0 3.373528656425151e-08
were O 0 8.375737792221116e-08
sporadic O 0 3.440992259129416e-06
. O 0 1.0538124115555547e-06

In O 0 1.6221065379795618e-07
two O 0 5.534712688159971e-09
familial O 0 1.6877487496458343e-06
cases O 0 6.9994157136932245e-09
and O 0 9.316716287344207e-10
one O 0 5.109398681923949e-09
sporadic O 0 1.1371974295570908e-07
case O 0 2.2658088738580773e-08
, O 0 8.871444912017523e-09
mosaicism O 0 7.87346507422626e-05
for O 0 5.908396971676666e-08
UBE3A O 1 0.7625917196273804
mutations O 0 3.574121976157585e-08
was O 0 3.492772648883147e-08
detected O 0 1.510903757662163e-08
in O 0 7.254233325149073e-10
the O 0 4.459872915418828e-09
mother O 0 5.916133005712254e-08
of O 0 6.541657171510451e-08
three O 0 3.0685587404377657e-08
AS B-Disease 1 0.9999990463256836
sons O 0 0.00480162026360631
, O 0 1.4894894206918252e-08
in O 0 3.03459692929664e-08
the O 0 4.6681446974616847e-07
maternal O 0 0.0001568830048199743
grandfather O 0 0.00039698995533399284
of O 0 1.1373279448889662e-05
two O 0 4.400078523758566e-08
AS B-Disease 1 0.9993009567260742
first O 0 2.200420681219839e-07
cousins O 0 4.1769942527025705e-07
, O 0 2.806761267848401e-09
and O 0 2.512109187335909e-09
in O 0 1.9736857481689185e-08
the O 0 3.04497547176652e-07
mother O 0 9.839398444455583e-06
of O 0 1.2685652109212242e-05
an O 0 7.3233300099673215e-06
AS B-Disease 1 1.0
daughter O 1 0.9980782270431519
. O 0 8.081665328063536e-06

The O 0 3.5766319683716574e-07
frequencies O 0 3.4413321969850585e-08
with O 0 5.684862580679351e-10
which O 0 3.5039393608826686e-10
we O 0 1.0515722737025612e-09
detected O 0 6.635071603255938e-09
mutations O 0 3.5712016677180713e-10
were O 0 2.3116606406858864e-09
5 O 0 3.1645870368635087e-09
( O 0 4.3731415710901445e-10
14 O 0 1.0749851009350664e-09
% O 0 2.8237170934808375e-10
) O 0 8.655984262695426e-11
of O 0 7.465245643878404e-10
35 O 0 2.3757420475334357e-09
in O 0 5.508328793091266e-10
sporadic O 0 1.7057971035683295e-08
cases O 0 3.8319539208409026e-10
and O 0 1.6186010864949196e-10
8 O 0 6.813061226296213e-09
( O 0 8.335393486547105e-10
80 O 0 2.3231085943820062e-09
% O 0 1.6012213777116813e-10
) O 0 4.100887684987953e-11
of O 0 4.358569061224671e-10
10 O 0 8.007496332673725e-10
in O 0 1.7744072877690087e-09
familial O 0 1.738193162736934e-07
cases O 0 2.5679960380387e-09
. O 0 6.0927844991454094e-09
. O 0 1.8675636681564356e-07

The O 0 9.327907901024446e-05
hemochromatosis B-Disease 1 0.999998927116394
845 O 0 0.00013487310206983238
G O 0 9.960374882211909e-06
- O 0 1.132676857196202e-06
- O 0 4.229376315834088e-07
> O 0 8.68251959218469e-08
A O 0 1.3212263283435277e-08
and O 0 5.5843760171647716e-11
187 O 0 8.496033876426168e-10
C O 0 8.889297298253496e-09
- O 0 8.027992492998237e-09
- O 0 4.383693763543306e-08
> O 0 7.397628110084042e-08
G O 0 5.503860833755425e-08
mutations O 0 4.728853975066727e-10
: O 0 1.3772148699242592e-10
prevalence O 0 3.027859518667242e-09
in O 0 4.299138822716486e-10
non O 0 1.2707931773547898e-07
- O 0 6.127517053755582e-07
Caucasian O 0 4.2858328015427105e-06
populations O 0 2.6634483063503467e-08
. O 0 3.283704330669934e-08

Hemochromatosis B-Disease 1 1.0
, O 0 1.286527663069137e-06
the O 0 0.00014553123037330806
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 1.1309720804320023e-07
leads O 0 1.32230837834868e-07
, O 0 2.2816457612151453e-09
if O 0 9.155272095995315e-09
untreated O 0 0.0027850004844367504
, O 0 1.007300820532464e-08
to O 0 1.0572909303618871e-07
progressive O 1 0.9999803304672241
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 9.346908314000757e-07
premature B-Disease 0 0.00015789207827765495
death I-Disease 0 1.130358850787161e-05
. O 0 1.106560034713766e-06

The O 0 0.001325094373896718
hemochromatosis B-Disease 1 1.0
gene O 0 0.004864309448748827
, O 0 5.32924673279922e-07
HFE O 1 0.9999995231628418
, O 0 1.1435090208067322e-08
recently O 0 7.922547951011438e-09
has O 0 6.532983182205854e-11
been O 0 3.106497836746769e-10
identified O 0 1.7922374695444887e-09
, O 0 1.609402749958022e-10
and O 0 2.418424904782057e-10
characterization O 0 1.0848751941239243e-07
of O 0 3.755276267725094e-08
this O 0 3.5649152518857363e-09
gene O 0 3.796932102062556e-09
has O 0 3.654424332588668e-11
shown O 0 1.367409796504404e-10
that O 0 6.5788203877648055e-12
it O 0 4.999302187502774e-12
contains O 0 2.5534777417512977e-11
two O 0 2.461827096345015e-11
mutations O 0 1.3461735198783131e-11
that O 0 3.620137392981726e-12
result O 0 1.3595896630747006e-10
in O 0 2.862642345391464e-10
amino O 0 3.537712345291766e-09
acid O 0 1.7058970902539272e-09
substitutions O 0 3.602152132131664e-09
- O 0 3.426529815442336e-08
cDNA O 0 1.1658985243911957e-07
nucleotides O 0 9.346017293410114e-09
845 O 0 2.5840446227221037e-08
G O 0 2.0968661473830252e-08
- O 0 1.379819281055461e-08
- O 0 5.241703249225793e-08
> O 0 3.6934050484660474e-08
A O 0 3.4147468852552265e-08
( O 0 1.0664893412837273e-09
C282Y O 0 3.400240444761948e-08
) O 0 2.2361142104632137e-10
and O 0 1.0524325161354042e-10
187 O 0 2.4832209621905577e-09
C O 0 1.985765329948208e-08
- O 0 2.866196524564657e-08
- O 0 2.0945202550137765e-07
> O 0 6.259076030801225e-07
G O 0 1.995600996451685e-06
( O 0 1.1244268449672745e-07
H63D O 0 8.728648390388116e-05
) O 0 1.1119948339910479e-07
. O 0 1.1319172443791103e-07

Although O 0 0.0015012465883046389
hemochromatosis B-Disease 1 1.0
is O 0 6.75970852626051e-08
common O 0 8.580330224106092e-09
in O 0 4.343831516706587e-09
Caucasians O 0 8.62346780650114e-08
, O 0 8.517793137485796e-10
affecting O 0 5.185872176127759e-09
> O 0 1.148580253129694e-08
= O 0 1.096463897454214e-08
1 O 0 5.8480749132172605e-09
/ O 0 7.49728457094534e-09
300 O 0 5.581631823403654e-10
individuals O 0 3.900582981608558e-11
of O 0 3.0320188026955464e-10
northern O 0 3.297748185637772e-10
European O 0 7.225813836164718e-10
origin O 0 1.195414101040626e-09
, O 0 8.470932982840296e-11
it O 0 3.442035892420314e-11
has O 0 1.026242198859384e-11
not O 0 2.2001858668296848e-11
been O 0 1.5539651510021457e-10
recognized O 0 2.1718102316548027e-10
in O 0 3.483920096858384e-10
other O 0 2.68618433052481e-10
populations O 0 5.612443843006076e-09
. O 0 4.25977582096948e-08

The O 0 2.737658633122919e-07
present O 0 2.3118733594174046e-08
study O 0 9.079590412852667e-09
used O 0 3.614237131799314e-09
PCR O 0 2.140275512374501e-08
and O 0 2.764283524303579e-10
restriction O 0 1.8485341257701293e-08
- O 0 1.4438168882691116e-08
enzyme O 0 4.703292422192362e-09
digestion O 0 8.13099543250928e-09
to O 0 2.358133965874032e-10
analyze O 0 6.6282033195363965e-09
the O 0 4.167338918392716e-09
frequency O 0 1.1044777536994843e-08
of O 0 5.387724932859328e-09
the O 0 2.3420076988855953e-09
845 O 0 2.165326762337827e-08
G O 0 1.9682499186046698e-08
- O 0 1.641647884298436e-08
- O 0 1.6013206760590037e-08
> O 0 9.864058014841248e-09
A O 0 1.7284568221143104e-09
and O 0 2.3621124153883066e-11
187 O 0 4.114286966672154e-10
C O 0 2.2381292374973327e-09
- O 0 3.1172959769065756e-09
- O 0 2.529202092205196e-08
> O 0 7.618955777388692e-08
G O 0 8.402539464213987e-08
mutations O 0 1.555448769785528e-09
in O 0 3.2653841852692267e-09
HLA O 0 1.7593349355138344e-07
- O 0 6.4498864027484615e-09
typed O 0 2.723190206666004e-08
samples O 0 1.4581212903763685e-09
from O 0 1.7895662729472406e-09
non O 0 7.27835498537388e-08
- O 0 1.1871536287344497e-07
Caucasian O 0 2.3400069437684579e-07
populations O 0 3.441066043219365e-10
, O 0 9.186626459545266e-11
comprising O 0 3.2551488171606024e-09
Australian O 0 2.0601569872269465e-07
Aboriginal O 0 1.0697780226109899e-06
, O 0 1.8056671713395644e-09
Chinese O 0 2.577841939910286e-08
, O 0 2.6263119456970685e-10
and O 0 8.029336640014151e-10
Pacific O 0 4.342210502272792e-07
Islanders O 0 9.232060733666003e-07
. O 0 4.0148088942260074e-07

Results O 0 1.4704729665027116e-06
showed O 0 1.1838951508025275e-07
that O 0 1.4500062262001734e-09
the O 0 1.2755474898540342e-08
845 O 0 2.9739058504674176e-07
G O 0 5.37193500349531e-07
- O 0 6.690838745271321e-07
- O 0 1.178273919322237e-06
> O 0 3.85975965855323e-07
A O 0 1.377846903238833e-08
mutation O 0 3.740068532653851e-10
was O 0 6.258002449577305e-10
present O 0 1.8587499595046353e-10
in O 0 7.908559224167888e-11
these O 0 5.805149069781912e-11
populations O 0 1.4412457338686124e-10
( O 0 1.1348881556738633e-10
allele O 0 8.370806825475086e-11
frequency O 0 1.3367074114256638e-10
0 O 0 1.6865165514134972e-11
. O 0 3.05894524120498e-12
32 O 0 9.118369254101921e-11
% O 0 2.8757695877401623e-11
) O 0 2.122875486509912e-11
, O 0 1.045026998963694e-11
and O 0 2.1490793519762796e-11
, O 0 9.80088579738414e-11
furthermore O 0 2.1658459470330627e-09
, O 0 8.459114658743161e-11
it O 0 4.6454437518939073e-11
was O 0 1.1184351222937039e-08
always O 0 7.221201858698123e-09
seen O 0 5.418290704994888e-09
in O 0 1.8421028036286202e-09
conjunction O 0 1.8833652859484573e-08
with O 0 1.3496359585474238e-08
HLA O 0 0.007974102161824703
haplotypes O 0 9.588843568053562e-07
common O 0 2.7902358201714605e-09
in O 0 3.799221381939333e-09
Caucasians O 0 4.705645650915358e-08
, O 0 1.0020078100581031e-09
suggesting O 0 1.0174557196762635e-08
that O 0 6.396760343641006e-10
845 O 0 4.65487879353077e-08
G O 0 1.5034144951187045e-07
- O 0 3.995862698502606e-07
- O 0 1.5459013411600608e-06
> O 0 3.701508717313118e-07
A O 0 1.8222650055577105e-08
may O 0 1.2289734507842098e-10
have O 0 5.2141715424502966e-12
been O 0 2.6855014739757266e-11
introduced O 0 7.395355161587958e-12
into O 0 1.9870200970717455e-11
these O 0 2.6588151819106898e-11
populations O 0 1.179237402171296e-10
by O 0 1.1753600315245194e-09
Caucasian O 0 1.8174040405938285e-06
admixture O 0 2.7713531380868517e-06
. O 0 3.7077126080475864e-07

187 O 0 1.0912311836364097e-06
C O 0 7.85836903105519e-07
- O 0 3.2975319186334673e-07
- O 0 4.5773350620947895e-07
> O 0 2.744057212566986e-07
G O 0 7.219716735562542e-08
was O 0 1.0683405271549873e-08
present O 0 1.838115659680284e-09
at O 0 7.642209531866229e-09
an O 0 6.047558009925069e-10
allele O 0 1.3754462013793045e-09
frequency O 0 7.517330757877971e-09
of O 0 2.0780257514729783e-08
2 O 0 5.560671638704662e-07
. O 0 3.6893990795761056e-07

68 O 0 1.1863338841067161e-05
% O 0 5.0965340392394864e-08
in O 0 1.896362622488823e-09
the O 0 7.789933142987593e-10
two O 0 2.0169267644920552e-10
populations O 0 7.515889299813949e-11
analyzed O 0 1.7105628025149144e-09
( O 0 1.7790703354947368e-09
Australian O 0 1.6031168570407317e-07
Aboriginal O 0 4.7382488332914363e-07
and O 0 2.275361676851162e-09
Chinese O 0 2.954586761916289e-07
) O 0 1.143953998195002e-08
. O 0 1.488438616803478e-08

In O 0 2.3490422051963833e-07
the O 0 5.3612183137374814e-08
Australian O 0 2.3687442762820865e-07
Aboriginal O 0 1.403035980729328e-07
samples O 0 1.803147853252085e-09
, O 0 3.2741701017080516e-10
187 O 0 2.3818402805630967e-09
C O 0 1.3136828513893306e-08
- O 0 1.4126242398049271e-08
- O 0 7.914153599131168e-08
> O 0 1.0235465452979042e-07
G O 0 3.383406976809056e-08
was O 0 3.692712802205733e-09
found O 0 1.2868531240606274e-10
to O 0 5.647315601264857e-11
be O 0 4.0469952389265984e-10
associated O 0 1.6591371831964352e-08
with O 0 5.353432186439022e-08
HLA O 1 0.9977637529373169
haplotypes O 0 3.577229563234141e-06
common O 0 5.97694604920207e-09
in O 0 6.561724053000262e-09
Caucasians O 0 2.3770743950990436e-07
, O 0 7.203974639047317e-10
suggesting O 0 6.695725751626469e-09
that O 0 9.372533998908139e-11
it O 0 1.4016537930316986e-10
was O 0 3.367361944839331e-09
introduced O 0 7.199784657352382e-10
by O 0 1.1965638480049279e-09
recent O 0 1.1747734340872285e-08
admixture O 0 5.149377102497965e-07
. O 0 9.735521189213614e-08

In O 0 3.4644426705199294e-07
the O 0 6.27800957886393e-08
Chinese O 0 2.999832204864106e-08
samples O 0 7.356842912642492e-10
analyzed O 0 1.908740276945764e-09
, O 0 1.465266102895768e-10
187 O 0 9.256086452857915e-10
C O 0 6.784118600222655e-09
- O 0 5.1511324095088185e-09
- O 0 4.3634809543391384e-08
> O 0 8.36963707229188e-08
G O 0 4.484150295525069e-08
was O 0 6.468761082345509e-09
present O 0 9.879945750412844e-10
in O 0 4.1965947383815205e-10
association O 0 5.242317691056542e-10
with O 0 3.5616086468959196e-11
a O 0 7.498538456829351e-10
wide O 0 1.1386245279965124e-09
variety O 0 1.9924186744901817e-09
of O 0 4.497577208439907e-07
HLA O 0 0.0003150344709865749
haplotypes O 0 2.756245294222026e-07
, O 0 3.081634947221801e-10
showing O 0 4.073948733918087e-09
this O 0 7.496819137697841e-11
mutation O 0 2.0277956397363184e-11
to O 0 1.4511418976181911e-11
be O 0 1.3903003748261256e-10
widespread O 0 7.545323810198568e-10
and O 0 2.6527480212479304e-10
likely O 0 1.5204140169089442e-09
to O 0 7.397196744030055e-10
predate O 0 1.0249902260284216e-07
the O 0 1.2389107517662978e-09
more O 0 5.312999692974607e-11
genetically O 0 1.7683721154071463e-10
restricted O 0 7.567331761215712e-10
845 O 0 2.0526449873159436e-08
G O 0 3.372151979874616e-08
- O 0 5.64161801719365e-08
- O 0 1.786060579433979e-07
> O 0 2.012961175523742e-07
A O 0 7.092929621421717e-08
mutation O 0 1.6595393503848754e-08
. O 0 1.3505244034206498e-08

Genotype O 0 0.00014996490790508687
- O 0 9.387364116264507e-06
phenotype O 0 9.154679219136597e-07
correlations O 0 1.7383584918206907e-06
in O 0 3.141058186884038e-07
attenuated B-Disease 0 0.030591821298003197
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999991655349731
. O 0 5.5345221880998e-06

Germ O 1 0.999984622001648
- O 0 8.626273483969271e-05
line O 0 1.187872044283722e-06
mutations O 0 1.779719482897235e-08
of O 0 9.915574139540695e-09
the O 0 7.550239899956068e-08
tumor B-Disease 0 0.0001035749155562371
suppressor O 0 1.1183389688085299e-05
APC O 0 1.3626109307551815e-07
are O 0 1.5445625334287172e-10
implicated O 0 6.820371112326029e-08
in O 0 1.4987834617841145e-07
attenuated B-Disease 0 0.3913175165653229
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999724626541138
AAPC B-Disease 1 1.0
) O 0 1.4762380828869937e-07
, O 0 2.2546249311972133e-09
a O 0 3.198315212671332e-08
variant O 0 1.2430616607161937e-06
of O 0 0.014221281744539738
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 1.0
FAP B-Disease 1 0.9994328618049622
) O 0 2.3258332930709003e-06
. O 0 9.576488082529977e-07

AAPC B-Disease 1 1.0
is O 0 1.0624722079910498e-07
recognized O 0 8.82362005683035e-09
by O 0 4.930886254861377e-10
the O 0 2.115383868073195e-09
occurrence O 0 9.459832028824167e-08
of O 0 1.033522067928061e-07
< O 0 2.079179284919519e-05
100 O 0 8.340616091118136e-07
colonic B-Disease 0 0.00047420943155884743
adenomas I-Disease 0 1.1833090866275597e-05
and O 0 9.57651957733674e-10
a O 0 2.729460213402035e-09
later O 0 1.410080407993064e-08
onset O 0 0.0015031391521915793
of O 1 0.9740923047065735
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.1219359294045717e-05
age O 0 5.7971633395936806e-06
> O 0 6.717231144648395e-07
40 O 0 2.295685597175634e-08
years O 0 1.0884624757068195e-08
) O 0 1.140616134875927e-08
. O 0 2.9639894094657393e-08

The O 0 5.8720632978293e-07
aim O 0 2.2189396986505017e-07
of O 0 8.743556101364902e-09
this O 0 6.710655919839326e-10
study O 0 1.3513404839571308e-09
was O 0 5.305268668820418e-09
to O 0 6.895208848334278e-10
assess O 0 1.1652605280687567e-07
genotype O 0 1.1828901733679231e-06
- O 0 2.0094159935979405e-06
phenotype O 0 7.559043524452136e-07
correlations O 0 3.6775506941921776e-06
in O 0 1.128765802604903e-06
AAPC B-Disease 1 1.0
families O 0 8.403258675571124e-07
. O 0 5.894945047657529e-07

By O 0 2.7123752488478203e-07
protein O 0 3.8555143078156107e-07
- O 0 8.845664467571623e-08
truncation O 0 7.306841212084692e-07
test O 0 6.543542241388423e-08
( O 0 1.6859907248090167e-07
PTT O 0 1.2325979696470313e-05
) O 0 1.9965957775980314e-09
assay O 0 8.269236850821926e-09
, O 0 9.657258326356555e-11
the O 0 5.131223779208938e-10
entire O 0 2.9041002491680956e-08
coding O 0 1.1037389668899777e-07
region O 0 5.8077467279815664e-09
of O 0 4.291180033533237e-08
the O 0 1.8906902710114082e-07
APC B-Disease 0 2.340554374313797e-06
gene O 0 4.079344861906975e-09
was O 0 1.0058340826901713e-08
screened O 0 2.9563205217186805e-09
in O 0 1.4209059484571185e-09
affected O 0 1.5741681291814302e-09
individuals O 0 5.699954397364593e-10
from O 0 3.682726656961677e-08
11 O 0 4.828933742828667e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.010976792313158512
, O 0 5.159411564648053e-09
and O 0 6.914410710656682e-10
their O 0 1.6538443947666792e-09
phenotypic O 0 8.092813175153424e-08
differences O 0 6.029101484728017e-08
were O 0 1.7253886142043484e-07
examined O 0 5.2422510634642094e-06
. O 0 9.147191804004251e-07

Five O 0 1.1873194125655573e-06
novel O 0 2.702452093217289e-06
germ O 1 0.7850947380065918
- O 0 0.00033451063791289926
line O 0 4.645247827284038e-06
APC B-Disease 0 1.621951696506585e-06
mutations O 0 3.571230644539014e-09
were O 0 4.481600424099952e-09
identified O 0 3.4527062098277383e-08
in O 0 1.9850761034945208e-08
seven O 0 5.797677431473858e-07
kindreds O 0 5.9355465054977685e-05
. O 0 2.2207950678421184e-06

Mutations O 0 1.1365592627043952e-06
were O 0 1.1219760409630908e-07
located O 0 5.018352311481067e-08
in O 0 8.147632568622498e-10
three O 0 2.444786317834513e-10
different O 0 1.3667006415474248e-10
regions O 0 1.45998291234406e-09
of O 0 4.7071001318954586e-08
the O 0 3.486443631572911e-07
APC B-Disease 0 1.2485495517466916e-06
gene O 0 3.999680142641182e-09
( O 0 8.601250822692919e-10
1 O 0 3.33582095279894e-09
) O 0 1.287551065765058e-09
at O 0 8.378354898752605e-09
the O 0 1.270865457314585e-08
5 O 0 1.877440070074954e-08
end O 0 9.00330192621368e-08
spanning O 0 5.866577907909232e-07
exons O 0 4.472669701272025e-08
4 O 0 6.688705589397159e-09
and O 0 1.9800673600745e-10
5 O 0 2.4692927702574252e-09
, O 0 3.459815767214991e-10
( O 0 1.0157430452295557e-09
2 O 0 4.5792143410494646e-09
) O 0 6.43057329607899e-10
within O 0 1.3593906000863853e-09
exon O 0 8.423283404113135e-09
9 O 0 2.909909868620275e-09
, O 0 1.6054997609149524e-10
and O 0 2.2912824415577404e-10
( O 0 1.4548459104091194e-09
3 O 0 3.315497210110152e-09
) O 0 7.949031988196964e-10
at O 0 6.1084701741265235e-09
the O 0 4.750444482226612e-09
3 O 0 2.315589142654062e-08
distal O 0 8.293312703244737e-08
end O 0 2.473380789069779e-08
of O 0 4.655029783862119e-08
the O 0 1.5697202115916298e-07
gene O 0 2.568679065007018e-07
. O 0 9.518581833845019e-08

Variability O 0 0.00011569361231522635
in O 0 2.443753821523842e-08
the O 0 4.808587306115442e-09
number O 0 7.123458711788544e-09
of O 0 2.1882524379179813e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 4.7657278628321365e-05
most O 0 1.0321461463291826e-09
apparent O 0 7.743214958111366e-09
in O 0 2.319193725952573e-10
individuals O 0 4.4503171980903033e-11
with O 0 3.633233644495526e-11
mutations O 0 5.092836707909498e-10
in O 0 7.858610984179393e-10
region O 0 2.285828593073802e-08
1 O 0 8.954202712629922e-08
, O 0 1.1984436776302232e-09
and O 0 1.189877307794518e-09
upper O 1 0.9652162194252014
- O 1 0.9293787479400635
gastrointestinal O 0 0.0002203891781391576
manifestations O 0 3.402776928851381e-05
were O 0 4.147034360357793e-08
more O 0 5.255171853235652e-10
severe O 0 2.7445796746405904e-08
in O 0 6.5059184706228734e-09
them O 0 1.701738305825984e-08
. O 0 1.3967212453280808e-07

In O 0 1.3372013540902117e-07
individuals O 0 5.574654959872305e-09
with O 0 4.4583395308883667e-10
mutations O 0 2.1667962979421418e-09
in O 0 1.2873595522933101e-09
either O 0 3.902365541819108e-09
region O 0 4.684672560983927e-08
2 O 0 6.739599456295764e-08
or O 0 8.540132157008884e-09
region O 0 5.592140972510151e-09
3 O 0 6.188354273461982e-09
, O 0 1.2365400370306645e-10
the O 0 4.210039539209731e-10
average O 0 2.452147818132744e-09
number O 0 1.9232036796434926e-10
of O 0 7.343247787616747e-09
adenomas B-Disease 0 3.0977050755609525e-06
tended O 0 5.940066660770071e-09
to O 0 2.1176191355998242e-10
be O 0 6.317606993100355e-10
lower O 0 6.241769767711958e-09
than O 0 1.1323519205630461e-10
those O 0 4.0751877566913564e-11
in O 0 7.542284158335022e-11
individuals O 0 4.7658862967203675e-11
with O 0 6.569769728237418e-11
mutations O 0 2.2373428110178395e-10
in O 0 2.4504540063752245e-10
region O 0 3.5398184383694797e-09
1 O 0 4.535292585927664e-09
, O 0 2.6202329195257335e-10
although O 0 4.241149653694265e-10
age O 0 2.1644183334501577e-08
at O 0 1.6038049466260418e-07
diagnosis O 0 7.360042104664899e-07
was O 0 1.0948258477583295e-07
similar O 0 2.72734865802704e-08
. O 0 1.7277201891374716e-07

In O 0 3.000798869834398e-06
all O 0 1.4727198731634417e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.0025950514245778322
, O 0 2.0673912359825408e-08
a O 0 1.9628624059464528e-08
predominance O 0 1.061770831256581e-06
of O 0 1.6016757626857725e-06
right O 0 0.0012333561899140477
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.001078786444850266
rectal B-Disease 1 1.0
polyp I-Disease 0 0.18251270055770874
sparing O 0 8.162335689121392e-06
was O 0 1.6709534520487068e-06
observed O 0 9.038381563186704e-07
. O 0 4.981721986041521e-07

No O 0 0.00029340109904296696
desmoid B-Disease 1 0.9999990463256836
tumors I-Disease 1 1.0
were O 0 3.788123876802274e-07
found O 0 2.413708344306542e-08
in O 0 8.081240565616099e-09
these O 0 1.7395770157691004e-08
kindreds O 0 3.3717475162120536e-05
. O 0 1.5350724424934015e-06

Our O 0 2.2255526346270926e-06
data O 0 5.328769248080789e-07
suggest O 0 5.429404126289228e-08
that O 0 1.7354866432839344e-09
, O 0 3.5319547286860598e-09
in O 0 5.110171130695562e-08
AAPC B-Disease 1 1.0
families O 0 1.6119420465088297e-08
, O 0 4.18413415026464e-10
the O 0 1.9485524305196122e-09
location O 0 1.0773547387543658e-07
of O 0 3.6137492998022935e-08
the O 0 1.847893003059653e-07
APC B-Disease 0 8.86978887137957e-06
mutation O 0 1.0519880966342043e-08
may O 0 3.900400891154732e-09
partially O 0 1.303681500530729e-07
predict O 0 1.5568058842063692e-08
specific O 0 4.916989038150632e-09
phenotypic O 0 4.643448505703418e-07
expression O 0 3.755530997295864e-07
. O 0 1.716846895760682e-07

This O 0 8.842948773235548e-08
should O 0 5.6615356847089515e-09
help O 0 7.861193473956973e-09
in O 0 1.7590682244161826e-09
the O 0 2.7722419915221508e-09
design O 0 3.6678653003718864e-08
of O 0 1.0639684688840134e-08
tailored O 0 2.2533365395815963e-08
clinical O 0 5.390006208472187e-06
- O 0 1.2723638747047517e-06
management O 0 1.607765085509527e-07
protocols O 0 3.3911472741010584e-08
in O 0 7.805133206417736e-10
this O 0 9.288185776057389e-10
subset O 0 6.904375027261267e-08
of O 0 3.608452914249938e-08
FAP B-Disease 0 1.361082581752271e-06
patients O 0 1.1379434283753653e-08
. O 0 8.697930375944907e-09
. O 0 8.258034256414248e-08

Wilms B-Disease 1 0.9999974966049194
' I-Disease 0 9.123019844992086e-05
tumor I-Disease 0 4.817187073058449e-05
1 O 0 1.514463292551227e-07
and O 0 1.0781314507823936e-08
Dax O 0 0.0001728043716866523
- O 0 2.018900033817772e-07
1 O 0 3.726514208324261e-08
modulate O 0 8.1488373382399e-08
the O 0 5.5544893129422235e-09
orphan O 0 1.2794978943020396e-07
nuclear O 0 1.024985863296024e-06
receptor O 0 1.3504569551514578e-06
SF O 0 2.8367834602249786e-05
- O 0 2.838044821373842e-08
1 O 0 3.640389101278174e-09
in O 0 3.6860681174033516e-10
sex O 0 1.5016805576806291e-09
- O 0 2.5658957181207143e-09
specific O 0 9.927718647162465e-10
gene O 0 1.2292514561806911e-08
expression O 0 2.092563100575262e-08
. O 0 3.056478803387108e-08

Products O 0 3.3738488127710298e-06
of O 0 4.453063866094453e-06
steroidogenic O 0 0.00035762545303441584
factor O 0 2.3349944058281835e-06
1 O 0 1.6066860553110018e-07
( O 0 4.0965161929307214e-08
SF O 0 3.5928533179685473e-05
- O 0 1.255680359690814e-07
1 O 0 3.7634286798038374e-08
) O 0 1.914716607487321e-09
and O 0 1.4264264214247646e-09
Wilms B-Disease 0 0.002062856685370207
tumor I-Disease 0 6.961088274692884e-06
1 O 0 9.267348133334963e-08
( O 0 1.498319690540484e-08
WT1 O 0 2.8837384888902307e-06
) O 0 4.4745085414632513e-10
genes O 0 1.619910594552465e-10
are O 0 9.28672416744547e-12
essential O 0 1.732324950154407e-09
for O 0 1.5528281993582027e-09
mammalian O 0 3.5598964132077526e-07
gonadogenesis O 0 2.282941068187938e-06
prior O 0 1.21070897307618e-07
to O 0 8.701182885317849e-09
sexual O 0 3.9240657656591793e-07
differentiation O 0 3.319161123727099e-06
. O 0 2.8782989147657645e-07

In O 0 3.307420968212682e-07
males O 0 5.813556569478351e-08
, O 0 2.570084944863993e-08
SF O 1 0.9724676609039307
- O 0 1.3934431990492158e-06
1 O 0 2.8266567753121308e-08
participates O 0 2.4298556500212953e-09
in O 0 6.316856759891465e-11
sexual O 0 1.8689848280128984e-10
development O 0 3.4205710486290286e-10
by O 0 8.699348880147895e-11
regulating O 0 3.5330596226401667e-09
expression O 0 3.377574886442858e-10
of O 0 1.0492422486407804e-09
the O 0 7.1915260413391024e-09
polypeptide O 0 2.102175585605437e-06
hormone O 0 1.552246260416723e-07
Mullerian O 0 3.2823558285599574e-05
inhibiting O 0 6.507770535790769e-07
substance O 0 2.1983798603741889e-07
( O 0 2.688699112241011e-07
MIS O 0 0.00027743043028749526
) O 0 5.4285965944700365e-08
. O 0 1.2309470776017406e-07

Here O 0 2.309690898982808e-06
, O 0 1.920166958768732e-08
we O 0 1.4439050843861878e-08
show O 0 6.331413260340923e-08
that O 0 3.738011145060227e-08
WT1 O 0 0.0011081198463216424
- O 0 0.0002604949695523828
KTS O 1 0.8842248916625977
isoforms O 0 6.636681604277328e-08
associate O 0 7.489312281450111e-08
and O 0 6.439557220794256e-10
synergize O 0 3.4861275821640447e-07
with O 0 2.956090838779346e-08
SF O 1 0.9066122174263
- O 0 1.0118676527781645e-06
1 O 0 6.548885522761339e-08
to O 0 6.3910081671281205e-09
promote O 0 2.0155871993665642e-07
MIS O 0 0.002317124977707863
expression O 0 2.440596347241808e-07
. O 0 8.86608688688284e-08

In O 0 5.886114422537503e-07
contrast O 0 5.110512688588642e-07
, O 0 1.8323204642456403e-07
WT1 O 0 0.0018230981659144163
missense O 0 6.893406407471048e-06
mutations O 0 3.089341760187381e-08
, O 0 1.279228167838653e-09
associated O 0 1.9056020761354375e-08
with O 0 1.2573849517139024e-08
male B-Disease 0 0.0003737010119948536
pseudohermaphroditism I-Disease 1 1.0
in O 0 8.661116225994192e-06
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.458852925244173e-08
fail O 0 6.592712793462852e-07
to O 0 8.569622167442503e-08
synergize O 0 6.448647036449984e-05
with O 0 1.1246622761973413e-06
SF O 1 0.9999998807907104
- O 0 0.0001644242147449404
1 O 0 2.4028233838180313e-06
. O 0 1.576005104197975e-07

Additionally O 0 2.8834469958383124e-06
, O 0 8.93631835197084e-09
the O 0 1.6513769907078313e-08
X O 0 1.9981928289780626e-06
- O 0 7.189937605289742e-07
linked O 0 5.307093715600786e-07
, O 0 1.0835939923126148e-09
candidate O 0 2.4389517072620492e-09
dosage O 0 3.6741177211752074e-08
- O 0 9.32354993210538e-08
sensitive O 0 7.710118410386713e-08
sex O 0 8.994320843669357e-09
- O 0 1.839498509070836e-08
reversal O 0 4.296749622767493e-08
gene O 0 1.682887051934756e-09
, O 0 6.064607704914238e-10
Dax O 0 4.806673587154364e-06
- O 0 5.92579993963227e-08
1 O 0 2.3185856790064463e-08
, O 0 3.327534248143138e-09
antagonizes O 0 5.257613793219207e-07
synergy O 0 1.9376541615656606e-07
between O 0 1.050392484103213e-07
SF O 0 0.0001158428713097237
- O 0 1.563660134706879e-07
1 O 0 1.5305927192343916e-08
and O 0 1.1906038377418326e-09
WT1 O 0 5.962958766758675e-06
, O 0 4.5701289974608983e-10
most O 0 5.6801990194754737e-11
likely O 0 7.348508607174509e-11
through O 0 1.281366818206564e-10
a O 0 1.5191965463401402e-09
direct O 0 1.6239858346978053e-09
interaction O 0 7.603564000646656e-09
with O 0 2.651677100118377e-09
SF O 0 0.2539016604423523
- O 0 1.01308887678897e-05
1 O 0 1.4999174027252593e-06
. O 0 2.586370158041973e-07

We O 0 5.470812993735308e-07
propose O 0 6.981711635489773e-07
that O 0 3.655057412288443e-08
WT1 O 0 3.624333839979954e-05
and O 0 1.204830084589048e-07
Dax O 0 0.04422556981444359
- O 0 1.186375357065117e-06
1 O 0 7.840771587552808e-08
functionally O 0 9.697584602008646e-08
oppose O 0 7.238380450580451e-10
each O 0 7.95585403112753e-11
other O 0 2.6201315422857974e-11
in O 0 5.546567649616918e-10
testis O 0 1.6978290773295157e-07
development O 0 6.964565368861031e-09
by O 0 3.594054165390048e-09
modulating O 0 1.4353455526361358e-06
SF O 0 0.0005671337712556124
- O 0 3.4022457384708105e-07
1 O 0 1.3633204787311115e-07
- O 0 1.902345161397534e-07
mediated O 0 4.5217126398711116e-07
transactivation O 0 5.334775778464973e-06
. O 0 7.27404980693791e-09
. O 0 5.157309246328623e-08

A O 0 1.0396613106422592e-05
mouse O 0 1.0375675856266753e-06
model O 0 1.4922527213911962e-07
for O 0 1.71934388504269e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999812841415405
- O 0 0.23827210068702698
centre O 0 4.8727684770710766e-05
mutations O 0 3.558606636033801e-07
. O 0 1.601468113676674e-07

Imprinting O 0 0.00026692921528592706
in O 0 2.2713719260991638e-07
the O 0 2.4508403839718085e-07
15q11 O 0 2.1793330233776942e-05
- O 0 4.825531959795626e-06
q13 O 0 6.226603090908611e-06
region O 0 3.991131691805094e-08
involves O 0 6.867364277240995e-08
an O 0 5.1798916267387085e-09
imprinting O 0 3.1397047450809623e-07
centre O 0 2.5570011530362535e-07
( O 0 1.8749673813545087e-08
IC O 0 1.3535941434383858e-06
) O 0 1.5308898593247022e-09
, O 0 2.736746385068045e-10
mapping O 0 3.130847403554071e-08
in O 0 9.249415677814454e-10
part O 0 4.806175457616746e-09
to O 0 3.0635158854153133e-09
the O 0 9.288955737929427e-08
promoter O 0 5.07086633660947e-06
and O 0 1.2493859280482411e-08
first O 0 8.398549766752694e-08
exon O 0 1.7859853187474073e-06
of O 0 8.329836873599561e-07
SNRPN O 0 0.011671978048980236
. O 0 1.768895458553743e-06

Deletion O 0 4.352450559963472e-05
of O 0 6.16904230810178e-07
this O 0 6.9244997291662e-08
IC O 0 3.0211691409931518e-05
abolishes O 0 4.2961309532074665e-07
local O 0 1.6441108030562646e-08
paternally O 0 4.7055740992618666e-07
derived O 0 2.0793104127392326e-08
gene O 0 1.6308644434914754e-09
expression O 0 3.8191849682789325e-10
and O 0 7.425719761311456e-11
results O 0 4.146526233483883e-09
in O 0 4.882078030732373e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9997598528862
PWS B-Disease 1 1.0
) O 0 5.356279416446341e-06
. O 0 6.649072474829154e-07

We O 0 8.090466963039944e-08
have O 0 1.391893156288404e-09
created O 0 3.1982401171859465e-09
two O 0 4.718546664506107e-10
deletion O 0 2.7529265977932482e-08
mutations O 0 1.2109618863220817e-09
in O 0 2.607471127902272e-09
mice O 0 2.174772006924286e-08
to O 0 5.875713249281489e-09
understand O 0 6.510337698273361e-05
PWS B-Disease 1 1.0
and O 0 4.3307135655368256e-08
the O 0 4.968521949422211e-08
mechanism O 0 4.418446337695059e-07
of O 0 5.4683148675849225e-08
this O 0 8.077144997287178e-08
IC O 0 5.5110820539994165e-05
. O 0 8.0840322880249e-07

Mice O 0 0.02483508549630642
harbouring O 0 0.004730988759547472
an O 0 6.699662549181085e-07
intragenic O 0 0.0001597011723788455
deletion O 0 1.106347917811945e-05
in O 0 1.3502956619504403e-07
Snrpn O 0 0.009894979186356068
are O 0 1.0428621521896275e-08
phenotypically O 0 8.108895599434618e-06
normal O 0 4.225368854804401e-07
, O 0 1.6195098595517265e-09
suggesting O 0 9.773378550903544e-09
that O 0 1.7731614787575012e-10
mutations O 0 6.361305926461114e-10
of O 0 1.2380445113535643e-08
SNRPN O 0 0.04035284370183945
are O 0 3.889226163344972e-10
not O 0 4.622130733711316e-10
sufficient O 0 9.245032828175681e-08
to O 0 1.9161650754995208e-07
induce O 0 0.0006203161319717765
PWS B-Disease 1 1.0
. O 0 1.5248110685206484e-05

Mice O 0 1.6961288565653376e-05
with O 0 4.0305736526136116e-09
a O 0 9.697933123220537e-09
larger O 0 4.141309517535774e-09
deletion O 0 3.43818307158017e-08
involving O 0 3.4841693974385635e-08
both O 0 5.409121150989904e-09
Snrpn O 0 4.9125861551146954e-05
and O 0 9.670096723368715e-09
the O 0 7.531441781338799e-08
putative O 0 9.517729631625116e-05
PWS O 1 1.0
- O 0 0.001492868410423398
IC O 0 0.0003504686465021223
lack O 0 1.3271851173612959e-07
expression O 0 1.585450526420118e-08
of O 0 6.4888787676409265e-09
the O 0 2.5348379395495613e-08
imprinted O 0 1.5138655271584867e-06
genes O 0 2.015748776784676e-07
Zfp127 O 0 8.38316700537689e-05
( O 0 2.4872974790923763e-07
mouse O 0 2.6956209353556915e-07
homologue O 0 5.622046046482865e-07
of O 0 8.800110151696572e-08
ZNF127 O 0 0.00040010843076743186
) O 0 5.768909261405497e-08
, O 0 2.1021039131596808e-08
Ndn O 0 0.0001024015509756282
and O 0 1.559507367687729e-08
Ipw O 0 5.024576967116445e-05
, O 0 4.040148215977979e-09
and O 0 2.3037376450929514e-09
manifest O 0 4.894632752439065e-07
several O 0 5.308054795705175e-08
phenotypes O 0 4.339517545304261e-06
common O 0 3.1840846759223496e-07
to O 0 2.796684839267982e-06
PWS B-Disease 1 1.0
infants O 1 0.9997151494026184
. O 0 2.1859857497474877e-06

These O 0 1.0019627438850875e-07
data O 0 1.9798717687535827e-07
demonstrate O 0 1.3545979449247625e-08
that O 0 3.766807421534679e-10
both O 0 4.3286446649304366e-10
the O 0 2.2847725933416996e-09
position O 0 1.2602374255266113e-08
of O 0 9.383597898704465e-09
the O 0 1.0588404819600328e-08
IC O 0 2.329864855710184e-06
and O 0 5.632236899089094e-10
its O 0 4.082004734229372e-10
role O 0 4.225390703993526e-09
in O 0 4.18397455570485e-10
the O 0 8.286332731088919e-10
coordinate O 0 6.014592823788689e-09
expression O 0 4.42651648668857e-09
of O 0 2.67956901112143e-09
genes O 0 1.30327992842183e-09
is O 0 6.329364116153258e-11
conserved O 0 4.643756490452233e-09
between O 0 1.566180740653067e-09
mouse O 0 6.968936538953585e-09
and O 0 5.291418345154675e-11
human O 0 4.318748414444684e-10
, O 0 6.931454021863459e-11
and O 0 5.845080669475422e-11
indicate O 0 3.4035478879701486e-09
that O 0 1.0901421432230052e-10
the O 0 2.401363774495735e-09
mouse O 0 1.70525069620453e-08
is O 0 6.933582874513178e-11
a O 0 2.0565854574883247e-10
suitable O 0 2.701533219351404e-09
model O 0 1.1971938995714027e-09
system O 0 6.934221530308093e-10
in O 0 1.9536199047376357e-10
which O 0 6.760859927457119e-11
to O 0 9.147564650202611e-11
investigate O 0 5.275984094055275e-09
the O 0 5.818312498462319e-09
molecular O 0 3.849639256259252e-07
mechanisms O 0 1.2005048688479292e-07
of O 0 3.390668723568524e-08
imprinting O 0 5.574539727604133e-07
in O 0 7.2832917474841e-10
this O 0 5.414352299837333e-10
region O 0 2.1469592770273493e-09
of O 0 2.7148183701086737e-09
the O 0 8.410553142823574e-09
genome O 0 2.6867965630117396e-08
. O 0 7.165156024058206e-09
. O 0 6.816495812245194e-08

Mutations O 0 3.4292577311134664e-06
of O 0 3.713494720614108e-07
the O 0 4.345798174654192e-07
ATM O 0 0.00012575939763337374
gene O 0 6.031045529653056e-08
detected O 0 7.353089870321128e-08
in O 0 2.5515829449318517e-08
Japanese O 1 0.9999610185623169
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 4.0572895159129985e-06
: O 0 2.1859161147830264e-09
possible O 0 1.3035094781344014e-08
preponderance O 0 7.889081643952522e-06
of O 0 3.448770513614363e-08
the O 0 1.0608173894866013e-08
two O 0 4.223053906571295e-09
founder O 0 1.6449504300908302e-06
mutations O 0 2.898489093183798e-08
4612del165 O 0 3.6078654375160113e-06
and O 0 1.449887321314236e-07
7883del5 O 0 0.0003019692958332598
. O 0 3.9541887417726684e-06

The O 0 6.013924121361924e-06
ATM O 0 0.0003096303844358772
( O 0 1.062298451870447e-06
A O 1 0.9999990463256836
- O 1 0.9987286925315857
T O 1 0.9999957084655762
, O 0 8.79009132148667e-09
mutated O 0 2.2636836405354188e-08
) O 0 3.869295106539994e-09
gene O 0 4.571125256092046e-09
on O 0 5.082232856779001e-09
human O 0 5.474785425008122e-08
chromosome O 0 2.4968685465864837e-06
11q22 O 0 3.860444121528417e-05
. O 0 1.3432896821541362e-06

3 O 0 1.905485987663269e-06
has O 0 6.5799845572200866e-09
recently O 0 9.70455626969624e-09
been O 0 1.240114122502689e-09
identified O 0 3.614650800898289e-09
as O 0 7.272214497255902e-10
the O 0 2.9045088556500787e-09
gene O 0 1.434685814594161e-09
responsible O 0 9.33215393850162e-10
for O 0 4.1025172148323463e-10
the O 0 8.519815963836663e-08
human O 0 2.8812350137741305e-05
recessive B-Disease 1 0.9999768733978271
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9973347783088684
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
) O 0 2.1032373354046285e-07
. O 0 1.5546834220003802e-07

In O 0 2.847849316367501e-07
order O 0 2.448830471735164e-08
to O 0 2.7588227258235065e-09
define O 0 2.0785966725611615e-08
the O 0 5.084637599850339e-09
types O 0 1.6598685093072163e-08
of O 0 1.1760376992242527e-06
disease O 1 0.9532371759414673
- O 0 0.00014358000771608204
causing O 0 2.5197607556037838e-06
ATM O 0 1.5793251805007458e-05
mutations O 0 1.3474078519593036e-09
in O 0 1.119010772931972e-09
Japanese O 0 2.489274493200355e-06
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.889752209186554
T I-Disease 1 0.9999983310699463
patients O 0 1.5937146047306783e-09
as O 0 2.6336308134311537e-10
well O 0 3.244968183047092e-10
as O 0 1.7931324480802147e-10
to O 0 1.0089092755682927e-10
look O 0 6.176794631329585e-10
for O 0 3.4839267581965316e-10
possible O 0 1.1282913270349582e-08
mutational O 0 2.8908812055306043e-06
hotspots O 0 1.1914021769143801e-07
, O 0 9.651868193572e-10
reverse O 0 2.63687045531924e-08
- O 0 7.930427159408282e-08
transcribed O 0 2.103738836467528e-07
RNA O 0 7.300726423409287e-08
derived O 0 7.175204874698693e-10
from O 0 2.1923744764063002e-10
ten O 0 6.216012149451444e-09
patients O 0 4.473570125451687e-10
belonging O 0 1.5952725362922138e-08
to O 0 1.3174333846066588e-09
eight O 0 2.2876779581793016e-08
unrelated O 0 5.815696795252734e-07
Japanese O 0 0.0032832107972353697
A B-Disease 1 1.0
- I-Disease 1 0.9956549406051636
T I-Disease 1 0.9987686276435852
families O 0 1.0313451204169155e-09
was O 0 4.9312460781436585e-09
analyzed O 0 2.397812171039959e-09
for O 0 4.4692097245224716e-11
mutations O 0 8.188071748405079e-11
by O 0 6.817915676471387e-11
the O 0 1.536673344126882e-09
restriction O 0 8.437771370495284e-09
endonuclease O 0 1.333285695181985e-07
fingerprinting O 0 4.3410508965280314e-08
method O 0 8.677254470512707e-08
. O 0 1.1715729897332494e-07

As O 0 2.2058330273466709e-07
has O 0 3.020309335965976e-09
been O 0 2.0798724964521398e-09
reported O 0 1.863681875491352e-09
by O 0 2.219000261316495e-10
others O 0 8.196310297137188e-10
, O 0 3.5520039687320093e-10
mutations O 0 3.8946007530071824e-10
that O 0 2.2767233931464403e-10
lead O 0 1.428180329554607e-08
to O 0 2.5126853486767686e-08
exon O 0 2.277128942296258e-06
skipping O 0 1.1173231087013846e-06
or O 0 4.350027538180257e-08
premature O 0 2.1210519207670586e-07
protein O 0 4.977969680908245e-08
truncation O 0 9.241168186235882e-07
were O 0 2.5851980112179263e-08
also O 0 7.352133124527427e-09
predominant O 0 1.4778932211356732e-07
in O 0 1.3587692748728841e-08
our O 0 2.0554489310598e-07
mutants O 0 1.682126253399474e-06
. O 0 2.9673955737052893e-07

Six O 0 1.580849158244746e-07
different O 0 1.2160331630539645e-09
mutations O 0 3.0025493202856524e-09
were O 0 1.1244371656005114e-08
identified O 0 2.5079359033952642e-08
on O 0 1.2251505587812517e-08
12 O 0 2.6595191826572773e-08
of O 0 3.7194627822145776e-08
the O 0 5.0462837464237964e-08
16 O 0 1.2143212302362372e-07
alleles O 0 1.3130740050826262e-08
examined O 0 5.466249604069162e-07
. O 0 4.436581662048411e-07

Four O 0 3.5122272379339847e-07
were O 0 9.067168349474741e-08
deletions O 0 2.821101929839642e-07
involving O 0 8.562478797102813e-07
a O 0 4.323904363445763e-07
loss O 0 2.205882310590823e-06
of O 0 2.8078713967261137e-06
a O 0 7.031961217762728e-07
single O 0 3.37609122880167e-07
exon O 0 1.0330702480132459e-06
exon O 0 6.590348675672431e-07
7 O 0 6.123264029156417e-08
, O 0 5.740193653736014e-09
exon O 0 2.682997717329272e-07
16 O 0 6.292982845934603e-08
, O 0 2.8074856217585875e-08
exon O 0 8.609298447481706e-07
33 O 0 4.922575271848473e-07
or O 0 3.824729617463163e-07
exon O 0 7.863963219278958e-06
35 O 0 4.309518317313632e-06
. O 0 7.378764621535083e-07

The O 0 5.534361093850748e-07
others O 0 1.4133438419605682e-08
were O 0 1.2764163059841849e-08
minute O 0 1.0388602333932795e-07
deletions O 0 1.533075391080274e-07
, O 0 6.882177938649647e-09
4649delA O 0 1.1313619552311138e-06
in O 0 7.31511136109475e-08
exon O 0 1.0953539231195464e-06
33 O 0 1.6857960360994184e-07
and O 0 1.699620177930683e-08
7883del5 O 0 8.522206371708307e-06
in O 0 3.3955134881580307e-07
exon O 0 1.2985958164790645e-05
55 O 0 1.4137826838123146e-06
. O 0 4.7442352979487623e-07

The O 0 2.0960778783774003e-06
mutations O 0 3.0198015110727283e-07
4612del165 O 0 1.9505857835611096e-06
and O 0 7.306057980827063e-09
7883del5 O 0 1.3621396419694065e-06
were O 0 9.30636723239786e-09
found O 0 3.835875617141937e-09
in O 0 4.730044689260637e-10
more O 0 4.471776421377527e-11
than O 0 6.448919870338798e-11
two O 0 1.6324974705383966e-10
unrelated O 0 6.090368209754615e-09
families O 0 1.902092372496611e-10
; O 0 9.112127719035357e-11
44 O 0 2.791161746173998e-09
% O 0 2.7975042282690765e-09
( O 0 9.796796707206568e-10
7 O 0 4.234701478367242e-09
of O 0 3.1409781442448548e-09
16 O 0 9.898396768903694e-09
) O 0 7.924795264457885e-10
of O 0 7.855134320777779e-10
the O 0 1.5759616944777122e-09
mutant O 0 2.6121119489630473e-08
alleles O 0 6.753002046444578e-10
had O 0 1.021556172986493e-09
one O 0 4.91987617312617e-10
of O 0 3.0925826344230245e-09
the O 0 6.296366095170924e-09
two O 0 1.4116358748594848e-08
mutations O 0 5.5812112265130054e-08
. O 0 1.1599628635394765e-07

The O 0 3.135538236165303e-06
4612del165 O 0 1.3359908734855708e-05
mutations O 0 8.340184542987572e-09
in O 0 1.0261336225170226e-09
three O 0 2.5176916107483294e-10
different O 0 1.935609034164898e-10
families O 0 5.838620698028762e-10
were O 0 1.8745409668952107e-09
all O 0 1.257717707758843e-09
ascribed O 0 1.0250156634583618e-07
to O 0 1.0362036784172801e-09
the O 0 5.951043657859145e-09
same O 0 1.027438489842325e-08
T O 0 1.3404036280917353e-07
- O 0 9.776291420848793e-08
- O 0 3.196668671989755e-07
> O 0 1.9810238427453442e-07
A O 0 4.2305298819655945e-08
substitution O 0 1.0528110827578985e-08
at O 0 1.591537390766007e-08
the O 0 5.419572346454515e-09
splice O 0 3.807544430856069e-07
donor O 0 2.0102385533959932e-08
site O 0 8.251831218331063e-08
in O 0 3.104564072486937e-08
intron O 0 1.8006308891926892e-05
33 O 0 1.627731535336352e-06
. O 0 2.584673666206072e-07

Microsatellite O 0 0.003234477946534753
genotyping O 0 4.481960058910772e-05
around O 0 5.627323957924091e-07
the O 0 1.8043776606191386e-07
ATM O 0 0.00028411217499524355
locus O 0 1.045064323079714e-06
also O 0 8.233114745515024e-10
indicated O 0 5.225847754530832e-09
that O 0 7.854594752387811e-10
a O 0 8.334396284226386e-09
common O 0 6.3776619541044965e-09
haplotype O 0 9.969719627633822e-08
was O 0 1.9503531234477123e-08
shared O 0 3.410735249786967e-09
by O 0 7.590706951887682e-10
the O 0 1.8500533327525659e-09
mutant O 0 1.3501071371990747e-08
alleles O 0 7.466655627119678e-10
in O 0 6.032834787284003e-10
both O 0 2.012247701799197e-09
mutations O 0 4.6602977477050445e-08
. O 0 1.9340541257406585e-07

This O 0 2.2780990605042462e-07
suggests O 0 1.1508834063533868e-07
that O 0 7.214438491054409e-10
these O 0 6.199905588921695e-10
two O 0 3.048814756212437e-09
founder O 0 1.0528381153562805e-06
mutations O 0 2.205006843780666e-09
may O 0 4.422699706463362e-10
be O 0 5.202513420066168e-10
predominant O 0 3.108041823907115e-08
among O 0 3.6280229931406893e-09
Japanese O 0 1.145889655163046e-06
ATM O 0 1.625386721570976e-05
mutant O 0 6.169047992443666e-07
alleles O 0 4.032113309904162e-08
. O 0 4.465475456072454e-08

W474C O 0 0.0003516080032568425
amino O 0 6.3481033976131584e-06
acid O 0 4.3893746237699816e-07
substitution O 0 4.4421231137903305e-08
affects O 0 7.1464851814084795e-09
early O 0 4.021527555408966e-09
processing O 0 1.5511950834934396e-08
of O 0 7.389783451827725e-09
the O 0 5.227881683111946e-09
alpha O 0 2.9170520221555307e-08
- O 0 1.4475635135013931e-09
subunit O 0 4.627937588708164e-09
of O 0 8.740134171958402e-10
beta O 0 2.2167013113971734e-08
- O 0 1.4736477815802118e-08
hexosaminidase O 0 3.1359491003968287e-07
A O 0 2.149898570280584e-08
and O 0 8.051800198805026e-11
is O 0 3.083645838675153e-10
associated O 0 3.5056186842297166e-09
with O 0 2.850210956140131e-09
subacute O 0 0.022583529353141785
G B-Disease 1 0.999424934387207
( I-Disease 0 0.00015567774244118482
M2 I-Disease 1 0.9999567270278931
) I-Disease 0 7.222491831271327e-07
gangliosidosis I-Disease 0 4.419382821652107e-05
. O 0 6.080870207370026e-07

Mutations O 0 3.2789248507469893e-06
in O 0 5.845244999136412e-08
the O 0 1.9660329542148247e-07
HEXA O 0 0.00020519716781564057
gene O 0 1.228810653230994e-08
, O 0 4.3052025833212326e-10
encoding O 0 1.7503128946216862e-09
the O 0 3.1553653023763673e-09
alpha O 0 2.31031727082609e-08
- O 0 3.0320899124802736e-09
subunit O 0 1.4354639255031998e-08
of O 0 3.711778884252226e-09
beta O 0 4.5615294652634475e-08
- O 0 1.942623484296746e-08
hexosaminidase O 0 7.210124408629781e-07
A O 0 3.248483437801042e-07
( O 0 5.1208624007870185e-09
Hex O 0 1.0860531318712674e-07
A O 0 3.32883729470268e-08
) O 0 5.317077333977238e-10
, O 0 6.20503717851939e-11
that O 0 9.64027260796918e-11
abolish O 0 3.116750590947959e-08
Hex O 0 2.4555854452046333e-06
A O 0 1.9517827354320616e-07
enzyme O 0 1.104735218859787e-07
activity O 0 4.31740630801869e-07
cause O 0 1.5771971447975375e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 1.0525460538701736e-06
TSD B-Disease 1 0.9743958711624146
) O 0 8.21943757500776e-09
, O 0 3.357996103403593e-10
the O 0 8.68071126092218e-09
fatal O 0 3.996015038865153e-07
infantile B-Disease 0 2.2721148695836746e-07
form I-Disease 0 7.425529524596186e-09
of I-Disease 0 4.718966465588892e-06
G I-Disease 0 0.0006361554260365665
( I-Disease 0 4.611546955857193e-06
M2 I-Disease 1 0.9997430443763733
) I-Disease 0 5.4041020547401786e-08
gangliosidosis I-Disease 0 1.409043306921376e-06
, I-Disease 0 1.2624266076954882e-08
Type I-Disease 0 7.89600562711712e-07
1 I-Disease 0 7.529077947765472e-07
. O 0 2.9732365192103316e-07

Less O 0 1.849396426223393e-06
severe O 0 7.127251592464745e-06
, O 0 1.1170903491120043e-07
subacute O 1 0.6508328318595886
( O 0 7.795090823492501e-06
juvenile O 1 0.5600599050521851
- O 0 0.05658284202218056
onset O 1 0.9999994039535522
) O 0 6.158472132256065e-08
and O 0 8.444469123958243e-09
chronic O 1 0.9986155033111572
( O 0 1.5314080314965395e-07
adult O 0 9.546806722937617e-07
- O 0 1.4171818065733532e-06
onset O 0 0.005220354069024324
) O 0 1.008276906411254e-09
variants O 0 2.6253355045469107e-10
are O 0 6.353563074962265e-12
characterized O 0 1.835389201731985e-10
by O 0 4.752659724105435e-11
a O 0 9.113053645037894e-10
broad O 0 7.585192474124369e-10
spectrum O 0 1.1101436436788958e-09
of O 0 2.2203561211853184e-09
clinical O 0 1.6230923449711554e-07
manifestations O 0 1.0357125290738622e-07
and O 0 5.866617192040735e-10
are O 0 1.7824626497020546e-10
associated O 0 4.188032587393309e-09
with O 0 6.248460637792164e-10
residual O 0 1.5677074770792387e-05
levels O 0 4.5463940523404744e-07
of O 0 1.6159906124357803e-07
Hex O 0 1.0066527465824038e-05
A O 0 2.4464523562528484e-07
enzyme O 0 6.728104295916637e-08
activity O 0 1.687984081399918e-07
. O 0 5.290538140911849e-08

We O 0 1.755973471517791e-06
identified O 0 9.0380973460924e-07
a O 0 2.3662201442675723e-07
1422 O 0 5.55850965611171e-06
G O 0 5.354888230613142e-07
- O 0 1.896107164611749e-07
- O 0 3.8893418263796775e-07
> O 0 3.026268018402334e-07
C O 0 4.0311604720955074e-07
( O 0 4.346467186167047e-09
amino O 0 1.0290780672050914e-08
acid O 0 3.74150443960275e-09
W474C O 0 8.933255202236978e-08
) O 0 6.936998753204193e-10
substitution O 0 1.7639397720259353e-09
in O 0 9.108327425622065e-10
the O 0 2.367771312350442e-09
first O 0 7.89120857547232e-09
position O 0 4.14629077738482e-08
of O 0 1.4254975155836291e-07
exon O 0 5.17920341280842e-07
13 O 0 8.719179334093496e-08
of O 0 1.3879721905141196e-07
HEXA O 0 0.003251141868531704
of O 0 1.4550637672527955e-07
a O 0 8.179560495591431e-08
non O 0 1.5278692444553599e-06
- O 0 2.2248291315918323e-06
Jewish O 0 4.259997695044149e-06
proband O 0 6.37962220935151e-05
who O 0 7.12480385800518e-09
manifested O 0 1.4119514446520043e-07
a O 0 5.3636529884215634e-08
subacute O 0 5.457683073473163e-06
variant O 0 3.136969155548286e-07
of O 0 5.02483590025804e-06
G B-Disease 0 0.0005866952706128359
( I-Disease 0 6.1957130128575955e-06
M2 I-Disease 1 0.999481737613678
) I-Disease 0 6.722146395077289e-07
gangliosidosis I-Disease 0 7.878106407588348e-05
. O 0 1.1927692185054184e-06

On O 0 1.4314073268906213e-06
the O 0 1.4007230220158817e-07
second O 0 5.745218345509784e-07
maternally O 0 2.777616828097962e-05
inherited O 0 6.542396022268804e-06
allele O 0 6.442744648893495e-08
, O 0 1.3211223226505808e-09
we O 0 1.1453288317753163e-09
identified O 0 1.9354631675128076e-08
the O 0 2.0819136636873736e-08
common O 0 2.439274737753294e-07
infantile O 1 0.9270091652870178
disease O 1 0.9924023151397705
- O 0 0.00011108726175734773
causing O 0 4.70883378511644e-06
4 O 0 2.9331254154385533e-06
- O 0 1.4522538549499586e-06
bp O 0 1.19037952117651e-06
insertion O 0 4.215290800857474e-07
, O 0 1.7229936588591954e-08
+ O 0 1.2531194215625874e-06
TATC O 0 0.00015702832024544477
1278 O 0 4.59365728602279e-05
, O 0 1.1601925642423794e-08
in O 0 3.582188767836669e-08
exon O 0 2.8224062589288224e-06
11 O 0 6.756369543836627e-07
. O 0 3.1643838838135707e-07

Pulse O 0 0.0005017601069994271
- O 0 9.702109309728257e-06
chase O 0 3.0482574402412865e-06
analysis O 0 1.2380709790704714e-07
using O 0 9.681580337428386e-08
proband O 0 1.724423054838553e-05
fibroblasts O 0 1.750011961121345e-06
revealed O 0 1.2247794245467958e-07
that O 0 4.3796274940000046e-10
the O 0 2.5509732104467275e-09
W474C O 0 2.1838674513219303e-07
- O 0 9.42158262517978e-09
containing O 0 6.232395044492023e-09
alpha O 0 2.1912521575018218e-08
- O 0 7.921580724712385e-09
subunit O 0 2.7139501312944958e-08
precursor O 0 9.810302792345738e-09
was O 0 3.0947777673873134e-09
normally O 0 3.976174389741516e-10
synthesized O 0 3.7940508512690485e-09
, O 0 1.393087728507325e-10
but O 0 7.585304606649856e-11
not O 0 1.9925773531159763e-10
phosphorylated O 0 5.9338077562642866e-08
or O 0 5.3415778467069686e-09
secreted O 0 1.652382231043248e-08
, O 0 1.5915629925089547e-10
and O 0 1.047550032828859e-10
the O 0 6.49642073469181e-09
mature O 0 8.847453614180267e-08
lysosomal O 0 1.7866252164822072e-05
alpha O 0 3.2678036632205476e-07
- O 0 2.316640568267303e-08
subunit O 0 5.186211282648401e-08
was O 0 6.731914137247941e-09
not O 0 1.0087828350435757e-09
detected O 0 1.4885954158216919e-07
. O 0 5.770472455424169e-08

When O 0 6.451082299463451e-07
the O 0 2.127636093973706e-07
W474C O 0 1.7834474874689477e-06
- O 0 7.67604717566428e-08
containing O 0 1.6882570008647235e-08
alpha O 0 8.09821685265888e-08
- O 0 1.8127940037970802e-08
subunit O 0 1.6888662912606378e-07
was O 0 8.372447268811811e-08
transiently O 0 3.7586733014904894e-07
co O 0 1.046151751893376e-07
- O 0 2.549393585127291e-08
expressed O 0 1.8545261992741757e-09
with O 0 2.658197828520059e-10
the O 0 5.971647176750139e-09
beta O 0 2.7985198158830826e-08
- O 0 4.960527544284332e-09
subunit O 0 2.391373499222027e-08
to O 0 2.7706759109236145e-10
produce O 0 3.942292714498308e-09
Hex O 0 2.357121502427617e-06
A O 0 7.283173317773617e-07
( O 0 2.210654947987223e-08
alphabeta O 0 1.1262098951192456e-06
) O 0 7.288924130932628e-09
in O 0 1.2978753183290337e-08
COS O 0 2.038652019109577e-05
- O 0 3.4042193419736577e-07
7 O 0 6.42680149098851e-08
cells O 0 8.095835113408612e-09
, O 0 1.8521710554164628e-10
the O 0 8.520457117633384e-10
mature O 0 5.428076210733934e-09
alpha O 0 1.5104310691071987e-08
- O 0 2.8409246066729565e-09
subunit O 0 1.0190618127126072e-08
was O 0 1.5688506049826856e-09
present O 0 3.7630734639471086e-10
, O 0 9.32403598774556e-11
but O 0 8.350044961025205e-11
its O 0 1.7403384289238488e-10
level O 0 6.592672630034713e-09
was O 0 8.951331231799031e-09
much O 0 1.2340666266652534e-09
lower O 0 1.414813155520278e-09
than O 0 1.5171999073748665e-11
that O 0 7.793432565961211e-12
from O 0 7.246456906750964e-11
normal O 0 4.261536901140062e-09
alpha O 0 9.50975920233077e-09
- O 0 2.927523778950558e-09
subunit O 0 1.0383605975050614e-08
transfections O 0 3.334512044261828e-08
, O 0 2.8989382075406134e-11
although O 0 3.212763735604973e-11
higher O 0 2.985911795594376e-10
than O 0 2.0129595906803743e-11
in O 0 6.691506376776957e-11
those O 0 1.3129826392788146e-10
cells O 0 2.781733732248881e-09
transfected O 0 4.343676351936665e-08
with O 0 1.1493724028088792e-10
an O 0 8.146514018925188e-10
alpha O 0 5.047910534017319e-08
- O 0 1.3572720725107956e-08
subunit O 0 5.453878060279749e-08
associated O 0 1.2046572628321428e-08
with O 0 5.497573063451e-09
infantile O 0 0.00011220038868486881
TSD B-Disease 0 0.09408462792634964
. O 0 8.735972869544639e-07

Furthermore O 0 3.936347184207989e-06
, O 0 8.422415653797088e-09
the O 0 1.2258237092055424e-08
precursor O 0 3.066540443796839e-07
level O 0 2.8615707492463116e-07
of O 0 4.7858790708232846e-08
the O 0 2.9588266059477064e-08
W474C O 0 1.0199348707828904e-06
alpha O 0 9.979689252759272e-08
- O 0 1.5038770229125475e-08
subunit O 0 1.4814033555410333e-08
was O 0 3.892308253483634e-09
found O 0 2.1494862834092743e-10
to O 0 2.170642277032897e-10
accumulate O 0 1.0776996184347354e-08
in O 0 2.9859588135394688e-09
comparison O 0 3.38654326803578e-09
to O 0 4.042751688970725e-10
the O 0 4.095451533459027e-09
normal O 0 5.347248333009702e-08
alpha O 0 1.2221681799928774e-07
- O 0 3.7749529724351305e-08
subunit O 0 9.128022782078915e-08
precursor O 0 1.9957863628405903e-07
levels O 0 3.844850482437323e-08
. O 0 4.301078959656479e-08

We O 0 6.455082370848686e-07
conclude O 0 1.9311471533001168e-06
that O 0 1.2118613668121725e-08
the O 0 1.139409846473427e-07
1422 O 0 1.0727841072366573e-05
G O 0 2.0235370357113425e-06
- O 0 4.1251277593801206e-07
- O 0 4.5419605498864257e-07
> O 0 2.8227569259797747e-07
C O 0 1.6529202184756286e-07
mutation O 0 9.521443633531135e-10
is O 0 9.25775914262239e-11
the O 0 1.1381989795111735e-09
cause O 0 2.4904130313530004e-08
of O 0 1.6141947867254203e-07
Hex B-Disease 0 0.024080082774162292
A I-Disease 0 0.1431492269039154
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.312162277779862e-07
the O 0 1.461550482417806e-06
proband O 0 0.0002820104418788105
. O 0 9.397892313245393e-07

The O 0 1.0422247669339413e-06
resulting O 0 4.840594556299038e-07
W474C O 0 4.2481269701966085e-06
substitution O 0 7.98164307980187e-08
clearly O 0 6.38296953070494e-08
interferes O 0 2.8627326287278265e-08
with O 0 1.848028119422196e-10
alpha O 0 1.357484435970946e-08
- O 0 2.825237599424213e-09
subunit O 0 5.160946781046505e-09
processing O 0 8.913270121979622e-09
, O 0 9.048100463315834e-11
but O 0 3.6295421529386473e-11
because O 0 1.042435512910167e-10
the O 0 8.788075822607766e-10
base O 0 1.0490106561178436e-08
substitution O 0 1.203880906075483e-08
falls O 0 4.4633006268668396e-07
at O 0 4.9333934271089674e-08
the O 0 6.06100281075328e-09
first O 0 6.146172015775164e-09
position O 0 4.37574954048614e-08
of O 0 3.535191694936657e-08
exon O 0 1.718706243991619e-07
13 O 0 2.7405206992625608e-08
, O 0 9.067990247579871e-10
aberrant O 0 5.4530669757468786e-08
splicing O 0 5.31100177170174e-08
may O 0 3.248989299819982e-09
also O 0 6.790341622320284e-10
contribute O 0 1.031270890905489e-08
to O 0 6.482942893626387e-08
Hex B-Disease 0 0.1059332862496376
A I-Disease 0 0.00048400613013654947
deficiency I-Disease 1 0.6548762321472168
in O 0 3.540131032764293e-08
this O 0 1.9210828483551268e-08
proband O 0 9.24371306609828e-06
. O 0 4.167968725710125e-08
. O 0 1.5696093669248512e-07

Two O 0 8.62436991155846e-07
frequent O 0 9.018560831464129e-07
missense O 0 8.789960702415556e-06
mutations O 0 4.734924345939362e-07
in O 0 2.5875247047224548e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.959646917588543e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.393763371510431e-05
an O 1 0.9984708428382874
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999721050262451
by O 0 9.669165592640638e-07
early O 1 0.9950498938560486
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9997382760047913
goiter B-Disease 1 1.0
. O 0 0.007101906929165125

A O 0 4.651724339055363e-06
century O 0 2.64329145238662e-07
after O 0 3.1424061575080486e-08
its O 0 1.0730554222959654e-09
recognition O 0 3.4921783242936044e-09
as O 0 2.343679028626866e-09
a O 0 2.5009423865185454e-08
syndrome O 0 4.7429145411115314e-07
by O 0 5.446162187894288e-09
Vaughan O 0 1.5996454294509022e-06
Pendred O 0 0.0014096307568252087
, O 0 3.647130597528303e-09
the O 0 4.540956055620882e-08
disease O 0 3.6530789202515734e-06
gene O 0 7.747739516617003e-08
( O 0 2.3519832836882415e-07
PDS O 0 1.7904820197145455e-05
) O 0 3.6486751398001616e-09
was O 0 3.8401456237124876e-08
mapped O 0 9.554086943808215e-08
to O 0 2.030314405487843e-08
chromosome O 0 3.1635556752007687e-06
7q22 O 0 7.45844590710476e-05
- O 0 8.096145757008344e-05
q31 O 0 0.0008243214688263834
. O 0 2.0017041606479324e-06

1 O 0 3.457201387391251e-07
and O 0 4.107123086072306e-09
, O 0 1.534198768027295e-09
recently O 0 5.823653115299976e-09
, O 0 7.567289017629264e-10
found O 0 1.061865595453071e-09
to O 0 1.901676149884679e-09
encode O 0 1.0291099528103587e-07
a O 0 2.294294318971879e-07
putative O 0 1.4568326150765643e-05
sulfate O 0 3.184100205544382e-05
transporter O 0 0.0008450859459117055
. O 0 1.7982034705710248e-06

We O 0 1.1021801071819937e-07
performed O 0 4.145025656043799e-08
mutation O 0 2.406618460071286e-09
analysis O 0 4.9936770274428e-09
of O 0 4.3179602116083515e-09
the O 0 8.159646824879019e-08
PDS B-Disease 0 0.00015093684487510473
gene O 0 9.26069976259214e-09
in O 0 9.418917867876075e-10
patients O 0 1.031136620532891e-09
from O 0 6.261634766246971e-09
14 O 0 2.397532909981237e-07
Pendred B-Disease 0 0.02696632780134678
families O 0 4.6614778703713e-09
originating O 0 7.899280340950554e-09
from O 0 7.326400042195758e-10
seven O 0 4.6464029845871835e-10
countries O 0 1.5383933710255704e-11
and O 0 1.441174124483524e-10
identified O 0 9.934409739287275e-09
all O 0 1.0945456985211877e-08
mutations O 0 5.208665143641156e-08
. O 0 1.3346303262551373e-07

The O 0 3.2681185757610365e-07
mutations O 0 2.1038607300738477e-08
include O 0 2.237254381753928e-09
three O 0 1.87534210382978e-09
single O 0 9.92592408266546e-09
base O 0 3.164473838523918e-08
deletions O 0 5.9443877375997545e-08
, O 0 2.3704644913635775e-09
one O 0 6.0955973602006e-09
splice O 0 6.329215693767765e-07
site O 0 2.583798242028479e-08
mutation O 0 1.728585385940562e-09
and O 0 1.0710494713350727e-09
10 O 0 7.893801523550792e-08
missense O 0 5.168454663362354e-06
mutations O 0 2.4297716549881443e-07
. O 0 1.5342529025019758e-07

One O 0 2.969659362861421e-06
missense O 0 1.0796215065056458e-05
mutation O 0 1.284503241549828e-07
( O 0 4.2994873439283765e-08
L236P O 0 2.442403911118163e-06
) O 0 1.138672889311465e-08
was O 0 5.460893603981276e-08
found O 0 2.764590556481039e-09
in O 0 1.7378085637176355e-09
a O 0 7.570800875100758e-09
homozygous O 0 2.635712537113477e-09
state O 0 5.085303844687417e-10
in O 0 8.485459002116613e-10
two O 0 1.896561352410231e-09
consanguineous O 0 4.13944071624428e-05
families O 0 2.5699904426801368e-09
and O 0 6.774856786684325e-10
in O 0 2.5308799500578516e-09
a O 0 6.128098473112686e-09
heterozygous O 0 1.1948624312196898e-09
state O 0 1.553337042325964e-10
in O 0 1.1318379566915837e-10
five O 0 1.322193049491105e-10
additional O 0 1.3064158643771862e-09
non O 0 1.2486460718719172e-06
- O 0 1.5055787116580177e-05
consanguineous O 0 0.001639256370253861
families O 0 2.166783588108956e-07
. O 0 1.609214734799025e-07

Another O 0 7.6575061029871e-06
missense O 0 1.9498753317748196e-05
mutation O 0 2.233299483123119e-07
( O 0 5.31549133597764e-08
T416P O 0 1.8726034340943443e-06
) O 0 1.1984008452259332e-08
was O 0 5.1515087307052454e-08
found O 0 2.6535893482559914e-09
in O 0 1.9749388791012734e-09
a O 0 8.324799516401526e-09
homozygous O 0 2.756887163002375e-09
state O 0 4.583922130763085e-10
in O 0 8.179381616457704e-10
one O 0 3.1156790480935115e-09
family O 0 6.835084054301888e-09
and O 0 3.1824781698830407e-10
in O 0 1.9436527942673365e-09
a O 0 1.2248747793819348e-08
heterozygous O 0 4.67601957154784e-09
state O 0 1.1372268682308118e-09
in O 0 2.3685571282072715e-09
four O 0 1.800245108540821e-08
families O 0 5.8108298617298715e-08
. O 0 1.3363498396756768e-07

Pendred B-Disease 1 0.9785876274108887
patients O 0 5.303768944031617e-07
in O 0 1.3589403380365184e-08
three O 0 1.4059875930172439e-08
non O 0 5.179566869628616e-06
- O 0 6.09687231190037e-06
consanguineous O 0 0.00024830418988130987
families O 0 2.1636659131019087e-09
were O 0 1.7405917818180683e-09
shown O 0 2.109291852292472e-09
to O 0 1.0974299247124009e-09
be O 0 9.993705418764876e-09
compound O 0 1.6328343690474867e-06
heterozygotes O 0 1.9809313300811482e-07
for O 0 8.000844431421683e-09
L236P O 0 5.902488283027196e-06
and O 0 8.886571833954804e-08
T416P O 0 0.00010246963211102411
. O 0 1.1923608553843223e-06

In O 0 3.8033746818655345e-07
total O 0 1.667901585733489e-07
, O 0 3.865061160013283e-09
one O 0 1.2034900853663544e-09
or O 0 9.671345946316023e-10
both O 0 2.644185703726265e-10
of O 0 3.4796916459356453e-09
these O 0 3.1880309503407034e-10
mutations O 0 1.0271441475140364e-09
were O 0 2.3895301293208604e-09
found O 0 2.19190310346562e-09
in O 0 9.301091563607145e-10
nine O 0 9.585332527706214e-09
of O 0 1.4781772250671565e-08
the O 0 2.1523232973663653e-08
14 O 0 5.160240945656369e-08
families O 0 2.6890665250078882e-09
analyzed O 0 3.026152342044952e-07
. O 0 1.675670802114837e-07

The O 0 2.537455827678059e-07
identification O 0 8.674673779296427e-08
of O 0 4.1728213773239986e-08
two O 0 1.3915832930422312e-08
frequent O 0 1.235934519172588e-07
PDS B-Disease 0 7.874364200688433e-06
mutations O 0 2.9549676039408723e-09
will O 0 3.193837139203737e-10
facilitate O 0 1.5462500613239172e-08
the O 0 2.3831319140299456e-08
molecular O 0 8.199904550565407e-05
diagnosis O 0 0.029718225821852684
of O 0 0.23062579333782196
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.4766317690373398e-05

Insertional O 0 0.0005130113568156958
mutation O 0 2.3326964537773165e-07
by O 0 1.584120568054459e-08
transposable O 0 6.438841410272289e-06
element O 0 9.423083611181937e-07
, O 0 1.6380633738322103e-08
L1 O 0 3.162580469506793e-05
, O 0 1.1349211570532702e-09
in O 0 3.786149616047396e-09
the O 0 8.270014006939164e-08
DMD B-Disease 1 1.0
gene O 0 3.519911828675504e-08
results O 0 5.328959495898289e-09
in O 0 1.2307904029285055e-08
X B-Disease 1 0.9981406927108765
- I-Disease 1 0.9993877410888672
linked I-Disease 1 0.9995774626731873
dilated I-Disease 1 0.9999953508377075
cardiomyopathy I-Disease 1 1.0
. O 0 2.26738825404027e-06

X B-Disease 1 0.9999794960021973
- I-Disease 1 0.9999700784683228
linked I-Disease 1 0.9999080896377563
dilated I-Disease 1 0.9999995231628418
cardiomyopathy I-Disease 1 1.0
( O 0 3.153990473947488e-05
XLDCM B-Disease 1 0.9999872446060181
) O 0 1.9764396341770407e-08
is O 0 2.1555266460637768e-09
a O 0 7.437578108948628e-09
clinical O 0 2.831554581916862e-07
phenotype O 0 1.7961468756766408e-07
of O 0 1.556005031488894e-07
dystrophinopathy B-Disease 0 0.010242035612463951
which O 0 1.3175214252925116e-09
is O 0 4.6332876424415304e-10
characterized O 0 1.8190796646777585e-09
by O 0 9.117922528112388e-10
preferential O 0 4.247055471751082e-07
myocardial B-Disease 1 1.0
involvement I-Disease 0 7.363278200500645e-07
without O 0 1.4326548836152142e-08
any O 0 5.624618104604906e-09
overt O 0 6.933512963769317e-08
clinical O 0 6.966267847019481e-07
signs O 0 3.199197067260684e-07
of O 0 0.0001164091590908356
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0002252657141070813

To O 0 2.8859778566925343e-08
date O 0 6.257781137719576e-08
, O 0 6.191916424036492e-10
several O 0 3.1730831850929064e-10
mutations O 0 1.8981500815584695e-09
in O 0 1.3482407412723774e-09
the O 0 4.403546540743264e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999226331710815
gene O 0 6.906250860083674e-07
, O 0 3.3643782870740324e-08
DMD O 1 1.0
, O 0 2.432071877223052e-09
have O 0 1.7197676616120816e-10
been O 0 9.951055535140085e-10
identified O 0 4.4246424302230025e-09
in O 0 2.9484537034107916e-09
patients O 0 1.2896254064642676e-09
with O 0 1.982157993296596e-09
XLDCM B-Disease 1 0.9999997615814209
, O 0 5.111279843816874e-09
but O 0 1.7960041787112857e-10
a O 0 1.0247293014131742e-09
pathogenic O 0 7.316876549090523e-10
correlation O 0 1.7259136342318016e-09
of O 0 5.827917037848351e-10
these O 0 2.0023802060897822e-10
cardiospecific O 0 2.0030790892633377e-06
mutations O 0 1.550003148054202e-08
in O 0 2.7992777873464547e-08
DMD O 1 1.0
with O 0 5.996883434278288e-09
the O 0 3.0511176873915247e-07
XLDCM B-Disease 1 0.9999810457229614
phenotype O 0 3.752741690732364e-07
has O 0 6.225596149711521e-10
remained O 0 6.057422297089943e-08
to O 0 1.6146427528340723e-09
be O 0 2.3923588443608423e-08
elucidated O 0 0.00010188356827711686
. O 0 1.2238143654030864e-06

We O 0 3.861372306346311e-07
report O 0 9.144333290578288e-08
here O 0 1.766270507630452e-08
the O 0 7.000831026005017e-09
identification O 0 2.1202321676128122e-08
of O 0 1.3618776328883087e-08
a O 0 1.624730039395672e-08
unique O 0 3.762603384416252e-08
de O 0 3.4344188861723524e-06
novo O 0 3.0800185868429253e-06
L1 O 0 3.367146564414725e-05
insertion O 0 2.762958786206582e-07
in O 0 1.433034668707478e-08
the O 0 4.6674056619622206e-08
muscle O 0 2.4940740672718675e-07
exon O 0 1.2223073326822487e-06
1 O 0 1.7058466994512855e-07
in O 0 1.1451945169937972e-07
DMD O 1 1.0
in O 0 2.7147681436190396e-08
three O 0 1.2910805757826438e-08
XLDCM B-Disease 1 0.7875183820724487
patients O 0 7.067726848219991e-09
from O 0 1.9442163434746362e-09
two O 0 3.4043010632700543e-09
unrelated O 0 7.172774871833099e-07
Japanese O 0 2.3903849069029093e-05
families O 0 1.458890466210505e-07
. O 0 1.7512128636099078e-07

The O 0 1.9187705220247153e-06
insertion O 0 2.635342752910219e-06
was O 0 9.259146622753178e-07
a O 0 1.2954137673659716e-07
5 O 0 6.593253942810406e-08
- O 0 1.7130778573459793e-08
truncated O 0 4.1461088784444655e-08
form O 0 1.9044383847699464e-09
of O 0 1.9959760066967647e-08
human O 0 2.3982615005024854e-08
L1 O 0 8.951638847065624e-06
inversely O 0 2.269559473688787e-07
integrated O 0 1.6524380441751418e-07
in O 0 1.9448913590736083e-09
the O 0 4.129690811538467e-09
5 O 0 1.703050145351881e-08
- O 0 3.428530348514869e-08
untranslated O 0 6.420752015401376e-06
region O 0 4.218692950530567e-08
in O 0 1.3257650977038793e-08
the O 0 2.0995154059733068e-08
muscle O 0 4.532570940796177e-08
exon O 0 6.368680516288805e-08
1 O 0 3.6601341957265277e-09
, O 0 3.972927889450695e-11
which O 0 2.0324306473917808e-11
affected O 0 9.086389973766984e-11
the O 0 6.671743157937726e-10
transcription O 0 4.8469786406712956e-08
or O 0 3.60895840989528e-10
the O 0 1.4659209401912676e-09
stability O 0 7.819578939916028e-08
of O 0 3.6714070006382826e-08
the O 0 1.6719843287660296e-08
muscle O 0 1.2985042374680233e-08
form O 0 2.7642637068225895e-09
of O 0 2.038026138961868e-07
dystrophin O 0 3.094855628660298e-06
transcripts O 0 3.609286238770437e-07
but O 0 2.0636228836856674e-10
not O 0 6.902232257965935e-11
that O 0 4.6512776269436173e-11
of O 0 2.434633827874677e-09
the O 0 9.494574726431892e-08
brain O 0 0.010263742879033089
or O 0 5.523520485439803e-07
Purkinje O 1 0.9999788999557495
cell O 0 4.129765147808939e-05
form O 0 5.4168647345420595e-09
, O 0 1.3937287990373193e-09
probably O 0 2.3177323171807984e-08
due O 0 1.4156748662230711e-08
to O 0 8.566964915246444e-10
its O 0 9.195273431572559e-10
unique O 0 3.522206970529851e-09
site O 0 2.635090545766161e-08
of O 0 2.240992280633236e-08
integration O 0 1.7630753745834227e-07
. O 0 4.6306553258546046e-07

We O 0 3.311906198177894e-07
speculate O 0 3.138860336093785e-07
that O 0 8.823380359679334e-10
this O 0 7.361222187363126e-10
insertion O 0 4.160661504215568e-08
of O 0 1.8974777304947565e-08
an O 0 3.6523534419075077e-08
L1 O 0 0.00011275274300714955
sequence O 0 1.0606586329231504e-06
in O 0 1.5522877561124915e-07
DMD O 1 1.0
is O 0 5.909543521198657e-09
responsible O 0 9.972112913203546e-09
for O 0 3.121828073826549e-10
some O 0 1.1918960263201939e-10
of O 0 9.407608025924219e-10
the O 0 7.281472091946739e-10
population O 0 3.530516504146597e-11
of O 0 9.494747210680998e-10
Japanese O 0 3.0849847121317e-07
patients O 0 9.18029041674373e-10
with O 0 1.5708327971708513e-09
XLDCM B-Disease 1 0.9210734367370605
. O 0 4.684082455241878e-08
. O 0 1.4211904897365457e-07

Severe O 0 0.000648314191494137
early O 0 0.0001751106174197048
- O 1 0.9986737966537476
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 8.223168697440997e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 5.791178864456015e-06
red O 0 0.00027708939160220325
hair O 1 0.9678939580917358
pigmentation O 1 0.5544641017913818
caused O 0 5.622953722195234e-06
by O 0 3.396138481548405e-07
POMC O 1 0.9999994039535522
mutations O 0 7.263183476879931e-08
in O 0 1.3605482962475435e-08
humans O 0 1.4409644677471078e-07
. O 0 1.1534368837828879e-07

Sequential O 0 8.674761920701712e-05
cleavage O 0 1.568886000313796e-05
of O 0 4.3311223407727084e-07
the O 0 7.105969501708387e-08
precursor O 0 4.597621625634929e-07
protein O 0 5.634133870557889e-08
pre O 0 8.374321964765841e-07
- O 0 1.3483387419910287e-06
pro O 0 2.1302948880475014e-06
- O 0 3.7702366171288304e-06
opiomelanocortin O 0 9.68238600762561e-05
( O 0 6.545645305777725e-07
POMC O 0 0.00013401266187429428
) O 0 9.291981406533978e-09
generates O 0 7.341063312793494e-09
the O 0 8.149501518062152e-09
melanocortin O 0 4.44480292571825e-06
peptides O 0 1.574213115418388e-07
adrenocorticotrophin O 0 9.929798579833005e-06
( O 0 9.346126716991421e-08
ACTH O 0 4.881338099949062e-06
) O 0 9.17791354027031e-09
, O 0 6.5845546792786536e-09
melanocyte O 0 1.3727306395594496e-05
- O 0 5.774012151960051e-06
stimulating O 0 2.879155090340646e-06
hormones O 0 1.640720341811175e-07
( O 0 1.4831561756523115e-08
MSH O 0 9.989456657422124e-07
) O 0 2.868348336626525e-10
alpha O 0 2.181026914627182e-09
, O 0 3.335283091376873e-11
beta O 0 2.9077443230995925e-10
and O 0 8.407076250438461e-12
gamma O 0 1.2501527590913497e-09
as O 0 6.574082250798696e-11
well O 0 4.201566178307914e-11
as O 0 1.0312817266822094e-10
the O 0 1.210483824287678e-09
opioid O 0 5.5514206565021595e-08
- O 0 6.33317682741108e-08
receptor O 0 5.7361912553233196e-08
ligand O 0 1.211184752492045e-07
beta O 0 2.405801069471636e-07
- O 0 3.020507222117885e-07
endorphin O 0 2.92695240204921e-05
. O 0 1.0659655913514143e-07

While O 0 5.789975148218218e-07
a O 0 1.1016163981025784e-08
few O 0 2.142884758526975e-09
cases O 0 1.0024474583758547e-09
of O 0 1.9152241748088272e-07
isolated O 0 0.2239815890789032
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
have O 0 4.393711172667736e-09
been O 0 2.271650600960129e-08
reported O 0 8.948995144919536e-08
( O 0 7.725117967538608e-08
OMIM O 0 0.001188652473501861
201400 O 0 3.1668880637880648e-06
) O 0 4.823587307356547e-09
, O 0 8.694161501843212e-10
an O 0 2.7813422676103983e-08
inherited O 1 0.9999998807907104
POMC O 1 1.0
defect O 1 0.9999983310699463
has O 0 8.003469886830317e-09
not O 0 7.9641776506989e-10
been O 0 5.142846593031436e-09
described O 0 4.343502268966404e-08
so O 0 7.565950532750776e-09
far O 0 3.6219265808767886e-08
. O 0 1.9744018686651543e-07

Recent O 0 1.56447143240257e-07
studies O 0 3.838160722580142e-08
in O 0 1.565634177858044e-09
animal O 0 3.814687676850781e-09
models O 0 1.8820787150986007e-09
elucidated O 0 8.237377642217325e-07
a O 0 8.287285524488652e-09
central O 0 1.4423084948589349e-08
role O 0 1.2364469448300497e-08
of O 0 4.107979023615371e-08
alpha O 0 1.933483872562647e-06
- O 0 1.3153422742107068e-06
MSH O 0 2.9749753593932837e-05
in O 0 2.2194162063726708e-09
the O 0 1.8632695386600062e-09
regulation O 0 8.253464578444891e-09
of O 0 1.56129231765334e-09
food O 0 2.218595307468263e-09
intake O 0 1.5260125385552215e-09
by O 0 1.4157328087627263e-10
activation O 0 1.0510134096364254e-08
of O 0 9.193769301418797e-09
the O 0 5.972640337859048e-08
brain O 0 1.0845591305042035e-06
melanocortin O 0 3.075797621931997e-06
- O 0 2.7858294515681337e-07
4 O 0 8.790716776729823e-08
- O 0 7.255263767547149e-08
receptor O 0 4.3377568204050476e-08
( O 0 1.3791634501103545e-09
MC4 O 0 1.7495581232651602e-06
- O 0 7.012942404571731e-08
R O 0 2.825792364546942e-07
; O 0 5.607090902692846e-10
refs O 0 3.945709892150262e-08
3 O 0 3.8414107450535084e-09
- O 0 2.6130622110542845e-09
5 O 0 1.6612359265977261e-09
) O 0 6.117149842221892e-11
and O 0 2.3761022663326692e-11
the O 0 8.549548291547637e-10
linkage O 0 2.1848757114639739e-07
of O 0 1.0891062274254182e-08
human O 0 1.528771349512681e-07
obesity B-Disease 1 0.9756719470024109
to O 0 2.4638306950208744e-09
chromosome O 0 5.402906566587262e-08
2 O 0 1.7161193355264004e-08
in O 0 4.600970271440019e-09
close O 0 1.910641458380269e-07
proximity O 0 1.4305419426818844e-07
to O 0 2.7029245508458644e-09
the O 0 8.855793254269884e-08
POMC O 0 0.005773068871349096
locus O 0 2.200309410227419e-07
, O 0 2.411809640889828e-10
led O 0 4.981497991884964e-10
to O 0 1.2426920603658687e-10
the O 0 9.552730828588096e-10
proposal O 0 1.643507996362814e-09
of O 0 8.198894008160096e-09
an O 0 5.230315291981924e-09
association O 0 2.9051198779939114e-08
of O 0 2.816416326822946e-07
POMC O 1 0.9987726807594299
with O 0 7.386799438791058e-08
human O 0 2.7081643565907143e-05
obesity B-Disease 1 1.0
. O 0 9.665856168794562e-07

The O 0 1.2960838375875028e-06
dual O 0 1.3068448652120424e-06
role O 0 3.576331550902978e-07
of O 0 8.985183512777439e-07
alpha O 0 9.235363540938124e-05
- O 0 0.00010849950922420248
MSH O 0 0.02684219554066658
in O 0 4.1857650678878144e-09
regulating O 0 6.492545168157449e-08
food O 0 1.713404707004429e-08
intake O 0 3.622403355052484e-08
and O 0 1.4315423291222373e-09
influencing O 0 5.082737970951712e-06
hair O 0 1.3269437658891547e-05
pigmentation O 0 2.038922320934944e-05
predicts O 0 6.245630146395342e-08
that O 0 1.883550121428712e-10
the O 0 3.805850301574765e-09
phenotype O 0 2.6018192045285105e-08
associated O 0 4.163374534016384e-09
with O 0 1.1097796015491213e-09
a O 0 2.1969482588701794e-07
defect O 0 2.991061819557217e-06
in O 0 4.4792351161504484e-08
POMC O 1 0.9981654286384583
function O 0 2.2726264603534219e-07
would O 0 8.911361648600291e-10
include O 0 8.630049563862485e-08
obesity B-Disease 1 1.0
, O 0 5.5788270003631624e-08
alteration O 0 0.00013739995483774692
in O 0 3.127380239220656e-07
pigmentation O 0 0.004489526618272066
and O 0 8.111470378935337e-06
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 6.506723366328515e-06

The O 0 7.928610443741491e-07
observation O 0 9.10227117856266e-06
of O 0 5.633703992202754e-08
these O 0 6.764530269265379e-09
symptoms O 0 4.5929502334729477e-07
in O 0 2.3534365567456916e-08
two O 0 1.6747387476812037e-08
probands O 0 5.034189234720543e-05
prompted O 0 6.60585399714364e-08
us O 0 1.1523237475330461e-08
to O 0 4.767797823213016e-10
search O 0 1.4698637862409214e-08
for O 0 9.645703125116256e-10
mutations O 0 6.979605338131023e-09
within O 0 2.8983953015426778e-08
their O 0 1.5677005649195053e-07
POMC O 1 0.9580270051956177
genes O 0 9.73082251221058e-07
. O 0 1.4632657041602215e-07

Patient O 0 5.404019611887634e-05
1 O 0 1.4343970633490244e-07
was O 0 6.349250725179445e-08
found O 0 2.375370566909396e-09
to O 0 8.299778087028642e-10
be O 0 2.3648600855352697e-09
a O 0 4.896122263176039e-08
compound O 0 7.731499636065564e-07
heterozygote O 0 1.2857607600835763e-07
for O 0 3.2571528807423533e-10
two O 0 4.797591213190344e-10
mutations O 0 8.717158661575297e-10
in O 0 1.2524010717385181e-09
exon O 0 8.812305196670422e-08
3 O 0 3.739408782621467e-08
( O 0 1.4696646566392246e-08
G7013T O 0 3.091110443165235e-07
, O 0 4.813762277677824e-09
C7133delta O 0 8.324235750478692e-06
) O 0 4.870124747924365e-09
which O 0 2.1966481411617167e-10
interfere O 0 1.544139038855974e-09
with O 0 1.4452095076222804e-10
appropriate O 0 2.0803973654892616e-08
synthesis O 0 2.6052734369841346e-07
of O 0 8.435426224195908e-08
ACTH O 0 5.154608061275212e-06
and O 0 2.3830228457200064e-08
alpha O 0 8.954200893640518e-06
- O 0 1.551043169456534e-05
MSH O 0 0.00043515575816854835
. O 0 3.336382974339358e-07

Patient O 0 5.4413969337474555e-05
2 O 0 2.8121354489485384e-07
was O 0 1.3017285027672187e-07
homozygous O 0 1.6006367786758346e-08
for O 0 8.787606753379862e-10
a O 0 5.39574607216764e-09
mutation O 0 1.042428143804841e-09
in O 0 3.954334637512602e-09
exon O 0 8.32248545634684e-08
2 O 0 4.53815935941293e-08
( O 0 2.3036422547306756e-08
C3804A O 0 1.4460721331488458e-06
) O 0 5.890357090976295e-09
which O 0 1.614153255502515e-09
abolishes O 0 1.5596328921674285e-06
POMC O 0 0.0007545329281128943
translation O 0 8.92541811481351e-06
. O 0 3.1826638746679237e-07

These O 0 3.241154900024412e-08
findings O 0 4.0082891672454934e-08
represent O 0 2.42021624963229e-09
the O 0 9.670535483508047e-10
first O 0 1.2024139461885852e-09
examples O 0 3.827777650400321e-09
of O 0 7.809797253344186e-09
a O 0 2.3507185176185885e-07
genetic B-Disease 1 0.9999996423721313
defect I-Disease 1 0.999764621257782
within O 0 4.3919200720665685e-08
the O 0 8.489563185776206e-08
POMC O 0 0.08027765154838562
gene O 0 2.622553951781015e-09
and O 0 6.200186891680559e-11
define O 0 2.100571938612461e-09
a O 0 5.0189723488358595e-09
new O 0 2.2135916211141193e-08
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9931275844573975
resulting O 0 1.058997895597713e-06
in O 0 2.60092605230966e-08
early O 0 2.9027354685240425e-05
- O 1 0.5848463773727417
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0011922767153009772
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.9346641693118727e-06
red O 0 3.1695431971456856e-05
hair O 0 0.0007451819838024676
pigmentation O 0 0.0007108071586117148
. O 0 3.893349855843553e-07
. O 0 1.377517833134334e-06

A O 0 4.72992815048201e-06
European O 0 2.8792982220693375e-07
multicenter O 0 0.0002808523422572762
study O 0 1.7525873090562527e-06
of O 0 3.598383773351088e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.2244691422201868e-08
classification O 0 1.153278503807087e-07
of O 0 5.263673941158231e-08
105 O 0 2.281282007743357e-07
mutations O 0 6.989993583950138e-10
and O 0 1.0753290619058831e-10
a O 0 1.2497570756053733e-09
general O 0 2.900877094091925e-09
system O 0 3.6645071421759212e-09
for O 0 1.0256523408358476e-09
genotype O 0 1.0545156925445553e-07
- O 0 1.6473180153298017e-07
based O 0 4.1613677836949137e-08
prediction O 0 1.2562244364744402e-06
of O 0 1.343285447319431e-07
metabolic O 0 0.00032925690175034106
phenotype O 0 1.8234509298054036e-06
. O 0 1.41569699962929e-07

Phenylketonuria B-Disease 1 0.9999784231185913
( O 0 6.589938857359812e-05
PKU B-Disease 0 0.4448280334472656
) O 0 8.083032554395686e-08
and O 0 1.0061027566621306e-08
mild B-Disease 0 3.7790734495501965e-05
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999998807907104
MHP B-Disease 1 1.0
) O 0 6.69480868964456e-07
are O 0 5.891581889017061e-09
allelic B-Disease 0 0.00010602390102576464
disorders I-Disease 1 0.999896764755249
caused O 0 4.942492068948923e-07
by O 0 6.391080997758536e-09
mutations O 0 2.2719011116834054e-09
in O 0 3.2464557708777875e-09
the O 0 3.470102782898721e-08
gene O 0 7.59539204864268e-08
encoding O 0 1.3011327837375575e-07
phenylalanine O 0 8.073253411566839e-06
hydroxylase O 0 3.931753235519864e-05
( O 0 3.157295850542141e-06
PAH O 1 0.9999537467956543
) O 0 1.8616117358760675e-06
. O 0 9.550805089020287e-07

Previous O 0 2.3290626813832205e-06
studies O 0 1.1336155125718506e-07
have O 0 4.718259116742729e-10
suggested O 0 1.109836667012587e-09
that O 0 5.396646671207428e-11
the O 0 9.894977059943244e-10
highly O 0 1.1171410463362008e-08
variable O 0 6.869170761092391e-07
metabolic O 0 0.0001529923902126029
phenotypes O 0 1.2119986422476359e-05
of O 0 0.011594891548156738
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.003063166281208396
with O 0 2.3586776478623506e-06
PAH O 1 1.0
genotypes O 0 0.0004932439769618213
. O 0 1.3992212188895792e-06

We O 0 2.56261586173423e-07
identified O 0 1.701914413843042e-07
both O 0 2.714840796613771e-08
causative O 0 1.778428486431949e-05
mutations O 0 7.19317512221096e-08
in O 0 1.4825848992927604e-08
686 O 0 1.0057095778392977e-06
patients O 0 1.8838060000803125e-09
from O 0 1.4827142846840502e-09
seven O 0 5.9351172865262924e-09
European O 0 2.8198179791161238e-08
centers O 0 1.3356503814065945e-07
. O 0 2.1212460410424683e-07

On O 0 4.081117879195517e-07
the O 0 9.678326584605657e-09
basis O 0 3.044800678253523e-08
of O 0 6.697577603631544e-09
the O 0 5.087013921212247e-09
phenotypic O 0 8.889691827107526e-08
characteristics O 0 2.098282436691079e-08
of O 0 6.476874858662995e-08
297 O 0 3.3499108553769474e-07
functionally O 0 9.204684943142638e-07
hemizygous O 0 2.852643774531316e-06
patients O 0 2.769229512367133e-09
, O 0 2.3511731450653883e-10
105 O 0 1.0959620766470834e-08
of O 0 2.5183555241170552e-09
the O 0 2.5035662432060235e-09
mutations O 0 6.508930616710984e-10
were O 0 9.785461330125145e-10
assigned O 0 1.8142502611340205e-08
to O 0 1.327039589327228e-09
one O 0 2.1073214284683672e-09
of O 0 8.56688853190235e-09
four O 0 6.39805763924528e-09
arbitrary O 0 4.018784593995406e-08
phenotype O 0 7.399546575470595e-08
categories O 0 2.920925226135296e-07
. O 0 2.2983873293469514e-07

We O 0 1.737114274646956e-07
proposed O 0 2.802108944877091e-08
and O 0 2.011610655827667e-09
tested O 0 5.6869691178462745e-09
a O 0 2.2866559756806737e-09
simple O 0 3.941382775707325e-09
model O 0 1.4049037488916838e-09
for O 0 2.065032450593307e-10
correlation O 0 8.728076927866368e-09
between O 0 3.0421754004805734e-09
genotype O 0 2.9004246115960086e-08
and O 0 1.2475682709123248e-09
phenotypic O 0 1.5272179609837622e-07
outcome O 0 7.096622880453651e-07
. O 0 3.4481988109291706e-07

The O 0 1.624795686439029e-06
observed O 0 6.020966338837752e-07
phenotype O 0 2.917787469414179e-07
matched O 0 1.1774231722938566e-07
the O 0 3.5797299346995715e-08
predicted O 0 2.6263202812515374e-07
phenotype O 0 5.824244908581022e-08
in O 0 2.028501810968919e-09
79 O 0 3.0445860943473235e-08
% O 0 1.1214635886602764e-09
of O 0 8.786969485363727e-10
the O 0 6.172425348616173e-10
cases O 0 1.745105171480077e-10
, O 0 9.700180242377954e-11
and O 0 6.237026867195183e-11
in O 0 4.760846161744325e-10
only O 0 2.8194921397606265e-10
5 O 0 4.682809695566448e-10
of O 0 5.298814165222154e-10
184 O 0 2.7998316998179007e-09
patients O 0 1.174655789304424e-10
was O 0 1.4224841304866231e-09
the O 0 1.0596966637521632e-09
observed O 0 2.4129613862555743e-09
phenotype O 0 9.700129588452455e-10
more O 0 6.655023320617515e-12
than O 0 9.964150164687435e-12
one O 0 7.883799169050576e-11
category O 0 1.4900257694350216e-09
away O 0 1.0522523963274466e-09
from O 0 5.989518325755228e-10
that O 0 4.863744962335659e-10
expected O 0 2.183941916200638e-08
. O 0 2.2558849366305367e-07

Among O 0 5.021837878871338e-08
the O 0 5.8222537901997384e-09
seven O 0 9.563017044911248e-09
contributing O 0 4.408697762414704e-08
centers O 0 5.163970140387164e-09
, O 0 9.376289328288934e-11
the O 0 3.0229299619044525e-10
proportion O 0 1.8580952332314382e-09
of O 0 1.6766714683313921e-09
patients O 0 1.969340662766328e-10
for O 0 7.987631389649863e-11
whom O 0 2.0030497260847824e-09
the O 0 9.55998924467849e-09
observed O 0 3.2431032082058664e-08
phenotype O 0 5.462704066871993e-09
did O 0 3.546223037442786e-10
not O 0 1.4838931472471728e-10
match O 0 5.83717563173991e-09
the O 0 1.926241566252429e-08
predicted O 0 6.465679547318359e-08
phenotype O 0 8.570369303129155e-09
was O 0 1.9563886510809425e-08
4 O 0 6.8325816116043825e-09
% O 0 4.4395520593099036e-10
- O 0 7.951245772908067e-10
23 O 0 2.6299022959364038e-09
% O 0 4.964841315846513e-10
( O 0 1.1227520024803539e-09
P O 0 3.21619353371716e-07
< O 0 5.260984181632011e-08
. O 0 1.9795651229337352e-10
0001 O 0 6.289569114414917e-07
) O 0 4.071507575531541e-10
, O 0 1.8720736766342227e-11
suggesting O 0 5.650033219062323e-10
that O 0 1.5390829236072712e-11
differences O 0 3.4789199299112283e-10
in O 0 1.510691849393453e-10
methods O 0 5.512059697565519e-10
used O 0 2.4671212295324096e-10
for O 0 1.8756558806121149e-10
mutation O 0 2.8035991306296637e-09
detection O 0 1.0344786005589413e-07
or O 0 9.356003971561222e-09
phenotype O 0 1.0595559984949432e-07
classification O 0 3.588281671795812e-08
may O 0 1.3792870179329952e-09
account O 0 2.5798718716885105e-09
for O 0 1.8213004715494918e-10
a O 0 1.3780774299476661e-09
considerable O 0 1.4809004689197991e-08
proportion O 0 5.227951405117892e-09
of O 0 3.945190840681789e-08
genotype O 0 5.077604328107554e-07
- O 0 7.679691975681635e-07
phenotype O 0 4.3226259549555834e-07
inconsistencies O 0 1.079225853573007e-06
. O 0 1.881331854747259e-07

Our O 0 1.6113629044411937e-06
data O 0 1.9583569610404084e-07
indicate O 0 3.103693657635631e-08
that O 0 7.675189928058046e-10
the O 0 6.039022082404699e-08
PAH O 1 0.9999018907546997
- O 0 1.6826011233206373e-06
mutation O 0 8.163067555244652e-09
genotype O 0 8.762037317922022e-09
is O 0 1.1769971108854804e-10
the O 0 5.273063652388998e-10
main O 0 2.6791461493758106e-08
determinant O 0 1.9517639771038375e-07
of O 0 2.138557597675117e-08
metabolic O 0 3.0561339372070506e-05
phenotype O 0 4.8708425737231664e-08
in O 0 1.6268100200278468e-09
most O 0 1.8514654254175866e-09
patients O 0 1.2522630932210177e-08
with O 0 1.0904115015364368e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 6.289909651968628e-05

In O 0 1.3786821284611506e-07
the O 0 5.732873731290056e-09
present O 0 2.8040001431861583e-09
study O 0 3.027663231236488e-09
, O 0 1.4232216793974573e-10
the O 0 9.374827580899137e-10
classification O 0 1.7333865898194745e-08
of O 0 5.8996135976485675e-08
105 O 0 6.181501521496102e-05
PAH O 1 1.0
mutations O 0 3.868352393965324e-08
may O 0 7.454588057953515e-10
allow O 0 5.811666148325401e-10
the O 0 4.1587235877216244e-09
prediction O 0 2.1122627913428005e-07
of O 0 4.460859237553905e-09
the O 0 9.85022108324074e-09
biochemical O 0 4.931041530653602e-07
phenotype O 0 2.0372112885524984e-08
in O 0 2.9023050629461977e-09
> O 0 1.2448616359961306e-08
10 O 0 7.321035999652281e-10
, O 0 1.7731614787575012e-10
000 O 0 8.537037743394649e-09
genotypes O 0 7.1069155005432094e-09
, O 0 1.0563259988938256e-10
which O 0 2.2143399960872223e-11
may O 0 1.1720596715392162e-10
be O 0 8.741229268194317e-11
useful O 0 6.493298787546564e-09
for O 0 6.761224358164952e-10
the O 0 2.389175968176005e-08
management O 0 3.1235340429702774e-06
of O 0 1.0816887879627757e-05
hyperphenylalaninemia B-Disease 1 1.0
in O 0 4.112740498385392e-06
newborns O 0 6.675842996628489e-06
. O 0 5.052264668847783e-07

Somatic O 0 9.257945202989504e-05
instability O 0 1.0409868991700932e-05
of O 0 7.92993375853257e-07
the O 0 1.7402676348865498e-06
CTG O 1 0.999906063079834
repeat O 0 3.2100817861646647e-06
in O 0 1.305786696548239e-07
mice O 0 1.3894408823489357e-07
transgenic O 0 2.68661217717181e-08
for O 0 1.5186112367615578e-09
the O 0 1.8544086515248637e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.727731782670162e-07
is O 0 6.584023326539068e-10
age O 0 2.6332001024087504e-09
dependent O 0 3.4632969825310056e-09
but O 0 3.13764569881414e-11
not O 0 4.0823608382645205e-11
correlated O 0 2.95937274685798e-09
to O 0 1.0077841339217741e-10
the O 0 4.3681751549229375e-09
relative O 0 6.468473543463915e-07
intertissue O 0 2.8106871468480676e-05
transcription O 0 2.2834983610664494e-06
levels O 0 4.4493649653531975e-08
and O 0 1.296467555533809e-08
proliferative O 0 0.0009390912600792944
capacities O 0 2.1963229301036336e-05
. O 0 2.0546760879369685e-06

A O 0 0.0004491229774430394
( O 0 1.1534226359799504e-05
CTG O 0 0.10983796417713165
) O 0 1.4066802123124944e-07
nexpansion O 0 1.5235825685522286e-06
in O 0 7.24342497093744e-09
the O 0 1.372459390580616e-08
3 O 0 4.468807190960433e-08
- O 0 1.2441024921372446e-07
untranslated O 0 2.349550231883768e-05
region O 0 1.5937554564970924e-07
( O 0 4.386211216456104e-08
UTR O 0 6.799500988563523e-05
) O 0 4.286826005284183e-09
of O 0 1.0450724730048933e-08
the O 0 1.418422783672213e-07
DM O 1 1.0
protein O 0 5.006696937925881e-06
kinase O 0 3.4231702557008248e-06
gene O 0 2.9965036674184375e-08
( O 0 9.508598353136222e-09
DMPK O 0 3.8664500607410446e-05
) O 0 3.7488621096315455e-09
is O 0 7.279458702491581e-10
responsible O 0 6.9325847285028885e-09
for O 0 2.8953119013408468e-08
causing O 1 0.9752739071846008
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999951124191284
DM B-Disease 1 1.0
) O 0 1.7357260730932467e-06
. O 0 3.4034658824566577e-07

Major O 0 2.705554652493447e-05
instability O 0 2.5910638214554638e-05
, O 0 6.772844063362982e-09
with O 0 6.783442141333751e-10
very O 0 1.8477083196799526e-09
large O 0 2.775093266293993e-09
expansions O 0 3.3880759531257354e-08
between O 0 5.643304490376977e-09
generations O 0 3.3310458835700274e-09
and O 0 2.2757856710242663e-10
high O 0 3.0674744966319167e-09
levels O 0 2.48953790915607e-09
of O 0 3.4005629423461414e-09
somatic O 0 7.053683503954744e-08
mosaicism O 0 8.945947229221929e-06
, O 0 4.4309741986658935e-10
is O 0 2.629574891166442e-10
observed O 0 3.672911086383124e-09
in O 0 5.62010304960836e-09
patients O 0 2.4612862858930384e-08
. O 0 1.1687907885971072e-07

There O 0 1.0370839618190075e-06
is O 0 1.5349311155432588e-08
a O 0 1.9957667518610833e-08
good O 0 2.037553414879767e-08
correlation O 0 5.003271041914559e-08
between O 0 4.096404548903365e-09
repeat O 0 3.426346850687878e-08
size O 0 4.6223295413483356e-08
( O 0 5.514028789121994e-09
at O 0 1.3200122772616396e-08
least O 0 7.341339758326626e-10
in O 0 5.827138771508089e-10
leucocytes O 0 4.5706261175837426e-07
) O 0 1.5274074227633605e-09
, O 0 1.4181815444214152e-10
clinical O 0 5.925604895651304e-09
severity O 0 3.1780288622940134e-08
and O 0 1.3417504884927212e-09
age O 0 9.135291634265741e-07
of O 0 8.079299732344225e-06
onset O 1 0.9985325336456299
. O 0 1.3267892882140586e-06

The O 0 8.408376743318513e-06
trinucleotide O 0 0.0013762296875938773
repeat O 0 4.198330316285137e-06
instability O 0 4.629141585610341e-06
mechanisms O 0 8.527246791345533e-06
involved O 0 3.038879640371306e-06
in O 0 2.400477796982159e-06
DM B-Disease 1 1.0
and O 0 6.198206392582506e-09
other O 0 1.5326077074107047e-09
human O 0 7.86622649684432e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 9.951648394235235e-09
unknown O 0 4.7988829464884475e-05
. O 0 1.5074128612013737e-07

We O 0 2.594876207240304e-07
studied O 0 1.2860369906775304e-06
somatic O 0 2.6126656393898884e-06
instability O 0 7.159345614127233e-07
by O 0 3.119617275615383e-08
measuring O 0 1.8300084775546566e-05
the O 0 2.299165515751156e-07
CTG O 0 0.015167978592216969
repeat O 0 7.670353596722634e-08
length O 0 1.0035651420992053e-08
at O 0 2.2731274640364063e-09
several O 0 3.4483443878130515e-11
ages O 0 5.136012171114146e-10
in O 0 1.2457725129255692e-10
various O 0 2.4056212577505676e-10
tissues O 0 8.541582552368254e-09
of O 0 1.816306927082678e-08
transgenic O 0 1.538086706887043e-07
mice O 0 2.8692361819793177e-09
carrying O 0 4.4960524192561024e-09
a O 0 1.679674888066529e-08
( O 0 5.903541833163217e-08
CTG O 0 0.001630975748412311
) O 0 2.4205224491424815e-08
55expansion O 0 9.674699867900927e-07
surrounded O 0 2.907825944475917e-07
by O 0 4.179159684980505e-09
45 O 0 4.106638940015728e-08
kb O 0 1.480935111430881e-06
of O 0 1.969034535420633e-08
the O 0 5.1335000250674057e-08
human O 0 4.7193799446176854e-07
DM B-Disease 1 1.0
region O 0 3.740706944199701e-08
, O 0 5.743629460930322e-10
using O 0 2.366841167500411e-09
small O 0 1.3677580845694592e-08
- O 0 2.3251715219885227e-07
pool O 0 3.052196461794665e-06
PCR O 0 4.9825193855213e-06
. O 0 2.3701248608176684e-07

These O 0 4.00310966597317e-07
mice O 0 4.129008459585748e-07
have O 0 4.0648731602921373e-10
been O 0 5.425806470782391e-10
shown O 0 3.4660840864120246e-10
to O 0 1.2002135396649294e-10
reproduce O 0 5.810715908438624e-09
the O 0 3.0593352295937848e-09
intergenerational O 0 9.164588021803866e-08
and O 0 6.263280449836373e-10
somatic O 0 6.292814447306228e-08
instability O 0 1.2537549309854512e-07
of O 0 1.949847217019851e-08
the O 0 6.784224382272441e-08
55 O 0 8.661791071062908e-07
CTG O 0 0.0020106472074985504
repeat O 0 8.686296126825255e-08
suggesting O 0 1.1881135186797565e-08
that O 0 6.910320232700329e-11
surrounding O 0 2.483533823038897e-09
sequences O 0 3.933617431783887e-09
and O 0 3.872054343823095e-10
the O 0 4.282543653033599e-09
chromatin O 0 1.3795383324577415e-07
environment O 0 1.2550056993632097e-08
are O 0 1.1602799276921871e-10
involved O 0 5.054584750752156e-09
in O 0 9.858340810353639e-09
instability O 0 1.4100717180554057e-06
mechanisms O 0 1.4086930605117232e-05
. O 0 1.154969595518196e-06

As O 0 1.1340718231167557e-07
observed O 0 8.858260258648443e-08
in O 0 2.464601411844569e-09
some O 0 3.476651466716163e-10
of O 0 4.025948019403813e-09
the O 0 1.0373550018982769e-08
tissues O 0 1.3308454072102904e-07
of O 0 3.636305336840451e-05
DM B-Disease 1 1.0
patients O 0 4.195750591406977e-07
, O 0 4.4401787802073045e-10
there O 0 7.750303732123598e-10
is O 0 4.099982853222883e-10
a O 0 9.674963052930252e-10
tendency O 0 1.5717619428201601e-09
for O 0 1.569717966720674e-10
repeat O 0 8.819447394614599e-09
length O 0 1.1843419578383418e-08
and O 0 1.7228580784234282e-09
somatic O 0 3.5153902899764944e-07
mosaicism O 0 3.2105258469528053e-06
to O 0 9.900659181383276e-10
increase O 0 5.956184989663882e-10
with O 0 6.377035011162491e-11
the O 0 2.535407217507668e-09
age O 0 2.0768052166886264e-08
of O 0 5.206579345440332e-08
the O 0 6.375900341026863e-08
mouse O 0 3.5676251286531624e-07
. O 0 4.0183707028518256e-08

Furthermore O 0 4.968957000528462e-06
, O 0 1.035275598582075e-08
we O 0 3.429646788788432e-09
observed O 0 1.3422271294416532e-08
no O 0 3.792126612722768e-09
correlation O 0 5.7082911730788055e-09
between O 0 1.1583876080578648e-09
the O 0 1.2188939857438186e-09
somatic O 0 9.427820302221335e-09
mutation O 0 3.2962388374357943e-10
rate O 0 7.749239583354495e-10
and O 0 2.489137784777995e-10
tissue O 0 8.956318424679921e-07
proliferation O 0 0.0004709004715550691
capacity O 0 8.66031496116193e-06
. O 0 3.898484806086344e-07

The O 0 2.684819833120855e-07
somatic O 0 3.413021829601348e-07
mutation O 0 4.727197744358591e-09
rates O 0 5.019993865040817e-10
in O 0 3.842198434411692e-11
different O 0 2.3465123941135424e-11
tissues O 0 1.6116827872281192e-09
were O 0 1.3126051356948665e-09
also O 0 1.53238477462736e-10
not O 0 1.1591008708400352e-10
correlated O 0 6.121381179724494e-09
to O 0 3.11735387503731e-10
the O 0 2.257895648227759e-09
relative O 0 1.2980181907096267e-07
inter O 0 1.982879211936961e-06
- O 0 2.06263325708278e-06
tissue O 0 3.139440991617448e-07
difference O 0 2.7772394162184355e-08
in O 0 2.545359700789618e-09
transcriptional O 0 4.412862253388994e-08
levels O 0 2.1656063609043485e-09
of O 0 6.042761846458689e-10
the O 0 9.618275065292892e-10
three O 0 5.104486833218402e-10
genes O 0 4.7580708262273674e-09
( O 0 3.324717612329664e-09
DMAHP O 0 4.6754344111832324e-06
, O 0 1.2289794959485789e-08
DMPK O 0 5.6809767556842417e-05
and O 0 9.142725687638631e-09
59 O 0 1.6585811124514294e-07
) O 0 6.954224751609672e-09
surrounding O 0 7.45097068488576e-08
the O 0 3.5066907599912156e-08
repeat O 0 3.5163495226697705e-07
. O 0 4.2903291586071646e-08
. O 0 1.547703902815556e-07

A O 0 3.643149284471292e-06
novel O 0 1.540720518278249e-06
missense O 0 4.587986495607765e-06
mutation O 0 1.668384541630985e-08
in O 0 1.8550426750252313e-09
patients O 0 2.5406063919319877e-09
from O 0 6.857491907652502e-09
a O 0 9.9045763590766e-08
retinoblastoma B-Disease 0 0.002697059651836753
pedigree O 0 4.712858753919136e-06
showing O 0 3.967965866991108e-08
only O 0 9.282924984255203e-10
mild O 0 4.597934921690694e-09
expression O 0 3.914486956801966e-09
of O 0 5.503963063091533e-09
the O 0 6.643850269938412e-08
tumor B-Disease 0 3.600515265134163e-05
phenotype O 0 8.650836775814241e-07
. O 0 1.2257399362169963e-07

We O 0 1.3667677478679252e-07
have O 0 1.5964618516051132e-09
used O 0 2.1435140329373326e-09
single O 0 7.137902713338917e-09
strand O 0 2.816544331096793e-08
conformation O 0 5.643595368809429e-09
polymorphism O 0 5.412341241850527e-09
analysis O 0 1.1086224160905545e-09
to O 0 9.940900880245351e-11
study O 0 1.1192690108074999e-09
the O 0 3.822014260634887e-09
27 O 0 4.817530552259086e-08
exons O 0 1.7916983452437307e-08
of O 0 3.7146048459391068e-09
the O 0 2.8613351688022703e-08
RB1 O 0 0.00020974685321561992
gene O 0 1.4381982271771676e-09
in O 0 1.2967382723161336e-10
individuals O 0 1.4836866457645925e-10
from O 0 1.8875285778818807e-09
a O 0 1.555793716079279e-08
family O 0 2.05378096751474e-08
showing O 0 5.534029767773063e-08
mild O 0 1.572122521054098e-08
expression O 0 1.1391485976730564e-08
of O 0 1.540703564728574e-08
the O 0 1.2859986497915088e-07
retinoblastoma B-Disease 0 4.932179217576049e-05
phenotype O 0 2.323505668755388e-06
. O 0 1.543904915024541e-07

In O 0 3.373551749064063e-07
this O 0 8.04172461954522e-09
family O 0 2.5791992541712716e-08
affected O 0 1.515249259398388e-09
individuals O 0 2.0380683252163578e-10
developed O 0 5.601599628590748e-09
unilateral B-Disease 0 3.809919917330262e-07
tumors I-Disease 1 1.0
and O 0 9.757137320320908e-09
, O 0 1.0215718271311403e-09
as O 0 3.6060343600041733e-10
a O 0 4.962796840146666e-10
result O 0 3.612098953276188e-10
of O 0 1.4459464736660266e-09
linkage O 0 4.9047585548578354e-08
analysis O 0 5.902796029744195e-09
, O 0 4.504513428926771e-10
unaffected O 0 2.8469958834875797e-08
mutation O 0 7.139097646380321e-10
carriers O 0 7.957405845360199e-10
were O 0 2.142140909100476e-09
also O 0 1.199655819128509e-09
identified O 0 1.5439395539829093e-08
within O 0 8.390912142886009e-08
the O 0 6.980313287385798e-07
pedigree O 0 2.571228651504498e-05
. O 0 6.67454912672838e-07

A O 0 4.470521616894985e-06
single O 0 9.473175310859006e-08
band O 0 2.0681530088495492e-07
shift O 0 1.1305019143037498e-07
using O 0 4.686084409399882e-08
SSCP O 0 3.633393862401135e-05
was O 0 2.1102312075527152e-07
identified O 0 5.2235787251220245e-08
in O 0 6.78013378774267e-09
exon O 0 1.2179260977518425e-07
21 O 0 6.686307507663969e-09
which O 0 1.0346626333479492e-10
resulted O 0 2.042727764717256e-09
in O 0 8.899607717438585e-10
a O 0 9.386820210011138e-09
missense O 0 3.523821234807656e-08
mutation O 0 1.0435660113827794e-09
converting O 0 8.40274338997915e-09
a O 0 1.759357459718558e-08
cys O 0 2.081800175801618e-06
- O 0 2.164463467124733e-06
- O 0 5.640462859446416e-06
> O 0 1.9801391317741945e-06
arg O 0 5.022479854233097e-07
at O 0 5.9185254031035583e-08
nucleotide O 0 1.527608475271336e-07
position O 0 2.6002364705846048e-08
28 O 0 4.726803126686718e-08
in O 0 4.662313646264238e-09
the O 0 1.3916368857280759e-07
exon O 0 5.633259206661023e-06
. O 0 2.9879518592679233e-07

The O 0 5.604839543593698e-07
mutation O 0 1.2491885570398154e-07
destroyed O 0 4.672238446801202e-06
an O 0 6.302280297632024e-08
NdeI O 0 6.599157495656982e-05
restriction O 0 4.189537037291302e-07
enzyme O 0 3.2067879374153563e-07
site O 0 4.911236715088307e-07
. O 0 1.4849118201709643e-07

Analysis O 0 5.425156814453658e-06
of O 0 1.29620971733857e-07
all O 0 1.0392779081769277e-08
family O 0 6.649960937465949e-08
members O 0 1.7119826667411076e-09
demonstrated O 0 6.205350899790574e-09
that O 0 4.772128248120566e-10
the O 0 1.1436332769676483e-08
missense O 0 5.064005677013483e-07
mutation O 0 1.2765770662781506e-08
co O 0 6.963344958421658e-07
- O 0 1.9084175164607586e-06
segregated O 0 1.5102519057563768e-07
with O 0 1.709401842298064e-09
patients O 0 1.845958585988683e-08
with O 0 3.406069382094756e-08
tumors B-Disease 1 1.0
or O 0 0.006995373405516148
who O 0 6.08975483373797e-08
, O 0 1.4847857388033958e-09
as O 0 1.7933932117131235e-09
a O 0 2.262249498841129e-09
result O 0 1.4542828052910295e-09
of O 0 1.6121079582376296e-08
linkage O 0 3.152510146264831e-07
analysis O 0 1.3116673081015051e-08
had O 0 5.0149435715241e-09
been O 0 4.623314620033625e-09
predicted O 0 1.4567182127223077e-08
to O 0 8.288482122864593e-10
carry O 0 7.758353071096735e-09
the O 0 1.2066813326327974e-07
predisposing O 0 3.393023507669568e-05
mutation O 0 2.2858836246086867e-07
. O 0 2.0898632158150576e-07

These O 0 2.5002373149618506e-07
observations O 0 2.015570998992189e-06
point O 0 1.91530986626276e-07
to O 0 1.3220373684674769e-09
another O 0 1.3968859846613668e-08
region O 0 2.6620009307976034e-08
of O 0 1.2725590181617008e-07
the O 0 8.135169196066272e-07
RB1 O 0 0.07859166711568832
gene O 0 2.6026032884374217e-08
where O 0 1.2220597866985372e-09
mutations O 0 2.8162566723111127e-10
only O 0 6.34020128065238e-11
modify O 0 1.569098323495055e-10
the O 0 2.5928001412545143e-10
function O 0 1.9228341141541705e-09
of O 0 2.0095245467643963e-09
the O 0 4.0863690209391734e-09
gene O 0 1.3973407986256348e-09
and O 0 5.4859408682439437e-11
raise O 0 8.523724503994856e-10
important O 0 1.362692736428528e-09
questions O 0 2.711796120991039e-09
for O 0 5.577885375807057e-10
genetic O 0 1.288405968580264e-07
counseling O 0 2.821082034643041e-08
in O 0 3.2991445686469945e-10
families O 0 1.0916007681105455e-10
with O 0 3.227085612622638e-11
these O 0 3.5714947665965724e-10
distinctive O 0 7.598359275107214e-09
phenotypes O 0 1.2277381244985008e-07
. O 0 1.2144945493730575e-08
. O 0 1.2700952822797262e-07

Maternal B-Disease 1 0.953304648399353
disomy I-Disease 1 0.9670450091362
and O 0 1.1170577636221424e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 4.603559500537813e-05
with O 0 1.1667211197163851e-08
gamete O 0 0.0001491376751800999
complementation O 0 1.3694983863388188e-05
in O 0 9.485266794229119e-09
a O 0 1.4285726379625885e-08
case O 0 3.119450298072479e-08
of O 0 3.3591308579161705e-07
familial O 0 2.8185977498651482e-05
translocation O 0 5.9705098465201445e-06
( O 0 4.1948300832928e-08
3 O 0 2.450157232658512e-08
; O 0 1.04002506606804e-09
15 O 0 8.593678657575765e-09
) O 0 5.4712856467631354e-09
( O 0 9.473478890242859e-09
p25 O 0 2.9015876634730375e-07
; O 0 8.841844478801875e-10
q11 O 0 2.696646959066129e-07
. O 0 2.7077957653887097e-09
2 O 0 1.1982801595422643e-07
) O 0 4.8681489062119e-08
. O 0 6.370004967948262e-08

Maternal B-Disease 1 0.9999996423721313
uniparental I-Disease 1 1.0
disomy I-Disease 1 0.9999998807907104
( I-Disease 1 0.5809648036956787
UPD I-Disease 1 1.0
) I-Disease 0 1.0369637237772622e-07
for I-Disease 0 5.165487149128012e-09
chromosome I-Disease 0 1.997164815747965e-07
15 I-Disease 0 2.0905684294802995e-08
is O 0 2.2142663258506445e-09
responsible O 0 1.0448172993449134e-08
for O 0 8.265023110354264e-10
an O 0 4.026685651581374e-09
estimated O 0 1.3345077931603555e-08
30 O 0 1.1595465920777315e-08
% O 0 6.267415475491589e-10
of O 0 1.3033445434018631e-09
cases O 0 1.7554616649206878e-09
of O 0 3.5966936593467835e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9977191090583801
PWS B-Disease 1 1.0
) O 0 2.028744575000019e-06
. O 0 2.723533896187291e-07

We O 0 2.2762661444630794e-07
report O 0 1.9066710876813886e-08
on O 0 2.137867438634089e-09
an O 0 9.179991766750106e-10
unusual O 0 1.870037680262726e-09
case O 0 6.20124529504551e-09
of O 0 1.477778965863763e-07
maternal B-Disease 0 0.0001623794378247112
disomy I-Disease 0 0.05724592134356499
15 I-Disease 0 7.876669201323239e-07
in O 0 2.0876164796845842e-07
PWS B-Disease 1 1.0
that O 0 1.4340236775822746e-09
is O 0 5.905326228017316e-10
most O 0 1.3491327499615124e-10
consistent O 0 6.535494367909678e-09
with O 0 2.0164768466113259e-10
adjacent O 0 1.3843130375335022e-07
- O 0 1.8885060626416816e-07
1 O 0 1.480805025266818e-07
segregation O 0 1.3513185592728405e-07
of O 0 1.9433498366083768e-08
a O 0 3.590574948475478e-08
paternal O 0 3.8341809727171494e-07
t O 0 2.2734624849363172e-08
( O 0 8.950950536323887e-10
3 O 0 1.686241590803661e-09
; O 0 9.078282570129659e-11
15 O 0 3.6614469234308444e-09
) O 0 2.5433117833983943e-09
( O 0 2.445240010473526e-09
p25 O 0 1.7095484849960485e-07
; O 0 4.786631646602757e-10
q11 O 0 6.240914274258103e-08
. O 0 4.933859432121324e-10
2 O 0 4.004122811096522e-09
) O 0 2.5093735422920815e-10
with O 0 2.5655275126545973e-10
simultaneous O 0 9.558735314385558e-08
maternal O 0 2.3415457235387294e-06
meiotic O 0 3.0801587854512036e-05
nondisjunction O 0 4.552814789349213e-05
for O 0 4.244585127821665e-08
chromosome O 0 1.334639819106087e-06
15 O 0 2.407118415703735e-07
. O 0 9.069105288972423e-08

The O 0 4.261065896571381e-06
patient O 0 1.7981366227104445e-06
( O 0 7.009759173115526e-08
J O 0 6.749652925464034e-07
. O 0 1.7272769881060412e-09
B O 0 1.0221457813486268e-07
. O 0 4.367140260530533e-10
) O 0 5.085061816068048e-10
, O 0 1.2313526587259815e-10
a O 0 2.6070134939715217e-09
17 O 0 6.6936953757590345e-09
- O 0 9.832763048223114e-09
year O 0 8.418818531197303e-09
- O 0 2.0468517902827443e-07
old O 0 8.794058885541745e-07
white O 0 8.798583905900159e-08
male O 0 5.3814734002344267e-08
with O 0 8.899374570603413e-09
PWS B-Disease 1 1.0
, O 0 1.0873336009353807e-08
was O 0 7.214114106091074e-08
found O 0 1.3879352112056154e-09
to O 0 5.401510350111494e-10
have O 0 7.855943673362731e-10
47 O 0 4.494956939993244e-08
chromosomes O 0 4.714557633178629e-08
with O 0 1.8296543169427082e-09
a O 0 1.2283025796477887e-07
supernumerary O 0 0.00017324519285466522
, O 0 1.1521215981247224e-08
paternal O 0 6.10923052590806e-07
der O 0 4.323158646002412e-05
( O 0 1.924188808288818e-08
15 O 0 4.938993214409493e-09
) O 0 5.212366649409717e-10
consisting O 0 2.9470033080514213e-09
of O 0 1.966362361827123e-08
the O 0 5.200832475793504e-08
short O 0 3.25986377447407e-07
arm O 0 2.069742367893923e-05
and O 0 3.638988843590596e-08
the O 0 1.9453470940788975e-06
proximal O 1 0.9978395700454712
long O 0 7.242809715535259e-06
arm O 0 0.00015191113925538957
of O 0 1.0043963811767753e-05
chromosome O 0 9.559347745380364e-06
15 O 0 1.7574936350683856e-07
, O 0 9.10034358980738e-09
and O 0 6.095181959153706e-08
distal O 1 0.5284307599067688
chromosome O 1 0.999895453453064
arm O 1 0.9999997615814209
3p O 1 1.0
. O 0 0.00019093017908744514

The O 0 1.0689615010051057e-05
t O 0 6.348723786686605e-07
( O 0 1.1038964409237906e-08
3 O 0 5.099779709638597e-09
; O 0 1.6094764410112816e-10
15 O 0 1.9089696490226515e-09
) O 0 2.961036693616137e-10
was O 0 2.262137366315642e-09
present O 0 1.0119026727650748e-09
in O 0 4.724517443932541e-10
the O 0 1.30423483124531e-09
balanced O 0 8.909020188241357e-09
state O 0 7.647688593515056e-10
in O 0 6.026302790118621e-10
the O 0 4.764309391447341e-09
patients O 0 2.906453966389222e-09
father O 0 1.0967905694769797e-07
and O 0 1.4259510905390016e-08
a O 0 9.52903292272822e-07
sister O 0 1.9872159100486897e-05
. O 0 8.306292329507414e-07

Fluorescent O 0 1.03117940852826e-06
in O 0 9.40926270232012e-09
situ O 0 7.212772743514506e-07
hybridization O 0 5.775030942345438e-08
analysis O 0 2.399643328487855e-08
demonstrated O 0 6.547060227291013e-09
that O 0 4.461112312892368e-10
the O 0 5.7336205117053396e-08
PWS B-Disease 1 1.0
critical O 0 1.5278284308806178e-06
region O 0 4.302604850181524e-08
resided O 0 3.8223558362915355e-07
on O 0 1.4279052606980258e-08
the O 0 1.5340708259259372e-08
derivative O 0 4.7364054012177803e-07
chromosome O 0 7.185852268776216e-08
3 O 0 4.932139585633877e-09
and O 0 1.2125907222770849e-10
that O 0 2.1144792861083062e-10
there O 0 1.4404960557712343e-09
was O 0 4.578439671831802e-08
no O 0 1.1459806437130737e-08
deletion O 0 9.42724796004768e-08
of O 0 2.0521466126410814e-07
the O 0 3.4303141092095757e-06
PWS B-Disease 1 1.0
region O 0 2.547506483097095e-06
on O 0 1.175731014768644e-07
the O 0 5.594171170741902e-08
normal O 0 1.1693359880382559e-07
pair O 0 1.4078929133631846e-08
of O 0 4.165537248468354e-08
15s O 0 2.0392931219248567e-06
present O 0 8.159459952139514e-08
in O 0 2.686695097509073e-07
J O 0 0.00010413662676000968
. O 0 6.44060776266997e-07

B O 0 0.0027419647667557
. O 0 1.649679325055331e-05

Methylation O 0 1.734328361635562e-05
analysis O 0 7.007519684520958e-07
at O 0 1.341587818615153e-07
exon O 0 3.601522564622428e-07
alpha O 0 2.7387230261410878e-08
of O 0 1.1957835832632213e-09
the O 0 7.672057988905578e-10
small O 0 3.3244640373908396e-09
nuclear O 0 4.3052892806372256e-07
ribonucleoprotein O 0 5.5700995289953426e-05
- O 0 9.51983224695141e-07
associated O 0 3.13160342102492e-07
polypeptide O 0 5.186476300877985e-06
N O 0 3.270901515861624e-06
( O 0 2.413791300170942e-08
SNRPN O 0 2.8265083528822288e-05
) O 0 6.840992661238943e-09
gene O 0 1.891745426974012e-09
showed O 0 1.7541965657841274e-09
a O 0 1.6210550679573998e-09
pattern O 0 1.94568627875924e-08
characteristic O 0 5.423088200728898e-09
of O 0 1.7614830483125843e-08
only O 0 5.7638254169489755e-09
the O 0 1.557979345534477e-08
maternal O 0 6.639390903728781e-07
chromosome O 0 9.49377749748237e-08
15 O 0 2.9066386630915986e-08
in O 0 6.866682866757401e-08
J O 0 5.2364204748300835e-05
. O 0 8.069128512033785e-07

B O 0 0.0026782802306115627
. O 0 1.432808676327113e-05

Maternal B-Disease 0 0.008056525141000748
disomy I-Disease 0 0.00015629187691956758
was O 0 6.678362751699751e-07
confirmed O 0 2.99651503610221e-08
by O 0 6.4275837985405815e-09
polymerase O 0 2.617663596993225e-07
chain O 0 2.0009350620853184e-08
reaction O 0 7.751989050674979e-10
analysis O 0 5.775270484065231e-09
of O 0 2.3258806436388113e-08
microsatellite O 0 1.4506841807815363e-06
repeats O 0 6.913599293056905e-08
at O 0 2.821372646621967e-08
the O 0 8.969686327020554e-09
gamma O 0 2.0858415439306555e-07
- O 0 1.532506814783119e-07
aminobutyric O 0 2.6667275960789993e-06
acid O 0 2.6691651555665885e-07
receptor O 0 2.654533091117628e-07
beta3 O 0 1.509163325863483e-06
subunit O 0 8.032259870560665e-07
( O 0 6.296560428609155e-08
GABRB3 O 0 2.1937667042948306e-05
) O 0 1.1997828153198498e-07
locus O 0 1.8742255178949563e-06
. O 0 1.4584119867322443e-07

A O 0 3.409816054045223e-05
niece O 0 2.7003783543477766e-05
( O 0 1.7463129609041061e-07
B O 0 7.327720368266455e-07
. O 0 1.9023327357814424e-09
B O 0 1.8274447199928545e-07
. O 0 6.82616907443645e-10
) O 0 3.0332567013680034e-10
with O 0 9.229902259155764e-11
45 O 0 1.8696275638774296e-09
chromosomes O 0 1.8246812949485047e-09
and O 0 9.61205212646199e-11
the O 0 1.9289978503422844e-09
derivative O 0 1.547584389527401e-07
3 O 0 5.763341359710239e-09
but O 0 1.2702801310826572e-10
without O 0 7.311964922429581e-10
the O 0 2.707697621673333e-09
der O 0 1.6143100083354511e-06
( O 0 5.522143631253584e-09
15 O 0 2.4667272668921214e-09
) O 0 5.214315645929446e-10
demonstrated O 0 1.1698380042446388e-09
a O 0 1.8640089471944066e-09
phenotype O 0 5.067771091660234e-09
consistent O 0 3.9532936924047135e-09
with O 0 4.523236993292379e-11
that O 0 1.3805892540297293e-10
reported O 0 2.373006680045364e-09
for O 0 1.3414716004689353e-09
haploinsufficiency O 0 1.3435275832307525e-05
of O 0 2.305907628397108e-06
distal O 0 1.199977850774303e-05
3 O 0 5.014256657887017e-06
p O 0 6.524320633616298e-05
. O 0 6.086434041208122e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 1.3970844520372339e-05
with O 0 4.0795800515525116e-08
unbalanced O 0 4.090116999577731e-05
segregation O 0 9.339192388324591e-07
of O 0 3.21178902140673e-07
non O 0 3.703318361658603e-05
- O 0 7.674869266338646e-05
Robertsonian O 1 0.9938194155693054
translocations O 0 6.517125711980043e-06
has O 0 1.788007075731457e-09
been O 0 1.1928222853896386e-09
reported O 0 2.0280375157000208e-09
previously O 0 1.1229576157845145e-09
but O 0 1.2066336818605805e-10
has O 0 4.406538675616467e-11
not O 0 4.0271036505501456e-11
, O 0 4.957202703881336e-11
to O 0 1.8758131159479774e-10
our O 0 3.4144456151352642e-09
knowledge O 0 4.4795811504627636e-07
, O 0 6.143824893278804e-10
been O 0 2.180698288611893e-09
observed O 0 6.1098801573677974e-09
in O 0 1.7230519233635277e-09
a O 0 1.728217036145452e-08
case O 0 6.840694766196975e-08
of O 0 7.303041911654873e-06
PWS B-Disease 1 1.0
. O 0 8.932009222917259e-06

Furthermore O 0 5.6177973419835325e-06
, O 0 5.888626919414719e-09
our O 0 6.707153055174331e-09
findings O 0 4.3191210608029e-09
are O 0 3.6676237047394977e-10
best O 0 2.8418187802969896e-09
interpreted O 0 1.9112732729809068e-08
as O 0 3.550447935651846e-09
true O 0 1.5856477375564282e-07
gamete O 0 2.069716720143333e-05
complementation O 0 1.8706023183767684e-05
resulting O 0 6.209141929502948e-07
in O 0 4.965542643731169e-07
maternal B-Disease 1 0.9871724843978882
UPD I-Disease 1 1.0
15 I-Disease 0 7.674561493331566e-05
and O 0 9.55065570451552e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.999956488609314
- I-Disease 1 0.9999936819076538
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999696016311646
type I-Disease 0 2.2803717001806945e-05
2 I-Disease 0 2.365519094382762e-06
and O 0 6.243867289867921e-08
Stuve B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9992167949676514
: O 0 1.2888090594742607e-09
a O 0 6.054856171999745e-09
case O 0 3.01631408738956e-09
for O 0 8.937473539027962e-10
" O 0 5.490094423521441e-08
lumping O 0 1.6987877415886032e-06
" O 0 5.273627721180674e-07
. O 0 1.5144907195008273e-07

Recent O 0 7.385347089439165e-07
studies O 0 1.1516474529571497e-07
demonstrated O 0 2.808358345873785e-08
the O 0 3.8200318464021166e-09
existence O 0 7.134829616006755e-08
of O 0 1.905576674232634e-08
a O 0 7.364877152582494e-09
genetically O 0 7.368836096866005e-10
distinct O 0 4.3512429770409256e-10
, O 0 5.195530117241276e-11
usually O 0 6.363475024695475e-11
lethal O 0 3.0848751331191693e-10
form O 0 6.03877503557726e-10
of O 0 3.1376085729561964e-08
the O 0 1.4220528044006642e-07
Schwartz B-Disease 0 0.010668875649571419
- I-Disease 0 0.2811410427093506
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.5119872841751203e-05
SJS B-Disease 1 1.0
) O 0 7.828518278074625e-08
of O 0 1.7125785234384239e-06
myotonia B-Disease 1 0.9999996423721313
and O 0 3.425542308832519e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.642179321645017e-08
which O 0 2.0881095963432017e-08
we O 0 6.154480303166565e-08
called O 0 4.57296846434474e-06
SJS B-Disease 1 0.9999856948852539
type I-Disease 0 3.525255306158215e-05
2 I-Disease 0 1.474685541325016e-05
. O 0 6.419696205739456e-07

This O 0 2.2605784124607453e-06
disorder O 0 0.0178946852684021
is O 0 2.210663474500052e-08
reminiscent O 0 9.627933650335763e-07
of O 0 2.2117268372312537e-07
another O 0 8.909687210234551e-08
rare O 0 5.440039529958085e-08
condition O 0 3.1079762266017497e-06
, O 0 1.1419788670252728e-08
the O 0 7.785823754602461e-07
Stuve B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999929666519165
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00019834944396279752
SWS B-Disease 1 0.9999938011169434
) O 0 1.9896740255376244e-08
, O 0 5.04813690849204e-10
which O 0 6.39105324218292e-10
comprises O 0 3.6334192543563404e-08
campomelia B-Disease 0 0.00011713147250702605
at O 0 4.1370431063114665e-06
birth O 0 4.3509676288522314e-06
with O 0 3.3048704040083976e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 3.7896195408393396e-06
contractures B-Disease 1 0.9999988079071045
, O 0 1.0433380737140396e-07
and O 0 1.6426438875782878e-08
early B-Disease 0 1.6203808854697854e-06
death I-Disease 0 2.0621553176169982e-06
. O 0 6.705582222821249e-07

To O 0 7.356737086183784e-08
test O 0 7.699357595924994e-09
for O 0 2.2294548429613315e-09
possible O 0 5.777740952339627e-08
nosologic O 0 0.024091096594929695
identity O 0 2.188122323332209e-07
between O 0 1.1412864431292746e-08
these O 0 1.7978455391087778e-09
disorders O 0 9.139813300862443e-06
, O 0 6.16881212778253e-10
we O 0 5.667972757805728e-10
reviewed O 0 5.2997868316140284e-09
the O 0 1.7910823935096687e-09
literature O 0 4.367708861252595e-09
and O 0 1.0692934732103865e-10
obtained O 0 4.1243777282318206e-09
a O 0 2.6768207650462728e-09
follow O 0 1.3218810490656097e-09
- O 0 6.356869697299317e-09
up O 0 3.2285543127841265e-09
of O 0 3.227975442499087e-09
the O 0 1.0991434429286073e-09
only O 0 1.8052599692897076e-10
two O 0 1.2385628633815315e-10
surviving O 0 3.196485920398118e-07
patients O 0 7.865569306986231e-10
, O 0 2.342873395289047e-10
one O 0 2.167358514881812e-09
with O 0 6.74249056586973e-09
SJS B-Disease 1 0.9998526573181152
type I-Disease 0 4.009771600976819e-06
2 I-Disease 0 2.7042005967814475e-07
at O 0 6.903307792072155e-08
age O 0 1.4755659805132382e-08
10 O 0 6.282255826661753e-10
years O 0 2.700764056839944e-10
and O 0 1.0100471847795944e-10
another O 0 7.783269140304583e-09
with O 0 1.3665508724614028e-08
SWS B-Disease 0 0.02059856802225113
at O 0 1.5837660782835883e-07
age O 0 2.1103579683767748e-07
7 O 0 5.621927812171634e-07
years O 0 1.1700767288402858e-07
. O 0 1.393058965959426e-07

Patients O 0 4.552508471533656e-06
reported O 0 6.775327676677989e-08
as O 0 3.8314733608046936e-09
having O 0 9.296186931351258e-08
either O 0 1.565828097227495e-05
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.25073540210723877
SWS B-Disease 1 0.9976404905319214
presented O 0 2.4227208683669232e-08
a O 0 8.443453936024525e-09
combination O 0 4.515319673714657e-09
of O 0 1.2209002697716187e-08
a O 0 1.5292096477992345e-08
severe O 0 2.457459231663961e-07
, O 0 7.658380951625077e-08
prenatal O 1 0.9999860525131226
- O 1 0.9999996423721313
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.25744202733039856
with O 0 9.727342694532126e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9997285008430481
respiratory O 1 1.0
and O 0 7.733888764960284e-07
feeding O 1 0.9683212041854858
difficulties O 1 0.9999949932098389
, O 0 1.1638134367331077e-07
tendency O 0 1.7162902565814875e-07
to O 0 1.2502559876281794e-08
hyperthermia B-Disease 1 0.9999974966049194
, O 0 9.949694401711895e-09
and O 0 3.616857702226639e-09
frequent O 0 4.228432004538263e-08
death O 0 3.908758827719794e-08
in O 0 3.8535358015678867e-08
infancy O 0 0.00016616865468677133
) O 0 5.176957973418439e-09
with O 0 4.266854092271899e-10
a O 0 1.542856331582243e-08
distinct O 0 1.3739975202042842e-07
campomelic B-Disease 1 0.999907374382019
- I-Disease 1 0.9999998807907104
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 0.9999994039535522
. O 0 1.5873250958975405e-05

The O 0 9.059627927854308e-07
similarity O 0 9.583321798345423e-07
of O 0 8.175380372676955e-08
the O 0 6.491654147566805e-08
clinical O 0 2.6106333734787768e-06
and O 0 4.31298818881487e-09
radiographic O 0 6.923008186277002e-05
findings O 0 1.6525467572137131e-07
is O 0 3.070512510916501e-09
so O 0 5.971518834968492e-10
extensive O 0 1.512178116058749e-08
that O 0 1.540143845790709e-10
these O 0 9.151967517162518e-10
disorders O 0 1.715948383207433e-05
appear O 0 1.1495270513250944e-08
to O 0 2.3360029466346077e-09
be O 0 8.471619850070056e-09
a O 0 3.491194178195656e-08
single O 0 3.653830660255153e-08
entity O 0 1.1119647069790517e-06
. O 0 4.00088822516409e-07

The O 0 1.5907883152976865e-06
follow O 0 3.3370321261827485e-07
- O 0 2.7021999926546414e-07
up O 0 3.272761972539229e-08
observation O 0 8.069643513408664e-07
of O 0 7.897849485516417e-09
an O 0 1.2799409310204624e-09
identical O 0 6.009960085151533e-09
and O 0 4.2817407952533415e-10
unique O 0 6.723240186801149e-09
pattern O 0 4.7161856286948023e-07
of O 0 5.400472218752839e-06
progressive O 1 0.9999886751174927
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9998835325241089
in O 0 1.7888639902707837e-08
the O 0 1.349502198877417e-08
two O 0 2.2601447380310447e-09
patients O 0 1.8605988971742704e-09
( O 0 7.752373187841499e-10
one O 0 1.7629711024369499e-09
with O 0 4.9948303271207806e-09
SJS B-Disease 1 0.9119184017181396
type I-Disease 0 1.0869811148950248e-06
2 I-Disease 0 1.2727070952678332e-07
, O 0 2.3634487700263662e-09
one O 0 3.966450723424941e-09
with O 0 8.547481833431902e-09
SWS B-Disease 1 0.9530998468399048
) O 0 2.74638125574711e-08
surviving O 0 1.8573060515336692e-05
beyond O 0 2.045771907432936e-06
infancy O 0 2.071575181616936e-05
adds O 0 1.571828711632861e-08
to O 0 6.774804606202167e-10
the O 0 2.442853030970582e-09
evidence O 0 1.6906769317870385e-08
in O 0 3.539615933689788e-09
favor O 0 1.3213472982442909e-08
of O 0 1.0458484922537536e-07
identity O 0 6.76815830047417e-07
. O 0 3.5827699207402475e-07

The O 0 1.177186732093105e-06
hypothesis O 0 1.559100610393216e-06
that O 0 8.797341166655315e-08
SWS B-Disease 0 0.0011551611823961139
and O 0 1.7259843332340097e-07
SJS B-Disease 1 0.9784871935844421
type I-Disease 0 1.295096694775566e-06
2 I-Disease 0 1.6596649743405578e-07
are O 0 7.370846155652089e-10
the O 0 5.681960235648376e-09
same O 0 1.6166220362379136e-08
disorder O 0 8.008120175873046e-07
should O 0 9.440285220208011e-10
be O 0 2.273374821726293e-09
testable O 0 1.4104709578077745e-07
by O 0 5.85068216096829e-10
molecular O 0 2.215872818567277e-08
methods O 0 8.277821983426747e-09
. O 0 4.790515983899013e-09
. O 0 3.373946810825146e-08

A O 0 1.034081378747942e-05
mouse O 0 1.2391310519888066e-06
model O 0 1.022763953528738e-07
of O 0 1.5400874531223963e-07
severe O 0 0.0006079706945456564
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0008331583812832832
defects O 1 0.9999898672103882
in O 0 8.83257939676696e-07
hemostasis O 1 0.9999991655349731
and O 0 1.268167579837609e-06
thrombosis B-Disease 1 0.999985933303833
. O 0 2.1610791009152308e-05

von B-Disease 1 0.9999213218688965
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9143232107162476
( I-Disease 0 0.00030526626505889
vWf I-Disease 1 0.9999997615814209
) I-Disease 0 0.0004989575245417655
deficiency I-Disease 1 1.0
causes O 0 0.168752059340477
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 3.0455841624643654e-05
humans O 0 7.52621690480737e-06
. O 0 2.854647220829065e-07

We O 0 4.894087055618002e-07
generated O 0 4.088898037934996e-07
a O 0 4.2196745653200196e-08
mouse O 0 1.0789542592704038e-08
model O 0 1.422739259737682e-09
for O 0 1.4482337551413593e-10
this O 0 1.3064158643771862e-09
disease O 0 6.191896328999746e-09
by O 0 3.9798622730735644e-10
using O 0 1.3095300843701807e-08
gene O 0 1.6550252723845915e-08
targeting O 0 4.1839790299036395e-08
. O 0 4.544135734363408e-08

vWf B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999990463256836
deficient I-Disease 1 0.9998805522918701
mice O 0 1.1871313745359657e-06
appeared O 0 3.103711421204025e-08
normal O 0 3.48957627238633e-08
at O 0 9.138401146913111e-09
birth O 0 2.580388569484171e-09
; O 0 2.2786642364658327e-11
they O 0 8.177582916379933e-11
were O 0 2.9030908788030274e-09
viable O 0 2.1536297367674706e-07
and O 0 1.8735409668124703e-08
fertile O 0 2.227877121185884e-05
. O 0 6.88227203227143e-07

Neither O 0 0.0007979497313499451
vWf O 0 0.006616442464292049
nor O 0 7.041745266178623e-05
vWf O 0 0.00155759253539145
propolypeptide O 0 0.0010512657463550568
( O 0 2.5862000256893225e-06
von B-Disease 0 0.0029049443546682596
Willebrand I-Disease 1 0.9808968305587769
antigen O 0 2.5249278223782312e-06
II O 1 0.5949965715408325
) O 0 2.4225638384223203e-08
were O 0 4.948695675466297e-09
detectable O 0 5.4121169767995525e-08
in O 0 6.110540962112054e-10
plasma O 0 4.1320014076973166e-08
, O 0 9.368750220062338e-10
platelets O 0 7.772338506129017e-08
, O 0 1.7125509899074132e-09
or O 0 2.655545117136171e-08
endothelial O 0 3.3195109949701873e-07
cells O 0 6.0498228648953045e-09
of O 0 1.4593322994471691e-08
the O 0 4.215925741846149e-08
homozygous O 0 4.6505618911396596e-07
mutant O 0 1.588358259141387e-06
mice O 0 4.90950412768143e-07
. O 0 5.3967063706750196e-08

The O 0 1.7172428670164663e-06
mutant O 0 2.6290761525160633e-05
mice O 0 3.3381093089701608e-06
exhibited O 0 6.374672238962376e-07
defects O 0 0.0033369516022503376
in O 0 2.996560866108666e-08
hemostasis O 1 0.8933662176132202
with O 0 3.3014124767305475e-09
a O 0 6.264970409119996e-08
highly O 0 2.684573985334282e-07
prolonged O 0 0.18913209438323975
bleeding O 0 0.07120218127965927
time O 0 1.1567570368242741e-07
and O 0 1.175432462474646e-08
spontaneous O 0 2.27376972361526e-06
bleeding O 0 4.629418981494382e-05
events O 0 6.749502734493262e-09
in O 0 8.099940163042163e-10
approximately O 0 2.984216651569227e-09
10 O 0 3.7010190467867687e-09
% O 0 2.8745055224987937e-09
of O 0 4.271842257708158e-08
neonates O 0 2.7618837066256674e-06
. O 0 3.859579180698347e-07

As O 0 1.4746916576768854e-07
in O 0 6.0130100898447836e-09
the O 0 1.3749930971584945e-08
human O 0 5.055060015024537e-08
disease O 0 4.150350889631227e-07
, O 0 3.7831521249032107e-10
the O 0 7.988538719416738e-09
factor O 0 6.382397543802654e-08
VIII O 0 9.174779734166805e-06
level O 0 6.965696570659929e-07
in O 0 1.2943962568456868e-09
these O 0 3.281860339043874e-10
mice O 0 4.1827084018564165e-09
was O 0 2.871414883642842e-09
reduced O 0 6.572330457643716e-10
strongly O 0 5.931967694827733e-10
as O 0 2.772134743977972e-10
a O 0 8.02003019551023e-10
result O 0 2.940965526665451e-10
of O 0 2.2832826740426526e-09
the O 0 3.6573286621433e-09
lack O 0 5.176496742365089e-08
of O 0 1.9763225722613242e-08
protection O 0 5.2744777434554635e-08
provided O 0 3.9633370363389986e-08
by O 0 5.569004102312647e-08
vWf O 0 2.975619281642139e-05
. O 0 5.335364789971209e-07

Defective O 1 0.9999483823776245
thrombosis B-Disease 1 0.9998356103897095
in O 0 2.4014025257201865e-07
mutant O 0 1.646019154577516e-05
mice O 0 5.741444510931615e-07
was O 0 2.9439426896260557e-08
also O 0 2.663298193095187e-10
evident O 0 4.332586733823973e-09
in O 0 3.69076047501693e-10
an O 0 5.838576289107777e-10
in O 0 1.4346202004134057e-09
vivo O 0 1.1684218748087005e-07
model O 0 2.1984234876981645e-08
of O 0 5.403967406891752e-07
vascular B-Disease 1 0.9999879598617554
injury I-Disease 1 0.9575430750846863
. O 0 4.784822158399038e-05

In O 0 1.5929836649775098e-07
this O 0 2.674891641518684e-09
model O 0 2.4980725044088103e-08
, O 0 2.461796766439761e-09
the O 0 2.2491413176339847e-08
exteriorized O 0 3.747427763300948e-05
mesentery O 0 6.965476495679468e-05
was O 0 2.7688645332091255e-06
superfused O 0 1.6160494851646945e-05
with O 0 4.603026226845941e-08
ferric O 0 0.0008642701432108879
chloride O 0 1.1280500075372402e-05
and O 0 6.452595613382073e-08
the O 0 2.559523863965296e-07
accumulation O 0 9.865155880106613e-05
of O 0 9.124989446718246e-06
fluorescently O 0 0.00046636321349069476
labeled O 0 4.4327639443508815e-06
platelets O 0 2.0468862658162834e-06
was O 0 1.7304112986948894e-07
observed O 0 5.0282782382282676e-08
by O 0 1.0953392859391897e-08
intravital O 0 1.2647069524973631e-05
microscopy O 0 4.8956826503854245e-06
. O 0 8.653188388052513e-07

We O 0 6.947292945369554e-07
conclude O 0 1.937529987117159e-06
that O 0 5.6763922451352755e-09
these O 0 4.815957410642113e-09
mice O 0 1.1799804866541308e-07
very O 0 2.7720621353921615e-09
closely O 0 1.0562065000385701e-07
mimic O 0 4.359215381555259e-06
severe O 0 2.4007022147998214e-05
human O 0 2.0989260519854724e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.6301429095477715e-09
will O 0 1.0999440941406036e-10
be O 0 1.2309817054578787e-10
very O 0 1.415155076456287e-10
useful O 0 2.1879684730663485e-09
for O 0 1.9102217030386726e-10
investigating O 0 2.6891550319874113e-08
the O 0 1.1653067844008547e-08
role O 0 6.459269741299067e-08
of O 0 1.9006930074283446e-07
vWf O 0 1.8807622836902738e-05
in O 0 1.257922299657821e-08
normal O 0 9.64007995207794e-07
physiology O 0 3.645766582849319e-06
and O 0 6.682428499438231e-10
in O 0 6.754357517735343e-09
disease O 0 2.50753942054871e-07
models O 0 8.496734871243916e-09
. O 0 7.86902454308347e-09
. O 0 8.983780475091407e-08

Oral O 1 0.9992456436157227
contraceptives O 0 0.00020316295558586717
and O 0 1.3129714204751508e-08
the O 0 4.162892253134487e-08
risk O 0 2.069735046461574e-06
of O 0 0.3331281542778015
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5540759563446045

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 1.0
Study O 0 0.0004825135983992368
Group O 0 1.3813960322295316e-06
. O 0 1.3408293852990028e-07

BACKGROUND O 0 0.0001427206298103556
Women O 0 7.084587139161158e-08
with O 0 1.9461827704958523e-09
mutations O 0 4.231972106083504e-09
in O 0 1.8921857414255783e-09
either O 0 7.441721461276529e-09
the O 0 5.985207707226436e-08
BRCA1 O 0 1.9080121660408622e-07
or O 0 9.876840678657572e-09
the O 0 3.377578394747616e-08
BRCA2 O 0 3.302765776425076e-07
gene O 0 1.9155057540132248e-09
have O 0 6.936452801031834e-11
a O 0 1.6087343679416222e-09
high O 0 1.3238447671426457e-08
lifetime O 0 1.549637147491012e-07
risk O 0 1.999405185415526e-06
of O 1 0.9972077012062073
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00012773493654094636

Oral O 1 0.9998893737792969
contraceptives O 1 0.8181679248809814
protect O 0 5.426336429081857e-06
against O 0 0.03523687273263931
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.8137733326948364e-07
general O 0 7.011123415168186e-08
, O 0 3.9649283856135753e-10
but O 0 4.676443260409613e-11
it O 0 1.056033299001724e-11
is O 0 1.2804963686607884e-11
not O 0 9.392053974821568e-12
known O 0 1.169246366394816e-10
whether O 0 1.205874428089615e-10
they O 0 6.192105717062191e-10
also O 0 1.4956321736647737e-09
protect O 0 1.7851828459924945e-08
against O 0 2.1407000616591176e-08
hereditary B-Disease 1 0.9906711578369141
forms I-Disease 0 1.2343716662144288e-05
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.0529743273509666e-05

METHODS O 0 5.962037448625779e-06
We O 0 1.6583690864990785e-07
enrolled O 0 6.266960212997219e-07
207 O 0 4.6907928208383964e-07
women O 0 1.1676584144026947e-08
with O 0 2.6933694385888884e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7696750092000002e-06
161 O 0 4.458586602140713e-07
of O 0 7.586878325582802e-08
their O 0 1.0859574572918973e-08
sisters O 0 2.62972918108062e-07
as O 0 4.134490527718526e-09
controls O 0 1.1172454961183576e-08
in O 0 8.384872796085574e-10
a O 0 4.306880629911802e-09
case O 0 2.2511025932203665e-08
- O 0 3.275573021710443e-07
control O 0 6.939942522876663e-07
study O 0 2.252284332371346e-07
. O 0 1.1275560041212884e-07

All O 0 6.582020262158039e-08
the O 0 3.383226498954173e-08
patients O 0 3.7226195459538758e-09
carried O 0 3.067258003142115e-09
a O 0 3.1725704285889833e-09
pathogenic O 0 3.0619387025865308e-09
mutation O 0 8.016894925688689e-10
in O 0 6.4106236985495e-10
either O 0 5.135740277495415e-09
BRCA1 O 0 2.5333976694241755e-08
( O 0 1.0206914202726125e-09
179 O 0 4.639320927424251e-09
women O 0 1.3538740128993254e-09
) O 0 2.9301550075189198e-09
or O 0 8.486531477558401e-09
BRCA2 O 0 5.60119666204173e-08
( O 0 9.106352116816652e-09
28 O 0 1.1675809474809284e-07
women O 0 4.091580763088132e-08
) O 0 6.510899197564868e-08
. O 0 1.5734205760509212e-07

The O 0 1.2519332130978e-06
control O 0 4.473037051866413e-07
women O 0 2.9725368833055654e-09
were O 0 4.379370643903258e-09
enrolled O 0 1.2229931733998e-08
regardless O 0 7.97357468940163e-09
of O 0 9.317325577740121e-09
whether O 0 2.2120036913264585e-09
or O 0 3.0425120201016398e-09
not O 0 4.857913515898815e-10
they O 0 6.898760451790054e-10
had O 0 1.6549686066014146e-08
either O 0 5.169106742641816e-08
mutation O 0 7.785840239193931e-08
. O 0 8.505625004318063e-08

Lifetime O 0 2.3674896510783583e-05
histories O 0 3.8088842302386183e-06
of O 0 9.369103963763337e-07
oral O 0 0.010074381716549397
- O 0 0.0003388469631318003
contraceptive O 0 1.5183795767370611e-06
use O 0 1.5402034092559802e-09
were O 0 1.6746324327243656e-09
obtained O 0 8.217023506063015e-09
by O 0 1.555543582831831e-09
interview O 0 2.4716548807646177e-08
or O 0 1.1801291055490992e-09
by O 0 1.88807136591862e-10
written O 0 4.776390394312102e-10
questionnaire O 0 4.0562994629844695e-10
and O 0 7.308671029493397e-11
were O 0 5.923692092402177e-10
compared O 0 5.061817631712984e-10
between O 0 1.8631594045359634e-09
patients O 0 4.349881843612735e-10
and O 0 2.7374147393288695e-10
control O 0 1.964207569926657e-07
women O 0 1.3267106302450316e-09
, O 0 1.3012574351378703e-10
after O 0 1.0525214033663133e-09
adjustment O 0 3.4857713160363346e-08
for O 0 1.871974658618214e-10
year O 0 8.925616912236478e-10
of O 0 1.3416308064506666e-08
birth O 0 3.281337868088485e-08
and O 0 7.929834566766658e-09
parity O 0 3.0735955078853294e-06
. O 0 1.3438851453884126e-07

RESULTS O 0 5.396656888478901e-06
The O 0 3.0438371823038324e-07
adjusted O 0 2.659329538801103e-06
odds O 0 2.4268754259537673e-06
ratio O 0 5.327925123310706e-07
for O 0 3.789496929584857e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.028697283800284e-06
with O 0 4.698735289743183e-10
any O 0 2.251165920341691e-09
past O 0 1.8854919847655083e-09
use O 0 1.453031583942277e-10
of O 0 4.664804542642287e-09
oral O 0 7.1104022936197e-07
contraceptives O 0 4.0893894492910476e-07
was O 0 3.178205361109576e-07
0 O 0 3.968654738173427e-08
. O 0 2.301292667539201e-08

5 O 0 1.4514315580527182e-06
( O 0 8.488105152082426e-08
95 O 0 9.290975100384458e-08
percent O 0 6.333004787251184e-09
confidence O 0 1.7794071993648686e-08
interval O 0 9.079611373863372e-08
, O 0 1.1163204804987004e-09
0 O 0 4.5612638666092664e-10
. O 0 3.238826568052744e-11
3 O 0 2.2890984940904247e-10
to O 0 9.38937122496597e-11
0 O 0 2.3904314638834023e-10
. O 0 1.463378029864515e-10
8 O 0 1.604898258733556e-08
) O 0 8.5162694674068e-09
. O 0 3.052586805551982e-08

The O 0 1.220660237777338e-06
risk O 0 1.335462343377003e-06
decreased O 0 3.779196617870184e-07
with O 0 5.077259723762495e-10
increasing O 0 5.896359400736628e-09
duration O 0 5.048247686545437e-08
of O 0 6.304249122734973e-09
use O 0 7.37550076568283e-10
( O 0 1.05643327419358e-09
P O 0 5.207443365407016e-08
for O 0 1.9567598930070318e-10
trend O 0 9.606857531707647e-09
, O 0 2.7477828346000877e-10
< O 0 9.527043154378134e-09
0 O 0 1.5018346288808715e-10
. O 0 2.1618404982826078e-11
001 O 0 1.2885393196881978e-08
) O 0 2.7535418389845745e-11
; O 0 3.864133839293071e-12
use O 0 9.828774079345681e-12
for O 0 5.909109312973726e-11
six O 0 9.6109942226974e-10
or O 0 1.98687044594692e-09
more O 0 5.039841113885224e-11
years O 0 4.402466724506837e-10
was O 0 7.745164509742608e-09
associated O 0 1.1719395454079518e-09
with O 0 1.1573843966550257e-10
a O 0 2.6694686461326e-09
60 O 0 3.0428948250005305e-09
percent O 0 3.215910315823578e-10
reduction O 0 1.3514178665019472e-09
in O 0 5.026684402054116e-09
risk O 0 3.115259232799872e-07
. O 0 2.385103812230227e-07

Oral O 1 0.6000841856002808
- O 0 8.984196756500751e-05
contraceptive O 0 3.266035946580814e-06
use O 0 1.159980200782229e-08
protected O 0 1.9082008293480612e-06
against O 0 1.708404852251988e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 4.8988284540030236e-09
for O 0 1.1127193610960262e-09
carriers O 0 1.4833477779419013e-09
of O 0 6.557082876668119e-09
the O 0 1.8303708770872618e-08
BRCA1 O 0 4.037900680486928e-08
mutation O 0 1.0516866266740976e-09
( O 0 8.418669650289701e-10
odds O 0 2.4156058486823895e-08
ratio O 0 5.929754021138933e-09
, O 0 1.1219038198451159e-10
0 O 0 8.523102362767432e-11
. O 0 9.873116213476862e-12
5 O 0 1.6326157092905191e-10
; O 0 2.4065424999997198e-11
95 O 0 1.1177501146875102e-09
percent O 0 3.036660645161504e-10
confidence O 0 4.045461299284625e-09
interval O 0 1.689416606609484e-08
, O 0 3.179292662469635e-10
0 O 0 2.828643985708368e-10
. O 0 2.2347913450349033e-11
3 O 0 1.3724056613373392e-10
to O 0 2.828502362883789e-11
0 O 0 4.667460862251005e-11
. O 0 8.025117896603984e-12
9 O 0 2.949239741312226e-10
) O 0 1.455535691974319e-11
and O 0 3.4486450153914383e-12
for O 0 3.010350649312876e-11
carriers O 0 5.514120826610736e-10
of O 0 3.335578924179572e-09
the O 0 4.766602401673481e-08
BRCA2 O 0 5.123962409925298e-07
mutation O 0 5.445143891336102e-09
( O 0 1.9462644829104647e-09
odds O 0 6.498417803868506e-08
ratio O 0 5.810427694541431e-09
, O 0 7.216306718849097e-11
0 O 0 7.913115995794584e-11
. O 0 5.372651976087717e-12
4 O 0 1.753727163489316e-10
; O 0 1.582921987930419e-11
95 O 0 1.356024181831117e-09
percent O 0 2.9404942369914977e-10
confidence O 0 2.1169619390803973e-09
interval O 0 1.0907817760141825e-08
, O 0 3.450135177551772e-10
0 O 0 4.129917241524339e-10
. O 0 5.000248826103615e-11
2 O 0 2.1715450271297954e-10
to O 0 1.7665988116810638e-10
1 O 0 2.826498812780187e-09
. O 0 5.841182537658085e-10
1 O 0 1.371182456466613e-08
) O 0 4.699490130377626e-09
. O 0 1.7605525926001064e-08

CONCLUSIONS O 0 6.527693767566234e-05
Oral O 0 0.28865474462509155
- O 0 7.738409476587549e-05
contraceptive O 0 3.4652989597816486e-06
use O 0 1.819850048434546e-09
may O 0 1.2239026458971125e-09
reduce O 0 1.1432510493847303e-09
the O 0 3.751494226378327e-09
risk O 0 6.579007845175511e-07
of O 1 0.7955073714256287
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.1773358933360214e-08
women O 0 2.5902593958626596e-10
with O 0 3.36076270979202e-11
pathogenic O 0 5.342981057587792e-10
mutations O 0 2.388544917408808e-10
in O 0 5.881159448328788e-10
the O 0 1.389122328276926e-08
BRCA1 O 0 3.2211383427238616e-07
or O 0 2.1523402438106132e-07
BRCA2 O 0 6.2250119299278595e-06
gene O 0 5.052701908425661e-06

A O 0 4.096749034943059e-05
Japanese O 0 9.304685227107257e-05
family O 0 4.5098911982677237e-07
with O 0 2.4568116430145892e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.0832144070604954e-08
a O 0 3.6707348272102536e-08
codon O 0 1.1998365323506732e-07
291 O 0 9.533150269191992e-09
deletion O 0 7.173798888260308e-09
: O 0 3.3202038340895967e-10
a O 0 2.640241136830923e-09
clinical O 0 6.442659383765204e-08
, O 0 1.4372329992795585e-09
biochemical O 0 1.3009634130867198e-05
, O 0 2.8227722381757303e-08
pathological O 0 0.3701366186141968
, O 0 8.536892082133818e-09
and O 0 2.4348580041078094e-08
genetic O 0 8.729478395252954e-06
report O 0 8.818792593956459e-07
. O 0 6.684690561087336e-07

We O 0 1.0621394039844745e-06
report O 0 4.660058152694546e-07
a O 0 1.5234853378842672e-07
Japanese O 0 2.2281010387814604e-06
family O 0 2.4904019824134593e-07
with O 0 5.7125419061776483e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 1 1.0
ALD B-Disease 1 1.0
) O 0 1.4519642377308628e-07
with O 0 2.3423560868707227e-09
a O 0 1.5897079208571085e-08
three O 0 2.6736164393525996e-09
base O 0 6.463213964025272e-08
pair O 0 1.679556902445256e-07
deletion O 0 1.6214352172028157e-06
( O 0 2.2756735518214555e-07
delGAG O 0 4.0612148950458504e-06
291 O 0 2.70971469262804e-07
) O 0 6.58136567466272e-09
in O 0 1.9368961545751517e-08
the O 0 1.3881444829166867e-06
ALD B-Disease 1 1.0
gene O 0 5.129466808284633e-05
. O 0 1.1095345371359144e-06

A O 0 2.5193908186338376e-06
variety O 0 5.672466585338043e-08
of O 0 3.21079056675444e-07
phenotypes O 0 5.986509563626896e-07
were O 0 2.6858437252030853e-08
observed O 0 4.838379297211759e-08
within O 0 2.2791285303469522e-08
this O 0 1.7116146722173653e-08
family O 0 3.89091098895733e-07
. O 0 1.9078083823842462e-07

While O 0 8.371663398065721e-07
the O 0 2.4003239218473027e-07
proband O 0 3.56742057192605e-05
( O 0 1.259448509927097e-07
patient O 0 1.5136214415178983e-07
1 O 0 3.475693333143681e-08
) O 0 3.7783651762879344e-09
was O 0 1.8582520411314363e-08
classified O 0 2.1148201412302114e-08
as O 0 1.0028355923452636e-09
having O 0 5.410297987396007e-09
a O 0 4.598706748737413e-09
rare O 0 1.1564714741396642e-09
intermediate O 0 1.5427326971462207e-08
type O 0 2.3489699074730197e-08
of O 0 1.809690530762964e-07
adult O 0 1.2978910035599256e-06
cerebral O 0 0.00010814253619173542
and O 0 4.315055690540248e-08
cerebello O 1 1.0
- O 1 0.9999986886978149
brain O 1 0.9999685287475586
stem O 0 4.740779786516214e-06
forms O 0 1.9379269744490557e-08
, O 0 3.0589033528372056e-09
his O 0 3.393800085405019e-08
younger O 0 5.8106635947297036e-08
brother O 0 1.1470235676824814e-06
( O 0 5.6390788927274116e-08
patient O 0 7.8557114591149e-08
2 O 0 2.7798096269293637e-08
) O 0 2.66884736532802e-09
and O 0 8.107698956649756e-10
nephew O 0 1.6981439330265857e-05
( O 0 2.556718357027421e-07
patient O 0 1.0015057796408655e-06
3 O 0 1.4957876715016027e-07
) O 0 1.4281368088120416e-08
had O 0 1.974830432516228e-08
a O 0 9.798167184271733e-07
childhood O 1 0.9999562501907349
ALD B-Disease 1 1.0
type O 1 0.9999562501907349
. O 0 1.7077483789762482e-05

Another O 0 1.980178785743192e-05
nephew O 0 0.00015423595323227346
( O 0 6.229877840269182e-07
patient O 0 4.719190940249973e-07
4 O 0 1.6352609577552357e-07
) O 0 9.085740160230671e-09
of O 0 2.2354852191597274e-08
patient O 0 2.384962840551452e-07
1 O 0 8.955090891049622e-08
was O 0 4.19173915133797e-07
classified O 0 4.4810084887103585e-07
as O 0 2.5747741716486416e-09
having O 0 1.5277548115477657e-08
an O 0 2.7270624869402127e-08
adolescent O 0 3.301463493698975e-06
form O 0 2.1665420035787974e-07
. O 0 1.3915853287471691e-06

The O 0 5.5015589168760926e-06
tau O 0 7.709265446464997e-06
level O 0 3.504250969399436e-07
in O 0 7.648771394030973e-09
the O 0 2.366761187033717e-08
cerebrospinal O 0 3.7320880892366404e-06
fluid O 0 1.1874170013470575e-05
( O 0 2.5580773126421263e-06
CSF O 1 0.9986346364021301
) O 0 1.0068460198908724e-07
in O 0 1.1642714348170102e-08
patient O 0 1.4034695539066888e-07
1 O 0 2.3819413996761796e-08
was O 0 7.516058531109593e-08
as O 0 1.4939557368975898e-09
high O 0 5.314201079187342e-09
as O 0 2.3311946817372586e-10
that O 0 5.2289537283423115e-11
of O 0 3.003918225275015e-09
patients O 0 6.179413869489281e-09
with O 0 6.142037278777934e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 9.421762001693423e-07
AD B-Disease 0 1.648190118430648e-05
) O 0 4.2319904025589494e-08
. O 0 3.075366805660451e-08

His O 0 1.1425099728512578e-05
brain O 0 3.222200757591054e-05
magnetic O 0 5.028009582019877e-06
resonance O 0 1.2229743333591614e-06
image O 0 5.468961035148823e-07
( O 0 3.594001185547313e-08
MRI O 0 3.053264299524017e-05
) O 0 2.9510939469901132e-08
showed O 0 7.865786955107978e-08
abnormalities B-Disease 0 5.681074981112033e-06
in I-Disease 0 5.6065374565150705e-09
the I-Disease 0 3.0363047187620396e-08
bilateral I-Disease 0 0.0001494548487244174
cerebellar I-Disease 1 0.9999990463256836
hemispheres I-Disease 0 2.4422115529887378e-05
and O 0 3.16850226056431e-08
brain O 0 0.08788277953863144
stem O 0 4.1630161717876035e-07
, O 0 2.1718599141351547e-10
but O 0 1.0613183248908697e-10
not O 0 1.7302040355993142e-10
in O 0 1.1209033701220505e-09
the O 0 2.0120413779523005e-08
cerebral O 0 1.8531431123847142e-05
white O 0 2.124770404066112e-08
matter O 0 6.213158343371106e-08
, O 0 1.2707993546356988e-09
where O 0 2.487364092473854e-09
marked O 0 7.028486237459219e-09
reductions O 0 9.609165907420447e-09
of O 0 8.195204515004662e-09
the O 0 2.166706636330673e-08
cerebral O 0 1.5888491589066689e-06
blood O 0 8.497047332411967e-08
flow O 0 2.5735880626598373e-07
and O 0 2.1381567627543063e-09
oxygen O 0 4.875876129517565e-07
metabolism O 0 8.327533009833132e-07
were O 0 3.2793090465332853e-09
clearly O 0 5.285300641588719e-09
demonstrated O 0 2.7722049100731283e-09
by O 0 1.1895687768159746e-09
positron O 0 7.43414858561664e-08
emission O 0 8.92633611471183e-09
tomography O 0 1.5963658483997278e-07
( O 0 2.5423430471960273e-08
PET O 0 7.075187795635429e-07
) O 0 3.156305794504988e-08
. O 0 4.810662446175229e-08

In O 0 2.2148424250190146e-07
patients O 0 7.83442999363615e-09
2 O 0 4.990839741481068e-09
and O 0 4.451856105980312e-10
3 O 0 4.354798743833044e-09
, O 0 2.121083586548167e-10
the O 0 2.2284514233916752e-09
autopsy O 0 4.016639110204778e-08
findings O 0 6.053297418873171e-09
showed O 0 5.031828465007493e-08
massive O 0 2.653715455380734e-06
demyelination B-Disease 1 1.0
of I-Disease 0 1.122351113735931e-05
the I-Disease 0 1.3114517969370354e-06
cerebral I-Disease 0 0.00024162181944120675
white I-Disease 0 2.6647848372363114e-08
matter I-Disease 0 2.4624226213632028e-08
with O 0 9.068284456681397e-10
sparing O 0 5.263633795493661e-08
of O 0 5.665103230967361e-08
the O 0 3.016442349235149e-07
U O 1 0.9994662404060364
- O 0 2.4146136638591997e-05
fibers O 0 1.7279127177971532e-06
, O 0 1.5768425454254498e-09
compatible O 0 1.0132667149775898e-08
with O 0 4.301515046933879e-11
the O 0 1.6242986955461447e-09
findings O 0 1.2476903066271916e-08
of O 0 6.437880415433028e-07
childhood O 1 0.9999876022338867
ALD B-Disease 1 1.0
. O 0 1.584687015565578e-05

Oleic O 0 0.004915168043226004
and O 0 1.3778462744085118e-06
erucic O 0 0.00518999295309186
acids O 0 2.4769510673650075e-06
( O 0 2.2862521120714518e-07
Lorenzos O 0 3.93411610275507e-05
Oil O 0 1.400354562974826e-06
) O 0 2.1367463354238225e-09
were O 0 7.968188886486871e-10
administered O 0 1.5990796464748769e-09
to O 0 8.609654100766306e-10
patients O 0 1.0632315028402672e-09
1 O 0 2.4027015932404083e-09
and O 0 2.581785618627208e-10
4 O 0 3.444659890661228e-09
, O 0 7.680839297918851e-11
but O 0 4.767359076951472e-11
sufficient O 0 8.163129727734031e-09
effectiveness O 0 4.370936323994101e-08
was O 0 5.519303769574435e-08
not O 0 3.5821119404033652e-09
obtained O 0 3.555085470452468e-07
. O 0 2.2053767168017657e-07

The O 0 4.850751906815276e-07
findings O 0 1.4384738733497215e-07
in O 0 3.9974992205316084e-09
this O 0 3.062627929040218e-09
family O 0 9.633390085639348e-09
suggest O 0 4.316164758932928e-09
that O 0 4.109071694013977e-10
delGAG291 O 0 6.495964299801926e-08
is O 0 9.507178377887726e-10
part O 0 4.245999996044247e-09
of O 0 1.573022423428938e-08
the O 0 1.980499853004858e-08
cause O 0 2.514555887955794e-07
of O 0 2.253269258289947e-06
Japanese O 1 0.9952918291091919
ALD B-Disease 1 1.0
with O 0 1.8167018112080768e-08
phenotypic O 0 7.857671562305768e-07
variations O 0 3.253890668020176e-07
. O 0 2.8107118055231695e-07

Moreover O 0 3.866534370899899e-06
, O 0 3.7234075822567547e-09
although O 0 4.1867526112682185e-10
the O 0 1.1521649190271432e-09
scale O 0 4.1740154443914435e-08
of O 0 3.765860956406186e-09
the O 0 1.6783608947079642e-09
study O 0 9.257905553283763e-10
is O 0 5.3622946361020496e-11
limited O 0 1.5651019369400387e-10
, O 0 3.546180710189972e-11
there O 0 2.4757287886423285e-10
is O 0 2.1569651620367836e-10
a O 0 5.361827093430804e-10
possibility O 0 7.4140662498223264e-09
that O 0 1.3950666177819926e-09
PET O 0 2.03149639332878e-07
can O 0 8.878278667800998e-10
detect O 0 1.4814970938914485e-07
an O 0 3.854167829331345e-08
insidious B-Disease 0 1.3616105206892826e-05
lesion I-Disease 0 0.00016256966046057642
which O 0 4.382877949460351e-10
is O 0 2.8843571975301074e-10
undetectable O 0 1.4545470605753508e-08
by O 0 5.946887982055671e-10
computed O 0 3.8476603236858864e-08
tomogram O 0 7.322285000554984e-07
( O 0 1.1229668750445398e-08
CT O 0 1.0110255743711605e-06
) O 0 1.4977389328763024e-09
or O 0 8.126726513957294e-10
MRI O 0 8.588767030914823e-08
analysis O 0 7.071259577884348e-09
, O 0 1.0659803595380879e-10
and O 0 7.595293838313921e-11
that O 0 7.016892622502269e-11
the O 0 1.2970060581096732e-09
higher O 0 1.725150866604963e-08
level O 0 6.845315425607623e-08
of O 0 8.473624468763319e-09
tau O 0 1.9294038366979294e-08
reflects O 0 7.071782048839736e-10
the O 0 1.0550292584010634e-10
process O 0 1.693203022234968e-09
of O 0 6.658667217607217e-08
neuronal B-Disease 0 0.434088796377182
degeneration I-Disease 1 0.9999580383300781
in O 0 3.214137677787221e-06
ALD B-Disease 1 1.0
. O 0 6.1585233197547495e-06

Lorenzos O 0 0.0011289498070254922
Oil O 0 6.6040547608281486e-06
should O 0 7.72066588439202e-09
be O 0 2.1046542286740078e-09
given O 0 2.833181023120801e-09
in O 0 1.333158694549752e-09
the O 0 4.561109712142297e-09
early O 0 5.633112820646602e-08
stage O 0 9.639568787633834e-08
. O 0 2.057776349317919e-08
. O 0 2.3711693586392357e-07

Nonsense O 0 0.00024097325513139367
mutation O 0 4.6882118454050214e-07
in O 0 6.743058378333444e-08
exon O 0 3.9407541407854296e-07
4 O 0 2.8367079352165092e-08
of O 0 2.0447634696552086e-08
human O 0 1.1144063449819441e-08
complement O 0 1.6098994137792033e-07
C9 O 0 0.24567364156246185
gene O 0 2.4660463893155793e-08
is O 0 3.1709293524251336e-10
the O 0 1.2725603903973592e-09
major O 0 2.187877790049697e-08
cause O 0 7.498974952113713e-08
of O 0 4.3552495299081784e-07
Japanese O 0 0.0006155280862003565
complement B-Disease 0 0.0001807402295526117
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999971389770508
. O 0 1.265148853235587e-06

Deficiency B-Disease 1 0.9999998807907104
of I-Disease 0 6.920762643858325e-06
the I-Disease 0 3.328558477733168e-07
ninth I-Disease 0 1.0281196409778204e-05
component I-Disease 0 9.434854746359633e-07
of I-Disease 0 2.49117810824373e-08
human I-Disease 0 8.141811669304388e-09
complement I-Disease 0 5.829946658764129e-08
( O 0 1.4061100728213205e-07
C9 O 0 0.1995372176170349
) O 0 3.6377585388436273e-09
is O 0 9.795764893683057e-11
the O 0 2.986954017458743e-10
most O 0 1.4415314775195753e-10
common O 0 2.8674087548807847e-09
complement B-Disease 1 0.999996542930603
deficiency I-Disease 1 1.0
in O 0 7.660096343897749e-07
Japan O 0 1.0184943448621198e-06
but O 0 5.021602578203499e-10
is O 0 1.986782266483189e-10
rare O 0 4.661298014241311e-10
in O 0 2.5993360242004826e-10
other O 0 1.3509532381661415e-10
countries O 0 3.61302238127692e-10
. O 0 4.0297145176282356e-08

We O 0 1.4353905442021642e-07
studied O 0 4.746733566207695e-07
the O 0 5.7239063266933954e-08
molecular O 0 5.061007755102764e-07
basis O 0 3.957974286095123e-07
of O 0 3.1320296329795383e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999078512191772
in O 0 1.0502362357556194e-07
four O 0 1.1822817924667106e-07
Japanese O 0 7.00301316101104e-05
C9 B-Disease 1 0.9999985694885254
- I-Disease 1 0.8776735663414001
deficient I-Disease 0 0.04281056672334671
patients O 0 1.0954313012234707e-08
who O 0 2.3143207350528883e-09
had O 0 1.273193817041829e-07
suffered O 0 9.996452718041837e-05
from O 0 2.7764461265178397e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 4.284324859327171e-06

Direct O 0 1.7957031559490133e-06
sequencing O 0 3.526645855345123e-07
of O 0 2.0156332425358414e-07
amplified O 0 3.726752765942365e-06
C9 O 0 4.517674824455753e-05
cDNA O 0 1.6567551028856542e-06
and O 0 1.430314200412397e-09
DNA O 0 4.641748319045291e-08
revealed O 0 3.6797565883261996e-08
a O 0 1.146927530726316e-08
nonsense O 0 7.727491180276047e-08
substitution O 0 1.0355440949183503e-08
( O 0 5.022371851737262e-09
CGA O 0 1.7064732560356788e-07
- O 0 6.772769012286517e-08
- O 0 4.609848929248983e-07
> O 0 8.14107522728591e-07
TGA O 0 1.2586443745021825e-06
) O 0 8.439409171501211e-10
at O 0 4.034388378926224e-09
codon O 0 1.5646797635326948e-08
95 O 0 9.54195478186648e-09
in O 0 2.0841732784049327e-09
exon O 0 3.3303169999499005e-08
4 O 0 6.817766795563784e-09
in O 0 1.5801483455035736e-09
the O 0 9.533841272002519e-09
four O 0 7.479875563376481e-08
C9 B-Disease 1 0.507240355014801
- I-Disease 0 0.023993007838726044
deficient I-Disease 0 1.900574170576874e-05
individuals O 0 1.797044113516222e-08
. O 0 1.346385261058458e-07

An O 0 1.4433659600854298e-07
allele O 0 4.080156301711213e-08
- O 0 4.930853592099993e-08
specific O 0 1.4145196125525672e-08
polymerase O 0 4.5644972601621703e-07
chain O 0 5.0127848538750186e-08
reaction O 0 2.8600077861540285e-09
system O 0 2.5114001989123835e-09
designed O 0 1.7358970927361383e-09
to O 0 4.21626705771061e-10
detect O 0 1.8279287417044543e-08
exclusively O 0 1.4892394872845216e-08
only O 0 4.863040525826534e-10
one O 0 1.0060633576225442e-10
of O 0 2.697649326144358e-10
the O 0 3.702556317097816e-10
normal O 0 3.3395195497831764e-09
and O 0 5.5945040267069146e-11
mutant O 0 2.3596382625612478e-09
alleles O 0 6.932445589802327e-11
indicated O 0 7.002266821931613e-11
that O 0 3.5480526936609857e-12
all O 0 1.20710958589898e-11
the O 0 8.496273129487975e-11
four O 0 9.243838333672372e-11
patients O 0 3.273843696138812e-11
were O 0 3.927587977070601e-10
homozygous O 0 8.621929836749587e-10
for O 0 1.4332245112935738e-10
the O 0 3.5398992626056724e-09
mutation O 0 1.5120878993357678e-09
in O 0 1.5783893081433575e-09
exon O 0 2.3235704915691713e-08
4 O 0 5.253350643386057e-09
and O 0 1.2759136802653614e-10
that O 0 5.059450775002361e-11
the O 0 1.0162468644381306e-09
parents O 0 8.264502970867227e-10
of O 0 7.31764737693652e-09
patient O 0 3.157895633876251e-08
2 O 0 3.17688986228859e-08
were O 0 5.1911200671383995e-08
heterozygous O 0 5.176783588467515e-07
. O 0 1.218422056581403e-07

The O 0 5.209142273088219e-07
common O 0 2.0745329010196656e-08
mutation O 0 1.219904000038241e-08
at O 0 3.948645854734423e-08
codon O 0 2.489304904429446e-07
95 O 0 8.499559811525614e-08
in O 0 3.6428620120432242e-09
exon O 0 8.312110821862007e-08
4 O 0 7.486138819956523e-09
might O 0 5.9121108009208e-10
be O 0 4.747588988607276e-10
responsible O 0 2.3511921298791094e-09
for O 0 1.9238686199685162e-09
most O 0 9.171893466941583e-09
Japanese O 0 0.0011436200002208352
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9996508359909058
. O 0 1.162126466169866e-07
. O 0 1.8811667246154684e-07

BRCA1 O 0 1.4586165661967243e-06
required O 0 2.397987053370798e-08
for O 0 1.7039013755493215e-08
transcription O 0 6.47047781967558e-05
- O 0 7.419185749313328e-06
coupled O 0 7.756766535749193e-06
repair O 0 2.5419622033950873e-05
of O 0 1.2485388651839457e-06
oxidative O 0 0.0002191543171647936
DNA O 0 0.0012611346319317818
damage O 0 0.0006109331152401865
. O 0 8.038275609578704e-07

The O 0 1.2832110769522842e-05
breast B-Disease 1 0.9999499320983887
and I-Disease 0 0.2605779469013214
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 1.0
gene O 0 8.444209015578963e-06
BRCA1 O 0 7.46593514122651e-07
encodes O 0 7.339316709931154e-08
a O 0 1.4570738393615557e-08
zinc O 0 2.843208449121448e-06
finger O 0 1.6914144680413301e-06
protein O 0 6.131140395382317e-08
of O 0 4.7115371160089126e-08
unknown O 0 1.039081507769879e-05
function O 0 2.7731377940654056e-06
. O 0 2.6799648367159534e-07

Association O 0 2.1932316940365126e-06
of O 0 3.3515692621222115e-07
the O 0 1.3430779688405892e-07
BRCA1 O 0 9.863310168611861e-08
protein O 0 3.029627437811655e-09
with O 0 1.0513009907064941e-10
the O 0 8.866843259625057e-09
DNA O 0 2.0025825051561696e-06
repair O 0 7.91160055086948e-05
protein O 0 9.362859714201477e-07
Rad51 O 0 6.084929282224039e-06
and O 0 1.1469678679043582e-10
changes O 0 8.836310155801996e-11
in O 0 1.1265268579085941e-10
the O 0 4.502400396955153e-10
phosphorylation O 0 3.570644890871222e-09
and O 0 3.002553761177751e-10
cellular O 0 5.4720707964861504e-08
localization O 0 1.6611549824574467e-07
of O 0 4.9688226866351215e-09
the O 0 5.85468207248141e-09
protein O 0 1.3863510339717777e-08
after O 0 7.383330391519394e-09
exposure O 0 4.9502283161473315e-08
to O 0 1.9285713026562235e-09
DNA O 0 3.0076434995862655e-06
- O 0 9.906982540996978e-07
damaging O 0 1.8954563074657926e-07
agents O 0 3.0774485182405442e-09
are O 0 9.172217152464412e-11
consistent O 0 2.2058188609008766e-09
with O 0 3.953169042114624e-11
a O 0 1.1346701356274025e-09
role O 0 7.458233142187964e-09
for O 0 3.189260855407383e-09
BRCA1 O 0 7.137769131304594e-08
in O 0 1.9735050926783515e-08
DNA O 0 8.032673576963134e-06
repair O 0 0.0006546505028381944
. O 0 9.02435942862212e-07

Here O 0 1.1368399555067299e-06
, O 0 3.0748141810477136e-09
it O 0 3.4046110375385297e-10
is O 0 3.464814823939122e-10
shown O 0 6.85329126781653e-10
that O 0 3.816104932052866e-10
mouse O 0 2.5660879643396584e-08
embryonic O 0 5.654221979511931e-08
stem O 0 2.3387218561765621e-07
cells O 0 1.2916032687826373e-07
deficient B-Disease 0 1.7675081664947356e-07
in I-Disease 0 8.714332588866114e-10
BRCA1 I-Disease 0 7.0546359864920305e-09
are O 0 8.950945540320276e-11
defective O 0 6.063084256879847e-09
in O 0 2.9145744151470865e-10
the O 0 1.453281717189725e-09
ability O 0 1.294494955672576e-09
to O 0 3.0210969836907964e-10
carry O 0 2.2685753275908382e-09
out O 0 7.488066167127272e-09
transcription O 0 3.909157385351136e-06
- O 0 2.732965640461771e-07
coupled O 0 4.893335585620662e-07
repair O 0 1.179142941509781e-06
of O 0 1.0137542716393e-07
oxidative O 0 2.0274778762541246e-06
DNA O 0 4.8942165449261665e-06
damage O 0 2.5525232558720745e-06
, O 0 5.769476008055108e-10
and O 0 8.034974352533197e-10
are O 0 1.0060581256965406e-09
hypersensitive O 0 7.637717089892249e-07
to O 0 1.4778219536992765e-08
ionizing O 0 5.1281462219776586e-05
radiation O 0 1.5312230971176177e-05
and O 0 5.235405886594435e-09
hydrogen O 0 7.398431733918187e-08
peroxide O 0 1.0075796126329806e-06
. O 0 3.106922008555557e-07

These O 0 2.2002255661845993e-07
results O 0 2.1987403897583135e-07
suggest O 0 1.981099444492429e-07
that O 0 6.087685466837911e-09
BRCA1 O 0 8.119405947581981e-08
participates O 0 1.4625981314964065e-08
, O 0 3.780656065988097e-10
directly O 0 1.7600750856772152e-09
or O 0 1.6919019518724099e-09
indirectly O 0 1.0963195684610128e-08
, O 0 3.092687217431944e-10
in O 0 4.298943867553362e-09
transcription O 0 2.0324357592471642e-06
- O 0 4.038787153604062e-07
coupled O 0 1.8039661426882958e-06
repair O 0 4.382771294331178e-06
of O 0 3.4852337194024585e-07
oxidative O 0 2.2577396521228366e-05
DNA O 0 8.046355651458725e-05
damage O 0 1.7776212189346552e-05
. O 0 1.1065419691647094e-08
. O 0 4.183803525847907e-08

Truncation O 0 0.0006301626563072205
mutations O 0 7.611684509356564e-07
in O 0 4.215009141717019e-08
the O 0 1.4131961734165088e-07
transactivation O 0 4.6698525693500414e-05
region O 0 2.8879995284114557e-07
of O 0 1.1726419870683458e-06
PAX6 O 0 0.12746869027614594
result O 0 1.8400078261038288e-07
in O 0 3.813423532506022e-08
dominant O 0 4.538734970083169e-07
- O 0 4.0964189906844695e-07
negative O 0 1.6578569272951427e-07
mutants O 0 1.0182204732700484e-06
. O 0 1.0306224140776976e-07

PAX6 O 0 0.048950303345918655
is O 0 2.371800604805685e-07
a O 0 2.917723520567961e-07
transcription O 0 2.116193627443863e-06
factor O 0 2.505220209059189e-08
with O 0 1.4483719779079252e-10
two O 0 2.3687560801732843e-09
DNA O 0 4.0975248793984065e-07
- O 0 2.444220683628373e-07
binding O 0 3.6872531694598365e-08
domains O 0 1.897248580462474e-07
( O 0 1.841238606026252e-09
paired O 0 5.143572678889541e-09
box O 0 4.9719535155645644e-08
and O 0 2.961975997806121e-09
homeobox O 0 1.19677645216143e-06
) O 0 2.504239704492761e-09
and O 0 9.068094053432674e-10
a O 0 2.9175417637361534e-08
proline O 0 4.390856815916777e-07
- O 0 7.935002486192388e-07
serine O 0 1.3007869483772083e-06
- O 0 2.9748778160865186e-06
threonine O 0 7.467661362170475e-06
( O 0 1.3322167546903074e-07
PST O 0 3.846277832053602e-05
) O 0 8.454771460719712e-08
- O 0 6.700398103021143e-07
rich O 0 5.220451271270576e-07
transactivation O 0 0.0001835437724366784
domain O 0 1.8739179722615518e-05
. O 0 4.71276422331357e-07

PAX6 O 1 0.9999994039535522
regulates O 0 0.0006654720637015998
eye O 0 0.00034448778023943305
development O 0 3.427321360049973e-07
in O 0 3.2378908443320142e-09
animals O 0 2.10833461800064e-09
ranging O 0 1.5462973124158452e-08
from O 0 9.83647829855272e-09
jellyfish O 0 6.980031663772479e-09
to O 0 1.0312113385424482e-09
Drosophila O 0 3.608315424230568e-08
to O 0 1.2914542768527326e-09
humans O 0 3.823241101486019e-08
. O 0 3.6592844310234796e-08

Heterozygous O 0 8.648883522255346e-06
mutations O 0 3.9713583532829944e-08
in O 0 2.8783186944991712e-09
the O 0 1.19666268005858e-08
human O 0 8.633308823391417e-08
PAX6 O 0 0.007124932482838631
gene O 0 1.2787215730725165e-08
result O 0 6.944068653425006e-10
in O 0 1.649776149026394e-10
various O 0 6.954831155425722e-10
phenotypes O 0 2.361408668605236e-08
, O 0 4.1058753619260813e-10
including O 0 2.639868323939254e-09
aniridia B-Disease 1 1.0
, O 0 3.404680342100619e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.462136876602017e-07
autosomal B-Disease 0 0.005494272336363792
dominant I-Disease 0 0.00013977609341964126
keratitis I-Disease 1 0.9842236638069153
, O 0 8.799354844768459e-08
and O 0 8.672520266372885e-07
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0008089568000286818

It O 0 1.985561226547361e-07
is O 0 2.4050228475402946e-08
believed O 0 3.354401911792593e-08
that O 0 2.778465790775897e-10
the O 0 3.951936555779412e-09
mutated O 0 8.082998270708686e-09
allele O 0 6.761201820637552e-09
of O 0 2.403889887148125e-08
PAX6 O 0 0.00014242900942917913
produces O 0 7.661036249828612e-09
an O 0 1.373019031802869e-09
inactive O 0 8.406546925243674e-08
protein O 0 6.039644517841225e-08
and O 0 4.013351428966416e-09
aniridia B-Disease 1 1.0
is O 0 9.649667731537193e-08
caused O 0 1.456229909990725e-07
due O 0 6.951230346885495e-08
to O 0 7.33223686211204e-08
genetic O 0 5.50345066585578e-05
haploinsufficiency O 0 0.019831417128443718
. O 0 1.5758504332552548e-06

However O 0 2.1724220289343066e-07
, O 0 3.435729478695748e-09
several O 0 1.6846406492021515e-09
truncation O 0 5.623676315735793e-07
mutations O 0 5.5860862602230554e-09
have O 0 1.6124752921786722e-10
been O 0 3.8962202908443544e-10
found O 0 9.503584030845502e-11
to O 0 6.773508837154552e-11
occur O 0 3.176958973671873e-10
in O 0 5.875172015556984e-10
the O 0 1.3750219629571347e-08
C O 0 6.087895962991752e-05
- O 0 1.1430507811382995e-06
terminal O 0 4.534118716037483e-07
half O 0 3.3171927427133596e-09
of O 0 1.4605491927000003e-08
PAX6 O 0 6.386676977854222e-05
in O 0 6.385816764264973e-09
patients O 0 2.156468337233264e-09
with O 0 1.1315752779239574e-09
Aniridia B-Disease 1 1.0
resulting O 0 2.6453770374246233e-07
in O 0 3.6678915460441885e-09
mutant O 0 1.1651155595870932e-08
proteins O 0 6.804096730483877e-10
that O 0 6.573554894861999e-11
retain O 0 1.7696079046558566e-09
the O 0 5.371441513801756e-09
DNA O 0 2.969156298604503e-07
- O 0 2.581472990925704e-08
binding O 0 8.710880017304135e-09
domains O 0 3.172100448978199e-08
but O 0 2.7821037140718374e-10
have O 0 2.9620536579066936e-10
lost O 0 8.403036133586284e-08
most O 0 6.731397661496885e-10
of O 0 2.6024940424917986e-08
the O 0 1.9212409085866966e-07
transactivation O 0 9.987086377805099e-05
domain O 0 9.089701052289456e-06
. O 0 2.6216483206553676e-07

It O 0 4.12995291299012e-08
is O 0 1.260179072204437e-09
not O 0 2.905992391166734e-10
clear O 0 1.8315852168271363e-09
whether O 0 2.337776860983354e-09
such O 0 1.8891852526792263e-09
mutants O 0 4.125757300244004e-07
really O 0 9.056209648861113e-08
behave O 0 1.7917189509830678e-08
as O 0 5.92843063529358e-09
loss O 0 2.339125586559021e-07
- O 0 1.5742296000098577e-07
of O 0 7.012206424406031e-07
- O 0 2.824686816893518e-06
function O 0 1.501361310829452e-07
mutants O 0 1.668989213499117e-08
as O 0 1.5326370172985548e-09
predicted O 0 4.482047089027219e-08
by O 0 1.504479563152472e-08
haploinsufficiency O 0 4.8335503379348665e-05
. O 0 1.2206578503537457e-06

Contrary O 0 3.4440618037479e-06
to O 0 2.8652002992402004e-09
this O 0 1.0622260848691667e-09
theory O 0 5.7806072817356835e-08
, O 0 4.786476770490822e-10
our O 0 2.0049455429216323e-09
data O 0 6.3183334120253676e-09
showed O 0 1.08487419048231e-09
that O 0 3.7958566845297526e-11
these O 0 5.0871935136642676e-11
mutants O 0 5.273750769418939e-09
are O 0 1.2046123820663723e-10
dominant O 0 6.39888719788928e-09
- O 0 5.900240740430718e-09
negative O 0 1.2123716475187507e-09
in O 0 8.692155328837714e-10
transient O 0 1.4779382695451204e-07
transfection O 0 2.95533368444012e-07
assays O 0 1.0861252341953787e-08
when O 0 7.390456580047555e-10
they O 0 4.0976530502057074e-10
are O 0 2.948694066695623e-10
coexpressed O 0 3.4451090868969914e-07
with O 0 4.602690673038978e-09
wild O 0 3.652733653325413e-07
- O 0 1.152444110630313e-05
type O 0 2.880822830775287e-05
PAX6 O 1 0.5207358598709106
. O 0 1.5727830486866878e-06

We O 0 2.5091421207434905e-07
found O 0 3.499340550661145e-08
that O 0 1.68173530656901e-09
the O 0 1.736778898475677e-08
dominant O 0 2.3524275150066387e-07
- O 0 2.8632513249249314e-08
negative O 0 3.2618798773143e-09
effects O 0 6.071717351119332e-09
result O 0 2.588698699845793e-10
from O 0 3.201522102980192e-10
the O 0 5.217837273363557e-10
enhanced O 0 6.4095875274006175e-09
DNA O 0 7.2747710078147065e-09
binding O 0 6.525912032984138e-10
ability O 0 1.2663955439862207e-09
of O 0 5.653723267329269e-09
these O 0 3.1641163023010677e-09
mutants O 0 5.906199476157781e-07
. O 0 8.466067669132826e-08

Kinetic O 0 2.4466968170600012e-05
studies O 0 3.263226062699687e-07
of O 0 2.8063237067499358e-08
binding O 0 1.313347031128842e-08
and O 0 2.7101725308398272e-09
dissociation O 0 8.556984880669916e-07
revealed O 0 5.834952432337559e-08
that O 0 1.979138519736523e-10
various O 0 1.3439428458994485e-09
truncation O 0 5.324116045812843e-07
mutants O 0 2.6628388383187485e-08
have O 0 3.874388587732369e-10
3 O 0 4.898996763813557e-09
- O 0 1.2593098119850765e-08
5 O 0 2.4005863963338925e-08
- O 0 3.4596478570847466e-08
fold O 0 2.9437183357572394e-08
higher O 0 1.4790148661347757e-08
affinity O 0 2.846657798372121e-09
to O 0 1.0802835015422119e-10
various O 0 6.243766614844048e-10
DNA O 0 4.567188227611041e-08
- O 0 3.864972786260523e-09
binding O 0 7.41295913542217e-10
sites O 0 8.81201112079566e-10
when O 0 1.8157855774525444e-10
compared O 0 4.4678141741805177e-10
with O 0 4.23033795493577e-11
the O 0 3.2391014315180655e-09
wild O 0 4.50493899961657e-08
- O 0 1.0616938652674435e-06
type O 0 3.4325394153711386e-06
PAX6 O 0 0.002580825239419937
. O 0 1.321600279879931e-06

These O 0 9.132742206929834e-08
results O 0 2.5946729209636032e-08
provide O 0 9.114901722284685e-09
a O 0 4.1856051957722684e-09
new O 0 1.5533376807042032e-09
insight O 0 6.031747545875987e-08
into O 0 3.25303828319079e-09
the O 0 5.144259684897179e-09
role O 0 4.9821306191688564e-08
of O 0 1.9791468730545603e-07
mutant O 0 7.734435712336563e-06
PAX6 O 0 0.011940580792725086
in O 0 3.0075091217440786e-07
causing O 0 5.383702955441549e-06
aniridia B-Disease 1 0.9999997615814209
. O 0 2.898296713738091e-07
. O 0 5.605256774288137e-07

Reversal O 0 0.00025844809715636075
of O 0 1.465457899030298e-05
severe O 1 0.9999845027923584
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 5.666448146257608e-07
excellent O 0 3.854182978102472e-06
neuropsychologic O 0 2.569615753600374e-05
outcome O 0 2.405851660114422e-07
in O 0 7.809395796698482e-09
very B-Disease 0 1.1020997447985792e-08
- I-Disease 0 2.1340088096621912e-07
long I-Disease 0 2.963800795896532e-07
- I-Disease 0 1.20494075872557e-06
chain I-Disease 0 5.9731416968134e-07
acyl I-Disease 0 3.478035068837926e-07
- I-Disease 0 9.190194418806641e-07
coenzyme I-Disease 0 3.848277174256509e-06
A I-Disease 0 2.927879359049257e-05
dehydrogenase I-Disease 0 0.00011616198753472418
deficiency I-Disease 0 0.0010264823213219643
. O 0 1.9700570419445285e-07

Very B-Disease 0 1.0850153557839803e-06
- I-Disease 0 1.8285862779521267e-06
long I-Disease 0 5.139609129400924e-07
- I-Disease 0 6.435026875806216e-07
chain I-Disease 0 1.8050624817078642e-07
acyl I-Disease 0 1.0449432608083953e-07
- I-Disease 0 1.0576701470199623e-07
coenzyme I-Disease 0 2.6296913802070776e-07
A I-Disease 0 4.71632944254452e-07
dehydrogenase I-Disease 0 1.8874168006277614e-07
( I-Disease 0 1.9293301178890943e-08
VLCAD I-Disease 0 0.019359111785888672
) I-Disease 0 5.556854887345253e-08
deficiency I-Disease 0 1.1676933354465291e-05
is O 0 2.8499935744719096e-09
a O 0 5.02808674696098e-08
disorder O 0 0.00014430552255362272
of O 0 5.105052696308121e-05
fatty O 0 0.0002381726517342031
acid O 0 7.99371537141269e-06
beta O 0 6.369834864017321e-07
oxidation O 0 8.693584518937314e-09
that O 0 3.521237745829353e-10
reportedly O 0 1.709050501119691e-08
has O 0 2.3771054569188266e-10
high O 0 2.1093402580163456e-09
rates O 0 2.977019075700582e-09
of O 0 9.458836380815683e-09
morbidity O 0 2.6558193439996103e-06
and O 0 1.1396984689326928e-08
mortality O 0 1.3311147995409556e-05
. O 0 2.800314575779339e-07

We O 0 3.437085354107694e-07
describe O 0 3.0061386269153445e-07
the O 0 2.9520116129333474e-08
outcome O 0 1.5370221717603272e-07
of O 0 1.1581511216718354e-07
a O 0 2.8555831477206084e-08
5 O 0 2.2900922047597305e-08
- O 0 1.3805669496491646e-08
year O 0 8.064549916753094e-09
- O 0 6.692128096119632e-08
old O 0 3.376564450263686e-07
girl O 0 1.2245404832356144e-06
with O 0 1.2613379851700302e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.6027231569969445e-07
was O 0 3.8810867408756167e-07
first O 0 1.7675040098197314e-08
seen O 0 2.8960300824110163e-08
at O 0 3.647716795285305e-08
5 O 0 5.468416386378294e-09
months O 0 2.443146573938293e-09
of O 0 2.781149976982533e-09
age O 0 4.402823705618175e-08
with O 0 2.5259287994572333e-08
severe O 1 0.9998297691345215
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 0 0.13807523250579834
hepatomegaly B-Disease 1 1.0
, O 0 0.17203521728515625
encephalopathy B-Disease 1 0.9999148845672607
, O 0 7.719394830019155e-07
and O 0 8.44342775963014e-06
hypotonia B-Disease 1 0.9997527003288269
. O 0 3.9031892811181024e-05

Biochemical O 1 0.6416192650794983
studies O 0 0.0003180068451911211
indicated O 1 0.9819386005401611
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 2.9337825253605843e-05
by O 0 3.3136007271394874e-09
a O 0 6.19321927075589e-09
stable O 0 1.7469785618118294e-08
yet O 0 2.9053954797575443e-09
inactive O 0 2.22522942294745e-07
enzyme O 0 2.579918430001271e-07
. O 0 1.267012947891999e-07

Molecular O 0 0.0003422660520300269
genetic O 0 2.695810962904943e-06
analysis O 0 1.6273408220968122e-07
of O 0 2.2866882432026614e-07
her O 0 3.201478648406919e-06
VLCAD O 1 0.9999970197677612
gene O 0 2.7426472115621436e-07
revealed O 0 1.8093643916472502e-07
a O 0 1.266306242087012e-07
T1372C O 0 4.927459485770669e-06
( O 0 1.441327270867987e-07
F458L O 0 3.609228315326618e-06
) O 0 2.4018779853918204e-08
missense O 0 4.678136349411943e-07
mutation O 0 1.3476347149321555e-08
and O 0 2.8944215912929394e-09
a O 0 1.0392659532953985e-06
1668 O 1 0.9198709726333618
ACAG O 1 0.9999929666519165
1669 O 1 0.9062198400497437
splice O 0 0.0003947650548070669
site O 0 6.296816536632832e-06
mutation O 0 4.0057256001091446e-07
. O 0 2.8198456902828184e-07

After O 0 3.2403519867330033e-07
initial O 0 1.4866135700231098e-07
treatment O 0 1.1115957043728031e-08
with O 0 1.6908857647379705e-09
intravenous O 0 1.133093860516965e-06
glucose O 0 2.538349008318619e-06
and O 0 2.0291557323304232e-09
carnitine O 0 2.9313525828911224e-06
, O 0 5.840670169732221e-10
the O 0 2.8070501478794085e-09
patient O 0 3.789402569509548e-08
has O 0 2.372394503069586e-10
thrived O 0 1.3350678784718184e-08
on O 0 2.5612749698922244e-09
a O 0 5.882890175001876e-09
low O 0 1.0324010446538523e-07
- O 0 8.389920225226888e-08
fat O 0 7.80229392205456e-09
diet O 0 1.4496219780113506e-09
supplemented O 0 1.6521134460489861e-09
with O 0 6.525510687360736e-11
medium O 0 7.65128476132304e-08
- O 0 6.433916155401675e-07
chain O 0 1.853314870459144e-07
triglyceride O 0 2.3627519851743273e-07
oil O 0 1.4348896115734533e-07
and O 0 4.91003504521359e-09
carnitine O 0 3.236360498704016e-06
and O 0 2.451176328577276e-08
avoidance O 0 2.3936383968248265e-06
of O 0 6.690914915452595e-07
fasting O 0 1.5634957890142687e-05
. O 0 9.70936184785387e-07

Her O 0 0.001057532848790288
ventricular O 1 0.999160647392273
hypertrophy O 0 0.015317310579121113
resolved O 0 7.081350304360967e-06
significantly O 0 7.95882471038567e-08
over O 0 6.144976527622248e-09
1 O 0 4.209238291252859e-09
year O 0 6.404830554807006e-10
, O 0 1.3467828241520152e-10
and O 0 5.482512777099657e-10
cognitively O 0 2.8800336622225586e-06
, O 0 1.7114505368454047e-09
she O 0 3.748232835221188e-09
is O 0 1.4246998025768676e-09
in O 0 4.444347390109016e-10
the O 0 1.8280951197269246e-09
superior O 0 6.530748919431062e-08
range O 0 4.6568413125669395e-08
for O 0 1.7794853590658022e-08
age O 0 2.4808753096294822e-06
. O 0 8.067950716394989e-07

Clinical O 0 0.008656910620629787
recognition O 0 8.939337021729443e-06
of O 1 0.9999309778213501
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.2776374660461443e-06
important O 0 3.3584989012069855e-08
because O 0 2.973068458089756e-10
it O 0 5.302642699933635e-11
is O 0 1.2004357230477325e-10
one O 0 1.3733351955647066e-10
of O 0 7.597587003971285e-10
the O 0 1.9356616309806896e-09
few O 0 3.555896910256706e-09
directly O 0 6.027261889585134e-08
treatable O 0 0.00011918234667973593
causes O 0 4.886923079538974e-07
of O 0 0.0001248792978003621
cardiomyopathy B-Disease 1 1.0
in O 0 7.910084605100565e-07
children O 0 5.783386214375241e-08
. O 0 3.164600670402251e-08
. O 0 2.0968546721178427e-07

Cloning O 0 4.3017698772018775e-05
of O 0 1.7740570967816893e-07
a O 0 4.498422256915546e-08
novel O 0 7.560313974863675e-08
member O 0 2.272465415842362e-08
of O 0 1.9972862475015063e-08
the O 0 3.4496785872306646e-08
low O 0 4.257434738974553e-06
- O 0 6.398916866601212e-06
density O 0 1.2590957112479373e-06
lipoprotein O 0 0.00016933822189457715
receptor O 0 2.9491129680536687e-06
family O 0 5.035107051298837e-07
. O 0 1.391785531268397e-07

A O 0 9.729274097480811e-06
gene O 0 2.3683467986757023e-07
encoding O 0 5.401711078434346e-08
a O 0 1.6615885556348076e-08
novel O 0 1.6038171679610969e-07
transmembrane O 0 1.5104665180842858e-06
protein O 0 2.458518189030201e-08
was O 0 3.783954927172317e-09
identified O 0 7.416268710258578e-10
by O 0 9.256206218166696e-11
DNA O 0 2.4477271320932914e-09
sequence O 0 1.3173880875072541e-09
analysis O 0 1.3181296054654013e-09
within O 0 8.525887218446826e-10
the O 0 1.7523873463431983e-09
insulin B-Disease 0 4.102029151908937e-07
- I-Disease 0 1.1310587069601752e-05
dependent I-Disease 0 0.003724687034264207
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 4.737855488201603e-05
IDDM B-Disease 1 0.9999010562896729
) O 0 5.714960593650176e-07
locus O 0 1.5431586462000269e-06
IDDM4 O 0 2.8697015295620076e-05
on O 0 3.140542901292065e-07
chromosome O 0 1.0560072951193433e-05
11q13 O 0 5.1493891078280285e-05
. O 0 1.7434588244213955e-06

Based O 0 1.0823922593772295e-06
on O 0 5.081750487079262e-08
its O 0 4.158739574933179e-09
chromosomal O 0 2.623156376557745e-07
position O 0 5.624621124411533e-08
, O 0 8.986326127669031e-10
this O 0 9.263451672403278e-10
gene O 0 3.092287759187684e-09
is O 0 5.105022515827784e-10
a O 0 3.306807050407201e-09
candidate O 0 2.7641635647057683e-09
for O 0 1.177931974183366e-09
conferring O 0 4.993270295017282e-07
susceptibility O 0 5.8672048908192664e-06
to O 0 1.8843537930024468e-07
diabetes B-Disease 1 0.9999719858169556
. O 0 2.0204574866511393e-06

The O 0 1.089748252525169e-06
gene O 0 9.047801796668864e-08
, O 0 2.669030774171688e-09
termed O 0 2.036155422047159e-07
low O 0 4.051957148476504e-06
- O 0 9.602839782019146e-06
density O 0 4.6199892267395626e-07
lipoprotein O 0 4.857881322095636e-06
receptor O 0 4.7573927020039264e-08
related O 0 4.845709611345228e-09
protein O 0 4.075907167333526e-09
5 O 0 2.2369515129128104e-09
( O 0 1.3703400636444485e-09
LRP5 O 0 2.1732787445216672e-06
) O 0 1.2527354709135352e-09
, O 0 2.305178270489705e-10
encodes O 0 4.0713850069096225e-09
a O 0 1.2080343392284476e-09
protein O 0 3.646393409439952e-09
of O 0 2.885480965275633e-09
1615 O 0 1.900624920381233e-05
amino O 0 8.062368550554311e-08
acids O 0 3.2400904181884016e-09
that O 0 4.669188299888383e-11
contains O 0 1.519955133977291e-10
conserved O 0 1.1946215572322672e-08
modules O 0 1.3423910871779299e-08
which O 0 5.733972671673193e-11
are O 0 8.928944389419158e-12
characteristic O 0 8.472682555549227e-10
of O 0 3.7252543272359162e-09
the O 0 2.980531732532654e-08
low O 0 1.3930166460340843e-06
- O 0 2.437482407913194e-06
density O 0 3.4627777267814963e-07
lipoprotein O 0 3.192202711943537e-05
( O 0 3.159405252972647e-07
LDL O 0 2.803772258630488e-05
) O 0 3.359664901836368e-08
receptor O 0 2.532197811433434e-07
family O 0 6.273065622508511e-08
. O 0 5.1007159385108025e-08

These O 0 5.632361066432168e-08
modules O 0 5.604080683951906e-07
include O 0 1.897470625067399e-08
a O 0 5.559738625038335e-08
putative O 0 5.291274760566012e-07
signal O 0 1.0107982717499908e-07
peptide O 0 1.0863262289717568e-08
for O 0 2.016665306969756e-10
protein O 0 1.3857792691140958e-09
export O 0 4.058143154850313e-09
, O 0 3.3102762198033986e-10
four O 0 2.808346222238356e-09
epidermal O 0 5.344363103176875e-07
growth O 0 3.241390089669949e-08
factor O 0 6.13635862123374e-08
( O 0 1.8448814032012706e-08
EGF O 0 4.687287400884088e-06
) O 0 1.6852383932786097e-09
repeats O 0 1.1520116416363635e-08
with O 0 8.90701179478981e-10
associated O 0 1.323423646226729e-07
spacer O 0 1.1782170076912735e-05
domains O 0 8.229085892708099e-07
, O 0 5.431556093782319e-09
three O 0 2.4266425313612672e-08
LDL O 0 1.5314113625208847e-05
- O 0 2.412453113720403e-06
receptor O 0 6.735846795891121e-07
( O 0 1.8301195225944866e-08
LDLR O 0 1.5357476513599977e-05
) O 0 5.343789410972022e-09
repeats O 0 1.2251364367443784e-08
, O 0 6.935834684362874e-10
a O 0 4.03854594210884e-09
single O 0 1.1939473409938728e-08
transmembrane O 0 6.621855277444411e-07
spanning O 0 1.1239267223572824e-06
domain O 0 1.6970923297776608e-06
, O 0 4.325312552566629e-09
and O 0 3.6167402406306337e-09
a O 0 2.1249006465495768e-07
cytoplasmic O 0 1.3151629900676198e-05
domain O 0 2.155176298401784e-05
. O 0 4.6198525183172023e-07

The O 0 1.5076916497491766e-06
encoded O 0 6.116750910223345e-07
protein O 0 7.76987789663508e-08
has O 0 2.803287602048954e-10
a O 0 1.144723871249198e-09
unique O 0 3.415018490215971e-09
organization O 0 1.1005012900966449e-08
of O 0 4.7626633659092477e-07
EGF O 1 0.9675830006599426
and O 0 2.9464819917279783e-08
LDLR O 0 0.30542078614234924
repeats O 0 1.5868518232764472e-07
; O 0 8.584401522959695e-10
therefore O 0 7.663169654392732e-09
, O 0 8.503219461886147e-09
LRP5 O 0 0.0002300180058227852
likely O 0 2.0887469531771785e-08
represents O 0 5.682198711554065e-09
a O 0 2.7065669705450546e-09
new O 0 8.768168413553212e-10
category O 0 7.249495581618248e-08
of O 0 4.969242439756272e-08
the O 0 5.43422117971204e-07
LDLR O 1 0.998665452003479
family O 0 6.999377546890173e-06
. O 0 5.603920385510719e-07

Both O 0 4.3638806346280035e-07
human O 0 1.7792416429074365e-07
and O 0 7.549131453288283e-08
mouse O 0 8.944317414716352e-06
LRP5 O 1 0.9790374040603638
cDNAs O 0 3.243757601012476e-05
have O 0 6.26445118001584e-10
been O 0 1.2623921907817248e-09
isolated O 0 3.3515861197486174e-09
and O 0 6.076368574969848e-11
the O 0 1.7127632645497215e-09
encoded O 0 4.153658306194075e-09
mature O 0 1.2207040933631674e-09
proteins O 0 1.7905008031782188e-10
are O 0 4.5986058710978384e-11
95 O 0 3.858859010108517e-09
% O 0 3.5515229646065904e-10
identical O 0 9.277207890789896e-10
, O 0 3.423495098520135e-10
indicating O 0 1.568043828115151e-08
a O 0 4.614319593088112e-09
high O 0 1.2658602166482069e-08
degree O 0 1.135979061928083e-07
of O 0 1.902108692775073e-08
evolutionary O 0 1.6294123383886472e-07
conservation O 0 1.942860450299122e-08
. O 0 2.1571142649889907e-09
. O 0 2.0987867443977848e-08

The O 0 8.406396773352753e-06
APC B-Disease 0 1.5604822692694142e-05
variants O 0 1.4491227773305582e-07
I1307K O 0 2.571596041889279e-06
and O 0 4.095435990336682e-09
E1317Q O 0 3.063937811020878e-06
are O 0 1.2763621271005832e-09
associated O 0 5.348135800886666e-07
with O 0 0.08147677779197693
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.002545110182836652
but O 0 7.792047007626479e-09
not O 0 9.715720450387266e-10
always O 0 6.1502762882525985e-09
with O 0 8.479278390538525e-10
a O 0 6.857494838641287e-08
family O 0 9.201825434956845e-08
history O 0 9.418205308975303e-07
. O 0 2.2788162823417224e-07

Classical O 1 0.9999984502792358
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9994951486587524
FAP B-Disease 0 0.04351228103041649
) O 0 2.8818963215826443e-08
is O 0 1.8139656443594276e-09
a O 0 2.242805585694896e-08
high O 0 0.00016491158748976886
- O 1 0.9999996423721313
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999953508377075
disease I-Disease 1 0.8444724082946777
that O 0 1.5847542167435336e-09
predisposes O 0 2.049551284244444e-07
to O 0 7.276349522911119e-10
hundreds O 0 3.494296851869194e-09
or O 0 4.5163703887851625e-09
thousands O 0 1.3390768494048189e-08
of O 0 0.19279056787490845
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9898560047149658
carcinoma I-Disease 1 1.0
and O 0 4.973051304091314e-09
that O 0 2.6203428316051713e-10
results O 0 1.0084538759613793e-09
from O 0 2.730637049808138e-09
truncating O 0 2.778363352717861e-07
mutations O 0 1.4912056034432908e-09
in O 0 2.30720731408951e-09
the O 0 4.358822636163495e-08
APC B-Disease 0 3.3676415114314295e-06
gene O 0 1.77623761032919e-07
. O 0 9.805555123421072e-08

A O 0 4.136254574405029e-06
variant O 0 6.722171974615776e-07
of O 0 9.511882126389537e-07
FAP B-Disease 0 0.00011211333185201511
is O 0 5.669631946148002e-07
attenuated B-Disease 0 0.10985764861106873
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9997606873512268
, O 0 8.196235690149933e-09
which O 0 1.000731941758204e-09
results O 0 2.7241344735529083e-09
from O 0 2.4729938985501576e-08
germ O 1 0.9760154485702515
- O 0 1.0349978765589185e-05
line O 0 1.4905813827681413e-07
mutations O 0 5.997394803003431e-10
in O 0 2.4883356486427033e-10
the O 0 9.679651524763244e-10
5 O 0 1.1954962575444483e-09
and O 0 9.966759362267652e-11
3 O 0 2.239333385389841e-09
regions O 0 4.865433611556114e-10
of O 0 1.3019937128433412e-08
the O 0 3.5195634495721606e-07
APC B-Disease 0 1.2296098248043563e-05
gene O 0 2.918934285389696e-07
. O 0 1.291726476893018e-07

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 6.459334144892637e-06
have O 0 1.074103805898119e-09
" O 0 3.3632876039746407e-08
multiple O 0 8.769186479185009e-07
" O 1 0.7371873259544373
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.8165465576203133e-07
typically O 0 2.057586989678839e-09
fewer O 0 1.7525100814985706e-10
than O 0 1.1412940037480723e-10
100 O 0 1.5046422996434217e-09
) O 0 1.975943852983164e-10
without O 0 2.3945842531070127e-10
the O 0 2.7438353811248817e-09
florid O 0 8.214243507609353e-07
phenotype O 0 1.0085893364930598e-07
of O 0 1.324244323086532e-07
classical O 0 1.5050015463202726e-05
FAP B-Disease 0 2.4363704142160714e-05
. O 0 4.855815518567397e-07

Another O 0 1.3157474541003467e-06
group O 0 1.40996210262756e-08
of O 0 2.541683485901558e-08
patients O 0 6.119548423555443e-09
with O 0 1.1653150666646184e-09
multiple O 0 1.4245708825910697e-06
adenomas B-Disease 1 0.7903688549995422
has O 0 1.7343614322484768e-09
no O 0 7.403690438501087e-10
mutations O 0 1.1281933720574955e-10
in O 0 4.420548649353151e-10
the O 0 1.4480861842969261e-08
APC B-Disease 0 1.9529127825990145e-07
gene O 0 1.130298188378731e-09
, O 0 7.22826382082431e-11
and O 0 8.427517711462329e-11
their O 0 3.55110996164143e-10
phenotype O 0 1.2318003506095465e-08
probably O 0 3.879463417177931e-09
results O 0 9.543588141980308e-10
from O 0 1.7148487074791774e-09
variation O 0 9.341204254553759e-09
at O 0 2.8738602608768815e-08
a O 0 2.0119376387128796e-08
locus O 0 4.4360778161944836e-08
, O 0 1.192375920222588e-10
or O 0 5.270148206726333e-10
loci O 0 2.478872218603101e-09
, O 0 2.495346151931699e-10
elsewhere O 0 2.6779647388508465e-09
in O 0 1.872339838726589e-09
the O 0 7.738405116697322e-08
genome O 0 5.565016181208193e-07
. O 0 1.6598453100868937e-07

Recently O 0 1.5684078107369714e-06
, O 0 4.027714606280597e-09
however O 0 4.54558080065226e-09
, O 0 1.6700838489924763e-09
a O 0 1.3873933113472958e-08
missense O 0 3.490069673262042e-07
variant O 0 5.629214072655486e-08
of O 0 1.294791672989959e-06
APC B-Disease 0 1.2627100659301504e-05
( O 0 1.7044709466063068e-07
I1307K O 0 1.0867782293644268e-05
) O 0 1.0735104361003778e-08
was O 0 3.32600684771478e-08
described O 0 1.1609496475273318e-08
that O 0 1.641608654567861e-10
confers O 0 4.2813756984116935e-09
an O 0 2.2131250998480567e-10
increased O 0 2.5736643927132263e-09
risk O 0 4.544122873539891e-07
of O 1 0.9999843835830688
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.1767062915168935e-06
including O 0 1.3036934198851213e-08
multiple O 0 5.753634582106315e-07
adenomas B-Disease 0 0.00012848647020291537
, O 0 1.2497053170079653e-08
in O 0 8.824044783750651e-08
Ashkenazim O 0 6.862831651233137e-05
. O 0 1.0314479368389584e-06

We O 0 2.2376102037924284e-07
have O 0 3.009469784487351e-09
studied O 0 6.563704602058351e-08
a O 0 6.437472777065523e-09
set O 0 4.600277048183443e-09
of O 0 1.69966152263612e-09
164 O 0 9.618591256810305e-09
patients O 0 6.26000806747129e-10
with O 0 6.003953445521404e-10
multiple O 0 0.05089717358350754
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.6538092494010925
/ I-Disease 1 0.9999998807907104
or I-Disease 0 0.045759737491607666
carcinoma I-Disease 1 1.0
and O 0 1.7909259852899595e-08
analyzed O 0 7.963256507537153e-07
codons O 0 8.172135608219833e-07
1263 O 0 1.5161343981162645e-05
- O 0 4.974600642526639e-07
1377 O 0 1.2228144441905897e-05
( O 0 1.1423954759948174e-07
exon O 0 9.445108730687934e-07
15G O 0 1.5363349348263e-06
) O 0 5.322052132328281e-09
of O 0 7.055927842003484e-09
the O 0 2.4478683968709447e-08
APC B-Disease 0 4.1295285768683243e-07
gene O 0 6.221693826802266e-09
for O 0 1.0709050535240294e-08
germ O 1 0.9999076128005981
- O 0 0.05969841778278351
line O 0 1.356379743810976e-05
variants O 0 1.2828545550291892e-06
. O 0 3.725263866272144e-07

Three O 0 3.612685191001219e-07
patients O 0 1.1940361588358428e-08
with O 0 6.534693341997411e-10
the O 0 3.837926598748709e-08
I1307K O 0 2.760495817710762e-06
allele O 0 1.4292104388857751e-08
were O 0 4.108956286330567e-09
detected O 0 1.564990093072538e-08
, O 0 1.983711528374954e-10
each O 0 5.630582666782402e-10
of O 0 5.076151410321472e-08
Ashkenazi O 0 1.336570676357951e-05
descent O 0 4.438189716893248e-05
. O 0 2.0197312551317737e-06

Four O 0 1.6141314063133905e-06
patients O 0 1.5554560661712458e-07
had O 0 3.3327186343967696e-08
a O 0 2.931253106908116e-07
germ O 1 0.9986646175384521
- O 0 0.0009173550643026829
line O 0 4.559269200399285e-06
E1317Q O 0 1.6737218174966983e-05
missense O 0 8.234660526795778e-07
variant O 0 7.654904976561738e-08
of O 0 6.791967166464019e-08
APC O 0 1.8623791220306884e-07
that O 0 2.7954974446409153e-10
was O 0 1.0446519205231652e-08
not O 0 2.0757102980883957e-10
present O 0 2.3204425048106714e-09
in O 0 3.162101247511373e-09
controls O 0 1.8786652233870882e-08
; O 0 2.0401956513094177e-10
one O 0 2.857552805490826e-10
of O 0 1.3540288890112606e-09
these O 0 2.0468139683149644e-10
individuals O 0 3.4048644459439004e-10
had O 0 3.0959645958006377e-09
an O 0 2.1957025087004922e-09
unusually O 0 6.923360995614303e-09
large O 0 5.762987309587686e-10
number O 0 2.28567476057151e-09
of O 0 6.693480969488519e-08
metaplastic B-Disease 0 6.957488949410617e-05
polyps I-Disease 0 6.530444238705968e-07
of I-Disease 0 3.359351694598445e-07
the I-Disease 0 1.2105557516406407e-06
colorectum I-Disease 0 0.0012464640894904733
. O 0 1.6756210925450432e-06

There O 0 3.6834404681940214e-07
is O 0 9.373830600623023e-09
increasing O 0 3.5790728158957563e-09
evidence O 0 1.3790142361358448e-08
that O 0 2.481486960359547e-10
there O 0 1.677493588481127e-09
exist O 0 8.984874177997426e-09
germ O 0 2.9486260245903395e-05
- O 0 2.691115810193878e-07
line O 0 1.8652261957186056e-08
variants O 0 5.421348370227008e-10
of O 0 1.6187933216116335e-09
the O 0 9.207720808035447e-09
APC B-Disease 0 4.050915265452204e-07
gene O 0 2.1254502602374714e-09
that O 0 5.6757695765519145e-11
predispose O 0 6.504169647314484e-09
to O 0 1.117476666756545e-10
the O 0 7.838477089627816e-10
development O 0 2.3793075953904008e-08
of O 0 3.2705193575566227e-07
multiple O 1 0.9994186162948608
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9988555908203125
carcinoma I-Disease 1 1.0
, O 0 5.2522284299527655e-09
but O 0 1.9678723928162611e-10
without O 0 1.3483231198208045e-09
the O 0 4.314189450127515e-09
florid O 0 5.130632416694425e-07
phenotype O 0 1.5648408790980284e-08
of O 0 5.072800401961786e-09
classical O 0 2.180060391765437e-06
FAP B-Disease 0 8.293833388961502e-07
, O 0 2.2345025829650922e-10
and O 0 1.0863997201848719e-10
possibly O 0 4.5313841567917734e-09
with O 0 3.769682344056946e-10
importance O 0 1.0134976037079468e-05
for O 0 0.47502604126930237
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.9999850988388062
in O 0 2.1523929305544698e-08
the O 0 8.229869230547138e-09
general O 0 1.2760049017401798e-08
population O 0 9.447022053521437e-10
. O 0 1.5018295496105338e-09
. O 0 4.626863159273853e-08

Genomic O 0 2.3280690584215336e-05
structure O 0 6.753265324732638e-07
of O 0 2.129802112449397e-07
the O 0 1.4246619457480847e-06
human O 1 0.9487290382385254
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 2.100494020851329e-05
gene O 0 9.70015321399842e-07
. O 0 2.5048720431186666e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 2.120468252542196e-06
is O 0 7.941246771281385e-09
caused O 0 2.2978012381713597e-08
by O 0 1.8041799165757766e-09
mutations O 0 3.6504990141850158e-09
in O 0 5.058983010286511e-09
a O 0 3.0033014297714544e-08
gene O 0 6.725997980794318e-09
which O 0 1.2833070162088234e-09
encodes O 0 5.917498313579017e-08
an O 0 9.523682287237989e-09
intestinal O 0 3.313935849291738e-06
anion O 0 5.6451448472216725e-05
transporter O 0 0.0014310585102066398
. O 0 1.2473797141865361e-06

We O 0 2.839935291376605e-07
report O 0 8.164659703879806e-08
here O 0 1.4830600747473e-08
the O 0 7.06980296527604e-09
complete O 0 7.170627469577084e-08
genomic O 0 1.795694686279603e-07
organization O 0 1.126399151729629e-08
of O 0 3.826450978294815e-08
the O 0 1.6654173862207244e-07
human O 0 3.4135598525608657e-06
CLD B-Disease 1 0.9999995231628418
gene O 0 6.965404963921173e-08
which O 0 1.1540057798242742e-09
spans O 0 6.006822417248259e-08
approximately O 0 1.908781399606596e-08
39kb O 0 9.466913297728752e-07
, O 0 2.85376855480024e-09
and O 0 2.9301046033936018e-09
comprises O 0 1.2009802219381527e-07
21 O 0 1.5236275885399664e-06
exons O 0 2.987606421811506e-06
. O 0 4.4325429371383507e-07

All O 0 4.194453140371479e-06
exon O 0 7.272606308106333e-05
/ O 0 1.2772056834364776e-05
intron O 0 1.2201923709653784e-05
boundaries O 0 6.844871336397773e-08
conform O 0 5.262549862550259e-08
to O 0 1.1477918171465262e-08
the O 0 3.74055730389955e-07
GT O 0 9.404432057635859e-05
/ O 0 0.000123849356896244
AG O 0 0.001340012764558196
rule O 0 2.685296067284071e-06
. O 0 7.9440883382631e-07

An O 0 8.999781897500725e-08
analysis O 0 6.381021933066222e-08
of O 0 2.0069361283958642e-08
the O 0 3.035088624869786e-08
putative O 0 3.1920249057293404e-06
promoter O 0 1.1226679816900287e-06
region O 0 2.755406036669683e-08
sequence O 0 8.494081527032904e-08
shows O 0 3.682283988837298e-08
a O 0 8.170096066351107e-08
putative O 0 5.150171091372613e-06
TATA O 0 2.9168324545025826e-05
box O 0 2.513285437544255e-07
and O 0 2.463529824581201e-09
predicts O 0 1.1507746933148155e-07
multiple O 0 7.701916615587834e-08
transcription O 0 6.994198884058278e-06
factor O 0 1.2185638809114607e-07
binding O 0 5.218221232894393e-08
sites O 0 2.397937635123526e-07
. O 0 1.901429129702592e-07

The O 0 7.742848424641124e-07
genomic O 0 7.686652452321141e-07
structure O 0 1.7107244332237315e-07
was O 0 5.963158145050329e-08
determined O 0 9.122484101453665e-09
using O 0 4.7114898649169845e-09
DNA O 0 8.784225791202971e-09
from O 0 5.029673899592524e-10
several O 0 1.7588390466283244e-10
sources O 0 1.1342417005621996e-09
including O 0 5.222275389904496e-11
multiple O 0 4.217047266941165e-10
large O 0 5.861386043193306e-09
- O 0 1.2467501164792338e-07
insert O 0 2.1191755195104633e-07
libaries O 0 1.0235187346552266e-06
and O 0 1.7735140023233953e-09
genomic O 0 1.2721633879664296e-07
DNA O 0 1.051735694090894e-07
from O 0 5.8796178592501747e-08
Finnish O 0 0.00897665973752737
CLD B-Disease 1 0.9999997615814209
patients O 0 3.548053939539386e-07
and O 0 3.034799433976332e-08
controls O 0 1.4583746406060527e-06
. O 0 4.121482390928577e-07

Exon O 0 4.995009658159688e-05
- O 0 1.7463797519212676e-07
specific O 0 2.6753048665284496e-09
primers O 0 4.379239371132826e-08
developed O 0 1.761982892922731e-09
in O 0 2.2035299973577338e-10
this O 0 5.5872848014892895e-11
study O 0 1.330003607247221e-10
will O 0 2.176063322589794e-11
facilitate O 0 1.0286811402693274e-09
mutation O 0 2.2486715267611146e-10
screening O 0 2.3139487548284876e-10
studies O 0 9.624274710517966e-10
of O 0 2.2817936429220254e-09
patients O 0 7.361306009201485e-10
with O 0 3.0654900839977017e-10
the O 0 9.943349823515746e-07
disease O 0 0.046103473752737045
. O 0 2.0789661903108936e-07

Genomic O 0 2.650102942425292e-05
sequencing O 0 2.1325756733858725e-06
of O 0 9.193209393743018e-07
a O 0 2.6808006623468827e-06
BAC O 1 0.9977194666862488
clone O 0 0.24989616870880127
H O 1 1.0
_ O 0 1.2658449577429565e-07
RG364P16 O 0 1.9784099549724488e-06
revealed O 0 9.4507065284688e-08
the O 0 6.429031085275483e-09
presence O 0 1.7172316901792328e-09
of O 0 2.508920182719976e-09
another O 0 3.4474663124228755e-09
, O 0 6.921166417761526e-10
highly O 0 6.5619119027360284e-09
homologous O 0 3.285934724317485e-08
gene O 0 2.003714527631928e-09
3 O 0 3.8237786270656215e-09
of O 0 1.1611489547647125e-08
the O 0 2.413260062894551e-07
CLD B-Disease 1 0.9999983310699463
gene O 0 7.846950467182978e-08
, O 0 3.3347247185844253e-10
with O 0 9.704583664449373e-11
a O 0 2.220449379919387e-09
similar O 0 5.730115826274584e-10
genomic O 0 2.7286805703852224e-08
structure O 0 8.603194601164432e-08
, O 0 5.263267044419706e-10
recently O 0 1.8710546445532827e-09
identified O 0 6.329116786218947e-09
as O 0 2.525618825188758e-09
the O 0 7.080493560351897e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 9.534455784887541e-06
( O 0 1.138264337896544e-06
PDS B-Disease 0 2.6612131478032097e-05
) O 0 1.1750536543786438e-08
. O 0 6.997133095154595e-09
. O 0 1.8215479258287814e-07

The O 0 4.492832431424176e-06
APCI1307K O 0 0.03134569153189659
allele O 0 1.5279361775810685e-07
and O 0 9.269411904710978e-09
cancer B-Disease 0 3.8861339817231055e-06
risk O 0 4.969527367393312e-07
in O 0 8.194829703711548e-09
a O 0 3.070162435392376e-08
community O 0 1.978671448910063e-09
- O 0 3.935944015154291e-09
based O 0 1.3008336630093709e-09
study O 0 3.2389533277665805e-09
of O 0 1.386827097604737e-08
Ashkenazi O 0 2.8029003260598984e-06
Jews O 0 3.8930119217184256e-07
. O 0 4.127197712477937e-07

Mutations O 0 1.867395894805668e-06
in O 0 7.849809691151677e-08
APC O 0 1.6477200688314042e-06
are O 0 1.3693628453381734e-09
classically O 0 1.921066541399341e-06
associated O 0 1.316526891059766e-06
with O 0 3.2048847060650587e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999986886978149
FAP B-Disease 0 0.2094125747680664
) O 0 1.6131783908690522e-08
, O 0 5.582376783053178e-10
a O 0 2.075609373264342e-08
highly O 0 2.176439738832414e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.23951558768749237
by O 0 3.152125316319143e-07
multiple O 0 5.4998203268041834e-05
intestinal O 1 0.9974645376205444
polyps B-Disease 0 3.018194320247858e-06
and O 0 7.94961252381654e-09
, O 0 2.76531331167007e-09
without O 0 2.351166372704938e-08
surgical O 0 0.09787224233150482
intervention O 0 0.00806835014373064
, O 0 4.239873785394366e-09
the O 0 3.5699112999054705e-08
development O 0 2.7012800273951143e-05
of O 1 0.9999992847442627
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999997615814209
CRC B-Disease 1 0.9999977350234985
) O 0 3.756533999421663e-07
. O 0 1.744568578487815e-07

APC B-Disease 0 7.705963798798621e-05
is O 0 1.9261501904566103e-07
a O 0 5.792708748231234e-07
tumour O 1 1.0
- O 0 0.000676823197863996
suppressor O 0 7.549848669441417e-05
gene O 0 8.608016521804984e-09
, O 0 1.7946925889855692e-10
and O 0 3.264765957577964e-10
somatic O 0 3.212416856968048e-07
loss O 0 1.867650667009002e-06
occurs O 0 6.917165933373326e-07
in O 0 1.9598212475102628e-06
tumours B-Disease 1 1.0
. O 0 6.2644598983752076e-06

The O 0 6.359131475619506e-06
germline O 0 3.776137964450754e-05
T O 0 4.230282229400473e-06
- O 0 1.8056394424093014e-07
to O 0 1.3018745192994174e-08
- O 0 2.3006703031569486e-07
A O 0 1.7525562157061358e-07
transversion O 0 5.119742354509071e-07
responsible O 0 1.6875132402560666e-08
for O 0 2.04686179117175e-09
the O 0 4.739767334172029e-08
APC O 0 7.563341455352202e-07
I1307K O 0 3.815505067450431e-07
allele O 0 3.210971932787743e-09
converts O 0 6.031546373463925e-10
the O 0 8.031680320819135e-10
wild O 0 2.1261434834940474e-09
- O 0 4.734993730437509e-09
type O 0 4.933503827686536e-09
sequence O 0 1.235181112946293e-08
to O 0 1.228847579248793e-09
a O 0 3.419374294821864e-08
homopolymer O 0 0.0007991711609065533
tract O 0 0.009865433908998966
( O 0 7.49516289033636e-07
A8 O 0 0.0001237792312167585
) O 0 6.955043208023426e-10
that O 0 4.1647366111341455e-11
is O 0 3.4916300406528933e-10
genetically O 0 2.9998474815329246e-09
unstable O 0 2.5729255526130146e-07
and O 0 7.214923769538473e-09
prone O 0 7.420668453050894e-07
to O 0 3.286273297931075e-08
somatic O 0 1.573276131239254e-05
mutation O 0 4.911049700240255e-07
. O 0 2.0043219706167292e-07

The O 0 9.801114174479153e-06
I1307K O 0 6.039508662070148e-05
allele O 0 2.9059381745355495e-07
was O 0 5.836855621055292e-07
found O 0 4.979071377420041e-08
in O 0 4.2557235957474404e-08
6 O 0 2.4971827770059463e-06
. O 0 7.15421322183829e-07

1 O 0 1.791939666873077e-06
% O 0 5.714219852848146e-08
of O 0 5.870384001127604e-08
unselected O 0 0.11374599486589432
Ashkenazi O 0 8.843040995998308e-05
Jews O 0 1.3718553759645147e-07
and O 0 4.22777679531805e-09
higher O 0 5.3770101260397496e-08
proportions O 0 9.263636258083352e-08
of O 0 7.753652653263998e-08
Ashkenazim O 0 8.827813871903345e-06
with O 0 1.0473872436023157e-08
family O 0 9.359467298963864e-07
or O 0 6.600224367048213e-08
personal O 0 3.104305960732745e-06
histories O 0 1.2386498383420985e-05
of O 0 0.0006311640609055758
CRC B-Disease 1 0.991459846496582
( O 0 1.6106439488794422e-06
ref O 0 1.7390286302543245e-05
. O 0 1.7732341817122688e-08
2 O 0 2.506458827156166e-07
) O 0 1.3228735440407036e-07
. O 0 2.205580642566929e-07

To O 0 1.2401164894981775e-07
evaluate O 0 3.6733374031427957e-07
the O 0 8.896306269434717e-08
role O 0 2.6174939193879254e-07
of O 0 6.759243547094229e-07
I1307K O 0 0.00010870269761653617
in O 0 9.209691853584445e-08
cancer B-Disease 0 1.1326120556987007e-06
, O 0 2.6803970154531953e-09
we O 0 1.7698045695624387e-08
genotyped O 0 1.176793193735648e-05
5 O 0 1.9295036679523037e-07
, O 0 1.6069106933969124e-08
081 O 0 4.748516948893666e-05
Ashkenazi O 0 2.044738266704371e-06
volunteers O 0 1.6356226240077376e-07
in O 0 1.5811863818271377e-08
a O 0 2.8157227660585704e-08
community O 0 1.4981397455926526e-08
survey O 0 3.9260382322936493e-07
. O 0 1.1334014970998396e-07

Risk O 0 6.443483289331198e-05
of O 0 4.087793513463112e-06
developing O 1 0.9584413170814514
colorectal B-Disease 1 1.0
, I-Disease 0 8.97331574378768e-06
breast I-Disease 1 0.9482452273368835
and I-Disease 0 1.5359269411874266e-08
other I-Disease 0 2.8560065423732794e-09
cancers I-Disease 0 3.415174887777539e-06
were O 0 2.3633237589137934e-08
compared O 0 3.600244369295069e-08
between O 0 3.1746544948418887e-08
genotyped O 0 2.528525328671094e-06
I1307K O 0 7.192351745288761e-07
carriers O 0 3.196306996855469e-09
and O 0 2.4972315881832685e-10
non O 0 5.694439764170056e-08
- O 0 4.8563617127683756e-08
carriers O 0 1.918218472951594e-09
and O 0 3.133497072926872e-10
their O 0 4.736816494599339e-10
first O 0 8.218183467079143e-09
- O 0 1.5637419892300386e-07
degree O 0 3.853124781016959e-06
relatives O 0 6.363775355566759e-07
. O 0 2.1789973914110305e-07

Sperm O 0 7.787586582708173e-06
DNA O 0 5.725975142922834e-07
analysis O 0 2.7416707126803885e-08
in O 0 1.0377982917475492e-08
a O 0 6.152279752313916e-07
Friedreich B-Disease 1 0.9965639710426331
ataxia I-Disease 1 0.9968103766441345
premutation O 0 0.14220258593559265
carrier O 0 1.6997065586110693e-06
suggests O 0 3.1406958100888005e-07
both O 0 6.901291094152384e-09
meiotic O 0 2.271314087920473e-06
and O 0 9.787146204587316e-09
mitotic O 0 7.475781558241579e-07
expansion O 0 4.262986408321012e-08
in O 0 1.0439367592596227e-08
the O 0 8.720493127611917e-08
FRDA B-Disease 0 0.007146756164729595
gene O 0 1.2561621360873687e-06
. O 0 2.178733353730422e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 2.6976420031132875e-06
usually O 0 1.640312063955207e-07
caused O 0 6.958234166631883e-08
by O 0 2.942111221315713e-09
an O 0 1.1322969228899638e-08
expansion O 0 2.576942961241002e-07
of O 0 6.034843522684241e-07
a O 0 1.2210549584779073e-06
GAA O 0 8.98271391633898e-05
trinucleotide O 0 3.7165573303354904e-05
repeat O 0 9.992838840844342e-07
in O 0 1.1889154194477669e-07
intron O 0 1.2409306691552047e-05
1 O 0 1.926216413039583e-07
of O 0 1.9982907417670503e-07
the O 0 4.68376100570822e-07
FRDA B-Disease 0 0.2222394198179245
gene O 0 3.4699585285125067e-06
. O 0 3.669916281978658e-07

Occasionally O 0 9.869264431472402e-06
, O 0 3.019538752369044e-08
a O 0 2.5524688140876606e-08
fully O 0 6.022780496550695e-08
expanded O 0 1.9962540065421308e-08
allele O 0 6.404857977315714e-09
has O 0 2.1822366136348137e-10
been O 0 3.4833685935709013e-10
found O 0 3.2717228926060216e-10
to O 0 2.1243913572721596e-10
arise O 0 1.7146863484640562e-08
from O 0 8.281848984381668e-09
a O 0 2.4767089712440793e-08
premutation O 0 1.553312586111133e-06
of O 0 6.420589926392495e-08
100 O 0 6.858685708266421e-08
or O 0 8.418127528386776e-09
less O 0 2.1746309641912376e-08
triplet O 0 6.343987934087636e-06
repeats O 0 2.235570036646095e-06
. O 0 4.3074169298051856e-07

We O 0 2.919312862559309e-07
have O 0 3.5188696401178277e-09
examined O 0 7.202648077964113e-08
the O 0 5.3348607309544605e-08
sperm O 0 1.387011536735372e-07
DNA O 0 1.545764263255478e-07
of O 0 6.969989385652298e-08
a O 0 2.1836800101482368e-07
premutation O 0 2.8114965971326455e-05
carrier O 0 2.395174988123472e-06
. O 0 7.035395697130298e-07

This O 0 7.996406452548399e-07
mans O 0 6.83553707858664e-06
leucocyte O 0 1.4281103176472243e-05
DNA O 0 1.1822382930404274e-06
showed O 0 7.421171233090718e-08
one O 0 3.6187275398447127e-09
normal O 0 1.4515039836737742e-08
allele O 0 1.5729795244112665e-09
and O 0 1.6927693968771251e-10
one O 0 5.058420904369143e-10
allele O 0 5.581439754820394e-10
of O 0 4.597864755595538e-09
approximately O 0 2.5922142654621894e-08
100 O 0 1.0628959046243835e-07
repeats O 0 2.7709964456335e-07
. O 0 1.6531835456135013e-07

His O 0 3.783289457715e-06
sperm O 0 1.697370748843241e-06
showed O 0 4.182877688663211e-08
an O 0 1.8299196602455936e-09
expanded O 0 6.855974898911654e-09
allele O 0 6.898053683812577e-09
in O 0 1.477454936171796e-09
a O 0 9.537697742700857e-09
tight O 0 7.454595163380873e-08
range O 0 4.1363463765264896e-08
centering O 0 2.5166215777971956e-07
on O 0 1.0769003466748472e-08
a O 0 5.830566252029712e-09
size O 0 4.47965176064713e-09
of O 0 1.0046108833705603e-08
approximately O 0 1.652376511174225e-07
320 O 0 5.92326216519723e-07
trinucleotide O 0 1.857630195445381e-05
repeats O 0 4.677133802033495e-06
. O 0 5.273275860417925e-07

His O 0 3.947754521504976e-05
affected O 0 3.629725370046799e-06
son O 0 6.16504912613891e-05
has O 0 4.048666824019165e-08
repeat O 0 1.3111062457937805e-07
sizes O 0 4.045532620011727e-08
of O 0 5.810230732095079e-07
1040 O 0 5.958127530902857e-06
and O 0 2.2216754302917252e-07
540 O 0 1.0636431397870183e-05
. O 0 4.910412485514826e-07

These O 0 7.796747780730584e-08
data O 0 1.7800903151510283e-07
suggest O 0 2.312384950187152e-08
that O 0 2.343092386780654e-10
expansion O 0 8.183645761050684e-09
occurs O 0 1.6651855450078301e-09
in O 0 2.1860985244259723e-10
two O 0 1.1693622459230113e-10
stages O 0 8.533277195965638e-09
, O 0 4.778559214990707e-10
the O 0 2.371884466612073e-09
first O 0 5.76224223891586e-09
during O 0 2.2726950987816963e-08
meiosis O 0 1.0200832178952624e-07
followed O 0 3.825121108746998e-09
by O 0 1.0448865106482685e-09
a O 0 1.0501918445982028e-08
second O 0 5.483438414444208e-08
mitotic O 0 1.400965061293391e-06
expansion O 0 1.0866847333090845e-06
. O 0 4.5389427327791054e-07

We O 0 4.828119131161657e-07
also O 0 7.54953077830578e-09
show O 0 5.894661203598162e-09
that O 0 2.0291703040076214e-10
in O 0 2.841427093613902e-10
all O 0 5.229215394031428e-10
informative O 0 5.876657738212998e-08
carrier O 0 1.6193995477919998e-08
father O 0 1.6518212575533653e-08
to O 0 2.722035929991762e-09
affected O 0 1.0225373436867358e-08
child O 0 6.658171969320392e-08
transmissions O 0 1.7201934099375649e-07
, O 0 1.559181533883347e-10
with O 0 6.605693769756726e-11
the O 0 3.010032223471626e-09
notable O 0 1.586013098631156e-08
exception O 0 5.479211750980539e-09
of O 0 1.871219801330426e-08
the O 0 2.9691724634517414e-08
premutation O 0 3.827425643976312e-06
carrier O 0 6.049801726248916e-08
, O 0 1.534292359828271e-09
the O 0 4.0816949820055015e-09
expansion O 0 3.5331762404666733e-08
size O 0 4.329870861852214e-08
decreases O 0 1.2213618560963369e-07
. O 0 5.630198973705092e-09
. O 0 1.090308003881546e-07

The O 0 3.302332515886519e-06
R496H O 0 5.768310802523047e-05
mutation O 0 1.5846288192733482e-07
of O 0 2.2189142612205615e-07
arylsulfatase O 0 0.0014647194184362888
A O 0 9.155080078926403e-06
does O 0 2.7334939645129452e-08
not O 0 4.0026968406436936e-08
cause O 0 5.497009988175705e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 9.823777872952633e-06

Deficiency B-Disease 1 1.0
of I-Disease 0 0.00046152601134963334
arylsulfatase I-Disease 1 0.9999591112136841
A I-Disease 1 0.6680196523666382
( O 0 1.722506567602977e-05
ARSA O 1 0.9999794960021973
) O 0 1.1011589151621592e-07
enzyme O 0 4.0128105638359557e-07
activity O 0 1.9976155272161122e-06
causes O 0 5.242506176728057e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 1 0.7670950889587402
MLD B-Disease 1 1.0
) O 0 2.425954562568222e-06
. O 0 4.364821677427244e-07

A O 0 1.182605956273619e-06
number O 0 2.781363761528155e-08
of O 0 3.498267062695959e-07
ARSA O 1 0.9855524897575378
gene O 0 1.3533613696381508e-07
mutations O 0 1.1560044477221254e-08
responsible O 0 7.85043923201556e-08
for O 0 2.619509018586541e-07
MLD B-Disease 1 1.0
have O 0 1.249867835895202e-07
been O 0 9.202351947124043e-08
identified O 0 5.824066988679988e-07
. O 0 3.081920851855102e-07

Recently O 0 5.705534931621514e-06
, O 0 2.3044684382966807e-08
the O 0 7.877948604573248e-08
R496H O 0 5.1555275604187045e-06
mutation O 0 3.948517957041986e-08
of O 0 1.6937698887886654e-07
ARSA O 1 0.9973211884498596
was O 0 3.693377266245079e-07
proposed O 0 9.504608655674929e-09
to O 0 3.060152353739909e-09
be O 0 5.564626537335471e-09
a O 0 4.902775785353697e-08
cause O 0 2.941488048691099e-07
of O 0 2.949034023913555e-05
MLD B-Disease 1 1.0
( O 0 4.468375846045092e-05
Draghia O 0 0.001446096459403634
et O 0 5.410596713772975e-06
al O 0 1.3891324215364875e-06
. O 0 1.513498881777764e-09
, O 0 1.0832799102189483e-09
1997 O 0 5.514526080219184e-08
) O 0 4.161185174211823e-08
. O 0 1.354665641883912e-07

We O 0 4.598248892762058e-07
have O 0 4.267255437895301e-09
investigated O 0 9.51143093175233e-08
the O 0 2.628314099695217e-08
R496H O 0 1.4150291463010944e-06
mutation O 0 1.9313173282853313e-09
and O 0 8.301420661993575e-11
found O 0 2.5765120592602386e-10
this O 0 1.1630473667478824e-10
mutation O 0 2.630227147193409e-10
at O 0 2.2308115354974234e-09
a O 0 1.4274089688015579e-09
relatively O 0 5.943769365579499e-10
high O 0 1.1037863956175897e-09
frequency O 0 8.812548468739578e-10
in O 0 1.178147163161114e-10
an O 0 3.0526942085273845e-10
African O 0 1.7114473171986333e-09
American O 0 1.2395844350976404e-09
population O 0 4.477707787886587e-11
( O 0 4.601597575204508e-11
f O 0 1.5580853274244078e-09
= O 0 3.519359692560897e-09
0 O 0 1.996480480936924e-10
. O 0 2.918511265992407e-11
09 O 0 5.100003086511151e-09
, O 0 2.421000067087675e-10
n O 0 1.4530552761016224e-08
= O 0 5.906965938606845e-08
61 O 0 1.573934760301654e-08
subjects O 0 8.67199361209714e-08
) O 0 5.2950003492924225e-08
. O 0 6.905862903749949e-08

The O 0 1.8661850845091976e-05
ARSA O 1 0.9992406368255615
enzyme O 0 1.4765338391953264e-06
activity O 0 1.9943821882861812e-07
in O 0 7.426602111060276e-10
subjects O 0 1.2756862233231914e-08
with O 0 4.4221090678142616e-10
and O 0 5.972623506877994e-10
without O 0 1.0119263649244203e-08
the O 0 2.2863519077986894e-08
R496H O 0 6.027745484971092e-07
mutation O 0 6.19512996458127e-10
was O 0 3.1381097720384332e-09
determined O 0 2.2532922194784533e-09
and O 0 3.2474015143613144e-10
found O 0 2.4727992986584013e-09
to O 0 1.4227174993663994e-09
be O 0 2.413975330739504e-08
normal O 0 1.5681238210163428e-06
. O 0 3.0661135497211944e-07

It O 0 1.4510312951188098e-07
is O 0 1.8928364653447716e-08
therefore O 0 2.7630264298750262e-08
concluded O 0 1.8929706868675567e-07
that O 0 3.197386133635405e-09
the O 0 2.8731040657703488e-08
R496H O 0 4.9416717047279235e-06
mutation O 0 5.350124965275427e-08
of O 0 4.053450197716302e-07
ARSA O 1 0.9977791905403137
does O 0 3.98934885126323e-09
not O 0 8.328607803420596e-10
negatively O 0 1.0617000612000993e-08
influence O 0 6.097853333386638e-09
the O 0 4.803481168380586e-09
activity O 0 1.7041442390564043e-07
of O 0 1.6518220036232378e-07
ARSA O 1 0.8846167325973511
and O 0 3.0106523940531815e-09
is O 0 2.1194346278008425e-09
not O 0 9.977054737930757e-10
a O 0 4.461542602030022e-08
cause O 0 5.575246859734762e-07
of O 0 5.184615292819217e-05
MLD B-Disease 1 1.0

Down O 0 0.0001136354694608599
- O 0 3.040755245820037e-06
regulation O 0 2.744695848377887e-07
of O 0 1.4324230335205357e-07
transmembrane O 0 1.3100219803163782e-05
carbonic O 0 0.0010422837221994996
anhydrases O 1 0.8281967043876648
in O 0 1.7540221961098723e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999982118606567
lines O 0 3.723945951605856e-07
by O 0 9.682795010235168e-09
wild O 0 7.706119475869855e-08
- O 0 1.0164120567424106e-06
type O 0 5.437240361061413e-06
von B-Disease 1 0.9999504089355469
Hippel I-Disease 1 0.9999996423721313
- I-Disease 1 0.9984898567199707
Lindau I-Disease 1 0.999339759349823
transgenes O 0 0.0008745617815293372
. O 0 2.6982802410202567e-06

To O 0 4.310038264065952e-07
discover O 0 2.069002675852971e-06
genes O 0 8.827966979652047e-08
involved O 0 4.446683732339807e-08
in O 0 7.376971211670025e-08
von B-Disease 1 0.9991514682769775
Hippel I-Disease 1 0.9999991655349731
- I-Disease 1 0.9999023675918579
Lindau I-Disease 1 0.9999995231628418
( O 0 4.779334631166421e-06
VHL B-Disease 0 0.007245913147926331
) O 0 7.294212167607839e-08
- O 0 1.8762594322652149e-07
mediated O 0 7.566132467218267e-07
carcinogenesis O 0 0.0005901240510866046
, O 0 2.320938330413469e-09
we O 0 8.491583436409655e-09
used O 0 1.7301169918937376e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 3.515207572490908e-05
stably O 0 6.359589315252379e-05
transfected O 0 3.918455149687361e-06
with O 0 1.7291229559290855e-09
wild O 0 6.369397453909187e-08
- O 0 2.9271454877743963e-06
type O 0 2.4120385205606e-05
VHL O 1 0.9997228980064392
- O 0 3.75571362383198e-05
expressing O 0 1.02632782272849e-06
transgenes O 0 5.9899633924942464e-05
. O 0 6.508310548269947e-07

Large O 0 2.589166342659155e-06
- O 0 1.2067750958522083e-06
scale O 0 1.213579707837198e-06
RNA O 0 3.0117596452328144e-06
differential O 0 1.256850765685158e-07
display O 0 1.759129553136063e-08
technology O 0 4.211144144505852e-08
applied O 0 3.604750054009287e-09
to O 0 2.647011498879692e-10
these O 0 1.1568001001549533e-09
cell O 0 1.6783161527200718e-07
lines O 0 3.0551716712068355e-09
identified O 0 9.733712724724342e-10
several O 0 9.338167045180867e-11
differentially O 0 2.1965330887496748e-08
expressed O 0 1.9697839193089095e-10
genes O 0 3.166288065070688e-10
, O 0 4.244044352064158e-11
including O 0 1.843409314083999e-10
an O 0 3.2795217652648034e-09
alpha O 0 3.025817818524956e-07
carbonic O 0 6.5962244661932345e-06
anhydrase O 0 2.8398637368809432e-05
gene O 0 5.314507944831348e-08
, O 0 9.873394546389136e-09
termed O 0 3.1416441288456554e-06
CA12 O 0 0.004654650576412678
. O 0 1.7069107798306504e-06

The O 0 1.4613623307013768e-06
deduced O 0 4.468825864023529e-06
protein O 0 7.791842193682896e-08
sequence O 0 6.60251586737104e-08
was O 0 8.816054020144293e-08
classified O 0 6.396522422846829e-08
as O 0 2.9706268556140003e-09
a O 0 1.2020545447910536e-08
one O 0 4.675225984129838e-09
- O 0 1.1118335407900304e-07
pass O 0 9.521922805788563e-08
transmembrane O 0 4.428993270266801e-05
CA O 0 4.481616088014562e-06
possessing O 0 3.817834794972441e-07
an O 0 7.522669420723105e-08
apparently O 0 1.614482357581437e-06
intact O 0 1.80344250111375e-05
catalytic O 0 1.0808585102495272e-06
domain O 0 7.155298362704343e-07
in O 0 9.61066870530658e-09
the O 0 1.4777324963688443e-07
extracellular O 0 0.00020261046302039176
CA O 0 0.00213834666647017
module O 0 0.006619226187467575
. O 0 2.985512765008025e-06

Reintroduced O 0 1.1939220030399156e-06
wild O 0 2.982676505780546e-07
- O 0 2.0846930510742823e-06
type O 0 2.343976575502893e-06
VHL B-Disease 0 0.013550047762691975
strongly O 0 2.6398696562068835e-08
inhibited O 0 5.4417416350815984e-08
the O 0 1.3158437672800005e-09
overexpression O 0 1.7998706525190755e-08
of O 0 2.322306569269017e-09
the O 0 6.641997618572759e-09
CA12 O 0 3.637058034655638e-05
gene O 0 6.714103051308484e-09
in O 0 1.108588443266001e-09
the O 0 4.158122735020697e-08
parental O 0 4.651279596146196e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.0001770693197613582
. O 0 7.937991881590278e-07

Similar O 0 9.662062439019792e-08
results O 0 1.2058825937799611e-08
were O 0 6.560685772427632e-09
obtained O 0 3.925045533037519e-08
with O 0 2.413587329996858e-09
CA9 O 1 0.5338039994239807
, O 0 5.32359534233251e-09
encoding O 0 2.4636817030909697e-08
another O 0 4.4234631957351667e-08
transmembrane O 0 2.5672784431662876e-06
CA O 0 5.438285484160588e-07
with O 0 2.618575356549968e-09
an O 0 1.0507291392514162e-07
intact O 0 0.00015124962374102324
catalytic O 0 1.1710345461324323e-05
domain O 0 1.9534378225216642e-05
. O 0 5.135992751092999e-07

Although O 0 1.3887229499687237e-07
both O 0 1.100646151996898e-08
domains O 0 1.9133747741761908e-07
of O 0 1.080507487927207e-07
the O 0 3.6436910022530355e-07
VHL B-Disease 1 0.9302851557731628
protein O 0 3.267361137204716e-07
contribute O 0 1.1152484269416618e-08
to O 0 1.9633481507241868e-09
regulation O 0 4.569261946585357e-08
of O 0 5.657339485765078e-08
CA12 O 0 0.0508669912815094
expression O 0 7.359095377523772e-08
, O 0 8.067699841518561e-10
the O 0 4.639993278487964e-09
elongin O 0 7.238689931909903e-07
binding O 0 2.3931987058745108e-08
domain O 0 2.859917458408745e-07
alone O 0 2.3581366193070608e-08
could O 0 1.0103140546391387e-08
effectively O 0 4.050907591590658e-07
regulate O 0 2.4304654289153405e-06
CA9 O 1 0.9999191761016846
expression O 0 4.979307504981989e-06
. O 0 3.154867727062083e-07

We O 0 2.428056177450344e-06
mapped O 0 3.158572144457139e-05
CA12 O 0 0.1157260462641716
and O 0 1.3910785128246062e-06
CA9 O 1 0.9997606873512268
loci O 0 4.088203695573611e-07
to O 0 1.4501757128471127e-08
chromosome O 0 2.8277494834583194e-07
bands O 0 1.6178087491880433e-07
15q22 O 0 1.4098045539867599e-05
and O 0 1.4314534269033174e-07
17q21 O 0 0.0001871016138466075
. O 0 2.3128209249989595e-06

2 O 0 1.0816730764418026e-06
respectively O 0 1.7093937287882e-07
, O 0 3.5338751924740563e-09
regions O 0 8.405035778480396e-09
prone O 0 1.583720887765594e-07
to O 0 2.6981652467839012e-09
amplification O 0 9.610275810700841e-07
in O 0 6.931990093050899e-09
some O 0 4.766245620402287e-09
human O 0 1.8693241088385548e-07
cancers B-Disease 0 2.6142455681110732e-05
. O 0 2.174278961319942e-07

Additional O 0 2.901504672081501e-07
experiments O 0 2.625879744755366e-07
are O 0 1.1581048342534928e-09
needed O 0 4.013267496105755e-09
to O 0 1.1047700532174076e-09
define O 0 2.9669589451941647e-08
the O 0 3.1795327259942496e-08
role O 0 4.4895591599924956e-07
of O 0 1.6982385204755701e-06
CA O 0 0.00011234117118874565
IX O 0 0.0004479006165638566
and O 0 5.085959031703169e-08
CA O 0 5.914145731367171e-06
XII O 0 1.747717396938242e-05
enzymes O 0 5.270110570165798e-09
in O 0 7.419239667072475e-10
the O 0 1.0375920123095739e-09
regulation O 0 4.80453499207556e-09
of O 0 1.0403747197074154e-08
pH O 0 2.126980831462788e-07
in O 0 2.6933013597130184e-09
the O 0 1.0164431962778053e-08
extracellular O 0 5.415578471001936e-06
microenvironment O 0 5.581611731031444e-06
and O 0 4.5035256079906105e-10
its O 0 1.7913000249780708e-10
potential O 0 2.3753661260172976e-09
impact O 0 8.353716829390123e-09
on O 0 2.8294778076087823e-08
cancer B-Disease 0 6.3871989368635695e-06
cell O 0 8.30531553219771e-06
growth O 0 7.699448900666539e-08
. O 0 3.265877879243817e-08

A O 0 6.619370196858654e-06
gene O 0 1.816456460801419e-07
encoding O 0 7.779546251640568e-08
a O 0 1.946153993515054e-08
transmembrane O 0 6.755029744454077e-07
protein O 0 1.6185502715870825e-08
is O 0 1.2294518181299452e-10
mutated O 0 5.105265654670177e-10
in O 0 3.9535483220554113e-10
patients O 0 2.447932523352847e-09
with O 0 3.383588591532316e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.398115436288208e-07
. O 0 2.1202954769705684e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9502667188644409
WFS B-Disease 1 1.0
; O 0 1.6830649656185415e-06
OMIM O 1 0.9999972581863403
222300 O 0 0.0006897863931953907
) O 0 5.615198972463986e-08
is O 0 5.926339419204396e-09
an O 0 1.9759275460273784e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
defined O 0 3.4029019388981396e-06
by O 0 2.7358305842994923e-08
young O 0 6.313493372545054e-07
- O 0 6.361529813148081e-05
onset O 1 0.9999957084655762
non O 1 0.9999696016311646
- O 1 0.9986571073532104
immune O 0 0.0017974063521251082
insulin B-Disease 0 0.06522897630929947
- I-Disease 0 0.3296757936477661
dependent I-Disease 1 0.9976662397384644
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 5.029352178098634e-05
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9997740387916565
. O 0 1.3520084394258447e-06

Linkage O 0 0.0008233347325585783
to O 0 2.0354875118755444e-07
markers O 0 4.368921054265229e-06
on O 0 7.206770078482805e-07
chromosome O 0 1.6516847608727403e-05
4p O 1 0.997670590877533
was O 0 4.375809567136457e-06
confirmed O 0 5.2036305930869275e-08
in O 0 6.854549816637245e-09
five O 0 2.9561642023168133e-08
families O 0 3.545563842521915e-08
. O 0 2.4860523240022303e-07

On O 0 3.285471734670864e-07
the O 0 9.406786460885996e-09
basis O 0 1.0166141350964608e-07
of O 0 1.3177223934235371e-07
meiotic O 0 0.0003378234978299588
recombinants O 1 0.5269773006439209
and O 0 1.9574214604745066e-07
disease O 0 0.07198847830295563
- O 0 2.9863358577131294e-06
associated O 0 1.5641134041288751e-06
haplotypes O 0 2.0382624370540725e-06
, O 0 2.5449422569323588e-09
the O 0 3.28175104868933e-08
WFS B-Disease 0 0.0008005709387362003
gene O 0 6.536055696670928e-09
was O 0 1.1777977704241493e-08
localized O 0 1.125664539358695e-08
to O 0 2.5496551536718925e-09
a O 0 3.1867031680121727e-07
BAC O 0 0.32019391655921936
/ O 0 3.0912080546841025e-05
P1 O 0 0.0001390580873703584
contig O 0 2.4665814635227434e-06
of O 0 3.826662364758704e-08
less O 0 8.338848722644343e-09
than O 0 5.6745736998209395e-09
250 O 0 9.625421881764851e-08
kb O 0 1.0428161658637691e-05
. O 0 2.1252127169191226e-07

Mutations O 0 2.005422629736131e-06
in O 0 2.1385085702263495e-08
a O 0 2.7786912326632773e-08
novel O 0 9.64863744457034e-08
gene O 0 3.215686916746563e-08
( O 0 1.2008903205185106e-08
WFS1 O 0 6.243999814614654e-05
) O 0 1.2707078944629302e-08
encoding O 0 1.1742986139040568e-08
a O 0 2.2542607780451362e-08
putative O 0 2.575577013885777e-07
transmembrane O 0 1.32636259309038e-07
protein O 0 4.568161404705506e-09
were O 0 4.658364805010251e-10
found O 0 1.6564352667280957e-10
in O 0 1.800373600202576e-10
all O 0 1.6086969256701167e-10
affected O 0 8.207996504694393e-10
individuals O 0 3.750347532527343e-10
in O 0 5.8512883427397355e-09
six O 0 7.088992788339965e-07
WFS B-Disease 1 0.9999997615814209
families O 0 9.269991996241345e-10
, O 0 5.25675336593423e-11
and O 0 2.3829554648968632e-11
these O 0 5.796485860742884e-11
mutations O 0 4.0551467739291525e-10
were O 0 2.2129489352096243e-09
associated O 0 1.9558887842663353e-08
with O 0 2.8779947314205856e-09
the O 0 2.2507049379782984e-06
disease O 0 0.00353435892611742
phenotype O 0 4.898708994005574e-06
. O 0 2.0280410240047786e-07

WFS1 O 0 0.10713081061840057
appears O 0 5.846370640938403e-07
to O 0 4.250951146644866e-09
function O 0 6.816105013740525e-08
in O 0 1.4482574250962443e-08
survival O 0 5.737132596550509e-06
of O 0 5.561647071772313e-07
islet O 0 1.670828896749299e-05
beta O 0 7.20967136658146e-07
- O 0 2.5568181172275217e-07
cells O 0 1.275803018785382e-08
and O 0 1.2766835366662121e-09
neurons O 0 1.2891494804989634e-07
. O 0 4.259099295467195e-09
. O 0 4.500207140267776e-08

Stable O 0 0.0002188855578424409
interaction O 0 7.177448537731834e-07
between O 0 1.4816463611566633e-08
the O 0 7.85323539531646e-09
products O 0 4.36369518297397e-09
of O 0 1.9969624176496836e-08
the O 0 6.668962981848381e-08
BRCA1 O 0 4.350791016349831e-07
and O 0 1.7751935033061272e-08
BRCA2 O 0 1.6031900713642244e-06
tumor B-Disease 0 4.977878688805504e-06
suppressor O 0 1.4164508002068033e-06
genes O 0 8.681920071751392e-09
in O 0 1.8971728632521945e-09
mitotic O 0 3.760189883905696e-07
and O 0 1.3812017307657243e-08
meiotic O 0 0.00012166827218607068
cells O 0 1.216436066897586e-05
. O 0 5.667707227985375e-07

BRCA1 O 0 5.5868506024125963e-05
and O 0 4.312373391712754e-08
BRCA2 O 0 3.106119095264148e-07
account O 0 4.452240354169135e-09
for O 0 6.698286370010464e-11
most O 0 2.470011001287631e-11
cases O 0 5.762412422227747e-11
of O 0 5.8870881503025885e-09
familial O 0 1.6656407751725055e-05
, O 0 2.8911275595788766e-09
early O 0 9.01266332675732e-07
onset O 1 0.9994775652885437
breast B-Disease 0 0.012969146482646465
and I-Disease 0 1.6036110537243076e-05
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.9107209204303217e-07
encode O 0 4.187819513390423e-08
products O 0 1.7385313189066665e-09
that O 0 2.650563102335468e-10
each O 0 5.325186958060613e-10
interact O 0 2.2431210222606524e-09
with O 0 6.617718817381046e-09
hRAD51 O 0 1.2956221326021478e-05
. O 0 5.384614496506401e-07

Results O 0 1.627905476198066e-06
presented O 0 5.056901954958448e-07
here O 0 1.9189410238595883e-07
show O 0 5.4043599817532595e-08
that O 0 3.619286870204519e-09
BRCA1 O 0 8.169021015191902e-08
and O 0 2.4560609102053377e-09
BRCA2 O 0 1.0583280385390026e-07
coexist O 0 5.510152689680581e-08
in O 0 4.3698751284182435e-09
a O 0 7.98133470425455e-09
biochemical O 0 6.4893765738816e-07
complex O 0 3.7084023460920434e-06
and O 0 1.7646810235305566e-08
colocalize O 0 0.0001127095238189213
in O 0 1.6156947424406098e-07
subnuclear O 0 3.9613347325939685e-05
foci O 0 4.3290469875501e-06
in O 0 5.980526740501091e-09
somatic O 0 5.5272046495247196e-08
cells O 0 2.994713810267058e-09
and O 0 1.513659753094032e-10
on O 0 1.6938941360677973e-09
the O 0 2.379256791584794e-09
axial O 0 4.567769718022419e-09
elements O 0 7.391276923840451e-09
of O 0 4.10903666647755e-08
developing O 0 2.7833064564219967e-07
synaptonemal O 0 0.0002414023329038173
complexes O 0 1.0642093911883421e-05
. O 0 5.082798111288866e-07

Like O 0 5.818454155814834e-06
BRCA1 O 0 1.2598364264704287e-05
and O 0 2.2786727527090989e-07
RAD51 O 0 0.011560454033315182
, O 0 7.290233838830318e-08
BRCA2 O 0 1.0194991091339034e-06
relocates O 0 6.069855658097367e-07
to O 0 2.1290462726142323e-08
PCNA O 0 0.000151982152601704
+ O 0 1.0048112244476215e-06
replication O 0 1.2718517439225252e-07
sites O 0 2.2483594985800437e-09
following O 0 8.389623995519457e-10
exposure O 0 3.7304754840761234e-08
of O 0 7.454865169620462e-08
S O 0 2.556296976763406e-06
phase O 0 1.038574396261538e-06
cells O 0 1.1777218844599702e-07
to O 0 1.2679624461497951e-08
hydroxyurea O 0 3.521981398080243e-06
or O 0 1.5517505858042568e-07
UV O 0 0.00010155222844332457
irradiation O 0 6.807498266425682e-06
. O 0 1.5701468214501801e-07

Thus O 0 6.6223437897861e-06
, O 0 8.187974032125567e-08
BRCA1 O 0 2.1440328623612004e-07
and O 0 2.260019726918472e-09
BRCA2 O 0 2.936551446452995e-08
participate O 0 1.8167980453398513e-09
, O 0 4.849562973419097e-10
together O 0 1.4050083319006035e-09
, O 0 7.279236657886656e-10
in O 0 1.2480086963861936e-09
a O 0 6.32472385575511e-09
pathway O 0 3.825232397502987e-08
( O 0 1.6521575219030638e-09
s O 0 1.1107648134611736e-08
) O 0 3.507710233385808e-10
associated O 0 6.663667395656603e-10
with O 0 2.2021687251516653e-10
the O 0 1.0516590265297054e-08
activation O 0 2.6445967193922115e-08
of O 0 4.1544762297007765e-08
double O 0 1.2387843639771745e-07
- O 0 5.254075290395122e-07
strand O 0 5.757394205829769e-07
break O 0 4.181194981356384e-07
repair O 0 5.507616606337251e-06
and O 0 4.906554806893837e-08
/ O 0 1.088311182684265e-05
or O 0 6.800963205932931e-07
homologous O 0 2.529328639866435e-06
recombination O 0 5.050692834629444e-06
. O 0 5.989593319100095e-07

Dysfunction O 1 0.9999988079071045
of O 0 4.047210950375302e-06
this O 0 1.3530748788070923e-07
pathway O 0 3.264628276156145e-06
may O 0 4.30143742846667e-09
be O 0 8.290316766412786e-10
a O 0 3.6985914331211234e-09
general O 0 9.894584707126342e-09
phenomenon O 0 1.4584507823656168e-07
in O 0 4.790806085175348e-10
the O 0 6.738205549083887e-10
majority O 0 6.739873242844752e-11
of O 0 1.091742918291061e-09
cases O 0 1.0181521181706898e-09
of O 0 1.2190368181563827e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9988592863082886
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.782010819326388e-06
. O 0 4.33418449574674e-07

A O 0 2.1784519049106166e-05
novel O 0 4.4652388169197366e-06
Arg362Ser O 0 0.00010478660260559991
mutation O 0 4.426451027939038e-08
in O 0 4.227914018883894e-09
the O 0 2.8664588924698364e-08
sterol O 0 1.3278183814691147e-06
27 O 0 5.909991500629985e-07
- O 0 1.2927065426993067e-06
hydroxylase O 0 4.704928414867027e-06
gene O 0 4.380509111001629e-08
( O 0 1.1053839621411043e-08
CYP27 O 0 1.060284921550192e-05
) O 0 8.961713038324604e-10
: O 0 8.203188128774741e-11
its O 0 6.876057362381616e-11
effects O 0 1.0473427680679492e-09
on O 0 2.562164258534949e-09
pre O 0 1.2734561494198715e-07
- O 0 7.685628133913269e-08
mRNA O 0 5.691084936643165e-08
splicing O 0 1.617559597377749e-08
and O 0 3.0283200946890076e-10
enzyme O 0 1.322602916076221e-08
activity O 0 7.370881149881825e-08
. O 0 5.2469442124447596e-08

A O 0 4.26636461270391e-06
novel O 0 4.449466928235779e-07
C O 0 1.5062558986755903e-06
to O 0 4.509174811317962e-09
A O 0 7.757498821092668e-08
mutation O 0 3.2646805259162193e-09
in O 0 1.3403333998240896e-09
the O 0 2.194234127728123e-08
sterol O 0 4.259654531324486e-07
27 O 0 3.783668773849058e-07
- O 0 7.548944154223136e-07
hydroxylase O 0 2.622991360112792e-06
gene O 0 4.601621839128711e-08
( O 0 7.744190178016197e-09
CYP27 O 0 9.988874808186665e-06
) O 0 2.140678745377045e-09
was O 0 7.013875702455152e-09
identified O 0 1.526003767793327e-09
by O 0 5.080689757797074e-10
sequencing O 0 6.464175328346755e-08
amplified O 0 4.5622866196026735e-07
CYP27 O 0 2.3831287762732245e-05
gene O 0 8.171229914921696e-09
products O 0 7.387271350189906e-10
from O 0 1.88880355800336e-09
a O 0 2.3561225859225488e-08
patient O 0 1.2515138791968639e-07
with O 0 1.0798045124715827e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 0.0018603764474391937
CTX B-Disease 1 0.9998689889907837
) O 0 4.862308173869678e-07
. O 0 1.8707277149587753e-07

The O 0 2.0362069790280657e-06
mutation O 0 4.1130837757918925e-07
changed O 0 3.2081706535791454e-07
the O 0 2.0347809481791046e-07
adrenodoxin O 0 3.168878174619749e-05
cofactor O 0 3.540098305165884e-06
binding O 0 9.806751677388093e-08
residue O 0 1.297209223594109e-06
362Arg O 0 6.983029834373156e-07
to O 0 2.4977961032845997e-08
362Ser O 0 3.836525593214901e-06
( O 0 3.006419433404517e-07
CGT O 0 1.0460800695000216e-05
362Arg O 0 1.62821913818334e-06
to O 0 5.45552190089893e-08
AGT O 0 9.09910086193122e-05
362Ser O 0 8.879165989128524e-07
) O 0 3.894543354476809e-09
, O 0 2.2273707878106563e-10
and O 0 2.3382928926451996e-10
was O 0 7.176812744091876e-08
responsible O 0 1.4208313814378926e-07
for O 0 5.006640435567533e-08
deficiency O 1 0.9997244477272034
in O 0 3.303455571312952e-07
the O 0 1.5221085050143301e-06
sterol O 0 2.5081735657295212e-06
27 O 0 5.657139467984962e-07
- O 0 6.164584078760527e-07
hydroxylase O 0 8.539335567547823e-07
activity O 0 2.0312361570518078e-08
, O 0 5.3249505499453065e-11
as O 0 2.8600321763661007e-11
confirmed O 0 5.3141248346211256e-11
by O 0 1.6685737513899568e-10
expression O 0 9.778483578415376e-10
of O 0 2.490725403703209e-09
mutant O 0 1.4991000441000324e-08
cDNA O 0 6.548599174038827e-08
into O 0 1.2222866274669286e-08
COS O 0 7.637070666532964e-06
- O 0 3.362319773714262e-07
1 O 0 1.9799736605818907e-07
cells O 0 1.4605109299736796e-07
. O 0 5.376630340947486e-08

Quantitative O 0 3.687039225042099e-06
analysis O 0 8.767825931954576e-08
showed O 0 8.408435725471008e-09
that O 0 7.503514476425721e-11
the O 0 7.506294474879383e-10
expression O 0 3.170930851226217e-09
of O 0 2.1352724033363302e-08
CYP27 O 0 6.0411039157770574e-05
gene O 0 2.0361470731700138e-08
mRNA O 0 1.717245723398264e-08
in O 0 3.851768348717144e-10
the O 0 2.518173003451807e-09
patient O 0 8.865000289404179e-09
represented O 0 2.02653840375433e-08
52 O 0 4.941671818414761e-07
. O 0 3.09936382336673e-07

5 O 0 3.226301714676083e-06
% O 0 7.572767657393342e-08
of O 0 3.400240444761948e-08
the O 0 7.114323352652718e-08
normal O 0 1.007145328912884e-06
level O 0 2.686177367650089e-06
. O 0 2.6107775852324266e-07

As O 0 1.2958524564510299e-07
the O 0 4.577182011189507e-08
mutation O 0 2.371632490394404e-08
occurred O 0 1.7596504164885118e-07
at O 0 2.341490734636409e-08
the O 0 1.4247603985495516e-08
penultimate O 0 6.170889719214756e-07
nucleotide O 0 2.596631532014726e-07
of O 0 4.344795101474119e-08
exon O 0 6.873995062051108e-08
6 O 0 2.198721027468764e-08
( O 0 1.927637161003304e-09
- O 0 5.224323196273417e-09
2 O 0 3.898749767472509e-09
position O 0 9.24097420806902e-09
of O 0 2.2309956548838272e-08
exon O 0 1.4846625617792597e-07
6 O 0 2.396460558884428e-07
- O 0 7.239069645947893e-07
intron O 0 6.166374987515155e-06
6 O 0 2.36886634752409e-07
splice O 0 4.913550810670131e-07
site O 0 2.0810560386053112e-08
) O 0 3.734529629983996e-10
of O 0 4.733600733608512e-10
the O 0 3.3976457203266364e-09
gene O 0 5.615185205698481e-09
, O 0 4.318913282563841e-10
we O 0 1.4479776266895783e-09
hypothesized O 0 5.1055824457080234e-08
that O 0 3.6063849129241987e-10
the O 0 2.573144364248492e-09
mutation O 0 1.493864587587268e-09
may O 0 1.5415729803791578e-09
partially O 0 1.345000697483556e-07
affect O 0 3.063667985969687e-09
the O 0 5.948456394122559e-09
normal O 0 3.21577289241759e-08
splicing O 0 1.1749953010564695e-08
efficiency O 0 4.6787587137941955e-09
in O 0 7.27135462952333e-10
exon O 0 1.5647394491224986e-08
6 O 0 1.8494678011293786e-09
and O 0 7.491215980870436e-11
cause O 0 1.9666539508023106e-09
alternative O 0 1.970731799971759e-09
splicing O 0 1.3228528494835246e-08
elsewhere O 0 1.7136521091032364e-09
, O 0 7.956824782384686e-11
which O 0 7.197474560793893e-11
resulted O 0 3.7384513262850305e-09
in O 0 3.5997482772387457e-09
decreased O 0 3.5755269323090033e-07
transcript O 0 3.8058490758885455e-07
in O 0 5.448894668802495e-09
the O 0 8.270281881550545e-08
patient O 0 7.759975915178075e-07
. O 0 1.914175982165034e-07

Transfection O 0 0.007099768612533808
of O 0 2.200293693022104e-06
constructed O 0 6.379385013133287e-05
minigenes O 0 7.855713920434937e-05
, O 0 5.769302369174056e-09
with O 0 4.845762680005805e-10
or O 0 5.21640730610784e-09
without O 0 4.456352176163136e-09
the O 0 8.352474267780963e-09
mutation O 0 4.480384119265324e-10
, O 0 2.657751796419916e-10
into O 0 1.8156004699676487e-08
COS O 0 0.00450175954028964
- O 0 4.3057430048065726e-06
1 O 0 1.7282671649354597e-07
cells O 0 9.902174191722679e-09
confirmed O 0 5.951779069590657e-10
that O 0 4.052523247533024e-11
the O 0 1.6335073294015956e-09
mutant O 0 3.2599405841438056e-08
minigene O 0 6.261362841541995e-07
was O 0 4.792547514398393e-08
responsible O 0 1.0439049624721974e-08
for O 0 7.765929566083685e-10
a O 0 9.75084990528785e-09
mRNA O 0 6.220711412652236e-08
species O 0 1.1345829831199694e-10
alternatively O 0 7.640198695924028e-09
spliced O 0 1.4939843140382436e-07
at O 0 3.9134214091518515e-08
an O 0 2.0707457082380643e-08
activated O 0 7.994599400262814e-07
cryptic O 0 1.8528530745243188e-06
5 O 0 7.59878162170935e-07
splice O 0 3.487275762381614e-06
site O 0 4.212453461605037e-07
88 O 0 2.3290819228805049e-07
bp O 0 8.356922194252547e-07
upstream O 0 4.7000483505144075e-07
from O 0 7.534699975053627e-09
the O 0 1.920862935378409e-08
3 O 0 5.187230556202849e-08
end O 0 1.0398673566669459e-07
of O 0 2.7754316533901147e-07
exon O 0 9.213553312292788e-06
6 O 0 2.928885351138888e-06
. O 0 3.335049996167072e-07

Our O 0 1.8144427258448559e-06
data O 0 2.0843499726197479e-07
suggest O 0 1.9189148048326388e-08
that O 0 4.78877826282087e-10
the O 0 4.049429236374635e-09
C O 0 1.365015691590088e-07
to O 0 2.507456242639705e-09
A O 0 6.589431933434753e-08
mutation O 0 1.0599997546378859e-09
at O 0 3.354169830771525e-09
the O 0 2.9165998505220614e-09
penultimate O 0 4.810745508621039e-07
nucleotide O 0 1.352241554286593e-07
of O 0 1.861948817349912e-08
exon O 0 4.418673427153408e-08
6 O 0 9.32194677005782e-09
of O 0 4.044373724809702e-09
the O 0 1.60069788535111e-08
CYP27 O 0 0.0006111958064138889
gene O 0 9.048937599231976e-09
not O 0 3.2262503779634244e-10
only O 0 6.323707113509158e-10
causes O 0 1.0801032068741279e-08
the O 0 3.8457670825664536e-08
deficiency B-Disease 0 0.00837488379329443
in I-Disease 0 6.682930830947953e-08
the I-Disease 0 2.961899383535638e-07
sterol I-Disease 0 1.0038534128398169e-06
27 I-Disease 0 2.756862897967949e-07
- I-Disease 0 3.2504294722457416e-07
hydroxylase I-Disease 0 5.317686486705497e-07
activity I-Disease 0 5.173545858383477e-08
, O 0 1.598365328980833e-10
but O 0 5.119968685129983e-11
also O 0 2.5611662790581136e-10
partially O 0 1.9078241209058433e-08
leads O 0 1.2982162012065146e-09
to O 0 2.453531267043729e-10
alternative O 0 4.3331898069709496e-09
pre O 0 3.1389708965434693e-07
- O 0 1.1020077295142983e-07
mRNA O 0 2.1245722336971085e-07
splicing O 0 7.211610864032991e-08
of O 0 4.883174309355809e-09
the O 0 2.755195893655582e-08
gene O 0 7.981247307498052e-08
. O 0 5.7117027552067157e-08

To O 0 3.4851439068006584e-07
our O 0 2.2253270515193435e-07
knowledge O 0 2.0426623450475745e-06
, O 0 2.4084001459812043e-09
this O 0 4.465539604758817e-10
is O 0 3.468848541743341e-10
the O 0 3.669373138670551e-10
first O 0 7.812281932473297e-10
report O 0 1.973041285907584e-09
regarding O 0 2.1457557952686557e-09
effects O 0 5.863454610732788e-09
on O 0 7.173634575252663e-09
pre O 0 3.5070527815150854e-07
- O 0 8.49602628250068e-08
mRNA O 0 6.356993509371023e-08
splicing O 0 1.1025960588995076e-08
of O 0 7.549801339656881e-10
a O 0 4.924325947008867e-10
mutation O 0 1.1803873156690514e-10
at O 0 1.9961692299119704e-09
the O 0 3.003471471529906e-09
- O 0 2.3223611478329076e-08
2 O 0 1.870013832672157e-08
position O 0 2.3729084475121454e-08
of O 0 4.323764102309724e-08
a O 0 8.331030443287091e-08
5 O 0 5.187675924389623e-07
splice O 0 4.761950094689382e-06
site O 0 1.8634179923537886e-06
. O 0 3.461304913798813e-07

ATM O 0 0.0018030839273706079
germline O 0 9.382450662087649e-05
mutations O 0 2.2754890949272522e-07
in O 0 6.21142817180953e-08
classical O 1 0.9997007846832275
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 7.0944624894764274e-06
in O 0 2.012608302237595e-09
the O 0 9.405853873545311e-09
Dutch O 0 4.141204044572078e-06
population O 0 6.111732897551292e-09
. O 0 2.4975532753046537e-08

Germline O 0 0.0003055621054954827
mutations O 0 4.0783980637115747e-08
in O 0 2.429447754082048e-09
the O 0 6.897869830879699e-09
ATM O 0 2.7428588964539813e-06
gene O 0 2.047845892860778e-09
are O 0 5.4478189320805726e-11
responsible O 0 3.3472675742274305e-09
for O 0 8.858323852223293e-09
the O 1 0.9998608827590942
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.541143425740302e-06
. O 0 5.942159759797505e-07

In O 0 1.501808100101698e-07
our O 0 9.396671885042451e-09
study O 0 5.794402735403992e-09
, O 0 1.439978830619637e-10
we O 0 1.421946310697919e-10
have O 0 4.9098523857704635e-11
determined O 0 2.5381459156648134e-09
the O 0 5.7291900112943495e-09
ATM O 0 7.261631367327936e-07
mutation O 0 2.2526809584366703e-10
spectrum O 0 4.6023285182883455e-10
in O 0 4.1838629782908754e-10
19 O 0 1.1366310559424164e-08
classical O 0 2.2262534002948087e-06
A B-Disease 1 1.0
- I-Disease 1 0.9989989399909973
T I-Disease 1 1.0
patients O 0 1.0808115513682992e-09
, O 0 1.6271869268669192e-11
including O 0 1.6213502762596477e-11
some O 0 1.5368390587910952e-11
immigrant O 0 2.6242341633064825e-10
populations O 0 6.214606607102269e-11
, O 0 1.800541139795886e-11
as O 0 6.661300677723858e-11
well O 0 1.0173285824865985e-10
as O 0 2.2743017191739767e-10
12 O 0 8.642246918100227e-10
of O 0 1.5769749950322876e-09
Dutch O 0 1.1586140402641831e-07
ethnic O 0 8.527192285612273e-09
origin O 0 1.1379677289369283e-07
. O 0 2.2212155670331413e-07

Both O 0 2.693573151191231e-07
the O 0 8.071000223708324e-08
protein O 0 8.291066677657e-08
truncation O 0 4.3777194491667615e-07
test O 0 6.113834416510144e-08
( O 0 2.6237620431857067e-07
PTT O 0 1.6286558093270287e-05
) O 0 1.1603690230899133e-09
and O 0 8.652716043666686e-11
the O 0 1.2975849283947127e-09
restriction O 0 6.2085354635144085e-09
endonuclease O 0 1.281329531366282e-07
fingerprinting O 0 3.656256453155038e-08
( O 0 1.2831289808445945e-08
REF O 0 1.5978417877704487e-06
) O 0 4.318822521831578e-10
method O 0 6.257990237124034e-10
were O 0 2.0996895888636402e-10
used O 0 1.9778177706708533e-10
and O 0 7.388732681246069e-11
compared O 0 1.2449797859304113e-09
for O 0 6.341556446631813e-11
their O 0 4.214297522064925e-10
detection O 0 1.8165286164162353e-08
efficiency O 0 6.405212360505175e-09
, O 0 2.1013642215184092e-10
identifying O 0 2.4556205957537713e-09
76 O 0 1.0779587000797619e-08
% O 0 5.272721703697414e-10
and O 0 1.0022825625011222e-10
60 O 0 3.639625489881837e-09
% O 0 5.246338918851734e-10
of O 0 5.549509185520662e-10
the O 0 2.972514012711258e-09
mutations O 0 3.269129411620497e-09
, O 0 1.6257677426523287e-09
respectively O 0 1.563722662467626e-07
. O 0 8.993021083369968e-08

Most O 0 1.5758955385081208e-07
patients O 0 1.4943099202469057e-08
were O 0 1.083511946831095e-08
found O 0 9.437949088919595e-09
to O 0 7.477391150700896e-09
be O 0 1.413623493817795e-07
compound O 0 0.00010222291166428477
heterozygote O 0 7.291710062418133e-05
. O 0 6.291098770816461e-07

Seventeen O 0 1.0716981705627404e-05
mutations O 0 1.0374583325756248e-07
were O 0 1.560781015541579e-08
distinct O 0 9.045555415809758e-09
, O 0 1.1711663860936028e-09
of O 0 1.8042566551912387e-08
which O 0 1.20813814508125e-09
10 O 0 3.976351248269339e-09
were O 0 6.396690732657362e-09
not O 0 2.06353734100162e-09
reported O 0 5.8741473907275576e-08
previously O 0 6.798174467803619e-07
. O 0 7.237274530780269e-07

Mutations O 0 7.701651156821754e-07
are O 0 3.3945686261915853e-09
small O 0 7.133111878943055e-09
deletions O 0 1.3261450249046902e-07
or O 0 6.3499889790819e-08
point O 0 8.35096273021918e-07
mutations O 0 7.263543722046961e-08
frequently O 0 7.340310759218482e-08
affecting O 0 4.3938268845522543e-07
splice O 0 8.14717077446403e-06
sites O 0 4.715924717402231e-07
. O 0 7.029735229480139e-07

Moreover O 0 3.902783282683231e-05
, O 0 1.4041845020074106e-07
a O 0 4.468602980978176e-07
16 O 0 7.327259368139494e-07
. O 0 2.5251466695408453e-07

7 O 0 1.650307240197435e-05
- O 0 2.629779373819474e-06
kb O 0 1.2808698556909803e-05
genomic O 0 4.202017578336381e-07
deletion O 0 5.528606905613742e-08
of O 0 1.886597367217746e-08
the O 0 1.4011554583248653e-08
3 O 0 1.5032346922794204e-08
end O 0 1.2392044723696927e-08
of O 0 1.549722306037893e-08
the O 0 1.6544383640848537e-08
gene O 0 5.84869930264631e-09
, O 0 2.0030485603506065e-10
most O 0 8.193602046846493e-11
likely O 0 6.20146711760583e-10
a O 0 3.4800233805754033e-09
result O 0 2.4034716439302883e-09
of O 0 8.845019827674605e-09
recombination O 0 1.734640342476723e-08
between O 0 8.419172026208344e-09
two O 0 1.7566674781477332e-09
LINE O 0 3.4165651641160366e-07
elements O 0 5.489926735435802e-08
, O 0 1.1774676345055468e-08
was O 0 5.016285626879835e-07
identified O 0 6.097147320360818e-07
. O 0 3.2646701697558456e-07

The O 0 3.808568749263941e-07
most O 0 1.7067759428002205e-09
frequently O 0 2.4957327315888733e-09
found O 0 7.173685534489493e-10
mutation O 0 2.1345372691605746e-10
, O 0 6.61241200683449e-11
identified O 0 1.020555195907491e-09
in O 0 4.917089513334361e-10
three O 0 1.3763490347429297e-09
unrelated O 0 1.0308210107723426e-07
Turkish O 0 3.943584033549996e-06
A B-Disease 1 1.0
- I-Disease 1 0.9998918771743774
T I-Disease 1 0.9999995231628418
individuals O 0 3.1962521518380527e-09
, O 0 4.679291953912923e-10
was O 0 2.449064062659545e-08
previously O 0 5.523007384766743e-09
described O 0 2.1594690480242207e-09
to O 0 1.4725055896835926e-10
be O 0 5.747662346067273e-10
a O 0 8.442262888763707e-09
Turkish O 0 5.027463885198813e-07
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9990350008010864
T I-Disease 1 0.9999992847442627
founder O 0 4.537890708888881e-05
mutation O 0 1.9039059395709046e-07
. O 0 1.0026854369016291e-07

The O 0 1.1800248103099875e-06
presence O 0 2.0076220152986934e-07
of O 0 2.7028647764382185e-07
a O 0 1.744440396578284e-07
founder O 0 1.5893523368504248e-06
mutation O 0 1.3428770317958083e-09
among O 0 2.1756027535069222e-11
relatively O 0 1.685693945541189e-10
small O 0 5.857379165030707e-11
ethnic O 0 9.589985749958174e-11
population O 0 2.3054497547136954e-11
groups O 0 1.4334725247089342e-11
in O 0 1.3359427453174533e-10
Western O 0 6.440874944502184e-09
Europe O 0 1.4619503385659982e-09
could O 0 3.9992356648532734e-10
indicate O 0 3.795693981345494e-09
a O 0 8.582175525795321e-10
high O 0 1.304404029234263e-09
carrier O 0 5.238499634074856e-10
frequency O 0 1.1361470653170613e-09
in O 0 1.704006935554503e-10
such O 0 6.19601592255492e-10
communities O 0 1.4578245277618862e-08
. O 0 1.674463163681139e-07

In O 0 2.3043526198307518e-07
patients O 0 8.083322455831876e-09
of O 0 5.49689183060309e-09
Dutch O 0 5.831770067743491e-06
ethnic O 0 7.83066500531504e-09
origin O 0 6.447204992099387e-09
, O 0 3.423560601678588e-10
however O 0 9.006557166735263e-10
, O 0 4.0412254098676215e-10
no O 0 1.6992725004882914e-09
significant O 0 7.3242243381344e-09
founder O 0 2.5284384719270747e-07
effect O 0 1.0611048040232163e-08
could O 0 1.6663291857454965e-09
be O 0 6.623198878230596e-09
identified O 0 2.939707428595284e-07
. O 0 2.688699112241011e-07

The O 0 3.490588937893335e-07
observed O 0 4.995280278308201e-07
genetic O 0 3.149291956106026e-07
heterogeneity O 0 1.6058788787631784e-07
including O 0 2.3449131525410394e-09
the O 0 8.567526244007695e-09
relative O 0 3.7268983987814863e-07
high O 0 7.834807291828838e-08
percentage O 0 2.983147950885723e-08
of O 0 2.6724755741724948e-08
splice O 0 1.9712683752004523e-06
- O 0 3.10040718431992e-07
site O 0 1.0861567290021412e-07
mutations O 0 5.697935456794312e-09
had O 0 4.115654483882736e-09
no O 0 3.5198364223276712e-09
reflection O 0 4.207290160707089e-08
on O 0 1.2668214921518484e-08
the O 0 5.043002815341424e-08
phenotype O 0 5.35981826033094e-07
. O 0 1.7308749988842465e-07

All O 0 1.9612595281159884e-07
patients O 0 4.767402828065315e-08
manifested O 0 1.9099219628060382e-07
classical O 0 5.0016402383334935e-05
A B-Disease 1 1.0
- I-Disease 1 0.9820178747177124
T I-Disease 1 0.9996408224105835
and O 0 4.109771634119852e-09
increased O 0 3.984909824339411e-08
cellular O 0 3.3596560911064444e-07
radioresistant O 0 2.494690534149413e-06
DNA O 0 1.3049070730630774e-06
synthesis O 0 1.349333047073742e-06
. O 0 7.342270436083709e-08

Determination O 0 2.3437260097125545e-06
of O 0 1.071608224378906e-07
the O 0 2.750753402835926e-08
genomic O 0 2.7765278787228453e-07
structure O 0 1.0939346140048656e-07
of O 0 3.844637674887963e-08
the O 0 8.20797296796627e-08
COL4A4 O 1 0.8023655414581299
gene O 0 8.867317546901177e-09
and O 0 1.6019391368971014e-10
of O 0 1.1095621310630577e-08
novel O 0 2.6658249225874897e-06
mutations O 0 7.796294994477648e-06
causing O 0 0.000393729074858129
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.644522313261405e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.690495067436132e-07
a O 0 9.359857358504087e-06
progressive O 1 0.9998898506164551
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.0009851162321865559
by O 0 1.8398602605884662e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9688529372215271
abnormalities I-Disease 0 0.1945408433675766
and O 0 6.277383945985093e-09
associated O 0 8.319231881159794e-08
with O 0 5.271397096606734e-09
mutations O 0 1.2791654846466827e-08
in O 0 1.094328627715413e-08
either O 0 7.861677175924342e-08
the O 0 1.6791130974525004e-06
COL4A3 O 1 0.9999723434448242
or O 0 2.3070484189702256e-07
the O 0 5.005953198633506e-07
COL4A4 O 1 0.9915287494659424
gene O 0 5.1926747346442426e-08
, O 0 1.029030527455177e-09
which O 0 8.347866842228768e-10
encode O 0 1.4413020998915727e-08
the O 0 2.725237457923413e-08
alpha3 O 0 1.2752521797665395e-05
and O 0 5.015902715399534e-08
alpha4 O 0 0.0008243952761404216
type O 0 0.0008177683339454234
IV O 1 1.0
collagen O 1 0.9999122619628906
chains O 0 6.592905992874876e-05
, O 0 5.782503720297427e-08
respectively O 0 3.0454971238214057e-06
. O 0 8.792306402938266e-07

To O 0 1.9845920462557842e-07
date O 0 6.088059762987541e-07
, O 0 6.7818541893416295e-09
mutation O 0 3.428292982832204e-09
screening O 0 4.079049098493215e-09
in O 0 1.400740523571642e-09
the O 0 1.68977665193637e-09
two O 0 6.696349030832494e-10
genes O 0 3.976699858299071e-09
has O 0 1.054872300620957e-10
been O 0 7.91944620992524e-10
hampered O 0 8.952050478683304e-08
by O 0 9.34251898065952e-10
the O 0 5.963610938408692e-09
lack O 0 2.1998786792210012e-08
of O 0 1.50127483777851e-08
genomic O 0 1.0735169553299784e-07
structure O 0 4.625460121587821e-07
information O 0 7.553134651061555e-07
. O 0 2.2237846053485555e-07

We O 0 3.7719738088526356e-07
report O 0 9.726278449306847e-08
here O 0 1.0659265470280843e-08
the O 0 4.228413619244975e-09
complete O 0 7.558352166370241e-08
characterization O 0 5.155922622179787e-07
of O 0 5.8612993569795435e-08
the O 0 4.358822636163495e-08
48 O 0 1.9449670674021036e-07
exons O 0 5.204623576560152e-08
of O 0 1.3239937146636294e-08
the O 0 2.5584542484580197e-08
COL4A4 O 0 0.0012425357708707452
gene O 0 1.3400580201050616e-08
, O 0 2.1896540136623344e-10
a O 0 8.270511497876498e-10
comprehensive O 0 4.06537914443561e-09
gene O 0 5.877795472564173e-10
screen O 0 5.369372502173064e-09
, O 0 1.6087642329409846e-10
and O 0 1.1874554117774494e-10
the O 0 1.2808787364093632e-09
subsequent O 0 1.2084130140976868e-08
detection O 0 1.8010142710522814e-08
of O 0 1.1198819649393954e-09
10 O 0 7.605010510225441e-10
novel O 0 1.2512048064294845e-09
mutations O 0 1.4747288112904045e-10
in O 0 1.3288194156135802e-10
eight O 0 2.2359532003690674e-09
patients O 0 2.9385963884465127e-08
diagnosed O 0 3.6276419450587127e-06
with O 0 2.1904743334744126e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.179242412443273e-05

Furthermore O 0 2.7892344860447338e-06
, O 0 7.178042160660425e-09
we O 0 6.391495332991326e-09
identified O 0 3.000804937869361e-08
a O 0 1.3833187040290795e-08
glycine O 0 5.18091241019647e-08
to O 0 2.6704003452948655e-09
alanine O 0 1.9560273756269453e-07
substitution O 0 3.256448266597545e-08
in O 0 1.126609650015098e-08
the O 0 5.5424170142259754e-08
collagenous O 0 0.00016013195272535086
domain O 0 3.3401525456611125e-07
that O 0 2.1662581450865304e-10
is O 0 1.2138269278594294e-09
apparently O 0 1.689197404175502e-08
silent O 0 1.529589468418635e-07
in O 0 2.327845693983477e-09
the O 0 4.494705940771837e-09
heterozygous O 0 5.480800702173383e-09
carriers O 0 5.924426504932967e-10
, O 0 3.1399824407252197e-10
in O 0 6.340643565749815e-09
11 O 0 5.401782345870743e-07
. O 0 3.8366900412256655e-07

5 O 0 5.499793473973114e-07
% O 0 1.1221617413070817e-08
of O 0 3.6000091796495326e-09
all O 0 3.304226614542216e-10
control O 0 9.142376633519689e-09
individuals O 0 2.662866593894364e-10
, O 0 2.337722238010542e-10
and O 0 3.3887448402936116e-10
in O 0 1.5768485406297827e-09
one O 0 1.212438704989438e-09
control O 0 2.981548341551843e-09
individual O 0 8.795923989168841e-10
homozygous O 0 1.2638016189114865e-09
for O 0 2.585708314128965e-10
this O 0 2.328218728919751e-09
glycine O 0 1.9809576201623713e-07
substitution O 0 4.080717417309643e-07
. O 0 3.937181531910028e-07

There O 0 6.000100825076515e-07
has O 0 3.641236201445963e-09
been O 0 2.4206594506637202e-09
no O 0 2.0132764344538145e-09
previous O 0 5.0587702915549926e-09
finding O 0 1.2245057412485494e-08
of O 0 5.94232130168848e-09
a O 0 2.3896393752664835e-09
glycine O 0 6.408316099992817e-09
substitution O 0 7.938546486840892e-10
that O 0 5.6365110495670834e-11
is O 0 5.890294502153282e-11
not O 0 4.3174776254151226e-11
associated O 0 8.876483992281692e-10
with O 0 3.0251565141803383e-10
any O 0 7.153958314631836e-09
obvious O 0 1.1267810151593949e-07
phenotype O 0 6.077234360191142e-08
in O 0 5.019460402877485e-09
homozygous O 0 5.406091929671675e-08
individuals O 0 1.3157565703636465e-08
. O 0 1.298435421404065e-07

Founder O 0 0.32545042037963867
BRCA1 O 0 2.0227254935889505e-05
and O 0 1.7925460227274925e-08
BRCA2 O 0 2.643891434672696e-07
mutations O 0 1.6662465851524644e-09
in O 0 7.834276560814146e-10
French O 0 2.3592664888383297e-07
Canadian O 0 0.0024494074750691652
breast B-Disease 1 1.0
and I-Disease 1 0.999994158744812
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0001120722881751135
. O 0 8.33644890008145e-07

We O 0 1.59897140861176e-07
have O 0 2.9826574543534434e-09
identified O 0 9.991455662827775e-09
four O 0 2.5397681735483957e-09
mutations O 0 1.0811249673281509e-09
in O 0 3.1830121871578854e-10
each O 0 4.247399376655636e-10
of O 0 2.074129312745754e-08
the O 0 5.543129759644216e-07
breast B-Disease 1 0.9963523149490356
cancer I-Disease 1 0.877778947353363
- O 0 0.011163389310240746
susceptibility O 0 2.0024464902235195e-05
genes O 0 2.4090446970603807e-08
, O 0 6.220421400193743e-10
BRCA1 O 0 6.742914226975927e-09
and O 0 3.11178138812096e-10
BRCA2 O 0 4.0884895469162075e-09
, O 0 5.90989757132121e-11
in O 0 2.618908701013112e-10
French O 0 1.0291942942330934e-07
Canadian O 0 6.12839066889137e-05
breast B-Disease 1 0.9996728897094727
cancer I-Disease 0 0.17871755361557007
and O 0 8.962983702076599e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.4043226883586613e-06
from O 0 1.4833703687600064e-07
Quebec O 0 3.1948843570717145e-06
. O 0 5.470797646012215e-07

To O 0 3.3621915918047307e-07
identify O 0 5.991786906633934e-07
founder O 0 7.425669537042268e-06
effects O 0 2.017873384829727e-06
, O 0 1.9807255835502247e-09
we O 0 1.4621427402161657e-09
examined O 0 2.8550223518664097e-08
independently O 0 1.9428235020768625e-08
ascertained O 0 2.1726437182678637e-07
French O 0 6.565795729329693e-08
Canadian O 0 4.739785310903244e-07
cancer B-Disease 0 1.2493613610331522e-07
families O 0 9.099657832800645e-11
for O 0 5.046718945522777e-11
the O 0 5.980066997146594e-10
distribution O 0 9.965148706214677e-10
of O 0 1.2672944915692597e-09
these O 0 4.305063250331642e-10
eight O 0 8.186924027597797e-09
mutations O 0 1.4097764733378426e-08
. O 0 6.697452903381418e-08

Mutations O 0 1.1857068784593139e-06
were O 0 4.619843707587279e-08
found O 0 8.34155233775391e-09
in O 0 6.2447704785029146e-09
41 O 0 6.713644751243919e-08
of O 0 1.4509191714751069e-07
97 O 0 8.093728865787853e-06
families O 0 1.4674132842174004e-07
. O 0 5.807737579743844e-07

Six O 0 1.377286707793246e-06
of O 0 1.647076146582549e-07
eight O 0 5.09255997371838e-08
mutations O 0 1.2964725293329593e-08
were O 0 1.34901316783953e-08
observed O 0 5.4026898510528554e-08
at O 0 7.89804843748243e-08
least O 0 8.860098432705854e-09
twice O 0 1.1240516784027932e-07
. O 0 1.1677769862217247e-07

The O 0 2.9630467906827107e-05
BRCA1 O 0 4.6171709982445464e-05
C4446T O 0 1.6619835150777362e-05
mutation O 0 3.741991605465955e-08
was O 0 2.4150898170205437e-08
the O 0 2.922000863492258e-09
most O 0 2.2363957907778342e-10
common O 0 3.9732028778161066e-10
mutation O 0 1.5688500498711733e-10
found O 0 4.1294917485501514e-10
, O 0 2.223351364127879e-10
followed O 0 1.6546236603076636e-09
by O 0 2.1092196877958713e-09
the O 0 4.498628314308917e-08
BRCA2 O 0 3.9335634482995374e-07
8765delAG O 0 1.4101309488978586e-06
mutation O 0 1.008379655331737e-07
. O 0 9.100590148136689e-08

Together O 0 7.815134495103848e-07
, O 0 4.177310497510689e-09
these O 0 3.488022370934374e-10
mutations O 0 1.4934030678759314e-09
were O 0 1.2764448387159177e-09
found O 0 8.622012548364921e-10
in O 0 1.3729404280127255e-09
28 O 0 1.0445941001080428e-08
of O 0 1.3288031119884636e-08
41 O 0 3.331174625031963e-08
families O 0 1.1740292071849012e-09
identified O 0 6.257922180452624e-09
to O 0 1.3003772503239475e-09
have O 0 1.5563685895614299e-09
a O 0 4.7809891157157836e-08
mutation O 0 4.774027217990806e-08
. O 0 8.101584825226382e-08

The O 0 1.4418541240956984e-06
odds O 0 6.213499545992818e-06
of O 0 1.0153254947908863e-07
detection O 0 3.824196994628437e-07
of O 0 3.648774438147484e-08
any O 0 8.223514313954183e-09
of O 0 7.55927587192673e-08
the O 0 5.742967346122896e-08
four O 0 5.943968162114288e-08
BRCA1 O 0 1.423299664793376e-07
mutations O 0 4.203798642521406e-09
was O 0 2.8782548611161474e-07
18 O 0 3.6682192217085685e-07
. O 0 4.123908183828462e-07

7x O 0 0.0074732666835188866
greater O 0 3.0404720519072725e-07
if O 0 9.477942874980272e-09
one O 0 1.8721362238238726e-09
or O 0 7.372266130900584e-10
more O 0 4.570039485729538e-11
cases O 0 9.195466610378844e-10
of O 0 0.0026208837516605854
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 3.126938463537954e-05
also O 0 1.4422719685214247e-09
present O 0 3.5893683580923152e-09
in O 0 6.385646234008391e-09
the O 0 8.702082965328373e-08
family O 0 6.705934083583998e-07
. O 0 1.648910199492093e-07

The O 0 9.250338166566507e-07
odds O 0 4.287231149646686e-06
of O 0 6.56922836128615e-08
detection O 0 3.612709349454235e-07
of O 0 3.759260636115869e-08
any O 0 1.700991880682068e-08
of O 0 8.314425770095113e-08
the O 0 6.840042487965547e-08
four O 0 1.1788568343717998e-07
BRCA2 O 0 2.0347692952782381e-07
mutations O 0 4.525562591339849e-09
was O 0 1.809164160704313e-07
5 O 0 1.3178843971672904e-07
. O 0 1.218134002556326e-07

3x O 0 0.00028563092928379774
greater O 0 7.522325518038997e-08
if O 0 2.907967866505601e-09
there O 0 3.8159830850759136e-09
were O 0 6.9856787021649325e-09
at O 0 8.044224841796677e-09
least O 0 1.6186751938818134e-10
five O 0 1.0038053721572737e-10
cases O 0 6.104015209951186e-11
of O 0 2.2366196006373684e-08
breast B-Disease 1 0.8986653685569763
cancer I-Disease 0 0.12175390124320984
in O 0 5.756257905886741e-07
the O 0 6.051809123164276e-06
family O 0 6.217488589754794e-06
. O 0 1.8129554746337817e-07

Interestingly O 0 1.1895592251676135e-05
, O 0 7.743998331477542e-09
the O 0 6.67265043219345e-09
presence O 0 1.923946690851608e-08
of O 0 8.110799853966455e-08
a O 0 6.797130254199146e-07
breast B-Disease 0 0.0009563823114149272
cancer I-Disease 0 5.339020844985498e-06
case O 0 5.868984658263798e-07
< O 0 5.740717369917547e-06
36 O 0 1.1312089043258311e-08
years O 0 5.662353363966588e-10
of O 0 1.5445219547771671e-09
age O 0 5.4874953470118726e-09
was O 0 2.631424145249639e-08
strongly O 0 9.884940643800633e-10
predictive O 0 1.2885393196881978e-08
of O 0 1.8484591635115066e-09
the O 0 8.765342340844029e-10
presence O 0 1.405590088765507e-09
of O 0 2.555755607147603e-09
any O 0 3.861863273613153e-09
of O 0 1.4214054822048183e-08
the O 0 1.4559792482771172e-08
eight O 0 2.7357994980548028e-08
mutations O 0 1.214916256486731e-08
screened O 0 1.0973241870715356e-07
. O 0 8.760972036725434e-08

Carriers O 0 1.850388002822001e-06
of O 0 6.888419079587038e-08
the O 0 8.566905407292325e-09
same O 0 4.949696652545299e-09
mutation O 0 9.944224332869567e-10
, O 0 4.4092209050550224e-11
from O 0 6.815653597058713e-11
different O 0 2.598755065308378e-11
families O 0 3.4930155989876255e-10
, O 0 1.5720789947604175e-10
shared O 0 2.499062512484329e-09
similar O 0 1.6799142077417173e-09
haplotypes O 0 5.6451483487762744e-08
, O 0 3.733290621088514e-10
indicating O 0 7.671155266564256e-09
that O 0 1.5014507692701073e-10
the O 0 1.1453987758258677e-09
mutant O 0 9.716003113169336e-09
alleles O 0 2.4300861323212075e-10
were O 0 3.324779340729833e-10
likely O 0 1.6903302368920237e-10
to O 0 1.2798230530908228e-10
be O 0 3.1223879037867164e-10
identical O 0 1.5891613580620856e-09
by O 0 6.283526476913437e-10
descent O 0 5.65353168724414e-08
for O 0 1.62712665563447e-09
a O 0 1.736838584065481e-08
mutation O 0 2.7269415614483705e-09
in O 0 1.7186274625657916e-09
the O 0 3.5376064744241376e-08
founder O 0 6.052131993783405e-06
population O 0 1.1949999212390594e-08
. O 0 7.841145333031818e-08

The O 0 1.0510798631457874e-07
identification O 0 4.675852594004937e-08
of O 0 5.890708010269918e-08
common O 0 5.842569805736275e-08
BRCA1 O 0 5.73924921809521e-07
and O 0 7.008901015126412e-09
BRCA2 O 0 7.555195935537995e-08
mutations O 0 6.050535072965602e-10
will O 0 1.097762297730398e-10
facilitate O 0 9.35150890057912e-09
carrier O 0 9.469937722883515e-09
detection O 0 8.356365555073353e-08
in O 0 2.496556517073145e-09
French O 0 3.1410763767780736e-07
Canadian O 0 9.208384290104732e-05
breast B-Disease 1 0.9994157552719116
cancer I-Disease 0 0.10670458525419235
and O 0 3.24928987538442e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.826544343610294e-05
. O 0 8.237817610279308e-07

Are O 0 1.0927037692454178e-06
Dp71 O 0 0.0018185297958552837
and O 0 4.0380669474870956e-07
Dp140 O 0 0.49328330159187317
brain O 1 0.809459924697876
dystrophin O 0 1.1842811545648146e-05
isoforms O 0 5.110697998134128e-08
related O 0 3.1666051114598304e-08
to O 0 8.851939625742489e-09
cognitive B-Disease 0 0.05367206782102585
impairment I-Disease 1 0.9999498128890991
in O 0 0.00012949382653459907
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
? O 0 4.3610762077150866e-05

Molecular O 0 5.445829810923897e-05
study O 0 4.964108057947669e-08
and O 0 1.0474227041257222e-09
neuropsychological O 0 8.435345222324031e-08
analysis O 0 1.218592338148028e-08
were O 0 1.8766301845829503e-09
performed O 0 5.277192016706067e-09
concurrently O 0 1.855216780199953e-08
on O 0 5.6468687503752335e-09
49 O 0 5.017605886337151e-08
patients O 0 4.4959662659493915e-09
with O 0 8.282355246080897e-09
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.413568139076233e-05
DMD B-Disease 1 1.0
) O 0 5.139964009970299e-09
in O 0 2.573339319411616e-10
order O 0 6.455765921842271e-10
to O 0 3.552898530934101e-10
find O 0 4.211904602868799e-09
a O 0 4.402746167642135e-09
molecular O 0 1.7600926938143857e-08
explanation O 0 2.0714083781570025e-09
for O 0 1.3512857499620168e-10
the O 0 7.85948461867747e-09
cognitive B-Disease 0 1.5096849892870523e-05
impairment I-Disease 0 1.1688364793371875e-05
observed O 0 3.89092171815264e-08
in O 0 1.1926113430149599e-08
most O 0 2.8392305395641415e-08
DMD B-Disease 1 1.0
patients O 0 1.0678311355150072e-06
. O 0 3.1280870871341904e-07

Complete O 0 4.835435902350582e-06
analysis O 0 6.594825663341908e-07
of O 0 1.0942038386474451e-07
the O 0 1.1316301140595897e-07
dystrophin O 0 1.3811662029183935e-05
gene O 0 8.934141249028471e-08
was O 0 7.788752043325076e-08
performed O 0 1.5977695611013587e-08
to O 0 2.10183426219146e-09
define O 0 3.596359832158669e-08
the O 0 1.8146794289464196e-08
localization O 0 1.1806530437752372e-06
of O 0 8.835897347125865e-09
deletions O 0 1.4043259000118269e-08
and O 0 2.46958964389421e-09
duplications O 0 7.57942814288981e-07
in O 0 9.73408820215127e-09
relation O 0 2.6208360281998466e-07
to O 0 6.227356852406274e-09
the O 0 8.234944459672988e-08
different O 0 3.9823422071094683e-07
DMD B-Disease 1 1.0
promoters O 0 0.0004480667121242732
. O 0 1.2431055438355543e-06

Qualitative O 0 1.7624697647988796e-05
analysis O 0 4.88706746182288e-07
of O 0 7.212849340021421e-08
the O 0 5.7237429018641706e-08
Dp71 O 0 5.597292329184711e-05
transcript O 0 1.0613031236061943e-06
and O 0 7.146399583213281e-10
testing O 0 8.366979886709203e-10
for O 0 2.5552329696587606e-10
the O 0 3.293952666183486e-09
specific O 0 2.0276507139982414e-09
first O 0 3.513753910056039e-08
exon O 0 1.8708186644289526e-07
of O 0 4.241493911649741e-08
Dp140 O 0 2.2730478121957276e-06
were O 0 2.8539769658664227e-08
also O 0 1.5664287644767683e-09
carried O 0 1.8973475235384285e-08
out O 0 2.263407417046892e-08
. O 0 2.081696095501684e-07

Neuropsychological O 0 0.00013332514208741486
analysis O 0 1.7293334622081602e-06
assessed O 0 2.0554953152895905e-06
verbal O 0 8.576171239838004e-06
and O 0 2.2780555752888176e-07
visuospatial O 1 0.9902620911598206
intelligence O 0 5.198591316002421e-05
, O 0 8.061538636638943e-08
verbal O 0 1.8675043975235894e-05
memory O 1 0.6163448691368103
, O 0 4.103225492713136e-08
and O 0 3.982858132189904e-08
reading O 0 2.1343668777262792e-05
skills O 0 0.001641100854612887
. O 0 7.3480391620250884e-06

Comparison O 0 5.034054993302561e-06
of O 0 2.578324540536414e-07
molecular O 0 2.0328620848886203e-06
and O 0 1.138737992789629e-08
psychometric O 0 5.03692172060255e-06
findings O 0 2.7607296004816817e-08
demonstrated O 0 1.0665549332600222e-08
that O 0 1.2231178569965806e-10
deletions O 0 4.1677923334759726e-09
and O 0 2.7684254888526993e-10
duplications O 0 4.1094914138284366e-08
that O 0 1.8187490402610251e-10
were O 0 3.488077604529849e-09
localized O 0 4.320746427310951e-08
in O 0 4.068551717750779e-09
the O 0 1.3764862138998524e-08
distal O 0 5.155342250873218e-07
part O 0 1.2312224129118476e-08
of O 0 1.943989786923339e-07
the O 0 1.4771745782127255e-07
gene O 0 2.7031218152728798e-08
seemed O 0 8.95737706230193e-09
to O 0 2.566594436981262e-10
be O 0 5.246599266151009e-10
preferentially O 0 1.7312984823547595e-08
associated O 0 2.0678330159284997e-08
with O 0 6.3010037187893886e-09
cognitive B-Disease 1 0.7682616114616394
impairment I-Disease 1 0.8729978203773499
. O 0 3.2235584512818605e-06

Two O 0 1.2615561217899085e-06
altered O 0 3.2225195809587603e-06
Dp71 O 0 8.521044946974143e-05
transcripts O 0 2.898428647313267e-06
and O 0 5.768829858254776e-09
two O 0 6.077556680139651e-09
deleted O 0 3.1917764431455e-07
Dp140 O 0 2.7908603783544095e-07
DNA O 0 2.048417258038171e-08
sequences O 0 3.3823732703552878e-09
were O 0 1.1993148696376466e-09
found O 0 6.253969009328841e-10
in O 0 2.3321020115041335e-10
four O 0 2.496313822319962e-09
patients O 0 5.59875534822396e-10
with O 0 2.7758981779868463e-09
severe O 1 0.9999998807907104
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 2.9723696570727043e-05

These O 0 4.422046018248693e-08
findings O 0 4.47973924622147e-08
suggest O 0 1.0050248633319825e-08
that O 0 2.4234811379919563e-10
some O 0 1.7538476226874877e-10
sequences O 0 6.552631770517792e-09
located O 0 1.437776564472415e-08
in O 0 1.0698999464153758e-09
the O 0 6.880366942851879e-09
distal O 0 1.5188227564522094e-07
part O 0 5.506692879464481e-09
of O 0 2.3662193981976998e-08
the O 0 1.3216245875469212e-08
gene O 0 1.855622988600203e-09
and O 0 1.5785631135578626e-10
, O 0 1.2392836756802694e-10
in O 0 1.8680226809841827e-10
particular O 0 1.7017829367915738e-09
, O 0 5.903310618116109e-10
some O 0 2.6047273227192136e-09
DMD B-Disease 1 0.9999998807907104
isoforms O 0 1.351996026244251e-08
expressed O 0 6.886087255963957e-10
in O 0 4.759021510203354e-10
the O 0 6.534360164067721e-09
brain O 0 1.725745505609666e-06
may O 0 1.2860538189940485e-09
be O 0 3.7990671719612124e-10
related O 0 5.061511210158187e-09
to O 0 8.846331445155897e-10
the O 0 7.431568604943095e-08
cognitive B-Disease 1 0.7251852750778198
impairment I-Disease 0 0.0642123594880104
associated O 0 5.421888090495486e-06
with O 0 5.639433879878197e-07
DMD B-Disease 1 1.0
. O 0 1.2385515901769395e-07
. O 0 3.3284570122305013e-07

I1307K O 0 0.001124025322496891
APC O 0 2.959844277938828e-05
and O 0 3.8935649371296677e-08
hMLH1 O 0 1.1689429584293975e-06
mutations O 0 1.6131352253978548e-08
in O 0 3.243806778741032e-09
a O 0 2.8450200417751148e-08
non O 0 1.7088881349991425e-06
- O 0 2.653758429005393e-06
Jewish O 0 3.6429582905839197e-06
family O 0 4.951455423451989e-08
with O 0 1.86074089469912e-09
hereditary B-Disease 1 0.9999998807907104
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.022814273834228516

We O 0 5.813451480207732e-07
describe O 0 7.010594345047139e-07
a O 0 1.988883582271228e-07
French O 0 1.3105965308568557e-06
Canadian O 0 1.2618204891623463e-05
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
HNPCC B-Disease 1 1.0
) O 0 3.1080382996151457e-06
kindred O 0 9.462090929446276e-06
which O 0 2.2085300255270113e-09
carries O 0 1.0654976456692111e-08
a O 0 7.325760886800481e-09
novel O 0 5.394462831986857e-08
truncating O 0 1.468414552618924e-06
mutation O 0 3.39895649403843e-08
in O 0 4.7637485067753005e-08
hMLH1 O 0 7.233814812934725e-06
. O 0 5.505261810867523e-07

Interestingly O 0 4.371463091956684e-06
, O 0 1.266541183042591e-08
the O 0 5.060703500703312e-08
I1307K O 0 1.4155192729958799e-05
APC O 0 1.921601551657659e-06
polymorphism O 0 1.3405008303379873e-07
, O 0 3.9970549092771535e-10
associated O 0 1.6361640930995236e-09
with O 0 1.900366114471197e-10
an O 0 3.536585690966376e-09
increased O 0 4.494288674550262e-08
risk O 0 2.1450177882798016e-06
of O 1 0.999969482421875
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.09633713616131e-07
is O 0 2.651798336472666e-09
also O 0 2.1317259069064676e-10
present O 0 1.1221996665256029e-09
in O 0 5.217581477978683e-09
this O 0 1.7171670307902787e-08
family O 0 4.6229288841459493e-07
. O 0 1.275881373885568e-07

The O 0 5.484303073899355e-06
I1307K O 0 5.568543201661669e-05
polymorphism O 0 1.9046501620323397e-06
has O 0 1.5997966285041798e-09
previously O 0 3.299372997034311e-09
only O 0 3.6666375491378744e-10
been O 0 6.054252099652047e-10
identified O 0 2.077612526463213e-09
in O 0 5.496878507926795e-10
individuals O 0 5.464743102479019e-10
of O 0 6.071788760664276e-08
self O 0 6.025093171047047e-05
- O 0 2.3676882847212255e-05
reported O 0 7.031277391433832e-07
Ashkenazi O 0 2.7393243726692162e-06
Jewish O 0 8.579103791817033e-07
origins O 0 3.801075308729196e-06
. O 0 1.214837936913682e-07

In O 0 2.2816561795480084e-07
addition O 0 2.5373195100542034e-08
, O 0 2.97510061031403e-09
in O 0 3.851873042748366e-09
this O 0 3.111462421045985e-09
family O 0 2.6891243010140897e-08
, O 0 9.061230099582929e-10
there O 0 3.933084524732067e-09
appears O 0 1.7256182260894093e-08
to O 0 1.008438443861337e-09
be O 0 5.952621950910952e-09
no O 0 1.129639315422537e-08
relationship O 0 3.118605818031028e-08
between O 0 9.571539116848271e-09
the O 0 1.1156483736840528e-08
I1307K O 0 8.002340905477467e-07
polymorphism O 0 3.9723506262134833e-08
and O 0 1.488794920678771e-10
the O 0 1.411382011262674e-09
presence O 0 4.14244727409141e-09
or O 0 3.7341183478645235e-09
absence O 0 6.403003993682432e-08
of O 0 1.7143580635092803e-06
cancer B-Disease 0 3.548379390849732e-05
. O 0 4.6581384083310695e-08
. O 0 3.378191024694388e-07

Identification O 0 3.0760118079342647e-06
of O 0 1.1668785759866296e-07
a O 0 5.190031160395847e-08
novel O 0 5.5929870512727575e-08
mutation O 0 4.412775922446599e-09
of O 0 1.1308464387127515e-08
the O 0 5.8909890299219114e-08
CPO O 0 9.523084008833393e-05
gene O 0 2.5782696866372135e-08
in O 0 1.2982195762845095e-08
a O 0 2.875407290048315e-07
Japanese O 0 0.002479921095073223
hereditary B-Disease 1 0.9999995231628418
coproporphyria I-Disease 1 0.9999940395355225
family O 0 6.264080730034038e-05
. O 0 1.3058768217888428e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
( O 1 0.712279736995697
HCP B-Disease 1 1.0
) O 0 5.495751338457922e-07
is O 0 1.768485269337816e-08
an O 0 1.997062071268374e-07
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999991655349731
disease I-Disease 1 0.9961366057395935
characterized O 0 6.279602189351863e-07
by O 0 2.6475493797306626e-08
a O 0 8.135207849591097e-07
deficiency B-Disease 0 0.1788041889667511
of I-Disease 0 0.0004827574302908033
coproporphyrinogen I-Disease 1 0.9992409944534302
oxidase I-Disease 0 4.2967799345206e-06
( O 0 1.860731657643555e-07
CPO O 0 1.693867307039909e-05
) O 0 1.0460855293104032e-08
caused O 0 1.0619065626826796e-08
by O 0 9.061195682669165e-10
a O 0 1.2596053977631527e-08
mutation O 0 6.144624808968047e-09
in O 0 5.923175283584214e-09
the O 0 2.2223832729650894e-07
CPO O 0 0.0003942413895856589
gene O 0 2.126117806255934e-06
. O 0 4.504715604980447e-07

Only O 0 3.6410546044862713e-07
11 O 0 1.0222159119166463e-07
mutations O 0 6.970478860779394e-09
of O 0 9.4318313159647e-09
the O 0 1.4319526897565993e-08
gene O 0 6.360945103978111e-09
have O 0 1.7871025492777193e-10
been O 0 4.102659989513313e-09
reported O 0 4.716644141922188e-08
in O 0 7.5098533613982e-08
HCP B-Disease 1 1.0
patients O 0 3.3597600577195408e-06
. O 0 5.742473945247184e-07

We O 0 5.322856964085076e-07
report O 0 8.083124214408599e-08
another O 0 2.2553313883122428e-08
mutation O 0 5.0038315713152315e-09
in O 0 2.736408655223954e-09
a O 0 9.66154658499363e-08
Japanese O 0 1.7133714209194295e-05
family O 0 1.2407178928697249e-06
. O 0 3.8355560150193924e-07

Polymerase O 0 8.542579598724842e-05
chain O 0 1.7438346731069032e-06
reaction O 0 2.9734513518064887e-08
- O 0 6.66491928313917e-08
single O 0 1.3404312326770196e-08
strand O 0 4.1897607161445194e-08
conformational O 0 5.680248271744404e-09
polymorphism O 0 4.116329943570918e-09
and O 0 9.121257221744727e-11
direct O 0 6.876244018627631e-10
sequence O 0 5.750461440356958e-09
analyses O 0 1.546090722115423e-08
demonstrated O 0 1.2848040853441489e-08
a O 0 5.3008180067593e-09
C O 0 5.658094792693191e-08
to O 0 1.706512264831872e-09
T O 0 3.266126924472701e-08
substitution O 0 5.7544662368513855e-09
in O 0 5.861274132712424e-09
exon O 0 4.371594641838783e-08
1 O 0 3.811865489922184e-09
of O 0 4.687083166032835e-09
the O 0 3.3034236679441165e-08
CPO O 0 3.197435717083863e-06
gene O 0 1.2416034422813027e-08
at O 0 5.384091039672967e-08
nucleotide O 0 1.1931237509088533e-07
position O 0 2.4561229494679537e-08
85 O 0 2.3156026429660415e-08
, O 0 3.883251775693708e-10
which O 0 3.464074860293209e-10
lies O 0 3.8278013647641274e-08
in O 0 1.5948092846329587e-09
the O 0 1.1646756448158158e-08
putative O 0 1.191128944810771e-06
presequence O 0 1.4194757795849e-06
for O 0 7.677536828509801e-09
targeting O 0 6.327477564127548e-08
to O 0 1.5597274583001308e-08
mitochondria O 0 1.6368038586733746e-06
. O 0 2.5577816131772124e-07

This O 0 3.8244515110363864e-08
mutation O 0 3.149436711424869e-09
changes O 0 6.141973596385242e-10
the O 0 4.165368494568611e-09
codon O 0 6.382337147670114e-08
for O 0 1.8461618900289523e-09
glutamine O 0 3.737326537134322e-08
to O 0 1.551587747172789e-09
a O 0 1.8672409396458534e-08
termination O 0 2.1921137260960677e-07
codon O 0 5.158244107406063e-07
at O 0 1.9409351637023065e-07
amino O 0 1.5989607504707237e-07
acid O 0 8.46464587311857e-08
position O 0 3.36154045044168e-07
29 O 0 3.7335830711526796e-06
. O 0 5.111087943987513e-07

MaeI O 0 0.0018871549982577562
restriction O 0 1.507560796198959e-06
analysis O 0 2.8617154157473124e-07
showed O 0 3.0687811403140586e-08
two O 0 7.756899567112896e-10
other O 0 3.345682897393232e-10
carriers O 0 2.2704367275139248e-09
in O 0 3.4370533086303112e-09
the O 0 1.9447445254172635e-07
family O 0 3.262816790083889e-06
. O 0 6.296344849943125e-07

The O 0 1.0639445463311858e-05
C O 0 0.1760382503271103
- O 0 0.021915597841143608
T O 0 2.239343484689016e-05
mutation O 0 5.422777782371213e-09
is O 0 7.835651572030145e-10
located O 0 2.055492442920581e-09
within O 0 1.3039339608056366e-09
a O 0 2.028525125652436e-09
recently O 0 2.2188659798416666e-09
proposed O 0 1.6360049981400948e-09
putative O 0 3.725995156855788e-08
alternative O 0 2.3361186318737737e-09
translation O 0 3.3563217982646165e-08
initiation O 0 2.5050672647353167e-08
codon O 0 1.8335084561726944e-08
( O 0 2.244567420817134e-09
TIC O 0 1.3495322548351396e-07
- O 0 9.011492885235839e-09
1 O 0 6.08096550891446e-09
) O 0 4.380771856382637e-10
, O 0 6.630320598111084e-11
supporting O 0 3.986808216893678e-09
that O 0 1.0432157360185101e-09
TIC O 0 1.6913758145165048e-06
- O 0 6.985641221035621e-08
1 O 0 2.47655300711358e-08
is O 0 6.435468824506074e-10
the O 0 3.443392015967106e-09
real O 0 3.398743331217702e-07
TIC O 0 4.909657945972867e-06
rather O 0 2.4988779045997944e-08
than O 0 7.761550513407656e-09
TIC O 0 3.271123205195181e-06
- O 0 1.800733144818878e-07
2 O 0 4.825945865150061e-08
. O 0 6.205255864699666e-09
. O 0 4.688498123073259e-08

Human B-Disease 0 3.912417469109641e-06
complement I-Disease 0 1.9957795302616432e-05
factor I-Disease 1 0.8717584609985352
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.09700978547334671
with O 0 0.0016573049360886216
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.02116105519235134

This O 0 1.661955337795007e-07
study O 0 2.7457527806973303e-08
reports O 0 1.7700680032817218e-08
on O 0 2.090061013149125e-09
six O 0 1.0206583356264787e-09
cases O 0 7.198837082000864e-10
of O 0 5.594822027887858e-08
deficiency B-Disease 1 0.9973828196525574
in I-Disease 0 3.60920999753489e-08
the I-Disease 0 3.2557029072677324e-08
human I-Disease 0 2.5178750195919974e-09
complement I-Disease 0 4.083805738019919e-09
regulatory I-Disease 0 1.1579111003356957e-08
protein I-Disease 0 1.5773066408542036e-08
Factor I-Disease 0 1.0924249949084697e-07
H I-Disease 0 0.05929283797740936
( O 0 1.1766661422996094e-08
FH O 0 5.22367599842255e-06
) O 0 1.3572085122426358e-10
in O 0 3.828095132552001e-11
the O 0 1.5271502118441305e-10
context O 0 3.317920160839094e-09
of O 0 2.6552298137971775e-09
an O 0 7.606729468534468e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0005222369800321758

Five O 0 4.5230970613374666e-07
of O 0 3.2406418881691934e-08
the O 0 7.0941439389571315e-09
cases O 0 1.039327068852458e-09
were O 0 1.8450846406281585e-09
observed O 0 4.099148132041819e-09
in O 0 6.992926793181198e-10
children O 0 1.7413489539208626e-09
presenting O 0 9.034006609454082e-08
with O 0 2.539610477469978e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.004848560784012079
. O 0 5.744260306528304e-06

Two O 0 1.1547400191602719e-07
of O 0 4.231651473673992e-08
the O 0 2.7534831303910323e-08
children O 0 1.375326252883724e-08
exhibited O 0 4.370661201846815e-07
a O 0 1.5082165418789373e-06
homozygous O 0 2.4176068109227344e-05
deficiency O 1 0.5821456909179688
characterized O 0 1.0604092182120439e-07
by O 0 4.0050545102587876e-09
the O 0 1.682396799651542e-08
absence O 0 4.3967478546846905e-08
of O 0 2.7527217838496654e-08
the O 0 8.307066146073794e-09
150 O 0 1.1096256358200662e-08
- O 0 9.768310604840735e-09
kD O 0 1.3125516034051543e-06
form O 0 2.88609758314351e-09
of O 0 5.400114488907093e-08
Factor O 0 4.372059720481047e-06
H O 1 0.999313235282898
and O 0 4.241036410945753e-10
the O 0 1.1909763175665944e-09
presence O 0 2.175758240241521e-09
, O 0 1.7084231251907056e-10
upon O 0 5.551110238144474e-09
immunoblotting O 0 3.988780861163832e-07
, O 0 7.637295240670028e-10
of O 0 2.4504456241913886e-09
the O 0 3.6832097372041517e-09
42 O 0 3.4004742133220134e-08
- O 0 9.08435779933825e-08
kD O 0 9.137968299910426e-05
Factor O 0 1.4523616300721187e-05
H O 1 0.9998170733451843
- O 0 3.584793262234598e-07
like O 0 4.8208375069691556e-09
protein O 0 1.0644576775575842e-08
1 O 0 1.4530940006807214e-08
( O 0 2.7008890679525166e-09
FHL O 0 5.002679586141312e-07
- O 0 1.3507536422707744e-08
1 O 0 3.417618632539643e-09
) O 0 1.5199405623000928e-10
and O 0 3.541719348354455e-11
other O 0 2.612029481596778e-10
FH O 0 9.473476893617772e-06
- O 0 2.0274764267469436e-07
related O 0 1.700043981145427e-07
protein O 0 2.3857634801061067e-07
( O 0 2.460432035888971e-08
FHR O 0 5.972088547423482e-05
) O 0 2.0208950957112393e-08
bands O 0 4.139973839301092e-07
. O 0 2.7240014333074214e-07

Southern O 0 2.297342689416837e-06
blot O 0 2.1940641090623103e-06
and O 0 9.894508323782247e-09
PCR O 0 7.84527429686932e-08
analysis O 0 1.8728683048863104e-09
of O 0 1.013169659280777e-09
DNA O 0 1.1949133238431386e-08
of O 0 5.493024257674506e-09
one O 0 2.2643387165288686e-09
patient O 0 1.490947454385605e-08
with O 0 2.008719635071543e-09
homozygous O 0 1.915196435220423e-06
deficiency O 0 0.04720475524663925
ruled O 0 4.077565662896632e-08
out O 0 1.114843661831344e-09
the O 0 2.319451297694286e-09
presence O 0 6.637460581160326e-10
of O 0 2.755551564703751e-09
a O 0 1.0825796925573172e-09
large O 0 9.751253138290394e-10
deletion O 0 7.86878384673173e-09
of O 0 1.1044482661759503e-08
the O 0 1.0013705065148315e-07
FH O 0 0.0026852996088564396
gene O 0 9.710796611273054e-09
as O 0 6.765132898323145e-10
the O 0 6.752979064827969e-09
underlying O 0 1.6384641639888287e-05
defect O 0 1.530431404717092e-06
for O 0 1.641932811935476e-08
the O 0 1.730650728859473e-05
deficiency O 1 0.9999992847442627
. O 0 1.1203224858036265e-05

The O 0 3.225414388907666e-07
other O 0 2.069686422245809e-09
four O 0 2.8754598702107614e-09
children O 0 1.4503741541105342e-09
presented O 0 2.213566396847e-08
with O 0 3.381626356713241e-08
heterozygous O 0 3.367865792824887e-05
deficiency O 0 0.18533919751644135
and O 0 4.244291584853954e-09
exhibited O 0 1.4105708032730035e-06
a O 0 4.5477906951418845e-07
normal O 0 2.8193098842166364e-06
immunoblotting O 0 3.2673535770300077e-06
pattern O 0 1.3131948151112738e-07
of O 0 1.9329988276695076e-08
proteins O 0 9.086641661326667e-09
of O 0 4.38914867118001e-07
the O 0 9.292220056522638e-06
FH O 1 0.9999994039535522
family O 0 5.624943696602713e-06
. O 0 5.506968250301725e-07

Factor B-Disease 1 1.0
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.6676654723823958e-08
the O 0 1.1049012371699973e-08
only O 0 1.6366893618169343e-08
complement B-Disease 1 0.9999948740005493
deficiency I-Disease 1 1.0
associated O 0 0.0005580848082900047
with O 0 1.73331932273868e-06
HUS B-Disease 1 1.0
. O 0 1.2674393474298995e-05

These O 0 6.487668002819191e-08
observations O 0 7.766113299112476e-07
suggest O 0 7.133659352120958e-08
a O 0 1.1788270803947398e-08
role O 0 1.7758878811946488e-08
for O 0 7.811332025653428e-09
FH O 0 0.0002675863797776401
and O 0 4.5662563508130916e-08
/ O 0 4.497111513046548e-05
or O 0 3.6199105579726165e-07
FH O 0 0.004724674858152866
receptors O 0 2.0146220691685812e-08
in O 0 7.522863998410401e-10
the O 0 5.946402925616212e-09
pathogenesis O 0 0.00010734781972132623
of O 0 7.3698438427527435e-06
idiopathic O 1 0.9999991655349731
HUS B-Disease 1 1.0
. O 0 5.475150146594387e-07
. O 0 7.60339219141315e-07

Further O 0 6.748501135689366e-08
evidence O 0 9.997292949037728e-08
for O 0 2.1198631738883478e-09
a O 0 1.0966354047070581e-08
major O 0 2.0353859042643307e-08
ancient O 0 6.414234121621121e-06
mutation O 0 1.9084066025243374e-06
underlying O 1 0.9985703229904175
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.7373271172546083e-07
linkage O 0 2.3297372536035255e-05
disequilibrium O 0 1.2028653145534918e-05
studies O 0 1.5331083957903502e-08
in O 0 5.389839685676634e-10
the O 0 2.4889206251543783e-09
Japanese O 0 3.804386778938351e-07
population O 0 3.1715721160452404e-09
. O 0 1.3938678655733838e-08

The O 0 0.0004111572925467044
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9613682627677917
DM B-Disease 1 1.0
) O 0 5.26811341217126e-08
mutation O 0 2.8303832610987456e-09
is O 0 4.888698335037134e-10
an O 0 3.121032099429044e-09
unstable O 0 4.106321284780279e-06
( O 0 1.043839233716426e-06
CTG O 0 0.026460517197847366
) O 0 4.501580619376e-08
n O 0 1.4924547997452464e-07
repeat O 0 9.621016516803138e-08
, O 0 1.665347526547123e-09
present O 0 2.022036404980554e-08
at O 0 1.3495167650035e-07
a O 0 9.197610673084e-09
copy O 0 2.6111255380101284e-08
number O 0 8.003266938061415e-10
of O 0 4.71932359857874e-09
5 O 0 1.0982136089410233e-08
- O 0 1.749245726045956e-08
37 O 0 9.022672387004604e-09
repeats O 0 5.895842036807153e-09
on O 0 2.4111947993787908e-09
normal O 0 3.890608279988328e-09
chromosomes O 0 1.079534239778468e-09
but O 0 5.2538664391255097e-11
amplified O 0 6.976996758112364e-09
to O 0 7.649585409552628e-10
50 O 0 9.640447551362286e-09
- O 0 3.419935268311747e-08
3000 O 0 9.54752863435715e-08
copies O 0 3.085813915504332e-08
on O 0 1.8924706068901287e-07
DM B-Disease 1 0.9999405145645142
chromosomes O 0 2.8308679702604422e-06
. O 0 1.8571471116501925e-07

Previous O 0 2.5169940727209905e-06
findings O 0 2.055927410538061e-07
in O 0 1.7507545635453425e-08
Caucasian O 0 1.3306922710398794e-06
populations O 0 8.171791243682947e-09
of O 0 1.2451447162220575e-07
a O 0 2.0267592844902538e-05
DM B-Disease 1 1.0
founder O 0 0.2310282289981842
chromosome O 0 7.688012374273967e-06
raise O 0 2.6300892130848297e-08
a O 0 9.544357304491768e-09
question O 0 1.136975757987102e-08
about O 0 9.155249891534822e-10
the O 0 3.596083875123668e-09
molecular O 0 3.705223505789945e-08
events O 0 3.83921339164317e-09
involved O 0 7.690521997005817e-09
in O 0 2.406416399480804e-09
the O 0 1.6317301287926966e-08
expansion O 0 6.61486808439804e-07
mutation O 0 1.5864947044974542e-07
. O 0 1.8584262306831079e-07

To O 0 2.445400468786829e-07
investigate O 0 4.7619226961614913e-07
whether O 0 5.66635698362461e-08
a O 0 1.5158259714098676e-07
founder O 0 2.7993237381451763e-06
chromosome O 0 2.637172826780443e-07
for O 0 5.194861429913544e-09
the O 0 1.289511260438303e-06
DM B-Disease 1 1.0
mutation O 0 1.299666330112359e-08
exists O 0 1.8596516548896602e-09
in O 0 1.197458243673566e-10
the O 0 4.6137457743178345e-10
Japanese O 0 2.9322977823653673e-08
population O 0 4.8288296972121e-11
, O 0 2.768160006771936e-11
we O 0 5.874724040566548e-10
genotyped O 0 2.5092475652854773e-07
families O 0 8.191153311187804e-10
using O 0 2.101445462088236e-09
polymorphic O 0 9.945899215324516e-09
markers O 0 4.194174252347693e-08
near O 0 2.9887016239626973e-07
the O 0 6.15936457393218e-08
( O 0 1.7349553615986224e-07
CTG O 0 0.000558963161893189
) O 0 1.5186062185534865e-08
n O 0 3.5593320291127384e-08
repeat O 0 6.602087410101376e-08
region O 0 3.4093709189164656e-08
and O 0 2.2514161202025207e-08
constructed O 0 5.134409366291948e-05
haplotypes O 0 6.373036012519151e-05
. O 0 1.0398390486443532e-06

Six O 0 3.1415137868862075e-07
different O 0 5.3299555879959826e-09
haplotypes O 0 1.9799604444870056e-07
were O 0 9.2061407386268e-09
found O 0 1.3440923041230235e-08
and O 0 4.190519931057679e-08
DM B-Disease 1 1.0
alleles O 0 1.1032864932758457e-07
were O 0 7.167564319843223e-08
always O 0 4.805985440725635e-07
haplotype O 0 3.6518420074571623e-06
A O 0 6.640342235186836e-06
. O 0 1.0169609367949306e-06

To O 0 9.832297820366875e-08
find O 0 6.089743465054198e-08
an O 0 3.6835958727721163e-09
origin O 0 1.0967734276334795e-08
of O 0 4.54821105222436e-08
the O 0 7.939463131378943e-08
( O 0 3.4170474805250706e-07
CTG O 0 0.00040494700078852475
) O 0 1.7863410306517835e-08
n O 0 4.3195271359763865e-08
repeat O 0 1.4489812905083e-08
mutation O 0 7.83370868173705e-10
and O 0 9.532231254327783e-11
to O 0 1.3971962475878286e-10
investigate O 0 6.9393584212207315e-09
the O 0 4.820800647564738e-09
mechanism O 0 1.3038679469445924e-07
of O 0 1.1279190026414199e-08
the O 0 2.0656480970160374e-09
expansion O 0 3.934262693405799e-09
mutation O 0 1.26377450171411e-10
in O 0 3.588406308208114e-11
the O 0 2.777797991626585e-10
Japanese O 0 2.1596676447188656e-08
population O 0 2.0277413428915203e-11
we O 0 4.9821514969128344e-11
have O 0 3.1444697540239375e-11
studied O 0 4.825106092454234e-09
90 O 0 1.521845049978765e-08
Japanese O 0 4.449256266525481e-06
DM B-Disease 1 1.0
families O 0 1.1959843115860735e-09
comprising O 0 3.039901441681536e-09
190 O 0 5.979431616509601e-09
affected O 0 2.5078661369803967e-10
and O 0 1.35313482640953e-10
130 O 0 1.3111545626998122e-08
unaffected O 0 1.1976655400758318e-07
members O 0 1.2188992037920343e-08
. O 0 6.893439774557919e-08

The O 0 8.627594638710434e-07
results O 0 1.292368523309051e-07
suggest O 0 7.496372234072624e-08
that O 0 7.424307835179889e-10
a O 0 4.18888745912227e-09
few O 0 2.313874869486199e-09
common O 0 2.7499547083920106e-09
ancestral O 0 9.3228453579286e-07
mutations O 0 1.7217871572938748e-09
in O 0 1.2140168870189427e-09
both O 0 1.4589363050987458e-09
Caucasian O 0 9.346275078314648e-07
and O 0 1.049810793851691e-09
Japanese O 0 8.604390586697264e-07
populations O 0 7.23036297500812e-10
have O 0 3.693821984396273e-11
originated O 0 1.2231722301692116e-09
by O 0 1.7414741870780404e-10
expansion O 0 6.144273090313845e-09
of O 0 6.192297785645451e-09
an O 0 9.422732816233292e-09
ancestral O 0 6.701151846755238e-07
n O 0 1.8963567072205478e-07
= O 0 1.4764026445845957e-07
5 O 0 1.264870519435135e-08
repeat O 0 7.2869088540983284e-09
to O 0 2.1364201518991877e-09
n O 0 2.0798941591237963e-07
= O 0 2.959595519769209e-07
19 O 0 8.404863649502659e-08
- O 0 9.079698060077135e-08
37 O 0 5.8969806815412085e-08
copies O 0 1.1451693637809512e-07
. O 0 6.87775880692243e-08

These O 0 8.710618715213059e-08
data O 0 7.459886575134078e-08
support O 0 4.834188604974088e-09
multistep O 0 2.253208037927834e-07
models O 0 1.9510897786290116e-08
of O 0 6.726166645876219e-08
triplet O 0 7.592605015815934e-06
repeat O 0 1.9781560922638164e-07
expansion O 0 8.942153328916902e-08
that O 0 2.9124291867077545e-10
have O 0 1.0587142273976724e-10
been O 0 3.759227928945563e-10
proposed O 0 6.138179409198585e-10
for O 0 1.1569037949854533e-09
both O 0 5.1433399761435794e-08
DM B-Disease 1 1.0
and O 0 1.6321851035172585e-06
Friedreichs B-Disease 1 0.9999845027923584
ataxia I-Disease 0 0.20731225609779358
. O 0 2.5002182724165323e-07
. O 0 4.117196397146472e-07

The O 0 7.262490271386923e-07
molecular O 0 1.5489974884985713e-06
basis O 0 1.7074496554414509e-06
of O 0 0.022143041715025902
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.822607273055837e-08
the O 0 1.4223492605935917e-08
western O 0 1.8508943711026404e-08
Cape O 0 1.3185118064029666e-07
, O 0 3.494543543425266e-09
South O 0 1.6869877583758353e-07
Africa O 0 1.7927960982433433e-07
. O 0 3.485841943984269e-07

Deficiency B-Disease 1 0.9999998807907104
of I-Disease 0 2.3390695787384175e-05
the I-Disease 0 1.0176166824749089e-06
sixth I-Disease 0 1.30335401991033e-05
component I-Disease 0 7.213052413135301e-06
of I-Disease 0 1.6377565259517723e-07
human I-Disease 0 5.115320078630248e-08
complement I-Disease 0 4.925721555082418e-07
( O 0 7.901903700258117e-07
C6 O 0 0.003249354660511017
) O 0 3.9004754981419865e-09
has O 0 1.7203780067198693e-10
been O 0 5.139432213141504e-10
reported O 0 1.1395283605608597e-09
in O 0 1.9678912666076798e-10
a O 0 6.253635387309942e-10
number O 0 3.6186775798086046e-10
of O 0 2.531068243882828e-09
families O 0 4.4209957916763187e-10
from O 0 7.703466753383736e-10
the O 0 4.003206210967392e-09
western O 0 1.1479932560121142e-08
Cape O 0 2.3739910659514862e-07
, O 0 3.037218254675622e-09
South O 0 2.0943645040460979e-07
Africa O 0 8.641842441647896e-08
. O 0 1.1074693873069918e-07

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9999325275421143
is O 0 7.210469021856625e-08
endemic O 0 6.05828915922757e-08
in O 0 1.3912508922686584e-09
the O 0 3.951032390148157e-09
Cape O 0 1.0995847787853563e-07
and O 0 5.613897124945311e-10
almost O 0 2.4689865707472336e-09
all O 0 4.691141364254747e-10
pedigrees O 0 8.817028884777756e-08
of O 0 8.7087080657966e-08
total O 0 0.00012433961092028767
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 9.79551623458974e-06
C6Q0 O 1 0.9998624324798584
) O 0 2.6951820775167334e-09
have O 0 7.591600958978262e-11
been O 0 7.572529825417007e-10
ascertained O 0 8.069230261753546e-08
because O 0 3.340557830355806e-09
of O 0 2.9867752004975046e-07
recurrent O 1 0.9998296499252319
disease O 1 0.9942800998687744
. O 0 2.200841663579922e-06

We O 0 2.542271033689758e-07
have O 0 3.1885127871333907e-09
sequenced O 0 5.5596963477455574e-08
the O 0 1.1846513991997654e-08
expressed O 0 7.053976514015403e-09
exons O 0 1.0074376177726663e-07
of O 0 2.7480265174517626e-08
the O 0 1.635564927937594e-07
C6 O 0 5.205144043429755e-05
gene O 0 1.0532322791689808e-09
from O 0 1.0817019502340486e-10
selected O 0 1.643895991554345e-10
cases O 0 1.3650854058244732e-10
and O 0 1.067282373590217e-10
have O 0 1.2107927160887044e-10
found O 0 2.136892884863073e-09
three O 0 1.198739152385997e-08
molecular O 0 0.0012891575461253524
defects O 0 0.001763496664352715
leading O 0 1.7302214416758943e-07
to O 0 8.311615395939498e-09
total O 0 2.7037594918510877e-05
deficiency O 1 0.9999996423721313
879delG O 0 0.00028496613958850503
, O 0 2.248299324492109e-09
which O 0 2.858855652210224e-10
is O 0 2.7182367468014945e-10
the O 0 1.1194206672726636e-09
common O 0 5.513555834113504e-09
defect O 0 1.259844850665104e-07
in O 0 1.8449931582509294e-09
the O 0 2.620145522769235e-08
Cape O 0 1.5512918025706313e-06
and O 0 1.7850595446233797e-09
hitherto O 0 7.599600166940945e-07
unreported O 0 6.745123073415016e-07
, O 0 3.46085854419087e-10
and O 0 2.139142751822476e-10
1195delC O 0 4.6725450175699734e-08
and O 0 9.457622462960558e-10
1936delG O 0 2.8295164611336077e-07
, O 0 7.533834112116722e-10
which O 0 1.479865535669589e-10
have O 0 2.547484619086493e-11
been O 0 5.574492534243802e-10
previously O 0 3.4684797256545608e-09
reported O 0 2.861759496042282e-09
in O 0 1.3940240073395671e-09
African O 0 1.1538703859059751e-07
- O 0 6.880572414047492e-07
Americans O 0 1.1115536580064145e-07
. O 0 1.5274962095190858e-07

We O 0 6.100735845393501e-07
also O 0 3.812682081161256e-08
show O 0 2.029431556138661e-08
that O 0 4.767870542821129e-10
the O 0 5.580314432762634e-09
879delG O 0 3.5881041071661457e-07
and O 0 1.7475917601927904e-08
1195delC O 0 6.140792538644746e-05
defects O 0 2.2142681700643152e-05
are O 0 1.0325438282166033e-09
associated O 0 4.3549004402620994e-08
with O 0 9.70707514369451e-09
characteristic O 0 0.45187002420425415
C6 O 1 1.0
/ O 1 0.9999666213989258
C7 O 1 0.9842289686203003
region O 0 2.7720747652892896e-07
DNA O 0 1.8396989389657392e-06
marker O 0 2.3668361848194763e-07
haplotypes O 0 6.519411499539274e-08
, O 0 1.034784966047475e-10
although O 0 1.6981764605628058e-10
small O 0 2.2946587685535036e-10
variations O 0 2.774791729720505e-09
were O 0 1.4705507034307175e-08
observed O 0 1.7166127008749754e-07
. O 0 2.727848880113015e-07

The O 0 1.0728464985731989e-05
1936delG O 0 0.0001571438042446971
defect O 0 6.82658574078232e-05
was O 0 4.827078328162315e-07
observed O 0 4.169567446865585e-08
only O 0 1.6839757366327035e-09
once O 0 5.704938743633647e-09
in O 0 1.002829930207838e-09
the O 0 5.013480297577644e-09
Cape O 0 3.4604306620167335e-07
, O 0 1.4538888981618925e-09
but O 0 3.178910745749164e-10
its O 0 5.999489238739386e-10
associated O 0 3.193170172721693e-08
haplotype O 0 1.5096168226591544e-07
could O 0 4.041366352680598e-09
be O 0 3.835357986758936e-08
deduced O 0 1.931357655848842e-05
. O 0 7.571250080218306e-07

The O 0 8.59589363244595e-07
data O 0 2.1429045204968133e-07
from O 0 4.9254555989364235e-09
the O 0 7.709703098157661e-09
haplotypes O 0 3.447643166509806e-07
indicate O 0 6.29783158956343e-09
that O 0 4.832819214262152e-11
these O 0 1.7923253159413122e-10
three O 0 2.480305072438682e-09
molecular O 0 5.430146757134935e-06
defects O 0 2.86164618046314e-06
account O 0 1.939720561949798e-08
for O 0 3.5230871553437737e-09
the O 0 3.0937704309508263e-07
defects O 0 5.901468830415979e-05
in O 0 4.0780845367294205e-09
all O 0 1.701643270735076e-09
the O 0 2.5452832730366026e-08
38 O 0 2.0496509023359977e-07
unrelated O 0 4.227799195177795e-07
C6Q0 O 0 0.0020277241710573435
individuals O 0 3.916750035415362e-09
we O 0 2.572732249461751e-09
have O 0 3.171455598138806e-10
studied O 0 3.159438222155586e-08
from O 0 8.081240565616099e-09
the O 0 7.734273310688877e-08
Cape O 0 4.999898010282777e-06
. O 0 1.8483584085515758e-07

We O 0 1.6007059855382977e-07
have O 0 2.416166600127667e-09
also O 0 7.212704877801457e-10
observed O 0 7.645883925988528e-09
the O 0 2.48208582576126e-08
879delG O 0 2.0821021280426066e-06
defect O 0 5.012947781324328e-07
in O 0 4.8087702708699e-09
two O 0 1.4498217737468622e-08
Dutch O 1 0.9585315585136414
C6 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
kindreds O 0 2.3370628696284257e-05
, O 0 2.5735271691473827e-09
but O 0 7.425709491748478e-10
the O 0 1.2667489279749589e-08
879delG O 0 2.795868567773141e-06
defect O 0 9.538043741486035e-07
in O 0 6.150346898436965e-09
the O 0 2.6275522202467982e-08
Cape O 0 2.453001343383221e-06
probably O 0 6.650036254995939e-08
did O 0 5.312508655208603e-09
not O 0 6.337110280973945e-10
come O 0 1.2467952226202783e-09
from O 0 2.69593258828138e-09
The O 0 4.700532585388828e-08
Netherlands O 0 1.3529303544146387e-07
. O 0 3.5019848354522765e-08
. O 0 1.7925619033576368e-07

Complement B-Disease 1 0.9999997615814209
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 8.910384252658332e-08
seven O 0 2.1006689721048133e-08
further O 0 2.7692310666793674e-08
molecular O 0 8.324036753037944e-05
defects O 0 1.3086134458717424e-05
and O 0 1.403719918080526e-09
their O 0 1.05787147930414e-08
associated O 0 2.1266655494400766e-06
marker O 0 1.5772331607877277e-05
haplotypes O 0 1.553577749291435e-05
. O 0 5.178151241125306e-07

Seven O 0 1.6864712506503565e-06
further O 0 1.0886954271427385e-07
molecular O 0 3.7210638765827753e-06
bases O 0 1.2944396985403728e-06
of O 0 0.40033844113349915
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.3848891689558513e-07
described O 0 2.0276384020689875e-06
. O 0 4.410186704717489e-07

All O 0 1.7715709788035383e-08
these O 0 9.945704260161392e-10
new O 0 4.359211214222114e-09
molecular O 0 5.267081178317312e-06
defects O 0 3.0749970392207615e-06
involve O 0 9.414436874521925e-08
single O 0 2.1884959267026716e-07
- O 0 1.091329068003688e-06
nucleotide O 0 1.377601961394248e-06
events O 0 9.585258808897379e-09
, O 0 1.900967994128422e-10
deletions O 0 1.7349967018631673e-09
and O 0 1.6295606530825069e-10
substitutions O 0 2.6712616563173697e-09
, O 0 5.713058914835756e-10
some O 0 7.86412879261178e-10
of O 0 1.5145102949531974e-08
which O 0 3.0894404812187304e-09
alter O 0 1.3898504391818278e-07
splice O 0 5.535222271646489e-07
sites O 0 1.6943635827715298e-08
, O 0 9.998886163486986e-10
and O 0 3.9781107297187646e-09
others O 0 6.540921049236204e-08
codons O 0 2.3816928660380654e-06
. O 0 9.9301291811571e-07

They O 0 2.676556754011017e-08
are O 0 7.896926446093744e-10
distributed O 0 2.2520334486131333e-09
along O 0 1.2020659134748257e-08
the O 0 6.705838728748859e-08
C7 O 0 0.00015922494640108198
gene O 0 9.671794032328762e-09
, O 0 1.7995153978045408e-10
but O 0 1.0245685549969963e-10
predominantly O 0 4.16559703397823e-10
towards O 0 5.651997536659792e-09
the O 0 4.253757346361908e-09
3 O 0 4.427430155828915e-08
end O 0 2.133593568487413e-07
. O 0 1.5974836742316256e-07

All O 0 4.062172109797757e-08
were O 0 2.6977138745110096e-08
found O 0 1.1121003673508767e-08
in O 0 7.131207180322008e-09
compound O 0 1.7076647509384202e-06
heterozygous O 0 8.501861969989477e-08
individuals O 0 1.0238995429290298e-08
. O 0 1.2548638039788784e-07

The O 0 0.00023815015447326005
C6 O 1 0.9999990463256836
/ O 1 0.9369332790374756
C7 O 0 0.2211536020040512
marker O 0 7.327229013753822e-06
haplotypes O 0 2.760809366009198e-06
associated O 0 7.798964674066156e-08
with O 0 4.571961920163403e-09
most O 0 1.4147576621326152e-07
C7 B-Disease 1 0.9999992847442627
defects I-Disease 0 0.020490363240242004
are O 0 6.274989861054792e-09
tabulated O 0 1.408025582350092e-05
. O 0 2.4702367795725877e-07
. O 0 8.080394309217809e-07

A O 0 4.75437218483421e-06
genome O 0 3.3550870170984126e-07
- O 0 6.066232316470632e-08
wide O 0 1.2496791157445841e-08
search O 0 3.9262733508849124e-08
for O 0 1.7108304772861516e-09
chromosomal O 0 3.6274998365115607e-06
loci O 0 1.2078695021955355e-07
linked O 0 9.055378313860274e-07
to O 0 6.168274335749402e-09
mental O 1 0.999988317489624
health O 0 1.1549724149517715e-05
wellness O 0 6.72598835080862e-05
in O 0 2.899046336324318e-09
relatives O 0 6.822632236946902e-09
at O 0 1.4299330608480432e-08
high O 0 4.501091055431061e-08
risk O 0 2.459672714394401e-07
for O 0 1.453728373235208e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
among O 0 3.189165553862949e-08
the O 0 2.343857516962089e-07
Old O 0 2.6507701477385126e-05
Order O 0 4.760451872698468e-07
Amish O 0 3.358903995831497e-05
. O 0 4.7537011482745584e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 1.0
BPAD B-Disease 1 1.0
; O 1 0.9999977350234985
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.176806098461384e-06
is O 0 7.782482214224729e-09
characterized O 0 1.023155693502531e-08
by O 0 2.3315158692582827e-09
episodes O 0 9.741502537963243e-08
of O 0 1.0694750471884618e-06
mania B-Disease 0 0.0007253726944327354
and O 0 7.145688414311735e-06
/ O 1 1.0
or O 1 0.9337390661239624
hypomania B-Disease 1 1.0
interspersed O 0 0.0003738364321179688
with O 0 2.220908079664241e-08
periods O 0 0.0002553380618337542
of O 0 0.009342186152935028
depression B-Disease 1 0.9999997615814209
. O 0 1.5982221157173626e-05

Compelling O 0 5.894899913982954e-06
evidence O 0 5.243363148110802e-07
supports O 0 2.2699138568782473e-08
a O 0 2.636245666209902e-09
significant O 0 2.7086377585305854e-09
genetic O 0 1.5927003715887622e-08
component O 0 8.65573284158927e-08
in O 0 1.5468215597280732e-09
the O 0 2.4255275121731756e-08
susceptibility O 0 2.8003998409076303e-07
to O 0 2.913976793195161e-08
develop O 0 1.0131072485819459e-05
BPAD B-Disease 1 1.0
. O 0 1.1478112355689518e-05

To O 0 5.3828898671781644e-08
date O 0 1.7487346326561237e-07
, O 0 1.5824889176840884e-09
however O 0 1.4747379983859332e-09
, O 0 9.940166467714562e-10
linkage O 0 9.991803295861246e-08
studies O 0 4.091968985875383e-09
have O 0 7.11061001745783e-11
attempted O 0 6.35611829835625e-09
only O 0 2.023994583044697e-10
to O 0 2.8586702449651114e-10
identify O 0 1.4424653471678539e-08
chromosomal O 0 5.1680603974091355e-06
loci O 0 6.11875705658349e-08
that O 0 4.919087914778686e-10
cause O 0 2.4830518086105258e-08
or O 0 3.0458155997337144e-09
increase O 0 1.0112852777410808e-09
the O 0 9.346765139639501e-09
risk O 0 8.031197751279251e-08
of O 0 6.319318117675721e-07
developing O 0 3.4582863008836284e-05
BPAD B-Disease 1 1.0
. O 0 5.017604962631594e-06

To O 0 3.0615549206913784e-08
determine O 0 2.6283341725275022e-08
whether O 0 4.9677328917141494e-09
there O 0 5.576781703098277e-09
could O 0 2.459173309432572e-09
be O 0 3.755281419159928e-09
protective O 0 8.269509521596774e-08
alleles O 0 1.6020164084196153e-09
that O 0 8.3682206997171e-11
prevent O 0 1.90094717744671e-09
or O 0 2.095098095011849e-09
reduce O 0 1.8721684202915867e-09
the O 0 5.6924602809260705e-09
risk O 0 8.09928266676252e-08
of O 0 6.229343085806249e-08
developing O 0 1.0662624845281243e-05
BPAD B-Disease 1 1.0
, O 0 8.575434251589797e-10
similar O 0 4.837633765797378e-11
to O 0 3.994933897577546e-11
what O 0 8.709708648746428e-11
is O 0 5.393251123475551e-11
observed O 0 4.398572062136452e-10
in O 0 1.1604171096246674e-10
other O 0 8.334392065378893e-10
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.1457475796182734e-09
we O 0 3.6941922854083487e-09
used O 0 1.391348973811546e-07
mental O 1 0.999110996723175
health O 0 8.397137776228192e-07
wellness O 0 1.0061708962894045e-05
( O 0 1.7572976407365104e-09
absence O 0 3.4865808018480493e-09
of O 0 2.504621621213232e-09
any O 0 1.3433567147558279e-08
psychiatric B-Disease 1 0.9933127760887146
disorder I-Disease 0 0.0013742271112278104
) O 0 5.069018094161493e-09
as O 0 1.977351171689179e-09
the O 0 5.804324576530462e-09
phenotype O 0 1.99373868525754e-08
in O 0 1.0212367618223084e-09
our O 0 8.381023874903804e-09
genome O 0 1.7996717005530627e-08
- O 0 2.744684479694115e-08
wide O 0 2.7357472731637245e-08
linkage O 0 3.7728011648141546e-07
scan O 0 4.140174425515397e-08
of O 0 5.812489600742765e-09
several O 0 1.1919785158909235e-09
large O 0 1.1377979447502184e-08
multigeneration O 0 2.7923835659748875e-05
Old O 0 4.414046543388395e-06
Order O 0 1.5478735804208554e-07
Amish O 0 4.2524884520389605e-06
pedigrees O 0 3.0451991506197373e-07
exhibiting O 0 3.177307661417217e-08
an O 0 4.041720735870058e-09
extremely O 0 5.162407035186334e-08
high O 0 3.5470253578751e-07
incidence O 0 2.7548454454517923e-05
of O 0 3.4937755117425695e-05
BPAD B-Disease 1 1.0
. O 0 1.011576023302041e-05

We O 0 9.16465765499197e-08
have O 0 1.0720244691952985e-09
found O 0 3.325072661652939e-09
strong O 0 1.7803127860815948e-09
evidence O 0 2.0743113893217924e-08
for O 0 3.009481330806807e-09
a O 0 1.2948197536388761e-07
locus O 0 2.887671826101723e-07
on O 0 2.4406281440292332e-08
chromosome O 0 5.384870860325464e-07
4p O 0 0.0004241525020916015
at O 0 2.2698070551996352e-06
D4S2949 O 0 3.5081905025435844e-06
( O 0 2.560206802115772e-08
maximum O 0 5.455636298279387e-08
GENEHUNTER O 0 1.0416045370220672e-05
- O 0 3.5492487882038404e-07
PLUS O 0 4.852921620113193e-07
nonparametric O 0 1.5128724726309883e-06
linkage O 0 3.1306569781008875e-07
score O 0 2.5964848049397915e-08
= O 0 7.234397969568818e-08
4 O 0 9.714297810603512e-09
. O 0 1.2247666214548758e-09
05 O 0 3.2108732739288826e-07
, O 0 4.563545985547535e-09
P O 0 1.2714602917185402e-06
= O 0 6.637390015384881e-08
5 O 0 4.51409665203073e-09
. O 0 1.8570808779649894e-10
22 O 0 1.272361327409044e-09
x O 0 3.31029070821387e-09
10 O 0 1.4739619524917202e-09
( O 0 5.313306461474099e-10
- O 0 3.06659098114892e-09
4 O 0 6.120879803006574e-09
) O 0 6.373985228513845e-10
; O 0 5.848015960374653e-10
SIBPAL O 0 1.605992110853549e-06
Pempirical O 0 2.0087454686290585e-06
value O 0 6.496954796375576e-08
< O 0 3.713437379815332e-08
3 O 0 1.0568282915457416e-09
x O 0 1.50594292591677e-09
10 O 0 4.4626616291232324e-10
( O 0 2.841730739611137e-10
- O 0 7.815396663168883e-10
5 O 0 1.1582949044353086e-09
) O 0 1.6529667912212886e-10
) O 0 3.9649037525402164e-11
and O 0 1.337010103324987e-11
suggestive O 0 5.127430036111491e-09
evidence O 0 5.739536845794646e-09
for O 0 1.2276715199988075e-09
a O 0 2.8847340516335862e-08
locus O 0 1.7053164924618613e-07
on O 0 3.151024685621451e-08
chromosome O 0 1.5857414155107108e-06
4q O 0 1.0616902727633715e-05
at O 0 3.020391829977598e-07
D4S397 O 0 2.6942025215248577e-06
( O 0 2.4725789415924737e-08
maximum O 0 1.230476271985026e-07
GENEHUNTER O 0 2.7727866836357862e-05
- O 0 6.680471074105299e-07
PLUS O 0 5.906075557504664e-07
nonparametric O 0 2.184249524361803e-06
linkage O 0 3.094537817105447e-07
score O 0 2.738002358171343e-08
= O 0 1.581783592996544e-08
3 O 0 2.7843982675079815e-09
. O 0 1.443113406551788e-10
29 O 0 3.817249627502406e-09
, O 0 9.729610450648352e-10
P O 0 3.9922289829519286e-07
= O 0 3.888443700361677e-08
2 O 0 2.3859141329296563e-09
. O 0 1.0878345446663218e-10
57 O 0 1.0495464497495277e-09
x O 0 1.4157498506861543e-09
10 O 0 3.7083591752917755e-10
( O 0 3.242691393179342e-10
- O 0 3.2201226130013083e-09
3 O 0 3.41559824867943e-09
) O 0 1.2614967959123646e-09
; O 0 3.857760499936802e-10
SIBPAL O 0 3.834294147964101e-06
Pempirical O 0 1.649446403462207e-06
value O 0 4.1473825262983155e-08
< O 0 2.841083102111952e-08
1 O 0 6.278470521259294e-10
x O 0 1.0650784698640337e-09
10 O 0 3.030330708586604e-10
( O 0 1.0075573014800554e-10
- O 0 3.538108694911557e-10
3 O 0 4.698547106940509e-10
) O 0 9.007703610786066e-11
) O 0 1.3085692252001735e-11
that O 0 6.552771780049538e-12
are O 0 4.671602341077552e-11
linked O 0 1.2737897847614477e-08
to O 0 4.9544666147482985e-09
mental O 1 0.99907386302948
health O 0 6.836247484898195e-05
wellness O 0 0.00704794330522418
. O 0 6.504593557110638e-07

These O 0 2.1795308668970392e-08
findings O 0 2.1410144768196915e-08
are O 0 3.507088508492018e-10
consistent O 0 5.241870049133013e-09
with O 0 4.976632994591057e-11
the O 0 1.1916669873102137e-09
hypothesis O 0 3.4973908213942195e-09
that O 0 1.5951543905212695e-11
certain O 0 1.1455249249170407e-10
alleles O 0 1.3790180108941286e-10
could O 0 2.4741000914652034e-10
prevent O 0 2.6828572696757647e-09
or O 0 2.1937434091512387e-09
modify O 0 3.2335458755028412e-09
the O 0 6.6389578279313355e-09
clinical O 0 1.4709148672409356e-06
manifestations O 0 4.3306081352056935e-06
of O 0 6.656743789790198e-05
BPAD B-Disease 1 1.0
and O 0 6.144905917437882e-09
perhaps O 0 7.2087340541315825e-09
other O 0 1.5353579518873062e-09
related O 0 8.104620064841583e-06
affective B-Disease 1 0.9998224377632141
disorders I-Disease 1 0.9999998807907104
. O 0 5.239402071310906e-06

Segregation O 0 0.005744608119130135
distortion O 0 0.043609846383333206
in O 0 5.309958214638755e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.4460248823743314e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999678134918213
DM B-Disease 1 1.0
) O 0 9.825884035308263e-07
is O 0 1.664119331223901e-08
an O 0 5.4593733977981174e-08
autosomal B-Disease 1 0.9887257218360901
dominant I-Disease 1 0.9941596984863281
disease I-Disease 0 0.05036626756191254
which O 0 1.0460570187831308e-09
, O 0 4.451660706727978e-10
in O 0 1.5120503737975355e-09
the O 0 1.3691884959143863e-08
typical O 0 1.2068395562891965e-06
pedigree O 0 2.6691827770264354e-07
, O 0 2.2884522055122147e-10
shows O 0 1.0047290777137619e-09
a O 0 1.3601297865761808e-09
three O 0 9.79311742810296e-10
generation O 0 1.5319426438509254e-07
anticipation O 0 1.8109938082488952e-06
cascade O 0 5.0517373892944306e-05
. O 0 1.278755348721461e-06

This O 0 7.438899984890668e-08
results O 0 8.131014084256094e-08
in O 0 1.7489163894879312e-07
infertility B-Disease 1 0.9999946355819702
and O 0 0.0003782952844630927
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.745955765247345
CDM B-Disease 1 0.9898908138275146
) O 0 2.7356101828246437e-09
with O 0 1.6996734575336347e-10
the O 0 1.8172148230632956e-08
disappearance O 0 5.416771273303311e-06
of O 0 1.8858847397495992e-05
DM B-Disease 1 1.0
in O 0 7.968483259901404e-07
that O 0 9.776851328524572e-08
pedigree O 0 3.2340034522349015e-05
. O 0 1.0306671356374864e-06

The O 0 9.519686727799126e-07
concept O 0 4.18188079720494e-07
of O 0 3.634487484305282e-07
segregation O 0 2.0383208720886614e-06
distortion O 0 4.094336418347666e-06
, O 0 1.1819785150635198e-09
where O 0 1.608826516452666e-09
there O 0 5.69193636668075e-10
is O 0 4.767134464955802e-10
preferential O 0 6.26744256493339e-09
transmission O 0 1.764055213016036e-08
of O 0 2.8355380266020802e-09
the O 0 4.380966256434249e-09
larger O 0 4.825455590662386e-09
allele O 0 2.7556306125831043e-09
at O 0 2.1937907490610087e-08
the O 0 1.0033244279838982e-07
DM B-Disease 1 1.0
locus O 0 8.343304784830252e-07
, O 0 4.4740988691671646e-10
has O 0 1.0290495539022615e-10
been O 0 2.972745105633834e-10
put O 0 7.516208766489285e-10
forward O 0 6.383527928477406e-09
to O 0 5.494889876445086e-09
explain O 0 1.0539406503085047e-07
partially O 0 8.184287025869708e-07
the O 0 7.002703483749428e-08
maintenance O 0 0.00014217432180885226
of O 0 2.3007605705060996e-05
DM B-Disease 1 1.0
in O 0 1.742913866564777e-07
the O 0 9.291382951914784e-08
population O 0 1.1154823731374108e-08
. O 0 2.0999239680463688e-08

In O 0 6.6251840280529e-07
a O 0 2.4783517460491566e-07
survey O 0 3.0391672112273227e-07
of O 0 8.195323175641533e-07
DM B-Disease 1 1.0
in O 0 2.7166024096914043e-07
Northern O 0 2.467623119173368e-07
Ireland O 0 3.140279147828551e-08
, O 0 5.705069305861343e-09
59 O 0 4.861171376546736e-08
pedigrees O 0 4.559728665753937e-07
were O 0 6.721985812419007e-08
ascertained O 0 6.463869340223027e-06
. O 0 4.955489885105635e-07

Sibships O 0 0.0015384232392534614
where O 0 1.6531693347587861e-07
the O 0 1.773629954016087e-08
status O 0 2.2149770018131676e-08
of O 0 2.0080733520444483e-08
all O 0 1.9096981773714106e-09
the O 0 5.9760112414153355e-09
members O 0 9.260836542068773e-10
had O 0 3.008298943285581e-09
been O 0 8.790942418457348e-10
identified O 0 2.982998736911213e-09
were O 0 1.8098013088163611e-09
examined O 0 1.3167833934346618e-08
to O 0 3.981456553336926e-10
determine O 0 8.567885956267673e-09
the O 0 1.3063169213012316e-08
transmission O 0 3.1195850169751793e-07
of O 0 5.598248620231061e-08
the O 0 5.161363674233144e-07
DM B-Disease 1 1.0
expansion O 0 2.3402546389661438e-07
from O 0 9.209705886803476e-09
affected O 0 5.039480832635945e-09
parents O 0 9.84401782311295e-10
to O 0 1.5749970216916154e-09
their O 0 1.2676480309892213e-08
offspring O 0 4.6183507151909e-07
. O 0 1.6363466670554772e-07

Where O 0 2.8827569167333422e-06
the O 0 1.467630454499158e-06
transmitting O 0 0.42064979672431946
parent O 0 8.724552571948152e-06
was O 0 1.92532388609834e-05
male O 0 1.2616042113222647e-06
, O 0 4.063179659397065e-08
58 O 0 1.6552296528971056e-06
. O 0 6.422218916668498e-07

3 O 0 7.276702262970502e-07
% O 0 1.1439758473841266e-08
of O 0 3.759645927914335e-09
the O 0 2.8427076248505045e-09
offspring O 0 5.078047315976164e-09
were O 0 1.6120087487081491e-09
affected O 0 7.828510617535756e-10
, O 0 9.683856494469012e-11
and O 0 1.078554051625602e-10
in O 0 7.985868633042514e-10
the O 0 3.915435087264996e-09
case O 0 8.778581417345777e-09
of O 0 2.408291166489107e-08
a O 0 1.3853207292413572e-07
female O 0 1.2959772277554293e-07
transmitting O 0 6.055227004253538e-06
parent O 0 9.345146878558808e-08
, O 0 1.0514785486748224e-08
68 O 0 1.6430329878858174e-06
. O 0 3.2397801419392636e-07

7 O 0 4.860271928919246e-06
% O 0 7.86638665317696e-08
were O 0 1.1018774159765599e-07
affected O 0 3.234346763747453e-07
. O 0 1.4130425540770375e-07

Studies O 0 4.56346288046916e-06
on O 0 2.79160332183892e-07
meiotic O 0 1.3344690160010941e-05
drive O 0 4.391082768506749e-07
in O 0 1.3609303550765617e-07
DM B-Disease 1 1.0
have O 0 8.181362809445147e-10
shown O 0 1.2012654204696105e-09
increased O 0 8.653974759020855e-10
transmission O 0 2.7766553500896407e-09
of O 0 3.5402622500235736e-10
the O 0 8.270227280782194e-10
larger O 0 9.86000947555965e-10
allele O 0 9.67747326718893e-10
at O 0 1.3773476581491195e-08
the O 0 5.900513500023408e-08
DM B-Disease 1 0.9999986886978149
locus O 0 1.2660525783303456e-07
in O 0 2.2625212814375573e-09
non O 0 4.156165402946499e-07
- O 0 1.66206755238818e-05
DM O 1 1.0
heterozygotes O 0 3.377580014785053e-06
for O 0 8.957311337098872e-08
CTGn O 0 0.00032125084544532
. O 0 1.2610508974830736e-06

This O 0 3.559413386255983e-08
study O 0 1.520713510672067e-08
provides O 0 2.163212053929442e-09
further O 0 6.360796334092811e-10
evidence O 0 9.454597105218454e-09
that O 0 8.281877406091098e-10
the O 0 2.402204017926124e-07
DM B-Disease 1 1.0
expansion O 0 8.166783231899899e-07
tends O 0 4.843549916699885e-08
to O 0 1.1877731020959459e-09
be O 0 4.602120018404321e-09
transmitted O 0 1.1403479760474511e-07
preferentially O 0 2.027654346647978e-07
. O 0 9.511104792636615e-08

Diagnosis O 1 0.9999994039535522
of O 1 0.9874502420425415
hemochromatosis B-Disease 1 1.0
. O 0 0.0009247353300452232

If O 0 5.324094308889471e-05
untreated O 1 1.0
, O 0 4.204280048725195e-05
hemochromatosis B-Disease 1 1.0
can O 0 1.2703301763394848e-05
cause O 1 0.9986246824264526
serious O 1 0.9999626874923706
illness O 1 0.999981164932251
and O 0 6.369734961708673e-09
early B-Disease 0 1.1538769939534177e-07
death I-Disease 0 2.8925962070047717e-08
, O 0 2.0640755771239583e-10
but O 0 1.4642155543587165e-10
the O 0 8.18878209685181e-09
disease O 0 7.392978886855417e-07
is O 0 7.677108393444598e-10
still O 0 1.864001841767049e-09
substantially O 0 2.4808553433786074e-08
under O 0 9.365093092128518e-07
- O 0 0.01021607220172882
diagnosed O 0 2.3679976948187687e-05
. O 0 2.937129295332852e-07

The O 0 2.084172137983842e-06
cornerstone O 0 2.3076823708834127e-05
of O 0 7.475696861547476e-08
screening O 0 1.84372765943408e-08
and O 0 9.019192059867009e-10
case O 0 4.8796922058613745e-09
detection O 0 1.0364496461079398e-07
is O 0 1.1255008036670233e-09
the O 0 4.951320686785721e-09
measurement O 0 2.2871985549954843e-07
of O 0 8.935180773050888e-08
serum O 0 8.32031491881935e-06
transferrin O 0 1.829677239584271e-05
saturation O 0 4.956780230713775e-07
and O 0 7.055560580226938e-10
the O 0 2.0192151950482184e-08
serum O 0 2.630597009556368e-06
ferritin O 0 2.2173471734276973e-05
level O 0 6.073276836104924e-06
. O 0 2.5780639134609373e-07

Once O 0 2.1282357920426875e-06
the O 0 1.7181179146064096e-07
diagnosis O 0 4.33868581239949e-06
is O 0 1.0981088927053406e-08
suspected O 0 1.6468827652715845e-06
, O 0 4.4659671516456e-09
physicians O 0 8.75244943188136e-09
must O 0 5.203776520801284e-09
use O 0 2.4289578348657415e-08
serum O 0 0.00010563103569438681
ferritin O 1 0.6493409276008606
levels O 0 2.4629403014841955e-06
and O 0 2.0071274420274676e-08
hepatic O 0 0.00029405078385025263
iron O 0 0.0006454911199398339
stores O 0 7.064320328709073e-08
on O 0 2.2756534434620335e-08
liver O 0 9.309370341270551e-08
biopsy O 0 4.07345339681342e-08
specimens O 0 3.938677384240918e-09
to O 0 2.958293332522288e-10
assess O 0 1.0685589302283915e-07
patients O 0 6.930509055536049e-09
for O 0 7.049332229058791e-10
the O 0 4.001696751743111e-08
presence O 0 2.612785010569496e-07
of O 0 7.373492280748906e-06
iron B-Disease 1 0.9999963045120239
overload I-Disease 1 0.9998226761817932
. O 0 5.333666649676161e-06

Liver O 1 0.9998258948326111
biopsy O 0 0.23519366979599
is O 0 5.44433724769533e-08
also O 0 1.4641604595411195e-09
used O 0 2.6997610813594974e-09
to O 0 5.443666628579535e-10
establish O 0 2.5130402647732808e-08
the O 0 2.2308595859499292e-08
presence O 0 1.5652110718633594e-08
or O 0 7.47954409519025e-09
absence O 0 8.582429700254579e-08
of O 0 1.6818727317513549e-06
cirrhosis B-Disease 1 0.9999998807907104
, O 0 2.297436463294389e-09
which O 0 1.901852841879048e-10
can O 0 3.740738829804968e-10
affect O 0 3.030726958286323e-08
prognosis O 0 5.9206959122093394e-05
and O 0 3.018588756731333e-08
management O 0 1.8625954908202402e-05
. O 0 1.249215415555227e-06

A O 0 4.569385055219755e-06
DNA O 0 6.511706374112691e-07
- O 0 6.768274829482834e-08
based O 0 1.3754147820677076e-09
test O 0 8.148037244914974e-10
for O 0 5.177726025706875e-10
the O 0 1.8576919558199734e-08
HFE O 0 0.002981528639793396
gene O 0 1.3461286529903305e-09
is O 0 1.881150790694619e-11
commercially O 0 1.4267005632451202e-10
available O 0 4.808490064456272e-11
, O 0 1.4382735454010476e-11
but O 0 2.0741776352029007e-11
its O 0 2.2218451037336884e-11
place O 0 6.465673552114026e-10
in O 0 2.8642915816945447e-10
the O 0 4.385983132237925e-09
diagnosis O 0 1.371074358758051e-05
of O 0 1.0123037100129295e-05
hemochromatosis B-Disease 1 1.0
is O 0 8.946748835114704e-07
still O 0 8.69896297217565e-08
being O 0 9.347606066967273e-08
evaluated O 0 4.817117655875336e-07
. O 0 3.086532842644374e-07

Currently O 0 6.918848498571606e-07
, O 0 2.870396587084656e-09
the O 0 2.0629824515339124e-09
most O 0 1.4504895895495196e-10
useful O 0 2.9376761023769404e-09
role O 0 4.331950353986258e-09
for O 0 4.0488942754102197e-10
this O 0 3.648659152588607e-10
test O 0 7.862899220612007e-10
is O 0 4.0195774486662117e-10
in O 0 5.680353964976348e-10
the O 0 5.00229546673836e-09
detection O 0 5.443848181130306e-07
of O 0 5.4638489928038325e-06
hemochromatosis B-Disease 1 1.0
in O 0 1.7227281432496966e-06
the O 0 5.923787966821692e-07
family O 0 7.778611887943043e-08
members O 0 5.673423397745125e-10
of O 0 5.782997192227413e-09
patients O 0 9.25345688962409e-10
with O 0 1.3050703573380673e-10
a O 0 1.2507282320939339e-08
proven O 0 1.630867529911484e-07
case O 0 7.403467616740045e-09
of O 0 2.044045999127775e-08
the O 0 2.240057170865839e-07
disease O 0 1.652521314099431e-05
. O 0 2.8852520017608185e-07

It O 0 2.7502444766014378e-08
is O 0 8.511820581702523e-09
crucial O 0 2.2161059121117432e-07
to O 0 1.5946875464578625e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.00537402369081974
because O 0 5.00277472781363e-08
phlebotomy O 1 0.9999991655349731
therapy O 0 0.006162096280604601
can O 0 4.839096234832141e-09
avert O 0 5.989118108118419e-06
serious O 1 0.9999935626983643
chronic O 1 1.0
disease O 1 1.0
and O 0 1.3346350691278985e-08
can O 0 5.577037054393941e-09
even O 0 6.398643392913073e-09
lead O 0 1.5141347731173482e-08
to O 0 2.333744975047125e-09
normal O 0 3.9826574038670515e-07
life O 0 6.546900266357625e-08
expectancy O 0 1.977673349529141e-07
. O 0 2.3523090142418823e-09
. O 0 3.076845445093568e-08

Prevalence O 0 0.00017278938321396708
of O 0 4.939852829011215e-07
the O 0 3.7741003211522184e-07
I1307K O 0 0.00020488613517954946
APC B-Disease 0 6.539245987369213e-06
gene O 0 1.4580079366055543e-08
variant O 0 8.577172749824058e-09
in O 0 4.781466889092201e-10
Israeli O 0 1.2609635113847162e-08
Jews O 0 1.2704577390110217e-09
of O 0 2.573633806068898e-10
differing O 0 6.128700325014336e-11
ethnic O 0 4.96466825983255e-11
origin O 0 3.8446998362751117e-10
and O 0 2.2381581310515486e-10
risk O 0 7.704355908799698e-08
for O 0 3.5651187317853328e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00021117138385307044

BACKGROUND O 0 0.0028002827893942595
& O 0 0.0001347373763564974
AIMS O 0 1.0105327419296373e-05
Israeli O 0 2.847571749953204e-06
Jews O 0 9.430179659375426e-08
of O 0 1.5348609494481025e-08
European O 0 1.9730186373578817e-09
birth O 0 5.258283142239861e-09
, O 0 2.07712819166872e-10
i O 0 2.6136952602229258e-09
. O 0 2.6505581063318573e-10
e O 0 6.0156257752908004e-09
. O 0 2.048649583308304e-10
, O 0 8.744353019451978e-10
Ashkenazim O 0 4.466280927317712e-07
, O 0 5.008097270220446e-10
have O 0 2.525025188937491e-10
the O 0 1.4609420340150336e-08
highest O 1 0.9104897379875183
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9999982118606567
of O 0 5.382570407164167e-07
any O 0 1.147170358706262e-08
Israeli O 0 5.078118192614056e-07
ethnic O 0 7.661182799267863e-09
group O 0 4.650521745475089e-08
. O 0 8.510606619438477e-08

The O 0 4.186955266050063e-05
I1307K O 0 0.001080821268260479
APC B-Disease 0 5.6843044148990884e-05
gene O 0 8.806894413737609e-08
variant O 0 3.190467268154862e-08
was O 0 6.056914259033874e-08
found O 0 8.424906106085928e-09
in O 0 2.217623240596822e-08
6 O 0 2.2208459995454177e-06
. O 0 7.295734576473478e-07

1 O 0 7.308674412342953e-07
% O 0 1.965305074236312e-08
of O 0 6.735870528018495e-09
American O 0 1.4469513587300753e-08
Jews O 0 7.860053941044498e-09
, O 0 4.125445263181149e-10
28 O 0 4.20168255743647e-09
% O 0 5.152525628382421e-10
of O 0 2.4707249579591917e-09
their O 0 9.631390440745236e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.553245551302098e-05
, O 0 8.68496274897268e-10
but O 0 1.3386183828068e-10
not O 0 1.9048296273638243e-10
in O 0 8.65470084487896e-10
non O 0 1.2506762914199498e-07
- O 0 3.527426315486082e-07
Jews O 0 4.82343352814496e-07
. O 0 2.188830023897026e-07

We O 0 6.476744829342351e-07
assessed O 0 8.84583130300598e-07
the O 0 6.333780788736476e-08
I1307K O 0 1.3756020962318871e-05
prevalence O 0 2.8653445838244807e-07
in O 0 7.406260604803094e-10
Israeli O 0 1.7160537879590265e-08
Jews O 0 2.6149717946566398e-09
of O 0 3.787310465241944e-10
differing O 0 8.765806136512566e-11
ethnic O 0 7.717551597785643e-11
origin O 0 2.0448591431243557e-10
and O 0 2.928672859781045e-10
risk O 0 7.40242640517863e-08
for O 0 1.320273781857395e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00010203728743363172

METHODS O 0 5.900991254748078e-06
DNA O 0 4.949850449520454e-07
samples O 0 1.1588257464723029e-08
from O 0 5.0203317059072106e-09
500 O 0 1.2248304592787917e-08
unrelated O 0 1.277322336790121e-08
Jews O 0 2.3527757520014347e-09
of O 0 2.3453425868069644e-09
European O 0 1.402141180939509e-09
or O 0 7.99315280630708e-10
non O 0 1.110834801920646e-08
- O 0 3.88704801679296e-09
European O 0 4.442559375927857e-10
origin O 0 5.290098914478847e-10
, O 0 6.852007156110673e-11
with O 0 2.1754159237885595e-11
or O 0 7.010969582665894e-10
without O 0 5.062843921876947e-09
a O 0 2.4481206395421395e-08
personal O 0 2.2917510023034993e-07
and O 0 8.087779335141931e-09
/ O 0 4.844256636715727e-06
or O 0 1.0438416353508728e-07
family O 0 3.8172661476210124e-08
history O 0 4.6723491209377244e-07
of O 0 1.1541580988705391e-06
neoplasia B-Disease 0 0.0013660109834745526
, O 0 4.430283695455728e-09
were O 0 1.0293568664110353e-08
examined O 0 8.329949707786e-08
for O 0 2.1664328109238795e-09
the O 0 4.198896874640923e-08
I1307K O 0 1.6061881069617812e-06
variant O 0 9.732862515932084e-09
by O 0 8.699121423205725e-10
the O 0 2.5778896795003448e-09
allele O 0 2.0617905160946748e-09
- O 0 5.172654748974992e-09
specific O 0 1.423032358616183e-09
oligonucleotide O 0 5.783496135336463e-07
( O 0 1.0596348687386126e-07
ASO O 0 1.7393536836607382e-05
) O 0 2.404793519872328e-08
method O 0 1.6375845746097184e-07
. O 0 1.2511988245478278e-07

RESULTS O 0 1.5752553963466198e-06
In O 0 1.422294992892148e-08
persons O 0 1.1635831853595846e-08
at O 0 1.8347259711504194e-08
average O 0 2.4248706154139654e-08
risk O 0 2.9059068040737657e-08
for O 0 6.391668421201757e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.840612746193074e-06
I1307K O 0 0.00013572382158599794
was O 0 3.2631575663799595e-07
found O 0 4.6941956988177935e-09
in O 0 1.3492910788670542e-08
5 O 0 2.591389431927382e-07
. O 0 1.4774435896924842e-07

0 O 0 6.793961802031845e-07
% O 0 1.4582973051346926e-08
of O 0 1.0312394493894317e-08
120 O 0 2.2565105339822367e-08
European O 0 2.5748427834315635e-09
and O 0 3.2939275751431296e-09
1 O 0 2.4141530730048544e-07
. O 0 9.880066897949291e-08

6 O 0 5.583730398939224e-06
% O 0 8.11329101679803e-08
of O 0 5.671027736298129e-08
188 O 0 3.9259592909957064e-08
non O 0 4.133499231784299e-08
- O 0 1.2838585305985362e-08
European O 0 1.2285810591095014e-08
Jews O 0 3.111131974264936e-08
( O 0 5.020858395710093e-09
P O 0 4.344401816069876e-07
= O 0 3.06668610505767e-08
0 O 0 1.343906985695753e-09
. O 0 3.052112174106725e-10
08 O 0 3.967883088762392e-08
) O 0 9.854580262924628e-09
. O 0 2.6102194183863503e-08

It O 0 1.2386229855110287e-06
occurred O 0 5.456819053506479e-06
in O 0 1.539403058359312e-07
15 O 0 1.1427881645431626e-06
. O 0 8.375512265956786e-07

4 O 0 2.225480557171977e-06
% O 0 4.43664482929762e-08
of O 0 5.206291575632349e-08
52 O 0 1.1514959652458856e-07
Ashkenazi O 0 1.300701342188404e-06
Israelis O 0 4.6463279090858123e-07
with O 0 9.178246607177698e-09
familial O 0 4.4997799705015495e-05
cancer B-Disease 0 1.500531561759999e-05
( O 0 4.86684029965545e-07
P O 0 0.0009931012755259871
= O 0 4.376116748971981e-07
0 O 0 3.75305431177253e-09
. O 0 2.7380309131075364e-10
02 O 0 8.513107019325616e-08
) O 0 2.685072719721404e-10
and O 0 4.637732559098495e-11
was O 0 5.398772984221978e-09
not O 0 3.2380867431847093e-10
detected O 0 4.299206324276383e-09
in O 0 6.464711543863189e-10
51 O 0 1.6222003296206822e-08
non O 0 1.6724331430850725e-07
- O 0 8.001214268915646e-08
European O 0 6.204913027829662e-09
Jews O 0 2.451054648133777e-08
at O 0 2.4658113773057266e-08
increased O 0 1.5229630889734835e-08
cancer B-Disease 0 5.572950385612785e-07
risk O 0 1.3321252367859415e-07
. O 0 4.048574098192148e-08

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999998807907104
occurred O 0 0.22226430475711823
personally O 0 5.500457064044895e-06
or O 0 1.791093495739915e-08
in O 0 1.4820893401434887e-09
the O 0 5.551756387944806e-09
families O 0 1.1970159308205552e-09
of O 0 1.7742898705819243e-08
13 O 0 4.4319254044467016e-08
of O 0 1.9592535238643904e-07
20 O 0 2.756849823981611e-07
Ashkenazi O 0 1.1491104032756994e-06
I1307K O 0 1.5677289866289357e-06
carriers O 0 9.033899850408034e-09
, O 0 1.4731664776945763e-09
8 O 0 2.6188015311845447e-08
of O 0 4.379047169322803e-08
whom O 0 3.650667679266917e-08
also O 0 1.1890135986902806e-08
had O 0 8.3761527491788e-08
a O 0 2.539714500926493e-07
personal O 0 2.3534521460533142e-05
or O 0 4.0885703356252634e-07
family O 0 4.836487619286345e-07
history O 0 7.5795464908878785e-06
of O 0 9.938531002262607e-05
noncolonic O 1 0.9999914169311523
neoplasia B-Disease 1 0.9999984502792358
. O 0 2.4289858629344963e-05

CONCLUSIONS O 0 7.166427531046793e-05
The O 0 3.1083259273145813e-06
I1307K O 0 0.00021724261750932783
APC O 0 7.902575816842727e-06
variant O 0 7.170955740321006e-08
may O 0 3.870475939748985e-09
represent O 0 3.790904479217261e-09
a O 0 1.7698788212783256e-08
susceptibility O 0 2.436319732623815e-07
gene O 0 5.381624035294408e-09
for O 0 3.826668315554116e-09
colorectal B-Disease 1 1.0
, I-Disease 0 2.4470841353263495e-08
or I-Disease 0 1.8971086035435292e-08
other I-Disease 0 4.722238156062986e-10
, I-Disease 0 3.191305442129533e-09
cancers I-Disease 0 2.4295873117807787e-06
in O 0 5.830510740878481e-09
Ashkenazi O 0 2.7103529646410607e-05
Jews O 0 1.389144017593935e-07
, O 0 1.0448267806495437e-09
and O 0 1.940811289458111e-09
partially O 0 1.6723084854675108e-06
explains O 0 6.824495812907116e-08
the O 0 5.766530808415382e-09
higher O 0 6.250468942425869e-08
incidence O 0 3.1629824661649764e-06
of O 0 0.0016335686668753624
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.440931545308558e-07
European O 0 1.2267621229966608e-07
Israelis O 0 6.173249857965857e-07
. O 0 1.2970839691206493e-07

Systematic O 0 4.768876351590734e-06
analysis O 0 1.964273081966894e-07
of O 0 1.473047035460695e-07
coproporphyrinogen O 0 0.004445163067430258
oxidase O 0 0.00010031191777670756
gene O 0 1.6836647773743607e-05
defects O 0 0.00026553875068202615
in O 0 5.052158513763061e-08
hereditary B-Disease 1 0.9999982118606567
coproporphyria I-Disease 1 0.9999808073043823
and O 0 1.643352902647166e-07
mutation O 0 1.3169648127586697e-07
update O 0 6.666482477157842e-07
. O 0 3.0135009865261964e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999994039535522
( O 0 0.00011966473539359868
HC B-Disease 1 1.0
) O 0 3.379606823727954e-06
is O 0 3.995877406737236e-08
an O 0 2.422857789952104e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.7084769606590271
autosomal O 1 1.0
dominant O 1 0.9999566078186035
inheritance O 1 0.86198890209198
caused O 0 1.9556149709387682e-05
by O 0 1.6721108409001317e-07
deficient B-Disease 0 0.00024945123004727066
activity I-Disease 0 3.5323416796018137e-06
of I-Disease 0 1.7369962961311103e-06
coproporphyrinogen I-Disease 0 0.0011273898417130113
III I-Disease 1 0.9999921321868896
oxidase I-Disease 0 1.908762351376936e-05
( O 0 8.191798883672163e-07
CPO O 0 5.985846291878261e-05
) O 0 2.160706600307094e-07
. O 0 3.0440580189861066e-07

Clinical O 0 0.42086902260780334
manifestations O 0 0.00013077117910142988
of O 0 1.4719616956426762e-06
the O 0 1.5166833691182546e-06
disease O 0 0.06545466929674149
are O 0 2.606490301371167e-10
characterized O 0 4.139193432450838e-09
by O 0 6.692938980812357e-10
acute O 0 2.570199103502091e-05
attacks O 0 2.8610731561684588e-08
of O 0 5.2326515287859365e-05
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.2987396047492439e-08
precipitated O 0 1.2379010172480776e-07
by O 0 8.557363151417974e-10
drugs O 0 5.051962848057201e-09
, O 0 1.0517748894045553e-09
fasting O 0 7.20377443030884e-07
, O 0 1.043077002549353e-08
cyclical O 0 0.0006748288287781179
hormonal O 0 2.2677715605823323e-05
changes O 0 5.314515050258706e-09
, O 0 4.969523903497475e-09
or O 0 3.149162637328118e-07
infectious B-Disease 1 0.9998668432235718
diseases I-Disease 1 0.9999992847442627
. O 0 1.2148152563895565e-05

Skin O 1 1.0
photosensitivity O 1 0.9999996423721313
may O 0 5.888236046303064e-06
also O 0 3.024420891506452e-08
be O 0 3.817572036268757e-08
present O 0 6.303891382231086e-07
. O 0 1.6828290654302691e-06

The O 0 4.252155576978112e-06
seven O 0 1.36344181100867e-06
exons O 0 1.1149228384965681e-06
, O 0 1.3051986158529871e-08
the O 0 6.666444818392847e-08
exon O 0 4.322871518525062e-06
/ O 0 1.719558554214018e-06
intron O 0 2.99971748063399e-06
boundaries O 0 7.407140234505505e-09
and O 0 1.006946859227753e-09
part O 0 2.308276902951434e-09
of O 0 3.733664399874215e-08
3 O 0 1.0695275420857797e-07
noncoding O 0 8.242909643740859e-07
sequence O 0 5.0930356820799716e-08
of O 0 3.3462161042052685e-08
the O 0 5.140966408134773e-08
CPO O 0 4.696840733231511e-06
gene O 0 3.0066811262940973e-09
were O 0 1.0322701582410332e-09
systematically O 0 8.150154329200632e-09
analyzed O 0 1.5973237177391297e-09
by O 0 4.718349044807724e-10
an O 0 1.3445325963701293e-09
exon O 0 1.5210122938924542e-08
- O 0 1.2149024009033838e-08
by O 0 9.743096995862288e-09
- O 0 3.1767808650329243e-07
exon O 0 7.604044185427483e-07
denaturing O 0 6.025416041666176e-06
gradient O 0 1.2085383787052706e-06
gel O 0 6.757767891940603e-07
electrophoresis O 0 3.1922347716317745e-06
( O 0 7.816850455810709e-08
DGGE O 0 6.852969818282872e-05
) O 0 5.0385291494592366e-09
strategy O 0 8.223420167041695e-09
followed O 0 9.322103089459688e-10
by O 0 7.89607892959232e-11
direct O 0 1.4338404907832114e-09
sequencing O 0 3.42569816957905e-09
in O 0 4.3521805603852215e-10
seven O 0 5.676089376294158e-09
unrelated O 0 1.4641828727235406e-07
heterozygous O 0 5.72268383791652e-08
HC B-Disease 0 0.3961629271507263
patients O 0 4.124820307538357e-08
from O 0 7.558478287705839e-09
France O 0 1.598165688676545e-08
, O 0 1.0231240299418687e-09
Holland O 0 7.105657573447388e-08
, O 0 1.4738859022145334e-09
and O 0 1.566984653145198e-09
Czech O 0 1.3914260534875211e-06
Republic O 0 6.216498604771914e-06
. O 0 1.82390817826672e-06

Seven O 0 5.362118713492237e-07
novel O 0 3.977605160798703e-07
mutations O 0 2.384955521961274e-08
and O 0 5.612312281577658e-10
two O 0 9.663823075101163e-10
new O 0 6.74699274227919e-09
polymorphisms O 0 5.48221407825622e-07
were O 0 2.1163781127597758e-07
detected O 0 1.7668874079390662e-06
. O 0 3.402868742341525e-07

Among O 0 3.763672751233571e-08
these O 0 2.2502557595061035e-09
mutations O 0 2.7990199047422948e-09
two O 0 8.018225527983702e-10
are O 0 1.5907777317636373e-09
missense O 0 4.213023885313305e-07
( O 0 3.744133181271536e-08
G197W O 0 1.4773578413951327e-06
, O 0 1.3388418373949662e-08
W427R O 0 1.1212994195375359e-06
) O 0 6.3207683531629755e-09
, O 0 3.384165447872789e-10
two O 0 6.127580665094001e-10
are O 0 5.294086280471788e-10
nonsense O 0 2.7627845611277735e-06
( O 0 1.9068896506269084e-07
Q306X O 0 6.663967269560089e-06
, O 0 2.7632161447854742e-08
Q385X O 0 3.23471567753586e-06
) O 0 8.09802891410527e-09
, O 0 3.525733871523329e-10
two O 0 3.5824720967525536e-10
are O 0 2.379414443254291e-10
small O 0 4.04817068755392e-09
deletions O 0 5.387008528145998e-08
( O 0 5.4919059522262614e-08
662de14bp O 0 3.03404681289976e-06
; O 0 6.9256334001011055e-09
1168del3bp O 0 7.335044301726157e-06
removing O 0 1.1037722060791566e-06
a O 0 2.497627633601951e-07
glycine O 0 2.8095863058297255e-07
at O 0 2.1529828586608346e-07
position O 0 6.078753500560197e-08
390 O 0 4.328277114495904e-08
) O 0 2.8006796881641094e-10
, O 0 4.825874422298426e-11
and O 0 4.3294184209896613e-11
one O 0 3.500899570241245e-10
is O 0 4.546177045927635e-10
a O 0 5.9349365422178835e-09
splicing O 0 4.02188256032332e-08
mutation O 0 3.1639835196273225e-09
( O 0 5.67489832903334e-09
IVS1 O 0 3.1651582048652926e-06
- O 0 2.3406609273024515e-07
15c O 0 2.8825645586039172e-06
- O 0 1.5582800472202507e-07
- O 0 2.411348418718262e-07
> O 0 1.3658164732532896e-07
g O 0 1.6375324207729136e-08
) O 0 5.043911399660317e-10
which O 0 7.333834234346526e-11
creates O 0 2.5194797359517906e-09
a O 0 3.4089142619819768e-09
new O 0 4.3899919255352415e-09
acceptor O 0 2.1012084516769391e-07
splice O 0 1.5252852790581528e-05
site O 0 3.3545222777320305e-06
. O 0 6.369767788783065e-07

The O 0 5.6699627748457715e-06
pathological O 0 0.000251271587330848
significance O 0 2.0153943296463694e-06
of O 0 2.750229555203987e-07
the O 0 6.238023075866295e-08
point O 0 4.6777347506576916e-07
mutations O 0 9.896735875258855e-09
G197W O 0 3.4463971587683773e-07
, O 0 2.3316406583262506e-09
W427R O 0 3.9217459857354697e-07
, O 0 1.3690911737640477e-09
and O 0 5.541470615710864e-10
the O 0 6.227380833223606e-09
in O 0 1.2347336486584481e-08
- O 0 2.964753491596639e-07
frame O 0 4.3759846448665485e-06
deletion O 0 1.545669761071622e-07
390delGly O 0 9.336059747511172e-08
were O 0 4.275312548429611e-09
assessed O 0 1.3109994867477326e-08
by O 0 4.476284065635383e-10
their O 0 5.170994743508572e-10
respective O 0 6.504318417199784e-09
expression O 0 8.328897571630023e-09
in O 0 3.179433827327216e-09
a O 0 1.0619430668157293e-08
prokaryotic O 0 1.2424421491630255e-08
system O 0 2.3591657516419673e-09
using O 0 3.0860243249719588e-09
site O 0 1.5581582601953414e-07
- O 0 1.7020394693645358e-07
directed O 0 2.7300870897306595e-07
mutagenesis O 0 1.1604242899920791e-05
. O 0 7.118035227904329e-07

These O 0 7.535925306001445e-08
mutations O 0 4.6531834385632465e-08
resulted O 0 6.119924478298344e-08
in O 0 4.041019519007705e-09
the O 0 6.880235936534973e-09
absence O 0 1.0963429986077244e-07
or O 0 1.0713953280117039e-08
a O 0 1.1589186499350035e-08
dramatic O 0 6.49924842832661e-08
decrease O 0 1.445968536017972e-07
of O 0 4.203660921575647e-07
CPO O 0 0.00029923123656772077
activity O 0 5.053275344835129e-06
. O 0 2.61149494917845e-07

The O 0 2.0105304088247067e-07
two O 0 6.074543534850818e-09
polymorphisms O 0 9.745851059506094e-08
were O 0 3.5448994850639792e-09
localized O 0 4.086480132059478e-08
in O 0 3.279108762299643e-09
noncoding O 0 5.009955543755495e-07
part O 0 1.830367324373583e-08
of O 0 9.247621335362055e-09
the O 0 2.6306701261802345e-09
gene O 0 1.937551924457992e-10
1 O 0 3.326333375408552e-10
) O 0 7.636111881703656e-11
a O 0 8.0205653230081e-10
C O 0 9.166353009959494e-08
/ O 0 1.0095651248320792e-07
G O 0 3.7816843700966274e-07
polymorphism O 0 7.658789513698139e-08
in O 0 2.1482742251777154e-09
the O 0 1.7653713157983475e-08
promotor O 0 1.920636532304343e-05
region O 0 5.5007856047950554e-08
, O 0 4.611240278507012e-09
142 O 0 7.643495791853638e-08
bp O 0 2.1795730731355434e-07
upstream O 0 1.6230831079155905e-07
from O 0 4.585166024639875e-09
the O 0 1.109342129268498e-08
transcriptional O 0 5.273839178698836e-07
initiation O 0 6.914891770293252e-08
site O 0 3.271825832484865e-08
( O 0 3.028229444979047e-09
- O 0 1.984447628444741e-08
142C O 0 5.767929565081431e-07
/ O 0 1.7468560997713212e-07
G O 0 1.907042559423644e-07
) O 0 2.3259949522014267e-09
, O 0 4.042890744404559e-10
and O 0 2.477377469833897e-10
2 O 0 8.466192191747268e-09
) O 0 1.5454826307603753e-09
a O 0 3.0068876277766776e-09
6 O 0 2.0579884463245435e-08
bp O 0 9.355704833069467e-08
deletion O 0 1.0653838700136475e-08
polymorphism O 0 8.667127460171287e-09
in O 0 5.974617467430221e-10
the O 0 4.088863914120111e-09
3 O 0 2.1166764341273847e-08
noncoding O 0 3.6159599403617904e-07
part O 0 1.235607616223433e-08
of O 0 3.5685634003357336e-08
the O 0 1.1484733875022357e-07
CPO O 0 1.4049419405637309e-05
gene O 0 2.776773300183777e-08
, O 0 2.9399571666033353e-09
574 O 0 5.05894718116906e-07
bp O 0 4.1570174857952225e-07
downstream O 0 2.1772007130493876e-07
of O 0 1.1199551508411787e-08
the O 0 8.965067799238113e-09
last O 0 1.1342855543716723e-08
base O 0 2.9735931050822728e-08
of O 0 2.458471115573957e-08
the O 0 3.6252853163887266e-08
normal O 0 2.5276690962527937e-07
termination O 0 3.3406365673727123e-07
codon O 0 2.5525204705445503e-07
( O 0 4.155490884727442e-08
+ O 0 2.561926919497637e-07
574 O 0 8.797061923360161e-07
delATTCTT O 0 7.969874786795117e-06
) O 0 1.0868966171528882e-07
. O 0 1.4783400104079192e-07

Five O 0 4.334930508775869e-06
intragenic O 0 8.725120278540999e-05
dimorphisms O 0 5.754498124588281e-05
are O 0 3.250588687109257e-09
now O 0 7.456455008991725e-09
well O 0 7.234257193289295e-09
characterized O 0 3.462697861777997e-08
and O 0 1.2792136239170304e-09
the O 0 5.731933594432803e-09
high O 0 2.9678419721790306e-08
degree O 0 3.76548285885292e-07
of O 0 2.8710443800150642e-08
allelic O 0 4.812213774130214e-07
heterogeneity O 0 1.6475079291922157e-06
in O 0 4.749649562540981e-08
HC B-Disease 1 0.9999995231628418
is O 0 7.689396142041005e-08
demonstrated O 0 2.1605082167752698e-08
with O 0 1.6360260368664115e-10
seven O 0 3.8205544283798076e-10
new O 0 4.423135815945223e-11
different O 0 4.9335931173732916e-11
mutations O 0 1.8248194622039193e-10
making O 0 7.257111578340414e-10
a O 0 1.6224532828346128e-09
total O 0 4.66049998593121e-09
of O 0 3.558571748385475e-08
nineteen O 0 6.0438669606810436e-06
CPO O 0 0.35451486706733704
gene B-Disease 0 9.663030141382478e-06
defects I-Disease 0 7.390036444121506e-06
reported O 0 7.680817759592173e-09
so O 0 9.925503752228337e-10
far O 0 4.301420997165906e-09
. O 0 5.2906967695776075e-09
. O 0 8.50969783527944e-08

Coincidence O 0 0.00015859672566875815
of O 0 8.323412430399912e-07
two O 0 2.816136124295099e-08
novel O 0 3.996167663444794e-07
arylsulfatase O 0 1.0196878065471537e-05
A O 0 1.8477450680620677e-07
alleles O 0 2.399065612834761e-09
and O 0 4.0670369849671317e-10
mutation O 0 3.274096771477275e-09
459 O 0 2.834877932400559e-07
+ O 0 1.0707681212807074e-06
1G O 0 8.572278602514416e-06
> O 0 1.0234683855969706e-07
A O 0 1.801409332813364e-08
within O 0 4.383741369906602e-09
a O 0 1.1406422473214661e-08
family O 0 1.9158830966148344e-08
with O 0 5.6902242917544754e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 3.9521648176332747e-08
molecular O 0 1.4812951576459454e-07
basis O 0 4.479328907791569e-08
of O 0 2.4254857677874497e-08
phenotypic O 0 8.345628543793282e-07
heterogeneity O 0 1.0321768058929592e-05
. O 0 5.988045472804515e-07

In O 0 3.2771433779998915e-06
a O 0 5.372585860641266e-07
family O 0 6.070862212936845e-08
with O 0 5.012607551257986e-10
three O 0 4.7145909398693675e-09
siblings O 0 1.1179835013308548e-07
, O 0 1.101918445378658e-09
one O 0 1.7128221063700266e-09
developed O 0 9.6098986546167e-09
classical O 0 2.350553131691413e-06
late O 0 4.1529001464368775e-05
infantile O 1 0.9917095303535461
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00019744577002711594
MLD B-Disease 1 1.0
) O 0 3.6206492382007127e-07
, O 0 2.157024781013206e-08
fatal O 0 1.6695676094968803e-06
at O 0 4.943981366523076e-07
age O 0 4.287551860215899e-07
5 O 0 1.1329194649079e-07
years O 0 1.4154130312249436e-08
, O 0 2.853224323473569e-09
with O 0 4.846097745314637e-09
deficient O 0 0.00025792032829485834
arylsulfatase O 0 0.0005929899634793401
A O 0 0.0002778563357423991
( O 0 9.073583555618825e-07
ARSA O 0 0.003976796753704548
) O 0 1.0002096040295783e-08
activity O 0 1.7218569681176632e-08
and O 0 2.706327939527853e-10
increased O 0 6.673974262128013e-09
galactosylsulfatide O 0 2.2519378035212867e-05
( O 0 1.522872253190144e-06
GS O 1 0.9999988079071045
) O 0 1.3752926975030277e-07
excretion O 0 5.97077303154947e-07
. O 0 1.3480541838362115e-07

The O 0 1.8413716134091374e-06
two O 0 2.249042729829398e-08
other O 0 2.6274706854678698e-09
siblings O 0 2.057565211543988e-07
, O 0 5.8494133980957486e-09
apparently O 0 3.1552710311189003e-07
healthy O 0 5.990186480175907e-08
at O 0 8.316963118204512e-08
12 O 0 2.578176250267461e-08
( O 0 3.2348783651769963e-09
1 O 0 1.1156632950815037e-08
/ O 0 1.1772228525330775e-08
2 O 0 5.917833778568138e-09
) O 0 2.6761048932399945e-10
and O 0 5.885914672321135e-11
15 O 0 2.3749799349381817e-10
years O 0 2.498079521018326e-10
, O 0 1.5644992246155454e-10
respectively O 0 5.935909985765875e-09
, O 0 2.570842150273478e-10
and O 0 1.860605142178784e-10
their O 0 9.831164771156864e-10
father O 0 2.179755966835728e-07
, O 0 6.644380157183605e-09
apparently O 0 2.220167374389348e-07
healthy O 0 1.2586231612488064e-08
as O 0 1.0337517508673955e-09
well O 0 1.393720805431542e-09
, O 0 1.3069642035290485e-09
presented O 0 1.5861861868415872e-07
ARSA O 1 0.9986522793769836
and O 0 1.0469562283788036e-07
GS O 1 0.9999992847442627
values O 0 1.793329218457984e-08
within O 0 2.1270523120620055e-09
the O 0 1.1351983797425191e-09
range O 0 1.4337619091975284e-08
of O 0 5.728132350668602e-07
MLD B-Disease 1 1.0
patients O 0 1.0368315088271629e-05
. O 0 7.822046654837322e-07

Mutation O 0 3.9931694573169807e-07
screening O 0 2.5581615048508866e-08
and O 0 6.4296901136629e-10
sequence O 0 1.5778512718611637e-08
analysis O 0 1.7486787129428194e-08
disclosed O 0 9.999962458095979e-08
the O 0 5.257350110809966e-09
involvement O 0 2.4595593117737735e-08
of O 0 6.4460121684817295e-09
three O 0 3.993191333151458e-10
different O 0 7.527485301750403e-10
ARSA O 0 0.00020774835138581693
mutations O 0 1.3460362824346817e-09
being O 0 1.4468651832189039e-09
the O 0 1.4502524736670352e-09
molecular O 0 1.617109290918961e-08
basis O 0 2.5104819556531766e-08
of O 0 5.993089757794223e-08
intrafamilial O 0 4.9012902309186757e-05
phenotypic O 0 9.576758202456404e-06
heterogeneity O 0 4.262916627340019e-05
. O 0 1.882971901068231e-06

The O 0 2.3150232664193027e-06
late O 0 4.937177072861232e-05
infantile O 1 0.8401755690574646
patient O 0 3.265240593464114e-05
inherited O 0 0.0001403208152623847
from O 0 5.357099439606827e-07
his O 0 8.538244173905696e-07
mother O 0 9.096396524910233e-07
the O 0 8.13389888776328e-08
frequent O 0 1.4986884622203434e-08
0 O 0 2.9502931209179906e-09
- O 0 4.607117354282764e-09
type O 0 1.3173034218993962e-08
mutation O 0 5.991212859157713e-09
459 O 0 1.4293050298874732e-07
+ O 0 1.5462404689969844e-07
1G O 0 1.313354232479469e-06
> O 0 1.650249714657548e-08
A O 0 1.3114796360014225e-08
, O 0 1.459453391472465e-10
and O 0 1.0059943156282003e-10
from O 0 1.7249789374673696e-09
his O 0 9.276186041518031e-09
father O 0 1.8447765626206092e-07
a O 0 8.178714594464509e-09
novel O 0 1.7175667110791437e-08
, O 0 1.146548411767867e-09
single O 0 1.979536889962219e-08
basepair O 0 1.8178131995227886e-06
microdeletion O 0 4.7797857405385e-06
of O 0 4.6781897822256724e-07
guanine O 0 2.2202318632480456e-06
at O 0 3.720335826074006e-07
nucleotide O 0 9.933396540873218e-07
7 O 0 1.4030572970114008e-07
in O 0 1.8180712046955705e-08
exon O 0 1.9617552027284546e-07
1 O 0 4.7376342848792774e-08
( O 0 2.073100979771425e-08
7delG O 0 6.8018579213458e-07
) O 0 8.953946206702312e-08
. O 0 6.967464116769406e-08

The O 0 6.223713739927916e-07
two O 0 8.610237500761286e-08
clinically O 0 7.080490468069911e-05
unaffected O 0 2.7921969376620837e-06
siblings O 0 2.747456164797768e-07
carried O 0 2.9248127475511865e-08
the O 0 1.7640955363162902e-08
maternal O 0 7.745211405563168e-07
mutation O 0 9.761977892708273e-09
459 O 0 1.6995852547552204e-07
+ O 0 1.8121291134320927e-07
1G O 0 1.0514945643080864e-06
> O 0 2.9181373761844043e-08
A O 0 7.1463759354628564e-09
and O 0 1.5339170211792208e-10
, O 0 1.2870003673892683e-10
on O 0 7.568775606259237e-10
their O 0 1.1751090100986517e-09
paternal O 0 8.618962255013685e-08
allele O 0 2.6543083286867386e-09
, O 0 2.701057710829957e-10
a O 0 2.2981903047281094e-09
novel O 0 1.1923360965226948e-08
cytosine O 0 9.032714132217734e-08
to O 0 2.4809014842475108e-09
thymidine O 0 1.1784942444137414e-06
transition O 0 9.082544352168043e-07
at O 0 8.248044878200744e-07
nucleotide O 0 5.858304120920366e-06
2435 O 0 1.7868502254714258e-05
in O 0 6.230041815769027e-09
exon O 0 8.992969924292993e-08
8 O 0 6.3057163934843175e-09
, O 0 1.2021014739183045e-10
resulting O 0 1.2071590393958331e-09
in O 0 5.533506985955228e-10
substitution O 0 3.11849723821922e-09
of O 0 6.600954804980574e-08
alanine O 0 1.5329922007367713e-06
464 O 0 8.429553304267756e-07
by O 0 7.776905164291747e-08
valine O 0 3.790103073697537e-05
( O 0 4.7022723492773366e-07
A464V O 0 6.596626917598769e-06
) O 0 2.3293974038551823e-07
. O 0 2.0850656312632054e-07

The O 0 7.503626875404734e-06
fathers O 0 1.1170492143719457e-05
genotype O 0 2.0011582364531932e-06
thus O 0 4.947532943333499e-07
was O 0 6.015736744302558e-06
7delG O 0 0.00015327025903388858
/ O 0 0.0002440233074594289
A464V O 0 0.0005855882773175836
. O 0 2.2091583105066093e-06

Mutation O 0 1.7455718989367597e-05
A464V O 0 2.9298178560566157e-05
was O 0 4.260426464952616e-07
not O 0 3.117759606041659e-09
found O 0 9.587379778963623e-09
in O 0 5.8267644043041855e-09
18 O 0 2.661727194208652e-07
unrelated O 0 0.001261019380763173
MLD B-Disease 1 1.0
patients O 0 7.356220976362238e-06
and O 0 4.4849542746305815e-08
50 O 0 4.969157316736528e-07
controls O 0 8.439301950602385e-07
. O 0 1.9961480290930922e-07

A464V O 0 0.00014525755250360817
, O 0 5.5710433599642784e-08
although O 0 2.8344201652430456e-08
clearly O 0 3.1619492801837623e-07
modifying O 0 2.2216891011339612e-06
ARSA O 1 0.9999326467514038
and O 0 6.474897986663564e-07
GS O 1 1.0
levels O 0 8.201835726140416e-07
, O 0 4.0087537733768386e-09
apparently O 0 6.94004995693831e-08
bears O 0 4.48438974842702e-08
little O 0 8.792808259272533e-09
significance O 0 3.70853250331038e-08
for O 0 2.815635058439625e-09
clinical O 0 1.178143634206208e-06
manifestation O 0 2.3526623408542946e-05
of O 0 5.3650357585866004e-05
MLD B-Disease 1 1.0
, O 0 4.7325588070634694e-07
mimicking O 0 9.315395800513215e-06
the O 0 5.62205627829826e-07
frequent O 0 3.7993140722392127e-06
ARSA O 0 0.011932391673326492
pseudodeficiency O 0 0.0003180998901370913
allele O 0 6.031084467394976e-06
. O 0 9.745011766426614e-07

Our O 0 6.21287369995116e-07
results O 0 2.685741229413452e-08
demonstrate O 0 3.2829512441878705e-09
that O 0 4.9045548872195255e-11
in O 0 9.239167070296261e-11
certain O 0 7.650810540660302e-10
genetic O 0 6.411375608195158e-08
conditions O 0 1.1333315796946408e-06
MLD B-Disease 1 1.0
- O 1 0.901022732257843
like O 0 5.761618240285316e-07
ARSA O 1 0.9996174573898315
and O 0 5.2492868718445607e-08
GS O 1 0.9999970197677612
values O 0 4.015824561776071e-09
need O 0 5.394323876473095e-10
not O 0 6.584171402534977e-11
be O 0 4.215905402560338e-10
paralleled O 0 2.2197731652795483e-08
by O 0 5.0308540666677e-10
clinical O 0 1.29301474771637e-06
disease O 0 4.780711151397554e-07
, O 0 1.0604441630368555e-10
a O 0 6.50347109498739e-10
finding O 0 1.4493233280177265e-09
with O 0 9.838155984320807e-11
serious O 0 2.7147267545046816e-08
diagnostic O 0 2.4174914869945496e-07
and O 0 1.618355938148852e-08
prognostic O 0 0.0001957495405804366
implications O 0 2.2842652924737195e-06
. O 0 5.184936071600532e-07

Moreover O 0 9.398104339197744e-06
, O 0 5.97717644268414e-08
further O 0 2.109873094013892e-07
ARSA O 0 0.015061461366713047
alleles O 0 7.569187232547847e-08
functionally O 0 3.756974535917834e-07
similar O 0 1.90703364211231e-09
to O 0 2.080007499571934e-09
A464V O 0 1.1767490377678769e-06
might O 0 6.353148673809983e-09
exist O 0 1.251012182734712e-08
which O 0 6.977871058744256e-10
, O 0 1.4950210514008688e-10
together O 0 7.620241659900273e-10
with O 0 6.349304970676428e-10
0 O 0 1.5715230006208003e-08
- O 0 3.0734554457012564e-08
type O 0 5.688577786600035e-08
mutations O 0 4.684473253746546e-09
, O 0 3.8130418267279254e-10
may O 0 7.017729508618231e-09
cause O 0 1.2923675285492209e-06
pathological O 1 0.9996546506881714
ARSA O 1 0.9999996423721313
and O 0 5.555953634939215e-07
GS O 1 1.0
levels O 0 6.878742908611457e-08
, O 0 1.1271888977759659e-10
but O 0 2.2890536688358054e-11
not O 0 6.555687936948829e-11
clinical O 0 1.0193690336279815e-08
outbreak O 0 3.983919860672813e-09
of O 0 1.4320728602967847e-08
the O 0 1.7570813781730976e-07
disease O 0 1.4074911632633302e-05
. O 0 1.0504241920727964e-08
. O 0 8.04622359851237e-08

Human O 1 0.9999910593032837
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.4240516424179077
to O 0 9.498710369371111e-07
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 1.4971219570725225e-06
neurofibromatosis B-Disease 1 0.9999899864196777
type I-Disease 0 0.002404156606644392
1 I-Disease 0 6.245644181035459e-05
. O 0 1.3003726735405507e-06

Heterozygous O 0 2.2685915610054508e-05
germ O 0 0.0016629049787297845
- O 0 4.465469373826636e-06
line O 0 7.671772550565947e-08
mutations O 0 2.484846328698609e-09
in O 0 4.5612463805966286e-10
the O 0 4.538736941839261e-09
DNA O 0 1.1339133152432623e-06
mismatch O 1 0.7546995282173157
repair O 1 0.9817365407943726
genes O 0 5.1230126700829715e-06
lead O 0 2.033435976045439e-06
to O 0 2.480264527093823e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0011983977165073156

The O 0 4.261818048689747e-06
disease O 0 0.00014395809557754546
susceptibility O 0 9.000980867313046e-07
of O 0 1.7728393686411437e-07
individuals O 0 1.3553086652962065e-08
who O 0 5.655092394363237e-09
constitutionally O 0 1.7030151866492815e-07
lack O 0 9.628355890356488e-09
both O 0 6.179929346039614e-10
wild O 0 8.111368465790747e-09
- O 0 3.967958406292382e-08
type O 0 5.843550709982992e-08
alleles O 0 4.143174248127934e-09
is O 0 2.131828491513943e-09
unknown O 0 6.501269353975658e-07
. O 0 9.960995583924159e-08

We O 0 1.5169206335485796e-07
have O 0 4.721916635475054e-09
identified O 0 1.783872427552069e-08
three O 0 2.2478363614908403e-09
offspring O 0 3.4654000558020925e-08
in O 0 6.588750434133317e-09
a O 0 3.046096423986455e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9999995231628418
who O 0 3.1242919362739485e-07
developed O 0 7.509998340538004e-06
hematological B-Disease 1 0.9999992847442627
malignancy I-Disease 1 0.9999995231628418
at O 0 1.9557248833734775e-06
a O 0 1.3092053663399383e-08
very O 0 6.184410206167001e-10
early O 0 3.394678982360233e-09
age O 0 9.926529820347696e-09
, O 0 5.318335216664138e-10
and O 0 5.65145596986838e-10
at O 0 4.5097447554098835e-08
least O 0 5.21461429592307e-10
two O 0 7.263546708546897e-11
of O 0 7.648855437913937e-10
them O 0 4.123722474602687e-10
displayed O 0 1.1948385747473367e-07
signs O 0 8.58136530723641e-08
of O 0 3.5946047205470677e-07
neurofibromatosis B-Disease 0 0.3016858398914337
type I-Disease 0 8.868941949913278e-05
1 I-Disease 0 5.6720666179899126e-05
( O 0 2.059897042272496e-06
NF1 B-Disease 0 0.0019357041455805302
) O 0 2.488381483090052e-07
. O 0 2.537533418944804e-07

DNA O 0 7.299674393834721e-07
sequence O 0 4.226891903158503e-08
analysis O 0 5.848755257886751e-09
and O 0 1.1444962338957865e-10
allele O 0 9.663473354848406e-10
- O 0 3.1577316317310533e-09
specific O 0 1.947534356006031e-09
amplification O 0 4.534550868129372e-08
in O 0 2.888961292413228e-09
two O 0 6.7889596166992305e-09
siblings O 0 1.5440727452187275e-07
revealed O 0 3.507126109525416e-07
a O 0 6.666393659315872e-08
homozygous O 0 1.52069091541307e-07
MLH1 O 0 1.5450079445145093e-05
mutation O 0 7.523212275373226e-09
( O 0 9.527987288038275e-09
C676T O 0 5.983027904221672e-07
- O 0 3.1353497433883604e-06
- O 0 2.892180418712087e-05
> O 0 1.6548110579606146e-05
Arg226Stop O 0 0.0003924432094208896
) O 0 2.73886513468824e-07
. O 0 2.035324371263414e-07

Thus O 0 1.881934281300346e-06
, O 0 1.56577240062461e-08
a O 0 2.999603054831823e-08
homozygous O 0 1.0970751418426516e-07
germ O 0 0.28146687150001526
- O 0 0.00043107985402457416
line O 0 9.161647540167905e-06
MLH1 O 0 0.3704173266887665
mutation O 0 2.5145073578869415e-08
and O 0 2.883929317576417e-09
consequent O 0 8.788172999629751e-05
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 3.859792286675656e-06
in O 0 1.2489147138694534e-07
a O 0 3.233461995932885e-07
mutator O 0 0.0016292507061734796
phenotype O 0 1.4857077701435628e-07
characterized O 0 1.080795630770126e-08
by O 0 3.2199325428194925e-09
leukemia B-Disease 1 0.6467769742012024
and O 0 1.3478245364240138e-06
/ O 1 1.0
or O 1 0.9999876022338867
lymphoma B-Disease 1 1.0
associated O 1 0.9988150596618652
with O 0 3.5465320706862258e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.013722892850637436
1 I-Disease 0 6.674162705166964e-06
. O 0 4.164631661751628e-08
. O 0 1.6942853164891858e-07

Missense O 0 0.0003898875438608229
mutations O 0 1.6770968613855075e-07
in O 0 5.131783886724861e-09
the O 0 4.0621856989275784e-09
most O 0 3.0082059065961175e-10
ancient O 0 9.889795649087318e-08
residues O 0 9.953360802228417e-08
of O 0 8.230265535758008e-08
the O 0 4.2432418467797106e-07
PAX6 O 1 0.9957689046859741
paired O 0 2.2741990051144967e-06
domain O 0 2.9388484108494595e-06
underlie O 0 7.517232916143257e-07
a O 0 8.264617434861066e-09
spectrum O 0 2.8084119918503347e-08
of O 0 1.3074183016215102e-06
human O 1 0.9999710321426392
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0004954232717864215

Mutations O 0 1.3610579117084853e-06
of O 0 1.552459423237451e-07
the O 0 1.1682893585884813e-07
human O 0 5.920467174291844e-07
PAX6 O 1 0.9999972581863403
gene O 0 7.446861127391458e-05
underlie O 1 0.9911474585533142
aniridia B-Disease 1 1.0
( O 1 0.9999688863754272
congenital B-Disease 1 1.0
absence I-Disease 0 1.621437149879057e-05
of I-Disease 0 3.4481239708838984e-05
the I-Disease 0 4.067199370183516e-06
iris I-Disease 0 0.0003099505265709013
) O 0 1.1384214104737111e-07
, O 0 5.590349516637616e-09
a O 0 1.6740607122756046e-07
rare O 0 6.1441564866981935e-06
dominant O 1 0.9999700784683228
malformation B-Disease 1 1.0
of I-Disease 1 0.9999204874038696
the I-Disease 1 0.9988834261894226
eye I-Disease 1 0.9999998807907104
. O 0 2.1980578821967356e-05

The O 0 5.301083660924633e-07
spectrum O 0 4.803547994924884e-07
of O 0 5.759437726737815e-07
PAX6 O 1 0.9966699481010437
mutations O 0 3.630891285411053e-07
in O 0 3.960480299269875e-08
aniridia B-Disease 1 1.0
patients O 0 6.490118664714828e-08
is O 0 1.1394175603030021e-09
highly O 0 3.537901527295162e-09
biased O 0 1.516996661621306e-08
, O 0 6.541062136378173e-11
with O 0 5.3154421836287824e-11
92 O 0 1.7149936581972725e-08
% O 0 3.963038230914151e-10
of O 0 5.338438024971026e-10
all O 0 4.2367676034160695e-10
reported O 0 1.1612707240260534e-08
mutations O 0 2.4138082643787584e-09
leading O 0 1.2817959138544666e-08
to O 0 1.870019916694332e-09
premature O 0 1.7455055001391884e-07
truncation O 0 1.2833685332225286e-06
of O 0 6.792718920678453e-08
the O 0 3.1451403259552535e-08
protein O 0 1.0199975974956033e-07
( O 0 7.047642469615312e-09
nonsense O 0 1.4664423986232578e-07
, O 0 1.1386788179024165e-09
splicing O 0 3.817892135771217e-08
, O 0 1.114335734797578e-09
insertions O 0 2.55303369556259e-08
and O 0 5.729820506950034e-10
deletions O 0 1.560870366290601e-08
) O 0 1.226695411915557e-09
and O 0 3.338263276919662e-10
just O 0 1.4243283885662095e-08
2 O 0 4.482200566258143e-08
% O 0 3.9622918279746955e-09
leading O 0 3.5593710201453632e-09
to O 0 1.9727089406451626e-10
substitution O 0 5.1676649626131166e-09
of O 0 1.1520116416363635e-08
one O 0 7.258070588989085e-09
amino O 0 1.793797821392218e-08
acid O 0 3.864146780330202e-09
by O 0 1.413839267883077e-09
another O 0 3.015188099197985e-08
( O 0 4.816006082819513e-08
missense O 0 8.850201993482187e-07
) O 0 4.629228911312566e-08
. O 0 1.0556486529367248e-07

The O 0 6.015192184349871e-07
extraordinary O 0 9.928368172040791e-07
conservation O 0 5.086201895210252e-07
of O 0 8.725167788270483e-08
the O 0 1.9293896968974877e-07
PAX6 O 0 0.00043670847662724555
protein O 0 2.7207042307964e-07
at O 0 2.352718553311206e-08
the O 0 6.336871472001349e-09
amino O 0 5.022422300271501e-08
acid O 0 1.5112581408516235e-08
level O 0 5.5560917644470464e-08
amongst O 0 2.6793044227702012e-08
vertebrates O 0 9.661165449870168e-07
predicts O 0 3.226906031272847e-08
that O 0 1.19395127118338e-09
pathological O 0 4.662815172196133e-06
missense O 0 5.744577151745034e-07
mutations O 0 2.1399029215274368e-09
should O 0 2.0119472754487333e-10
in O 0 4.978914502906662e-10
fact O 0 2.60036880916914e-09
be O 0 1.6080625719894215e-09
common O 0 1.9988668498172046e-09
even O 0 6.002361940815604e-10
though O 0 6.982584510595302e-10
they O 0 3.9341629953781876e-10
are O 0 3.7905481531375074e-10
hardly O 0 4.82645212684929e-08
ever O 0 2.958747735704037e-08
seen O 0 7.469738960708128e-08
in O 0 8.058863443238806e-08
aniridia B-Disease 1 1.0
patients O 0 2.4856663003447466e-06
. O 0 7.280069098669628e-07

This O 0 1.5168758693562268e-07
indicates O 0 2.9448762006722973e-07
that O 0 1.450368602995411e-09
there O 0 2.875031990257071e-09
is O 0 3.160443018401793e-09
a O 0 2.1199653588155343e-08
heavy O 0 8.656845125187829e-07
ascertainment O 0 0.0002919061516877264
bias O 0 1.9545002771792497e-07
in O 0 1.2522052283969742e-09
the O 0 4.963790489753706e-10
selection O 0 7.67252650302197e-10
of O 0 4.33813562850105e-09
patients O 0 4.797536257150625e-10
for O 0 8.051481703574837e-10
PAX6 O 0 0.0001535583141958341
mutation O 0 1.805467331195132e-09
analysis O 0 1.886283351737461e-09
and O 0 2.6422936755254867e-11
that O 0 4.598965305802061e-11
the O 0 7.481856023616729e-09
missing O 0 9.387337740918156e-06
PAX6 O 1 0.9907063841819763
missense O 0 4.195172368781641e-05
mutations O 0 6.45278035449337e-08
frequently O 0 8.966333453486186e-09
may O 0 5.721611628928258e-09
underlie O 0 1.3872419231120148e-06
phenotypes O 0 1.6596032992310938e-07
distinct O 0 1.4754871102695688e-08
from O 0 8.875984747191978e-08
textbook O 0 0.00013671358465217054
aniridia B-Disease 1 0.9999996423721313
. O 0 4.709093900601147e-06

Here O 0 3.399778051971225e-06
we O 0 7.804067791994385e-08
present O 0 6.499384852531875e-08
four O 0 2.1489621815362625e-07
novel O 0 4.82681161884102e-06
PAX6 O 0 0.0026838253252208233
missense O 0 1.0552159437793307e-05
mutations O 0 2.383059261035214e-08
, O 0 1.0377819714690872e-09
two O 0 1.0617480228347631e-09
in O 0 3.789935476561368e-09
association O 0 1.1943983579953965e-08
with O 0 8.7941502968647e-09
atypical O 0 9.537766345601995e-06
phenotypes O 0 1.5681485820095986e-05
ectopia B-Disease 0 0.0025368384085595608
pupillae I-Disease 0 0.002028635237365961
( O 0 1.8560564285508008e-07
displaced B-Disease 0 2.1559313267971447e-07
pupils I-Disease 0 1.1022894597090271e-07
) O 0 1.082617870906688e-07
and O 0 2.529019411667832e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 0 0.3088219165802002
( O 0 3.550955170794623e-06
searching B-Disease 0 8.087926835287362e-05
gaze I-Disease 0 4.2495634261285886e-05
) O 0 2.9251085109649466e-08
, O 0 1.4535811443394664e-09
and O 0 7.927017375841672e-10
two O 0 1.971592888949658e-09
in O 0 9.621380137048163e-09
association O 0 1.5290346766505536e-08
with O 0 1.7989706391219329e-09
more O 0 1.942608562899295e-08
recognizable O 0 2.665729152795393e-05
aniridia B-Disease 1 1.0
phenotypes O 0 5.8216493926011026e-05
. O 0 7.752756232548563e-07

Strikingly O 0 6.753575235052267e-06
, O 0 2.955486300137977e-09
all O 0 7.146290781356868e-10
four O 0 1.7131194240960212e-09
mutations O 0 9.225700203785436e-10
are O 0 2.53036230857262e-10
located O 0 1.5615968962379156e-08
within O 0 1.7065520552250746e-08
the O 0 1.0234254688157307e-07
PAX6 O 0 0.0024125538766384125
paired O 0 3.0458875244221417e-07
domain O 0 3.192537576524046e-07
and O 0 1.1652461218147891e-09
affect O 0 6.1424687558542246e-09
amino O 0 1.3338614657243397e-08
acids O 0 5.78865566591702e-10
which O 0 2.5057803054728822e-11
are O 0 8.200351855891519e-12
highly O 0 2.1228360735925378e-10
conserved O 0 7.605275520461419e-09
in O 0 3.8739897401107726e-10
all O 0 2.8233670956723245e-10
known O 0 5.827675231273588e-09
paired O 0 9.980222159811092e-08
domain O 0 1.063771492226806e-06
proteins O 0 1.2217952871651505e-07
. O 0 1.425727305104374e-07

Our O 0 1.2235424264872563e-06
results O 0 5.205199116176118e-08
support O 0 2.544476185306621e-09
the O 0 2.2196955384856665e-09
hypothesis O 0 7.261268919478425e-09
that O 0 4.21492250823885e-11
the O 0 2.322150388645028e-10
under O 0 3.7497418503562585e-09
- O 0 1.8309993521370416e-08
representation O 0 8.502425430378935e-09
of O 0 1.8442587901290608e-08
missense O 0 1.4006525361764943e-06
mutations O 0 5.3238693453749875e-09
is O 0 7.791686740254988e-10
caused O 0 3.5508274098816628e-09
by O 0 1.8662926759560605e-09
ascertainment O 0 0.005438477732241154
bias O 0 3.8652996181554045e-07
and O 0 1.5133170272463303e-09
suggest O 0 7.4267898497737406e-09
that O 0 1.5902400229972358e-10
a O 0 1.393502868651808e-09
substantial O 0 7.817204661364485e-09
burden O 0 1.8046597460852354e-07
of O 0 3.6509716210275656e-06
PAX6 B-Disease 1 0.9999998807907104
- I-Disease 0 0.1955636590719223
related I-Disease 0 0.012171224690973759
disease I-Disease 1 0.6300089955329895
remains O 0 2.0895603825010767e-07
to O 0 8.397804673876408e-10
be O 0 3.1594966642956024e-09
uncovered O 0 5.764449269918259e-06
. O 0 2.5009807558262764e-08
. O 0 4.745828263708063e-08

The O 0 9.361235129290435e-07
chromosomal O 0 3.956958153139567e-06
order O 0 4.3050345510664556e-08
of O 0 4.376091737867682e-07
genes O 0 3.949196525354637e-07
controlling O 0 8.516161869920325e-06
the O 0 1.0931593124041683e-06
major O 0 6.775121619284619e-06
histocompatibility O 1 0.9934606552124023
complex O 0 0.004272701218724251
, O 0 7.890832876000786e-09
properdin O 0 4.458184321265435e-06
factor O 0 2.0490801944106352e-07
B O 0 1.1194072158104973e-06
, O 0 1.1995894277916364e-09
and O 0 2.1586989973343407e-09
deficiency B-Disease 0 0.323818564414978
of I-Disease 0 4.952880408382043e-05
the I-Disease 0 1.169520601251861e-06
second I-Disease 0 2.6367808914073976e-06
component I-Disease 0 3.718048446899047e-06
of I-Disease 0 5.229425710240321e-07
complement I-Disease 0 1.9670055735332426e-06
. O 0 1.401293843628082e-06

The O 0 8.240033366746502e-07
relationship O 0 2.8793036221941293e-07
of O 0 3.914862034548605e-08
the O 0 1.493437906674444e-08
genes O 0 1.6663681989825818e-08
coding O 0 7.106010002644325e-08
for O 0 2.902448947850189e-09
HLA O 0 5.120655828250165e-07
to O 0 3.677388393796832e-10
those O 0 1.2203896782025936e-09
coding O 0 3.8719178974133683e-08
for O 0 8.801394613122682e-10
properdin O 0 2.1130415461811936e-06
Factor O 0 8.804943831819401e-07
B O 0 6.160182124403946e-07
allotypes O 0 6.812101673858706e-07
and O 0 7.460221329580463e-10
for O 0 2.4380912844179647e-09
deficiency B-Disease 0 0.00039127992931753397
of I-Disease 0 5.2765204827665e-07
the I-Disease 0 5.083737875111183e-08
second I-Disease 0 4.285193000441723e-08
component I-Disease 0 7.844885629992859e-08
of I-Disease 0 6.951068165506058e-09
complement I-Disease 0 4.8034195287982584e-08
( O 0 3.558877281761852e-08
C2 O 0 3.964803909184411e-06
) O 0 1.0871837874404378e-09
was O 0 7.017087355620788e-09
studied O 0 8.170170318066994e-09
in O 0 8.717241373190632e-10
families O 0 5.943735503777248e-10
of O 0 6.002295993567941e-09
patients O 0 1.0903907998738305e-08
with O 0 1.8173609817040415e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.09461405873298645

Patients O 0 7.152160037549038e-07
were O 0 8.963563224995141e-09
selected O 0 3.5632767847459945e-09
because O 0 1.1379428510593925e-09
they O 0 3.3617900130344935e-10
were O 0 6.282235176513495e-09
heterozygous O 0 4.41232330672392e-08
or O 0 1.1144084766101514e-08
homozygous O 0 2.6946392495119653e-07
for O 0 1.1392071428417694e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00012717478966806084

12 O 0 1.8721819969869102e-06
families O 0 1.871687338450556e-08
with O 0 2.2038675329127955e-09
15 O 0 6.495716320387146e-08
matings O 0 3.1988081445888383e-06
informative O 0 4.118066499358974e-06
for O 0 1.0265060836900375e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.3148580819688505e-06
found O 0 5.368288498175389e-07
. O 0 2.2508928054776334e-07

Of O 0 6.998763637966476e-06
57 O 0 2.320316980330972e-06
informative O 0 2.4249134185083676e-06
meioses O 0 7.171405286499066e-06
, O 0 1.6546805037265244e-09
two O 0 6.844512734360819e-10
crossovers O 0 3.556371863666641e-09
were O 0 2.2307222735662435e-09
noted O 0 8.18442558170318e-09
between O 0 3.057335717926435e-08
the O 0 3.080750047956826e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.581458247163937e-08
and O 0 1.4779565349343216e-09
the O 0 3.1661102184443735e-08
HLA O 0 4.088042715011397e-06
- O 0 8.21981529952609e-07
B O 0 6.59462693874957e-06
gene O 0 4.377257667442791e-09
, O 0 6.33846031217189e-11
with O 0 2.5422519991935566e-11
a O 0 2.377301466793824e-09
recombinant O 0 3.957903782492167e-09
fraction O 0 9.671462741778214e-09
of O 0 2.34248265229553e-08
0 O 0 7.815970803903838e-08
. O 0 3.343950893963665e-08

035 O 0 0.07730939984321594
. O 0 4.736875416710973e-05

A O 0 2.69329575530719e-05
lod O 0 0.00015880829596426338
score O 0 1.2533485005405964e-07
of O 0 3.486443134192996e-08
13 O 0 1.6847538475417423e-08
was O 0 2.4368977946664927e-08
calculated O 0 5.679730818997086e-08
for O 0 2.4235145001938463e-09
linkage O 0 1.428065274922119e-06
between O 0 1.7397715055267327e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.984811603961134e-07
HLA O 0 3.0733302992302924e-05
- O 0 5.10882671278523e-07
B O 0 7.387735081465507e-07
at O 0 9.143771961817038e-09
a O 0 4.265845177098271e-10
maximum O 0 8.220436553685317e-10
likelihood O 0 7.923631195616565e-10
value O 0 9.68046420801727e-10
of O 0 9.830958269674284e-10
the O 0 8.25572776808059e-10
recombinant O 0 3.387499614149192e-09
fraction O 0 6.935864771406841e-09
of O 0 1.5751419724097104e-08
0 O 0 4.458275881802365e-08
. O 0 2.2015450795720426e-08

04 O 0 0.003590639913454652
. O 0 2.0133091311436146e-05

18 O 0 3.12967085847049e-06
families O 0 2.8894477921426187e-08
with O 0 2.7980699979224255e-09
21 O 0 9.208603302113261e-08
informative O 0 1.607613455689716e-07
matings O 0 1.5536740249899594e-07
for O 0 1.7826845555291015e-09
both O 0 2.393156117719286e-09
properdin O 0 2.029354163823882e-06
Factor O 0 5.805079581477912e-07
B O 0 1.8824894709723594e-07
allotype O 0 5.621177479042672e-07
and O 0 5.664019919748853e-09
HLA O 0 9.39868982641201e-07
- O 0 1.6909486078020564e-07
B O 0 5.708249659619469e-07
were O 0 3.430649897495641e-08
found O 0 3.3402535848381376e-08
. O 0 9.559519043023101e-08

Of O 0 1.8964694390888326e-05
72 O 0 1.1870977687067352e-05
informative O 0 7.899034244474024e-06
meioses O 0 2.9334301871131174e-05
, O 0 7.394788337222735e-09
three O 0 3.5393594721710997e-09
recombinants O 0 6.684677487100998e-07
were O 0 1.1080605766267126e-08
found O 0 2.917000418989346e-09
, O 0 8.462620049165537e-10
giving O 0 1.8267914958514098e-09
a O 0 5.007278147672878e-09
recombinant O 0 6.061488644348856e-09
fraction O 0 2.2547721911791996e-08
of O 0 5.6393158587297876e-08
0 O 0 1.1776028685517304e-07
. O 0 9.816071155910322e-08

042 O 0 0.024956561625003815
. O 0 5.988341581542045e-05

A O 0 4.901477586827241e-05
lod O 0 0.00010277936235070229
score O 0 8.770719261974591e-08
of O 0 3.8926586398702057e-08
16 O 0 2.1099127778256843e-08
between O 0 1.159290086150122e-08
HLA O 0 3.4746599908430653e-07
- O 0 3.308537444013382e-08
B O 0 2.174200375293367e-07
and O 0 1.801779614396537e-09
Factor O 0 1.322500082778788e-07
B O 0 1.2890400569176563e-07
allotypes O 0 2.856635319403722e-07
was O 0 1.8669558343731296e-08
calculated O 0 3.241921930907665e-08
at O 0 5.124712210147209e-09
a O 0 4.0095926578942453e-10
maximum O 0 1.2387831871407684e-09
likelihood O 0 1.4961399896762373e-09
value O 0 2.243480290431421e-09
of O 0 1.7489181214358496e-09
the O 0 1.7100866278596527e-09
recombinant O 0 3.342151000396143e-09
fraction O 0 5.920961054783902e-09
of O 0 2.319072223144758e-08
0 O 0 2.493583473039962e-08
. O 0 3.409058990655467e-08

04 O 0 0.009593418799340725
. O 0 2.514841253287159e-05

A O 0 5.429307748272549e-06
crossover O 0 6.231375664356165e-07
was O 0 1.2666879456446622e-07
shown O 0 5.252088097762453e-09
to O 0 1.0365436287074203e-09
have O 0 2.0626547692081942e-10
occurred O 0 2.0187377103297877e-08
between O 0 1.002829930207838e-09
genes O 0 2.444702495996154e-10
for O 0 1.3398726572688702e-10
Factor O 0 1.685592820876991e-08
B O 0 2.1681618278535097e-08
and O 0 1.5925082363921206e-09
HLA O 0 2.7774308364314493e-07
- O 0 7.659330236720052e-08
D O 0 1.7386042827638448e-07
, O 0 9.514036225510836e-10
in O 0 1.4533343417610922e-09
which O 0 1.8589032535487604e-09
HLA O 0 2.2176132574713847e-07
- O 0 8.519376848425964e-08
D O 0 5.975130079605151e-07
segregared O 0 2.3410655103361933e-06
with O 0 2.3513457847457175e-08
HLA O 0 9.625578968552873e-06
- O 0 2.165562733580373e-07
A O 0 3.110619104518264e-07
and O 0 9.258757316388255e-09
B O 0 3.708091298904037e-06
. O 0 2.3928842551868e-07

These O 0 6.045026879064608e-08
studies O 0 5.378753797913305e-08
suggest O 0 1.1740073802002371e-08
that O 0 1.2627457413039167e-10
the O 0 7.539181501314829e-10
genes O 0 1.1069911654004727e-09
for O 0 6.36633135098208e-10
Factor O 0 9.154949793810374e-07
B O 0 8.52827142807655e-05
and O 0 8.742340469325427e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.243756261487988e-09
located O 0 1.7330924251268698e-08
outside O 0 6.767988836031691e-09
those O 0 1.3419032551809096e-10
for O 0 1.209431443882636e-09
HLA O 0 4.8248002713080496e-06
, O 0 1.043390929211796e-09
that O 0 4.0082162588994663e-10
the O 0 1.3790503183841452e-09
order O 0 2.991111802685964e-09
of O 0 3.2030644803171526e-08
genese O 0 1.103569047700148e-06
is O 0 1.2823852202359376e-08
HLA O 0 8.523520733660916e-08
- O 0 7.376405264380992e-09
A O 0 1.3699695600166706e-08
, O 0 6.080960041066064e-11
- O 0 5.399964919661215e-10
B O 0 8.815276508755687e-09
, O 0 2.196220844075114e-10
- O 0 4.0720067318034125e-09
D O 0 3.1504356456935056e-08
, O 0 1.6670477220870339e-09
Factor O 0 1.78463395172912e-07
B O 0 2.0657694221881684e-06
allotype O 0 0.00023855330073274672
, O 0 6.872840572214045e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.1796272847419687e-09
that O 0 6.683904124615836e-11
the O 0 1.2280040317946828e-09
genes O 0 6.29682261887865e-09
coding O 0 2.6966444011122803e-07
for O 0 6.182976619584224e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.802877562795402e-07
Factor O 0 1.5734291082480922e-05
B O 0 1.571693019286613e-06
allotypes O 0 6.972169899199798e-07
are O 0 1.9526252836854496e-10
approximately O 0 2.2922366227362545e-09
3 O 0 4.595234415205596e-09
- O 0 6.939437469100085e-09
- O 0 1.927630854936524e-08
5 O 0 1.3047979585678604e-08
centimorgans O 0 1.4518369084726146e-07
from O 0 3.105071755271638e-09
the O 0 8.629880809962742e-09
HLA O 0 1.3461837511385966e-07
- O 0 1.2937897864162551e-08
A O 0 4.028546740642014e-08
and O 0 2.1991226617501525e-09
HLA O 0 2.8930938356097613e-07
- O 0 8.682056318320974e-08
B O 0 2.925650619545195e-07
loci O 0 5.976637851290434e-09
, O 0 1.2999971932270427e-10
and O 0 6.455454920617498e-11
that O 0 5.0468535600645126e-11
the O 0 1.5787867679861733e-09
apparent O 0 5.869880581599318e-08
lack O 0 3.289597216848961e-08
of O 0 1.543798155978493e-08
recombinants O 0 4.962432171851106e-07
between O 0 5.528329793946796e-09
the O 0 1.2633950774443292e-08
Factor O 0 4.6580541379626084e-07
B O 0 6.2157873799151275e-06
gene O 0 1.3786456065645325e-06
and O 0 2.4940720777522074e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.216065925291332e-06
suggests O 0 7.819934033648224e-09
that O 0 2.507788421368673e-11
these O 0 2.415620481421854e-11
two O 0 3.4035008145139045e-10
genes O 0 5.5293107870113545e-09
lie O 0 8.988191666503553e-07
in O 0 2.776174845564583e-08
close O 0 1.3226151622802718e-06
proximity O 0 5.945657335360011e-07
to O 0 3.5846201562605984e-09
one O 0 1.3859359881962519e-08
another O 0 1.4290473870914866e-07
. O 0 1.5623660942765127e-07

Distribution O 0 2.6808133952727076e-06
of O 0 1.0856384733415325e-06
emerin O 0 0.0006296865176409483
and O 0 1.4575721252185758e-07
lamins O 0 0.036491475999355316
in O 0 5.054356222444767e-08
the O 0 6.401355534535469e-08
heart O 0 1.0542286190684536e-06
and O 0 1.2309729902071354e-09
implications O 0 9.32273209741652e-08
for O 0 5.272898206953869e-08
Emery B-Disease 1 0.9832081198692322
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999566078186035
. O 0 1.2785492344846716e-06

Emerin O 0 0.016405748203396797
is O 0 2.778890859644889e-07
a O 0 1.9189666033980757e-07
nuclear O 0 8.859517947712447e-06
membrane O 0 1.5961184544721618e-05
protein O 0 7.429895987343116e-08
which O 0 5.697780580682377e-10
is O 0 1.4526111424828514e-09
missing O 0 1.3090085815292696e-07
or O 0 3.76754414332936e-08
defective O 0 1.632787643757183e-06
in O 0 1.6502679045515833e-07
Emery B-Disease 1 0.8951147198677063
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00046478508738800883
EDMD B-Disease 1 1.0
) O 0 1.8561497654445702e-06
. O 0 3.595811790546577e-07

It O 0 1.249629519861628e-07
is O 0 1.4364719191917175e-08
one O 0 4.1835699349235256e-09
member O 0 9.056396521600618e-09
of O 0 1.5084670224041474e-07
a O 0 1.8051038352950854e-07
family O 0 1.7239658234302624e-07
of O 0 1.1540502100615413e-06
lamina O 1 0.9999960660934448
- O 1 0.6653808355331421
associated O 0 1.4084374697631574e-06
proteins O 0 1.962420626000494e-08
which O 0 1.2559725481864348e-09
includes O 0 8.512632376778129e-09
LAP1 O 0 0.0006756482762284577
, O 0 2.363138840166812e-08
LAP2 O 0 0.00012743566185235977
and O 0 2.9541913804109754e-08
lamin O 0 2.6617310140863992e-05
B O 0 5.948403850197792e-05
receptor O 0 1.4634440049121622e-05
( O 0 6.764454383301199e-07
LBR O 0 0.003476799698546529
) O 0 2.806118573062122e-07
. O 0 2.7970264682153356e-07

A O 0 1.0711218237702269e-05
panel O 0 6.378308512466901e-07
of O 0 2.481076251115155e-07
16 O 0 1.4688190219658281e-07
monoclonal O 0 1.272425436127378e-07
antibodies O 0 1.0392879445930703e-08
( O 0 1.278811811999958e-08
mAbs O 0 3.173994969074556e-07
) O 0 1.1326786175658299e-09
has O 0 3.2603711397349855e-11
been O 0 8.246123228694557e-11
mapped O 0 9.922663801731346e-10
to O 0 9.737383122043752e-11
six O 0 3.8879355290788453e-10
specific O 0 2.5181429164078395e-10
sites O 0 9.011935642178059e-10
throughout O 0 1.5854556556504917e-09
the O 0 8.281848984381668e-09
emerin O 0 6.557922915817471e-07
molecule O 0 1.2734884258236434e-08
using O 0 1.3721027647406459e-09
phage O 0 1.1711535741198986e-08
- O 0 5.842121009180801e-09
displayed O 0 6.159115883974664e-09
peptide O 0 1.4685186400242856e-08
libraries O 0 1.986370401496629e-09
and O 0 6.41176972626667e-11
has O 0 4.954244306465405e-11
been O 0 2.8704716381611206e-10
used O 0 6.846079259048565e-10
to O 0 2.32854735493504e-09
localize O 0 1.1950239240832161e-05
emerin O 0 8.035575592657551e-05
in O 0 3.6721772289638466e-08
human O 0 2.4780558049997126e-08
and O 0 1.5474803660708858e-08
rabbit O 0 1.2029019671899732e-05
heart O 0 3.831916183116846e-05
. O 0 4.808525204680336e-07

Several O 0 6.624666184507078e-07
mAbs O 0 4.540429017652059e-06
against O 0 1.7957558995362888e-08
different O 0 2.051361391863793e-08
emerin O 0 2.603914799692575e-05
epitopes O 0 2.744847506619408e-06
did O 0 2.2656751141880704e-08
not O 0 2.18904516735563e-09
recognize O 0 8.956419605965493e-09
intercalated O 0 4.11884411732899e-06
discs O 0 2.2928338694327977e-06
in O 0 1.1531108512485844e-08
the O 0 2.6957387433412805e-08
heart O 0 2.0276809209462954e-06
, O 0 1.1499386998181649e-09
though O 0 4.771809614112499e-10
they O 0 1.3556562816763318e-10
recognized O 0 2.7983368955375454e-09
cardiomyocyte O 0 5.542569283534249e-07
nuclei O 0 1.986783075835774e-07
strongly O 0 4.842845235941695e-09
, O 0 1.00012131909466e-09
both O 0 1.365442869882827e-09
at O 0 1.0027580543692238e-07
the O 0 4.410388143583077e-08
rim O 0 5.755950951424893e-07
and O 0 3.7340472935909474e-09
in O 0 2.1537113426006727e-08
intranuclear O 0 1.8710554286371917e-05
spots O 0 8.666601161166909e-07
or O 0 2.5931620939445565e-07
channels O 0 1.3540266081690788e-06
. O 0 4.924547170048754e-07

A O 0 0.00011783995432779193
polyclonal O 0 0.00025029340758919716
rabbit O 0 9.977630725188646e-06
antiserum O 0 1.2589572179422248e-05
against O 0 1.265636058178643e-07
emerin O 0 2.2137359337648377e-05
did O 0 3.8996518014755566e-08
recognize O 0 1.2598047938183754e-08
both O 0 3.78809250634049e-09
nuclear O 0 2.910072453232715e-06
membrane O 0 2.712323066589306e-06
and O 0 4.103223538720613e-09
intercalated O 0 1.1480665307317395e-06
discs O 0 2.2846741387638758e-07
but O 0 6.496986282300554e-10
, O 0 2.4712801249826555e-10
after O 0 2.708911539528458e-09
affinity O 0 1.0895883306716314e-08
purification O 0 7.221204612051224e-08
against O 0 1.1899369489754008e-08
a O 0 6.44733049171009e-08
pure O 0 1.4739226799065364e-06
- O 0 4.420368497903837e-07
emerin O 0 3.4386271181574557e-06
band O 0 1.438536969544657e-07
on O 0 1.5795224683756715e-08
a O 0 6.536978069959787e-09
western O 0 1.8015674285720706e-08
blot O 0 5.450575599752483e-07
, O 0 2.4253921093730924e-09
it O 0 6.684723330430131e-10
stained O 0 2.2499571628031845e-07
only O 0 6.8925825047472244e-09
the O 0 4.49379129463523e-08
nuclear O 0 9.0978801381425e-06
membrane O 0 7.091559382388368e-05
. O 0 1.1654154832285712e-06

These O 0 1.0710504483313343e-07
results O 0 2.3616834710082912e-08
would O 0 1.1554793788448592e-09
not O 0 9.259459310406726e-10
be O 0 3.845750384812163e-09
expected O 0 2.7586979811644596e-08
if O 0 3.588370489637782e-08
immunostaining O 0 2.5797469788813032e-05
at O 0 9.116857881963369e-07
intercalated O 0 4.424638063937891e-06
discs O 0 4.640872077743552e-07
were O 0 9.067009365537615e-09
due O 0 8.395759643065048e-09
to O 0 1.1306475755645806e-09
a O 0 2.8023001696908523e-09
product O 0 1.142089423034065e-09
of O 0 3.0660178840236085e-09
the O 0 9.226021724373368e-09
emerin O 0 2.2232045466807904e-06
gene O 0 1.5204894010523162e-09
and O 0 1.0220838758678852e-10
, O 0 5.871506059129672e-11
therefore O 0 5.623241872143581e-10
, O 0 7.2293115938038e-11
cast O 0 1.1056490167860034e-09
some O 0 6.257748486060422e-11
doubt O 0 1.6268100200278468e-09
upon O 0 9.211370000095087e-10
the O 0 7.840375570999925e-10
hypothesis O 0 1.2091830647875668e-08
that O 0 1.089945245169588e-09
cardiac B-Disease 1 0.5797866582870483
defects I-Disease 0 0.0007129220757633448
in O 0 1.4400993677554652e-06
EDMD B-Disease 1 1.0
are O 0 9.087165153687238e-08
caused O 0 1.3268660836729396e-07
by O 0 5.745089293185401e-09
absence O 0 8.141827834151627e-07
of O 0 2.093311195494607e-06
emerin O 0 0.0005358877242542803
from O 0 7.135733426366642e-07
intercalated O 0 0.00014117815589997917
discs O 0 4.505060860537924e-05
. O 0 2.365020463912515e-06

Although O 0 3.7320664887374733e-06
emerin O 0 7.125567935872823e-05
was O 0 1.020962486109056e-06
abundant O 0 1.9618150304268056e-07
in O 0 1.3734387849240193e-08
the O 0 4.587416668755395e-08
membranes O 0 7.342557069023314e-07
of O 0 3.03814744029296e-07
cardiomyocyte O 0 0.00024058092094492167
nuclei O 0 5.060272542323219e-06
, O 0 4.89638107836754e-09
it O 0 6.118541784339016e-10
was O 0 3.707945239739274e-08
absent O 0 2.1614686929183335e-08
from O 0 2.0654196131175695e-09
many O 0 5.006416392561164e-10
non O 0 1.3434315349059034e-07
- O 0 7.709072633588221e-07
myocyte O 0 0.0009687112760730088
cells O 0 9.067738915291557e-08
in O 0 7.160579240661491e-09
the O 0 1.8207158802852064e-07
heart O 0 1.43590559673612e-05
. O 0 5.599518431154138e-07

This O 0 5.932449553824881e-08
distribution O 0 2.085419126274246e-08
of O 0 6.594461154918463e-08
emerin O 0 3.763184940908104e-05
was O 0 1.484457214928625e-07
similar O 0 8.887411362401565e-10
to O 0 3.101625067891689e-10
that O 0 3.065396547707877e-10
of O 0 2.3257078041183377e-08
lamin O 0 3.057609546885942e-06
A O 0 2.549724911204976e-07
, O 0 7.603792040455915e-10
a O 0 2.8260567219717814e-09
candidate O 0 1.90501969754564e-09
gene O 0 7.700043935798817e-10
for O 0 3.1240560138812157e-10
an O 0 5.999285956903577e-09
autosomal O 0 1.5235274020142242e-07
form O 0 1.5829552069135389e-07
of O 1 0.7354609966278076
EDMD B-Disease 1 1.0
. O 0 8.811130828689784e-05

In O 0 6.555565619237314e-07
contrast O 0 4.962006983078027e-07
, O 0 1.252908674587161e-07
lamin O 0 0.00021211538114584982
B1 O 0 0.03613788262009621
was O 0 7.04392164152523e-07
absent O 0 3.827557577551488e-07
from O 0 4.748544668586874e-08
cardiomyocyte O 0 4.328023351263255e-06
nuclei O 0 8.381776410715247e-07
, O 0 5.3476942873942335e-09
showing O 0 8.305548959697262e-08
that O 0 6.970079624579739e-09
lamin O 0 7.581606951134745e-06
B1 O 0 0.0004023624351248145
is O 0 7.162064830090742e-10
not O 0 1.0320963528265281e-10
essential O 0 4.040179302222668e-09
for O 0 1.1060244942129316e-09
localization O 0 3.3462242754467297e-06
of O 0 1.1417822065595828e-07
emerin O 0 7.212076525320299e-06
to O 0 3.194766406977578e-08
the O 0 6.579158480235492e-07
nuclear O 0 0.00029981747502461076
lamina O 1 0.9986041188240051
. O 0 4.253993211023044e-06

Lamin O 1 0.999983549118042
B1 O 1 0.9999533891677856
is O 0 7.213701991304333e-08
also O 0 1.5521354201908366e-09
almost O 0 1.698521501225514e-08
completely O 0 2.3058144904553046e-07
absent O 0 7.821576559763344e-07
from O 0 3.469795899491146e-07
skeletal O 1 0.9579599499702454
muscle O 0 4.733424793812446e-05
nuclei O 0 0.0006255284533835948
. O 0 3.836997620965121e-06

In O 0 2.1643932996084914e-05
EDMD B-Disease 1 1.0
, O 0 2.4580959490094756e-08
the O 0 9.674745449217426e-09
additional O 0 1.4628072975142459e-08
absence O 0 2.4256991082438617e-07
of O 0 2.277713065268472e-06
lamin O 0 0.05857423320412636
B1 O 1 0.9999924898147583
from O 0 2.292313411089708e-06
heart O 1 0.6065054535865784
and O 0 1.2961284028278897e-06
skeletal O 1 1.0
muscle O 0 0.025914981961250305
nuclei O 0 0.2300104796886444
which O 0 2.5991010232928602e-08
already O 0 1.8269387780378565e-08
lack O 0 3.5340394788363483e-07
emerin O 0 2.6635594622348435e-05
may O 0 2.3075197308486395e-09
offer O 0 1.9010042151546003e-10
an O 0 1.3523042408092323e-10
alternative O 0 7.750450836674361e-10
explanation O 0 4.919352925014664e-09
of O 0 2.4107809082352105e-09
why O 0 1.326821874592099e-09
these O 0 4.5451797880957656e-10
tissues O 0 7.852666961127852e-09
are O 0 4.106118223212718e-10
particularly O 0 5.925842039289364e-09
affected O 0 8.838948239997535e-09
. O 0 7.24943705066039e-09
. O 0 1.6059891549957683e-07

Genetic O 0 4.9351059715263546e-05
mapping O 0 1.2045895346091129e-05
of O 0 2.4060886971710715e-06
the O 0 4.998448275728151e-06
copper B-Disease 1 0.99998939037323
toxicosis I-Disease 1 1.0
locus O 0 0.001599353039637208
in O 0 1.3656358532898594e-06
Bedlington O 1 0.8721421957015991
terriers O 0 3.386755270184949e-05
to O 0 3.6895045241180924e-08
dog O 0 2.7293580728837696e-07
chromosome O 0 1.126444644228286e-07
10 O 0 4.549102428086371e-09
, O 0 2.2276003264209976e-10
in O 0 7.240189003887565e-10
a O 0 8.30109581073657e-09
region O 0 5.2467843403292136e-08
syntenic O 0 5.565092124015791e-06
to O 0 1.0477068990155658e-08
human O 0 7.940523261140697e-08
chromosome O 0 4.5003960735812143e-07
region O 0 3.0292881092464086e-07
2p13 O 0 0.0003221829829271883
- O 0 0.0001415852748323232
p16 O 0 5.662512194248848e-05
. O 0 6.192123578330211e-07

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 0.9999994039535522
is O 0 1.9362651926257968e-07
recognized O 0 2.3002000304472858e-08
as O 0 7.342533692167308e-09
an O 0 2.836213752743788e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.0007926743128336966
man O 1 0.7281484007835388
, O 0 4.5989813202140795e-07
mouse O 0 1.0897745596594177e-05
, O 0 4.570194533926042e-08
rat O 0 1.5081020137586165e-05
and O 0 3.6445317874722605e-08
dog O 0 1.8332068066229112e-05
. O 0 1.8937737422675127e-06

The O 0 4.418831395014422e-06
major O 0 6.502833457489032e-06
cause O 0 9.351418157166336e-06
of O 0 0.0006431168876588345
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 1.0
in O 0 1.8540090422902722e-06
man O 0 1.0765166734927334e-05
is O 0 3.02206828450835e-08
a O 0 1.564235816431392e-07
dysfunctional O 0 9.961958130588755e-05
ATP7B O 1 0.9862098097801208
gene O 0 1.8225331643861864e-07
, O 0 4.8410258024489394e-09
causing O 0 6.067309641366592e-07
Wilson B-Disease 0 0.000250263576162979
disease I-Disease 1 0.9991975426673889
( O 0 0.00021212590218055993
WD B-Disease 1 0.999998927116394
) O 0 1.0744157634690055e-06
. O 0 4.088048228823027e-07

Mutations O 0 7.410474154312396e-06
in O 0 9.858908356363827e-08
the O 0 2.8061052148586896e-07
ATP7B O 1 0.9927198886871338
genes O 0 1.1149638368124215e-07
have O 0 9.394983679911206e-10
also O 0 4.267244890776567e-10
been O 0 2.093117013046708e-09
demonstrated O 0 2.3999730203172476e-08
in O 0 2.4575147250516238e-08
mouse O 0 5.209807909523079e-07
and O 0 3.888147404040865e-08
rat O 0 4.658061880036257e-05
. O 0 3.8685965364493313e-07

The O 0 9.690133992990013e-06
ATP7B O 1 0.9585565328598022
gene O 0 3.768248859614687e-07
has O 0 1.7570160881774655e-09
been O 0 2.329497927888724e-09
excluded O 0 6.854667500277856e-09
in O 0 5.393397950470558e-10
the O 0 1.7995059886644071e-09
much O 0 1.648469272197417e-08
rarer O 0 5.64700030736276e-07
human O 0 2.656690867297584e-07
copper B-Disease 1 0.9999996423721313
overload I-Disease 1 1.0
disease O 1 0.9999833106994629
non B-Disease 1 0.5553271174430847
- I-Disease 0 5.3674822993343696e-05
Indian I-Disease 0 2.3011642042547464e-05
childhood I-Disease 0 0.3065897822380066
cirrhosis I-Disease 1 0.9999309778213501
, O 0 2.3910664559423367e-09
indicating O 0 2.109476611167338e-07
genetic O 0 2.3561926809634315e-07
heterogeneity O 0 8.177304380296846e-07
. O 0 1.0506609982030568e-07

By O 0 1.0847344356079702e-07
investigating O 0 8.342875048583664e-07
the O 0 2.1152038698346587e-07
common O 0 6.83996404404752e-07
autosomal O 0 0.008771004155278206
recessive O 0 0.0008724560611881316
copper B-Disease 1 0.9999998807907104
toxicosis I-Disease 1 1.0
( O 0 0.005700439680367708
CT B-Disease 1 0.9999998807907104
) O 0 2.3940026494528865e-07
in O 0 8.345503488271788e-08
Bedlington O 0 0.16387982666492462
terriers O 0 3.7716320093750255e-06
, O 0 6.135522090389145e-10
we O 0 9.859990601768231e-10
have O 0 1.4229828426692848e-10
identified O 0 2.2054484904998617e-09
a O 0 1.8514512145628714e-09
new O 0 1.1385637987970654e-09
locus O 0 8.200586876228044e-08
involved O 0 1.3328644854482263e-08
in O 0 2.0058497796071606e-07
progressive O 1 0.9999996423721313
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.71252013387857e-05

We O 0 2.86316208075732e-07
examined O 0 6.091387376727653e-07
whether O 0 1.248695582489745e-07
the O 0 1.7227462194568943e-06
WD B-Disease 1 0.9948539137840271
gene O 0 7.707816394031397e-07
ATP7B O 0 0.00017043032858055085
was O 0 2.705105828226806e-07
also O 0 3.5087295291447163e-09
causative O 0 1.277263095289527e-07
for O 0 2.4832922385087386e-09
CT B-Disease 0 6.61040621707798e-06
by O 0 6.050377088229197e-09
investigating O 0 4.084377280832996e-07
the O 0 1.3172788726478757e-07
chromosomal O 0 8.326903298438992e-06
co O 0 6.68565699015744e-05
- O 0 0.00016991498705465347
localization O 0 0.000692659814376384
of O 0 1.7993494338952587e-06
ATP7B O 0 0.025032198056578636
and O 0 3.6007115511438315e-08
C04107 O 0 2.062928388113505e-06
, O 0 1.0468793609774707e-09
using O 0 1.2744987287760523e-09
fluorescence O 0 6.896212045859329e-09
in O 0 2.1979735809196654e-09
situ O 0 8.730509648557927e-07
hybridization O 0 9.701081893354058e-08
( O 0 2.3467666920851116e-08
FISH O 0 3.0316351740111713e-07
) O 0 1.7661324847040305e-08
. O 0 4.7388812873805364e-08

C04107 O 0 0.00034519837936386466
is O 0 1.0749060663783894e-07
an O 0 2.83172383319652e-08
anonymous O 0 5.942919187873485e-07
microsatellite O 0 7.135732175811427e-06
marker O 0 1.6457569245176273e-06
closely O 0 2.9165911996642535e-07
linked O 0 2.2722219910065178e-06
to O 0 2.489038877229177e-07
CT B-Disease 1 0.9994944334030151
. O 0 5.24785309607978e-06

However O 0 3.984047452831874e-06
, O 0 1.2096049886167748e-06
BAC O 0 0.004860747139900923
clones O 0 1.5674628457418294e-06
containing O 0 2.9913249477431236e-07
ATP7B O 0 0.0014107479946687818
and O 0 4.411279874716456e-08
C04107 O 0 3.1846236652199877e-06
mapped O 0 2.1096396096709213e-07
to O 0 4.002725262353124e-09
the O 0 3.8192325746422284e-08
canine O 0 1.2676185860982514e-06
chromosome O 0 4.04061751169138e-07
regions O 0 1.5670092778918843e-08
CFA22q11 O 0 0.0002309011179022491
and O 0 1.6585550710601638e-08
CFA10q26 O 0 0.0009723099647089839
, O 0 4.696909083889977e-09
respectively O 0 1.9669325723725706e-08
, O 0 1.34347899471976e-09
demonstrating O 0 8.725584876856374e-08
that O 0 1.344502464917241e-08
WD B-Disease 0 2.9992141207912937e-05
cannot O 0 2.4680886667738378e-08
be O 0 1.3139133336892428e-08
homologous O 0 3.1469829764319e-07
to O 0 1.0275957151861803e-07
CT B-Disease 0 0.04147633910179138
. O 0 2.8778481464541983e-06

The O 0 1.7665386621956713e-05
copper O 0 0.0006637339829467237
transport O 0 1.1480564353405498e-05
genes O 0 1.4895178537699394e-05
CTR1 O 1 0.9822606444358826
and O 0 1.1135568911413429e-07
CTR2 O 1 0.869939923286438
were O 0 7.780704436299857e-08
also O 0 1.1133605148927472e-09
excluded O 0 2.5126940528252817e-09
as O 0 3.600282016957834e-10
candidate O 0 1.4951757609793503e-09
genes O 0 8.730720590932606e-10
for O 0 8.924730954262827e-10
CT B-Disease 0 9.820404375204816e-05
since O 0 6.595062274072916e-09
they O 0 5.889421172966536e-10
both O 0 1.3295478051844611e-09
mapped O 0 1.2464087717489747e-07
to O 0 1.5036103917509536e-08
canine O 0 4.3559780351642985e-06
chromosome O 0 2.587171820778167e-06
region O 0 1.1049876320612384e-06
CFA11q22 O 1 0.6641640067100525
. O 0 1.0708968147810083e-06

2 O 0 4.157147850492038e-05
- O 0 2.9072292818455026e-05
22 O 0 8.216560672735795e-06
. O 0 1.2132325082347961e-06

5 O 0 9.880671859718859e-05
. O 0 1.0827808182511944e-05

A O 0 1.0945395843009464e-05
transcribed O 0 4.104570962226717e-06
sequence O 0 1.8218328534658212e-07
identified O 0 4.103350903505998e-08
from O 0 4.029681921480233e-09
the O 0 1.4689445215765318e-08
C04107 O 0 4.9418599701311905e-06
- O 0 8.685432248967118e-07
containing O 0 4.5389512592919345e-07
BAC O 0 0.00020439617219381034
was O 0 2.542566157615056e-08
found O 0 6.212737546640312e-10
to O 0 2.6027593968969143e-10
be O 0 4.726797842025121e-10
homologous O 0 1.6257656554330424e-08
to O 0 5.943384118189954e-10
a O 0 8.869583290049832e-09
gene O 0 1.5537318098779451e-09
expressed O 0 2.767359119637547e-10
from O 0 2.982043056931616e-09
human O 0 1.0748196110910158e-08
chromosome O 0 9.301383130377872e-08
2p13 O 0 1.549804210299044e-06
- O 0 7.710492013757175e-07
p16 O 0 3.991292487626197e-07
, O 0 1.8523121925184682e-10
a O 0 6.594756962741144e-10
region O 0 1.1138108213515352e-09
devoid O 0 9.549222568239202e-08
of O 0 4.3867696142285695e-09
any O 0 5.418352433395057e-09
positional O 0 4.2417488543833315e-07
candidate O 0 2.070477762572409e-07
genes O 0 1.503370015143446e-07
. O 0 1.0973764830168875e-07

Molecular O 0 7.909269334049895e-05
analysis O 0 1.1256300922468654e-06
of O 0 9.866357686405536e-08
the O 0 1.4514796475850744e-07
APC B-Disease 0 1.4017027751833666e-06
gene O 0 2.3145814154190703e-09
in O 0 6.531677421151016e-10
205 O 0 1.0823344887000985e-08
families O 0 9.279155221975088e-10
: O 0 4.726455338222024e-10
extended O 0 2.9585221383854332e-08
genotype O 0 3.4583422348077875e-07
- O 0 4.255512635609193e-07
phenotype O 0 1.1538351429862814e-07
correlations O 0 1.0766235192249951e-07
in O 0 4.567072497962954e-09
FAP B-Disease 0 6.826904552781343e-08
and O 0 7.541334917648967e-11
evidence O 0 3.456572361670851e-09
for O 0 3.47817025181385e-10
the O 0 2.4858464175991912e-09
role O 0 2.2821168954578752e-08
of O 0 1.193854473058309e-07
APC B-Disease 0 6.840146511422063e-07
amino O 0 1.9073402413027907e-08
acid O 0 6.252183659682942e-09
changes O 0 2.8293682952096333e-09
in O 0 4.521701157500502e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 1.1661309144983534e-05

BACKGROUND O 0 0.022143324837088585
/ O 0 0.0001703301095403731
AIMS O 0 3.931886112695793e-06
The O 0 8.355313951824428e-08
development O 0 1.2581510873133084e-06
of O 0 0.005092444829642773
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.57466597936218e-09
a O 0 3.2302789332305792e-09
variable O 0 4.253611241011868e-09
range O 0 2.289012090983533e-09
of O 0 1.1012466494264572e-08
extracolonic O 0 1.2381419765006285e-05
manifestations O 0 1.3159973605070263e-05
in O 0 6.275857685977826e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.8335839509963989
FAP B-Disease 0 0.00036571722012013197
) O 0 4.698728073293523e-09
is O 0 3.025012185187137e-10
the O 0 1.8889692032786343e-09
result O 0 1.0173256903556194e-08
of O 0 1.2025262208226195e-07
the O 0 7.30023828054982e-07
dominant O 0 6.115371797932312e-05
inheritance O 0 0.000537243380676955
of O 1 0.8358059525489807
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.06970690935850143
APC B-Disease 0 0.0006196029135026038
) O 0 2.1072165168334323e-07
gene O 0 2.726397667629499e-07
mutations O 0 2.0437113334992318e-07
. O 0 5.817982469125127e-07

In O 0 8.6075772287586e-08
this O 0 1.2136788241079444e-09
study O 0 1.9057972977520876e-09
, O 0 8.377611798726647e-11
direct O 0 4.3190778731272417e-10
mutation O 0 8.633592452067518e-11
analysis O 0 4.321566160481183e-10
of O 0 1.0779253045711812e-09
the O 0 6.8753296389445495e-09
APC B-Disease 0 3.672139428090304e-07
gene O 0 1.5491776750309327e-09
was O 0 5.024939575548615e-09
performed O 0 2.2668624755084466e-09
to O 0 3.9534578388789043e-10
determine O 0 1.6255082613270133e-08
genotype O 0 4.5515261604123225e-07
- O 0 2.493049180429807e-07
phenotype O 0 1.6734423624598094e-08
correlations O 0 1.330913423913671e-08
for O 0 4.05790900881442e-10
nine O 0 1.8860324857428168e-08
extracolonic O 0 2.4924124772951473e-06
manifestations O 0 2.0702903213987156e-07
and O 0 7.657131595451006e-10
to O 0 4.1948741702491077e-10
investigate O 0 9.222837604738743e-09
the O 0 4.842956258244158e-09
incidence O 0 3.1859011073720467e-07
of O 0 5.174759465376155e-08
APC B-Disease 0 2.7133711455462617e-07
mutations O 0 7.041108807115393e-10
in O 0 2.1272064110178235e-09
non O 0 5.1798611821141094e-05
- O 1 0.9999347925186157
FAP O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.584904778923374e-06

METHODS O 0 5.456085636978969e-05
The O 0 6.859861969132908e-06
APC B-Disease 0 1.1493160855025053e-05
gene O 0 4.093345040701024e-08
was O 0 5.126650748366046e-08
analysed O 0 1.4711825713220605e-07
in O 0 1.9374541082584074e-08
190 O 0 1.1520012321852846e-07
unrelated O 0 4.3935290250374237e-07
FAP B-Disease 0 2.9366222520366136e-07
and O 0 1.675303451520449e-09
15 O 0 5.7190717939192837e-08
non O 0 0.00017491601465735584
- O 1 0.9998519420623779
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.192175471322116e-08
using O 0 1.200217081276378e-08
denaturing O 0 4.3831274524563923e-05
gradient O 0 8.813025260678842e-07
gel O 0 1.435360417190168e-07
electrophoresis O 0 3.647425046438002e-07
, O 0 5.612440512337002e-10
the O 0 1.2294617546260156e-09
protein O 0 2.7630195909011945e-09
truncation O 0 2.4083739447178232e-08
test O 0 5.022713911451149e-10
, O 0 1.4992787567003063e-10
and O 0 3.590640007544721e-10
direct O 0 3.659465974692466e-08
sequencing O 0 5.275202283883118e-07
. O 0 7.572825921897675e-08

RESULTS O 0 6.609794945688918e-05
Chain O 0 2.025959111051634e-05
terminating O 0 1.2065495411661686e-06
signals O 0 6.898451232473235e-08
were O 0 1.8322071637655313e-09
only O 0 2.882173943952182e-10
identified O 0 1.3790923958367785e-09
in O 0 1.3080341254578798e-09
patients O 0 1.2342313837621077e-09
belonging O 0 1.4942420989427774e-07
to O 0 4.6825525679139446e-09
the O 0 4.09057889783071e-07
FAP B-Disease 0 2.188094185839873e-06
group O 0 9.903571296376867e-09
( O 0 5.459474650137963e-09
105 O 0 1.6033322935982142e-07
patients O 0 5.052810614358805e-09
) O 0 1.259989801383199e-08
. O 0 5.812880488065275e-08

Amino O 0 3.7797444747411646e-06
acid O 0 6.398401097840178e-08
changes O 0 7.596602236148442e-10
were O 0 2.0963972779952655e-09
identified O 0 5.361257215952264e-09
in O 0 5.5224463890724e-10
four O 0 1.2678941230248597e-09
patients O 0 3.2248353987185396e-10
, O 0 2.2263429988456096e-10
three O 0 9.043653048657063e-10
of O 0 6.421692688718394e-08
whom O 0 5.572042383050757e-08
belonged O 0 1.8694752725423314e-05
to O 0 5.982990991526549e-09
the O 0 6.769320748389873e-08
non O 0 9.052822861121967e-06
- O 0 6.048087925591972e-06
FAP O 0 1.9314841210871236e-06
group O 0 8.225428338448637e-09
of O 0 8.836877896101214e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0032354509457945824
. O 0 6.065429261070676e-07

Genotype O 0 0.0028006499633193016
- O 0 4.098449062439613e-05
phenotype O 0 1.02924286693451e-06
correlations O 0 1.9833809972169547e-07
identified O 0 2.4093294470617366e-08
significant O 0 2.585482716810361e-09
differences O 0 3.2921125825424724e-09
in O 0 7.797811840681845e-10
the O 0 1.6517416323580392e-09
nature O 0 8.90895268668146e-09
of O 0 4.068605896634381e-09
certain O 0 2.774696472584992e-09
extracolonic O 0 5.1874062592105474e-06
manifestations O 0 5.948555781287723e-07
in O 0 4.01499988811338e-08
FAP B-Disease 0 1.5855297306188731e-06
patients O 0 2.3941835181062743e-09
belonging O 0 2.4351090033292166e-08
to O 0 2.4503803430775406e-09
three O 0 1.5566396172062014e-08
mutation O 0 4.824298827088569e-08
subgroups O 0 1.0178787306358572e-06
. O 0 2.53150744811137e-07

CONCLUSIONS O 0 3.169990668538958e-05
Extended O 0 6.377727459039306e-06
genotype O 0 6.726899300701916e-06
- O 0 1.8031302033705288e-06
phenotype O 0 2.426411640499282e-07
correlations O 0 7.963075887573723e-08
made O 0 2.6548752085631122e-09
in O 0 7.073333030405138e-10
this O 0 2.8519714367902793e-10
study O 0 1.0427860797079802e-09
may O 0 4.0575529047792713e-10
have O 0 6.804574265162344e-11
the O 0 5.856756191136014e-10
potential O 0 1.5201935266162536e-09
to O 0 1.378802350071595e-10
determine O 0 1.3686760613751403e-09
the O 0 5.327859264880885e-10
most O 0 3.502741152683342e-11
appropriate O 0 3.6975597583754904e-10
surveillance O 0 5.38908162539542e-09
and O 0 1.4479797916244763e-10
prophylactic O 0 1.5252676632826478e-07
treatment O 0 1.1925408216484357e-08
regimens O 0 2.6517492202060566e-08
for O 0 1.44587675166008e-10
those O 0 1.27226354451615e-10
patients O 0 1.4550644023003656e-10
with O 0 2.373294095969758e-11
mutations O 0 1.2994029185975364e-09
associated O 0 7.184205230714724e-09
with O 0 2.2390087561774408e-09
life O 0 2.0826898889936274e-06
threatening O 0 9.196427868118917e-07
conditions O 0 2.6387328944110777e-06
. O 0 8.152636041813821e-07

This O 0 7.607817309462916e-08
study O 0 1.7007032226956653e-08
also O 0 1.529266435706944e-10
provided O 0 1.5518452078921996e-09
evidence O 0 3.003987059102542e-09
for O 0 9.130465133955212e-11
the O 0 3.179688512489065e-09
pathological O 0 1.4946353985578753e-06
nature O 0 1.3882244687124512e-08
of O 0 9.796222499858231e-09
amino O 0 5.593837837380988e-09
acid O 0 2.08723260897159e-09
changes O 0 4.499713379679804e-10
in O 0 3.3230311835552584e-09
APC O 0 7.17341848144315e-08
associated O 0 3.143986848641589e-09
with O 0 2.689726774640633e-10
both O 0 4.604025161114578e-09
FAP B-Disease 0 3.8906551935724565e-07
and O 0 5.264404023819225e-09
non O 0 0.15622958540916443
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.839684596750885e-06
. O 0 1.62359334865414e-08
. O 0 5.0489791902919023e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.00023926170251797885
cancer B-Disease 1 0.9999938011169434
risk O 0 0.0008987041073851287
of O 0 0.0040509505197405815
the O 0 0.0001290645741391927
APC O 0 0.00017802311049308628
I1307K O 0 5.637199865304865e-05
polymorphism O 0 4.291591267246986e-06
. O 0 3.266140140567586e-07

Germ O 1 0.9997321963310242
- O 0 4.8233418056042865e-05
line O 0 5.245879037829582e-07
and O 0 6.58598642289121e-09
somatic O 0 1.9974315534909692e-07
truncating O 0 9.513206578048994e-07
mutations O 0 4.8798787233295116e-09
of O 0 5.615291787108845e-09
the O 0 1.7645263028498448e-08
APC B-Disease 0 3.741156717751437e-07
gene O 0 8.592854761069191e-10
are O 0 4.454291449573766e-11
thought O 0 2.8045030742163135e-09
to O 0 1.1381403597354733e-09
initiate O 0 1.7530419427203014e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9999998807907104
formation O 1 0.997631311416626
in O 1 0.9766309261322021
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0001769564114511013
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.2330661926826e-06
respectively O 0 2.8976026442251168e-05
. O 0 2.460665427861386e-06

Recently O 0 2.3291981960937846e-06
, O 0 1.802055393795854e-08
an O 0 2.4765247630398335e-08
isoleucine O 0 8.79828894539969e-06
- O 0 9.763367415871471e-06
- O 0 1.3291424693306908e-05
> O 0 6.207429123605834e-06
lysine O 0 1.1033217788281036e-06
polymorphism O 0 2.2975872582264856e-07
at O 0 8.835210962843121e-08
codon O 0 2.7363793719814566e-07
1307 O 0 3.980504061473766e-06
( O 0 2.157107203970554e-08
I1307K O 0 4.7261266900022747e-07
) O 0 5.047099183030923e-09
of O 0 1.3717894375986361e-08
the O 0 6.570330413069314e-08
APC B-Disease 0 1.9543583675840637e-06
gene O 0 6.15367889977847e-09
has O 0 1.7763095161438258e-10
been O 0 6.465821211776301e-10
identified O 0 2.9489541919502926e-09
in O 0 9.617778795600884e-10
6 O 0 2.1520893511706163e-08
% O 0 3.1003017930686383e-09
- O 0 5.802808455968034e-09
7 O 0 2.3747467992052407e-08
% O 0 1.1837157920524533e-09
of O 0 1.3976713120200657e-09
the O 0 3.246486635077872e-09
Ashkenazi O 0 2.257815481243597e-07
Jewish O 0 1.2280274575005024e-07
population O 0 3.0029216890881116e-09
. O 0 1.4827149286134045e-08

To O 0 4.902841155285387e-08
assess O 0 2.079578820257666e-07
the O 0 1.1022279977623839e-08
risk O 0 3.645845936262049e-08
of O 0 1.3151018052326435e-08
this O 0 3.752782529176102e-09
common O 0 1.053307219223143e-08
APC B-Disease 0 4.476865171909594e-07
allelic O 0 1.288562003765037e-07
variant O 0 1.7300746435466863e-07
in O 0 4.401303854706384e-08
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.933635722181862e-09
we O 0 1.0219382007292666e-09
have O 0 1.1056484894300667e-10
analyzed O 0 8.393613804003053e-09
a O 0 1.2242948876917126e-09
large O 0 2.136558707732661e-09
cohort O 0 7.523129141873142e-08
of O 0 1.621025091935735e-08
unselected O 0 0.00080834049731493
Ashkenazi O 0 5.837173375766724e-06
Jewish O 0 1.8343207841553522e-07
subjects O 0 1.7970533860989235e-07
with O 0 1.4880667364991496e-08
adenomatous B-Disease 0 0.0006273907492868602
polyps I-Disease 0 1.242485723196296e-06
and O 0 5.7922591167880455e-09
. O 0 5.505540556782762e-08
or O 1 0.9985079169273376
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 8.709071721568762e-07
for O 0 4.505789874542643e-08
the O 0 1.830083306231245e-06
APC O 0 2.445903555781115e-05
I1307K O 0 2.474694156262558e-05
polymorphism O 0 3.3215012535947608e-06
. O 0 2.118896560432404e-07

The O 0 7.149342127377167e-05
APC O 0 0.00010982921958202496
I1307K O 0 2.308111470483709e-05
allele O 0 1.6606735186996957e-07
was O 0 1.7824567066782038e-07
identified O 0 3.1540551503894676e-08
in O 0 4.658766705745165e-09
48 O 0 1.3682199373477033e-08
( O 0 1.2164181883989045e-09
10 O 0 5.527842072972078e-10
. O 0 6.654594930655122e-11
1 O 0 2.0585919635607297e-09
% O 0 8.132200468580209e-10
) O 0 3.453256014473993e-10
of O 0 5.843257877558017e-09
476 O 0 3.446387495387171e-07
patients O 0 4.524961028096186e-08
. O 0 1.371099500602213e-07

Compared O 0 7.591444273202796e-07
with O 0 6.758155701724888e-10
the O 0 1.9803969575349356e-09
frequency O 0 2.5474578002615544e-09
in O 0 6.043635036867556e-11
two O 0 5.3012347116243586e-12
separate O 0 6.388124751399715e-11
population O 0 2.2473540389755797e-11
control O 0 6.739234170716202e-10
groups O 0 4.779540999089171e-11
, O 0 1.266163146551591e-10
the O 0 1.2069295785011036e-08
APC O 0 7.50142760352901e-07
I1307K O 0 5.931091209276929e-07
allele O 0 5.428252070061035e-09
is O 0 3.0079533308580153e-10
associated O 0 7.155919745649442e-10
with O 0 1.1187284432168099e-10
an O 0 8.017460584319736e-10
estimated O 0 4.684598486903724e-09
relative O 0 8.903826653750002e-08
risk O 0 4.179528190206838e-08
of O 0 1.7389507434018014e-07
1 O 0 1.597594973645755e-06
. O 0 2.1169697106415697e-07

5 O 0 1.251491266884841e-05
- O 0 1.1452918442955706e-05
1 O 0 3.0500955290335696e-06
. O 0 7.501349159610982e-07

7 O 0 8.959094884630758e-06
for O 0 7.65764980314998e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999229907989502
( O 0 3.0007615805516252e-06
both O 0 1.1242231323649321e-07
P O 0 0.000748923106584698
= O 0 2.9173470466048457e-06
. O 0 2.0258580590848396e-08
01 O 0 4.516107310337247e-06
) O 0 5.5843738522298736e-08
. O 0 6.892901183164213e-08

Furthermore O 0 2.5628610273997765e-06
, O 0 1.311889974431324e-08
compared O 0 1.5100855677019354e-08
with O 0 4.5217491972948665e-09
noncarriers O 0 4.298591738916002e-05
, O 0 1.0588590981797097e-07
APC O 0 9.608354957890697e-06
I1307K O 0 4.779170467372751e-06
carriers O 0 2.5797010749784022e-08
had O 0 7.0214252190226034e-09
increased O 0 2.956940914344841e-09
numbers O 0 4.331190517348205e-09
of O 0 8.526805572728335e-08
adenomas B-Disease 1 0.9731467962265015
and O 0 5.814809469484317e-07
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9952511787414551
per O 0 5.412237896962324e-06
patient O 0 9.269890028917871e-07
( O 0 1.6078702813615564e-08
P O 0 3.0661944947496522e-06
= O 0 6.944524955088127e-08
. O 0 5.010580839126533e-10
03 O 0 1.186712168532722e-07
) O 0 2.3553381467422696e-10
, O 0 5.274771591734506e-11
as O 0 9.222863445179641e-11
well O 0 3.48765655244776e-10
as O 0 7.936003521002988e-10
a O 0 1.045881958816608e-08
younger O 0 1.2992201980921436e-08
age O 0 1.8832975001714658e-07
at O 0 3.408368002055795e-06
diagnosis O 0 4.016989259980619e-05
. O 0 5.044700515099976e-07

We O 0 6.330072324089997e-07
conclude O 0 3.2595728498563403e-06
that O 0 3.544819904277574e-08
the O 0 3.119563984910201e-07
APC O 0 9.130612852459308e-06
I1307K O 0 8.410446753259748e-06
variant O 0 4.901522743239184e-07
leads O 0 4.9047024219817104e-08
to O 0 3.773547252450271e-09
increased O 0 4.0877358742363867e-07
adenoma B-Disease 1 1.0
formation O 0 4.224259555485332e-06
and O 0 7.458289985606825e-09
directly O 0 1.905674729130169e-08
contributes O 0 2.403113930071754e-09
to O 0 1.0531112093481454e-10
3 O 0 9.088751973251874e-10
% O 0 2.793301423498207e-10
- O 0 3.947685789373878e-10
4 O 0 5.581759499051486e-10
% O 0 3.877950391362184e-11
of O 0 1.440064040236777e-10
all O 0 4.1589756638593656e-10
Ashkenazi O 0 5.1195161177020054e-06
Jewish O 0 0.028288941830396652
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.7434324339265e-06

The O 0 8.75262031740931e-08
estimated O 0 2.4400977238769883e-08
relative O 0 8.889606561979235e-08
risk O 0 1.0854066090359993e-08
for O 0 9.95637128298199e-10
carriers O 0 8.312661670117905e-09
may O 0 2.1814263728714423e-09
justify O 0 2.188103032096933e-08
specific O 0 1.3325334169422831e-09
clinical O 0 1.4821607940973536e-08
screening O 0 8.300410914152678e-10
for O 0 1.791163467546042e-10
the O 0 1.851338304881267e-09
360 O 0 5.854949858274949e-09
, O 0 6.20517873195503e-11
000 O 0 2.822867495311243e-09
Americans O 0 1.8657367317764795e-10
expected O 0 3.5213787441534805e-10
to O 0 4.751366522448564e-10
harbor O 0 9.676502799038644e-08
this O 0 1.799916882205821e-10
allele O 0 4.0995445926839125e-10
, O 0 4.3920977965683505e-11
and O 0 4.1629418662259e-11
genetic O 0 1.7200343371825966e-09
testing O 0 3.9103656424011035e-10
in O 0 3.3669492194299266e-10
the O 0 1.5612804382669765e-09
setting O 0 4.155252852910962e-08
of O 0 2.729659343003732e-08
long O 0 2.6155918320114324e-08
- O 0 2.7702611760105356e-08
term O 0 5.645181033742119e-08
- O 0 1.879453748188098e-08
outcome O 0 1.293950191438853e-08
studies O 0 5.393616220317199e-09
may O 0 3.781233104405146e-10
impact O 0 2.2115735909267187e-09
significantly O 0 5.6879998489023365e-09
on O 0 2.865251644834643e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.06656192243099213
in O 0 2.497185125349688e-09
this O 0 9.691104585485277e-10
population O 0 8.753581193232662e-10
. O 0 1.0193963007054663e-08

Localization O 0 0.0007049150299280882
of O 0 1.038611117110122e-06
human O 0 5.918457191000925e-07
BRCA1 O 0 2.6469038516552246e-07
and O 0 1.787430758959374e-09
its O 0 3.3896063733607207e-09
loss O 0 1.14282372010166e-07
in O 0 1.3873799886710003e-08
high O 0 4.947925162923639e-07
- O 0 4.4028956835973077e-07
grade O 0 1.7594231394468807e-05
, O 0 2.0837887859670445e-08
non B-Disease 0 0.000574611418414861
- I-Disease 1 0.72117018699646
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 5.903979854338104e-06

Although O 0 2.567153387644794e-07
the O 0 6.018278497776919e-08
link O 0 5.435869070424815e-07
between O 0 9.244609344705168e-08
the O 0 3.1741430461806885e-07
BRCA1 O 0 4.607152004609816e-05
tumour B-Disease 1 1.0
- O 0 0.004876942373812199
suppressor O 0 0.0002501540584489703
gene O 0 2.4868342052286607e-08
and O 0 2.622894346160365e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 8.036167855607346e-06
established O 0 1.7147817743534688e-07
, O 0 1.9614608548490509e-10
the O 0 9.058863104094428e-10
role O 0 3.399512671364846e-09
, O 0 7.919185446292332e-11
if O 0 1.0629228053282702e-10
any O 0 5.91114102110879e-10
, O 0 4.5665560222118984e-10
of O 0 1.4907712397871364e-08
BRCA1 O 0 4.598095060259766e-08
in O 0 8.871714918257112e-09
non B-Disease 0 0.08878841251134872
- I-Disease 1 0.9986181259155273
familial I-Disease 1 0.999971866607666
cancers I-Disease 1 0.9976085424423218
is O 0 1.2379317126942624e-07
unclear O 0 1.8187755586041021e-06
. O 0 1.6412698755630117e-07

BRCA1 O 0 3.516401557135396e-05
mutations O 0 1.019155533299454e-07
are O 0 5.890432031030457e-10
rare O 0 5.791551682676754e-09
in O 0 7.772869459188314e-09
sporadic B-Disease 0 0.00010830971586983651
cancers I-Disease 0 0.12114699184894562
, O 0 1.1372793373709555e-08
but O 0 7.085287023755882e-09
loss O 0 1.1405093118810328e-06
of O 0 5.55482017716713e-07
BRCA1 O 0 4.8745413039341656e-08
resulting O 0 1.6997262486384557e-09
from O 0 3.5560035471782214e-10
reduced O 0 1.0069719502681096e-09
expression O 0 2.318601977080448e-09
or O 0 7.717821381980627e-10
incorrect O 0 4.373904971544107e-08
subcellular O 0 1.456053723813966e-06
localization O 0 3.771412480091385e-07
is O 0 4.6446752000051106e-10
postulated O 0 8.817765184687687e-09
to O 0 1.423153817015077e-10
be O 0 2.681270205862063e-10
important O 0 2.343370608670625e-09
in O 0 3.930152647768637e-09
non B-Disease 0 0.00012805494770873338
- I-Disease 1 0.6934759020805359
familial I-Disease 1 0.9999996423721313
breast I-Disease 1 1.0
and I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00013359441072680056

Epigenetic O 0 0.032058656215667725
loss O 0 1.7682255929685198e-05
, O 0 1.1775394881397006e-08
however O 0 8.00861599259406e-09
, O 0 1.189650489230587e-09
has O 0 1.2400212801022548e-10
not O 0 7.520019329465555e-11
received O 0 4.119288798953846e-10
general O 0 5.055018625910179e-09
acceptance O 0 2.6073582404251283e-08
due O 0 1.1291911405919564e-08
to O 0 8.728854861139723e-10
controversy O 0 1.967896956500681e-08
regarding O 0 1.454558162805597e-08
the O 0 1.6691675597257927e-08
subcellular O 0 6.626848517043982e-06
localization O 0 2.354315483898972e-06
of O 0 5.2464439903587845e-08
BRCA1 O 0 4.018508548142563e-08
proteins O 0 1.5519102669614426e-09
, O 0 2.559403522450765e-10
reports O 0 3.4228111456258148e-09
of O 0 6.1344600510437886e-09
which O 0 2.57441928885882e-10
have O 0 8.919757293890385e-11
ranged O 0 2.292202871956306e-08
from O 0 1.5042205259163666e-09
exclusively O 0 6.255774120944579e-09
nuclear O 0 7.826606918115431e-08
, O 0 4.571663048125174e-10
to O 0 1.878412564382259e-10
conditionally O 0 1.173264152498632e-08
nuclear O 0 9.727410343884912e-08
, O 0 8.770192350127104e-10
to O 0 8.245498728243206e-10
the O 0 1.0292905017195153e-07
ER O 0 0.010460054501891136
/ O 0 2.225073103545583e-06
golgi O 0 1.2662855624512304e-05
, O 0 3.1736477890120796e-09
to O 0 6.487393733323188e-09
cytoplasmic O 0 2.1392670532804914e-06
invaginations O 0 9.218641935149208e-06
into O 0 5.5357290307256335e-08
the O 0 1.3311601776422322e-07
nucleus O 0 1.3918036529503297e-05
. O 0 9.732065109346877e-07

In O 0 3.789121194586187e-07
an O 0 2.031925916412547e-08
attempt O 0 2.2631008178564116e-08
to O 0 1.136814753444071e-09
resolve O 0 2.8829409970398956e-08
this O 0 1.393646420488892e-09
issue O 0 5.521964663302015e-09
, O 0 5.711827677501446e-10
we O 0 9.477848506023179e-10
have O 0 5.283010140466615e-10
comprehensively O 0 1.8612675489748653e-07
characterized O 0 6.384504303014182e-08
19 O 0 1.071771791316678e-07
anti O 0 1.8119821731943375e-07
- O 0 3.4620486530911876e-06
BRCA1 O 0 4.3808350369545224e-07
antibodies O 0 3.165457940212946e-08
. O 0 6.401330665539717e-08

These O 0 1.0988929233235467e-07
reagents O 0 1.3101492868372588e-06
detect O 0 6.818627298343927e-07
a O 0 2.0343249218512938e-07
220 O 0 4.909082349513483e-07
- O 0 4.4188425363245187e-07
kD O 0 3.4594970202306286e-05
protein O 0 4.642270923227443e-08
localized O 0 2.0408982948083576e-08
in O 0 2.301040191721171e-10
discrete O 0 4.863673019883663e-09
nuclear O 0 4.796644503812786e-08
foci O 0 4.2561745772218273e-07
in O 0 1.0377344539236333e-09
all O 0 1.3617339478244617e-09
epithelial O 0 2.26941961045668e-06
cell O 0 3.633912456280086e-06
lines O 0 2.1102911418324766e-08
, O 0 9.256470590024435e-11
including O 0 9.162513109339798e-11
those O 0 2.1466510513601378e-10
derived O 0 6.396107465889145e-08
from O 0 3.9882027635940176e-07
breast B-Disease 0 0.0682143047451973
malignancies I-Disease 0 0.0014540788251906633
. O 0 1.5910691217868589e-06

Immunohistochemical O 0 0.132012739777565
staining O 0 4.2210282117594033e-05
of O 0 1.9102712940366473e-06
human O 0 1.931450924530509e-06
breast O 0 3.403425944270566e-05
specimens O 0 2.6136701762879966e-06
also O 0 2.0752768392640064e-08
revealed O 0 2.1562882466241717e-06
BRCA1 O 0 2.483424452748295e-07
nuclear O 0 3.834275958070066e-06
foci O 0 6.491621024906635e-05
in O 0 1.2078161581996483e-08
benign O 0 0.0005028284504078329
breast O 0 2.412779394944664e-05
, O 0 6.653792183897167e-08
invasive B-Disease 0 0.032431408762931824
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9551123976707458
and O 0 1.4109390633620933e-07
low B-Disease 1 0.9999181032180786
- I-Disease 1 0.9999834299087524
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 9.62794729275629e-06

Conversely O 0 3.592609937186353e-05
, O 0 1.1475625427692648e-07
BRCA1 O 0 2.8033286980644334e-07
expression O 0 9.426255331845823e-09
was O 0 1.97909511001626e-08
reduced O 0 2.386587816260999e-09
or O 0 1.4742654874666528e-09
undetectable O 0 7.4625475576795e-08
in O 0 1.2898959678153687e-09
the O 0 8.875434276411909e-10
majority O 0 3.714765717255375e-10
of O 0 8.314533062048213e-09
high O 0 2.120303435049209e-07
- O 0 1.1015807785952347e-06
grade O 0 0.023085270076990128
, O 0 2.1006544557167217e-06
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.3424985567667136e-08
suggesting O 0 4.419954890977351e-08
that O 0 4.240664486232504e-10
absence O 0 2.690314460096488e-08
of O 0 7.185879979942911e-08
BRCA1 O 0 8.55897113183346e-08
may O 0 1.2557738182650269e-09
contribute O 0 2.7778526145993965e-09
to O 0 8.539590146128262e-10
the O 0 2.15643254364295e-08
pathogenesis O 0 0.00100846984423697
of O 0 9.277814072561341e-09
a O 0 1.2445191543974943e-09
significant O 0 5.820074977513912e-10
percentage O 0 2.4630224526589473e-09
of O 0 2.4379238627858513e-09
sporadic B-Disease 0 7.459062999259913e-06
breast I-Disease 0 0.06669700890779495
cancers I-Disease 0 0.0001669696212047711
. O 0 4.80829598359378e-08
. O 0 2.4087603378575295e-07

